<SEC-DOCUMENT>0001558370-19-010798.txt : 20191112
<SEC-HEADER>0001558370-19-010798.hdr.sgml : 20191112
<ACCEPTANCE-DATETIME>20191112160418
ACCESSION NUMBER:		0001558370-19-010798
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		73
CONFORMED PERIOD OF REPORT:	20190930
FILED AS OF DATE:		20191112
DATE AS OF CHANGE:		20191112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Editas Medicine, Inc.
		CENTRAL INDEX KEY:			0001650664
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				464097528
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37687
		FILM NUMBER:		191209247

	BUSINESS ADDRESS:	
		STREET 1:		11 HURLEY ST.
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02141
		BUSINESS PHONE:		617-401-9000

	MAIL ADDRESS:	
		STREET 1:		11 HURLEY ST.
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02141
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>edit-20190930x10qc6fb6d.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.4.7193.41938 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 11/12/2019 9:02:04 PM -->
      <!-- iXBRL Library version: 1.0.7193.41955 -->
      <!-- iXBRL Service Job ID: 77b2d649-61bb-4769-a0b1-9ca4cdd00f7c -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:edit="http://www.editasmedicine.com/20190930" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" xs:nil="true" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" name="us-gaap:CommitmentsAndContingencies" id="Hidden_h6VG0qiHoEyay1EhTfDk_w"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" xs:nil="true" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" name="us-gaap:CommitmentsAndContingencies" id="Hidden_BJ15kV5Xp0GyL7mvevxAxQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" xs:nil="true" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" name="us-gaap:PreferredStockValue" id="Hidden_L7eslJNbgkKEO1HBmZSNGg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" xs:nil="true" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" name="us-gaap:PreferredStockValue" id="Hidden_YAlOUFWUaUCCEGBek868bQ"></ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="Hidden_qxfAEboOfUyoL_gpNTXraA">us-gaap:ServiceMember</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="Hidden_IdhogenAO0uj_i0Sg0yxzw">us-gaap:ServiceMember</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="Hidden_yB5PE3LhYUyZ_fd2Gl8HLQ">us-gaap:ServiceMember</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="Hidden_Ro2J8_6UIEy8qFcxHonyng">us-gaap:ServiceMember</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_lLBeRbK1dkqISfajDjUCGA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_FjdVttUkiUqSdOE6f0lKew">0</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="dei:EntityCentralIndexKey" id="Hidden_SA-Sn93bZUeV8TJ2a_Ppgg">0001650664</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="dei:AmendmentFlag" id="Hidden_3HcjKOGPekKrPOJ7K9I2Xg">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="dei:CurrentFiscalYearEndDate" id="Hidden_UYw-oM8r8kmjn6Ek3L6uZw">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="dei:EntityFilerCategory" id="Hidden_jlBHd2duokWV3uAGcnCc8Q">Large Accelerated Filer</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="dei:DocumentFiscalYearFocus" id="Hidden_R84zHJlrqkqIc_XObvSLUg">2019</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="dei:DocumentFiscalPeriodFocus" id="Hidden_AetiG5IjEkq8fqsRxDks2w">Q3</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="edit-20190930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_7_1_2019_To_9_30_2019_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarketOfferingMember_-kac0ehTwkynz560Ie4IPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edit:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarketOfferingMember_Ow36SSy4wUiSEqoR3C4BvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edit:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2018_To_6_30_2018_srt_CounterpartyNameAxis_edit_BroadInstituteIncMember_us-gaap_TypeOfArrangementAxis_edit_SponsoredResearchAgreementMember_e3dA74ixPEqD64XeFIza9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:BroadInstituteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:SponsoredResearchAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ro8GtWifX0-HMTWgk5pKjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8SsTB3T8jEeFeLgDK5Xq4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_QDEnyWCKbE-v_F_kksLS2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CLnS6hMVNk2ckOkEXszSCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OpvknL2x3ESG-o3hybcgdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_UQYMfrodxUe3emORrxVIsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2019_2G5oRVxKzkqQpy_gyikO0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nMeFIR_iT0a90Nmvw6wHEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vgNcL3n5HUes97GAN6fT0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_BoilOwqVH0CvgLnHZM0KIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wisiSvmZ8E-68zg_-iKPEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CFIibCPWyUS3wh08WaAL2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Al0rqf8nLUSh7WEbnbdGzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NnhClH-fjkiCwW8cwRH_Kg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bKV0YxMVaESgorD_NKUdmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_45_zEcvCkkiGkk1UjUVA3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2018_k2-PAGdm9k2xoicTgC3nXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9kN0cK_j1U-lUz16kqWtFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JikrGEaYFEypNiwSuiHOuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_r16dcPMx-kOPqovKKF9rIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-tPNp-KA0UuSArvAtBVJpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TUxeAzXexUCs6hW2FNI9iA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_nqEnFNcXVUSFrUGRoV0Jlg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LwBc87JgzUC7Dp8J7KafdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7H2GbZDTB0WB00Z3wAbzxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GwYJtLes4kK1jip8o4AlWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2019_To_10_31_2019_srt_TitleOfIndividualAxis_edit_ChiefMedicalOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_ER3lg9N5AUW1GcUOCxl1VQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">edit:ChiefMedicalOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_9_30_2019_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_dmEKC8zRkUGaNSfj2wtDJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2019_To_10_31_2019_srt_TitleOfIndividualAxis_edit_ChiefMedicalOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_oocRI-BsJkm3KP9_DGx7bQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">edit:ChiefMedicalOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_9_30_2018_us-gaap_RelatedPartyTransactionAxis_edit_RentAndFacilityRelatedFeesMember_Exbi6JGLz0aiPwGT7WbBAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">edit:RentAndFacilityRelatedFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2016_To_10_1_2016_srt_CounterpartyNameAxis_edit_HurleyStreetLeaseMember_msxFNwKEn0ud3R-lueFJbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:HurleyStreetLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-10-01</xbrli:startDate><xbrli:endDate>2016-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_ydne4f47BUCTZCvWtZzh0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_SBBNY-YWV0KhHhYb30myIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_xWgifcmBZESG7eQtghdpug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_H7ziJoGIK0maKshFPMdlhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_guUaGiUbe0iwk4T9ixbwSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_edit_LaboratoryEquipmentMember_AVb7DBqk10uTIad92YeUNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">edit:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_MnMT4XcDHE2E28jOhj7_4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_U6z0qkSp50GiyOi7BDlDRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_DjJ0hyYREUOZJlShodxbbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_VqUZ0FvBIkWcvm4vgvlr_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember_qQjfOtD8P0q3C93XNNQvxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_edit_LaboratoryEquipmentMember_jNlcWv83W0a_5q-w_7GeGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">edit:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_us-gaap_OtherCommitmentsAxis_edit_CommitmentToReimburseLicensorMember_DOloV0XhME-N4IXu1IWfqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">edit:CommitmentToReimburseLicensorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_9_30_2019_us-gaap_OtherCommitmentsAxis_edit_CommitmentToReimburseLicensorMember_qcBes6J9yk26oesBBlSUnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">edit:CommitmentToReimburseLicensorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2018_To_9_30_2018_us-gaap_OtherCommitmentsAxis_edit_CommitmentToReimburseLicensorMember_KLzreovHakCeVBoLv9ifJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">edit:CommitmentToReimburseLicensorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_9_30_2018_us-gaap_OtherCommitmentsAxis_edit_CommitmentToReimburseLicensorMember_niHDm0_cQUaXcYlHB5oJPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">edit:CommitmentToReimburseLicensorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_9_30_2019_us-gaap_SubsidiarySaleOfStockAxis_edit_PublicAndAtMarketOfferingMember_i5xMXJaYNESBo9i_qecDHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edit:PublicAndAtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_7zcER-83lEe2S7gZNEWllQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_3_31_2018_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_3_knFgtCBkGl58HqlEgFpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2019_GHVQq8gUCEOZOt-m471YvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_edit_HurleyStreetLeaseMember_zmU6W-bAi0i3mDk8ot7nVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:HurleyStreetLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember_Ax4WwMw3P0elxef4gwaY2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember_PL8oKMla10qvL9b1_2n3mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember_6CXnaUT_fUyJlybGjgEz6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember_jT19XV8GLEu0RJbMbTBl4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember_p7E6BE0SyUaMQWxS2Qggjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember__QoCNZ0YnEedNiRHAIMKIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_9_30_2019_srt_TitleOfIndividualAxis_edit_EmployeeAndDirectorMember_VQVIkfmCb0mvWmtS1VrR7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">edit:EmployeeAndDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_srt_TitleOfIndividualAxis_edit_EmployeeAndDirectorMember_DG1Lr8lP_0-bT3_QEQxdtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">edit:EmployeeAndDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2018_srt_CounterpartyNameAxis_edit_BroadInstituteIncMember_us-gaap_ShortTermDebtTypeAxis_edit_InitialNotesMember_us-gaap_TypeOfArrangementAxis_edit_SponsoredResearchAgreementMember_wPlaEbCo9EqUmdryXl5j9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:BroadInstituteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">edit:InitialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:SponsoredResearchAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rKm1TiBfs0S-9aWTsi7EdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_h9POT0cgJEyb9tv7R3bH6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nEEqv36RBUWlQnEYMf__yQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2P57q7rCIUifNMWJ6Qp70Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2019_lev25mtbBUGfkyljGiogTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2019_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9DeFqajq70i8txpvpYC8_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9iZLSKC4mUiK1QS-diuQfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_i8q1DkQ_KUOWY2XOlmooKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KeqS4HNt1kuKQRTSA9H2zg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_B_Z2yUNGJ0K-xnVe_pA-9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2018_PRyW2BO7NEavIwfH50AVbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2018_To_9_30_2018_srt_CounterpartyNameAxis_edit_JunoTherapeuticsMember_us-gaap_TypeOfArrangementAxis_edit_CollaborationAndLicenseAgreementMember_O_MITT2wVkKnx6b-sggXmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:JunoTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2018_To_9_30_2018_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_RhdoXjew9EeVWvTWLV9vCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:AllerganMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:StrategicAllianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_9_30_2018_srt_CounterpartyNameAxis_edit_JunoTherapeuticsMember_us-gaap_TypeOfArrangementAxis_edit_CollaborationAndLicenseAgreementMember_DrDthce0AkygyZ1M-rBEkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:JunoTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_9_30_2018_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_L3rm1o4tuUiQrTClwY11ug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:AllerganMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:StrategicAllianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_srt_CounterpartyNameAxis_edit_JunoTherapeuticsMember_us-gaap_TypeOfArrangementAxis_edit_CollaborationAndLicenseAgreementMember_MrTxHdu-80almYvZDCtdRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:JunoTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_r45DsPeVZECbm550Uuu09w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:AllerganMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:StrategicAllianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_srt_CounterpartyNameAxis_edit_JunoTherapeuticsMember_us-gaap_TypeOfArrangementAxis_edit_CollaborationAndLicenseAgreementMember_cKDlyfBM_E-va2ua4o2xGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:JunoTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_qZ56Qn1U9Ee0sa4UlEgnKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:AllerganMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:StrategicAllianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2018_Uh3BMLH9xEeftU-M2ZH8Ug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2017_senIwq2LvEuADH5a682MHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_1OsS_I8aF0i-YCo7hdwLcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_HSTFzN1cUEGtvQd0OurLMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USTreasurySecuritiesMember_iVSO5aonCEuoXoKsnk9nUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_iX-oyBzhE0myrSoqcNnSbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USTreasurySecuritiesMember_uFibcieSKUaoBtsZ19bZYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_hhO6rw5Ou0moEGgauWWhJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_XK4JhgmU5UmZfBzH85zD9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_4CMDEP4Sg0WuJwCo3kj0GA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_raku3VZFuke0alBYy9wNpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_CKHO6pDGjkSBIsBw4K4g0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_hb4a5ntSUEWmOa45e5et6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_42lI8pTd2ECGwclymtSQgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_BE9yOipzFkWXXQU9jYhEMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uKPmiw8XwU2KdTnZuxwZtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USTreasurySecuritiesMember_zC8nQ0u0v0SygQronrDnrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember_A5vc1SsXOE2RfS4UDgR6RA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_715p9lT5NU-M643EcMceow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USTreasurySecuritiesMember_szWaKGRTnEi252qXZlUVrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember_KrXYO9EUiEyt_axAoghfkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_TGB4lxKzZkuI8R6wI2ygoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_lwnhc_OPt02yW0Img1-sjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_g8uPs61fLU-iP_S2ZoytqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_NK-fhmMl0UyDtfCFPjlwog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_C2kDm64hKk6izw1I5D_EAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_e71_GfWuOkmuF7nNBglBJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_MsohzaC6nEGF9IKQbiwTLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2019_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_YkEer4ZbSEqfJGFr2l-94A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_9_30_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_Onzl5CFXo0u2R96djFM_ag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_9_30_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_MMdAUyO5fE6SZ9Hb9jRH_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_9_30_2018_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_WBkfEEnpwE-fkbIkbfPsmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_9_30_2018_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_1CwvMLjJmEu4BIw00uKzhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_wZjwFdhl40-qubyppSmKOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_r_4eSnuC80mudfKuh14VtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_aNajZe-YxUercIojM7dr8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_MupqsEB1_kKTyw545CGbAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2018_To_9_30_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_kzBgCnpG60KUgNvcF9BukA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2018_To_9_30_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_Ra72AcdpGUyjMWqQfhIMxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_9_30_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_iZuu8Cy3U0irlLMZI7Q0TQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_9_30_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_TvpaFuwJQkG6gdsSbxfjjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_glvMcDSGgEK7XZEP1zULNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_f703YUdgg0ypJsTTIsOBXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EmQrsfCBQUC6f66ZGe1HZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ezqBpnSOV0CfZMYTrjUW-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_H2z2rvDZXkOkv51mcbXxgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UKNKz4e0eEu5S7yXBgg4mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_hscTLrz67Emlv2qjXnQvGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_66x9bELQuEiMrFfDAUufxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2019_To_6_30_2019_-E0JkxGkvUqIxq8-rSrd2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_GigIkbq07E-4a5thn7D8wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BKKnagJhZUiQ6JZnEBvRvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VR9IQo6tqkWK5mvhHDkVjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_w2MduKaWh0K0KsF7xNNuCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_3_31_2019_g469-FKLDES3WXIXPTgVBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_SlLFJ70IdkulefAZvOR4-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YQeK5YPDZE6CK0bMIfhrGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_U69fKqLuvUeTW_gO2s8dmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_kZBghsf38ECtgyS7q_eESQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_srt_CounterpartyNameAxis_edit_BroadInstituteIncMember_us-gaap_ShortTermDebtTypeAxis_edit_InitialNotesMember_us-gaap_TypeOfArrangementAxis_edit_SponsoredResearchAgreementMember_wmULTOG4pU6RGgo-NX-daA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:BroadInstituteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">edit:InitialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:SponsoredResearchAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2018_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarket2018MarchOfferingMember_DsmZE9rWKUiDZb1Yzi_Ong"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edit:AtMarket2018MarchOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_12_2019_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarket2018MarchOfferingMember_3TF1cgWHa06EgyHnRTyzJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edit:AtMarket2018MarchOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2018_To_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_67JgMcg-AU-r8nQZpiGRBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2018_To_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bUbGp4Vam0KtxOlIe1z2Ow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2018_To_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_xxLzL0DPwky5SLbxx4KehQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2018_To_6_30_2018_k2bzYrObrkCCSC2SDouEQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PcyLV57phkSeAKHvNp6DsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KQblBVk_v0SKWAMPvbYtyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Wtxux8gUD0CRzeyMEreftQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_3_31_2018_BPXZh5LFWk-0JSgUuxyu1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2018_To_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rB_fSol7XE2Vj1rue5g-gQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__7w520kExUi4RwvUKsrFcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_i04SOq9XXU-b-tSVEl5LSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:StrategicAllianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_9_30_2019_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_FOjXNGrOA0OHMOM6s36fPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:StrategicAllianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_xU8d1nrnWkeSzheIpGvdWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:AllerganMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:StrategicAllianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarket2018MarchOfferingMember_lU5PtQ9W90CR1Z6ITvsgSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edit:AtMarket2018MarchOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2019_To_11_12_2019_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarket2018MarchOfferingMember_War5uqaMHkqlCu0UPhd7qA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edit:AtMarket2018MarchOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-11-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_9_30_2019_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarket2018MarchOfferingMember_ktbBPLx-c0WQog7UyrWNPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edit:AtMarket2018MarchOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2019_To_11_12_2019_srt_CounterpartyNameAxis_edit_CowenAndCompanyLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarket2018MarchOfferingMember_X-YMQBtmS0Ov-EDgiiJGQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:CowenAndCompanyLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edit:AtMarket2018MarchOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-11-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2019_To_7_31_2019_-qHYqTPBg0-JDU51y1HWrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2017_To_3_31_2017_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_2xE0WJjMoEOm6FHj79hUVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:AllerganMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:StrategicAllianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_Nw7YnWbU5EWBxR7zlJEm8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:AllerganMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:StrategicAllianceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_zrodnEw_VUizLBhcAZpOsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_1_1_2019_uaR1Uv2lmUWJZyFgpnp2JQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2018_srt_CounterpartyNameAxis_edit_BroadInstituteIncMember_us-gaap_OtherCommitmentsAxis_edit_ResearchFundingPaymentsMember_us-gaap_TypeOfArrangementAxis_edit_SponsoredResearchAgreementMember_7EHzXBh5f0uI6WsTuZTqoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:BroadInstituteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">edit:ResearchFundingPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:SponsoredResearchAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2019_To_11_30_2019_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_edit_JunoTherapeuticsMember_9ZN4nSHh5EeubrbKBSQ-Jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:JunoTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2017_srt_CounterpartyNameAxis_edit_FacilitySubleaseArrangementMember_7tYFtpo8HkifSJ3u_1lnhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:FacilitySubleaseArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_1_2016_srt_CounterpartyNameAxis_edit_HurleyStreetLeaseMember_2ldT7Pk_sEy-LRFeHacLUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:HurleyStreetLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2019_lR7Cn3S_YUa3NkSSGGHXEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_sqft_zyr2ZacpEkijqHVLi1q1mA"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_rl1kcwMXZkCIZ-rzvXYVSA"><xbrli:measure>edit:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_lease_WLwIHlVjbEGdHYRUV0R8Yw"><xbrli:measure>edit:lease</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_E8xeiPkPjUOaCmQYBNvdag"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><div style="padding-top:1.0px;border-top:3.0pt solid #000000;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-top:1pt;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><a id="_32615ff9_d694_4b4a_9778_625d3145f8b5"></a></div><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><div style="font-family:'Times New Roman';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="dei:DocumentType" id="Narr_iUIYuE5IQEu55-vPi9d1wQ"><b style="font-size:14pt;font-weight:bold;">10-Q</b></ix:nonNumeric></p><div style="font-family:'Times New Roman';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">(Mark One)</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="dei:DocumentQuarterlyReport" id="Narr_z4zlVWGrvkKaflEJWk-XAg"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934</b></p></td></tr></table><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the quarterly period ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="dei:DocumentPeriodEndDate" id="Narr_b17ZhTQ9_0iexipW-gGmfg"><b style="font-weight:bold;">September 30, 2019</b></ix:nonNumeric></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="dei:DocumentTransitionReport" id="Narr_tE5BykV0k06N-G7Gi6yudA"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934</b></p></td></tr></table><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the transition period from ____________ to ________</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Commission File Number </b><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="dei:EntityFileNumber" id="Narr_hafVRCfjo0Gdt7ehwEWtcw"><b style="font-weight:bold;">001-37687</b></ix:nonNumeric></p><div style="font-family:'Times New Roman';font-size:10.0pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="dei:EntityRegistrantName" id="Narr_3NHhB2OLyUa6cfzKkXrVtg"><b style="font-size:16pt;font-weight:bold;">EDITAS MEDICINE,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><div style="font-family:'Times New Roman';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:33.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="dei:EntityIncorporationStateCountryCode" id="Narr_flP1_4e3CEyhkFA4P42Ecw"><b style="font-weight:bold;">Delaware</b></ix:nonNumeric><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">(State or other jurisdiction of<br />incorporation or organization)</b></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="dei:EntityTaxIdentificationNumber" id="Narr_R2cQVG6F50GtE8GsKvHtLQ"><b style="font-weight:bold;">46-4097528</b></ix:nonNumeric><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">(I.R.S. Employer<br />Identification No.)</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:27.6pt;"><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;padding-left:10pt;text-align:center;text-indent:-10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="dei:EntityAddressAddressLine1" id="Narr_jt9r4X27r0CXqCeFQo-Sow"><b style="font-weight:bold;">11 Hurley Street</b></ix:nonNumeric><b style="font-weight:bold;"><br /></b><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="dei:EntityAddressCityOrTown" id="Narr_6gz42S-QmE2cprtkiq-V3w"><b style="font-weight:bold;">Cambridge</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="dei:EntityAddressStateOrProvince" id="Narr_OUduXkxbcEimcW6KyS6PIg"><b style="font-weight:bold;">Massachusetts</b></ix:nonNumeric><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:bottom;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="dei:EntityAddressPostalZipCode" id="Narr_K_V65LUXg0ygnH4KSPQH2A"><b style="font-weight:bold;">02141</b></ix:nonNumeric><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="dei:CityAreaCode" id="Narr_1PE7KRDTskGQ6MrerJzwsA"><b style="font-weight:bold;">617</b></ix:nonNumeric><b style="font-weight:bold;">)&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="dei:LocalPhoneNumber" id="Narr_9asZvvYQoUS_MKT8lskmGw"><b style="font-weight:bold;">401-9000</b></ix:nonNumeric></p><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-indent:36pt;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><a id="_945a01ae_7db4_4de5_8933_e1200e7bf535"></a><a id="Tc_xYOuGJWDd0WFQyzfASxEvg_2_0"></a><a id="Tc_uG4_-W1Lb0CB9oLwzSplwQ_2_1"></a><a id="Tc_Ipu6L-0zxUuB8gaOhhedaw_2_2"></a><a id="Tc_oHTWHby_ykWMI8szWhU-mw_3_0"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:2.45pt;"><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><div style="height:2.45pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><div style="height:2.45pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><div style="height:2.45pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:8.15pt;"><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr style="height:6.35pt;"><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="dei:Security12bTitle" id="Narr_TbpWdLgQUUOzFkyx5b9fzw">Common Stock</ix:nonNumeric>, $0.0001 par value per share</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="dei:TradingSymbol" id="Tc_ShQ6sfMMSkKsNu01f8m6sw_3_1">EDIT</ix:nonNumeric></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="dei:SecurityExchangeName" id="Tc_nCcwy8Qg7UWCTCoauMHyog_3_2">The Nasdaq Stock Market LLC</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-indent:36pt;margin:0pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. <ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="dei:EntityCurrentReportingStatus" id="Narr_confx3Ae_E6U-Arn78nZvw">Yes</ix:nonNumeric>&#160;<span style="font-family:'Wingdings';"><span style="font-family:'Times New Roman';">&#8999;</span></span> No&#160;<span style="font-family:'Wingdings';"><span style="font-family:'Times New Roman';">&#9723;</span></span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-indent:36pt;margin:0pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;&#160;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="dei:EntityInteractiveDataCurrent" id="Narr_2ztxblvoFUSq2bSG_I2Q3A">Yes</ix:nonNumeric>&#160;<span style="font-family:'Wingdings';"><span style="font-family:'Times New Roman';">&#8999;</span></span><span style="white-space:pre-wrap;">  No&#160;</span><span style="font-family:'Wingdings';"><span style="font-family:'Times New Roman';">&#9723;</span></span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-indent:36pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_4042d6b1_0c8e_45e5_ba72_63baf03ed036"></a><a id="Tc_OybdDY2ywUuDnKe92iU-dA_0_0"></a><a id="Tc_eOZK0ED-PkeTTgv5StizgQ_0_1"></a><a id="Tc_eF8AE8jjbEWsr-4x6LhFGA_0_2"></a><a id="Tc_92NwY3n2HkK8Uqa0G9L0hA_0_3"></a><a id="Tc_jWL8BKU6AU-XXjCT44xvCQ_2_0"></a><a id="Tc_Sf10M9XJTkurp28yaGut4w_2_1"></a><a id="Tc_391DJjemHUyfuHecqZzNxw_2_2"></a><a id="Tc_dC0VfZIxSkuDSdBD5RbWmw_3_2"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:16.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;padding-left:10pt;text-indent:-10pt;margin:0pt;">Large&#160;accelerated&#160;filer</p></td><td style="vertical-align:top;width:42.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><span style="font-family:'Wingdings';"><span style="font-family:'Times New Roman';">&#8999;</span></span></p></td><td style="vertical-align:top;width:22.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;">Accelerated&#160;filer&#160;</p></td><td style="vertical-align:top;width:18.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><span style="font-family:'Wingdings';"><span style="font-family:'Times New Roman';">&#9723;</span></span></p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:top;width:16.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:10pt;text-indent:-10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:18.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:16.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;padding-left:10pt;text-indent:-10pt;margin:0pt;">Non-accelerated&#160;filer</p></td><td style="vertical-align:top;width:42.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><span style="font-family:'Wingdings';"><span style="font-family:'Times New Roman';">&#9723;</span></span>&#160;&#160;</p></td><td style="vertical-align:top;width:22.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;">Smaller&#160;reporting&#160;company</p></td><td style="vertical-align:top;width:18.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="dei:EntitySmallBusiness" id="Tc_htDlxf3glEabxIhhSawhvw_2_3"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:16.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:10pt;text-indent:-10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:22.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;">Emerging&#160;growth&#160;company</p></td><td style="vertical-align:top;width:18.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="dei:EntityEmergingGrowthCompany" id="Tc_hLWTB8Y4Gk2H8-i7xSlLvw_3_3"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-indent:36pt;margin:3pt 0pt 0pt 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.<span style="display:inline-block;width:1.22pt;"></span><span style="display:inline-block;width:36pt;"></span><span style="font-family:'Wingdings';"><span style="font-family:'Times New Roman';">&#9723;</span></span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-indent:36pt;margin:0pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;<ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="dei:EntityShellCompany" id="Narr_AVDtmBhXykyzOk-adOeEEw"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric><span style="white-space:pre-wrap;">  No&#160;</span><span style="font-family:'Wingdings';"><span style="font-family:'Times New Roman';">&#8999;</span></span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-indent:36pt;margin:0pt;">The number of shares of Common Stock outstanding as of November 1, 2019 was <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_11_1_2019_lR7Cn3S_YUa3NkSSGGHXEQ" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_dKCBHA_sMUaj86C9hZK-VA">51,302,885</ix:nonFraction>. </p><div style="padding-bottom:1.0px;border-bottom:3.0pt solid #000000;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-bottom:1pt;border-bottom:1.0pt solid #000000;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></div><p style="display:none;font-family:'Times New Roman';font-size:10pt;line-height:0pt;margin:0pt 0pt 8pt 0pt;"><span style="font-size:0pt;font-weight:bold;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="font-weight:bold;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><a id="_dd447121_122f_431f_b734_72ff470b756c"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Editas Medicine,&#160;Inc.</b></p><a id="TOC"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:88.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:88.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:88.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#PARTIFINANCIALINFORMATION_111893"><b style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;line-height:1.19;text-align:left;text-decoration:underline;">PART&#160;I. FINANCIAL INFORMATION</b></a></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">3</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:88.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item1FinancialStatements_866395"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Item&#160;1.</span></a></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Item1FinancialStatements_866395"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Financial Statements (unaudited)</span></a></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ConsolidatedBalanceSheets_770063"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Condensed Consolidated Balance Sheets as of September 30, 2019 and December 31, 2018</span></a></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ConsolidatedStatementsofOperationsandCom"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2019 and 2018</span></a></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#CondensedConsolidatedStatementsofCompreh"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Condensed Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2019 and 2018</span></a></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#CondensedConsolidatedSSE"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Condensed Consolidated Statements of Stockholders&#8217; Equity for the three and nine months ended September 30, 2019 and 2018</span></a></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#ConsolidatedStatementsofCashFlows_280444"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2019 and 2018</span></a></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">8</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#EditasMedicineInc_40397"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Notes to Condensed Consolidated Financial Statements </span></a></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">9</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Item 2.</span></a></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">21</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Item 3.</span></a></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">33</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item4ControlsandProcedures_796610"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Item 4.</span></a></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Item4ControlsandProcedures_796610"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">34</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:88.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#PARTIIOTHERINFORMATION_124074"><b style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:bold;line-height:1.19;text-align:left;text-decoration:underline;">PART&#160;II. OTHER INFORMATION</b></a></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">35</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item1LegalProceedings_433402"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Item 1.</span></a></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item1LegalProceedings_433402"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">35</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item1ARiskFactors_661144"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Item 1A.</span></a></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item1ARiskFactors_661144"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">35</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Item5_Other_Info"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Item 5.</span></a></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Item5_Other_Info"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Other Information</span></a></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">88</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item6Exhibits_459407"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Item 6.</span></a></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><a href="#Item6Exhibits_459407"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Exhibits</span></a></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">90</p></td></tr><tr><td style="vertical-align:top;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:88.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#SIGNATURES_262108"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Signatures</span></a></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">91</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:88.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_6e061bd0_0bda_482b_ad79_efc42c1f9f13"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PARTIFINANCIALINFORMATION_111893"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">PART&#160;I. FINANCIAL INFORMATION</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Item1FinancialStatements_866395"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Item&#160;1.&#160;&#160;&#160;&#160;Financial Statements.</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Editas Medicine, Inc.</b></p><a id="ConsolidatedBalanceSheets_770063"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Balance Sheets</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(amounts in thousands, except share and per share data)</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_87c50e5c_b0d5_4c4e_9c95_1d28838c703d"></a><a id="Tc_PFu_T0NxxkmIez2PlarJsw_1_2"></a><a id="Tc_TrIhkl15GUKwQ2NcTZR6lQ_1_5"></a><a id="Tc_SKsDp8JIc0CULYRawpELkQ_2_2"></a><a id="Tc_hdrDdUnWUkS7THa0CSqejg_2_5"></a><a id="Tc_zP-gXg52Z0mGHKuVullG4w_3_0"></a><a id="Tc_U--sNiQGm0WZ_71bChMdTQ_4_0"></a><a id="Tc_uBo_Wuc690ylTzsK6A6w4Q_5_0"></a><a id="Tc_fif5FeDeHUSktgZVlZJ9iw_5_2"></a><a id="Tc_vlYog4kAkUmtTNF1XN7Etw_5_5"></a><a id="Tc_CXeq8rBTOUyPInHc3eRMRg_6_0"></a><a id="Tc_ZzzSQihSQUqxQJ-fNZuwDA_7_0"></a><a id="Tc_QmDTET8Sn02qYESfyFxM3Q_8_0"></a><a id="Tc_POqJec3jmEKm7EIcv0PINA_9_0"></a><a id="Tc_Owf26zW_rU6eEob34nhXeg_10_0"></a><a id="Tc_RWJ0Y5thT0mvapSK9NqlyA_11_0"></a><a id="Tc_mb-bi8Zn50aNW4oPVCfZ7w_11_6"></a><a id="Tc_GtfAXehemUqqD75mbWjVuA_12_0"></a><a id="Tc_7Bedvn28YUusXjGsACF2gA_13_0"></a><a id="Tc_4ndUIXvX-0i0oi5UXJtsGA_13_2"></a><a id="Tc_rwNnCihkukGgZwMGFwli8A_13_5"></a><a id="Tc_XuBqK7uTOkO0R4ogGvsfKw_14_0"></a><a id="Tc_xlcEGKo6sEWvdQsiyywW3w_15_0"></a><a id="Tc_DFamL6OlS064s--Uh25z-Q_16_0"></a><a id="Tc_vd_k8_rMB0Gk4sibwVtreQ_16_2"></a><a id="Tc_Tly5Uhsojku_6EzgDaG3Lw_16_5"></a><a id="Tc_WF8xiH7NEE2L5nslsicbbw_17_0"></a><a id="Tc_MqZAVpd-7UevnZUVRuGr2g_18_0"></a><a id="Tc_-5oYBfAb006ykA-VSOjK2Q_19_0"></a><a id="Tc_K71-y-C6uEK63nf-b0pz_Q_19_6"></a><a id="Tc_cU_TFpdV0k2SI62NX9E9fA_20_0"></a><a id="Tc_iorWbDq_JU2_MU6y9IvApw_21_0"></a><a id="Tc_RxOh5bdhBUyZH1QNMkbYTA_22_0"></a><a id="Tc_xq4WXYB-FkOrbRhvoX4C8Q_22_6"></a><a id="Tc_-EC2p8_vhUu8YztCxT2piA_23_0"></a><a id="Tc_7TI4U1nj_kaaAVtlEcjMmw_24_0"></a><a id="Tc_3aQ2MlcP10iHDtUd5_BKTA_24_3"></a><a id="Tc_Ip-mdRhwV0ye7rhqGu-K5Q_25_0"></a><a id="Tc_RIesrjmRZUCffYKeu43dBA_26_0"></a><a id="Tc_qx10g1Qsr028N1E-dGAJeA_27_0"></a><a id="Tc_MIXT5In_S0O4JSAlyNoRVw_28_0"></a><a id="Tc_BuKn-HRiuEG6C3xA0DvXyA_29_0"></a><a id="_1f0bb29f_2c76_4011_a6e8_038a88299692"></a><a id="Tc_5Wtyvz-e2UqRa8PYWU9C3w_29_3"></a><a id="Tc_JSiEdgT_9EyMTh2QbxW4kg_29_6"></a><a id="Tc_AwEEzw0kRUe5HevBi6cUGQ_30_0"></a><a id="Tc_LUuUZDbPO0SBC2FesqS_DQ_31_0"></a><a id="Tc_vuSjHbaZ2Um6GSWenxzvcA_32_0"></a><a id="Tc_4CGmC2iNqEGGE7DxVT4lOQ_33_0"></a><a id="Tc_FP1RCuVpMkiy66Irc5bdug_34_0"></a><a id="Tc_NX8Jkf8wMUaCBXBeyBXTOg_35_0"></a><a id="Tc_jsaHGl8m00is4d-lRPBO9g_35_2"></a><a id="Tc_H5Kw4qpC00Gm3Ze8KSRBdg_35_5"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_Fq_ljOnEW0er2Dh3qcVVUw_5_3">104,772</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_8xm_hcOhwkimAsMaAK4ulw_5_6">134,776</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="Tc_PG6vCWlFGUSzySuCakXtEA_6_3">227,844</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="Tc_ebGFQxlUM0mHfOnVGqj96g_6_6">234,179</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Accounts receivable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="3" id="Tc_g-B1mQlOLUSPtVrkbj8QqA_7_3">311</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="3" id="Tc_9VW7a_xrr0OR2URMq6exgw_7_6">30</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_IPKHYjdDDUWEVdzUvdt8Dg_8_3">6,284</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_6QfPhpoYnk2oUGptabYNyw_8_6">5,791</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Total current assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_ZX7cuZ9GrUO_rF4vAKMzyQ_9_3">339,211</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_tqPBf-U6FEiNFL7co_j0cg_9_6">374,776</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_zFUDLZGi-Um8uqfZ2lg_iA_10_3">10,075</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_QqqlLeY4p0-a0YbU0NLkRQ_10_6">40,232</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;">Right-of-use asset</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_JND5z6MTX0KYiIqQ_DFFqQ_11_3">17,681</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;">Restricted cash and other non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_ykVV3sY7qU2471CeplPcYg_12_3">5,392</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_nNvIqGnQnkmm2Ux4-cuWzg_12_6">5,378</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Total assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_IqaeXeyKAka131VkSww0vg_13_3">372,359</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_fQDX7kf3JEWDUTSA66RArg_13_6">420,386</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;">Current liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_BFxVZFN8EUSS83HufRczgw_16_3">6,624</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_RTINkI38fU-pBrxzHjBVLA_16_6">5,327</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Accrued expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_Z_xaBWHBaEK_c7qeXmK1nA_17_3">8,138</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_Rp-kj-F85UyXC7RrI-yLpQ_17_6">12,813</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Deferred revenue, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_bo1Hdi7C2EWLx8gB2ZiMsA_18_3">46,019</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_EHmBSJwpx0m8ICTc-fAlyg_18_6">15,712</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Operating lease liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_KvF8QMJWCkO06Bj2t0sh8A_19_3">4,448</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Other current liabilities </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_Yn91HT7sXEyOaONKwZ5MOw_20_3">1,558</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_eaWtwA5SjEi7tGXdXfyddg_20_6">2,048</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Total current liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_U7dHZ5_gYEmtUNm9pMemqA_21_3">66,787</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_ArPZH1NCjkKg0wL7VdFdKQ_21_6">35,900</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;">Operating lease liability, net of current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_wnQW-mj_BEapEwx6Dt8dIg_22_3">13,202</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;">Deferred revenue, net of current portion</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="Tc_HYDEUThSQEyFfqTTvmn8Aw_23_3">82,379</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="Tc_5xXTbdRKEUK2KzSYEooPGw_23_6">115,614</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;">Construction financing lease obligation, net of current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="Tc_kb8ROt6oC0O4z8w4xBoSNQ_24_6">32,417</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;">Other non-current liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_9c31PWyNhECaxVkCwuGcGQ_25_3">1</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_sxg9MQB3QkK9jjqSWgHR3A_25_6">293</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_tEs0MJ7ijkKpYOK3HEyUww_26_3">162,369</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_a43EvaYbaU-AJ18O4xcTlQ_26_6">184,224</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;">Commitments and contingencies (see note&#160;7)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;">Stockholders&#8217; equity </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockNoParValue" scale="0" id="Narr_P98_NjDFDUypgtvuVAcsJw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockNoParValue" scale="0" id="Narr_vwRfZR4RH0q7p1rJNtZm9Q">0.0001</ix:nonFraction></ix:nonFraction> par value per share: <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_DScrtPzG9k66V-r44co_3g"><ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_f-ZwMJQ9rka74aJnQsFWVA">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_99L1a6H5i0q0uIeiD4uX3w"><ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_wGFoPftf7ki3m3gFPbw36Q">no</ix:nonFraction></ix:nonFraction> shares issued or outstanding</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_m2tzGemfBES7hPnBc0zSKA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_W_XfBrw4EEO0MhtCWMKSeA">0.0001</ix:nonFraction></ix:nonFraction> par value per share: <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_OBT8sbHumUWvyyrlTetd9g"><ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_aSFpLdVd8ke_gB25XwR_Ww">195,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_YFTKbC2H0UikRbemQx7CoA">51,528,020</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_wCR_sZUb1kuyLlnVhj8VCA">49,028,907</ix:nonFraction> shares issued, and <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_LOLewTjbYUCLZIZwH6vL1Q">51,076,198</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_j620onv7kkCep50eo7CEmg">48,758,951</ix:nonFraction> shares outstanding at September 30, 2019 and December 31, 2018, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_0bn1NZZ8Lk6CZCUgX2ALmQ_30_3">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_feMtGn7GNEaGQN_z1QdLYA_30_6">5</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Additional paid-in capital</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_q1NPw485DE6QPH_rURudew_31_3">721,397</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_oRo-JhgI6E6C2P9o0mO_PQ_31_6">652,464</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Accumulated other comprehensive income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc_3oUxaaKHDkCeosG54lXZvQ_32_3">39</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_qrHNSOKpHE-XcJI869C_aw_32_6">29</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Accumulated deficit</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_tNQtTBl0iEmmy2VoTA3Jww_33_3">511,451</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc__OB_jyLBi0qBqioCHI1y4A_33_6">416,278</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Total stockholders&#8217; equity </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_rAxoE_rZVEC7bE8R7XHXQw_34_3">209,990</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_SoU_Y71zu0ykr5FHkGPNbA_34_6">236,162</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Total liabilities and stockholders&#8217; equity </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_Jiq82nGdKEmgc604J4s2bA_35_3">372,359</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_IMMxP46U8Euf52V06HMjnw_35_6">420,386</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">The accompanying notes are an integral part of the condensed consolidated financial statements.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_80917e71_a32b_4eba_8c96_8f9db288aa20"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Editas Medicine,&#160;Inc.</b></p><a id="ConsolidatedStatementsofOperationsandCom"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Operations</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(amounts in thousands, except per share and share data)</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_fd773bd5_e15e_49bf_bd9f_a55c6f9df12e"></a><a id="Tc_qmiidAt3xE6oElhItJNUWQ_1_2"></a><a id="Tc_PByIfRnouEuNviohTlIHuQ_1_8"></a><a id="Tc_JpohyQx9i0KWR8cWQRDDFw_2_2"></a><a id="Tc_HluXCQdW-kyodlMFGoID7A_2_8"></a><a id="Tc_ubazdxpQ10K9qMUmAUuOlg_3_2"></a><a id="Tc_lQsSVDYtMUyqN1sGRIZ-sw_3_5"></a><a id="Tc_5xOkQz2KeE2dkgaAbpqi1Q_3_8"></a><a id="Tc_1BMp5wGf7E-624aSb_fMuw_3_12"></a><a id="Tc_QgD6YTEevEyto3MQ83trJA_4_0"></a><a id="Tc_Ke1NdUBENkCBqjJfFlAETA_4_2"></a><a id="Tc_8eN2PZ7v2kuH4S0EE65gXg_4_5"></a><a id="Tc_0Q-gVseCtECjFIONsb-6Sg_4_8"></a><a id="Tc_rVbTq0mnF0iL8mtIybvU3g_4_11"></a><a id="Tc_QXdAYHQAYE6g7URViedv4w_5_0"></a><a id="Tc_lGCfgSQeu0-c4_6wWDMpkg_6_0"></a><a id="Tc__bWvWeaIP0OIatP-Z5YOIQ_7_0"></a><a id="Tc_xo3_MA8IIUye4R09aOYuIg_8_0"></a><a id="Tc_7muUCN5KG0GFmWUgAvSmPg_9_0"></a><a id="Tc_5dvWBKtPIEOvy6uoL8dy3A_10_0"></a><a id="Tc_PNxm-oMWZkq4R_qf3x611g_11_0"></a><a id="Tc_u-c3_rhQCUG5eScICF53Xw_12_0"></a><a id="Tc_xkX4Ku3FPUmFucLQ9Fzfaw_13_0"></a><a id="Tc_V_11OGE7g068utTllVQrdw_14_0"></a><a id="Tc_DlNZEfvYU0q8slmtCVnFIA_14_2"></a><a id="Tc_ymF0g0kpTkW0HPdfrSXxYA_14_5"></a><a id="Tc_DMv0s2NW2kyvGWXhcUx5Zg_14_8"></a><a id="Tc_pPTMkCaQvEi3DSE9qPRJxw_14_11"></a><a id="Tc_ZhkduPsNhkyqxYNGQEaBbg_15_0"></a><a id="Tc_Od3qq8uTkEuidjUDGX05HA_15_2"></a><a id="Tc__NKURFRTVU6xiCAcIe8EUw_15_5"></a><a id="Tc_dWxWEpT7V0-9Otfgx1pktQ_15_8"></a><a id="Tc_8cAHgAUhG02M6hSjsVMsDQ_15_11"></a><a id="Tc_J6bas3oVXUG7iJgUU2d1qA_16_0"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:-3.78014%;padding-left:0pt;padding-right:0pt;width:107.56%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:55.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:22.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:22.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:55.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:22.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:22.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:55.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Collaboration and other research and development revenues</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_yVtYbl0azUCp0YxrcGA-XA_4_3">3,848</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_9RwnzFO7ek2LCcKPc_5e_g_4_6">14,519</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_BB68KFijJ0GaGmEXwWILJw_4_9">8,247</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_vVGJU5UVxUu9FH5CgAtQIg_4_12">25,818</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_bSK1UsmwWUGOa6fCgk9kgw_6_3">22,702</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_C5qkhRX0a0KRsLo4C4eZjQ_6_6">17,443</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_CLJtyJJntk6ARwFJeWL29A_6_9">62,109</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_cIR1_oYk-USr5aknPMiQsw_6_12">71,460</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_XbiNaXByDkypKz0CfDXxcA_7_3">15,734</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_ij7q54s-SUeuxk0pujJtrw_7_6">13,334</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_l_Qj8phSbkm9sxWxrQQ8Rw_7_9">47,638</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_BDwufR2AhkKrqMJdb62Byg_7_12">41,832</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Total operating expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_iBmJrWSPAUOKjs-H5j4sow_8_3">38,436</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_fMcg_pikeUeK9yAmrkV9bg_8_6">30,777</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_RTZMG8PlLkSR-4MHLvWpiQ_8_9">109,747</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_Fzd6ys45TEmE_w7Bgj5JXA_8_12">113,292</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Operating loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_hMjCXmoo00KLr-RasyDPQg_9_3">34,588</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_ioI_nEyjLEmjvc45pnlPkQ_9_6">16,258</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_lEKjf_Tb90q7JhwmWWEqEg_9_9">101,500</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc__jGeyqNrd0O1iwTygsPwjg_9_12">87,474</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Other income, net:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Other (expense) income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_ZxADWvSL7kq1c2UP6EmqSw_11_3">33</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_xCKgDCBL10-KJw3-sn8veA_11_6">4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_9lbBxIywWUuKMdYlWHLFcA_11_9">144</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_AhyIFjgEmEOlJL8x3cslVw_11_12">332</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Interest income, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNet" scale="3" id="Tc_tCXJwmEtk0a9K6T9-mpUGw_12_3">1,680</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNet" scale="3" id="Tc_Wg_tc4LACEC5RqVxEMoSzQ_12_6">1,024</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNet" scale="3" id="Tc_IFUjvS1E7EOtQtQ5OdQUcw_12_9">5,668</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNet" scale="3" id="Tc_rj2l2gJfHECjmG3VjvzfkQ_12_12">2,243</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Total other income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_RUqyfiy5Gk2prszPIMZvWQ_13_3">1,647</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_wgfaMk3yukWV_PZ2aO-j4Q_13_6">1,020</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_h9iBmuMwN0-Bq8h5iLI55g_13_9">5,524</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_DFl4IFV-QUaBNTxOw6z8-Q_13_12">2,575</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_GzNT-fgvD0m-Ggi1s7CqZQ_14_3">32,941</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_ajERkqIm0Uu86Jf4flGsWg_14_6">15,238</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_HlN5NYugGkuXbJTdk678kw_14_9">95,976</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_RWxn5QhpXUeVBIbSznxBsg_14_12">84,899</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Net loss per share attributable to common stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA" contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_hDr7WIC_PUyXk4vsNQwyKQ_15_3">0.66</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA" contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_dWOjUGDJO0WoB0jsotiGDQ_15_6">0.32</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_JxhAlpu3WEGb6b95FBwUaA_15_9">1.95</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_KklgzjkNo06YpW3s2LX1iw_15_12">1.81</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:55.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Weighted-average common shares outstanding, basic and diluted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_v-cDETGPf0-tIarcu-Q2eA_16_3">49,820,455</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_F7Fl-eyz00iMIQnF0mHdbg_16_6">47,414,271</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_8lLJcmp08U-rhwgCqoHQ5w_16_9">49,246,684</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_UF4DeD0JSkqw0_xQstn1FQ_16_12">46,791,322</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">The accompanying notes are an integral part of the condensed consolidated financial statements.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p><a id="_86128736_1472_4ec8_a07a_f8b506bbda47"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Editas Medicine,&#160;Inc.</b></p><a id="CondensedConsolidatedStatementsofCompreh"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Comprehensive Loss</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(amounts in thousands)</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_b9bbc04b_dfba_4d45_aedb_afb6cef1051e"></a><a id="Tc_eF0k6wLiqkuPtkDbN4KqIg_1_2"></a><a id="Tc_1lYYcB9KrEKqy9gsMJBTow_1_8"></a><a id="Tc_gbMwS-4T-0aP302SpU0VZw_2_2"></a><a id="Tc__XbadGYIE0Ky-8au3fv6ag_2_8"></a><a id="Tc_CRCW8UETiUOAx9ceyRKE8Q_3_2"></a><a id="Tc_8KNh4hDwyUqL6aqlktqdzw_3_5"></a><a id="Tc_unwHFC6PakyFvWIp8oxrTA_3_8"></a><a id="Tc_XL-A4VYfz0uYayXrDHDF4A_3_11"></a><a id="Tc_SqmBlCxsYESW0D7rjivfag_4_0"></a><a id="Tc_gDwVIIuSV0a0re8VrJU2ow_4_2"></a><a id="Tc_UuNFaEk7uU6PiUWsP6P_gw_4_5"></a><a id="Tc_Rc6t1nnffk2xT0zYBkPrIg_4_8"></a><a id="Tc_wN0MO92D3kS6NPrxH817bQ_4_11"></a><a id="Tc_XoFP6m7XuUOCB80MwsGueA_5_0"></a><a id="Tc__2QkvKhWOUKa1AA5Yv9dUg_6_0"></a><a id="Tc_1RdBfJvyD0q82oZB_XwCTg_7_0"></a><a id="Tc_a4zl_GMZFkOSsbF3Efr64g_7_2"></a><a id="Tc_-yCt0XkUvEG0SgdoiC2PEw_7_5"></a><a id="Tc_lBsCXzin70aw81O2aFqWTg_7_8"></a><a id="Tc_5RmWHO7RbUGcaEzRN1qE-w_7_11"></a><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:101.12%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:25.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:25.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:25.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:25.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_HYSqRbxQm06Wgg8mRD2BBQ_4_3">32,941</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_UqaTpa7jX0uQJ7MMY-C7hQ_4_6">15,238</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_3XkSukynFkOAjKnggb6Ftw_4_9">95,976</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_uqpS6XgKOEKsVbGFnekUUQ_4_12">84,899</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:43.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Other comprehensive (loss) income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Unrealized (loss) gain on marketable debt securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" sign="-" scale="3" id="Tc_v7NFnEPcSU25J-Atj2d8NA_6_3">6</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" sign="-" scale="3" id="Tc_QEnqazN3-UO-SKSiPXQqhQ_6_6">83</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="Tc__aFBA6Pb_UGl8HZiM1LrjQ_6_9">68</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" sign="-" scale="3" id="Tc_pzswhRtbW0eOMELOeHTmdg_6_12">6</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:43.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_JIoQEcTxuU2NQTAR2oprCg_7_3">32,947</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_2oD6sT2S8kKdFXH0hvdOaA_7_6">15,321</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_aqd9EUl6a0--Ybo3KuKBSg_7_9">95,908</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_MgFKVswoAEaH0d7LULkxHA_7_12">84,905</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">The accompanying notes are an integral part of the condensed consolidated financial statements.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><a id="_e75a3e2d_42d5_45a6_8490_133fc37e6ed3"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Editas Medicine,&#160;Inc.</b></p><a id="CondensedConsolidatedSSE"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Stockholders&#8217; Equity</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(amounts in thousands, except share data)</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_f4740980_3338_4c8f_bcd6_3c0100f51939"></a><a id="Tc_tmjnBypE6UWbDkxxn6WNFQ_1_10"></a><a id="Tc_9VHqQiNhQUuVg5WS3Nr7lg_2_7"></a><a id="Tc_IDhJ7AMBM0qiymtprs5Sog_2_10"></a><a id="Tc__cWrgACkt0uT5kscSl_pBQ_2_13"></a><a id="Tc_A4k6XWnFjkqT1UBEBSv1iQ_2_16"></a><a id="Tc_5c_4JVZOC02Sb0ZJJoibZQ_3_2"></a><a id="Tc_udZxHMsah0S9b0NlPyMQkA_3_7"></a><a id="Tc_q2Qv9yNcWEqIg2cmzJHXMg_3_10"></a><a id="Tc_PL8p1vv2qUKbdxlkXeddhw_3_13"></a><a id="Tc_qNFSWu_vvE61ZU1diQzJ4Q_3_16"></a><a id="Tc_It827CCzVECmrF79oUsR9A_4_2"></a><a id="Tc_-bGsS1l2fk-GcCGRDB3yXQ_4_4"></a><a id="Tc_iBBdGH-vcEGqVXmIPVJhFg_4_7"></a><a id="Tc_hbo1WEqIzUy2lkknQnOyVA_4_10"></a><a id="Tc_Rcbo1bOMeUKLWqGuiYegjQ_4_13"></a><a id="Tc_TaQwvdg1LUmlvnsWzsfiEQ_4_16"></a><a id="Tc_9EQcLN5P0Euve7UbeR0vQg_5_0"></a><a id="Tc_Lv_OOd8Ne06BJFNlHHcYbg_5_4"></a><a id="Tc_5_0PdL5PZ0i-0pERaat_Zg_5_7"></a><a id="Tc_RB1pNid4wkqK9YwGrXKQrw_5_10"></a><a id="Tc_uJLB6cFqDkumpbhWxsF5xg_5_13"></a><a id="Tc_py6h7Nw1LEaPVuom5ZGeeg_5_16"></a><a id="Tc_yHU42Fbtgk-Oj60qEVMtPA_6_0"></a><a id="Tc_EYUI3ipD6k6SqF2TgJlB9Q_6_2"></a><a id="Tc_8BXStJHupkaaTs1t9h-oKw_6_5"></a><a id="Tc_4ow1PyEAjECJD-4RbwZKIQ_6_8"></a><a id="Tc_QEpfnp0EkkarxIolq98XyQ_6_11"></a><a id="Tc_IG69B3fM-02HwWGRRyLLxA_7_0"></a><a id="Tc_ySEs3ZzdfUmgHxuP9FJ13g_7_5"></a><a id="Tc_oDEVjUD0mUKhx7yW2yyXWQ_7_11"></a><a id="Tc_Tqb9ZNGSfUusz5vnhnhxLw_7_14"></a><a id="Tc_j1JZDS-pAEepXycLrDmM6w_8_0"></a><a id="Tc_LElZ9fu5C0KidSsEmlTmAg_8_5"></a><a id="Tc_ybF8y9ClVkiqYXlNVvESpQ_8_8"></a><a id="Tc_zNeMl5CobEGdt6pb9ycCAA_8_11"></a><a id="Tc_6VsDs3sZikatNkRo5JDRHA_8_14"></a><a id="Tc_e2TcAbkZYE68LgNkuMo9Hg_8_17"></a><a id="Tc_OlXBxX0eBUefh8WbXqP84w_9_0"></a><a id="Tc_kwDVKphnzkGmQ-4D0qAAEg_9_2"></a><a id="Tc_8GcC_WfkFU2pOFvLYB-HfQ_9_5"></a><a id="Tc_drL_ZDSu20mgassKLsdy5g_9_11"></a><a id="Tc_wwsWbSr9WE6cKDvs2tcGwQ_9_14"></a><a id="Tc_QW0j1z3JskGcIAXfGrRCdw_10_0"></a><a id="Tc_iUvQxoD_KUWB_Ow-K2EJOw_10_2"></a><a id="Tc_H43qm30dQ0C2mRNpgbtCeA_10_5"></a><a id="Tc_nkhtwDKlJUOryFVmCQqJNg_10_8"></a><a id="Tc_eS8jBT-FzEyyghwEZSmjEw_10_14"></a><a id="Tc_hW-VoZUM0EegrEAWSKWU_g_11_0"></a><a id="Tc_KAZmWsfZNk6tUfTMW4VhGA_11_2"></a><a id="Tc_kTr26H7KI0WXz9h4cQdX0A_11_5"></a><a id="Tc_1t3sYjcBbkWhqajpXVsHNQ_11_8"></a><a id="Tc_WnTtixnIzEWYwPenxear8g_11_11"></a><a id="Tc_hX50nA-XFkyOX4pgDNHN5A_12_0"></a><a id="Tc_0evM1vXkAEW7Kq2ukRzwXw_12_4"></a><a id="Tc_-JbK1jRWn0uZg5vf6TxSXA_12_7"></a><a id="Tc_127HhUw4dkaHYlCSjgenFA_12_10"></a><a id="Tc_eskg7QGuLEqpaYd26gsNUg_12_13"></a><a id="Tc_2ijluQnkRki87X6EbLj0uw_12_16"></a><a id="Tc_axnzcL7ImEyB8wHkCDS5tg_13_0"></a><a id="Tc_5daPBKDxFkW0taKeUwc0pw_13_5"></a><a id="Tc_Vk_EL0t8aUmjjh6pNZy66g_13_11"></a><a id="Tc_Rz74SQSoLEi_a9z-xsIlBg_13_14"></a><a id="Tc_J62CLG7ELkuZEgL9wfbcbA_14_0"></a><a id="Tc_gLbEK-zpdUWW5Gfcbm44GQ_14_5"></a><a id="Tc_UsyAzyDxREee25_4q5f7QA_14_8"></a><a id="Tc_xhjBl6ODvU-UIHzNqPlGpA_14_11"></a><a id="Tc_lyBQsrGX7EiJcd0RIufDOg_14_14"></a><a id="Tc_VYmiJnDMsECY8KLn9SZjOA_14_17"></a><a id="Tc_26GhZfIyAEeHZAxJ6kM2Kg_15_0"></a><a id="Tc_QIuWrx_f1UmUQJK_valXhQ_15_5"></a><a id="Tc_TR71JOhwykOo-EncEFWD_A_15_11"></a><a id="Tc_t3L2ZH82RUWMycS8OoayeQ_15_14"></a><a id="Tc_1GgYgDsuWE6UR4_vSvUwew_16_0"></a><a id="Tc_Vkyo1C09YkKSHicWO7AJWw_16_2"></a><a id="Tc_ni_vLjBMpUqxo_y8t0Vgvg_16_5"></a><a id="Tc_mM7_BwIoREufCNBRvmBF5w_16_11"></a><a id="Tc_SM4v39bh9USqew7o-phQ1g_16_14"></a><a id="Tc_C5zHn51_A0O-ktDlVexKGQ_17_0"></a><a id="Tc_iCYsrycNhUSKoF-b1Xq4VA_17_2"></a><a id="Tc_frrqFT_nLk24FpXBi8w3hQ_17_5"></a><a id="Tc_--3fCYwvGEuz9zxzN-bvww_17_8"></a><a id="Tc_LiipTR8Yp0eC0DKxZYbkwg_17_14"></a><a id="Tc_bLpj5IAxoE-EWnwKeOI69A_18_0"></a><a id="Tc_qICs8_tCGU6u3ObHu_-FDA_18_2"></a><a id="Tc_hs4bXuCGEkW_fcL6fjiQMQ_18_5"></a><a id="Tc_e8Vx5cZ_JkSdl1eyMwctuw_18_8"></a><a id="Tc_8ZkZ09-uQUeQYrHYEmZz9g_18_11"></a><a id="Tc_Jxnow-xW4025Zk4Z0niPLQ_19_0"></a><a id="Tc_qFS8yy68u0OLSD9bo7oK4Q_19_4"></a><a id="Tc_B7AFUalGg02yss1VXn9DVQ_19_7"></a><a id="Tc_38i9k9ulY023Ja9pA88CQw_19_10"></a><a id="Tc_ZxgL22KRyk6JfVB5oPMTbg_19_13"></a><a id="Tc_4ImDpZdvvEiOjMxrv9jobw_19_16"></a><a id="Tc_TGM37cww6k2EGwg-mzLO8A_20_0"></a><a id="Tc_P5xMWTWSmE6AYLFkMDe6hA_20_5"></a><a id="Tc_udUfH_8pa0CZjdP8lWTCGg_20_11"></a><a id="Tc_apcUZegLbUql_0G6QWTZtw_20_14"></a><a id="Tc_KXjUsG5T7Eu5JNSjg53sBg_21_0"></a><a id="Tc_HALdM4uEdUWg_qiKlRYbaA_21_5"></a><a id="Tc_SR9CRmUWwUW7oOeynVEMpw_21_8"></a><a id="Tc_JdC9ms8izE6z3SSapTvKHw_21_11"></a><a id="Tc_a1Es-PNNPUOeykdZGtc-MQ_21_14"></a><a id="Tc_9LPT68V2OEy1PW0DLTtxSw_21_17"></a><a id="Tc_hbMJrasXEUmN5kZVWy-4DA_22_0"></a><a id="Tc_RyfTJeCjEU68F55Cm0WkNA_22_2"></a><a id="Tc_WMC3f4vrEU2xxApHN-hoBQ_22_5"></a><a id="Tc_2BTmKiGF6U6ZVulWPwmwaA_22_11"></a><a id="Tc_yvKp-bdRB06s7dKcXFSPlA_22_14"></a><a id="Tc_i3eHxPU9m0-gH2oHqEy2Pg_23_0"></a><a id="Tc_EfdCXx-l_0KtEJYEm2MMPQ_23_5"></a><a id="Tc_KZqZ2hDdt0qXJOVMXcENYQ_23_11"></a><a id="Tc_JDKi_jIUbE2eTYd8FkKtVQ_23_14"></a><a id="Tc_n7udNt_ndkS7h4FhihcYsg_24_0"></a><a id="Tc_uh56GVi1o0KP8oNlcJkCDA_24_2"></a><a id="Tc_4QICalThn02ea8LDdEMaeA_24_5"></a><a id="Tc_jFAIx4CYh0ugx4tyDBUV9Q_24_8"></a><a id="Tc_drKXGItV5UKrXJre8aM27Q_24_14"></a><a id="Tc_ak02bkLnQE6n5SyoEvffIg_25_0"></a><a id="Tc_yqLJjwzMUECznutffR3PVw_25_2"></a><a id="Tc_dQyDSlA7CUGUDM4QaLd-kA_25_5"></a><a id="Tc_APbZzO13X025Jpzm2lSrKQ_25_8"></a><a id="Tc_3KxBod0TzkWDWW3OA_G4zw_25_11"></a><a id="Tc_xd8Hy2fwy0iXzMp_tTfcXQ_26_0"></a><a id="Tc_2CFIfwibfk6IQq102OaVrw_26_4"></a><a id="Tc_uKtdvNwcJUy1BLePoBs4QQ_26_7"></a><a id="Tc_c3GIIIzqmk-72Ege4rugtg_26_10"></a><a id="Tc_aqZiwNEYIEeDxUdb_zZH4A_26_13"></a><a id="Tc_J7p5U6_C9UO7kusFAfgYsA_26_16"></a><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:103.14%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:17.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Comprehensive</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:6.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Loss) Income</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2018</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_nqEnFNcXVUSFrUGRoV0Jlg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_PW853cBCGUyOiD19k_lmtA_5_2">48,758,951</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_nqEnFNcXVUSFrUGRoV0Jlg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Bk8-26WK60Oni4v8n2WXow_5_5">5</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vgNcL3n5HUes97GAN6fT0Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_l4MvERyWZUil1lWXk-I_Cw_5_8">652,464</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_BoilOwqVH0CvgLnHZM0KIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_d5q3yhay7U-aTQmCDu2O0w_5_11">29</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nMeFIR_iT0a90Nmvw6wHEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_w76B66l9dE6o9FOYRsqyOA_5_14">416,278</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_5oKjW0rqukafCqmo8AsJDA_5_17">236,162</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Cumulative effect adjustment for adoption of new accounting guidance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rKm1TiBfs0S-9aWTsi7EdQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" scale="3" id="Tc__Dw0-o6txE633pTwWQPHkQ_6_14">803</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_3_31_2019_lev25mtbBUGfkyljGiogTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" scale="3" id="Tc_CFsWrdt5F0CFkQbg-EtWvw_6_17">803</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Exercise of stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BKKnagJhZUiQ6JZnEBvRvg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_fMq7buNrxkipd9dfTsH0rA_7_2">146,171</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VR9IQo6tqkWK5mvhHDkVjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_KiUMja_xPUetPknd1E4aPQ_7_8">1,533</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_3_31_2019_g469-FKLDES3WXIXPTgVBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_QBwWtwethUu3ddNOaXwkkw_7_17">1,533</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Vesting of restricted common stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BKKnagJhZUiQ6JZnEBvRvg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="Tc_2olRNQ23rUaY2-rGPsZFGA_8_2">18,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Stock-based compensation expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VR9IQo6tqkWK5mvhHDkVjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_YaDsZT-MOU2zUYZ_6k1KSw_9_8">7,855</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_3_31_2019_g469-FKLDES3WXIXPTgVBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_54xexqDLWkyZGQ-g5zdx4w_9_17">7,855</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Unrealized gain on marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_w2MduKaWh0K0KsF7xNNuCQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc_-VMKqsKjHkKD1ELA7B8nAQ_10_11">58</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_3_31_2019_g469-FKLDES3WXIXPTgVBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc_HotVK6Ihpk-Xf1vyoVWc_Q_10_17">58</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_GigIkbq07E-4a5thn7D8wg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_7CxxqS1kzUWJOHl2H6Nfew_11_14">29,249</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_3_31_2019_g469-FKLDES3WXIXPTgVBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_cFNL_krYPUyYvsVdmX7kZg_11_17">29,249</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Balance at March&#160;31,&#160;2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_h9POT0cgJEyb9tv7R3bH6g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_9YvVeiVDc0yz7x0bh5-gUw_12_2">48,923,122</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_h9POT0cgJEyb9tv7R3bH6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ZMyVJICMTE-U7GALp0maEA_12_5">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nEEqv36RBUWlQnEYMf__yQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_q8xNow-uU06Wg42fy65rIA_12_8">661,852</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2P57q7rCIUifNMWJ6Qp70Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_u2tcx_sDX0iNiTHEwK6QGg_12_11">29</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rKm1TiBfs0S-9aWTsi7EdQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_fB2oL9aLDEijviLEOtA6mQ_12_14">444,724</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_3_31_2019_lev25mtbBUGfkyljGiogTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_e0XAEpe_6EaL4tNLNjKtBA_12_17">217,162</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Exercise of stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UKNKz4e0eEu5S7yXBgg4mg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_EQtvdUOqGkSyGnp2pxkWig_13_2">277,259</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_hscTLrz67Emlv2qjXnQvGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_OWvcsG6g6kiify7BWj2j7Q_13_8">2,894</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_4_1_2019_To_6_30_2019_-E0JkxGkvUqIxq8-rSrd2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_Imh8qSubOkGHT2sAA9kDtQ_13_17">2,894</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Vesting of restricted common stock units and awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UKNKz4e0eEu5S7yXBgg4mg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="Tc_jl3P1h92sk6LLX2DvL0G1w_14_2">24,486</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Purchase of common stock under benefit plan</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UKNKz4e0eEu5S7yXBgg4mg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" scale="0" id="Tc_abHfaIZLI0Wgn4JWCMHWJg_15_2">16,226</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_hscTLrz67Emlv2qjXnQvGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_I9vvBh4_40WGCuMRfz4JLg_15_8">283</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_4_1_2019_To_6_30_2019_-E0JkxGkvUqIxq8-rSrd2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_B-NPKSRoE02viPPlwxz_aw_15_17">283</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Stock-based compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_hscTLrz67Emlv2qjXnQvGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_VcS_2Rok4kWYiggtOXlLGA_16_8">6,493</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_4_1_2019_To_6_30_2019_-E0JkxGkvUqIxq8-rSrd2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_wQ8-tnJhgUu1Yu44rVB1VA_16_17">6,493</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Unrealized gain on marketable securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_66x9bELQuEiMrFfDAUufxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc_ZFrswRcWQ0yJ_4PWY9df4g_17_11">16</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_4_1_2019_To_6_30_2019_-E0JkxGkvUqIxq8-rSrd2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc_MDN9133OQES9zbxMT1ldKQ_17_17">16</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_H2z2rvDZXkOkv51mcbXxgw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_uDq6ZRjp9E2htOrm0yEw3w_18_14">33,786</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_4_1_2019_To_6_30_2019_-E0JkxGkvUqIxq8-rSrd2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_df6nChkbME6o2fymSMrrwQ_18_17">33,786</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TUxeAzXexUCs6hW2FNI9iA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_O6CxX8uD-0icJ5AkZlpvqQ_19_2">49,241,093</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TUxeAzXexUCs6hW2FNI9iA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Id4VTkiGL0iDXdOrl9dX1w_19_5">5</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OpvknL2x3ESG-o3hybcgdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_X_WTwvrgBkqmxiGy1RTmkg_19_8">671,522</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_UQYMfrodxUe3emORrxVIsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_rPQh7CmUr0i2C8eDXmIhyA_19_11">45</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CLnS6hMVNk2ckOkEXszSCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_SZbmrnOJcUeYJaj6xbYOTg_19_14">478,510</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_6_30_2019_2G5oRVxKzkqQpy_gyikO0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_dA7zYFNEeUK05Nj5v2sDXA_19_17">193,062</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_f703YUdgg0ypJsTTIsOBXA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_vvgKIBx29kymh8lYNIkoxw_20_2">78,804</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EmQrsfCBQUC6f66ZGe1HZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_ZQYQdmkBqEWB-Ok4msKD_A_20_8">1,329</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_4OOA9JZr_UK_Eup8p2Mwgg_20_17">1,329</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Vesting of restricted common stock units and awards</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_f703YUdgg0ypJsTTIsOBXA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="Tc_JDy-b_R4y0myhk34YdFQyA_21_2">34,566</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Stock-based compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EmQrsfCBQUC6f66ZGe1HZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_krd3FV_VcE29-aWt6cNtZA_22_8">6,559</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_sNjEt6EoEka9Xkqycga1qA_22_17">6,559</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Issuance of common stock from public offering, net of issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_7zcER-83lEe2S7gZNEWllQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_qsWevZuRR0uN5N6t2U57jg">0.1</ix:nonFraction> million</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_f703YUdgg0ypJsTTIsOBXA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_N0vZ9lDOdESb_0UOsFzZxQ_23_2">1,721,735</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EmQrsfCBQUC6f66ZGe1HZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_mComzcCR8UaVi_iZGzLJ-A_23_8">41,987</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_sVPXNxOWPUiMoOeV1oyvSQ_23_17">41,987</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Unrealized loss on marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ezqBpnSOV0CfZMYTrjUW-w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_-MhAiKiIhEKNfJCKiekkmw_24_11">6</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_uXQ_bhIKIEmhlnMOcv5lbg_24_17">6</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_glvMcDSGgEK7XZEP1zULNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_eBG5vWZ6-keCUwICrI8dQg_25_14">32,941</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_3Sn29t9NpUGDxwIW2HKRvg_25_17">32,941</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:37.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Balance at September&#160;30,&#160;2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-tPNp-KA0UuSArvAtBVJpA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_qmk7dZc2EEiFIpavDmTGDg_26_2">51,076,198</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-tPNp-KA0UuSArvAtBVJpA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_a56N3zuQnUGlB-yVxywsSQ_26_5">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8SsTB3T8jEeFeLgDK5Xq4Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_uOBx0WskiEO9B8tbkymQpw_26_8">721,397</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_QDEnyWCKbE-v_F_kksLS2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_nc82If56CkGnUUyo7WG_gg_26_11">39</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ro8GtWifX0-HMTWgk5pKjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_peTSap7NDU-V-ne794_JJg_26_14">511,451</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_2qjJxm1aTUajDdnmNNVvUw_26_17">209,990</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">The accompanying notes are an integral part of the condensed consolidated financial statements.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Editas Medicine,&#160;Inc.</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Stockholders&#8217; Equity</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(amounts in thousands, except share data)</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_87aa4f24_d1ea_4277_a61a_2ff5d08837fe"></a><a id="Tc_2GTpyvU1MUqDk1LbkMJsYg_1_10"></a><a id="Tc_1AVydY6ggUav_nxBqfGKiQ_2_7"></a><a id="Tc_fl8j292rRUKphBQRpaif9w_2_10"></a><a id="Tc_W3JV8nFX6EixJHdLXoJILw_2_13"></a><a id="Tc_hCaCIB4AXU6jVgsjmej1yg_2_16"></a><a id="Tc_6o8DUQehAESUsHHm1sgcig_3_2"></a><a id="Tc_H1CjXalQg0KJNHwj7cZ_JQ_3_7"></a><a id="Tc_r6jJG-iqmkuLpxDvj4niiw_3_10"></a><a id="Tc_HanIAfbTWEu4EWbRQ1pWAA_3_13"></a><a id="Tc_BDwSwlwCYUeMyORQKM7o-w_3_16"></a><a id="Tc_sPiDlRcaCEmvHGCtRkHCFg_4_2"></a><a id="Tc_Z725KtOK7UKNH3DvNQM8lw_4_4"></a><a id="Tc_7oBwD-7_9k6klxPyv5Kr5A_4_7"></a><a id="Tc_HsADIo49nE6eZAcuzd4H2A_4_10"></a><a id="Tc_nMwweWbXqkO9Vy44G29cOA_4_13"></a><a id="Tc_ZX-ulaTaQE2baVON7z4tEw_4_16"></a><a id="Tc_8DMDStqMXEWa51Zy00HK_Q_5_0"></a><a id="Tc_DmYc0vy-tk21ypo8ciO1Zw_5_4"></a><a id="Tc_f-JVaYgpYkips1jwPbllAA_5_7"></a><a id="Tc_3NdtSdFBO0ab1c0rCcuzWA_5_10"></a><a id="Tc_76DdUV-Mg0WUIPpdCaC2hA_5_13"></a><a id="Tc__LRIINIOsUmtsbcT8jL9Ag_5_16"></a><a id="Tc_eMa0iF-l10SG36Iwcmpt8g_6_0"></a><a id="Tc_15RizX422EqErepVAQWtpQ_6_2"></a><a id="Tc_tMIoupJulUuMr90FGTDANQ_6_5"></a><a id="Tc_1N6i8SYEZ0qBz1y0j76KWg_6_8"></a><a id="Tc_y1Avats56UOV6jjmGPWAYw_6_11"></a><a id="Tc_cmps33BoUEOhQPA85zDxgg_7_0"></a><a id="Tc_j4GlMFSnAU2AuC-EGgnefg_7_5"></a><a id="Tc_Zs2xtmHKP0y19LsaqCnCTw_7_11"></a><a id="Tc_nR7t2BanekGRyrK1uRe8pg_7_14"></a><a id="Tc_70vcDBcSoUeCFX0BJSXtIQ_8_0"></a><a id="Tc_20WkY7HqE0WZd8oq1fyi1Q_8_5"></a><a id="Tc_araobLHUjUOAFJzOggTm5Q_8_11"></a><a id="Tc_PhYnomnaWU65NZ9-uhYAeA_8_14"></a><a id="Tc_I-5adFstokipJuA2rPi3_Q_9_0"></a><a id="Tc_EMIeRJi6PkCByjx9d0FOmg_9_5"></a><a id="Tc_lWrr0eVlHESeF3tRK3IMdQ_9_11"></a><a id="Tc_gon9kr5m6U--pmX3Z8NJ_g_9_14"></a><a id="Tc_NGkUVtk3w0i6StdxuNXDzg_10_0"></a><a id="Tc_QjVcDPCXDkGRW-ddDCVEVQ_10_5"></a><a id="Tc_fyMLO6nGRkajurcdQHRCPg_10_11"></a><a id="Tc_7Y5KY-7jXkmQpQF7RzFAEg_10_14"></a><a id="Tc_amG4HTA7I0afsuorcB7Eew_11_0"></a><a id="Tc_qmH23Cv620WvBPVCMkjikg_11_5"></a><a id="Tc_KwNqTCTovEyI-u5f0509sQ_11_8"></a><a id="Tc_upmqJj0dXUOhLvebewgikQ_11_11"></a><a id="Tc_gAv9AiZP4U6S8S3eXm4PRw_11_14"></a><a id="Tc_wtCOe1RJ4kOCpyLFjcG6Og_11_17"></a><a id="Tc__yOs9YFxcEav1AL8muVIyw_12_0"></a><a id="Tc_tNMLRTTR-E-bR0Nn3U7k2g_12_2"></a><a id="Tc_72Xkfy4sDEqAVOFiCDCtQw_12_5"></a><a id="Tc_hxttc51rvkOxbpdHpQtS8Q_12_11"></a><a id="Tc_tne2GqZpx0ixBRADtMv8FA_12_14"></a><a id="Tc_KB3pOqiT6U2RpzcWbzc5Dw_13_0"></a><a id="Tc_94QYaAHJtkCNKVdT7cNCcg_13_2"></a><a id="Tc_Ad8ykm6yv0WwVedLx5Z7qQ_13_5"></a><a id="Tc_RTmB4DQlNk2MUSymr40McA_13_8"></a><a id="Tc_cNTx3lhD6UqSnuzWcf5q1w_13_14"></a><a id="Tc_XR1FPq4YIkOSq9TQ67Tt2Q_14_0"></a><a id="Tc_Q5cW27dapEa_OBG-jzOaQw_14_2"></a><a id="Tc_4YVG5T-GAEG8Ed7AyQ2apA_14_5"></a><a id="Tc_001FNgxVfU-XF6SMtZUvnA_14_8"></a><a id="Tc_YpjmchpM1U6dyRA1zq10sg_14_11"></a><a id="Tc_lfLe0_WlNk2xg-56U6q0vQ_15_0"></a><a id="Tc_qrrgi1Z6vUi1OkQzW4Di0w_15_4"></a><a id="Tc_ATug6cgFKU2-chry1bkB3A_15_7"></a><a id="Tc_iy_jAS_g_EOOJ_F1aYIbYA_15_10"></a><a id="Tc_Lpnrya9s_Eqk3Z6--aO62A_15_13"></a><a id="Tc_n-W8JA4pnEe0cPhF0JlCdg_15_16"></a><a id="Tc_tOUQQgkIR0KzCMxvUBZRvg_16_0"></a><a id="Tc_yzLoWXzjy0yo97xM9WIXwg_16_11"></a><a id="Tc_lSPUGyAYT0SQlRJM9HvjHw_16_14"></a><a id="Tc_135L2qcl2U27dFeSWvgavQ_17_0"></a><a id="Tc_qqQk3z0p40CRjZS-w-FeNA_17_5"></a><a id="Tc_yLctzxJA_UqrKIa-9EuDXw_17_11"></a><a id="Tc_RX48HmBKdE-hyqiWoFw8Ew_17_14"></a><a id="Tc_umJXLMeYsECzDjCUuURz7g_18_0"></a><a id="Tc_TxR2Yo2PvkW4iml1SGP6bg_18_5"></a><a id="Tc_hdbd-_G-KEuzh2YPk7f3Jw_18_8"></a><a id="Tc_r1qJr9QXVk2XdHiPHAtM2w_18_11"></a><a id="Tc_abIUwrwYYUSp0Cs51sFj3w_18_14"></a><a id="Tc_nrlgk8NmC0OjvoBHikyVOw_18_17"></a><a id="Tc_td73hQtTrkKJZzB4lpiQUw_19_0"></a><a id="Tc_luynQu6XkU2O_8Jsq-P1mg_19_5"></a><a id="Tc_ewKhuJUJQEe3GSoi8Say9A_19_11"></a><a id="Tc_EaI0JumGS0yaiPsOFDgpqA_19_14"></a><a id="Tc_PmxqCLGfHUKqff8okoInVw_20_0"></a><a id="Tc_8_d1_45Qr0OnlOxzw1rtwA_20_2"></a><a id="Tc_Ici35WfpvEWRMmVYA4CKKA_20_5"></a><a id="Tc_VIYZODYPm0qEjSeBc2SK8A_20_11"></a><a id="Tc_hxr64-nhC02zI0JXlz5nvA_20_14"></a><a id="Tc_3-iSdwqHG0KiV94o9SaPiw_21_0"></a><a id="Tc_mw2GGYIOxEyD9ljc-3q9_Q_21_2"></a><a id="Tc_c1SbRmZ7SESfcv4FreVM_A_21_5"></a><a id="Tc_LhuXAwxYMkm7oKMSBxDw_w_21_8"></a><a id="Tc_USEn5UjvfkSsrD60HfJa0Q_21_14"></a><a id="Tc_mhD6A8qYP0ybVCz7AHOCrg_22_0"></a><a id="Tc_Holk95L5FkSdL5kAmMuAew_22_2"></a><a id="Tc_1H07MNIj0kq6mNDKlXrguA_22_5"></a><a id="Tc_0vpEBA3dGkqfa5ChFaiByA_22_8"></a><a id="Tc_gkrxR_svhUCrv8EpfverOQ_22_11"></a><a id="Tc_JFnwpcb7i0q-mDbmfHDiFw_23_0"></a><a id="Tc_zasH-aIjfUeT1uOtqHAjSA_23_4"></a><a id="Tc_6mqr7kRKH0W6C_kLIfKjTg_23_7"></a><a id="Tc_R7u7bgz9dUuVxpSBO7auWQ_23_10"></a><a id="Tc_0-i9X9m3AUK9hd3M5GqmGA_23_13"></a><a id="Tc_evo6P92v-kG3sx4-lXY-1Q_23_16"></a><a id="Tc_3RRGK8IkHUukqDHJ_C3CLA_24_0"></a><a id="Tc_WpS7VVumEEqIjWA_gNLAKg_24_5"></a><a id="Tc_1tsi6skIiUGIyV-O3D9T6w_24_11"></a><a id="Tc_cOeghUCNnUOzSIFS1kosbQ_24_14"></a><a id="Tc_hxYkHpBwDUCEbdy0foQOag_25_0"></a><a id="Tc__uVaNPyNWE6eyBpyl4LZVw_25_5"></a><a id="Tc_8ozuLqH3Wk2kyFuAQJPHIg_25_8"></a><a id="Tc_ZaR-QeXJj0ykXmFusp63Hg_25_11"></a><a id="Tc_KhyvF9fZKkSnejxGy4YPXw_25_14"></a><a id="Tc_zH_NG_GPikK8BdnfGimTTw_25_17"></a><a id="Tc_Eklwm6Pos0C-mNW1oKbTsg_26_0"></a><a id="Tc_JodqL1c9nEeA0cOvU7X6gA_26_2"></a><a id="Tc_tj3JMUPK3kKZz3gDvXgTdw_26_5"></a><a id="Tc_Ja9p8v_ByUGf3QoDhFVLnw_26_11"></a><a id="Tc_7etDyIpilEq_GD4kgw4d2A_26_14"></a><a id="Tc_Ssy4Y1xzJ0mG1P7dlWadcQ_27_0"></a><a id="Tc_Y7Bg3WMgp0u3ATt6exC7OA_27_2"></a><a id="Tc_QqYQrGhHK0yZPAEy52SgNA_27_5"></a><a id="Tc_OhVEYBtgjUm6u5Y93xJ9Pw_27_8"></a><a id="Tc_Y7EK62SMckSfrP5XhoeLQQ_27_14"></a><a id="Tc_Mql5Vlozw0-2KuqnDLTDQA_28_0"></a><a id="Tc_3JCItQFgdki9kYo5l4ymAg_28_2"></a><a id="Tc_bXi0Ryy9Ekit8KFJHxUibw_28_5"></a><a id="Tc_vx1H0DH72k2WVwxzoIFKqw_28_8"></a><a id="Tc_uAclt_Rhu0yHJjYilZsRgA_28_11"></a><a id="Tc_9qZkbf2RW0WXYI_VR1KzWg_29_0"></a><a id="Tc_FiZVaIOtrUO8_jpIR_K00A_29_4"></a><a id="Tc_hx5IXDofYEy7bI3iColZZg_29_7"></a><a id="Tc_qolsdHP4eECf4YZ_cTcJ5w_29_10"></a><a id="Tc_7wnqA3nrMk6Wf3fQAb1aFg_29_13"></a><a id="Tc_c6EqIQSa1UWp1v3BCDZO1w_29_16"></a><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:102.25%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:36.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:36.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:36.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Comprehensive</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:36.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:5.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Loss) Income</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2017</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GwYJtLes4kK1jip8o4AlWw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_4NaYqr8sNkaqPftnLpEmHA_5_2">44,507,960</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GwYJtLes4kK1jip8o4AlWw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_rbBlXspEPUqDpiKx9Vtpzw_5_5">4</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JikrGEaYFEypNiwSuiHOuQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_-ASGUtGJjUm9ZqsHIGNMww_5_8">514,002</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_r16dcPMx-kOPqovKKF9rIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_Gtr1HJHBi0S0UxgClrbYbg_5_11">76</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9kN0cK_j1U-lUz16kqWtFQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_l0rl0B5FMEu9DKXS9Mw9CQ_5_14">305,850</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2017_senIwq2LvEuADH5a682MHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ss9H0sqQeEGGlFaRm3QHuA_5_17">208,080</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Cumulative effect adjustment for adoption of new accounting guidance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9iZLSKC4mUiK1QS-diuQfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" sign="-" scale="3" id="Tc_MRao8O2lbkiffO0r5NRbUQ_6_14">474</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_3_31_2018_PRyW2BO7NEavIwfH50AVbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" sign="-" scale="3" id="Tc_owaFKjSud0iV0MxPQb6ulw_6_17">474</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Issuance of common stock from public offering, net of issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_3_knFgtCBkGl58HqlEgFpQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_Dr1oho5nUkKPMg0JZFQrHw">0.1</ix:nonFraction> million</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__7w520kExUi4RwvUKsrFcQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_B_pDlMwGCkePbx-JzFssww_7_2">1,429,205</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KQblBVk_v0SKWAMPvbYtyQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_PK_exSNsj0-KJQXt4MwUAA_7_8">48,493</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_3_31_2018_BPXZh5LFWk-0JSgUuxyu1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_EgmnmXV2wUu5MqcKfr6NNA_7_17">48,493</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Issuance of common stock for repayment of notes payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__7w520kExUi4RwvUKsrFcQ" decimals="INF" format="ixt:numdotdecimal" name="edit:StockIssuedDuringPeriodSharesRepaymentOfDebt" scale="0" id="Tc_xsgoB8k7eUWVDhdexWP2cA_8_2">305,909</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KQblBVk_v0SKWAMPvbYtyQ" decimals="-3" format="ixt:numdotdecimal" name="edit:StockIssuedDuringPeriodValueRepaymentOfNotes" scale="3" id="Tc_zDmlzvpgtEy8wLewGcN8sg_8_8">9,530</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_3_31_2018_BPXZh5LFWk-0JSgUuxyu1Q" decimals="-3" format="ixt:numdotdecimal" name="edit:StockIssuedDuringPeriodValueRepaymentOfNotes" scale="3" id="Tc_pT6Uh_AJIkKTeVw2NMtPWw_8_17">9,530</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Issuance of common stock for asset purchase agreement</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__7w520kExUi4RwvUKsrFcQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" scale="0" id="Tc_NksQ430hxE6J7ksMQYHA6w_9_2">56,099</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KQblBVk_v0SKWAMPvbYtyQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" scale="3" id="Tc_p40kAUP2vk-FWIfISBKKCw_9_8">1,942</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_3_31_2018_BPXZh5LFWk-0JSgUuxyu1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" scale="3" id="Tc_GxEvNJBm9UmNBUYhUnyhQg_9_17">1,942</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__7w520kExUi4RwvUKsrFcQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_Gdof2Yf3a0C1DKpo5o_2cw_10_2">305,408</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KQblBVk_v0SKWAMPvbYtyQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_jrxxf5rRiEWvZXgvQYQhIA_10_8">4,328</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_3_31_2018_BPXZh5LFWk-0JSgUuxyu1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_Xyb7pIlKj0yFgGAB6GroZw_10_17">4,328</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Vesting of restricted common stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__7w520kExUi4RwvUKsrFcQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="Tc_KyWDefMaLUeD1wuTiR7LzQ_11_2">107,114</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KQblBVk_v0SKWAMPvbYtyQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_NOhYf47JjUOSHDYluyTDog_12_8">6,530</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_3_31_2018_BPXZh5LFWk-0JSgUuxyu1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_ROl7himTLE27688v7kessQ_12_17">6,530</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:36.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Unrealized gain on marketable securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Wtxux8gUD0CRzeyMEreftQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc_8QlIOQbc-kmGisjOgnvQMQ_13_11">24</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_3_31_2018_BPXZh5LFWk-0JSgUuxyu1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc_q3KA8eCSp0y5LrMNetnhhA_13_17">24</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PcyLV57phkSeAKHvNp6DsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_QLJmaBTvjkWGChzRKb0DUA_14_14">30,939</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_3_31_2018_BPXZh5LFWk-0JSgUuxyu1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Xo1qdgcRgU-gFda3NjSioA_14_17">30,939</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Balance at March&#160;31,&#160;2018</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="As_Of_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_i8q1DkQ_KUOWY2XOlmooKQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_7Iy_o9Ot_kKGhT5aiBh-ow_15_2">46,711,695</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_i8q1DkQ_KUOWY2XOlmooKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ImskcNZqu0WnlaUuf8pGVw_15_5">4</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KeqS4HNt1kuKQRTSA9H2zg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_xkK95YnU7E-D55AQ2bOOBw_15_8">584,825</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_B_Z2yUNGJ0K-xnVe_pA-9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_KNNiST4s1UaFoaZSonNxTA_15_11">52</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9iZLSKC4mUiK1QS-diuQfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_Be1y2oE0TU6U_MqoB3yYzA_15_14">337,263</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_3_31_2018_PRyW2BO7NEavIwfH50AVbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_yTW-z9ygbEKr0ZiDKtI8eg_15_17">247,514</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Issuance of common stock for repayment of notes payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_4_1_2018_To_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rB_fSol7XE2Vj1rue5g-gQ" decimals="INF" format="ixt:numdotdecimal" name="edit:StockIssuedDuringPeriodSharesRepaymentOfDebt" scale="0" id="Tc_eOy3jAso6UerkKBePQMPVA_16_2">330,617</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_4_1_2018_To_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rB_fSol7XE2Vj1rue5g-gQ" decimals="-3" format="ixt:numdotdecimal" name="edit:StockIssuedDuringPeriodValueRepaymentOfNotes" scale="3" id="Tc_qDxtaAY5zUSrj0EDmb0mGQ_16_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_4_1_2018_To_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bUbGp4Vam0KtxOlIe1z2Ow" decimals="-3" format="ixt:numdotdecimal" name="edit:StockIssuedDuringPeriodValueRepaymentOfNotes" scale="3" id="Tc_wiBTTFVhLUGPKt7nCzqJGg_16_8">12,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_4_1_2018_To_6_30_2018_k2bzYrObrkCCSC2SDouEQw" decimals="-3" format="ixt:numdotdecimal" name="edit:StockIssuedDuringPeriodValueRepaymentOfNotes" scale="3" id="Tc_5JSGQ5BLu0yebuzY6_V1tg_16_17">12,501</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Exercise of stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_4_1_2018_To_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rB_fSol7XE2Vj1rue5g-gQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_J25Zwiwxgki39j4NS_VTsA_17_2">192,687</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_4_1_2018_To_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bUbGp4Vam0KtxOlIe1z2Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_dN19MudOr0SAQE1or6zjjw_17_8">2,597</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_4_1_2018_To_6_30_2018_k2bzYrObrkCCSC2SDouEQw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_P2cUfHkSQUKzYssIvdcHAA_17_17">2,597</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Vesting of restricted common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_4_1_2018_To_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rB_fSol7XE2Vj1rue5g-gQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="Tc_xo2J7JE0206bBLKveFX7cg_18_2">103,481</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Purchase of common stock under benefit plan</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_4_1_2018_To_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rB_fSol7XE2Vj1rue5g-gQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" scale="0" id="Tc_Bm-_uVSG5UKlPZvdOOyj0w_19_2">14,273</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_4_1_2018_To_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bUbGp4Vam0KtxOlIe1z2Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_xzxrHqA3NEqfm77HaszUWw_19_8">362</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_4_1_2018_To_6_30_2018_k2bzYrObrkCCSC2SDouEQw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_KUi6eSc7eket0cZY-q5Pdg_19_17">362</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_4_1_2018_To_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bUbGp4Vam0KtxOlIe1z2Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_ciFDar3bDUaBfpHeu2KA_Q_20_8">7,026</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_4_1_2018_To_6_30_2018_k2bzYrObrkCCSC2SDouEQw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_PtYDTikQY0KdpAfm6nx4MQ_20_17">7,026</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Unrealized gain on marketable securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_4_1_2018_To_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_xxLzL0DPwky5SLbxx4KehQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc_Aw5E-1zSFUGL4Nab0UIn2w_21_11">53</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_4_1_2018_To_6_30_2018_k2bzYrObrkCCSC2SDouEQw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="Tc_eKwelPf9SEOyScFtfQj9Rg_21_17">53</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_4_1_2018_To_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_67JgMcg-AU-r8nQZpiGRBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_z-1YxTyZtUS3JXJRSw0JtQ_22_14">38,723</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_4_1_2018_To_6_30_2018_k2bzYrObrkCCSC2SDouEQw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_O6n38RjneU-AVmjKGTQivQ_22_17">38,723</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2018</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="As_Of_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7H2GbZDTB0WB00Z3wAbzxA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_vAcElrDXDkWdoGvxph-OOg_23_2">47,352,753</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7H2GbZDTB0WB00Z3wAbzxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_yYkb7n39kU6pyTaRJLzT5A_23_5">5</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bKV0YxMVaESgorD_NKUdmA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_yWYJVx-Ty0izLTmwvZvEUA_23_8">607,310</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_45_zEcvCkkiGkk1UjUVA3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_mdgg4KdTR0-4tpiO_blNOQ_23_11">1</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NnhClH-fjkiCwW8cwRH_Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_wu-hjRaiLUehUm7CXPE82g_23_14">375,986</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_6_30_2018_k2-PAGdm9k2xoicTgC3nXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_RpT36JpciESjV4dqQrZrIQ_23_17">231,330</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_7_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YQeK5YPDZE6CK0bMIfhrGA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_kcz_ffqlsUu3GFu1ImxkOw_24_2">132,856</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_U69fKqLuvUeTW_gO2s8dmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_zek4b--TikytVNMk09PPFQ_24_8">1,739</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_3gTZUNiBB0y2w37XneD3UQ_24_17">1,739</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Vesting of restricted common stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_7_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YQeK5YPDZE6CK0bMIfhrGA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="Tc_3BQHLnmOg06P-52xLHAkfA_25_2">18,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:36.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_U69fKqLuvUeTW_gO2s8dmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_a_FaS9c1ekOTT1DUMuY5dA_26_8">6,699</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_eumgKdTNsEu71I6ZvbXiWQ_26_17">6,699</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:36.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Unrealized (loss) on marketable securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_kZBghsf38ECtgyS7q_eESQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_gYBmqvSZ-kuvI21iRpCuEA_27_11">83</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_dmbfQuTpMEOZmgcCU2AqrA_27_17">83</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:36.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_SlLFJ70IdkulefAZvOR4-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_C-llumSAH0ezsnkEjWgNZA_28_14">15,238</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_YX1DGZP3zkKqgCu22ncxjg_28_17">15,238</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:36.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Balance at September&#160;30,&#160;2018</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LwBc87JgzUC7Dp8J7KafdA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_XUS1m4FrOk-sYxAlEwPUrQ_29_2">47,503,609</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LwBc87JgzUC7Dp8J7KafdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc__oLR9SgY10SVgvY-JP0duA_29_5">5</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CFIibCPWyUS3wh08WaAL2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_QvjreW4TukSLMqDbunvYDQ_29_8">615,748</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Al0rqf8nLUSh7WEbnbdGzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_k2eBpoe0qUa8yvo1vFctyw_29_11">82</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wisiSvmZ8E-68zg_-iKPEA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_GROiG7EfTEix7zEcM7ioBQ_29_14">391,224</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2018_Uh3BMLH9xEeftU-M2ZH8Ug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_-AFRV6R3zkGBRgrg2IjJ8g_29_17">224,447</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">The accompanying notes are an integral part of the condensed consolidated financial statements.</p><a id="_15931c8e_eb11_4502_a2dd_4cfe7370412d"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Editas Medicine,&#160;Inc.</b></p><a id="ConsolidatedStatementsofCashFlows_280444"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Cash Flows</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(amounts in thousands)</b></p><a id="_3806a431_3d14_4155_8c83_743a581de077"></a><a id="Tc_GVZAp9wSDEaFhFr3skqhcg_1_2"></a><a id="Tc_3xTtLJnOOUyhu9hqMHNmog_2_2"></a><a id="Tc_qpZKle1j70aOO6dEAvFmkA_3_2"></a><a id="Tc_0xUaKjG2wES_wOYVGNnRgQ_3_5"></a><a id="Tc_wgILLyVpkkqKJI3xfROdlA_4_0"></a><a id="Tc_el9_RgYMIE2MSarYEGL4QQ_5_0"></a><a id="Tc_kgApbozCgEKvMmXI3bnlJQ_5_2"></a><a id="Tc_UfEInLSAz0SbDZnUIRYIwQ_5_5"></a><a id="Tc_SXaFPQJeKkmErNV1CDbEZQ_6_0"></a><a id="Tc_NEnCJyFs_ESxtIgbt0hntw_7_0"></a><a id="Tc_byex1TQiYkGATBSrlv-ayw_8_0"></a><a id="Tc_ZsSVimJjb02buY2UGh5STQ_9_0"></a><a id="Tc_UcbkmYgYfE6myKr0zPbj8g_9_3"></a><a id="Tc_iBiIy-dbWEOm9iCMsNtIyA_10_0"></a><a id="Tc_F6RVkOLAHkW1e3ToDsGBxg_10_3"></a><a id="Tc_sQf4Eox_mU6tl3KDqHRzAg_11_0"></a><a id="Tc_Py7dHXkgokKYUrCb-4kQuw_12_0"></a><a id="Tc_Y_MMrWuANki4IQ7t1Q4WBg_13_0"></a><a id="Tc_g4O5fAKMwEiUT9y66w63iw_14_0"></a><a id="Tc_020SdbuSpEikju_2iQNAFA_15_0"></a><a id="Tc_vHRs0zYgqUeldV32AP4_0Q_15_6"></a><a id="Tc_Nalqt-g66UOy2uHv-c3f9Q_16_0"></a><a id="Tc_1NAHVCfhhUyTajVHUlvDAA_17_0"></a><a id="Tc_maIKzjRJXkKgLXeq-Fpf8Q_18_0"></a><a id="Tc_L1mEBj7_wkqHooh8_uXAFg_19_0"></a><a id="Tc_blFKCmrNQUa6XPvfAvYOmg_20_0"></a><a id="Tc_Vy0O0RWip0uenrB1uODYqA_20_6"></a><a id="Tc_QyhJNIOdOUCq8aJgl6Ev4A_21_0"></a><a id="Tc_PVP7Ynl4DEagX2TvFO_RQQ_21_6"></a><a id="Tc_KWdGShHRh0q--XHw1qlvCA_22_0"></a><a id="Tc_g19Fd6-jI0uVD5xDpGAvqQ_23_0"></a><a id="Tc_ck3vVy_yX0awAoRzGOIBOw_24_0"></a><a id="Tc_i0Y3DW48dkuNuly_PHaDrQ_25_0"></a><a id="Tc_shKyeqgo5kG60bmgnxR34g_26_0"></a><a id="Tc_S45T-nKSGkG1P2puX92Crg_27_0"></a><a id="Tc_QRMaC2LuC067TgzEW1qRGw_28_0"></a><a id="Tc_ZHLDwVbmvEqdtrPBfSKDkQ_29_0"></a><a id="Tc_OkAGkRfWs0WfLpkr0oE2VQ_30_0"></a><a id="Tc_e08SWk3bMUWaEAEzOAZOhw_31_0"></a><a id="Tc_Bq2S_x34F0SEl1EU5A0BRw_32_0"></a><a id="Tc_RCtchKIunUSN1XTtS_zFLw_33_0"></a><a id="Tc_K-MblLd4uUGKJaykIim0HA_33_3"></a><a id="Tc_2QdqwGK2ZEu3q-2VyGGBVg_34_0"></a><a id="Tc_prLYW5gz_EGWEHtGUSXxOg_35_0"></a><a id="Tc_FXsjAQJBVkGIfoA-uaqVoQ_36_0"></a><a id="Tc_kuDnUqJtj0ibSn-kfxabRA_37_0"></a><a id="Tc_Ruljr3hOnUCH2UToXLGS-w_37_2"></a><a id="Tc_c9ZRqA0GQku-1Cqde-bNng_37_5"></a><a id="Tc_u3Mx1Lctg0al65YDP_WOxQ_38_0"></a><a id="Tc_axjx1QdpWEaNAYMTs1j1DA_39_0"></a><a id="Tc_nfPYpW5zyUS9JVJb7axwlA_39_2"></a><a id="Tc_rLUxcSfFWEW1rplkSjU4XQ_39_5"></a><a id="Tc_EdQc2mdfKkKnbosV_p8uFA_40_0"></a><a id="Tc_xsy26hGh_0u96s3SGa1DKQ_40_6"></a><a id="Tc_2h-zH_DlSECgee8JzjQHbw_41_0"></a><a id="Tc_d1pXadNq50aUnRlPhJiXhw_41_6"></a><a id="Tc_pyYVuLswCkqq7BkYmrxBiw_42_0"></a><a id="Tc_e8CfCYQ9AUWW0PQj4VsWcQ_42_6"></a><a id="Tc_zUhkeNr7WEGpVqQbl4XuUw_43_0"></a><a id="Tc_w9epHtFowk22Bg4T_hGNxQ_43_3"></a><a id="Tc_QRCtVeLY7E-SU7ttnQWJmQ_44_0"></a><a id="Tc_Hf8jy5hTH0a2b3CmqWce_g_44_3"></a><a id="Tc_zdCtXqZZrk66ExGb6CT7uw_45_0"></a><a id="Tc_P-iCeOBnNUCIWeg0FUvKDQ_45_3"></a><a id="Tc_2Fjm1tTq3keYo2jDKzunzA_46_0"></a><a id="Tc_I1digCQShUCM1i6BGJaNzw_46_3"></a><a id="Tc_wohTI2Q5tUKH5MTCiJTRow_47_0"></a><a id="Tc_RoO0hlEsJUKywihHB4vA0g_47_3"></a><a id="Tc_jY1R2j3oEkaQpepiZBqk-Q_48_0"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:22.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:22.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Cash flow from operating activities</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_tXR1DpScwk6agprEnTbCcw_5_3">95,976</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_YuvzZbnpuEOOZhQmvTitPg_5_6">84,899</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_biJY8Nz1L0Oa__zmMtx_zg_7_3">20,907</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_o4CdEW97REmIGPKH_JCpEQ_7_6">20,251</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Depreciation </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_ayKxYeQjeEqth6bShT43Hw_8_3">2,048</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_0otFrEgLfkmXVyyz8Q0TOA_8_6">2,374</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Non-cash research and development expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="3" id="Tc_e7DLCPrVykS6b9i8mN57vw_9_6">14,442</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Non-cash investment in equity securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="edit:NoncashInvestmentInEquitySecurities" scale="3" id="Tc_th1odD2WUE2-2jM6GM1mpg_10_6">3,667</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Other non-cash items, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="Tc_RMte_aop0E2mTNGZ93g0-A_11_3">2,427</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="Tc_6R8592c-mUqDC2gdN3Tu-A_11_6">2,129</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Changes in operating assets and liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Accounts receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_cpagh28P_UyWdSub1M0Lig_13_3">281</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" sign="-" scale="3" id="Tc_9UPdWO_lfEuR2FKLUH-nEQ_13_6">636</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Prepaid expenses and other current assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_UJ1O3UqgvEuaBcEkZNZu_w_14_3">263</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_7zgdasMbzkC7tspUkILwWw_14_6">2,349</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="edit:IncreaseDecreaseInRightOfUseAssets" sign="-" scale="3" id="Tc_7YTTPLPB-E68oeayJmsSbA_15_3">1,780</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Other non-current assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="Tc_i7bSGP2RqEuvBIlMXsRw3g_16_3">14</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="Tc_WYs5KKDAPUecO4oIaM4oBg_16_6">92</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_RF2p3feCFka0i6wgcPX0Ag_17_3">1,005</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_zET7ZHrjx0qZWaOo4AP8oA_17_6">1,667</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Accrued expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="3" id="Tc_WlhZBfnR-EqeHMP0QLANog_18_3">4,491</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="Tc_BiOLS07lIE64P-JxFBH60w_18_6">2,344</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_LBW1_rz5tkC_rknP_EYGyw_19_3">2,928</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="Tc_ucbVlkfBI0-CQVWw91CGrw_19_6">4,388</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Operating lease liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="edit:IncreaseDecreaseInRightOfUseLiability" sign="-" scale="3" id="Tc_ULE970UaTUq4T712NzPinw_20_3">2,107</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Other current and non-current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="Tc_-7nDmOwiWk68-LysRtl-9g_21_3">528</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Net cash used in operating activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_4flNQHEI7Emg5FeaRNM52w_22_3">81,693</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_VzJwMcR7VEKeTYyn-OlgQg_22_6">47,034</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Cash flow from investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Purchases of property and equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_FbJ311uwwUmMd7iKVIr3Cg_24_3">4,476</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_BA8Bgc4J70uBqFXfaBK5Ww_24_6">3,339</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Proceeds from the sale of equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" scale="3" id="Tc_C_aHnXAA6kOF3TNKAVoKbw_25_3">36</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" scale="3" id="Tc_VVIbmDG2Y0miYnVs3N1EXg_25_6">18</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Purchases of marketable securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="Tc_9wWvRuZvsU6vjddgOQpVLQ_26_3">305,126</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="Tc_SOVVIgozg0aPJJii25Mv6g_26_6">351,162</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Proceeds from maturities of marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="Tc_LExRQo2LrEi5aSDVxQ4idQ_27_3">314,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="Tc_ajeKf4200EGvNK5VgiojaA_27_6">310,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Net cash provided by (used in) investing activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_QZyZQ2F-dECMwKXvdvQTTg_28_3">4,434</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_tHL4jC8R40SVJ9cJo4ARXw_28_6">44,483</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Cash flow from financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Proceeds from offering of common stock, net of issuance costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_Alb0vFYGFUymmgl_uAJffQ_30_3">41,216</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_4jgGYrdFvUei48Ulq5Y4Vg_30_6">48,471</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Proceeds from exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_ok1Ku6RV80uku2PwJv_1jQ_31_3">5,756</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_lV4XRfbUSkGEvlYwgzSgTA_31_6">8,376</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Issuances of common stock under benefit plans</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="Tc_mQSmroFqtkyIZXq0Ai6S_w_32_3">283</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="Tc_VrNQlgwZTU-hlBMM7LvzNw_32_6">362</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Payments on construction financing lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" scale="3" id="Tc_4LvrZh4FH0KBdS8NbY1lig_33_6">621</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Net cash provided by financing activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_A5VgU__kL0Omndn9Octdlw_34_3">47,255</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc__mM3KkyZ806Pdu2CbZhDOw_34_6">56,588</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Net decrease in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_gje_rPYhbUetfZ26ZZIH4Q_35_3">30,004</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_gJrmR7BJckaf2o6J--PRqw_35_6">34,929</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Cash, cash equivalents and restricted cash, beginning of period</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_BizSHh-a-k-mRXLh9na3pw_36_3">136,395</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2017_senIwq2LvEuADH5a682MHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_sYlApk5huUCOFmPeXeicxw_36_6">148,249</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Cash, cash equivalents and restricted cash, end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_gVKCwkPTREyi7O--aEyw3Q_37_3">106,391</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2018_Uh3BMLH9xEeftU-M2ZH8Ug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_dIKXw8nptUOoCOeGuSu0_A_37_6">113,320</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Supplemental disclosure of cash and non-cash activities:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Fixed asset additions included in accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_fiOLQArwBUqvOm9aw6ipiw_39_3">772</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_3z3EYmM4bEaRCk54-M0VxQ_39_6">676</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Receivable of proceeds from offering of common stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="edit:ReceivableOfProceedsFromExerciseOfStockOptions" scale="3" id="Tc_QhfPFg2J6UuRJMEXZASYPA_40_3">756</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Cash paid in connection with operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_xtisn8iUcU6LCI9mPwbvYA_41_3">4,604</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Right-of-use assets obtained in exchange of operating lease obligations</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_YxJUO1SCZ0eHAzYdU_bPIQ_42_3">19,461</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Reclassification of liability for common stock subject to repurchase</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="edit:ReclassificationOfLiabilityForFounderStockRepurchase" scale="3" id="Tc_r5c0O42yh0iM7UALxsHojQ_43_6">4</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Issuance of common stock for settlement of success payments (see note 7)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssued1" scale="3" id="Tc_1ujE3EpAFUWVSSESCBDqtg_44_6">9,530</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Issuance of common stock for asset acquisition </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="edit:StockIssuedForAssetAcquisition" scale="3" id="Tc_juYKstSorEG2Jy4OVLVCYQ_45_6">1,942</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Issuance of common stock for settlement of notes payable (see note 7)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesIssued1" scale="3" id="Tc_52oVpeZeX0KfY0HVph_1bQ_46_6">12,500</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Adjustment to deferred revenue for revenue adoption</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="edit:DeferredRevenueAdjustmentFromEffectOfNewAccountingPrinciple" scale="3" id="Tc_VFNfxRtzSUO5NACzTaxQSQ_47_6">474</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:74.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Offering costs included in accounts payable and accrued expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="edit:StockIssuanceCostsIncurredButNotYetPaid" scale="3" id="Tc_RM0qKLbEhkKq2QcO7QyJSA_48_3">15</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="edit:StockIssuanceCostsIncurredButNotYetPaid" scale="3" id="Tc_l3gidDLIA0-FE0vxiPSQoQ_48_6">22</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</span><br />The accompanying notes are an integral part of the condensed consolidated financial statements. </p><a id="_a6b2ddc7_c7b6_437b_8cbd_c31dac19f471"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="EditasMedicineInc_40397"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Editas Medicine,&#160;Inc.</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes to Condensed Consolidated Financial Statements</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="us-gaap:NatureOfOperations" id="Tb_SvikllY-2U-nrcZ0MhYmnA" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">1. Nature of Business</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Editas Medicine,&#160;Inc. (the &#8220;Company&#8221;) is a leading, clinical stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The Company was incorporated in the state of Delaware in September 2013. Its principal offices are in Cambridge, Massachusetts.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, and raising capital. The Company has primarily financed its operations through various equity financings, payments received under a research collaboration with Juno Therapeutics, Inc., a Celgene company that is a wholly-owned subsidiary of Celgene Corporation (&#8220;Juno Therapeutics&#8221;), and payments received under a strategic alliance and option agreement with Allergan Pharmaceuticals International Limited (&#8220;Allergan&#8221;). </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company is subject to risks common to companies in the biotechnology industry, including but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations and ability to transition from pilot-scale manufacturing to large-scale production of products.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-style:italic;font-weight:bold;">Liquidity</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">As of September 30, 2019, the Company has raised an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_SubsidiarySaleOfStockAxis_edit_PublicAndAtMarketOfferingMember_i5xMXJaYNESBo9i_qecDHw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" id="Narr_ieIXgCskhEmPD7DJGi2X_Q">370.4</ix:nonFraction> million in net proceeds through the sale of shares of its common stock in public offerings. In March 2018, the Company entered into a sales agreement with Cowen and Company, LLC (&#8220;Cowen&#8221;), under which the Company from time to time can issue and sell shares of its common stock through Cowen in at-the-market offerings for aggregate gross sales proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_3_31_2018_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarket2018MarchOfferingMember_DsmZE9rWKUiDZb1Yzi_Ong" decimals="-5" format="ixt:numdotdecimal" name="edit:StockSalesAgreementThresholdSaleProceedsThatCanBeRaised" scale="6" id="Narr_cY3l3Gi7_EWsWyZWABJLaQ">150.0</ix:nonFraction> million (the &#8220;March 2018 ATM Program&#8221;). Beginning in August 2019 and through the date of filing this Quarterly Report on Form 10-Q, the Company sold an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_8_1_2019_To_11_12_2019_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarket2018MarchOfferingMember_War5uqaMHkqlCu0UPhd7qA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_zcJ381bhS0egpdNwKrZhww">1,727,555</ix:nonFraction> shares of its common stock pursuant to the March 2018 ATM Program, of which <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarket2018MarchOfferingMember_ktbBPLx-c0WQog7UyrWNPA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_Mz9sEoyxz0aMBWzDlzusqw">1,721,735</ix:nonFraction> shares were sold during the three months ended September 30, 2019, at a weighted-average price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA" contextRef="Duration_8_1_2019_To_11_12_2019_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarket2018MarchOfferingMember_War5uqaMHkqlCu0UPhd7qA" decimals="2" format="ixt:numdotdecimal" name="edit:SharesIssuedWeightedAveragePricePerShare" scale="0" id="Narr_JnbeFKFCsE6nsZM8BqwGMQ">25.15</ix:nonFraction> per share for gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_8_1_2019_To_11_12_2019_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarket2018MarchOfferingMember_War5uqaMHkqlCu0UPhd7qA" decimals="-5" format="ixt:numdotdecimal" name="edit:ProceedsFromIssuanceOfCommonStockGross" scale="6" id="Narr_IJdqmefFXEG9kmT7Zvs28Q">43.6</ix:nonFraction> million under the March 2018 ATM Program. The Company paid Cowen a <ix:nonFraction unitRef="Unit_Standard_pure_E8xeiPkPjUOaCmQYBNvdag" contextRef="Duration_8_1_2019_To_11_12_2019_srt_CounterpartyNameAxis_edit_CowenAndCompanyLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarket2018MarchOfferingMember_X-YMQBtmS0Ov-EDgiiJGQQ" decimals="2" format="ixt:numdotdecimal" name="edit:PercentageOfCashCommissionsPaid" scale="-2" id="Narr_7zqX00R9lkiDyd29PvQm8g">3</ix:nonFraction>% cash commission on the gross sales price per share of its common stock sold under the March 2018 ATM Program. As of the three months ended September 30, 2019, the Company received net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarket2018MarchOfferingMember_ktbBPLx-c0WQog7UyrWNPA" decimals="-5" format="ixt:numdotdecimal" name="edit:ProceedsFromIssuanceOfCommonStockGross" scale="6" id="Narr_ufYkA2VdQUKHIq_sTpd7Tw">42.1</ix:nonFraction> million, of which $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarket2018MarchOfferingMember_lU5PtQ9W90CR1Z6ITvsgSA" decimals="-5" format="ixt:numdotdecimal" name="edit:ProceedsFromIssuanceOfCommonStockReceivable" scale="6" id="Narr_ps8SGGaWLEiQpNmhFqhduA">0.8</ix:nonFraction> million was recorded as a receivable in other current assets in the condensed consolidated balance sheet. As of the date of this Quarterly Report on Form 10-Q, the Company has an ability to raise an additional $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_11_12_2019_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarket2018MarchOfferingMember_3TF1cgWHa06EgyHnRTyzJA" decimals="-5" format="ixt:numdotdecimal" name="edit:StockSalesAgreementAdditionalSaleProceedsThatCanBeRaised" scale="6" id="Narr_beFwgM0ld0ez_FYYB8J1Dg">106.4</ix:nonFraction> million in aggregate gross sales proceeds under the March 2018 ATM Program.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;">The Company has incurred annual net operating losses in every year since its inception. The Company expects that its existing cash, cash equivalents and marketable securities</span> <span style="font-size:10pt;">at September 30, 2019 and anticipated interest income will enable it to fund its operating expenses and capital expenditure requirements for at least 24 months following the date of this Quarterly Report on Form 10-Q. The Company had an accumulated deficit of </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="6" id="Narr_xUU2_O6n-k2SEwk2kv7wfw">511.5</ix:nonFraction></span><span style="font-size:10pt;"> million at September 30, 2019 and will require substantial additional capital to fund its operations. The Company has never generated any product revenue. There can be no assurance that the Company will be able to obtain additional debt or equity financing or generate product revenue or revenues from collaborative partners, on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company&#8217;s business, results of operations, and financial condition.</span></p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk8074871"></a><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_TRuhwncKwUSIHJN0kyGeWw" continuedAt="Tb_TRuhwncKwUSIHJN0kyGeWw_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">2. Summary of Significant Accounting Policies</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_WN2HbNItwE26N5Sh8yOPaQ" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-style:italic;font-weight:bold;">Unaudited Interim Financial Information</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;) have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2018 (the &#8220;Annual Report&#8221;).</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The unaudited condensed consolidated financial statements include the accounts of Editas Medicine, Inc. and its wholly owned subsidiary, Editas Securities Corporation. All intercompany transactions and balances of the subsidiary have been eliminated in consolidation. In the opinion of management, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the results for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The three months ended September 30, 2019 and 2018 are referred to as the third quarter of 2019 and 2018, respectively. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period.</p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Summary of Significant Accounting Policies</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-family:'inherit';visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company&#8217;s significant accounting policies are described in Note 2, &#8220;Summary of significant accounting policies,&#8221; to the consolidated financial statements included in the Annual Report. There have been no material changes to the significant accounting policies previously disclosed in the Annual Report other than as noted below. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_tgMUttXIRkqfbRUIpjkLSg" continuedAt="Tb_tgMUttXIRkqfbRUIpjkLSg_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements &#8211;Adopted</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Leases </i></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Effective January 1, 2019, the Company adopted Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, <i style="font-style:italic;">Leases</i> (Topic 842) (&#8220;ASC 842&#8221;), which amends a number of aspects of lease accounting and requires entities to recognize right-of-use assets and operating lease liabilities on the balance sheet. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">At the inception of an arrangement the Company determines whether the arrangement contains a lease. If a lease is identified in an arrangement, the Company recognizes a right-of-use asset and liability on its balance sheet and determines whether the lease should be classified as a finance or operating lease. The Company does not recognize assets or liabilities for leases with lease terms of less than 12 months. Lease payments for short-term leases are recorded to operating expense on a straight-line basis over the lease term and variable lease payments are recorded in the period in which the obligation for those payments is incurred. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, and (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Finance and operating lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the rate is not readily determinable, the Company utilizes its incremental borrowing rate at the lease commencement date. Operating lease assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the </p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_TRuhwncKwUSIHJN0kyGeWw_cont1" continuedAt="Tb_TRuhwncKwUSIHJN0kyGeWw_cont2"><ix:continuation id="Tb_tgMUttXIRkqfbRUIpjkLSg_cont1" continuedAt="Tb_tgMUttXIRkqfbRUIpjkLSg_cont2"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 9pt 0pt;">straight-line method as an operating expense over the lease term. Finance lease assets are amortized to depreciation expense using the straight-line method over the shorter of the useful life of the related asset or the lease term. Finance lease payments are bifurcated into (i) a portion that is recorded as imputed interest expense and (ii) a portion that reduces the finance liability associated with the lease.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">The Company does not separate lease and non-lease components when determining which lease payments to include in the calculation of its lease assets and liabilities. Variable lease payments are expensed as incurred. If a lease includes an option to extend or terminate the lease, the Company reflects the option in the lease term if it is reasonably certain it will exercise the option.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">The Company elected the modified-retrospective transition method, pursuant to which the Company recognized a cumulative-effect adjustment of $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_1_1_2019_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9DeFqajq70i8txpvpYC8_Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" scale="6" id="Narr_Mm7lLmZEV0aN6PGpvsTtlQ">0.8</ix:nonFraction> million to the opening balance of accumulated deficit on January 1, 2019 associated with de-recognizing the net asset balance recorded in property and equipment, net and the offsetting construction financing lease liability related to the Company&#8217;s headquarters which was previously accounted for under the built-to-suit guidance in Accounting Standards Codification (&#8220;ASC&#8221;) 840, <i style="font-style:italic;">Leases </i>(&#8220;ASC 840&#8221;). This resulted in a reversal of $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_1_1_2019_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_YkEer4ZbSEqfJGFr2l-94A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="Narr_6F05i4M4r0ueux1EUKdQCQ">32.6</ix:nonFraction> million from total assets and $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_1_1_2019_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_YkEer4ZbSEqfJGFr2l-94A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="Narr_eUQ0vbzgF0aiF_c9y9YMCg">33.4</ix:nonFraction> million from total liabilities. All prior period balances are presented in accordance with ASC 840. As of January 1, 2019, the Company recorded a right-of-use asset of $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_1_1_2019_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_YkEer4ZbSEqfJGFr2l-94A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="Narr_7KMNhXMWV0Ka7NndmP8Hrw">19.5</ix:nonFraction> million and lease liability of $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_1_1_2019_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_YkEer4ZbSEqfJGFr2l-94A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="Narr_xUPK7Fq5ZkmUP6J_Q07XvQ">19.7</ix:nonFraction> million associated with the adoption of ASC 842. In addition, the Company elected to adopt the package of three <ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" format="ixt:booleantrue" name="us-gaap:LeasePracticalExpedientsPackage" id="Narr_YHzGm5Ci9EGU6gh-mm5uLw">practical expedients</ix:nonNumeric> for leases that commenced prior to January 1, 2019, allowing it not to reassess (i) whether any expired or existing contracts contain leases, (ii) the lease classification for any expired or existing leases and (iii) the initial indirect costs for any existing leases. The Company did not elect the <ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" format="ixt:booleanfalse" name="us-gaap:LeasePracticalExpedientUseOfHindsight" id="Narr_aRcstP91PkCfwgrNwpvmhA">hindsight practical expedient </ix:nonNumeric><span style="white-space:pre-wrap;">which allows the Company to reassess the lease term as it was not relevant to the Company&#8217;s leases.  </span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"><i style="font-style:italic;">Stock-Based Compensation Expense </i></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Effective January 1, 2019, the Company adopted ASU No. 2018-07, <i style="font-style:italic;">Compensation &#8211; Stock Compensation: Improvements to Nonemployee Share-Based Payment Accounting </i>(&#8220;ASU 2018-07&#8221;), which simplified the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expands the scope of ASC 718, <i style="font-style:italic;">Compensation &#8211; Stock Compensation </i>(&#8220;ASC 718&#8221;), which supersedes the guidance in ASC 505-50, <i style="font-style:italic;">Equity-Based Payments to Non-Employees </i>(&#8220;ASC 505-50&#8221;). In accordance with the new guidance, the Company accounts for share-based payments to non-employees by recognizing stock-based compensation expense equal to the grant date fair value of the share-based payment ratably over the requisite service period. The Company estimates the grant date fair value for each stock option using the Black-Scholes option-pricing model. For restricted stock awards and restricted stock unit awards, the Company estimates the value of each award using intrinsic value, which is based on the value of the underlying common stock less any purchase price. On the date of adoption, the Company estimated the fair value for all unvested non-employee stock options and restricted shares. The unvested stock-based compensation will be recorded over the remaining requisite service period.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:24pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:24pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements &#8211; Issued But Not Yet Adopted</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>In August 2018, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2018-13, <i style="font-style:italic;">Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement </i>(&#8220;ASU 2018-13&#8221;), which modifies certain disclosure requirements on fair value measurements. The amendments regarding changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements and the narrative description of measurement uncertainty are required to be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments are required to be applied retrospectively to all periods presented upon their effective date. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019 and interim periods within those years. The Company does not anticipate a material impact to disclosures as a result of the adoption of ASU 2018-13.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In June 2016, the FASB issued ASU No. 2016-13, <i style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </i>(&#8220;ASU 2016-13&#8221;). The standard requires that a financial asset or a group of financial assets measured at amortized cost basis to be presented at the net amount expected to be collected. Under current GAAP, a company only considered past events and current conditions in measuring an incurred loss. Under ASU 2016-13, the information that a company must consider is broadened in developing an expected credit </p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_TRuhwncKwUSIHJN0kyGeWw_cont2"><ix:continuation id="Tb_tgMUttXIRkqfbRUIpjkLSg_cont2"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">loss estimate for assets measured either collectively or individually. The use of forecasted information incorporates more timely information in the estimate of expected credit loss. The new guidance will be effective for annual and interim periods beginning after December 15, 2019. Early adoption is permitted for annual and interim periods beginning after December 15, 2018. The guidance is applied using a modified retrospective, or prospective approach, depending on a specific amendment. The Company does not anticipate a material impact on its consolidated financial statements as a result of the adoption of ASU 2016-13.</p></ix:continuation></ix:continuation><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:24pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:24pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_890413bc_5f81_4cee_8d07_1b116f953e8e"></a><a id="Tc_P8A6ibAuMEy8gj4HmuXDqQ_1_5"></a><a id="Tc_TGbsEGkV1kSobc0Odlo_YA_1_8"></a><a id="Tc__z5L8uMuHUe3Sh3KK80-3g_2_2"></a><a id="Tc_Ci9QR-cq8UaFG_dm2R7Dpw_2_5"></a><a id="Tc_wcNA0AoMfUSUjWJ69QnEUw_2_8"></a><a id="Tc_XEr9RqCLpkCUIyUCk3VKlQ_2_11"></a><a id="Tc_4P5xYQEWM0mfYAzTmo4dqg_3_0"></a><a id="Tc_eeOguzazPk2BIEBcZOT9hA_3_2"></a><a id="Tc_n5bBFqAApUm5RCyqcKqtpA_3_5"></a><a id="Tc_m5FT5R1XsE-xUf5A1142jA_3_8"></a><a id="Tc_SgcPmh2SPEGtfhaLmI0-mg_3_11"></a><a id="Tc_HGu36qFjxkKi5fUJiGnDuQ_4_0"></a><a id="Tc_cqx2isha7ESJL5RkPWo9uQ_5_0"></a><a id="Tc_A0gGZ83ZXUG5zol2bmPjRA_5_2"></a><a id="Tc_Kqo4aUi6oUaiGbUwwU7AjQ_5_5"></a><a id="Tc_Eh4uv-qiUEOYEWg6U6-O3Q_5_6"></a><a id="Tc_J_tU-BDGYUqMdPWHIZUedw_5_8"></a><a id="Tc_1c6bxkLAGkSZUAGYfKIJmA_5_9"></a><a id="Tc_1InIh1ZmdES_KR4lFuVSeQ_5_11"></a><a id="Tc_l69KB72_BECeZM9WZclxKA_6_0"></a><a id="Tc_hSIlhWLkP06nVYjX0Ulh1Q_6_9"></a><a id="Tc_0iK6ZVuq_Ey-pWi_4ni7Rg_7_0"></a><a id="Tc_RuYdrLikokqbiVqWxSZHMw_7_9"></a><a id="Tc_5HPMA3cCSki9bSUjaRoK1w_8_0"></a><a id="Tc_iw4lCXUr1EqeynFuloA9hA_9_0"></a><a id="Tc_-aEIAYxH8kmg0guMJEkqsA_9_6"></a><a id="Tc_cXZzl6ubCEu20Sxabj9YcQ_9_9"></a><a id="Tc__ckFIDqKZkSrik1sJgDsfw_10_0"></a><a id="Tc_yv9bE82LeEiRCME3Mg-DZA_10_2"></a><a id="Tc_Fq-7aKatwEKCIB0oAjGMdA_10_5"></a><a id="Tc_KbWrOzzs5EGe2tUwPQctYw_10_8"></a><a id="Tc_RD-DvZ1rcEqP-Iswu5CtjQ_10_9"></a><a id="Tc_2FIPKjdCmE2UjlDvSyV-0A_10_11"></a><a id="_b45ab71f_3a05_4dfb_99a2_47ceaf373ae8"></a><a id="Tc_0sFnGYUdmESG7NH4rOYn4g_1_5"></a><a id="Tc_s_HcvIi4dEmkz0XQWbxUMQ_1_8"></a><a id="Tc_5VG5q6CaaUCZeiFPeKxI_g_2_2"></a><a id="Tc_AObSLjgzbUOcmgabdifLvw_2_5"></a><a id="Tc_ZGle6IvAe0eeIBI9R2G0hA_2_8"></a><a id="Tc_orCR4NkQ3UKtmQJQDecbDQ_2_11"></a><a id="Tc_zvDvy1-MLkWQQs3dCrJZCQ_3_0"></a><a id="Tc_m3gJhEGe60y2KFqqSrJLEQ_3_2"></a><a id="Tc_YrfF-jRag0GnrpasoK9D5A_3_5"></a><a id="Tc_vlBZGqrJSESJHrZEsVNs1g_3_8"></a><a id="Tc_2pIW9jTeQkWHG0JWcFDDRQ_3_11"></a><a id="Tc_OCyRrOhZPUu6M0TCJNSfWA_4_0"></a><a id="Tc_nYUi0KK3L0uXLUTn98qe6w_5_0"></a><a id="Tc_0Y-5r36yrkaQ6yceMqRneA_5_2"></a><a id="Tc_UtdcJ3m5Hk6-Nm49b2cD5Q_5_5"></a><a id="Tc_G-0mIRsncEG2jNNqRS4bCA_5_6"></a><a id="Tc_dio--4rplUSLoiW0RBuqqQ_5_8"></a><a id="Tc_vBVeGFpGRka7aoYz5kUUwg_5_9"></a><a id="Tc_Y35jdfCmLEG7wiV3t_Iieg_5_11"></a><a id="Tc_bHUqKTUSuk-pErJavt3_Kw_6_0"></a><a id="Tc_MUKyViL2d0Sp2dMyis4B5g_6_6"></a><a id="Tc_zXexMOdli0ClILoRHXUdUw_7_0"></a><a id="Tc_ebVbxe4f7EaW3DUSNZZLIw_7_6"></a><a id="Tc_3ivRDLHGk0WN3q_W14uGgQ_8_0"></a><a id="Tc_I4FhnZBGxUCcTZH3MPj-AQ_9_0"></a><a id="Tc_jshIX9OWhUug0MazhZ8-fg_9_6"></a><a id="Tc_cEz-SGUN5kWv3gNKk6PJRg_9_9"></a><a id="Tc_0vbFNykbBkSCf2_5VNeZ7w_10_0"></a><a id="Tc_X1HHHS36qk6lpSj4sp0UzQ_10_2"></a><a id="Tc_7lyIh83KzkOsd1al8v5zAw_10_5"></a><a id="Tc_n_HnlSR8p0-H8VtNJ1tRYw_10_6"></a><a id="Tc_VsHvqAcRKUyKj1HiBvNibw_10_8"></a><a id="Tc_hOyh8uUjckOo01nH_HHlkg_10_11"></a><a id="S165936630"></a><a id="T9"></a><a id="T11"></a><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="Tb_6GOs_j_K_UKPpKOezxwLuA" continuedAt="Tb_6GOs_j_K_UKPpKOezxwLuA_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">3. Cash Equivalents, Marketable Securities and Equity Securities </b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="Tb_C64Kwb2pkk-60p_cWZndDA" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Cash equivalents, marketable securities and equity securities consisted of the following at September 30, 2019 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Cash equivalents and marketable securities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_715p9lT5NU-M643EcMceow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_yruINJ63KEywesZRr-Xw8Q_5_3">104,772</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_715p9lT5NU-M643EcMceow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_00gP4tyS9kaIZ_PQJLyiDw_5_12">104,772</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">U.S. Treasuries</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USTreasurySecuritiesMember_zC8nQ0u0v0SygQronrDnrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_I0vTsnE7XEqxARtKrEJMJQ_6_3">83,564</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USTreasurySecuritiesMember_zC8nQ0u0v0SygQronrDnrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_H_dEQpPePk2itE8fubhAeQ_6_6">23</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USTreasurySecuritiesMember_zC8nQ0u0v0SygQronrDnrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_hJIEMPo4vEeUvVKrwwbbXg_6_12">83,587</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember_A5vc1SsXOE2RfS4UDgR6RA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_E1WMVWVP30KXzWkGaf2kHA_7_3">144,241</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember_A5vc1SsXOE2RfS4UDgR6RA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_fxAXP64sEkS_olrN6SYCJg_7_6">16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember_A5vc1SsXOE2RfS4UDgR6RA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_b6rpzoizR0Ojn0ub6cnxSg_7_12">144,257</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Equity securities included in other non-current assets:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Corporate equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember_p7E6BE0SyUaMQWxS2Qggjw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiCost" scale="3" id="Tc_9WWJenTkcEy3w-DhrW13kQ_9_3">3,667</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember_p7E6BE0SyUaMQWxS2Qggjw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="Tc_suuAapnigU61pxBeZHlroQ_9_12">3,667</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 24pt;">Total </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="edit:MarketableSecuritiesAmortizedCost" scale="3" id="Tc_tEsdOvOjyUCVD2LzeUTFUg_10_3">336,244</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="edit:MarketableSecuritiesUnrealizedGain" scale="3" id="Tc_g0YBkpJEsU-5Na7rOazWxQ_10_6">39</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecurities" scale="3" id="Tc_JeE-TxCVZUq4ZnXXAQwadw_10_12">336,283</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:24pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Cash equivalents, marketable securities and equity securities consisted of the following at December 31, 2018 (in thousands):<b style="font-weight:bold;"><br /></b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Cash equivalents and marketable securities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_TGB4lxKzZkuI8R6wI2ygoQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_2C08MW1w30ilya4qNvTpHQ_5_3">130,049</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_TGB4lxKzZkuI8R6wI2ygoQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_ICRHGmneEUKH2SVI993Hqg_5_12">130,049</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">U.S. Treasuries</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USTreasurySecuritiesMember_szWaKGRTnEi252qXZlUVrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_-mC4tFbimESQg1Ko4Jx0Ng_6_3">208,754</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USTreasurySecuritiesMember_szWaKGRTnEi252qXZlUVrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_xcpODkkQsEOTkCY3mwTiLA_6_9">24</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USTreasurySecuritiesMember_szWaKGRTnEi252qXZlUVrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_-TRTIh4ce0mwhEt4AYTPFg_6_12">208,730</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember_KrXYO9EUiEyt_axAoghfkQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc__tQeIhfL40eFSt83NhN0wg_7_3">29,940</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember_KrXYO9EUiEyt_axAoghfkQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_OFUPCCe8Lkqt2zGjlnEb8g_7_9">5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember_KrXYO9EUiEyt_axAoghfkQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_iZJUu0fAYEut46SBpvdIkA_7_12">29,935</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Equity securities included in other non-current assets:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Corporate equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember__QoCNZ0YnEedNiRHAIMKIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiCost" scale="3" id="Tc_bxUVBMLLf0qDR6bhYyMZEA_9_3">3,667</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember__QoCNZ0YnEedNiRHAIMKIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="Tc_aTKg4VK1nkq_W8sjQ_0P-Q_9_12">3,667</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 24pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="edit:MarketableSecuritiesAmortizedCost" scale="3" id="Tc_KivQU_GExEu8KxV4IADesQ_10_3">372,410</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_12_31_2018_zrodnEw_VUizLBhcAZpOsg" decimals="-3" format="ixt:numdotdecimal" name="edit:MarketableSecuritiesUnrealizedLoss" scale="3" id="Tc_yBeFi6cK4kqVAk4tYIdE0Q_10_9">29</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecurities" scale="3" id="Tc_UbJlzaFqAUGu1YKl2c89Yg_10_12">372,381</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:24pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">At September 30, 2019, the Company held <ix:nonFraction unitRef="Unit_Standard_item_rl1kcwMXZkCIZ-rzvXYVSA" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="Narr_4VRHxdSAVUig1dgrcYOiaQ">five</ix:nonFraction> securities that were in an unrealized loss position. The aggregate fair value of securities held by the Company in an unrealized loss position for less than 12 months at September 30, 2019 was $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="Narr_GkTFRB68R0OVVzVjYbfPAQ">51.9</ix:nonFraction> million, and there were <ix:nonFraction unitRef="Unit_Standard_item_rl1kcwMXZkCIZ-rzvXYVSA" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="Narr_SIF4DtkSfEKIuguyymOXyQ">no</ix:nonFraction> securities held by the Company in an unrealized loss position for more than 12 months. Pursuant to the adoption of ASU No. 2016-01, <i style="font-style:italic;">Recognition and Measurement of Financial Assets and Financial Liabilities</i>, the Company records changes in the fair value of its investments in corporate equity securities to &#8220;Other (expense) income, net&#8221; in the Company&#8217;s condensed consolidated statements of operations. The Company records unrealized gains (losses) on available-for-sale debt securities as a component of accumulated other comprehensive income (loss) until such gains and losses are realized. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">As of September 30, 2019, the Company did not intend to sell, and was not more likely than not required to sell, the debt securities in an unrealized loss position before recovery of their amortized cost bases. Furthermore, the Company has determined that there were no material changes in the credit risk of the debt securities. As a result, the Company determined it did not hold any marketable securities with any other-than-temporary impairment as of September 30, 2019. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_6GOs_j_K_UKPpKOezxwLuA_cont1"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">There were <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="6" id="Narr_zFXj0XBubUqlWHj3_aBuhg"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="6" id="Narr_kTP1N0ttEkCTC450lHJRYg">no</ix:nonFraction></ix:nonFraction> realized gains or losses on available-for-sale securities during the nine months ended September 30, 2019 or 2018. </p></ix:continuation><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:24pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_bb565a68_c54a_4e2d_8fe4_ac5115e4c95b"></a><a id="Tc_TK4vFW_l4kSh81LSI93SNA_1_5"></a><a id="Tc_K-ZT65lP2E2mSPttxvi-9A_1_8"></a><a id="Tc_13eKItJFDEyu-_5WgXgtUQ_2_5"></a><a id="Tc_-hx6MYZoT0G2yAZR-XW_ew_2_8"></a><a id="Tc_hNPPmA6w6kO8NsqS8KQGXA_2_11"></a><a id="Tc_Ckj7rZ3jh02nV8qdK6tW5w_3_5"></a><a id="Tc_ZIxjyPXYh0KGLmusISwjQQ_3_8"></a><a id="Tc_rSCjErw7x0G3KNYsdrxLgQ_3_11"></a><a id="Tc_FruaA06wh0G-jl3DAgTWIw_4_2"></a><a id="Tc_pMUQ99IXGEO0CsmKwh3ifA_4_5"></a><a id="Tc_898HI8KYskmex9NKdDUwog_4_8"></a><a id="Tc_r9FvFkS4e0eh43b-aL4VHQ_4_11"></a><a id="Tc_SKGrfcwB0kGlNYglfQNW1w_5_0"></a><a id="Tc_JOR0RDsQBkavjWzJxI6nsQ_5_2"></a><a id="Tc_5gNcdY7yAUCTR3KVq6bltw_5_5"></a><a id="Tc_qcIMyf6ec0u_DBWleE1SAg_5_8"></a><a id="Tc_o9rQiyF2HkCZeMSa3AcyMA_5_11"></a><a id="Tc_mVXXeXtiQ0WFMvr9huO1cA_6_0"></a><a id="Tc_sTAF4TyJDEKuoayH-Y7oxw_7_0"></a><a id="Tc_t9ghcVFWuUW6RY_USqg3dA_7_2"></a><a id="Tc_KOQi98V0lUSpxlj1seNDuA_7_5"></a><a id="Tc_EV8RPxFuZ0ONXNpkKcb_Dw_7_8"></a><a id="Tc_Is-QYmpZhUe54GPjQF3iVQ_7_9"></a><a id="Tc_YkvZo8MbAEmzSWnTKLsAdg_7_11"></a><a id="Tc_gBcmqPxQsUifCal2VadDjw_7_12"></a><a id="Tc_a7fmsvgdQkOk9-K8CQxo_Q_8_0"></a><a id="Tc_N3Bv4co5cUuJYsVUXJDFCQ_9_0"></a><a id="Tc_K3wpEBJgLUe5RydZnv9Y7w_9_9"></a><a id="Tc_RlwBDBjpWUGtsKeuWgwEcg_9_12"></a><a id="Tc_CFJQHkVCbkyWzZwCRJHSIw_10_0"></a><a id="Tc_L7_lxL13U0C4H5_FhirzVQ_10_9"></a><a id="Tc_4aQ7BXdHJEScojnVcWIsYw_10_12"></a><a id="Tc_Et_-E27hxU2J5Vr4YvkKjA_11_0"></a><a id="Tc_ZtDdLSebHk-oYggEtw3AaQ_12_0"></a><a id="Tc_F6W8dPI7m0Gk0lMq82O5Lw_12_6"></a><a id="Tc_51cqJbow2Empdr4HsAcHEw_12_12"></a><a id="Tc_1cn_Gu4C80CS1xbt28UZNw_13_0"></a><a id="Tc_HsxBjWY_bE-ynbpfnv-Ubw_13_9"></a><a id="Tc_ubdI27tQGkiIIxjNtj4r7Q_13_12"></a><a id="Tc_HaepPmc2h0CZhHBKB9dMXA_14_0"></a><a id="Tc_frOlkJTo7EWyNOS71RFiTA_14_2"></a><a id="Tc_qcgqJaLt002JxWu0OxUQ9g_14_5"></a><a id="Tc_d9mpn0ZdrkCIQjTj_JII2w_14_8"></a><a id="Tc_n9ALeW6N20WhRs3BLXLstg_14_11"></a><a id="Tc_0bM1_zU0v0-GJ0AY6t2sYQ_14_12"></a><a id="_cccbad85_4084_472e_9be4_75caffe3ebc3"></a><a id="Tc_hlDtWDOM0U6-dd_A6-VO_A_1_5"></a><a id="Tc_SOeWwxseaEWobOVRbtYA6w_1_8"></a><a id="Tc_Cgr5UPwv8EC3O6W1gHxxYQ_2_5"></a><a id="Tc_U1QgV3-H3UqLYLUSJ7kYxQ_2_8"></a><a id="Tc_X4YOOHuMWUGdNz3xxuUNRQ_2_11"></a><a id="Tc_6tAguqzapEC65MMm41zdTw_3_5"></a><a id="Tc_CaTgwMeiI0m0gnl2RSon2A_3_8"></a><a id="Tc_bPu71SCKAk2TvjIXTiga2g_3_11"></a><a id="Tc_g-mgs9Qmw0yzt6gtqH2tCw_4_2"></a><a id="Tc_kAzkVZAl4kmG2NaOcxvmwg_4_5"></a><a id="Tc_RUdxUlQyLU6kDce0jdBRpA_4_8"></a><a id="Tc_lhmlCiU4FEmYMaH6f13oKQ_4_11"></a><a id="Tc_TfAqEa2VuUCh65iYa1ZU7Q_5_0"></a><a id="Tc_BTNTZAsOX0SmoIPQRMkGeA_5_2"></a><a id="Tc_HySA-rh43U6bIlARUpLPbQ_5_5"></a><a id="Tc_PP1--GNK20etiLWFl_8fNg_5_8"></a><a id="Tc_WSG5UU1MJUmBJaZlmbUKig_5_11"></a><a id="Tc_a8xdzNMJ_0WBKIfU8a7AtA_6_0"></a><a id="Tc_M_blXwqM4Ui_zdzeEzCanA_7_0"></a><a id="Tc_9UUPQPaxXEmfkaXL6QBNfA_7_2"></a><a id="Tc_Bx0f7AZHokiq8K_s7pDQQg_7_5"></a><a id="Tc_lbaOmLzxokuhZxjl9E-VMw_7_8"></a><a id="Tc_IZ9om-OIJEWkH3xXk1U5mA_7_9"></a><a id="Tc_-msHuV0qd0W1_V2rcRDlZg_7_11"></a><a id="Tc_9pWMTUi6kk20bWIC-XOvlg_7_12"></a><a id="Tc_ZP5qcBjLTUCTUi46aKIgbw_8_0"></a><a id="Tc_XfFuciOVh06-A5mwt0RkBA_8_9"></a><a id="Tc_lvf7kIVsdEGFQsod5GRVRw_8_12"></a><a id="Tc_pEWpnK7rXk20sRfdPMQGKg_9_0"></a><a id="Tc_LoajfwZ7u0SqL5gYSMU1VQ_10_0"></a><a id="Tc_B586RSMNdEaxZCWj842nzg_10_9"></a><a id="Tc_X5PeNMGWpE2hhQh7ymqdoQ_10_12"></a><a id="Tc_s_fpWkE30EmavY_neK9lbQ_11_0"></a><a id="Tc_rCb7v4ixWEmqC63rz9I19g_11_9"></a><a id="Tc_d0iBNNcom0qf5W1MsFJ6Jg_11_12"></a><a id="Tc_sh4SyiVdLkWwn2yM6WHIxw_12_0"></a><a id="Tc_42jh8loPQEycKsdHViyi-A_13_0"></a><a id="Tc_CwrJb7vNqk-n0vX-pN9GqA_13_6"></a><a id="Tc_KWW4OwmUgE6ZSyjbs0g0ZA_13_12"></a><a id="Tc_VHXEghfAsEeX-y4VLs6Mwg_14_0"></a><a id="Tc_WvJ92Y5ddkCpS4UNlThogw_14_9"></a><a id="Tc_DVa6laIu10O5NOYxTBMxjQ_14_12"></a><a id="Tc_2JEiDqqHXUuccnfKRv2pAA_15_0"></a><a id="Tc_CRjr3ah_REKYxQaEyD8Sxg_15_2"></a><a id="Tc_8Cu2aLf_vUevSL6Y8GHdUg_15_5"></a><a id="Tc_jVWgNkwPhEi86KeO-9o6xA_15_8"></a><a id="Tc_fzA3_mI7cUKp5ReOd5fbeQ_15_11"></a><a id="Tc_X4Xx3nDkAkmqj9bXabkyFw_15_12"></a><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb__L-S_yzHU0WhFoGSsQ4u0g" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">4. Fair Value Measurements</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="Tb_4HDVtoj_HkK33c41D95nEA" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Assets measured at fair value on a recurring basis as of September 30, 2019 were as follows (in thousands):</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">  </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">in&#160;Active</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Markets&#160;for</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical&#160;Assets</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Financial Assets</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Cash equivalents:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_HSTFzN1cUEGtvQd0OurLMA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_Yshd_OYqIkWWQgf4bJk1ew_7_3">104,772</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_1OsS_I8aF0i-YCo7hdwLcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_IeztJUM0h0-q_gi8idXbaA_7_6">104,772</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Marketable securities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">U.S. Treasuries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_raku3VZFuke0alBYy9wNpQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_Npxy0oReSUCnaA55ISdvWw_9_3">83,587</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_XK4JhgmU5UmZfBzH85zD9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_I9o8bXGl3E-0X1y4g_HSsA_9_6">83,587</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Government agency securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_CKHO6pDGjkSBIsBw4K4g0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_hUQNQGlNV0uaX84DAlKQtw_10_3">144,257</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_4CMDEP4Sg0WuJwCo3kj0GA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_tK9ohXMHQEW7_peiKJLsXQ_10_6">144,257</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Restricted cash and other non-current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Corporate equity securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember_PL8oKMla10qvL9b1_2n3mg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiCost" scale="3" id="Tc_zBuqDVwYk0eXNWCKiwMoug_12_3">3,667</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember_Ax4WwMw3P0elxef4gwaY2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiCost" scale="3" id="Tc_YEMGr90f6kCWe6bVAVkfGg_12_9">3,667</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_HSTFzN1cUEGtvQd0OurLMA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="Tc_5LJ0UrmNBEGv7z2tR5kZgQ_13_3">1,619</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_1OsS_I8aF0i-YCo7hdwLcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="Tc_aVgWQWuXME-etuZmrs65Wg_13_6">1,619</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Total financial assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_NK-fhmMl0UyDtfCFPjlwog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_senYD8yNyku5G_GFnCEYFg_14_3">337,902</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_g8uPs61fLU-iP_S2ZoytqQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_dHGx2Gx5WEG0DmEcNRNOJw_14_6">334,235</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_lwnhc_OPt02yW0Img1-sjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_mOlsZc2mgESZabFv3hsWBw_14_9">3,667</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Assets measured at fair value on a recurring basis as of December&#160;31, 2018 were as follows (in thousands):</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:-0.020606995%;padding-left:0pt;padding-right:0pt;width:100.04%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">in&#160;Active</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Markets&#160;for</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical&#160;Assets</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Financial Assets</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Cash equivalents:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_hhO6rw5Ou0moEGgauWWhJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_JqYw0GHRekuC1iEFd8QaNA_7_3">130,049</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_iX-oyBzhE0myrSoqcNnSbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_kOcguPVnrE2cA5bXiDnn1A_7_6">130,049</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">U.S. Treasuries</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USTreasurySecuritiesMember_uFibcieSKUaoBtsZ19bZYg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_3-QnBz7jzUiYawvwRJridw_8_3">4,487</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USTreasurySecuritiesMember_iVSO5aonCEuoXoKsnk9nUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_5ysDQHb4sky3Hcg7yP0nWA_8_6">4,487</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">U.S. Treasuries</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_BE9yOipzFkWXXQU9jYhEMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_hxEXmruBMEm3us-Jftd-lA_10_3">204,243</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_hb4a5ntSUEWmOa45e5et6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_VM-m4BqCyEWpYtSjKQ25xw_10_6">204,243</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uKPmiw8XwU2KdTnZuxwZtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_KdEiLtOIGkCxGvOmBR5Mfw_11_3">29,935</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_42lI8pTd2ECGwclymtSQgw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_0iVAZ9WP10aaqU0dGStYMQ_11_6">29,935</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Restricted cash and other non-current assets:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Corporate equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember_jT19XV8GLEu0RJbMbTBl4Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiCost" scale="3" id="Tc_3jWwnr9VK0GIYUgkoEqkmw_13_3">3,667</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember_6CXnaUT_fUyJlybGjgEz6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiCost" scale="3" id="Tc_7ob_lulOkE6RD87gyC_zpg_13_9">3,667</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Money market funds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_hhO6rw5Ou0moEGgauWWhJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="Tc_kIGTUrWaLk-hGgYZ5QXUhg_14_3">1,619</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_iX-oyBzhE0myrSoqcNnSbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="Tc_Vea2NgTbgkOCfzpV8enkrg_14_6">1,619</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Total financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_MsohzaC6nEGF9IKQbiwTLw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_a0d8dY7YE0yuDEBvv7lrTg_15_3">374,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_e71_GfWuOkmuF7nNBglBJQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_kKLDaaVz9UuszOotb_n1Vw_15_6">370,333</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_C2kDm64hKk6izw1I5D_EAw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_7n2kDHAQYEmi8_RgDsQEVg_15_9">3,667</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">There were <ix:nonFraction unitRef="Unit_Standard_item_rl1kcwMXZkCIZ-rzvXYVSA" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="INF" format="ixt-sec:numwordsen" name="edit:FairValueAssetsAndLiabilitiesTransfers" scale="0" id="Narr_G6Sr5XII_0KFMzptFRoxkw">no</ix:nonFraction> transfers between fair value measurement levels during the nine months ended September 30, 2019.</p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'inherit';font-size:1pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_fa7c276b_f1c7_414d_b194_00cbd754aab8"></a><a id="Tc_ipr0o6zdSkiHn0TQQWL2VQ_1_2"></a><a id="Tc_L-FZeFJ-CEmNEPVf5zj-hw_2_2"></a><a id="Tc_fuyK4PmC9kKI-XpXrehU5A_2_5"></a><a id="Tc_IyD7W4aUlkmOC7R7mZw84Q_3_2"></a><a id="Tc__NMtYkAIo02_ufticWOcGg_3_5"></a><a id="Tc_--IbuLVsnEG-upHh-tL3nA_4_0"></a><a id="Tc_jnpFOFjWDkKUezD_TMbP-g_4_2"></a><a id="Tc_cxcWDyMkMkmeAjP0eFMLKA_4_5"></a><a id="Tc_da9kPY7Oy0ySDuTtNAGzbw_5_0"></a><a id="Tc_nCqyHWgEbEu9Imm67vh7EQ_6_0"></a><a id="Tc_C2yIRvkwOE22FPGOBgGaHA_7_0"></a><a id="Tc_UTj2IHm-EkyE_N38XbuH-w_8_0"></a><a id="Tc_no1J5-KyzEqhfkFjVvraLw_9_0"></a><a id="Tc_4XLiPgBAhkS-U7ANIZNUhw_9_3"></a><a id="Tc_3pUWSbRUL0yso1Psoy0ATw_10_0"></a><a id="Tc_E5vSNm3G9E6kWqNgsuNK-A_10_2"></a><a id="Tc_X0AtZLuRf0668gtA5SwjZg_10_5"></a><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Tb_obpeRYGmOUS1cXAAGxKLew" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">5. Accrued Expenses</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_LZNwjLSPaECxSSJyxpAnbg" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Accrued expenses consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:normal;width:27.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:normal;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:normal;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:normal;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:normal;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Employee related expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc__VCx3vaxrUap2d1HXg9F8Q_4_3">4,134</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_SDyde_uFA0ySzCxOj-YQBA_4_6">5,201</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Intellectual property and patent related fees</p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="edit:AccruedIntellectualPropertyFees" scale="3" id="Tc_XBfbTdGIr0WL3YQXuSVHTQ_5_3">1,645</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="edit:AccruedIntellectualPropertyFees" scale="3" id="Tc_UHB1nDQk80eHN2PzvGpDTw_5_6">1,939</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Process and platform development expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="edit:ProcessAndPlatformDevelopmentCostsCurrent" scale="3" id="Tc_VpY8PmjW3EOL5Gn-SqjUrQ_6_3">1,171</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="edit:ProcessAndPlatformDevelopmentCostsCurrent" scale="3" id="Tc_VCXH9UjZ_E6n9jxnfDMvhw_6_6">1,044</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Professional service expenses</p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_7K6Spl38v0uz5jeAneniAg_7_3">853</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_f4RySEGuskKYvCRPuwu_RQ_7_6">475</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Other expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_thxk9jIux0OhEYELP94rfQ_8_3">335</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_PnQ79waiuk-0Y5EB74gVQQ_8_6">404</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Sublicensing expenses</p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="edit:SublicensingAndSuccessPaymentExpenses" scale="3" id="Tc_BpPqb1LKd0ehHGOjCWdfFQ_9_6">3,750</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Total accrued expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_DIoYN0JIM0STSTcG4V2Cyg_10_3">8,138</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_zRcPiXtqNUmzB4k7iVB39A_10_6">12,813</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><a id="_e6a184bf_a6e8_411e_bca1_1299681c2c16"></a><a id="Tc_8rskwJjMIE2FItgDNuNAuw_1_2"></a><a id="Tc_NVXHPMkzOkifUC7We-FiZQ_2_2"></a><a id="Tc_lbZQbAVgRkKC2wm2zBmhhg_2_5"></a><a id="Tc_TCTsf93fIESnF2EZzZ5GKg_3_2"></a><a id="Tc_qGaiLzLi5kaW_q1y6OTSaA_3_5"></a><a id="Tc_MvUHxlx94kmwf7kjyeAh7w_4_0"></a><a id="Tc_YZNnEvVDf0ClXlxsXY8ChA_4_2"></a><a id="Tc_V9RiCwbg9kyoK6A8pUAPGw_4_5"></a><a id="Tc_ceW5Kbp0Gk-MChTfmooZpw_5_0"></a><a id="Tc_sELVzfjKyEKNtp3EV0Ssew_6_0"></a><a id="Tc_HSnVkFEvR0mZZPwuWbB0Rg_7_0"></a><a id="Tc_qz9TxOwP1UyUgBAATg6sKw_7_6"></a><a id="Tc_-qOQ9V65306_Bq1jrLTuuQ_8_0"></a><a id="Tc_Ajb9OhNGz0eephBHKg6EnQ_9_0"></a><a id="Tc_nMLu-Jxz4kCi4_Xxkk41eA_10_0"></a><a id="Tc_jdC5ryPGmkm4b2UxTtUpNg_10_3"></a><a id="Tc_BJV-oUMv60WOQqOJCxlMIA_11_0"></a><a id="Tc_GdkXguOk_kS3cMv5Vw0HLQ_12_0"></a><a id="Tc_uDUKKdxIYEiBxqAO7O73dQ_13_0"></a><a id="Tc_CnVV4skPi0CD2A8UFwIcbw_13_2"></a><a id="Tc_Ez6wg1tBJU2ZMWCa_S_YLw_13_5"></a><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_kexGQf5vS02dSmRFV1slzg" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">6. Property and Equipment, net</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_ey5CfoZpEE-2gumqB4uDeQ" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Property and equipment, net consisted of the following (in thousands):<b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:27.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Laboratory equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_edit_LaboratoryEquipmentMember_AVb7DBqk10uTIad92YeUNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_DS92dTw1Xk-2RfeCSHhU-g_4_3">14,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_edit_LaboratoryEquipmentMember_jNlcWv83W0a_5q-w_7GeGw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_zaSz9C0tiU2qOdHdw7rZgw_4_6">10,892</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_SBBNY-YWV0KhHhYb30myIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_W7G_RUz1uUSrbWMnYuIPpA_5_3">974</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_U6z0qkSp50GiyOi7BDlDRA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_ZafL4udyWkuic0C4R-j7Zg_5_6">289</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Computer equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_guUaGiUbe0iwk4T9ixbwSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_DcVVImLUD0ylfiAYpX0S4Q_6_3">826</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_VqUZ0FvBIkWcvm4vgvlr_A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_svsCCq45V0W1wNB1di_2iw_6_6">733</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Construction-in-progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_H7ziJoGIK0maKshFPMdlhw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_uWTU3WxGMUyisnl9d-DaeA_7_3">451</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Furniture and office equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_xWgifcmBZESG7eQtghdpug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_AnJaP3jv0UOgZV7vhHCY4A_8_3">166</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_DjJ0hyYREUOZJlShodxbbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_lVpf4VP_QEyuyFAdgVz1yg_8_6">166</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_ydne4f47BUCTZCvWtZzh0Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_aWTLTkeYxka_5uGXMwHAGA_9_3">118</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_MnMT4XcDHE2E28jOhj7_4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_JR7xpch7Tk-A2jRziEeCqQ_9_6">118</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Building</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember_qQjfOtD8P0q3C93XNNQvxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_YtehB3T6QUqtwjYB7v8dnA_10_6">35,167</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Total property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_RVsC-lZa7UCJOZb0AMa2lw_11_3">16,535</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_fFN0YgsF506wmNMSATtG7g_11_6">47,365</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Less: accumulated depreciation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_WtJ5liQW-02iEzYTRouDSQ_12_3">6,460</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_2gKBlYW8bUClal-TtjRy9A_12_6">7,133</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_o7zK4heOCUmSfI2rQvzFTQ_13_3">10,075</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_WmYeU5B2DUmFRwkt6Vh2Pw_13_6">40,232</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">For additional information related to the removal of the building asset, refer to Note 7.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk7446306"></a><a id="Tc_rJktcdlNcUuD4F9MeFJ76g_1_1"></a><a id="Tc_FjinVnW4iUeuvMk5Q_iPLw_2_1"></a><a id="Tc_3byjZWxWf0uV-OQPTu19Kg_3_0"></a><a id="Tc_WHJxf57vD0aTfaC3wV9FAw_3_1"></a><a id="Tc_EasLQau_z0Cogi5PlXPHBg_4_0"></a><a id="Tc_XEa5k6pzJ02s6BOyjcYuCw_4_1"></a><a id="Tc_xR0VZc6820WwpC1VtD_cqw_5_0"></a><a id="Tc_D2xDM9LStUGcoYW-YRzmSA_5_1"></a><a id="Tc_glw-AuUiOkm85FrqIdik7A_6_0"></a><a id="Tc_wg4D7aBkXU-iA7Cni08b2Q_6_1"></a><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_UD5TkFcegk-Tlcx1TtoDgg" continuedAt="Tb_UD5TkFcegk-Tlcx1TtoDgg_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">7. Commitments and Contingencies</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In 2016, the Company entered into a lease agreement for <ix:nonFraction unitRef="Unit_Standard_sqft_zyr2ZacpEkijqHVLi1q1mA" contextRef="As_Of_10_1_2016_srt_CounterpartyNameAxis_edit_HurleyStreetLeaseMember_2ldT7Pk_sEy-LRFeHacLUw" decimals="0" format="ixt:numdotdecimal" name="edit:AreaOfLeasedSpace" scale="0" id="Narr_flrizsc2W0OJhSGZKj7E4w">59,783</ix:nonFraction> square feet of office and laboratory space located on Hurley Street in Cambridge, Massachusetts. The term of the lease began on October 1, 2016 and continues until October 2023. The Company has the <ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_edit_HurleyStreetLeaseMember_zmU6W-bAi0i3mDk8ot7nVw" format="ixt:booleantrue" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="Narr_km40cFzdZ0KBbkLJEbUccA"><span style="white-space:pre-wrap;">option to extend</span></ix:nonNumeric><span style="white-space:pre-wrap;"> the lease for an additional </span><ix:nonNumeric contextRef="As_Of_10_1_2016_srt_CounterpartyNameAxis_edit_HurleyStreetLeaseMember_2ldT7Pk_sEy-LRFeHacLUw" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_B3k3c8gj0ECqjRBGPyrgSg"><span style="white-space:pre-wrap;">five-year</span></ix:nonNumeric><span style="white-space:pre-wrap;"> term at market-based rates. The base rent payments commenced in November 2016 and continue through the term of the lease and are subject to increases over the term of the lease. The Company subleased approximately <ix:nonFraction unitRef="Unit_Standard_sqft_zyr2ZacpEkijqHVLi1q1mA" contextRef="As_Of_2_28_2017_srt_CounterpartyNameAxis_edit_FacilitySubleaseArrangementMember_7tYFtpo8HkifSJ3u_1lnhA" decimals="0" format="ixt:numdotdecimal" name="edit:AreaOfLeasedSpace" scale="0" id="Narr_RqMGsXftzEuXoCVYms82yA">10,000</ix:nonFraction> square feet of the Hurley Street premises pursuant to a sublease, which commenced in February 2017 and terminated in June 2018. </span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In accordance with ASC 840 and for accounting purposes, the Company was deemed the owner of the building during the construction period due to the fact that the Company was involved in the construction project, including having responsibilities for cost overruns for planned tenant improvements that did not qualify as &#8220;normal tenant improvements&#8221; under the lease accounting guidance<i style="font-style:italic;">. </i>Throughout the construction period, the Company recorded the project construction costs incurred as an asset, along with a corresponding construction financing lease obligation, on its balance sheet for the total amount of the project costs incurred whether funded by the Company or the landlord. Construction was completed in October 2016 and the Company considered the requirements for sale-leaseback accounting treatment, which included an evaluation of whether all risks of ownership had transferred back to the landlord, as evidenced by a lack of continuing involvement in the leased property. The Company determined that the arrangement did not qualify for sale-leaseback accounting treatment, the building asset would remain on the Company&#8217;s balance sheet at its historical cost, and such asset would be depreciated over its estimated useful life of <ix:nonNumeric contextRef="Duration_10_1_2016_To_10_1_2016_srt_CounterpartyNameAxis_edit_HurleyStreetLeaseMember_msxFNwKEn0ud3R-lueFJbQ" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_ZcufFjMEnE-huyP4NVV5UQ">30 years</ix:nonNumeric>. The Company bifurcated its future lease payments pursuant to the lease into (i) a portion that was allocated to the building and (ii) a portion that was allocated to the land on which the building is located, which was recorded as rental expense. Although the Company did not begin making lease payments pursuant to the lease until November 2016, the portion of the lease obligation allocated to the land was treated for accounting purposes as an operating lease that commenced upon execution of the lease in February 2016. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Effective January 1, 2019, the Company adopted ASC 842 and derecognized the balances relating to the building, accumulated depreciation and the corresponding construction financing lease as summarized in the table below (in thousands). In applying the ASC 842 transition guidance, the Company determined that the lease should be classified as an operating lease and recorded a right-of-use asset and lease liability on the effective date, accordingly. </p><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="Tb_c6yVsK13tUigZocVwPrFRA" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:middle;white-space:nowrap;width:23.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of </b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:middle;white-space:nowrap;width:23.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">January 1, 2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Property and equipment, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_1_1_2019_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_YkEer4ZbSEqfJGFr2l-94A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_9BFEd6zgmUqOFKpOVhM_6g_3_2">32,627</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_1_1_2019_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_YkEer4ZbSEqfJGFr2l-94A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" sign="-" scale="3" id="Tc_vha--vT3SUS_9JNhqiXt1A_4_2">1,014</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Construction financing lease obligation, net of current portion</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_1_1_2019_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_YkEer4ZbSEqfJGFr2l-94A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" sign="-" scale="3" id="Tc_-nsuZOhT-UiTx3wKQ2yxEQ_5_2">32,417</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Accumulated deficit </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_1_1_2019_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_YkEer4ZbSEqfJGFr2l-94A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="Tc_p4s9heUczEus3Ig57jmXXw_6_2">803</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">At adoption, the Company had <ix:nonFraction unitRef="Unit_Standard_item_rl1kcwMXZkCIZ-rzvXYVSA" contextRef="Duration_1_1_2019_To_1_1_2019_uaR1Uv2lmUWJZyFgpnp2JQ" decimals="INF" format="ixt-sec:numwordsen" name="edit:LesseeOperatingLeaseLaboratorySpaceNumber" scale="0" id="Narr_eWV8cR3WUUqiFulO5ktrZQ">two</ix:nonFraction> other operating leases for laboratory space. One of those leases, which commenced in April 2017, was amended in April 2018 and continues until March 2021. The second lease commenced in January 2018 and continues until June 2021. Base rent payments commenced at the beginning of each lease term and continue through the term of the respective lease. Base rent is also subject to increases over the term of the lease. In prior periods, the Company accounted for these leases as operating leases under ASC 840 and recognized straight-line rent expense over the remaining non-cancellable lease terms. As part of its adoption of ASC 842, effective January 1, 2019, the Company elected to apply the package of practical expedients which, among other things, allowed the Company to carry forward its existing lease classification under ASC 840. Additionally, the Company recorded right-of-use assets and lease liabilities for these operating leases on the effective date.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company has <ix:nonFraction unitRef="Unit_Standard_lease_WLwIHlVjbEGdHYRUV0R8Yw" contextRef="Duration_7_1_2019_To_7_31_2019_-qHYqTPBg0-JDU51y1HWrQ" decimals="INF" format="ixt-sec:numwordsen" name="edit:NumberOfOperatingLeasesForManufacturingSpace" scale="0" id="Narr__UvCXCU5hEOhzznFwjdi8w">two</ix:nonFraction> other operating leases for manufacturing space that commenced in July 2019. The leases continue until December 2020 and March 2024, respectively. The lease that continues until March 2024 is subject to base rent increases over the term of the lease and the lease that continues until December 2020 has a fixed base rent payment through the term of the lease. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_8e8d0e98_b1f8_47df_9e07_5d6f17141db1"></a><a id="Tc_pDbz-k9kH0SI9tbE4jOpEA_1_1"></a><a id="Tc_TAUEDX-HMUiVnzHjodvSdw_2_1"></a><a id="Tc_bRyskpJyVkC-lXVfFkQ8xQ_2_4"></a><a id="Tc_zitViri1vk2t0-xZ8FnaYw_3_1"></a><a id="Tc_Ju-YJH50Kkqm9Au4wcsAaw_3_4"></a><a id="Tc_MEpPc3GNckyBD2qs7frDhg_4_0"></a><a id="Tc_qJwihGE8Yki06Qc3kJl80g_4_1"></a><a id="Tc_Ua18UUIi_E2enGGZl5_6iA_4_4"></a><a id="Tc__RFFuK8WcE2YXDZtcBIxPg_5_0"></a><a id="Tc_FiuTA_R7EkideGRp62J3eQ_5_1"></a><a id="Tc_GzmlRCIqY0uxfWmABVIEjQ_5_4"></a><a id="Tc_wFBTkluMLEO_IJuYzjWW-A_6_0"></a><a id="Tc_K_MtkS5A1kaU43fjwQRgWw_6_1"></a><a id="Tc_N8Ym6fXKXEmbvg7Q_qKB6g_6_4"></a><a id="_1b6131ef_b332_49ec_823b_b4a26c2c6d8e"></a><a id="Tc_5kbiK0qvw0qzErM7mLmHFg_1_1"></a><a id="Tc_w2TNVKes8UaVsH_EdZTE3A_1_4"></a><a id="Tc_HBISadfEZEeASXTsZ5Ryrg_2_1"></a><a id="Tc_oW7wINo9ZEyesmRn0atsiQ_3_0"></a><a id="Tc_e7wNuz8QU0ic60QaU9Ijaw_3_1"></a><a id="Tc_Qa_7704GTE-m4vwZ1ohIOQ_3_4"></a><a id="Tc_Rk5JUGr2W0-Ebl5Nsf6NVw_4_0"></a><a id="Tc_5DYssqAVD0e4v_9ONVDtqg_4_1"></a><a id="Tc_TLFYjRnq7U-RbfJhNrmGsQ_4_4"></a><a id="Tc_tWKE0c2EKE2bDEYSMzhRSg_5_0"></a><a id="Tc_wCb-Me03Z0ijdJsBWwgZsQ_5_1"></a><a id="Tc_XRxmfFmjg0ipyHsqUN5FKw_5_4"></a><a id="_326e7335_9510_4e48_ba19_0e0159340d84"></a><a id="Tc_7gASYwKDJUeDRyDlCaifXQ_1_2"></a><a id="Tc_v3xeuzbna0yN8FHj4FKJrg_2_0"></a><a id="Tc_KCCCAcqMtUOMQTENIG9SSA_2_2"></a><a id="Tc_NyXQkm4270eqAIN6lL10yQ_3_0"></a><a id="Tc_2oc9JFn0DUKYccUhfcUOrQ_3_1"></a><a id="Tc_ru89c8ROkkCEJprNytzi1Q_4_0"></a><a id="Tc_b1wCROLBl0qirGw0rr_C5Q_4_1"></a><a id="Tc_Ta9GQWswL06gUr5pM0a8Bg_5_0"></a><a id="Tc_Hdw2_hOVXk29cxjmaveTkA_5_1"></a><a id="Tc_DngMJ5NNE0aN-tifLOj53Q_6_0"></a><a id="Tc_ZrdNHRjGnE-y8L8Ax8U9hQ_6_1"></a><a id="Tc_Kbju7O7EEEGXEnSpX7UlrQ_7_0"></a><a id="Tc_7m-T3OooIEOW6gYsKg1EWA_7_1"></a><a id="Tc_eIn94nzaE0SYOjDITw_8yQ_8_0"></a><a id="Tc_YazxJfKAHEC7AlbemDLocQ_8_1"></a><a id="Tc_l5ciRBcU8USd3c9ru6yR7A_9_0"></a><a id="Tc_unBsgbafIkaTeQNWo85tLg_9_1"></a><a id="Tc_6yQTLBLka0qHXehcf5zV0g_10_0"></a><a id="Tc_EzrewzURs0OwCbqV0QRY5Q_10_1"></a><a id="Tc_TRXVzpld7UK_YCgovDJDVw_11_0"></a><a id="Tc_KIHrxsCInkqWe5YH9WZFsw_11_1"></a><ix:continuation id="Tb_UD5TkFcegk-Tlcx1TtoDgg_cont1" continuedAt="Tb_UD5TkFcegk-Tlcx1TtoDgg_cont2"><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="edit:AssetsAndLiabilitiesLesseeOperatingLeaseTableTextBlock" id="Tb_X1-VNQgNL0W9lX7EZaSFWA" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company&#8217;s leases are included on its condensed consolidated balance sheet as follows (in thousands):</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:64.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:64.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:35.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:64.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">January 1,</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:64.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:64.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Right-of-use asset</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_h6zlmOGtXkqK3_JMkZWH9A_4_2">17,681</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_1_1_2019_GHVQq8gUCEOZOt-m471YvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_QuEy2zhLDkyDAKdRYjN4ig_4_5">19,461</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:64.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Lease liability, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_1xboUfxyTEKxF8h8DclJ1w_5_2">4,448</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_1_1_2019_GHVQq8gUCEOZOt-m471YvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_wa4EWiJCVEaF3Xg3KnyZZg_5_5">3,848</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:64.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Lease liability, noncurrent </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_fIcE1Il3R0ebMrrgXAxjfQ_6_2">13,202</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_1_1_2019_GHVQq8gUCEOZOt-m471YvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_4V50yEmxnkirHs-dcX5sag_6_5">15,909</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="background-color:#ffff00;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="us-gaap:LeaseCostTableTextBlock" id="Tb_7rNQ-_aGo0Ox6qicguQHnw" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The following table contains a summary of the operating lease costs recognized under ASC 842 and other information pertaining to the Company&#8217;s operating leases during the three and nine months ended September 30, 2019 (in thousands):</p><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_irfKLo-41Ua1K2G7DexNWg" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:60.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:middle;width:19.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="background-color:auto;vertical-align:middle;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:middle;width:17.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:60.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:middle;width:39.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Operating lease costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_pvEEBPzQf0yFZ_2hCQ3CoA_3_2">1,451</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_YO1uM4P9FEie8-eSu8LX8A_3_5">4,293</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Variable lease costs</p></td><td style="vertical-align:bottom;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="Tc_FJLUczfrL0e4GOPtKK3E4w_4_2">276</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="Tc_gL7AsYzHyUagaUwuNuhpTg_4_5">804</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Total lease costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_N58P9_sfaEu1Ni4oICU9qw_5_2">1,727</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_NnrcR1msZU2WsieyJp2I_A_5_5">5,097</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Maturities of the Company&#8217;s lease liabilities in accordance with ASC 842 as of September 30, 2019 were as follows (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:21.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:middle;width:21.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Maturity of lease liabilities:</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:middle;width:21.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="Tc_R2WZoo8T4ECV42Of4H_esA_3_2">1,091</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_fMQc3QhcLEy6gCw_KfNUmA_4_2">6,398</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_xMiFVym9z0CZiv4b5cy0wA_5_2">4,875</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_Zg7dHF81PUG1NHTSJh7x9A_6_2">4,588</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">2023</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="Tc_lGaPUO8VK0CJR_C7MKjaGQ_7_2">3,924</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="Tc_Tw85xGqji0S1YUecxakzxA_8_2">30</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Total minimum lease payments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc__hw-K-Pu3U-7KVZWlO6iRA_9_2">20,906</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_cCXH6svF5EiG_bR_E1aHlQ_10_2">3,256</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Total operating lease liabilities at September 30, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_bhcal9qFLEap_XOdghXHCw_11_2">17,650</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The weighted-average remaining lease terms are <ix:nonNumeric contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Narr_mNqxo7UNvk-yQTIi3pxF4w">3.7</ix:nonNumeric> years and the weighted-average discount rate is <ix:nonFraction unitRef="Unit_Standard_pure_E8xeiPkPjUOaCmQYBNvdag" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="4" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Narr_-xTKlKvJOkqDO-2KF-LcRw">9.27</ix:nonFraction>%.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-style:italic;font-weight:bold;">Licensor Expense Reimbursement</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-style:italic;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company is obligated to reimburse The Broad Institute, Inc. (&#8220;Broad&#8221;) and the President and Fellows of Harvard College (&#8220;Harvard&#8221;) for expenses incurred by each of them associated with the prosecution and maintenance of the patent rights that the Company licenses from them pursuant to the license agreement by and among the Company, Broad and Harvard, including the interference and opposition proceedings involving patents licensed to the Company under the license agreement, and other license agreements between the Company and Broad. As such, the Company anticipates that it has a substantial commitment in connection with these proceedings until such time as these proceedings have been resolved, but the amount of such commitment is not determinable. During the three and nine months ended September 30, 2019, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_OtherCommitmentsAxis_edit_CommitmentToReimburseLicensorMember_DOloV0XhME-N4IXu1IWfqQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfessionalAndContractServicesExpense" scale="6" id="Narr_vB-NLN1_dk-QGxlwINgpEQ">3.1</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_OtherCommitmentsAxis_edit_CommitmentToReimburseLicensorMember_qcBes6J9yk26oesBBlSUnQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfessionalAndContractServicesExpense" scale="6" id="Narr_nMNEyRDTkkiz2f-8pHoFvQ">10.1</ix:nonFraction> million in expense for such reimbursement, respectively. During the three and nine months ended September 30, 2018, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2018_To_9_30_2018_us-gaap_OtherCommitmentsAxis_edit_CommitmentToReimburseLicensorMember_KLzreovHakCeVBoLv9ifJA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfessionalAndContractServicesExpense" scale="6" id="Narr_mcU6seBpNESdH9nJoUVDgA">2.9</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_OtherCommitmentsAxis_edit_CommitmentToReimburseLicensorMember_niHDm0_cQUaXcYlHB5oJPA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfessionalAndContractServicesExpense" scale="6" id="Narr_rCf5d1gsjkmLRtRdgtiZcg">11.0</ix:nonFraction> million in expense for such reimbursement, respectively. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-style:italic;font-weight:bold;">Success Payments </span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-style:italic;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In 2016, the Company entered into patent license agreements with each of The General Hospital Corporation, d/b/a Massachusetts General Hospital (&#8220;MGH&#8221;), and Broad (collectively, the &#8220;2016 License Agreements&#8221;). Pursuant to the terms of the 2016 License Agreements, the Company is required to make certain success payments to MGH, Broad and Wageningen University (&#8220;Wageningen&#8221; and such payments, collectively, the &#8220;Success Payments&#8221;), payable in cash </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_UD5TkFcegk-Tlcx1TtoDgg_cont2"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">or, at the Company&#8217;s election, common stock in the case of MGH or, in the case of Broad and Wageningen, promissory notes payable in cash or, at the Company&#8217;s election subject to certain conditions, common stock of the Company. The Success Payments are payable, if and when, the Company&#8217;s market capitalization reaches specified thresholds for a specific period of time or upon a sale of the Company for consideration in excess of those thresholds (collectively, the &#8220;Payment Conditions&#8221;). </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Success Payments were historically accounted for under the provisions of ASC 505-50. Effective January 1, 2019, the Company adopted ASU 2018-07, which expands the scope of ASC 718 and superseded ASC 505-50. In accordance with ASC 718, the Company will recognize a Success Payment when it becomes probable that the Payment Conditions will be met. However, the Company has the right to terminate any of the 2016 License Agreements at will upon written notice. Absent any of the Payment Conditions being achieved prior to termination, the Company would not be obligated to pay any Success Payments. As such, the Company will recognize the expense and liability associated with each Success Payment when it is probable that the amounts will become due. The Company records this expense as a research and development expense in its condensed consolidated statements of operations. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-style:italic;font-weight:bold;">Research Funding Payments</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In June 2018, the Company entered into a sponsored research agreement (the &#8220;Sponsored Research Agreement&#8221;) with Broad. Pursuant to the terms of the Sponsored Research Agreement, the Company is required to make certain research funding payments to Broad, payable by promissory note, cash or common stock. Under the Sponsored Research Agreement, the Company is obligated to make payments of research funding to Broad in the event the Company&#8217;s market capitalization reaches specified thresholds ranging from a mid-nine digit dollar amount to a low-eleven digit dollar amount (&#8220;Market Cap Research Funding&#8221;) or a Company sale for consideration ranging from a mid-nine digit dollar amount to a low-eleven digit dollar amount (&#8220;Company Sale Research Funding&#8221; and, collectively with the Market Cap Research Funding, the &#8220;Research Funding Payments&#8221;). In connection with entering into the Sponsored Research Agreement, the Company confirmed that the first two Research Funding Payments of $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_6_30_2018_srt_CounterpartyNameAxis_edit_BroadInstituteIncMember_us-gaap_OtherCommitmentsAxis_edit_ResearchFundingPaymentsMember_us-gaap_TypeOfArrangementAxis_edit_SponsoredResearchAgreementMember_7EHzXBh5f0uI6WsTuZTqoQ" decimals="-5" format="ixt:numdotdecimal" name="edit:FundingPaymentsDueAndPayableOne" scale="6" id="Narr_viQ7nwBuAEeIURZEJxRE6A">5.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_6_30_2018_srt_CounterpartyNameAxis_edit_BroadInstituteIncMember_us-gaap_OtherCommitmentsAxis_edit_ResearchFundingPaymentsMember_us-gaap_TypeOfArrangementAxis_edit_SponsoredResearchAgreementMember_7EHzXBh5f0uI6WsTuZTqoQ" decimals="-5" format="ixt:numdotdecimal" name="edit:FundingPaymentsDueAndPayableTwo" scale="6" id="Narr_QdtaC6YWqEGi2wLWVMjO1g">7.5</ix:nonFraction> million were due and payable to Broad (the &#8220;Initial Research Payments&#8221;). </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Other than the Initial Research Payments, the Company is not required to make additional Research Funding Payments if the Company, whether directly or through its affiliates or sublicensees, is not researching, developing, or commercializing products based on or incorporating inventions developed under the Sponsored Research Agreement and exclusively licensed to the Company from Broad or based on or incorporating CRISPR technology owned, co-owned, or controlled by Broad and otherwise licensed to the Company, subject to certain exclusions. The Research Funding Payments were historically accounted for under the provisions of ASC Topic 505-50. Effective January 1, 2019, the Company adopted ASU 2018-07, which expands the scope of ASC 718 and superseded ASC 505-50. Under ASC 718, the Company will recognize the expenses and liability associated with each Research Funding Payment when it is probable that the amounts will become due. The Company records this expense as a research and development expense in its statements of operations. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In June 2018, in connection with the Company&#8217;s entry into the Sponsored Research Agreement and the trigger of the Initial Research Payments, the Company issued promissory notes in an aggregate principal amount of $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_6_30_2018_srt_CounterpartyNameAxis_edit_BroadInstituteIncMember_us-gaap_ShortTermDebtTypeAxis_edit_InitialNotesMember_us-gaap_TypeOfArrangementAxis_edit_SponsoredResearchAgreementMember_wPlaEbCo9EqUmdryXl5j9w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="6" id="Narr_LRZ4fG-ewE2LdaLx2U7yjA">12.5</ix:nonFraction> million to Broad (the &#8220;Initial Research Notes&#8221;) bearing interest at a rate of <ix:nonFraction unitRef="Unit_Standard_pure_E8xeiPkPjUOaCmQYBNvdag" contextRef="As_Of_6_30_2018_srt_CounterpartyNameAxis_edit_BroadInstituteIncMember_us-gaap_ShortTermDebtTypeAxis_edit_InitialNotesMember_us-gaap_TypeOfArrangementAxis_edit_SponsoredResearchAgreementMember_wPlaEbCo9EqUmdryXl5j9w" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_soMdz5K6fEKE2cK0v8lr8Q">4.8</ix:nonFraction>% per annum, except with respect to $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_srt_CounterpartyNameAxis_edit_BroadInstituteIncMember_us-gaap_ShortTermDebtTypeAxis_edit_InitialNotesMember_us-gaap_TypeOfArrangementAxis_edit_SponsoredResearchAgreementMember_wmULTOG4pU6RGgo-NX-daA" decimals="-5" format="ixt:numdotdecimal" name="edit:ThresholdPeriodInterestFreeDebtInstrumentFaceAmount" scale="6" id="Narr_6auklxNgN0ueLpWPiTbiyQ">7.5</ix:nonFraction> million of the principal, which would not start accruing interest until November 2018. The Company fully settled the outstanding principal and accrued interest on the Initial Research Notes by issuing <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_6_1_2018_To_6_30_2018_srt_CounterpartyNameAxis_edit_BroadInstituteIncMember_us-gaap_TypeOfArrangementAxis_edit_SponsoredResearchAgreementMember_e3dA74ixPEqD64XeFIza9A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="Narr_ouVUIAr4Rkyu-22O1Nk7mw">330,617</ix:nonFraction> shares of common stock to Broad in June 2018.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-style:italic;font-weight:bold;">Litigation</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company is not a party to any litigation and did not have contingency reserves established for any litigation liabilities as of September 30, 2019 or December 31, 2018.</p></ix:continuation><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="part_1_2_2"></a><a id="item_1_31_1"></a><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="Tb_ZfiSiebApUqWNMzeIP_ysQ" continuedAt="Tb_ZfiSiebApUqWNMzeIP_ysQ_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">8</b>. <b style="font-weight:bold;">Collaboration and License Agreements</b><span style="white-space:pre-wrap;">  </span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company has entered into multiple collaboration, license and strategic agreements with third parties that </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_IR2uUbGIskyzt8toqYzhlw_1_0"></a><a id="Tc_swB6giF1Cka71TT-XIvIWw_1_1"></a><a id="Tc_RzZ7zkBOLEe-eNnAYLflwQ_1_4"></a><a id="Tc_en972sISlEKHBtemwKKgdw_1_7"></a><a id="Tc_3VlC2FMefUqskGXAMmlYmg_1_10"></a><a id="Tc_sZ-UrJ8Ax0i7lIDvrRTrFQ_2_0"></a><a id="Tc_U75G5AcmsUuLMjvG5YHK_A_2_1"></a><a id="Tc_yOzUk7CNBUmjvj06akd8vw_2_4"></a><a id="Tc_yMjFVhb4Ak2GN7jN67RASA_2_7"></a><a id="Tc_Gtt8BPp8CkeRcr9zGcNazQ_2_10"></a><a id="Tc_H0stW3fE2kCqIDmftKgwAQ_3_0"></a><a id="Tc_xyEYytV8SEO_d26T895ScQ_4_0"></a><a id="Tc_iLdAqq5Y4E6z6HFk7pHCdQ_4_1"></a><a id="Tc_WMwgFzuExUG10sB9kjvKZg_4_4"></a><a id="Tc_3Q7jL4STA0qzSlSZrSlXYQ_4_7"></a><a id="Tc_7h-Mco5vCUyC4b2Vq1rZ0Q_4_10"></a><a id="_49aa9162_d93f_4b3f_9ab7_2795f8451fc6"></a><a id="Tc_M2eeBdASkUuI9ozB_MQ-fA_1_1"></a><a id="Tc_xqReMs2mnE-yj_fBuoKYaA_1_4"></a><a id="Tc_gRTGz0G6JEqa-rgKkj08Dw_2_0"></a><a id="Tc_MWJqpCQPp0iDChCEnlIwpw_2_1"></a><a id="Tc_dLaeJbfcpkq7qAVBrvRfTA_3_0"></a><a id="Tc_mi5_o9xapEmJHpiyp0S8jw_3_1"></a><a id="Tc_GqgWmlyEZkC3VeIxqcQlyw_3_4"></a><a id="Tc_bzzOvBooc0yUF1DzTPdgTQ_4_0"></a><a id="Tc_sioLzqZnp0OxB5Ykv5WWRA_4_1"></a><a id="Tc_qJOVF1OmZEeoP4Y63nZbHA_4_4"></a><a id="S143731731"></a><a id="_Hlk512592594"></a><ix:continuation id="Tb_ZfiSiebApUqWNMzeIP_ysQ_cont1" continuedAt="Tb_ZfiSiebApUqWNMzeIP_ysQ_cont2"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">typically involve the Company granting licenses to the Company&#8217;s intellectual property, receiving licenses to intellectual property rights and/or performing research and development services in exchange for upfront fees, milestone payments and royalty payments to or from the Company. The terms and conditions as well as the accounting analysis for the Company&#8217;s significant collaboration, license and strategic agreements are described in Note 9, &#8220;Significant Agreements,&#8221; to the consolidated financial statements included in the Annual Report. There have been no material changes to the terms and conditions, or the accounting conclusions previously disclosed in the Annual Report. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Collaboration Revenue</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">As of September 30, 2019, the Company&#8217;s contract liabilities were primarily related to the Company&#8217;s collaboration with Juno Therapeutics and strategic alliance with Allergan. <ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="edit:ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock" id="Group_hbm0RhZlZ02d0mCKGAReQQ" continuedAt="Group_hbm0RhZlZ02d0mCKGAReQQ_2" escape="true">The following table presents changes in the Company&#8217;s accounts receivable and contract liabilities for the nine months ended September 30, 2019 (in thousands):</ix:nonNumeric></p><ix:continuation id="Group_hbm0RhZlZ02d0mCKGAReQQ_2"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">For the nine months ended September 30, 2019</b></p></td><td colspan="2" style="background-color:auto;vertical-align:middle;width:13.51%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2018</b></p></td><td style="background-color:auto;vertical-align:middle;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:middle;width:11.97%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additions</b></p></td><td style="background-color:auto;vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:middle;width:11.35%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deductions</b></p></td><td style="background-color:auto;vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:middle;width:13.78%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at September&#160;30,&#160;2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Accounts receivable</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="3" id="Tc_wFhTaVWGqE-qRy3rD_lFow_2_2">30</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="edit:AccountsReceivableAdditions" scale="3" id="Tc_ns0oxaymU0yKE208DuEJvg_2_5">311</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:middle;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="edit:AccountsReceivableDeductions" scale="3" id="Tc_xPCr_nhiLUC9yjMIYPOmZA_2_8">30</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="3" id="Tc_i2Yu3FkB4EeJNEdi4_ZKdw_2_11">311</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Contract liabilities:</p></td><td style="vertical-align:bottom;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:45.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"><span style="white-space:pre-wrap;">  Deferred revenue</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:middle;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="Tc_bTv-ObLdbUug-s-5LeJ9hg_4_2">131,326</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="edit:ContractWithCustomerLiabilityAdditions" scale="3" id="Tc_dCvewnzqRkehb26ZEmgnXw_4_5">5,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:middle;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="edit:ContractWithCustomerLiabilityDeductions" scale="3" id="Tc_4fBrA1PezUaWGiZ9TNVenw_4_8">7,928</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="Tc_WtJJw79uWUy49b5_MTMHdg_4_11">128,398</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="edit:ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock" id="Tb_Y2ZI_-g4Ok6Mb2N5VQBzBg" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">During the three and nine months ended September 30, 2019, the Company recognized the following collaboration revenue (in thousands):</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:62.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:15.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:15.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:62.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:middle;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="background-color:auto;vertical-align:middle;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:middle;width:17.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="background-color:auto;vertical-align:middle;width:62.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Revenue recognized in the period from:</b></p></td><td colspan="5" style="background-color:auto;vertical-align:middle;width:37.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:62.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Amounts included in deferred revenue at the beginning of the period</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:middle;width:15.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="Tc_MynIM7cofkujAs9QEZjFtQ_3_2">2,354</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:middle;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="Tc_8XPFdUFTgEK2gfmSKtXj8w_3_5">6,733</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:62.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Performance obligations satisfied in previous periods</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:middle;width:15.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="3" id="Tc_QA6T6_9tBUCxx4vveYSBzQ_4_2">1,194</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:middle;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="3" id="Tc_bWb79DtdU0ykvGFS_r2_5Q_4_5">1,194</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Juno Therapeutics Collaboration Agreement </span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In May 2015, the Company entered into a Collaboration and License Agreement with Juno Therapeutics and in May 2018 the Company and Juno Therapeutics entered into an Amended and Restated Collaboration and License Agreement (collectively, the &#8220;Juno Agreement&#8221;). </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">There have been no material changes to the transaction price in the three or nine months ended September 30, 2019. As of September 30, 2019, the only milestones that were included in the transaction price were milestones that had been contractually earned and received. The outstanding milestones were fully constrained, as a result of the uncertainty regarding whether any of the milestones will be achieved. As of September 30, 2019, Juno Therapeutics has not exercised any of its options associated with the material rights identified in the Juno Agreement and no revenue has been recognized related to the material rights. Amounts allocated to each of the material rights will be recognized when the material right has been exercised or when the respective option has lapsed.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">During the three and nine months ended September 30, 2019, the Company did not recognize revenue related to the Juno Agreement. During the three and nine months ended September 30, 2018, the Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2018_To_9_30_2018_srt_CounterpartyNameAxis_edit_JunoTherapeuticsMember_us-gaap_TypeOfArrangementAxis_edit_CollaborationAndLicenseAgreementMember_O_MITT2wVkKnx6b-sggXmw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="Narr_PEdDQmw27E6UHxr8lRW76w">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_srt_CounterpartyNameAxis_edit_JunoTherapeuticsMember_us-gaap_TypeOfArrangementAxis_edit_CollaborationAndLicenseAgreementMember_DrDthce0AkygyZ1M-rBEkg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="Narr_DYQz2qFVLUSHllSoAOCOiQ">5.2</ix:nonFraction> million in revenue related to the Juno Agreement. As of September 30, 2019 and December 31, 2018, there was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_srt_CounterpartyNameAxis_edit_JunoTherapeuticsMember_us-gaap_TypeOfArrangementAxis_edit_CollaborationAndLicenseAgreementMember_MrTxHdu-80almYvZDCtdRw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_4Ra3H5PwYEG_N7v546SPdA"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_edit_JunoTherapeuticsMember_us-gaap_TypeOfArrangementAxis_edit_CollaborationAndLicenseAgreementMember_cKDlyfBM_E-va2ua4o2xGA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_3_236uygw0iHVLK4gxf3IA">32.0</ix:nonFraction></ix:nonFraction> million of deferred revenue related to the Juno Agreement, of which $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_srt_CounterpartyNameAxis_edit_JunoTherapeuticsMember_us-gaap_TypeOfArrangementAxis_edit_CollaborationAndLicenseAgreementMember_MrTxHdu-80almYvZDCtdRw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="Narr_3vT_oUGr-k-d06k8CVJ2mQ">32.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_edit_JunoTherapeuticsMember_us-gaap_TypeOfArrangementAxis_edit_CollaborationAndLicenseAgreementMember_cKDlyfBM_E-va2ua4o2xGA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="Narr_qyj2tXjiqkObgGlwpz_drA">2.8</ix:nonFraction> million were classified as short-term, respectively, in the accompanying condensed consolidated balance sheets. In addition, there were <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_srt_CounterpartyNameAxis_edit_JunoTherapeuticsMember_us-gaap_TypeOfArrangementAxis_edit_CollaborationAndLicenseAgreementMember_MrTxHdu-80almYvZDCtdRw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ReceivablesNetCurrent" scale="6" id="Narr_SXe7DUg3rkiW7QKVqDE67g"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_edit_JunoTherapeuticsMember_us-gaap_TypeOfArrangementAxis_edit_CollaborationAndLicenseAgreementMember_cKDlyfBM_E-va2ua4o2xGA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ReceivablesNetCurrent" scale="6" id="Narr_QLgVSZZoM0a8szCboh7vEQ">no</ix:nonFraction></ix:nonFraction> amounts classified in accounts receivable on the condensed consolidated balance sheets related to the Juno Agreement as of September 30, 2019 or December 31, 2018.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;min-height:10.0pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Allergan Pharmaceuticals Strategic Alliance and Option Agreement and Profit-Sharing Agreement</span></p><p style="font-family:'Times New Roman';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In March 2017, the Company entered into a Strategic Alliance and Option Agreement with Allergan to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders (the &#8220;Allergan Agreement&#8221;). Over a <ix:nonNumeric contextRef="Duration_3_1_2017_To_3_31_2017_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_2xE0WJjMoEOm6FHj79hUVg" format="ixt-sec:durwordsen" name="edit:ResearchProgramTerm" id="Narr_3klupBCLF0yFG8FIy66aXQ">seven-year</ix:nonNumeric> research term, Allergan will have an exclusive option to exclusively license from the </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk528762951"></a><ix:continuation id="Tb_ZfiSiebApUqWNMzeIP_ysQ_cont2"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Company up to <ix:nonFraction unitRef="Unit_Standard_item_rl1kcwMXZkCIZ-rzvXYVSA" contextRef="Duration_3_1_2017_To_3_31_2017_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_2xE0WJjMoEOm6FHj79hUVg" decimals="INF" format="ixt-sec:numwordsen" name="edit:NumberOfCollaborationDevelopmentPrograms" scale="0" id="Narr_QyBtA99WIEuWA_GzyNL_Qg">five</ix:nonFraction> collaboration development programs for the treatment of ocular disorders (each a &#8220;CDP&#8221;), including the Company&#8217;s Leber congenital amaurosis 10 (&#8220;LCA10&#8221;) program and the related experimental therapeutic EDIT-101 to treat LCA10 (the &#8220;LCA10 Program&#8221;).</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">There have been no material changes to the transaction price in the three or nine months ended September 30, 2019. As of September 30, 2019, the only milestone that was included in the transaction price had been contractually earned and received. The outstanding milestones were fully constrained, as a result of the uncertainty regarding whether any of the milestones will be achieved. The Company has concluded that the options to purchase <ix:nonFraction unitRef="Unit_Standard_item_rl1kcwMXZkCIZ-rzvXYVSA" contextRef="Duration_1_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_Nw7YnWbU5EWBxR7zlJEm8g" decimals="INF" format="ixt-sec:numwordsen" name="edit:NumberOfAdditionalDevelopmentAndCommercializationLicenseToBePurchased" scale="0" id="Narr_Vtoct5J0o0iXKezJwApRJw">five</ix:nonFraction><span style="white-space:pre-wrap;"> development and commercialization licenses are considered a marketing offer as the options did not provide any discounts or other rights that would be considered a material right in the arrangement. In August 2018, Allergan exercised its right to the LCA10 Program and the option fee was recognized as revenue during the three months ended September 30, 2018 when the control transferred to Allergan.  </span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">During the three and nine months ended September 30, 2019, the Company recognized revenue related to the Allergan Agreement of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_xU8d1nrnWkeSzheIpGvdWg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="Narr_UXeDdZsvMEWay8ecksKzAw">3.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_Nw7YnWbU5EWBxR7zlJEm8g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="Narr_gvtyph14pk6l8Z9B6Dsk_A">7.7</ix:nonFraction> million, respectively. During the three and nine months ended September 30, 2018, the Company recognized revenue related to the Allergan Agreement of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2018_To_9_30_2018_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_RhdoXjew9EeVWvTWLV9vCA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="Narr_RA2S-AEBtUu1BF5XIzs1cg">13.8</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_L3rm1o4tuUiQrTClwY11ug" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="Narr_KKY9iYe2TUifDEzYCKcpeA">16.7</ix:nonFraction> million, respectively. As of September 30, 2019 and December 31, 2018, there was $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_r45DsPeVZECbm550Uuu09w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_SECKh8DA6EqPyWmwG6Q8ug">91.6</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_qZ56Qn1U9Ee0sa4UlEgnKA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_9BYCDNKFG0SjRgy53-v_Ew">99.2</ix:nonFraction> million of deferred revenue related to the Allergan Agreement, respectively, of which $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_r45DsPeVZECbm550Uuu09w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="Narr_sM00V3-ivEO7wBG5lx3gow">79.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_qZ56Qn1U9Ee0sa4UlEgnKA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="Narr_MPPX_Iol-UGDNseZO4AgXQ">86.4</ix:nonFraction> million is classified as long-term on the condensed consolidated balance sheet, respectively. There were <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_r45DsPeVZECbm550Uuu09w" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ReceivablesNetCurrent" scale="6" id="Narr_JKFUDNlE1kOaxTnM1HFvWw"><ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_qZ56Qn1U9Ee0sa4UlEgnKA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ReceivablesNetCurrent" scale="6" id="Narr_GGgdktEcKECroUWYzF5eNA">no</ix:nonFraction></ix:nonFraction> amounts classified in accounts receivable on the condensed consolidated balance sheets related to the Allergan Agreement. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:31.7pt;margin:0pt 0pt 0pt 4.3pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company and an affiliate of Allergan (together with Allergan, the &#8220;Allergan Entities&#8221;) agreed to equally split U.S. profits and losses for the LCA10 Program in the United States and to co-develop the LCA10 Program in the United States (the &#8220;Profit-Sharing Agreement&#8221;). The Company accounts for the Profit-Sharing Arrangement with respect to the LCA10 Program within the scope of ASC Topic 808, <i style="font-style:italic;">Collaborative Arrangements</i>, given that the Company and the Allergan Entities are active participants in future research and development activities and all parties are exposed to significant risks and rewards dependent on the commercial success of such activities. During the three and nine months ended September 30, 2019, the Company and the Allergan Entities incurred $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_xU8d1nrnWkeSzheIpGvdWg" decimals="-5" format="ixt:numdotdecimal" name="edit:ProgramExpense" scale="6" id="Narr_Xjo_H7TZrEGM9-CDEU6nYw">4.9</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_Nw7YnWbU5EWBxR7zlJEm8g" decimals="-5" format="ixt:numdotdecimal" name="edit:ProgramExpense" scale="6" id="Narr_U5NjSa_jJESL5dp1nwRCUA">13.9</ix:nonFraction> million in expense associated with the LCA10 Program, respectively, of which the Company recognized <ix:nonFraction unitRef="Unit_Standard_pure_E8xeiPkPjUOaCmQYBNvdag" contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_FOjXNGrOA0OHMOM6s36fPg" decimals="2" format="ixt:numdotdecimal" name="edit:ShareOfExpenseRecognizedPercentage" scale="-2" id="Narr_1_JBo8bUBE2EHMW8oYvn-g"><ix:nonFraction unitRef="Unit_Standard_pure_E8xeiPkPjUOaCmQYBNvdag" contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_i04SOq9XXU-b-tSVEl5LSA" decimals="2" format="ixt:numdotdecimal" name="edit:ShareOfExpenseRecognizedPercentage" scale="-2" id="Narr_k-hIcrtfZ0G5aJ7ldZ849g">50</ix:nonFraction></ix:nonFraction>% in operating expense during such periods.<span style="white-space:pre-wrap;">  </span></p></ix:continuation><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_449e046b_d21c_4b95_91dc_819c40d6570f"></a><a id="Tc_NmOwYR4Ff0i3PKFadqejXw_3_2"></a><a id="Tc_wkWzhWsf20Wt3VRcESKhUQ_3_8"></a><a id="Tc_kx-vAANj-0O6-KnytmUnHQ_4_2"></a><a id="Tc_2QUvuOuR90aFMfjrqRxvwA_4_8"></a><a id="Tc_oSPFB8QapkaKX95CjBBWTA_5_2"></a><a id="Tc_dGgBt9AdQkqjNLSPi09Igg_5_5"></a><a id="Tc_uzhwwhB5sEObpkdLHZx8IA_5_8"></a><a id="Tc_qIRxiU5J3E6PWq12xcSOZw_5_11"></a><a id="Tc_jULaXUP2xEOAhdRKYItENg_6_0"></a><a id="Tc_2Bjb60olx0ecdCPzB_zFBQ_6_2"></a><a id="Tc_r4LKqrr6I0-GZa-qSBmrjg_6_5"></a><a id="Tc_8wuakRsdmkq_k8Y-s-a1Rw_6_8"></a><a id="Tc_GH5XiE0g0kWhCMGLNhIYWQ_6_11"></a><a id="Tc_tEu9TFKve0y--cYgrFSBig_7_0"></a><a id="Tc_X8gA7GZlt0S6mlelPSk5hw_8_0"></a><a id="Tc_-CpUurQNqUWqDl2ZMhaTkA_8_2"></a><a id="Tc_WtkEvi1nDEuZ7cEXaDUtmA_8_5"></a><a id="Tc_NNBErOZd6Em_DDcWobbVuQ_8_8"></a><a id="Tc_gTg8sFgwJECfrnsLz6z48g_8_11"></a><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb__U0toaE7U06YCU8hVP0VJw" continuedAt="Tb__U0toaE7U06YCU8hVP0VJw_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">9</b>. <b style="font-weight:bold;">Stock-based Compensation</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_2QZibGcvtUGVLl3RcSnEpA" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Stock-based compensation expense by classification included in the condensed consolidated statements of operations was as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.04%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:22.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:middle;white-space:nowrap;width:20.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:middle;white-space:nowrap;width:22.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_wZjwFdhl40-qubyppSmKOA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_wdFJ_a_wo02PkjfVGPeTJg_6_3">3,619</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2018_To_9_30_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_kzBgCnpG60KUgNvcF9BukA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_4H10lNivfkukj9nX3F_pUg_6_6">3,506</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_aNajZe-YxUercIojM7dr8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_13fjCH205Ee83Qkd41IJCQ_6_9">10,854</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_iZuu8Cy3U0irlLMZI7Q0TQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_yTvXndE91kCKsWcy6NYbzA_6_12">11,412</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_r_4eSnuC80mudfKuh14VtQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_sVcFwUUsFEe556nbxfYm7g_7_3">2,940</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2018_To_9_30_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_Ra72AcdpGUyjMWqQfhIMxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_vCLJxZ9UsU2ry2HVAEzstg_7_6">3,193</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_MupqsEB1_kKTyw545CGbAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_E2EgieR3EUupdhTS7J2DYw_7_9">10,053</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_TvpaFuwJQkG6gdsSbxfjjw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_glGBGvEUq0-sVj4fHZbNVA_7_12">8,839</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Total stock-based compensation expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_cKrfQzryfk6tQ5mROSQU4A_8_3">6,559</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_rZyp4HmROECdEBsl4O59kQ_8_6">6,699</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_wEm76r3da0ms8DP88TCM6A_8_9">20,907</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_XEUJzT9vdEiE5bOWBK-nMg_8_12">20,251</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-style:italic;font-weight:bold;">Restricted Stock and Restricted Stock Unit Awards</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="Tb_YRLQ0llqPkar_3QClLiz2A" continuedAt="Tb_YRLQ0llqPkar_3QClLiz2A_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The following table summarizes restricted stock and restricted stock unit awards activity for the nine months ended September 30, 2019:</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7fa4cb83_c29f_4659_b55f_9da843385cbe"></a><a id="Tc_ZtM5So15cUWAPzJZe1WgLQ_1_4"></a><a id="Tc_ywvD2IlWf0GrzaySLVnXuA_2_4"></a><a id="Tc_z6w4RkSkgkO-hxT8hSoISA_3_4"></a><a id="Tc_RkQa7k2MP0CR15D0l6fwWA_4_4"></a><a id="Tc_7ou9qDYC7EuFvXbW4yFkHQ_5_2"></a><a id="Tc_KQtFIhBrdkyuoOO8yRLXYw_5_4"></a><a id="Tc_R5nTzVWfrkKZ-Pz6rJg__g_6_0"></a><a id="Tc_kxvDsVk3sEOtshuQft9ORA_6_4"></a><a id="Tc_8zvWvR7Ouke4SYxJsSIA4Q_7_0"></a><a id="Tc_V4-WOMnDPk25LLAEzRKSCQ_7_4"></a><a id="Tc_XPkodxJBhEGnf8mzpFfmoQ_8_0"></a><a id="Tc_S09A7ovMgkupwaSuH1tu5A_8_4"></a><a id="Tc_5s3QnmzZvUuzs5LL0VC2XA_9_0"></a><a id="Tc_6gSm7Z8O5E-3SESPdbgmlA_9_4"></a><a id="Tc_se2PgfqtXUGN1zgN1Cf69g_10_0"></a><a id="Tc_Cu_nBE3WTUmAy8Uo3trzhw_10_4"></a><a id="_0655dac7_cd01_4fc5_b121_da862b7c3584"></a><a id="Tc_sDRn_nos8USk1YGWVG67mw_1_4"></a><a id="Tc_bwb2wTG0EU6KyTkQJ6olkw_1_7"></a><a id="Tc_rrAdrPwgskGu6WpwBtkkKQ_1_9"></a><a id="Tc_ruk1vEK-xkyv1cqny6hjSA_2_2"></a><a id="Tc_mgzEA-neYUSNdG6MEuWFEw_2_4"></a><a id="Tc_e5QsG6HbFU62F9g3NkMpWw_2_7"></a><a id="Tc_kRavoTQLf0GGfJj3Yp9N9g_2_9"></a><a id="Tc_a9mZ0CV4HUebjXD7bX6EsA_3_0"></a><a id="Tc_fCzZix6xG0GFUZ0Vqi4L2Q_3_4"></a><a id="Tc_I1hOqfehkUKfBlQYc3hlnA_3_9"></a><a id="Tc_3lJqCkt2-k2h_W5ObcLPfA_4_0"></a><a id="Tc_8biUmSGMvUKlUrR6U9wAEg_4_4"></a><a id="Tc_9lAwd_KujEaUKqbM4rwMLg_5_0"></a><a id="Tc_5o89LrsdWUSzfEgaKqEv4w_5_4"></a><a id="Tc_0UrZanehz0OpBoqjX21mqA_6_0"></a><a id="Tc_nSuMjGE5gUqPeR_tRva3AA_6_4"></a><a id="Tc_f7uHc1xjREyy-NOmTxkfrA_7_0"></a><a id="Tc_2KeDL_0VhU25ZytOtKHp3w_7_4"></a><a id="Tc_QT1ESBQCYEORZ1-ZPKf-WQ_7_9"></a><a id="Tc_wk-DSfvU10e2YZiDSGwinQ_8_0"></a><a id="Tc_tNhxIGf2kkyTOBVPNNd4dQ_8_4"></a><a id="Tc_ogsF1dIK502vmEs3-W60ig_8_9"></a><ix:continuation id="Tb__U0toaE7U06YCU8hVP0VJw_cont1"><ix:continuation id="Tb_YRLQ0llqPkar_3QClLiz2A_cont1"><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant&#160;Date</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Per&#160;Share</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Unvested restricted stock and restricted stock unit awards as of December&#160;31,&#160;2018</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_hR1_hOzi8U-JsdyKF-ouEg_6_2">270,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_Ofn2wj5VDka2uMI7PnuzBQ_6_5">28.05</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_z_etvWkh9EKOAYpXhPrUPg_7_2">445,126</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_-VkosgBrbEuztEmLi0sDqA_7_5">21.94</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Vested</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_zBq-y1XrJUSCPuE-Zqz4ag_8_2">77,052</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_1tRilcdMi06E34-jvD5Jyg_8_5">26.47</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Tc_ZfumXWt9OUSeUE1dzJZQBA_9_2">51,182</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="Tc_CSYKem6hQkG88y7U_n5r9g_9_5">21.40</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Unvested restricted stock and restricted stock unit awards as of September 30, 2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_Src3gru270yYn6QbtZPNgQ_10_2">586,892</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_gMp2Qf3U50Chb3zPYgiJoQ_10_5">24.20</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">As of September 30, 2019, the Company had $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="Narr_ah7_ygEBvkeMLN39fq2XmA">9.8</ix:nonFraction> million in unrecognized stock-based compensation expense related to unvested restricted stock and unvested restricted stock unit awards.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-style:italic;font-weight:bold;">Stock Options</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_owSKrmD0lUa9OgyIChbPPQ" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The following table summarizes stock option activity for the nine months ended September 30, 2019:</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate&#160;Intrinsic</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:17.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual&#160;Life (years)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value&#160;(in&#160;thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Outstanding at December&#160;31,&#160;2018</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_VoIrlRhZgECWwjHv6DWUog_3_2">4,689,786</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_Md0cXRjNj0K1e_ezSRhCeA_3_5">23.80</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2018_To_12_31_2018_zrodnEw_VUizLBhcAZpOsg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_3KtGDTjz30uYsMw-h4P5xA_3_7"> 7.9</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_QRlmsMJcq0mKAc-w6yFTaA_3_10">20,686</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_y1Z4kjvoeUKYhWCGets99Q_4_2">1,500,502</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_U2I9CFu4MkWwMIrbIQAMsw_4_5">24.30</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_65XfnVWiGUmTMg-cRWM-wQ_5_2">502,234</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_6JeZSfPbgE2RFse7mb3XxA_5_5">11.46</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="Tc_IilO5R9m5EWQ5ukopEe93Q_6_2">546,799</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_Omlk2rdPfUam4XIM0kycIA_6_5">28.15</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Outstanding at September 30, 2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_E-UD6FOgb0OU5q-KT8V_jg_7_2">5,141,255</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_8uMbigJPPUeD3J5Zob1A6Q_7_5">24.69</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_w_fMiNXZj0K_CWE8G5S6mw_7_7"> 7.5</ix:nonNumeric></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_H_jnsxV0OUCavztryWYF1A_7_10">14,899</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Exercisable at September 30, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_-32e8Kt1iEmNCFZpoh5ZJQ_8_2">2,386,635</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_IcsbWfWGjE6rPqR-FTRe2A_8_5">21.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_odJhoKDQbUikZHiL8KRvqg_8_7"> 7.0</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="Tc_Vw2IHVWCJkG6LtIf6HYlDA_8_10">13,238</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The stock options granted in the nine months ended September 30, 2019 include an option granted to the Company&#8217;s Chief Executive Officer to purchase <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_1_1_2019_To_9_30_2019_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_dmEKC8zRkUGaNSfj2wtDJQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_3pU8SHZF50atL5xDZ2SLyg">250,000</ix:nonFraction> shares of the Company&#8217;s common stock that contains market-based vesting provisions. The Company is recognizing the fair value of these options over the earlier of the derived service period, valued using the Monte-Carlo simulation model, or when the market-based vesting conditions are met. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">As of September 30, 2019, the Company had unrecognized stock-based compensation expense related to its employee and director stock options that contain service-based vesting of $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="As_Of_9_30_2019_srt_TitleOfIndividualAxis_edit_EmployeeAndDirectorMember_DG1Lr8lP_0-bT3_QEQxdtQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="Narr_BpQcS0XJcEy-Fl4mFIB3Jw">38.1</ix:nonFraction> million, which the Company expects to recognize over the remaining weighted average vesting period of <ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_srt_TitleOfIndividualAxis_edit_EmployeeAndDirectorMember_VQVIkfmCb0mvWmtS1VrR7A" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_tcxWla1U80CGPqth5KtA1Q">2.64</ix:nonNumeric> years.</p></ix:continuation><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_cp_text_4_32"></a><a id="_cp_text_1_33"></a><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="us-gaap:EarningsPerShareTextBlock" id="Tb_4aESkqvYokqcE7OZFvq3lQ" continuedAt="Tb_4aESkqvYokqcE7OZFvq3lQ_cont1" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">10. Net Loss per Share</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury stock and if converted methods. Contingently issuable shares are included in the calculation of basic loss per share as of the beginning of the period in which all the necessary conditions have been satisfied. Contingently issuable shares are included in diluted loss per share based on the number of shares, if any, that would be issuable under the terms of the arrangement if the end of the reporting period was the end of the contingency period, if the results are dilutive.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">For purposes of the diluted net loss per share calculation, stock options are considered to be common stock equivalents, but they were excluded from the Company&#8217;s calculation of diluted net loss per share allocable to common stockholders because their inclusion would have been anti-dilutive. Therefore, basic and diluted net loss per share applicable to common stockholders was the same for all periods presented.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In connection with at-the-market offerings consummated by the Company during 2018 and during the third quarter of 2019, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarketOfferingMember_Ow36SSy4wUiSEqoR3C4BvA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_CBlyT3oUVEW93F9G-MnLUw">2,536,205</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarketOfferingMember_-kac0ehTwkynz560Ie4IPQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_uyCMlsmsM0WBLfGwc4S4zg">1,721,735</ix:nonFraction> shares of its common stock, respectively. The issuance of </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e01e5798_207a_4f5d_83c1_b9417bd3adda"></a><a id="Tc_NAR2suSJx0mJlYIJvO50hw_1_3"></a><a id="Tc_r3g_UT0rlUahOaRX0MjafQ_2_3"></a><a id="Tc_taOoyzk_eUmyzkOTDCW1Hw_2_5"></a><a id="Tc_Map03iXsOEex8GAfBimF9A_3_0"></a><a id="Tc_mJZgrM91FU6wNcm34FPFOg_4_0"></a><a id="Tc_yOvqAZKSCkeSYco7HqC25A_5_0"></a><ix:continuation id="Tb_4aESkqvYokqcE7OZFvq3lQ_cont1"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">these shares resulted in a significant increase in the Company&#8217;s weighted-average shares outstanding and is expected to continue to impact the year-over-year comparability of the Company&#8217;s net loss per share calculations for the remainder of 2019 and 2020.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_nDIFvXt7IU2-xh3WCEvsyA" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The following common stock equivalents were excluded from the calculation of diluted net loss per share allocable to common stockholders because their inclusion would have been anti-dilutive:</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:73.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:21.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of September&#160;30,&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:73.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Unvested restricted stock and restricted stock unit awards</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_Onzl5CFXo0u2R96djFM_ag" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_7qXsvjIKnkmoa3TrVC9ybA_3_3">586,892</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_WBkfEEnpwE-fkbIkbfPsmQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_6fJP79XifE-x3bT5BUJRCQ_3_5">288,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Outstanding stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_MMdAUyO5fE6SZ9Hb9jRH_A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_Wb-aALSW8Uim5oInDpisYQ_4_3">5,141,255</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_1CwvMLjJmEu4BIw00uKzhw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_IIwNZ3KbnUyyiWoECGZ9kg_4_5">4,822,486</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_6GTQ_ffYe0GkSEJ1rVrRcg_5_3">5,728,147</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_zrUAbPPrfkq7RJxKPRxgvQ_5_5">5,110,486</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="Narr_lXNNHWW-X0qZhLLbGwWF7Q"></a><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_lADh72CDJE6-0zWiy7qqdQ" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">11. Related-Party Transactions </b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company received $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_RelatedPartyTransactionAxis_edit_RentAndFacilityRelatedFeesMember_Exbi6JGLz0aiPwGT7WbBAw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" scale="6" id="Narr_J6tkY7rsdUGVK1TR3Lg6_A">0.4</ix:nonFraction> million in rent and facility-related fees from a related party during the nine months ended September 30, 2018 in connection with the Company&#8217;s Hurley Street sublease. No rent or facility-related payments were received from this related party during the nine months ended September 30, 2019. </p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA" name="us-gaap:SubsequentEventsTextBlock" id="Tb_kAHSBUDHkE-pkp41fFvDSA" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">12. Subsequent Events</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In November 2019, the Company entered into a Second Amended and Restated Collaboration and License Agreement with Juno, pursuant to which the Company is entitled to receive a $<ix:nonFraction unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg" contextRef="Duration_11_1_2019_To_11_30_2019_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_edit_JunoTherapeuticsMember_9ZN4nSHh5EeubrbKBSQ-Jw" decimals="-5" format="ixt:numdotdecimal" name="edit:CollaborationAndLicenseAgreementAmendmentFeeReceived" scale="6" id="Narr_imk9VWL5BkOMU7icuuoQBA">70.0</ix:nonFraction> million payment, and a related License Agreement.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In October 2019, the Company&#8217;s board of directors approved an inducement grant to the Company&#8217;s recently hired Chief Medical Officer, including an option to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_10_1_2019_To_10_31_2019_srt_TitleOfIndividualAxis_edit_ChiefMedicalOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_ER3lg9N5AUW1GcUOCxl1VQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_F6ENTTYMfkWfz7Uq9KC2pg">150,000</ix:nonFraction> shares of the Company&#8217;s common stock and an award of <ix:nonFraction unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ" contextRef="Duration_10_1_2019_To_10_31_2019_srt_TitleOfIndividualAxis_edit_ChiefMedicalOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_oocRI-BsJkm3KP9_DGx7bQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_uL4HdvpntUSB7uGn4SEv-A">25,000</ix:nonFraction> restricted stock units.</p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_4e58a4c4_a0ed_4be6_ac94_8406f068d41b"></a><a id="Item2ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Item&#160;2.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">The following discussion and analysis of our financial condition and results of operations should be read together with our condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2018, which was filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on March 1, 2019 (the &#8220;2018 Annual Report&#8221;).</i></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><i style="font-style:italic;">This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. There are a number of important risks and uncertainties that could cause our actual results to differ materially from those indicated by forward-looking statements. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Quarterly Report on Form 10-Q, particularly in the section entitled &#8220;Risk Factors&#8221; in Part II, Item 1A that could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make.</i></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">&#160;</i></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><i style="font-style:italic;">You should read this Quarterly Report on Form 10-Q and the documents that we have filed as exhibits to this Quarterly Report on Form&#160;10-Q completely and with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements contained in this Quarterly Report on Form 10-Q are made as of the date of this Quarterly Report on&#160;Form&#160;10-Q, and we do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.</i></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk496712610"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">We are a leading, clinical stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. We have developed a proprietary genome editing platform based on CRISPR technology and we continue to expand its capabilities. Our product development strategy is to target genetically addressable diseases where gene editing can be used to enable or enhance therapeutic outcomes for patients. Genetically addressable diseases include genetically defined diseases that may be treated by correcting a disease-causing gene and genetically treatable diseases that do not necessarily have a single, disease causing gene, but which nonetheless may be treated by editing the genome to ameliorate or eliminate the signs or symptoms of the disease. We are advancing both <i style="font-style:italic;">in vivo</i> CRISPR medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body, and engineered cell medicines, in which cells are edited with our technology and then administered to the patient. While our discovery efforts have ranged across several different genetically addressable diseases and therapeutic areas, the two areas where our programs are more mature are ocular diseases and engineered cell medicines to treat blood diseases and cancer.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>In ocular diseases, our most advanced program is designed to address a specific genetic form of retinal degeneration called Leber congenital amaurosis 10 (&#8220;LCA10&#8221;), a disease for which we are not aware of any available therapies and only one other potential treatment in clinical trials in the United States and Europe. In mid-2019, we initiated a Phase 1/2 clinical trial for EDIT-101 (also known as AGN-151587), an experimental medicine to treat LCA10, pursuant to an investigational new drug application (&#8220;IND&#8221;) that we filed in October 2018 and which was accepted by the United States Food and Drug Administration (&#8220;FDA&#8221;) in November 2018. We and our partner Allergan Pharmaceuticals International Limited (together with its affiliate, &#8220;Allergan&#8221;) recently began patient screening and aim to begin patient dosing by early 2020. We expect to enroll approximately 18 patients in the United States and Europe.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>As part of our long term strategy, we have developed and articulated goals for our pipeline of experimental medicines and our company that we are working to achieve by the end of 2022. These goals, which we call &#8220;EM22,&#8221; include having at least three experimental medicines in early stage clinical trials and at least two additional experimental medicines in or ready for late stage clinical trials. In addition, we aim to have a pipeline characterized by potential best-in-class medicines and to be a company with the leading genome editing platform and organizational culture.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>In May 2015, we entered into a collaboration with Juno Therapeutics, Inc., a Celgene company that is a wholly-owned subsidiary of Celgene Corporation (&#8220;Juno Therapeutics&#8221;), a leader in the emerging field of immuno-oncology, to develop novel engineered T cell therapies for cancer, which was amended and restated in each of May 2018 and November 2019, at which time we also entered into a related license agreement with Juno Therapeutics, which we collectively refer to as our collaboration with them. In March 2017, we entered into a strategic alliance and option agreement with Allergan to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders. In July 2018, Allergan exercised its option to develop and commercialize EDIT-101 and paid us $15.0 million in connection with such exercise (the &#8220;EDIT-101 Option Exercise Payment&#8221;). We and Allergan subsequently entered into a co-development and commercialization agreement under which we will co-develop and equally split profits and losses for EDIT-101 in the United States. In December 2018, we also received a $25.0 million payment from Allergan in connection with the acceptance of the IND for EDIT-101 (the &#8220;EDIT-101 Milestone Payment&#8221;).</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Since our inception in September 2013, our operations have focused on organizing and staffing our company, business planning, raising capital, establishing our intellectual property portfolio, assembling our core capabilities in genome editing, seeking to identify potential product candidates, and undertaking preclinical studies. Except for EDIT-101, all of our research programs are still in the preclinical or research stage of development and the risk of failure of all of our research programs is high. We have not generated any revenue from product sales. We have funded our operations primarily through the initial public offering of our common stock, follow-on public offerings of our common stock including through at-the-market offerings, private placements of our preferred stock, payments received under our collaboration with Juno Therapeutics and payments received under our strategic alliance and co-development and commercialization agreements with Allergan and its affiliate. From inception through September 30, 2019, we raised an aggregate of $725.3 million to fund our operations. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Since inception, we have incurred significant operating losses. Our net losses were $96.0 million and $84.9 million for the nine months ended September 30, 2019 and 2018, respectively. As of September 30, 2019, we had an accumulated deficit of $511.5 million. We expect to continue to incur significant expenses and operating losses for the foreseeable future. Our net losses may fluctuate significantly from quarter to quarter and from year to year. We anticipate that our expenses will increase substantially as we continue our current research programs and our preclinical development activities; progress the clinical development of EDIT-101 with Allergan; seek to identify additional research programs and additional product candidates; initiate preclinical testing and clinical trials for other product candidates we identify and develop; maintain, expand, and protect our intellectual property portfolio, including reimbursing our licensors for such expenses related to the intellectual property that we in-license from such licensors; further develop our genome editing platform; hire additional clinical, quality control, and scientific personnel; and incur additional costs associated with operating as a public company. We do not expect to be profitable for the year ending December 31, 2019 or the foreseeable future.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Financial Operations Overview</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Revenue</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To date, we have not generated any revenue from product sales and we do not expect to generate any revenue from product sales for the foreseeable future. In connection with entering into our collaboration with Juno Therapeutics in May 2015, we received an upfront payment of $25.0&#160;million, and, in each of May 2016 and July 2017, we received a milestone payment of $2.5&#160;million. In May 2018, in connection with the amendment and restatement of our collaboration agreement with Juno Therapeutics to expand our collaboration to add an additional research program, we received $5.0 million for amending the agreement and two $2.5 million milestone payments for technical progress in a research program. In addition, we were entitled to receive up to $22.0&#160;million in research support over the five years of the collaboration and across the four programs under the collaboration, subject to adjustment in accordance with the terms of the agreement and, as of September 30, 2019, we had recognized an aggregate of $17.7 million of such research support. During the nine months ended September 30, 2019, we did not recognize any research support from Juno Therapeutics. As of September 30, 2019, we recorded $32.0 million of deferred revenue, all of which is classified as current on our condensed consolidated balance sheet, related to the collaboration. In November 2019, we further amended and restated our collaboration with Juno Therapeutics. Pursuant to the amended and restated collaboration, we are entitled to receive a $70.0 million payment from Juno Therapeutics and will no longer receive research support under such collaboration.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> In connection with entering into our strategic alliance with Allergan, we received an upfront payment of $90.0 million from Allergan and in 2018 we received $15.0 million for the EDIT-101 Option Exercise Payment and $25.0 million for the EDIT-101 Milestone Payment. Through September 30, 2019, we had recognized an aggregate of $38.4 million in revenue related to our strategic alliance with Allergan, which includes all of the EDIT-101 Option Exercise Payment and a portion of the EDIT-101 Milestone Payment. During the nine months ended September 30, 2019, we recognized $7.7 million in revenue related to our strategic alliance with Allergan. As of September 30, 2019, we recorded $91.6 million of deferred revenue, $79.0 million of which is classified as long-term on the condensed consolidated balance sheet, related to the upfront payment from Allergan and a portion of the EDIT-101 Milestone Payment. For additional information about our revenue recognition policy related to the Juno Therapeutics collaboration or the Allergan agreement, see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Critical Accounting Policies and Estimates&#8212;Revenue Recognition&#8221; in the 2018 Annual Report.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the foreseeable future, we expect substantially all of our revenue will be generated from our collaboration with Juno Therapeutics, our strategic alliance with Allergan, any other collaborations or agreements we may enter into and anticipated interest income.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Expenses</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Research and development expenses consist primarily of costs incurred for our research and development activities, including our drug discovery efforts and preclinical studies under our research programs, which include:</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">employee-related expenses including salaries, benefits, and stock-based compensation expense;</span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">costs of funding research performed by third parties that conduct research and development and preclinical activities on our behalf;</span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">costs of purchasing lab supplies and non-capital equipment used in our preclinical activities and in manufacturing preclinical study materials;</span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">consultant fees;</span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">facility costs including rent, depreciation, and maintenance expenses; and</span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">fees for acquiring and maintaining licenses under our third-party licensing agreements, including any sublicensing or success payments made to our licensors. </span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Research and development costs are expensed as incurred. At this time, we cannot reasonably estimate or know the nature, timing, and estimated costs of the efforts that will be necessary to complete the development of any product candidates we may identify and develop. This is due to the numerous risks and uncertainties associated with developing such product candidates, including the uncertainty of:</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">successful completion of preclinical studies, IND-enabling studies and natural history studies;</span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">successful enrollment in, and completion of, clinical trials;</span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">receipt of marketing approvals from applicable regulatory authorities;</span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;</span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">obtaining and maintaining patent and trade secret protection and non-patent exclusivity;</span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">launching commercial sales of a product, if and when approved, whether alone or in collaboration with others;</span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">acceptance of a product, if and when approved, by patients, the medical community, and third-party payors;</span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">effectively competing with other therapies and treatment options;</span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">a continued acceptable safety profile following approval;</span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">enforcing and defending intellectual property and proprietary rights and claims; and</span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">achieving desirable medicinal properties for the intended indications.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">A change in the outcome of any of these variables with respect to the development of any product candidates we develop would significantly change the costs, timing, and viability associated with the development of that product </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">candidate. As a result of Allergan&#8217;s exercise of its option to license EDIT-101 and our entry into a profit-sharing arrangement with Allergan in the United States for EDIT-101, our obligations to fund such program in the United States will represent 50% of the total costs related to developing and commercializing the program in the United States.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>We do not track research and development costs on a program-by-program basis except for reimbursable amounts that relate to third-party agreements.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>Research and development activities are central to our business model. We expect research and development costs to increase significantly for the foreseeable future as our development programs progress, including as we continue to progress the clinical development of EDIT-101 with Allergan as well as supporting preclinical studies for our other research programs. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">General and Administrative Expenses</i></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation for personnel in executive, finance, investor relations, business development, legal, corporate affairs, information technology, facilities and human resource functions. Other significant costs include corporate facility costs not otherwise included in research and development expenses, legal fees related to intellectual property and corporate matters, and fees for accounting and consulting services.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">We anticipate that our general and administrative expenses will increase in the future to support continued research and development activities and potential commercialization of any product candidates we identify and develop. These increases will include increased costs related to the hiring of additional personnel and fees to outside consultants. We also anticipate increased expenses related to reimbursement of third-party patent-related expenses and expenses associated with operating as a public company, including costs for audit, legal, regulatory, and tax-related services, director and officer insurance premiums, and investor relations costs. With respect to reimbursement of third-party intellectual property related expenses specifically, given the ongoing nature of the opposition and interference proceedings involving the patents licensed to us under our license agreement with The Broad Institute, Inc. (&#8220;Broad&#8221;) and the President and Fellows of Harvard College (&#8220;Harvard&#8221;), we anticipate general and administrative expenses will continue to be significant. Some of our in-licensed patents and patent applications under our license agreement with Broad and Harvard are also subject to priority disputes, and we anticipate that our obligation to reimburse Broad and Harvard for expenses related to these disputes during future periods will be substantial until such proceedings are resolved.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Other Income (Expense), Net</i></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>For the nine months ended September 30, 2019, other income (expense), net consisted primarily of interest income and accretion of discounts associated with marketable securities, partially offset by loss on disposal of property and equipment.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>For the nine months ended September 30, 2018, other income (expense), net consisted primarily of interest income, accretion of discounts associated with marketable securities, and rental income from our former subtenant, partially offset by interest expense on our construction financing lease obligation.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Critical Accounting Policies and Estimates</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with United States generally accepted accounting principles. The preparation of our condensed consolidated financial statements requires us to make judgments and estimates that affect the reported amounts of assets, liabilities, revenues, and expenses, and the disclosure of contingent assets and liabilities in our condensed consolidated financial statements. We base our estimates on historical experience, known trends and events, and various other factors that we believe to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts, and experience. The effects of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">material revisions in estimates, if any, will be reflected in the condensed consolidated financial statements prospectively from the date of change in estimates.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">There have been no material changes to our critical accounting policies from those described in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our 2018 Annual Report.</p><a id="_Hlk512525674"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Comparison of the Three Months ended September 30, 2019 and 2018 </span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The following table summarizes our results of operations for the three months ended September 30, 2019 and 2018, together with the changes in those items in dollars (in thousands) and the respective percentages of change:</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_bf185503_c280_4e00_8498_1d1cc2553ad0"></a><a id="_b9b25859_a452_4b36_9407_1bdf78621f36"></a><a id="_5ffb00e5_c1f1_4caa_a875_2bb6ad41cbed"></a><a id="_e408c7ef_7376_4f8f_bd7e_7b62617c9264"></a><a id="_6adee082_bc4f_4d80_ab8f_9842ac476c0f"></a><a id="_b28394eb_3e74_4b43_bfb2_54d5c095a78f"></a><a id="_5e004aaa_789b_4230_8105_de8ad50ede46"></a><a id="_e786582d_d3d5_4eff_ae20_ce7d7b7786fd"></a><a id="_da52c782_c7cc_42c5_9022_23bc1d81d08a"></a><a id="_f01f6dcb_fec6_4d5d_9b8d_69273f97099b"></a><a id="_493b8e40_4c42_4a76_806d_cfa6a1077852"></a><a id="_56c729cf_af21_4643_b9cc_5fc8065e3ed2"></a><a id="_c13d756d_8f71_454c_851d_2763a8c05c50"></a><a id="_2605caab_16f2_4af4_baca_814e1159ee1f"></a><a id="_88137e79_72de_4564_9429_d66241c71679"></a><a id="_f8944eb1_b7b9_4b77_b0b4_595ae7bf1cb9"></a><a id="_004fc8ae_737e_4644_90cc_f5b7bed2d59a"></a><a id="_8c4da1cc_49ac_4fd1_924b_34313342c204"></a><a id="_f1eb4480_9b7a_4f62_8f0b_1b98a792f6ea"></a><a id="_e9ca13ac_1f05_4b87_ab37_908aaac48e44"></a><a id="_3a57f573_34ef_4856_9c8b_ea968b37c609"></a><a id="_eeefe11c_dba7_4b97_bc4f_52f102088ea5"></a><a id="_7796f868_d699_44d0_b43d_c9b38255d52f"></a><a id="_112bfea0_58ef_458a_8e40_2debaf2d4bdb"></a><a id="_862a08e8_8124_45fc_bc23_d0cc5381f017"></a><a id="_3dd96c0a_5f39_4a3d_82e9_a491aeb6fb3e"></a><a id="_10dfc3fa_411b_4d41_8b0e_2dcf0c33d130"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:11.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:50.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:normal;width:20.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:50.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:normal;width:20.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="background-color:auto;vertical-align:bottom;white-space:normal;width:22.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:50.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:normal;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:normal;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:normal;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dollar Change</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:normal;width:13.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage Change</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Collaboration and other research and development revenues</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,848</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,519</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (10,671)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (73)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:50.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,702</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 17,443</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,259</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:50.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,734</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,334</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,400</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Total operating expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 38,436</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30,777</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,659</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 25</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:50.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Other income, net:</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Other expense, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (33)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (29)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">n/m</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Interest income, net</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,680</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,024</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 656</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 64</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Total other income, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,647</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,020</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 627</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 61</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:50.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (32,941)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (15,238)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (17,703)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">n/m</p></td><td style="vertical-align:bottom;white-space:normal;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>For our results of operations, we have included the respective percentage of changes, unless greater than 100% or less than (100)%, in which case we have denoted such changes as not meaningful (n/m).</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Collaboration and other research and development revenues </i></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Collaboration and other research and development revenues decreased by $10.7 million, to $3.8 million for the three months ended September 30, 2019 from $14.5 million for three months ended September 30, 2018. This decrease was primarily attributable to a $10.4 million decrease in revenue recognized related to our strategic alliance with Allergan, of which $15.0 million was related to the EDIT-101 Option Exercise Payment recognized during the third quarter of 2018, and a $0.7 million decrease in revenue recognized pursuant to our collaboration agreement with Juno Therapeutics.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Research and development expenses</i></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Research and development expenses increased by $5.3 million, to $22.7 million for the three months ended September 30, 2019 from $17.4&#160;million for the three months ended September 30, 2018. The following table summarizes </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">our research and development expenses for the three months ended September 30, 2019 and 2018, together with the changes in those items in dollars (in thousands) and the respective percentages of change: </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_b5d68a16_d0f2_44ed_bb86_da5b8f715431"></a><a id="_989f9b47_2593_466b_ad81_6937693f5b0b"></a><a id="_5b53c087_1fff_4bc8_b1a8_6addfcfe0f96"></a><a id="_3c907fdb_e10f_49d0_a9d3_a5d1821928f3"></a><a id="_5c767fa6_8495_4e2f_b580_129ecf5318a2"></a><a id="_e2965b66_3a2e_4d4c_9d04_5806ac2f1315"></a><a id="_8f20b966_b8ed_4d44_85e0_423ff05b3b13"></a><a id="_ba89b9ab_d7bf_4ad9_9eb1_8045334abd27"></a><a id="_e6c8faa1_52b8_44c6_b1fb_094e2f716bcb"></a><a id="_a2a014d0_c739_42b5_adb1_5fd70193c5a0"></a><a id="_19fd3c11_4e8c_4ec7_be52_f7ddb871df84"></a><a id="_ec634974_29a6_41ed_9037_784c6bbec200"></a><a id="_3de7003a_04a6_4a0c_b7e8_4ab00eb37bc9"></a><a id="_6217ae9f_dc06_4b96_9976_eaa6e7607328"></a><a id="_3222240e_bedb_4537_8b04_080e7e4929af"></a><a id="_5d3697f0_1214_4dee_8188_7666b3160e40"></a><a id="_1dddaffe_f2fb_4a21_9815_bed2beed38cf"></a><a id="_459aa8bf_d8c7_44e1_beb8_af5dbbadfd64"></a><a id="_9340bc60_ff59_4b42_9500_efd9d106d38f"></a><a id="_f7b4db40_9031_49f0_aa8f_8795cd7cd1e6"></a><a id="_00200dcc_585e_4455_a789_f875f4a6033f"></a><a id="_da4ae3d7_0482_4b28_a137_3199ba7b409f"></a><a id="_d2e0eed0_3fb7_4d0a_a4dc_25e1cf99daa4"></a><a id="_9e37e102_f411_4e4e_9af3_df29c45f57c0"></a><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:21.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:21.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:24.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dollar Change</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage Change</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Process and platform development expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,334</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,838</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,496</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">n/m</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Employee related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,357</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,190</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,167</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Stock-based compensation expenses </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,619</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,506</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 113</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Facility expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,468</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,538</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 930</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 60</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Other expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 924</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,121</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (197)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (18)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Sublicensing expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,250</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,250)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">n/m</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Total research and development expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,702</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 17,443</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,259</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>The increase in research and development expenses for the three months ended September 30, 2019 compared to the three months ended September 30, 2018 was primarily attributable to:</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">approximately $5.5 million in increased process and platform development expenses driven by increased manufacturing and clinical related costs, including under our profit-sharing arrangement with Allergan in the United States for EDIT-101; </span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">approximately $1.2 million in increased employee related expenses primarily driven by an increase in the size of our workforce; </span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">approximately $0.9 million in increased facility related expenses; and</span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">approximately $0.1 million in increased stock-based compensation.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>These increases were partially offset by approximately $2.3 million in decreased sublicensing expenses due to sublicensing expenses owed to certain of our licensors in connection with receiving the LCA10 Option Exercise Payment during the third quarter of 2018, and approximately $0.2 million in decreased other expenses.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">General and administrative expenses</i></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">General and administrative expenses increased by $2.4 million, to $15.7&#160;million for the three months ended September 30, 2019 from $13.3 million for the three months ended September 30, 2018. The following table summarizes our general and administrative expenses for the three months ended September 30, 2019 and 2018, together with the changes in those items in dollars (in thousands) and the respective percentages of change:</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_3a8a260b_63a6_4cf3_8e0a_f8ac5a16bfc6"></a><a id="_bd2f0d77_398d_4354_aece_bbe6ae76de2f"></a><a id="_94564892_048f_4563_9c8e_957e63cce45d"></a><a id="_0262c7f4_2322_4f73_b758_b2013bcc0ff6"></a><a id="_fd3b8daa_e0d6_435d_a4a3_11f32f872a9c"></a><a id="_5884e2e4_92c6_4a0b_aa07_c8560de60547"></a><a id="_329b43bf_677d_474f_82d1_66623af3e2ea"></a><a id="_d25e163d_8e61_4e34_b47a_de3a99365bfa"></a><a id="_e7072279_55b9_4ba9_a6d6_d5af73a3c6d0"></a><a id="_200d5108_156f_4905_bcee_7c1e70cd15b5"></a><a id="_6d673672_d8d8_42de_8682_fca482ab66e6"></a><a id="_ca7a604d_a77d_4a09_abe9_3b0ae4ebed4e"></a><a id="_13916321_255a_4824_beac_60f1af057ff6"></a><a id="_05698265_f5aa_4fb5_8cba_049cb09b91ee"></a><a id="_8eacdffe_2e95_4b7a_89f2_7df2fc824a2a"></a><a id="_7854d307_dbbc_433c_a8d6_86ad9227956f"></a><a id="_c67208af_da16_4cc0_945a_8d5b454ee44e"></a><a id="_9ef9f02c_6258_4a16_accd_ef272cc4b7f4"></a><a id="_9b293ac8_cf3a_4013_b9f9_86d7e56db3b5"></a><a id="_1815d05f_3a87_4c85_b0a8_2d27cb376a48"></a><a id="_76492295_d38a_491c_9e34_bdb066dd8a46"></a><a id="_de8618e5_d23a_4fe1_b25f_29362f637db4"></a><a id="_27726f90_30c8_4c24_a2e8_be1c8ed3238e"></a><a id="_19e1816c_f4cb_4e57_8fdc_71042c57be88"></a><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:21.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:21.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:24.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dollar Change</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage Change</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Intellectual property and patent related fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,227</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,176</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 51</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Professional service expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,980</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,922</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,058</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">n/m</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Employee related expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,311</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,030</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 281</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Stock-based compensation expenses </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,940</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,193</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (253)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (8)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Other expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,276</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,013</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 263</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 26</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Total general and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,734</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,334</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,400</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>The increase in general and administrative expenses for the three months ended September 30, 2019 compared to the three months ended September 30, 2018 was primarily attributable to:</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">approximately $2.1 million in increased professional service expenses due to an increase in our use of professional service providers; </span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">approximately $0.3 million in increased employee related expenses due to an increase in the size of our workforce; </span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">approximately $0.3 million in increased other expenses; and</span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">approximately $0.1 million in increased intellectual property and patent related fees.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">       These increases were partially offset by $0.3 million in decreased stock-based compensation expenses.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Other income, net</i></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">For the three months ended September 30, 2019, other income, net was $1.6 million, which was primarily attributable to interest income and accretion of discounts associated with marketable securities.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>For the three months ended September 30, 2018, other income, net was $1.0 million, which was primarily attributable to interest income and accretion of discounts associated with marketable securities, partially offset by interest expense on our construction financing lease obligation.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Comparison of the Nine Months ended September 30, 2019 and 2018</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>The following table summarizes our results of operations for the nine months ended September 30, 2019 and 2018, together with the changes in those items in dollars (in thousands) and the respective percentages of change:</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_473fcf6a_4bf6_4950_91fe_d3e1d8cdc873"></a><a id="_3a18c0b8_9b36_46b3_b778_de413c90a3fe"></a><a id="_37639bef_2523_4087_87d1_850a69d7c8c0"></a><a id="_24d21fff_27ce_4500_b4c6_aff5e87fc6b7"></a><a id="_a9da82a1_9451_4f90_b1e2_d937f2663552"></a><a id="_ea1e8e24_5a1c_4641_89db_ab762da48f42"></a><a id="_983becf8_839c_4c36_8215_4a9ad55ae838"></a><a id="_a97ec77f_10a3_4104_b6ca_3c5c9072ee5b"></a><a id="_2d4981d9_caa3_492e_8024_9ffb82314890"></a><a id="_b4587a0a_1d3f_46b3_94a7_dd7eff1c5ef2"></a><a id="_5a465247_6b70_4232_9406_438cf59745fc"></a><a id="_f43267d6_d28c_4ea0_9946_b6b53125858c"></a><a id="_07245caf_7b2c_42e4_b829_e4fd65047d4d"></a><a id="_f19b4f71_2230_460f_904f_441c91767333"></a><a id="_9534da5c_41a0_4825_b9c2_a4617b99c35f"></a><a id="_f3c7e858_5410_4242_8582_b451af2268ee"></a><a id="_76386913_69ae_44c8_ba99_83daef4fe784"></a><a id="_89efafa1_d8a8_44ca_8799_b33f9811fcdc"></a><a id="_0cbba3f5_0f3f_4745_bb23_431dc478d8f0"></a><a id="_fc30115b_514d_404f_bc7e_db394c21c12b"></a><a id="_5c711929_b9e6_4fde_aac2_9a8719f0224f"></a><a id="_57a0d5f9_3b7e_4c07_9d35_f3164267dc3f"></a><a id="_4b1f0a3b_1fd5_401a_8149_dc6c9df9f027"></a><a id="_b6105dc6_6fe2_4622_be85_d1d816640e45"></a><a id="_7ae8e12f_5236_4c3c_9af4_f0a9c1279991"></a><a id="_5e2b7463_2e1d_4ab0_9848_60a28a044e5c"></a><a id="_f20a960f_c6eb_4bd7_8fc8_4d9411be274e"></a><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:8.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:11.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:normal;width:20.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:normal;width:20.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:normal;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:normal;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:normal;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dollar&#160;Change</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:normal;width:13.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage Change</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Collaboration and other research and development revenues</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,247</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 25,818</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (17,571)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (68)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 62,109</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 71,460</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (9,351)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (13)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 47,638</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 41,832</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,806</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Total operating expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 109,747</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 113,292</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,545)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Other income, net:</p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Other (expense) income, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (144)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 332</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (476)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">n/m</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Interest income, net</p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,668</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,243</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,425</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">n/m</p></td><td style="vertical-align:bottom;white-space:normal;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;">Total other income, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,524</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,575</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,949</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">n/m</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:normal;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (95,976)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:8.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (84,899)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (11,077)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Collaboration and other research and development revenues </i></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Collaboration and other research and development revenues decreased by $17.6 million, to $8.2 million for the nine months ended September 30, 2019 from $25.8 million for nine months ended September 30, 2018. This decrease was primarily attributable to a $9.0 million decrease in revenue recognized related to our strategic alliance with Allergan, of which $15.0 million was related to the EDIT-101 Option Exercise Payment recognized during the third quarter of 2018, a $5.2 million decrease in revenue recognized pursuant to our collaboration agreement with Juno Therapeutics and $3.9 million in revenue recognized related to an upfront payment in connection with an out-license arrangement entered into during the second quarter of 2018.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Research and development expenses</i></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>Research and development expenses decreased by $9.4 million, to $62.1 million for the nine months ended September 30, 2019 from $71.5 million for the nine months ended September 30, 2018. The following table summarizes our research and development expenses for the nine months ended September 30, 2019 and September 30, 2018, together with the changes in those items in dollars (in thousands) and the respective percentages of change:</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_dce727ca_5ef7_4f56_bc79_e4fdee6af577"></a><a id="_7f146057_e81d_4127_b8fc_030fe4c9784d"></a><a id="_d8e81fce_92cc_406e_8ced_d41aa2a0d2e4"></a><a id="_bd0b72e9_7ae6_428d_bfe1_b0764aa6bdbb"></a><a id="_4b1a2450_bb18_4189_b419_c58526b4bc2f"></a><a id="_6d7fdb5b_6ac9_4064_934c_4e0de411ba74"></a><a id="_b008a00e_56bc_462e_8d1e_9ad22812ae02"></a><a id="_662ba77b_ba7a_4c75_ac42_97e543de9455"></a><a id="_fc25c84d_38fb_49b8_8777_ade11e6d9836"></a><a id="_f44a75b2_8cd4_43f1_a854_a6bbe9523760"></a><a id="_51daa1ab_834a_47ab_baa9_6e2362ef8d25"></a><a id="_a886d3da_285e_4f5a_b49c_9c8888e8bb78"></a><a id="_5d1a073d_339d_4d02_b1d1_0a716f63cbd7"></a><a id="_9fdd6b7c_ef5b_4665_b08c_5983055a3a1c"></a><a id="_cb08682d_b02f_4f8f_8b4a_2a62e803dd93"></a><a id="_b09e1979_6d23_4797_b085_51610da0cfa3"></a><a id="_c3314a2c_9c9b_4ace_93e9_9e94daa5c191"></a><a id="_580a1dae_566c_45b9_a9c8_4f06437fc2ef"></a><a id="_59384a4f_df9f_4f9b_9a8a_389b62f83bbd"></a><a id="_f4803e9c_1b82_4b0a_85f3_ff316b3496b0"></a><a id="_d8a19d0c_7a83_4241_a582_c4a3cfe22903"></a><a id="_71c91685_e91f_482a_bf2c_4d001a14554d"></a><a id="_dc25d461_48bf_4ca6_9548_b6b29bad948b"></a><a id="_3a11e63a_b077_4e8a_976e_8467297aeab6"></a><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:21.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:21.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dollar&#160;Change</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage Change</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Process and platform development expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 24,351</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,966</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,385</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Employee related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 17,054</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,996</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,058</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Stock-based compensation expenses </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,854</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,412</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (558)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (5)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Facility expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,338</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,418</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,920</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 43</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Other expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,117</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,741</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 376</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Sublicensing and success payment expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 395</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,927</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (16,532)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (98)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Total research and development expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 62,109</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 71,460</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (9,351)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (13)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>The decrease in research and development expenses for the nine months ended September 30, 2019 compared to the nine months ended September 30, 2018 was primarily attributable to: </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">approximately $16.5 million in decreased sublicensing and success payment expenses, mostly related to $12.5 million in notes payable that were issued to Broad and settled during the second quarter of 2018 in connection with us entering into a sponsored research agreement with Broad, $4.4 million in sublicensing fees owed to certain of our licensors in connection with receiving the LCA10 Option Exercise Payment during the third quarter of 2018, certain amendment and milestone payments received from Juno Therapeutics during the second quarter of 2018 under our collaboration and an upfront payment received from a licensee in connection with an out-license arrangement entered into during the second quarter of 2018; and</span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">approximately $0.6 million in decreased stock-based compensation expense mostly due to a decrease in non-employee stock option expense.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">These decreases were partially offset by approximately $3.4 million in increased process and platform development expenses related to manufacturing and clinical related costs, including under our profit-sharing arrangement with Allergan in the United States for EDIT-101, approximately $2.1 million in increased employee related expenses due to an increase in the size of our workforce, approximately $1.9 million in increased facility related expenses, and approximately $0.4 million in increased other expenses.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">General and administrative expenses</i></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">General and administrative expenses increased by $5.8 million, to $47.6 million for the nine months ended September 30, 2019 from $41.8 million<b style="font-weight:bold;"> </b>for the nine months ended September 30, 2018. The following table summarizes our general and administrative expenses for the nine months ended September 30, 2019 and 2018, together with the changes in those items in dollars (in thousands) and the respective percentages of change: </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_34fa5ef3_16a3_440a_8d09_4794bbec0750"></a><a id="_d9c73700_7fba_44e0_a812_8a01d392b4d4"></a><a id="_d612057a_4d87_4b5c_becb_968b1603053f"></a><a id="_617c27f6_5df3_4df0_896d_1a7e9c607aae"></a><a id="_08e63874_70bb_41e2_a77c_8949674ac7cd"></a><a id="_348ad8f7_4772_4ee0_9e55_68b4a0864565"></a><a id="_6413b41a_a89c_4246_be22_0d5ae92d3518"></a><a id="_1f2b3408_51c0_4b43_8c60_cabb5de06c17"></a><a id="_3fefddd1_f8c0_4349_a6f4_2dd4c0003a2c"></a><a id="_dd4bda24_4d68_4400_ad21_8f6195ac8f96"></a><a id="_65ed74be_032b_4b0e_a30a_8bf4d6e890e4"></a><a id="_ac4c0ccd_2b11_4baa_872d_2987062d37d6"></a><a id="_8e2fe8fe_46fb_4874_a62b_f2609c516d22"></a><a id="_74d6e8d2_d958_43c7_8801_3838f41ff0bc"></a><a id="_3456b093_bdec_4644_bbe5_cbfcb9bf6cfd"></a><a id="_8e03827a_1447_4f40_b6b4_5bc3d6231645"></a><a id="_989cde2a_70cb_430a_acc6_aab9a77c046f"></a><a id="_fbbd1e62_cf9d_4883_9a0a_11d1d08736ca"></a><a id="_99376293_f570_46df_b2ed_822d948033c1"></a><a id="_6c779b32_c7a7_46bc_85f6_a6424175aedd"></a><a id="_bfbe2be6_b9c3_41be_9860_9ad81523a476"></a><a id="_009d4394_a436_4ec9_84e1_a70ceef0a175"></a><a id="_a8a0a589_6063_49ec_968b_470bf68632b2"></a><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100.02%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:21.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:21.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dollar&#160;Change</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentage Change</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Intellectual property and patent related fees</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,570</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,009</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,439)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (15)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Professional service expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,809</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,176</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,633</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">n/m</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Stock-based compensation expenses </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,053</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,839</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,214</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Employee related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,571</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,649</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 922</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Other expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,635</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,159</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 476</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Total general and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 47,638</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 41,832</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,806</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">%</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>The increase in general and administrative expenses for the nine months ended September 30, 2019 compared to the nine months ended September 30, 2018 was primarily attributable to:<br /><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">approximately $5.6 million in increased professional service expenses primarily related to an increase in our use of consulting services; <br /></span><span style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">approximately $1.2 million in increased stock-based compensation expenses due to an increase in employee stock option expense;<br /></span><span style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">approximately $0.9 million in increased employee related expenses due to an increase in the size of our workforce; and</span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">approximately $0.5 million in increased other expenses including facility related expenses.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">These increases were partially offset by approximately $2.4 million in decreased intellectual property and patent related fees. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Other income, net</i></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">For the nine months ended September 30, 2019, other income, net was $5.5 million, which was primarily attributable to interest income and accretion of discounts associated with marketable securities, partially offset by a loss on disposal of property and equipment.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">For the nine months ended September 30, 2018, other income, net was $2.6 million, which was primarily attributable to interest income, accretion of discounts associated with marketable securities, and rental income from our former subtenant, partially offset by interest expense on our construction financing lease obligation.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Sources of Liquidity</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">From inception through September 30, 2019, we funded our operations primarily through proceeds from private placements of our preferred stock of $163.3&#160;million, net proceeds of $370.4 million from our public offerings of our common stock, and payments from Allergan and Juno Therapeutics. As of September 30, 2019, we had cash, cash equivalents and marketable securities of $332.6 million. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="background-color:#ffffff;">In addition to our existing cash, cash equivalents and marketable securities, we are eligible to earn milestone and option exercise payments under our collaboration agreement with Juno Therapeutics and are entitled to receive a $70.0 million payment in connection with amending our collaboration with Juno Therapeutics in November 2019. Additionally, under our strategic alliance with Allergan, we are eligible to earn milestone payments, certain reimbursement for EDIT-101 costs in the United States and certain option exercise or extension payments. Our ability to earn and the timing of the milestone payments are dependent upon the timing and outcome of our development, regulatory and commercial activities and, as such, are uncertain at this time. As of September 30</span>, 2019,<span style="background-color:#ffffff;"> our right to contingent payments under our collaboration agreement with Juno Therapeutics and our strategic alliance with Allergan are our only significant committed potential external sources of funds.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="background-color:#ffffff;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="background-color:#ffffff;font-style:italic;font-weight:bold;">2019 At-The-Market Offerings</span><span style="display:inline-block;width:17.34pt;"></span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="background-color:#ffffff;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="background-color:#ffffff;">In March 2018, we entered into a sales agreement with Cowen and Company, LLC (&#8220;Cowen&#8221;), under which we are able from time to time to issue and sell shares of our common stock through Cowen for aggregate gross sales proceeds of $150.0 million, with Cowen being entitled to a 3% cash commission on the gross sales price per share of common stock sold under the sales agreement (the &#8220;ATM Facility&#8221;). </span>Beginning in August 2019 and through the date of filing this Quarterly Report on Form 10-Q<span style="background-color:#ffffff;">, we sold </span>1,727,555 <span style="background-color:#ffffff;">shares of our common stock </span>at a weighted-average price </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">of $25.15 per share for gross proceeds of $43.6 million. All shares sold pursuant to the sales agreement were sold pursuant to a shelf registration statement, which automatically became effective on March 12, 2018. As of the date of this Quarterly Report on Form 10-Q, we have an ability to raise an additional $106.4 million in aggregate gross sales proceeds under the ATM Facility.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Cash Flows</i></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The following table provides information regarding our cash flows for the nine months ended September 30, 2019 and 2018 (in thousands): </p><a id="_bd912b3e_f239_465a_bb73_1baec94ac373"></a><a id="_242b6d66_19df_484d_8c29_b880ab559bd9"></a><a id="_cda76927_9efd_4cd4_90bf_d9f36964f676"></a><a id="_f5c24632_959a_4af2_a77f_8eac5a902492"></a><a id="_3c056a40_4ec2_4b0d_a91b_7c7bbfb47d01"></a><a id="_3575c9db_b8f4_43ac_9d69_caaae9d43863"></a><a id="_39f2598f_4815_412f_91ca_8db6c04af58a"></a><a id="_3e01728b_ad30_44b0_a1ae_3bafe624b77c"></a><a id="_22640e2e_4d29_49a7_8087_b383ee364fd4"></a><a id="_da637af0_87ed_4ea9_9366_d1fdbd2e6402"></a><a id="_6df57afc_079b_4592_b8c3_7973a61acd19"></a><a id="_f7b85d7a_1104_435f_a62d_af4f07a9563f"></a><a id="_3e22aa73_566c_47fd_972e_30d9dbac6354"></a><a id="_b10ecf88_54c3_49fb_9f95_c21b48ff867e"></a><a id="_b31cb713_182b_4b80_a2ea_bdfc48ce443a"></a><a id="_6c27e81b_117a_481f_811d_8aaab9c77d90"></a><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="background-color:auto;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:normal;width:26.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:normal;width:26.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:normal;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:normal;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Net cash provided by (used in):</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Operating activities</p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (81,693)</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:normal;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (47,034)</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Investing activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,434</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (44,483)</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Financing activities</p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 47,255</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 56,588</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Net decrease in cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (30,004)</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (34,929)</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Net Cash Used in Operating Activities</i></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><a id="S168140190"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>The use of cash in all periods resulted primarily from our net losses adjusted for non-cash charges and changes in components of working capital.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">During the nine months ended September 30, 2019, we recognized revenue related to our strategic alliance with Allergan which decreased deferred revenue, partially offset by an upfront payment received related to an out-license arrangement. This amount was offset by operating expenses that relate to our on-going preclinical and clinical activities, patent costs and license fees, costs related to obtaining additional research facilities and increased costs as a result of staffing needs due to our expanding operations.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="background-color:#ffff00;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>During the nine months ended September 30, 2018, we received $15.0 million related to the EDIT-101 Option Exercise Payment which was fully recognized in revenue during the third quarter of 2018. We also received a $10.0 million payment related to the amended and restated collaboration agreement with Juno Therapeutics from 2018, which was partially recognized during the second quarter of 2018, resulting in a net increase of deferred revenue of $3.9 million. This amount was offset by operating expenses that related to our on-going preclinical activities, sublicensing and success payments, patent costs, and increased employee related expenses due to an increase in the size of our workforce.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Net Cash Provided by (Used in) Investing Activities</i></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>The cash provided by investing activities for the nine months ended September 30, 2019 was primarily the result of higher proceeds from maturities of marketable securities than purchases of marketable securities that were partially offset by $4.5 million in equipment purchases.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>The cash used in investing activities for the nine months ended September 30, 2018 was primarily the result of purchases of marketable securities that were partially offset by maturities of marketable securities and $3.3 million in equipment purchases.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Net Cash Provided by Financing Activities</i></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>The cash provided by financing activities for the nine months ended September 30, 2019 was related to $41.2 million in proceeds received from at-the-market offerings of our common stock, $5.8 million in proceeds for exercises of options for our common stock and $0.3 million from the issuance of our common stock under our equity plans.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>The cash provided by financing activities for the nine months ended September 30, 2018 was related to $48.5 million in net proceeds received from at-the-market offerings of our common stock, $8.4 million in proceeds for </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">exercises of options for our common stock and $0.4 million from the issuance of our common stock under our equity plans, partially offset by payments on the construction financing obligation of $0.6 million.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Funding Requirements</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">We expect our expenses to increase in connection with our ongoing activities, particularly as we further advance our current research programs and our preclinical development activities; progress the clinical development of EDIT-101 with Allergan; seek to identify product candidates and additional research programs; initiate preclinical testing and clinical trials for other product candidates we identify and develop; maintain, expand, and protect our intellectual property portfolio, including reimbursing our licensors for expenses related to the intellectual property that we in-license from such licensors; hire additional clinical, quality control, and scientific personnel; and incur costs associated with operating as a public company. In addition, if we obtain marketing approval for any product candidate that we identify and develop, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing, and distribution to the extent that such sales, marketing, and distribution are not the responsibility of a collaborator. We do not expect to generate significant recurring revenue unless and until we obtain regulatory approval for and commercialize a product candidate. <span style="background-color:#ffffff;">Furthermore, since 2016 we have incurred, and in future years we expect to continue to incur, significant costs associated with operating as a public company. </span>Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce, or eliminate our research and development programs or future commercialization efforts.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">We expect that our existing cash, cash equivalents, and marketable securities at September 30, 2019 and anticipated interest income will enable us to fund our operating expenses and capital expenditure requirements for at least 24 months following the date of this Quarterly Report on Form 10-Q. We have based our estimates on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including: </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the scope, progress, results, and costs of drug discovery, preclinical development, laboratory testing, and clinical trials for the product candidates we develop;</span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the costs of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property and proprietary rights, and defending intellectual property-related claims;</span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the costs, timing, and outcome of regulatory review of the product candidates we develop;</span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the costs of future activities, including product sales, medical affairs, marketing, manufacturing, and distribution, for any product candidates for which we receive regulatory approval;</span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the success of our collaboration with Juno Therapeutics and our strategic alliance with Allergan;</span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">whether Juno Therapeutics exercises any of its options to extend the research program term and/or to certain of the research programs under our collaboration;</span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">whether Allergan exercises any additional options under our strategic alliance;</span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">our ability to establish and maintain additional collaborations on favorable terms, if at all;</span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the extent to which we acquire or in-license other medicines and technologies; </span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the costs of reimbursing our licensors for the prosecution and maintenance of the patent rights in-licensed by us; and</span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the costs of operating as a public company.</span></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>Identifying potential product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive, and uncertain process that takes many years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, any product candidate that we identify and develop, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of genomic medicines that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our stockholders&#8217; ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">If we raise funds through additional collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Contractual Obligations </b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>During the three months ended September 30, 2019, there were no material changes to our contractual obligations and commitments described under Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations in our 2018 Annual Report and in our Quarterly Report on Form 10-Q for the quarter ending March 31, 2019, which was filed with the Securities and Exchange Commission on May 8, 2019. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Off-Balance Sheet Arrangements</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">We did not have, during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under applicable SEC rules.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Effects of Inflation</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>Inflation would generally affect us by increasing our cost of labor and clinical trial costs. We do not believe that inflation had a material effect on our business, financial condition or results of operations during the nine months ended September 30, 2019 or 2018.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;font-size:9pt;visibility:hidden;">&#8203;</span></p><a id="_cfd8ef55_9cb1_4bce_9f38_f300cde5b63d"></a><a id="Item3QuantitativeandQualitativeDisclosur"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Item&#160;3.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk.</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">We are exposed to market risk related to changes in interest rates. <span style="background-color:#ffffff;">As of September 30</span>, 2019<span style="background-color:#ffffff;">, we had cash and cash equivalents of $104.8 million, primarily held in money market mutual funds, and marketable securities of $227.8 million, primarily consisting of U.S. government-backed securities. </span>Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our investments, including cash equivalents, are in the form, or may be in the form of, money market funds or marketable securities and are or may be invested in U.S. Treasury and U.S. government agency obligations. Due to the short-term maturities and low risk profiles of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our investments.</p><a id="_cp_text_1_239"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">While we contract with certain vendors and institutions internationally, substantially all of our total liabilities as </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">of September 30, 2019 were denominated in the United States dollar and we believe that we do not have any material exposure to foreign currency exchange rate risk.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_65bd6e5f_05ad_4e2b_ba63_e06b1f8f704f"></a><a id="Item4ControlsandProcedures_796610"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Item 4.&#160;&#160;&#160;&#160;Controls and Procedures.</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Evaluation of Disclosure Controls and Procedures</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;">Our management, with the participation of our Chief Executive Officer and interim Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30</span>, 2019<span style="background-color:#ffffff;">. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of </span>September 30, 2019<span style="background-color:#ffffff;">, our Chief Executive Officer and interim Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Changes in Internal Control over Financial Reporting</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="background-color:#ffffff;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;">There were no changes in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_2c05d00b_a913_4c43_aa8b_b265251179a2"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PARTIIOTHERINFORMATION_124074"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">PART&#160;II. OTHER INFORMATION</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="Item1LegalProceedings_433402"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Item&#160;1.&#160;&#160;&#160;&#160;Legal Proceedings.</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">From time to time, we may become involved in litigation or other legal proceedings relating to claims arising from the ordinary course of business. There can be no assurance that any proceedings that result from these third-party actions will be resolved in our favor. In addition, if they are not resolved in our favor, there can be no assurance that the result will not have a material adverse effect on our business, financial condition, results of operations, or prospects. Certain of our intellectual property rights, including ones licensed to us under our licensing agreements, are subject to, and from time to time may be subject to, priority and validity disputes. For additional information regarding these matters, see &#8220;Item 1A. Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221; Regardless of outcome, litigation or other legal proceedings can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_f89cbd7c_144b_4ab7_b687_a0280442e1dc"></a><a id="Item1ARiskFactors_661144"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Item 1A.&#160;&#160;&#160;&#160;Risk Factors.</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;">Our business is subject to numerous risks. The following important factors, among others, could cause our actual results to differ materially from those expressed in forward-looking statements made by us or on our behalf in this Quarterly Report on Form 10-Q and other filings with the Securities and Exchange Commission (the &#8220;SEC&#8221;), press releases, communications with investors, and oral statements. Actual future results may differ materially from those anticipated in our forward-looking statements. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Financial Position and Need for Additional Capital</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have incurred significant losses since inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability.</span></p><a id="_Hlk506284397"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since inception, we have incurred significant operating losses. Our net losses were $110.0 million, $120.3 million, $97.2 million, and $72.9&#160;million for the years ended December&#160;31, 2018, 2017, 2016 and 2015, respectively. As of September 30, 2019, we had an accumulated deficit of $511.5 million. We have financed our operations primarily through public offerings of our common stock, private placements of our preferred stock, our collaboration with Juno Therapeutics, Inc., a Celgene company that is a wholly-owned subsidiary of Celgene Corporation (&#8220;Juno Therapeutics&#8221;), and payments under our strategic alliance with Allergan Pharmaceuticals International Limited (together with its affiliate, &#8220;Allergan&#8221;). We have devoted substantially all of our efforts to research and development. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. The net losses we incur may fluctuate significantly from quarter to quarter. We anticipate that our expenses will increase substantially if and as we:</p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">continue our current research programs and our preclinical development of product candidates from our current research programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">seek to identify additional research programs and additional product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">initiate preclinical testing and clinical trials for any product candidates we identify and develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">commence enrollment in and progress the clinical development with Allergan of EDIT-101 (also known as </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">AGN-151587)</span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;"> </span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">to treat Leber congenital amaurosis (&#8220;LCA&#8221;) 10 (&#8220;LCA10&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">maintain, expand, and protect our intellectual property portfolio and provide reimbursement of third-party expenses related to our patent portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">seek marketing approvals for any of our product candidates that successfully complete clinical trials;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">ultimately establish a sales, marketing, and distribution infrastructure to commercialize any medicines for which we may obtain marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">further develop our genome editing platform;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">hire additional clinical, quality control, and scientific personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">add operational, financial, and management information systems and personnel, including personnel to support our product development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">acquire or in-license other medicines and technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">validate a commercial-scale current Good Manufacturing Practices (&#8220;cGMP&#8221;) manufacturing facility; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">continue to operate as a public company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have only recently initiated clinical development with Allergan of EDIT-101 and expect that it will be many years, if ever, before we have a product candidate ready for commercialization. To become and remain profitable, we must develop and eventually commercialize a medicine or medicines with significant market potential. This will require us to be successful in a range of challenging activities, including identifying product candidates, completing preclinical testing and clinical trials of product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing, and selling those medicines for which we may obtain marketing approval, and satisfying any post-marketing requirements. We may never succeed in these activities and, even if we do, may never generate revenues that are significant or large enough to achieve profitability. Other than EDIT-101, we are currently only in the preclinical testing stages for our most advanced research programs. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business, or continue our operations. A decline in the value of our company could cause our stockholders to lose all or part of their investments in us.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We will need substantial additional funding. If we are unable to raise capital when needed, we would be forced to delay, reduce, or eliminate our research and product development programs or commercialization efforts.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect our expenses to increase in connection with our ongoing activities, particularly as we identify, continue the research and development of, initiate clinical trials of, and seek marketing approval for, product candidates. In addition, if we obtain marketing approval for any product candidates we develop, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing, and distribution to the extent that such sales, marketing, manufacturing, and distribution are not the responsibility of a collaborator. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce, or eliminate our research and product development programs or future commercialization efforts.</p><a id="_Hlk506290571"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect that our existing cash, cash equivalents, and marketable securities at September 30, 2019 and anticipated interest income will enable us to fund our operating expenses and capital expenditure requirements for at least 24 months following the date of this Quarterly Report on Form 10-Q. Our future capital requirements will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the scope, progress, results, and costs of drug discovery, preclinical development, laboratory testing, and clinical or natural history study trials for the product candidates we develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the costs of progressing the clinical development with Allergan of EDIT-101 to treat LCA10;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the costs of preparing, filing, and prosecuting patent applications, maintaining and enforcing our </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">intellectual property and proprietary rights, and defending intellectual property-related claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the costs, timing, and outcome of regulatory review of the product candidates we develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the costs of future activities, including product sales, medical affairs, marketing, manufacturing, and distribution, for any product candidates for which we receive regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the success of our collaboration with Juno Therapeutics and our strategic alliance with Allergan;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">whether Juno Therapeutics exercises any of its options to extend the research program term and/or to certain of the research programs under our collaboration</span><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">whether Allergan exercises any additional options under our strategic alliance;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">our ability to establish and maintain additional collaborations on favorable terms, if at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the extent to which we acquire or in-license other medicines and technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the costs of reimbursing our licensors for the prosecution and maintenance of the patent rights in-licensed by us; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the costs of operating as a public company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive, and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, even if we successfully identify and develop product candidates and those are approved, we may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of medicines that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, and licensing arrangements. We do not have any significant committed external source of funds, other than the $70.0 million payment we are entitled to receive from Juno Therapeutics in connection with amending and restating our collaboration with them in November 2019. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our stockholders may be materially diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we raise funds through additional collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates, or we may have to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our short operating history may make it difficult for our stockholders to evaluate the success of our business to date and to assess our future viability.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are an early-stage company. We were founded and commenced operations in the second half of 2013. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, acquiring and developing our technology, identifying potential product candidates, undertaking preclinical studies and preparing to undertake clinical trials. Except for EDIT-101 to treat LCA10, all of our research programs are still in the preclinical or research stage of development, and their risk of failure of all of our research programs is high. We have not yet demonstrated an ability to successfully complete any clinical trials, including large-scale, pivotal clinical trials, obtain marketing approvals, manufacture a commercial-scale medicine, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. Typically, it takes about 10 to 15&#160;years to develop a new medicine from the time it is discovered to when it is available for treating patients. Consequently, any predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, as a new business, we may encounter unforeseen expenses, difficulties, complications, delays, and other known and unknown factors. We will need to transition from a company with a research focus to a company capable of supporting commercial activities. We may not be successful in such a transition.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect that our financial condition and operating results will continue to fluctuate significantly from quarter-to-quarter and year-to-year due to a variety of factors, many of which are beyond our control. Accordingly, our stockholders should not rely upon the results of any quarterly or annual periods as indications of future operating performance.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have never generated revenue from product sales and may never be profitable.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our ability to generate revenue from product sales and achieve profitability depends on our ability, alone or with collaboration partners, to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize, product candidates we may identify for development. We do not anticipate generating revenues from product sales for the next several years, if ever. Our ability to generate future revenues from product sales depends heavily on our, or our collaborators&#8217;, ability to successfully:</p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">identify product candidates and complete research and preclinical and clinical development of any product candidates we may identify;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">seek and obtain regulatory and marketing approvals for any of our product candidates for which we complete clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">launch and commercialize any of our product candidates for which we obtain regulatory and marketing approval by establishing a sales force, marketing, and distribution infrastructure;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">qualify for adequate coverage and reimbursement by government and third-party payors for any our product candidates for which we obtain regulatory and marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">develop, maintain, and enhance a sustainable, scalable, reproducible, and transferable manufacturing process for the product candidates we develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">establish and maintain supply and manufacturing relationships with third parties that can provide adequate, in both amount and quality, products and services to support clinical development and the market demand for any of our product candidates for which we obtain regulatory and marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">obtain market acceptance of any product candidates we develop as viable treatment options;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">address competing technological and market developments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">implement internal systems and infrastructure, as needed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">negotiate favorable terms in any collaboration, licensing, or other arrangements into which we may enter and performing our obligations in such arrangements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">maintain, protect, and expand our portfolio of intellectual property rights, including patents, trade secrets, and know-how;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">avoid and defend against third-party interference or infringement claims; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">attract, hire, and retain qualified personnel.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if one or more of the product candidates we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Our expenses could increase beyond expectations if we are required by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;), the European Medicines Agency (the &#8220;EMA&#8221;), or other regulatory authorities to perform clinical and other studies in addition to those that we currently anticipate. Even if we are able to generate revenues from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Discovery, Development, and Commercialization</b></p><a id="_Hlk506290922"></a><a id="_Hlk496779244"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We intend to identify and develop product candidates based on a novel genome editing technology, which makes it difficult to predict the time and cost of product candidate development. </span><span style="font-style:italic;font-weight:bold;">No therapeutic products that utilize genome editing technology have been approved in the United States or in Europe, and there have only been a limited number of human clinical trials of a genome editing product candidate.</span></p><a id="_Hlk496779256"></a><a id="_Hlk506290943"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have concentrated our research and development efforts on our genome editing platform, which uses CRISPR technology. Our future success depends on the successful development of this novel genome editing therapeutic approach. To date, no therapeutic product that utilizes genome editing, including CRISPR technology, has been approved in the United States or Europe and there have been only a limited number of clinical trials involving the use of a therapeutic utilizing genome editing technologies. Because we have not yet dosed any patients with our product candidates, we have not yet been able to assess safety in humans, and there may be long-term effects from treatment with any of our future product candidates that we cannot predict at this time. Any product candidates we develop will act at the level of DNA, and, because animal DNA differs from human DNA, it will be difficult for us to test our future product candidates in animal models for either safety or efficacy. Also, animal models do not exist for some of the diseases we expect to pursue in our programs. As a result of these factors, it is more difficult for us to predict the time and cost of product candidate development, and we cannot predict whether the application of our genome editing platform, or any similar or competitive genome editing platforms, will result in the identification, development, and regulatory approval of any medicines. There can be no assurance that any development problems we experience in the future related to our genome editing platform or any of our research programs will not cause significant delays or unanticipated costs, or that such development problems can be solved. We may also experience delays in developing a sustainable, reproducible, and scalable manufacturing process or transferring that process to commercial partners. Any of these factors may prevent us from completing our preclinical studies or any clinical trials that we may initiate or commercializing any product candidates we develop on a timely or profitable basis, if at all.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Because genome editing is novel and the regulatory landscape that will govern any product candidates we develop is uncertain and may change, we cannot predict the time and cost of obtaining regulatory approval, if we receive it at all, for any product candidates we develop.</span></p><a id="_Hlk496779357"></a><a id="_Hlk506291006"></a><a id="_Hlk496779321"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The regulatory requirements that will govern any novel genome editing product candidates we develop are not entirely clear and may change. Within the broader genomic medicine field, we are aware of a limited number of gene </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk506291062"></a><a id="_Hlk506291094"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">therapy products that have received marketing authorization from the FDA and the EMA. Even with respect to more established products that fit into the categories of gene therapies or cell therapies, the regulatory landscape is still developing. Regulatory requirements governing gene therapy products and cell therapy products have changed frequently and will likely continue to change in the future. Moreover, there is substantial, and sometimes uncoordinated, overlap in those responsible for regulation of existing gene therapy products and cell therapy products. For example, in the United States, the FDA has established the Office of Tissues and Advanced Therapies within its Center for Biologics Evaluation and Research (&#8220;CBER&#8221;) to consolidate the review of gene therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. Gene therapy clinical trials are also subject to review and oversight by an institutional biosafety committee (&#8220;IBC&#8221;), a committee that reviews and oversees the use of biological agents. Although the FDA decides whether individual gene therapy protocols may proceed, the review process and determinations of other reviewing bodies can impede or delay the initiation of a clinical trial, even if the FDA has reviewed the trial and allowed its initiation. The same applies in the European Union. The EMA&#8217;s Committee for Advanced Therapies (&#8220;CAT&#8221;) is responsible for assessing the quality, safety, and efficacy of advanced-therapy medicinal products. The role of the CAT is to prepare a draft opinion on an application for marketing authorization for a gene therapy medicinal candidate that is submitted to the EMA. In the European Union, the development and evaluation of a gene therapy medicinal product must be considered in the context of the relevant European Union guidelines. The EMA may issue new guidelines concerning the development and marketing authorization for gene therapy medicinal products and require that we comply with these new guidelines. As a result, the procedures and standards applied to gene therapy products and cell therapy products may be applied to any CRISPR product candidates we develop, but that remains uncertain at this point.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adverse developments in clinical trials conducted by others of gene therapy products, cell therapy products, or products developed through the application of a CRISPR or other genome editing technology may cause the FDA, the EMA, and other regulatory bodies to revise the requirements for approval of any product candidates we develop or limit the use of products utilizing genome editing technologies, either of which could materially harm our business. In addition, the clinical trial requirements of the FDA, the EMA, and other regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty, and intended use and market of the potential products. The regulatory approval process for novel product candidates such as ours can be more expensive and take longer than for other, better known, or more extensively studied pharmaceutical or other product candidates. Regulatory agencies administering existing or future regulations or legislation may not allow production and marketing of products utilizing genome editing technology in a timely manner or under technically or commercially feasible conditions. In addition, regulatory action or private litigation could result in expenses, delays, or other impediments to our research programs or the commercialization of resulting products.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The regulatory review committees and advisory groups described above and the new guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies or trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of these treatment candidates, or lead to significant post-approval limitations or restrictions. As we advance our research programs and develop future product candidates, we will be required to consult with these regulatory and advisory groups and to comply with applicable guidelines. If we fail to do so, we may be required to delay or discontinue development of any product candidates we identify and develop.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Adverse public perception of genomic medicines, and genome editing in particular, may negatively impact regulatory approval of, or demand for, our potential products.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our potential therapeutic products involve editing the human genome. The clinical and commercial success of our potential products will depend in part on public understanding and acceptance of the use of genome editing therapy for the prevention or treatment of human diseases. Public attitudes may be influenced by claims that genome editing is unsafe, unethical, or immoral, and, consequently, our products may not gain the acceptance of the public or the medical community. Adverse public attitudes may adversely impact our ability to enroll clinical trials. Moreover, our success will depend upon physicians prescribing, and their patients being willing to receive, treatments that involve the use of product candidates we develop in lieu of, or in addition to, existing treatments with which they are already familiar and for which greater clinical data may be available.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, genome editing technology is subject to public debate and heightened regulatory scrutiny due to ethical concerns relating to the application of genome editing technology to human embryos or the human germline. For example, academic scientists in several countries, including the United States, have reported on their attempts to edit the genome of human embryos as part of basic research and, in November 2018, it was reported that Dr. Jiankui He, a Chinese biophysics researcher who was an associate professor in the Department of Biology of the Southern University of Science and Technology in Shenzhen, China, claimed he had created the first human genetically edited babies, twin girls. This claim, and another that Dr. He had helped create a second gene-edited pregnancy, was subsequently confirmed by Chinese authorities and was negatively received by the public, in particular those in the scientific community. In the United States, germline editing for clinical application has been expressly prohibited since enactment of a December 2015 U.S. FDA ban on such activity. Prohibitions are also in place in the United Kingdom, across most of Europe, in China, and many other countries around the world. In the United States, the NIH has announced that it would not fund any use of genome editing technologies in human embryos, noting that there are multiple existing legislative and regulatory prohibitions against such work, including the Dickey-Wicker Amendment, which prohibits the use of appropriated funds for the creation of human embryos for research purposes or for research in which human embryos are destroyed. Laws in the United Kingdom prohibit genetically modified embryos from being implanted into women, but embryos can be altered in research labs under license from the Human Fertilisation and Embryology Authority. Basic research on embryos is more tightly controlled in many other European countries.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Moreover, in an annual worldwide threat assessment report delivered to the U.S. Congress in February 2016, the U.S. Director of National Intelligence stated that research into genome editing probably increases the risk of the creation of potentially harmful biological agents or products, including weapons of mass destruction. He noted that the broad distribution, low cost, and accelerated pace of development of genome editing technology could result in the deliberate or unintentional misuse of such technology.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although we do not use our technologies to edit human embryos or the human germline, such public debate about the use of genome editing technologies in human embryos and heightened regulatory scrutiny could prevent or delay our development of product candidates. More restrictive government regulations or negative public opinion would have a negative effect on our business or financial condition and may delay or impair our development and commercialization of product candidates or demand for any products we may develop. Adverse events in our preclinical studies or clinical trials or those of our competitors or of academic researchers utilizing genome editing technologies, even if not ultimately attributable to product candidates we may identify and develop, and the resulting publicity could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of potential product candidates we may identify and develop, stricter labeling requirements for those product candidates that are approved, and a decrease in demand for any such product candidates. Use of genome editing technology by a third party or government to develop biological agents or products that threaten the United States&#8217; national security could similarly result in such negative impacts to us.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be successful in our efforts to identify, develop, or commercialize potential product candidates.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The success of our business depends primarily upon our ability to identify, develop, and commercialize products based on our genome editing platform. Other than EDIT-101 to treat LCA10, all of our product development programs are still in the preclinical or research stage of development. Our research programs, including those subject to our collaboration with Juno Therapeutics and our strategic alliance with Allergan, may fail to identify potential product candidates for clinical development for a number of reasons. Our research methodology may be unsuccessful in identifying potential product candidates, or our potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the products impractical to manufacture, unmarketable, or unlikely to receive marketing approval.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which would have a material adverse effect on our business, financial condition, results of operations, and prospects. Research programs to identify new product candidates require substantial technical, financial, and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The genome editing field is relatively new and is evolving rapidly. We are focusing our research and development efforts on CRISPR gene editing technology using Cas9 and Cpf1 enzymes, but other genome editing technologies may be discovered that provide significant advantages over CRISPR/Cas9 or CRISPR/Cpf1, which could materially harm our business.</span></p><a id="_Hlk506291343"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To date, we have focused our efforts on genome editing technologies using CRISPR and the Cas9 and Cpf1 enzymes. Other companies have previously undertaken research and development of genome editing technologies using zinc finger nucleases, engineered meganucleases, and transcription activator-like effector nucleases, but to date none has obtained marketing approval for a product candidate. There can be no certainty that the CRISPR/Cas9 or CRISPR/Cpf1 technology will lead to the development of genomic medicines, that other genome editing technologies will not be considered better or more attractive for the development of medicines or that either Cas9 or Cpf1, the two CRISPR associated proteins that we use, may be useful or successful in developing therapeutics. For example, Cas9 or Cpf1 may be determined to be less attractive than other CRISPR enzymes, including CRISPR enzymes that have yet to be discovered. Similarly, a new genome editing technology that has not been discovered yet may be determined to be more attractive than CRISPR. Moreover, if we decide to develop genome technologies other than CRISPR technology using a Cas9 or Cpf1 enzyme, we cannot be certain we will be able to obtain rights to such technologies. Any of these factors could reduce or eliminate our commercial opportunity, and could have a material adverse effect on our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We depend heavily on the success of EDIT-101. Except for EDIT-101, all of our product development programs are at the preclinical or research stage. Preclinical testing and clinical trials of product candidates may not be successful. If we are unable to commercialize any product candidates we develop or experience significant delays in doing so, our business will be materially harmed.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have invested a significant portion of our efforts and financial resources in the identification and development of EDIT-101 to treat LCA10. Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of EDIT-101 by Allergan for the treatment of LCA10 and other product candidates that we may identify in the future. The success of product candidates we identify and develop will depend on many factors, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">sufficiency of our financial and other resources to complete the necessary clinical trials for EDIT-101;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">successful completion of preclinical studies and investigational new drug (&#8220;IND&#8221;)-enabling studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">successful enrollment in, and completion of, clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">receipt of marketing approvals from applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">obtaining and maintaining patent and trade secret protection and non-patent exclusivity for our medicines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">launching commercial sales of the medicines, if and when approved, whether alone or in collaboration with others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">acceptance of the medicines, if and when approved, by patients, the medical community, and third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">effectively competing with other therapies and treatment options;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">a continued acceptable safety profile of the medicines following approval;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">enforcing and defending intellectual property and proprietary rights and claims; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">achieving desirable medicinal properties for the intended indications.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The foregoing also applies to our collaborators to the extent we have partnered, sold or licensed any of our research programs to them. For instance, Allergan has exercised its option to license EDIT-101 and, although we have entered into a profit-sharing arrangement to equally split the profits and costs of such program in the United States and we will continue to work with Allergan on the development and commercialization of such program, in the event a dispute arises, Allergan will have final decision making authority. If we or our collaborators do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize any product candidates we develop, which would materially harm our business.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Of the large number of biologics and drugs in development in the pharmaceutical industry, only a small percentage result in the submission of a Biologics License Application (a &#8220;BLA&#8221;) to the FDA or a marketing authorization application (an &#8220;MAA&#8221;) to the EMA. Not all BLAs or MAAs that are submitted to a regulatory agency are approved for commercialization. Furthermore, even if we do receive regulatory approval to market any product candidates that we may identify and develop, any such approval may be subject to limitations on the indicated uses for which we may market the product. Accordingly, even if we are able to obtain the requisite financing to continue to fund our research programs, we cannot assure you that we or our collaborators will successfully develop or commercialize EDIT-101, or any of our other research programs. If we or any of our collaborators and future development partners are unable to develop, or obtain regulatory approval for, or, if approved, successfully commercialize, any product candidates we may identify and develop, we may not be able to generate sufficient revenue to continue our business.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If serious adverse events, undesirable side effects, or unexpected characteristics are identified during the development of any product candidates we develop, we may need to abandon or limit our further clinical development of those product candidates.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have not evaluated any product candidates in human clinical trials, and our proposed delivery modes, combined with CRISPR technology, have a limited history, if any, of being tested clinically. It is impossible to predict when or if any product candidates we develop will prove safe in humans. In the genomic medicine field, there have been several significant adverse events from gene therapy treatments in the past, including reported cases of leukemia and death. There can be no assurance that genome editing technologies will not cause severe or undesirable side effects.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A significant risk in any genome editing product is that the edit will be &#8220;off-target&#8221; and cause serious adverse events, undesirable side effects, or unexpected characteristics. For example, off-target cuts could lead to disruption of a gene or a genetic regulatory sequence at an unintended site in the DNA, or, in those instances where we also provide a segment of DNA to serve as a repair template, it is possible that following off-target cut events, DNA from such repair template could be integrated into the genome at an unintended site, potentially disrupting another important gene or genomic element. We cannot be certain that off-target editing will not occur in any of our clinical studies. There is also the potential risk of delayed adverse events following exposure to genome editing therapy due to the potential for persistent biological activity of the genetic material or other components of products used to carry the genetic material.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If any product candidates we develop are associated with serious adverse events, or undesirable side effects, or have characteristics that are unexpected, we may need to abandon their development or limit development to certain uses or subpopulations in which the serious adverse events, undesirable side effects or other characteristics are less prevalent, less severe, or more acceptable from a risk-benefit perspective, any of which would have a material adverse effect on our business, financial condition, results of operations, and prospects. Many product candidates that initially showed promise in early stage testing for treating cancer or other diseases have later been found to cause side effects that prevented further clinical development of the product candidates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If any of the product candidates we develop or the delivery modes we rely on cause undesirable side effects, it could delay or prevent their regulatory approval, limit the commercial potential, or result in significant negative consequences following any potential marketing approval.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Product candidates we develop may be associated with off-target editing or other serious adverse events, undesirable side effects, or unexpected characteristics. There also is the potential risk of delayed adverse events following exposure to gene editing therapy due to persistent biologic activity of the genetic material or other components of products used to carry the genetic material. In addition to serious adverse events or side effects caused by any product candidate we develop, the administration process or related procedures also can cause undesirable side effects. If any such events occur, our clinical trials could be suspended or terminated.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If in the future we are unable to demonstrate that such adverse events were caused by factors other than our product candidate, the FDA, the EMA or other regulatory authorities could order us to cease further development of, or deny approval of, any product candidates we are able to develop for any or all targeted indications. Even if we are able to demonstrate that all future serious adverse events are not product-related, such occurrences could affect patient recruitment or the ability of enrolled patients to complete the trial. Moreover, if we elect, or are required, to delay, suspend or terminate any clinical trial of any product candidate we develop, the commercial prospects of such product candidates may be harmed and our ability to generate product revenues from any of these product candidates may be delayed or eliminated. Any of these occurrences may harm our ability to identify and develop product candidates, and may harm our business, financial condition, result of operations, and prospects significantly.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, if we successfully develop a product candidate and it receives marketing approval, the FDA could require us to adopt a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) to ensure that the benefits of treatment with such product candidate outweighs the risks for each potential patient, which may include, among other things, a medication guide outlining the risks of the product for distribution to patients, a communication plan to health care practitioners, extensive patient monitoring, or distribution systems and processes that are highly controlled, restrictive, and more costly than what is typical for the industry. Furthermore, if we or others later identify undesirable side effects caused by any product candidate that we to develop, several potentially significant negative consequences could result, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">regulatory authorities may suspend or withdraw approvals of such product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">regulatory authorities may require additional warnings on the label;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">we may be required to change the way a product candidate is administered or conduct additional clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">we could be sued and held liable for harm caused to patients; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">our reputation may suffer.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any of these events could prevent us from achieving or maintaining market acceptance of any product candidates we may identify and develop and could have a material adverse effect on our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have not tested any of our proposed delivery modes and product candidates in clinical trials.</span></p><a id="_Hlk496779887"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our proposed delivery modes, combined with our product candidates, have a limited history, if any, of being evaluated in human clinical trials. Any product candidates we develop may fail to show the desired safety and efficacy in later stages of clinical development despite having successfully advanced through initial clinical trials.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">There is a high failure rate for drugs and biologics proceeding through clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in later stage clinical trials even after </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">achieving promising results in earlier stage clinical trials. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit, or prevent regulatory approval. In addition, regulatory delays or rejections may be encountered as a result of many factors, including changes in regulatory policy during the period of product development.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any such adverse events may cause us to delay, limit, or terminate planned clinical trials, any of which would have a material adverse effect on our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Because we are developing product candidates for the treatment of diseases in which there is little clinical experience using new technologies, there is increased risk that the FDA, the EMA, or other regulatory authorities may not consider the endpoints of our clinical trials to provide clinically meaningful results and that these results may be difficult to analyze.</span></p><a id="_Hlk496779963"></a><a id="_Hlk506291965"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the regulatory review process, we will need to identify success criteria and endpoints such that the FDA, the EMA, or other regulatory authorities will be able to determine the clinical efficacy and safety profile of any product candidates we develop. As we are initially seeking to identify and develop product candidates to treat diseases in which there is little clinical experience using new technologies, there is heightened risk that the FDA, the EMA, or other regulatory authorities may not consider the clinical trial endpoints that we propose to provide clinically meaningful results (reflecting a tangible benefit to patients). In addition, the resulting clinical data and results may be difficult to analyze. Even if the FDA does find our success criteria to be sufficiently validated and clinically meaningful, we may not achieve the pre-specified endpoints to a degree of statistical significance. This may be a particularly significant risk for many of the genetically defined diseases for which we plan to develop product candidates because many of these diseases have small patient populations, and designing and executing a rigorous clinical trial with appropriate statistical power is more difficult than with diseases that have larger patient populations. Further, even if we do achieve the pre-specified criteria, we may produce results that are unpredictable or inconsistent with the results of the non-primary endpoints or other relevant data. The FDA also weighs the benefits of a product against its risks, and the FDA may view the efficacy results in the context of safety as not being supportive of regulatory approval. Other regulatory authorities in the European Union and other countries, such as the CAT, may make similar comments with respect to these endpoints and data. Any product candidates we develop will be based on a novel technology that makes it difficult to predict the time and cost of development and of subsequently obtaining regulatory approval. No genome editing therapeutic product has been approved in the United States or in Europe.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If clinical trials of any product candidates we may identify and develop fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of such product candidates.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Before obtaining marketing approval from regulatory authorities for the sale of any product candidates we may identify and develop, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy in humans of any such product candidates. Clinical testing is expensive, difficult to design and implement, can take many years to complete, and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses. Many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We or our collaborators may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize any product candidates we may identify and develop, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">delays in reaching a consensus with regulators on trial design;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">regulators, institutional review boards (&#8220;IRBs&#8221;) or independent ethics committees (&#8220;IECs&#8221;) may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">delays in reaching or failing to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective contract research organizations (&#8220;CROs&#8221;) and clinical trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">clinical trials of any product candidates we develop may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development or research programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">difficulty in designing well-controlled clinical trials due to ethical considerations which may render it inappropriate to conduct a trial with a control arm that can be effectively compared to a treatment arm;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">difficulty in designing clinical trials and selecting endpoints for diseases that have not been well-studied and for which the natural history and course of the disease is poorly understood;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the number of patients required for clinical trials of any product candidates we develop may be larger than we anticipate; enrollment of suitable participants in these clinical trials, which may be particularly challenging for some of the rare genetically defined diseases we are targeting in our most advanced programs, may be delayed or slower than we anticipate; or patients may drop out of these clinical trials at a higher rate than we anticipate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">regulators, IRBs, or IECs may require that we or our investigators suspend or terminate clinical research or clinical trials of any product candidates we develop for various reasons, including noncompliance with regulatory requirements, a finding of undesirable side effects or other unexpected characteristics, or that the participants are being exposed to unacceptable health risks or after an inspection of our clinical trial operations or trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the cost of clinical trials of any product candidates we develop may be greater than we anticipate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the supply or quality of any product candidates we develop or other materials necessary to conduct clinical trials of any product candidates we develop may be insufficient or inadequate, including as a result of delays in the testing, validation, manufacturing, and delivery of any product candidates we develop to the clinical sites by us or by third parties with whom we have contracted to perform certain of those functions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">delays in having patients complete participation in a trial or return for post-treatment follow-up;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">clinical trial sites dropping out of a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">occurrence of serious adverse events associated with any product candidates we develop that are viewed to outweigh their potential benefits;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">occurrence of serious adverse events in trials of the same class of agents conducted by other sponsors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we or our collaborators are required to conduct additional clinical trials or other testing of any product candidates we develop beyond those that we currently contemplate, if we or our collaborators are unable to successfully complete clinical trials of any product candidates we develop or other testing, or if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we or our collaborators may:</p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">be delayed in obtaining marketing approval for any such product candidates we develop or not obtain marketing approval at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">be subject to changes in the way the product is administered;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">have regulatory authorities withdraw, or suspend, their approval of the product or impose restrictions on its distribution in the form of a modified risk evaluation and mitigation strategy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">be sued; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">experience damage to our reputation.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Product development costs will also increase if we or our collaborators experience delays in testing or marketing approvals. We do not know whether any clinical trials will begin as planned, will need to be restructured, or will be completed on schedule, or at all. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize any product candidates we develop, could allow our competitors to bring products to market before we do, and could impair our ability to successfully commercialize any product candidates we develop, any of which may harm our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We or our collaborators may not be able to initiate or continue clinical trials for any product candidates we identify or develop if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or analogous regulatory authorities outside the United States, or as needed to provide appropriate statistical power for a given trial. Enrollment may be challenging for the rare genetically defined diseases we are targeting. In addition, if patients are unwilling to participate in our genome editing trials because of negative publicity from adverse events related to the biotechnology, gene therapy, or genome editing fields, competitive clinical trials for similar patient populations, clinical trials in competing products, or for other reasons, the timeline for recruiting patients, conducting studies, and obtaining regulatory approval of any product candidates we develop may be delayed. Moreover, some of our competitors may have ongoing clinical trials for product candidates that would treat the same indications as any product candidates we develop, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates. For example, ProQR Therapeutics N.V. has already enrolled LCA10 patients in its clinical trial, which may limit the number of potential patients available to enroll in the ongoing Phase 1/2 clinical study for EDIT-101.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Patient enrollment is also affected by other factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">severity of the disease under investigation;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><div style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:24pt;text-align:center;text-indent:0pt;">47</div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><div style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:30pt;margin-left:0pt;text-indent:0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></div></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">size of the patient population and process for identifying patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">design of the trial protocol;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">availability and efficacy of approved medications for the disease under investigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">availability of genetic testing for potential patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">ability to obtain and maintain patient informed consent;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">risk that enrolled patients will drop out before completion of the trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">eligibility and exclusion criteria for the trial in question;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">perceived risks and benefits of the product candidate under trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">perceived risks and benefits of genome editing as a therapeutic approach;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">efforts to facilitate timely enrollment in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">patient referral practices of physicians;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">ability to monitor patients adequately during and after treatment; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">proximity and availability of clinical trial sites for prospective patients.</span></td></tr></table><div style="margin-top:12pt;"><a id="_Hlk506292293"></a></div><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In particular, EDIT-101 for the treatment of LCA10 has a limited patient pool from which to draw for enrollment in a clinical trial, as the global incidence of LCA10 is estimated to be two to three per 100,000 live births worldwide. The eligibility criteria of our clinical trials will further limit the pool of available trial participants. Additionally, the process of finding and diagnosing patients may prove costly.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our ability to successfully initiate, enroll, and complete a clinical trial in any foreign country is subject to numerous risks unique to conducting business in foreign countries, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">difficulty in establishing or managing relationships with CROs and physicians;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">different standards for the conduct of clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">different standard-of-care for patients with a particular disease;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">inability to locate qualified local consultants, physicians, and partners; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">potential burden of complying with a variety of foreign laws, medical standards, and regulatory requirements, including the regulation of pharmaceutical and biotechnology products and treatment.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Enrollment delays in our clinical trials may result in increased development costs for any product candidates we develop, which would cause the value of our company to decline and limit our ability to obtain additional financing. If we or our collaborators have difficulty enrolling a sufficient number of patients to conduct our clinical trials as planned, we may need to delay, limit, or terminate ongoing or planned clinical trials, any of which would have an adverse effect on our business, financial condition, results of operations, and prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications among many potential options. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial medicines or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable medicines. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing, or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. Any such event could have a material adverse effect on our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to successfully identify patients who are likely to benefit from therapy with any medicines we develop, or experience significant delays in doing so, we may not realize the full commercial potential of any medicines we may develop.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our success may depend, in part, on our ability to identify patients who are likely to benefit from therapy with any medicines we may develop, which requires those potential patients to have their DNA analyzed for the presence or absence of a particular sequence. For example, although LCA can be diagnosed based on a patient&#8217;s symptoms and retinal scans, DNA samples are taken from LCA patients in order to test for the presence of the known gene mutations that cause LCA and, where possible, to identify the specific genetically defined disease, such as LCA10. If we, or any third parties that we engage to assist us, are unable to successfully identify such patients, or experience delays in doing so, then:</p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">our ability to develop any product candidates may be adversely affected if we are unable to appropriately select patients for enrollment in our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">any product candidates we develop may not receive marketing approval if safe and effective use of such product candidates depends on an </span><i style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:normal;line-height:1.19;text-align:left;">in vitro</i><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;"> diagnostic; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">we may not realize the full commercial potential of any product candidates we develop that receive marketing approval if, among other reasons, we are unable to appropriately select patients who are likely to benefit from therapy with our medicines.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a result, we may be unable to successfully develop and realize the commercial potential of any product candidates we may identify and develop, and our business, financial condition, results of operations, and prospects would be materially adversely affected.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize a product candidate we develop, and any such approval may be for a more narrow indication than we seek.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We cannot commercialize a product candidate until the appropriate regulatory authorities have reviewed and approved the product candidate. Even if any product candidates we develop meet their safety and efficacy endpoints in clinical trials, the regulatory authorities may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA Advisory Committee or other regulatory authority recommends non-approval or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory authority policy during the period of product development, clinical trials, and the review process.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Regulatory authorities also may approve a product candidate for more limited indications than requested or they may impose significant limitations in the form of narrow indications, warnings or a REMS. These regulatory authorities </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">may require precautions or contra-indications with respect to conditions of use, or they may grant approval subject to the performance of costly post-marketing clinical trials. In addition, regulatory authorities may not approve the labeling claims that are necessary or desirable for the successful commercialization of any product candidates we develop. Any of the foregoing scenarios could materially harm the commercial prospects for any product candidates we develop and materially adversely affect our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if any product candidates we develop receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors, and others in the medical community necessary for commercial success.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The commercial success of any of our product candidates will depend upon its degree of market acceptance by physicians, patients, third-party payors, and others in the medical community. Ethical, social, and legal concerns about genomic medicines generally and genome editing technologies specifically could result in additional regulations restricting or prohibiting our products. Even if any product candidate we develop receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare payors, and others in the medical community. The degree of market acceptance of any product candidates we develop, if approved for commercial sale, will depend on a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the efficacy and safety of such product candidates as demonstrated in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the potential and perceived advantages compared to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the limitation to our targeted patient population and limitations or warnings contained in approved labeling by the FDA or other regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the ability to offer our medicines for sale at competitive prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">convenience and ease of administration compared to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the clinical indications for which the product candidate is approved by the FDA, the European Commission, or other regulatory agencies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">public attitudes regarding genomic medicine generally and genome editing technologies specifically;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies, as well as their willingness to accept a therapeutic intervention that involves the editing of the patient&#8217;s genome;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">product labeling or product insert requirements of the FDA, the EMA, or other regulatory authorities, including any limitations or warnings contained in a product&#8217;s approved labeling;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">relative convenience and ease of administration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the timing of market introduction of competitive products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">publicity concerning our products or competing products and treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the strength of marketing and distribution support;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">sufficient third-party coverage or reimbursement; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the prevalence and severity of any side effects.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If any product candidates we develop do not achieve an adequate level of acceptance, we may not generate significant product revenues, and we may not become profitable.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any product candidates we develop, we may not be successful in commercializing those product candidates if and when they are approved.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not have a sales or marketing infrastructure and have no experience in the sale, marketing, or distribution of pharmaceutical products. To achieve commercial success for any approved medicine for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization or outsource these functions to third parties. In the future, we may choose to build a focused sales, marketing, and commercial support infrastructure to sell, or participate in sales activities with our collaborators for, some of our product candidates if and when they are approved.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There are risks involved with both establishing our own commercial capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force or reimbursement specialists is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing and other commercialization capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our commercialization personnel.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Factors that may inhibit our efforts to commercialize our medicines on our own include:</p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">our inability to recruit and retain adequate numbers of effective sales, marketing, reimbursement, customer service, medical affairs, and other support personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future medicines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement, and other acceptance by payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">restricted or closed distribution channels that make it difficult to distribute our products to segments of the patient population;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the lack of complementary medicines to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">unforeseen costs and expenses associated with creating an independent commercialization organization.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we enter into arrangements with third parties to perform sales, marketing, commercial support, and distribution services, our product revenues or the profitability of these product revenues to us may be lower than if we were to market and sell any medicines we may develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to commercialize our product candidates or may be unable to do so on terms that are favorable to us. We may have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our medicines effectively. If we do not establish commercialization capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We face significant competition in an environment of rapid technological change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer or more advanced or effective than ours, which may harm our financial condition and our ability to successfully market or commercialize any product candidates we develop.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The development and commercialization of new drug products is highly competitive. Moreover, the biotechnology and pharmaceutical industries, including in the gene therapy, genome editing and cell therapy fields, are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on intellectual property and proprietary products. We will face competition with respect to any product candidates that we may seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization.</p><a id="_Hlk496780363"></a><a id="_Hlk506293641"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for the treatment of the disease indications for which we have research programs. Some of these competitive products and therapies are based on scientific approaches that are the same as or similar to our approach, and others are based on entirely different approaches.</p><a id="_Hlk506293686"></a><a id="_Hlk496780384"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our platform and product focus is the development of therapies using CRISPR technology. Other companies developing CRISPR technology or therapies using CRISPR technology include Arbor Biotechnologies, Caribou Biosciences, Casebia Therapeutics, CRISPR Therapeutics, ERS Genomics, Exonics Therapeutics, Intellia Therapeutics, Locus Biosciences, ToolGen&#160;Inc. (&#8220;ToolGen&#8221;) and TRACR Hematology. In addition, there have been and may continue to be discoveries of new CRISPR-based gene editing technologies. There are additional companies developing therapies using other genome editing technologies, including base editing, transcription activator-like effector nucleases, meganucleases, Mega-TALs, and zinc finger nucleases. These companies include Beam Therapeutics Inc., bluebird bio, Cellectis, Poseida Therapeutics, Precision Biosciences and Sangamo Therapeutics. Additional companies developing gene therapy products include Abeona Therapeutics, Adverum Biotechnologies, AGTC Therapeutics, Audentes Therapeutics, Homology Medicines, Nightstar Therapeutics, REGENXBIO, Sarepta Therapeutics, Solid Biosciences, Spark Therapeutics, uniQure and Voyager Therapeutics. In addition to competition from other genome editing therapies, gene therapies or cell medicine therapies, any products that we may develop may also face competition from other types of therapies, such as small molecule, antibody, protein, oligonucleotide, or ribonucleic acid therapies. For example, ProQR Therapeutics N.V. is conducting a clinical trial for its experimental treatment using antisense oligonucleotide technology for LCA10.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Many of our current or potential competitors, either alone or with their collaboration partners, may have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical, biotechnology, and gene therapy industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop or that would render any products that we may develop obsolete or non-competitive. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing any product candidates we develop against competitors.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In addition, as a result of the expiration or successful challenge of our patent rights, we could face more litigation with respect to the validity and/or scope of patents relating to our competitors&#8217; products. The availability of our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">competitors&#8217; products could limit the demand, and the price we are able to charge, for any products that we may develop and commercialize.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if we are able to commercialize any product candidates, such products may become subject to unfavorable pricing regulations, third-party reimbursement practices, or healthcare reform initiatives, which would harm our business.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The regulations that govern marketing approvals, pricing, and reimbursement for new medicines vary widely from country to country. In the United States, recently enacted legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a medicine before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a medicine in a particular country, but then be subject to price regulations that delay our commercial launch of the medicine, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the medicine in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if any product candidates we develop obtain marketing approval.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our ability to commercialize any medicines successfully also will depend in part on the extent to which reimbursement for these medicines and related treatments will be available from government health administration authorities, private health insurers, and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any medicine that we commercialize and, if reimbursement is available, the level of reimbursement. Reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There may be significant delays in obtaining reimbursement for newly approved medicines, and coverage may be more limited than the purposes for which the medicine is approved by the FDA or similar regulatory authorities outside the United States. Moreover, eligibility for reimbursement does not imply that any medicine will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale, and distribution. Interim reimbursement levels for new medicines, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the medicine and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost medicines and may be incorporated into existing payments for other services. Net prices for medicines may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of medicines from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved medicines we may develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize medicines, and our overall financial condition.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Due to the novel nature of our technology and the potential for any product candidates we develop to offer therapeutic benefit in a single administration or limited number of administrations, we face uncertainty related to pricing and reimbursement for these product candidates.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Our initial target patient populations for our most advanced programs are relatively small, as a result of which the pricing and reimbursement of any product candidates we develop, if approved, must be adequate to support the necessary commercial infrastructure. If we are unable to obtain adequate levels of reimbursement, our ability to successfully market and sell any such product candidates will be adversely affected. The manner and level at which </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">reimbursement is provided for services related to any product candidates we develop, e.g.,&#160;for administration of our product to patients, is also important. Inadequate reimbursement for such services may lead to physician resistance and adversely affect our ability to market or sell our products. In addition, it may be necessary for us to develop new reimbursement models in order to realize adequate value. Payors may not be able or willing to adopt such new models, and patients may be unable to afford that portion of the cost that such models may require them to bear. If we determine such new models are necessary but we are unsuccessful in developing them, or if such models are not adopted by payors, our business, financial condition, results of operations, and prospects could be adversely affected.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect the cost of a single administration of genomic medicine products, such as those we are seeking to develop, to be substantial, when and if they achieve regulatory approval. We expect that coverage and reimbursement by government and private payors will be essential for most patients to be able to afford these treatments. Accordingly, sales of any such product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of any product candidates we develop will be paid by health maintenance, managed care, pharmacy benefit, and similar healthcare management organizations, or will be reimbursed by government authorities, private health coverage insurers, and other third-party payors. Coverage and reimbursement by a third-party payor may depend upon several factors, including the third-party payor&#8217;s determination that use of a product is:</p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">a covered benefit under its health plan;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">safe, effective, and medically necessary;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">appropriate for the specific patient;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">cost-effective; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">neither experimental nor investigational.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Obtaining coverage and reimbursement for a product from third-party payors is a time-consuming and costly process that could require us to provide to the payor supporting scientific, clinical, and cost-effectiveness data. There is significant uncertainty related to third-party coverage and reimbursement of newly approved products. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. If coverage and reimbursement are not available, or are available only at limited levels, we may not be able to successfully commercialize any product candidates we develop. Even if coverage is provided, the approved reimbursement amount may not be adequate to realize a sufficient return on our investment.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Moreover, the downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products such as ours. If we are unable to obtain adequate levels of reimbursement, our ability to successfully market and sell any product candidates we develop will be harmed.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If the market opportunities for any product candidates we develop are smaller than we believe they are, our revenues may be adversely affected, and our business may suffer. Because the target patient populations for many of the product candidates we develop are small, we must be able to successfully identify patients and achieve a significant market share to maintain profitability and growth.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Some of our most advanced programs, including EDIT-101, focus on treatments for rare genetically defined diseases. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with product candidates we develop, are based on estimates. These estimates may prove to be incorrect and new studies may change the estimated incidence or prevalence of these diseases. The number of patients in the United States, Europe, and elsewhere may turn out to be lower than expected, and patients may not be amenable to treatment with our products, or may become increasingly difficult to identify or gain access to, all of which would adversely affect our business, financial condition, results of operations, and prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any medicines that we may develop.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We face an inherent risk of product liability exposure related to the testing in human clinical trials of any product candidates we develop and will face an even greater risk if we commercially sell any medicines that we may develop. If we cannot successfully defend ourselves against claims that our product candidates or medicines caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">decreased demand for any product candidates or medicines that we may develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">injury to our reputation and significant negative media attention;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">withdrawal of clinical trial participants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">significant time and costs to defend the related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">substantial monetary awards to trial participants or patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">loss of revenue; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the inability to commercialize any medicines that we may develop.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although we maintain product liability insurance coverage, it may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage if we successfully commercialize any medicine. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we or any contract manufacturers and suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We and any contract manufacturers and suppliers we engage are subject to numerous federal, state, and local environmental, health, and safety laws, regulations, and permitting requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment, and disposal of hazardous and regulated materials and wastes; the emission and discharge of hazardous materials into the ground, air, and water; and employee health and safety. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. Under certain environmental laws, we could be held responsible for costs relating to any contamination at our current or past facilities and at third-party facilities. We also could incur significant costs associated with civil or criminal fines and penalties.</p><a id="_Hlk497335839"></a><a id="_Hlk496780769"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our research and product development efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological or hazardous waste insurance coverage, and our commercial general liability and umbrella liability policies (under which we currently have an aggregate of $7.0&#160;million in coverage) specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, we may incur substantial costs in order to comply with current or future environmental, health, and safety laws, regulations, and permitting requirements. These current or future laws, regulations, and permitting requirements may impair our research, development, or production efforts. Failure to comply with these laws, regulations, and permitting requirements also may result in substantial fines, penalties, or other sanctions or business disruption, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any third-party contract manufacturers and suppliers we engage will also be subject to these and other environmental, health, and safety laws and regulations. Liabilities they incur pursuant to these laws and regulations could result in significant costs or an interruption in operations, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Genomic medicines are novel, and any product candidates we develop may be complex and difficult to manufacture. We could experience production problems that result in delays in our development or commercialization programs, limit the supply of our products, or otherwise harm our business.</span></p><a id="_Hlk496780884"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any product candidates we develop will likely require processing steps that are more complex than those required for most chemical pharmaceuticals. Moreover, unlike chemical pharmaceuticals, the physical and chemical properties of a biologic such as the product candidates we intend to develop generally cannot be fully characterized. As a result, assays of the finished product may not be sufficient to ensure that the product will perform in the intended manner. Problems with the manufacturing process, even minor deviations from the normal process, could result in product defects or manufacturing failures that result in lot failures, product recalls, product liability claims, or insufficient inventory. If we successfully develop product candidates, we may encounter problems achieving adequate quantities and quality of clinical-grade materials that meet FDA, EMA or other comparable applicable foreign standards or specifications with consistent and acceptable production yields and costs. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the FDA, the EMA, and other regulatory authorities may require us to submit samples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA, or other regulatory authorities may require that we not distribute a lot until the agency authorizes its release. Slight deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures or product recalls. Lot failures or product recalls could cause us to delay clinical trials, including the ongoing Phase 1/2 clinical trial for EDIT-101, or product launches, which could be costly to us and otherwise harm our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We also may encounter problems hiring and retaining the experienced scientific, quality control, and manufacturing personnel needed to manage our manufacturing process, which could result in delays in our production or difficulties in maintaining compliance with applicable regulatory requirements.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Given the nature of biologics manufacturing, there is a risk of contamination during manufacturing. Any contamination could materially harm our ability to produce product candidates on schedule and could harm our results of operations and cause reputational damage. Some of the raw materials that we anticipate will be required in our manufacturing process are derived from biologic sources. Such raw materials are difficult to procure and may be subject to contamination or recall. A material shortage, contamination, recall, or restriction on the use of biologically derived substances in the manufacture of any product candidates we develop could adversely impact or disrupt the commercial manufacturing or the production of clinical material, which could materially harm our development timelines and our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Any problems in our manufacturing process or the facilities with which we contract could make us a less attractive collaborator for potential partners, including larger pharmaceutical companies and academic research institutions, which could limit our access to additional attractive development programs. Problems in third-party manufacturing process or facilities also could restrict our ability to ensure sufficient clinical material for any clinical </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">trials we may be conducting or are planning to conduct and meet market demand for any products we develop and commercialize. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Dependence on Third Parties</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We expect to depend on collaborations with third parties for the research, development, and commercialization of certain of the product candidates we develop or for development of certain of our research programs. If any such collaborations are not successful, we may not be able to capitalize on the market potential of those product candidates or research programs.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We anticipate seeking third-party collaborators for the research, development, and commercialization of certain of the product candidates we develop or for development of certain of our research programs. For example, in May 2015, we entered into a collaboration with Juno Therapeutics focused on research and development of engineered T cell immunotherapies that utilize or incorporate our genome editing technologies, and, in March 2017, we entered into a strategic alliance with Allergan focused on discovering, developing, and commercializing new gene editing medicines for a range of ocular disorders. Our likely collaborators for any other collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies, and biotechnology companies. If we enter into any such arrangements with any third parties, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of any product candidates we may seek to develop with them and, in the case of our strategic alliance with Allergan, whether they exercise any additional options to commercialize a product. Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements. We cannot predict the success of any collaboration that we enter into.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Collaborations involving our research programs or any product candidates we develop, including our collaboration with Juno Therapeutics, and alliance arrangements we may enter into under which our research programs may be involved and potential product candidates may be developed, including our strategic alliance with Allergan, pose the following risks to us:</p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Collaborators may have significant discretion in determining the efforts and resources that they will apply to these collaborations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Collaborators may not pursue development and commercialization of any product candidates we develop or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#8217;s strategic focus or available funding or external factors such as an acquisition that diverts resources or creates competing priorities. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our medicines or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Collaborators with marketing and distribution rights to one or more medicines may not commit sufficient resources to the marketing and distribution of such medicine or medicines.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Collaborators may not properly obtain, maintain, enforce, or defend our intellectual property or proprietary rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation. </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><div style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:24pt;text-align:center;text-indent:0pt;">57</div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><div style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:30pt;margin-left:0pt;text-indent:0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></div></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Disputes may arise between the collaborators and us that result in the delay or termination of the research, development, or commercialization of our medicines or product candidates or that result in costly litigation or arbitration that diverts management attention and resources.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">We may lose certain valuable rights under circumstances identified in our collaborations, including if we undergo a change of control.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program under such collaboration could be delayed, diminished, or terminated.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If our collaborations do not result in the successful development and commercialization of products, or if one of our collaborators terminates its agreement with us, we may not receive any milestone or royalty payments under such collaborations. If we do not receive the funding we expect under these agreements, our development of product candidates could be delayed, and we may need additional resources to develop product candidates. In addition, if one of our collaborators terminates its agreement with us, we may find it more difficult to find a suitable replacement collaborator or attract new collaborators, and our development programs may be delayed or the perception of us in the business and financial communities could be adversely affected. All of the risks relating to product development, regulatory approval, and commercialization described in this Quarterly Report on Form 10-Q apply to the activities of our collaborators.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may in the future decide to collaborate with pharmaceutical and biotechnology companies for the development and potential commercialization of any product candidates we develop. These relationships, or those like them, may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business. In addition, we could face significant competition in seeking appropriate collaborators, and the negotiation process is time-consuming and complex. Our ability to reach a definitive collaboration agreement will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#8217;s evaluation of several factors. If we license rights to any product candidates we or our collaborators may develop, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are not able to establish collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our product development and research programs and the potential commercialization of any product candidates we develop will require substantial additional cash to fund expenses. For some of the product candidates we develop or certain of our research programs, we may decide to collaborate with other pharmaceutical and biotechnology companies for the development and potential commercialization of those product candidates or programs.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may also be restricted under existing collaboration agreements from entering into future agreements on certain terms with potential collaborators or allies. For example, under our amended and restated collaboration with Juno Therapeutics, we may not use directly or indirectly, or license others to use, genome editing technology in connection with any research, development, manufacture, commercialization or other exploration of certain T cells, subject to certain exceptions, as more fully described in &#8220;Item 5. Other Information.&#8221; Collaborations are also complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop product candidates or bring them to market and generate product revenue.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We expect to rely on third parties to conduct our clinical trials and some aspects of our research and preclinical testing, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research, or testing.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect to rely on third parties, such as CROs, clinical data management organizations, medical institutions, and clinical investigators, to conduct our clinical trials. We currently rely and expect to continue to rely on third parties to conduct some aspects of our research and preclinical testing. Any of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements, it would delay our product development activities.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with standards, commonly referred to as Good Clinical Practices, for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity, and confidentiality of trial participants are protected. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity, and civil and criminal sanctions.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines, or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for any product candidates we develop and will not be able to, or may be delayed in our efforts to, successfully commercialize our medicines.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We also expect to rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of any product candidates we develop or commercialization of our medicines, producing additional losses and depriving us of potential product revenue.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We contract with third parties for the manufacture of materials for our research programs and preclinical studies and expect to continue to do so for clinical trials and for commercialization of any product candidates that we develop. This reliance on third parties increases the risk that we will not have sufficient quantities of such materials, product candidates, or any medicines that we may develop and commercialize, or that such supply will not be available to us at an acceptable cost, which could delay, prevent, or impair our development or commercialization efforts.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have a limited ability to manufacture materials for our research programs and preclinical studies and we do not operate any significant manufacturing facilities. We primarily rely on third-party manufacturers for the manufacture of our materials for preclinical studies and expect to continue to do so for clinical testing and for commercial supply of any product candidates that we develop and for which we or our collaborators obtain marketing approval. We do not have a long term supply agreement with any of the third-party manufacturers, and we purchase our required supply on a purchase order basis.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the possible breach of the manufacturing agreement by the third party;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">reliance on the third party for regulatory compliance, quality assurance, safety, and pharmacovigilance and related reporting.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocations, seizures or recalls of product candidates or medicines, operating restrictions, and criminal prosecutions, any of which could significantly and adversely affect supplies of our medicines and harm our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any medicines that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We do not currently have arrangements in place for redundant supply for bulk drug substances. If any one of our current contract manufacturer cannot perform as agreed, we may be required to replace that manufacturer. Although we believe that there are several potential alternative manufacturers who could manufacture any product candidates we develop, we may incur added costs and delays in identifying and qualifying any such replacement.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our current and anticipated future dependence upon others for the manufacture of any product candidates we develop may adversely affect our future profit margins and our ability to commercialize any product candidates that receive marketing approval on a timely and competitive basis.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Risks Related to Our Intellectual Property  </b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to obtain and maintain patent protection for any products we develop and for our technology, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize any product candidates we develop, and our technology may be adversely affected.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our CRISPR platform technology and any proprietary product candidates and technology we develop. We seek to protect our proprietary position by in-licensing intellectual property relating to our platform technology and filing patent applications in the United States and abroad related to our technologies and product candidates that are important to our business. If we or our licensors and/or collaborators are unable to obtain or maintain patent protection with respect to our CRISPR platform technology and any proprietary products and technology we develop, our business, financial condition, results of operations, and prospects could be materially harmed.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">No consistent policy regarding the scope of claims allowable in the field of genome editing, including CRISPR technology, has emerged in the United States. The scope of patent protection outside of the United States is also uncertain. Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our inventions, obtain, maintain, and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our owned and licensed patents. With respect to both in-licensed and owned intellectual property, we cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The patent prosecution process is expensive, time-consuming, and complex, and we may not be able to file, prosecute, maintain, enforce, or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors, and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#160;months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our owned or any licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or product candidates or which effectively prevent others from commercializing competitive technologies and product candidates.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we license or own issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents that we hold or in-license may be challenged, narrowed, circumvented, or invalidated by third parties. Consequently, we do not know whether any of our platform advances and product candidates will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner. For example, we are aware that third parties have suggested the use of the CRISPR technology in conjunction with a protein other than Cas9 or Cpf1. Our owned and in-licensed patents may not cover CRISPR technology in conjunction with a protein other than Cas9 or Cpf1. If our competitors commercialize the CRISPR technology in conjunction with a protein other than Cas9 or Cpf1, our business, financial </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">condition, results of operations, and prospects could be materially adversely affected.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. Our licensors are currently, and we or our licensors may in the future become, subject to a third party pre-issuance submission of prior art to the United States Patent and Trademark Office (the &#8220;USPTO&#8221;) or opposition, derivation, revocation, re-examination, post-grant and <i style="font-style:italic;">inter partes</i> review, or interference proceedings and other similar proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Moreover, we, or one of our licensors, may have to participate in interference proceedings declared by the USPTO to determine priority of invention or in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge priority of invention or other features of patentability. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. As discussed below, some of our in-licensed patents are subject to interference, opposition and <i style="font-style:italic;">ex parte</i> re-examination proceedings and therefore subject to these risks. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. Moreover, some of our owned and in-licensed patents and patent applications are, and may in the future be, co-owned with third parties. If we are unable to obtain an exclusive license to any such third party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we or our licensors may need the cooperation of any such co-owners of our owned and in-licensed patents in order to enforce such patents against third parties, and such cooperation may not be provided to us or our licensors. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, our owned and in-licensed patents and patent applications may be subject to a reservation of rights by one or more third parties. For example, the research resulting in certain of our owned and in-licensed patent rights and technology was funded in part by the U.S. government. As a result, the U.S. government has certain rights, including march-in rights, to such patent rights and technology. When new technologies are developed with government funding, the government generally obtains certain rights in any resulting patents, including a non-exclusive license authorizing the government to use the invention. For example, our licensors, including The Broad Institute,&#160;Inc. (&#8220;Broad&#8221;), have granted the U.S. government non-exclusive, non-transferable, irrevocable, paid-up licenses to practice or have practiced for or on behalf of the United States, the inventions described in certain of our in-licensed patents and patent applications, including certain aspects of our in-licensed CRISPR technology. If the government decides to exercise these rights, it is not required to engage us as its contractor in connection with doing so. These rights may permit the U.S. government to disclose our confidential information to third parties and to exercise march-in rights to use or allow third parties to use our licensed technology. The U.S. government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in the United States. Any exercise by the government of any of the foregoing rights could harm our competitive position, business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our rights to develop and commercialize our technology and product candidates are subject, in part, to the terms and conditions of licenses granted to us by others.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">We are heavily reliant upon licenses to certain patent rights and proprietary technology from third parties that </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">are important or necessary to the development of our genome editing technology, including our CRISPR technology, and product candidates. These and other licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products in the future. As a result, we may not be able to prevent competitors from developing and commercializing competitive products in territories included in all of our licenses. For example, pursuant to our license agreements with Broad, and Broad and the President and Fellows of Harvard College (&#8220;Harvard&#8221;), the licensors may, under certain circumstances, grant a license to the patents that are the subject of such license agreements to a third party. Such third party would have full rights to the patent rights that are the subject of such licenses, which could impact our competitive position and enable a third party to commercialize products similar to our future product candidates and technology. Furthermore, under these license agreements, Broad has the right, after specified periods of time and subject to certain limitations, to designate gene targets for which Broad, whether alone or together with an affiliate or third party, has an interest in researching and developing products that would otherwise be covered by rights licensed to us under the agreements. Any of the foregoing would narrow the scope of our exclusive rights to the patents and patent applications we have in-licensed from Broad. The terms of these license agreements are described more fully under &#8220;Part I&#8212;Business&#8212;Our Collaborations and Licensing Strategy&#8221; in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018. In addition, our rights to our in-licensed patents and patent applications are dependent, in part, on inter-institutional or other operating agreements between the joint owners of such in-licensed patents and patent applications. If one or more of such joint owners breaches such inter-institutional or operating agreements, our rights to such in-licensed patents and patent applications may be adversely affected, which could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</p><a id="_Hlk7446768"></a><a id="_Hlk496781431"></a><a id="_Hlk506296387"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, we may not have the right to control the preparation, filing, prosecution, maintenance, enforcement, and defense of patents and patent applications covering the technology that we license from third parties. For example, pursuant to each of our intellectual property licenses with Broad, Harvard, and The General Hospital Corporation, d/b/a Massachusetts General Hospital, our licensors retain control of preparation, filing, prosecution, and maintenance, and, in certain circumstances, enforcement and defense of their patents and patent applications. Therefore, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interests of our business. If our licensors fail to prosecute, maintain, enforce, and defend such patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, and our right to develop and commercialize any of our products that are subject of such licensed rights could be adversely affected. Additionally, given that we are required to reimburse our licensors for all of their expenses related to the prosecution, maintenance, enforcement and defense of patents and patent applications that we in-license from them, given the ongoing nature of the interference, opposition and re-examination proceedings involving the patents licensed to us under our license agreement with Harvard and Broad, and given that our obligation to make such reimbursements are not subject to any limitations, we anticipate that our obligation to reimburse our licensors for expenses related to these matters will continue to be substantial. In connection with these reimbursement obligations, we incurred expenses in aggregate amounts of $14.2 million, $18.7 million, $23.6 million, and $9.4 million during the years ended December&#160;31, 2018, 2017, 2016, and 2015, respectively, and we incurred expenses in an aggregate amount of $10.1 million during the nine months ended September 30, 2019.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our licensors may have relied on third party consultants or collaborators or on funds from third parties such that our licensors are not the sole and exclusive owners of the patents and patent applications we in-license. For example, certain patent applications licensed to us by Broad are co-owned with NIH. Broad does not and does not purport to grant any rights in NIH&#8217;s interest in these patent applications under our agreement. If other third parties have ownership rights to our in-licensed patents and patent applications, they may be able to license such patents and patent applications to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In spite of our best efforts, our licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize products and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products identical to ours. In addition, we may seek to obtain additional licenses from our licensors and, in connection with obtaining such licenses, we may agree to amend our existing licenses in a manner that </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">may be more favorable to the licensors, including by agreeing to terms that could enable third parties (potentially including our competitors) to receive licenses to a portion of the intellectual property that is subject to our existing licenses. Any of these events could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Some of our in-licensed patents are subject to priority and validity disputes. In addition, our owned and in-licensed patents, patent applications and other intellectual property may be subject to further priority and validity disputes, and other similar intellectual property proceedings including inventorship disputes. If we or our licensors are unsuccessful in any of these proceedings, we may be required to obtain licenses from third parties, which may not be available on commercially reasonable terms or at all, or to cease the development, manufacture, and commercialization of one or more of the product candidates we develop, which could have a material adverse impact on our business. </span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain U.S. patents (U.S. Patent Nos.&#160;8,697,359; 8,771,945; 8,795,965; 8,865,406; 8,871,445; 8,889,356; 8,895,308; 8,906,616; 8,932,814; 8,945,839; 8,993,233; and 8,999,641) and a U.S. patent application (U.S. Serial No.&#160;14/704,551) that are co-owned by Broad and the Massachusetts Institute of Technology (&#8220;MIT&#8221;), and in some cases Harvard, and in-licensed by us were involved in a first interference with a U.S. patent application (U.S. Serial No.&#160;13/842,859, now U.S. Patent No. 10,266,850) that is co-owned by the University of California, the University of Vienna, and Emmanuelle Charpentier. An interference is a proceeding before the Patent Trial and Appeal Board of the USPTO (&#8220;PTAB&#8221;) to determine priority of invention of the subject matter of patent claims filed by different parties. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the preliminary motions phase of the proceeding, the PTAB held that there was no interference-in-fact, meaning that no interference was needed to resolve priority between the parties because the in-licensed claims are directed to subject matter that is patentably distinct from those of the University of California, the University of Vienna, and Emmanuelle Charpentier. The interference proceeding was therefore ended without reaching the priority phase. On appeal, the Court of Appeals for the Federal Circuit (the &#8220;CAFC&#8221;) affirmed the PTAB&#8217;s holding and the University of California, the University of Vienna, and Emmanuelle Charpentier did not appeal to the U.S. Supreme Court for review of this decision. The judgment of no interference-in-fact is therefore final and bars any further interference between the same parties for claims to the same invention that was considered in the interference. The invention that was considered in this first interference was related to a method that involves contacting a target DNA in a eukaryotic cell with certain defined CRISPR/Cas9 components for the purpose of cleaving or editing a target DNA molecule or modulating transcription of at least one gene encoded thereon.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a result, the 12 U.S. patents and one U.S. patent application that we have in-licensed from Broad, acting on behalf of itself, MIT, and Harvard, with respect to which the PTAB had declared an interference were not modified or revoked as a result of this first interference proceeding. However, as discussed below, these 12 U.S. patents and one U.S. patent application are, and may in the future be, subject to further intellectual property proceedings and disputes, including interference proceedings.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">On June&#160;24, 2019, the PTAB declared a second interference between 10 pending U.S. patent applications (U.S. Serial No. 15/947,680; 15/947,700; 15/947,718; 15/981,807; 15/981,808; 15/981,809; 16/136,159; 16/136,165; 16/136,168; and 16/136,175) that are owned by the University of California, the University of Vienna, and Emmanuelle Charpentier and the same 12 U.S. patents and one U.S. patent application involved in the first interference that are co-owned by Broad and MIT, and in some cases Harvard, and in-licensed by us. One additional U.S. patent (U.S. Patent No. 9,840,713) that is co-owned by Broad and MIT and in-licensed by us and not involved in the first interference is also included in this second interference. On August 26, 2019, the PTAB re-declared the interference to add four pending U.S. patent applications (U.S. Serial No. 16/276,361; 16/276,365; 16/276,368; and 16/276,374) that are owned by the University of California, the University of Vienna, and Emmanuelle Charpentier<span style="font-size:12pt;">. </span>The declaration of interference described the interfering subject matter as related to a eukaryotic cell that comprises a target DNA and certain defined CRISPR/Cas9 components including a single-molecule guide RNA that are capable of cleaving or editing the target DNA molecule or modulating transcription of at least one gene encoded thereon. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Although we cannot predict with any certainty how long the second interference will actually take, each phase may take approximately a year or longer before a decision is made by the PTAB. It is possible for motions filed in the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">preliminary motions phase to be dispositive of the interference proceeding, such that the second priority phase is not reached. It is also possible that other third parties may seek to become a party to this interference. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The University of California, the University of Vienna, and Emmanuelle Charpentier or other third parties may file&#160;a separate Suggestion of Interference against the Broad patents and patent application that are subject to the interference or other U.S. patents and patent applications that we own or in-license. For example, ToolGen&#160;filed Suggestions of Interference in the USPTO on April&#160;13, 2015 suggesting that they believe some of the claims in pending U.S. applications owned by ToolGen (U.S. Serial No.&#160;14/685,568 and U.S. Serial No.&#160;14/685,510) interfere with certain claims in five U.S. patents, which we have in-licensed from Broad, acting on behalf of itself, MIT, and Harvard. These five U.S. patents are among the 13 U.S. patents with respect to which the PTAB has declared a second interference. The Suggestions of Interference that were filed by ToolGen are still pending and it is uncertain when and in what manner the USPTO will act on them.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our owned and in-licensed patents and patent applications are, or may in the future become, subject to validity disputes in the USPTO and other foreign patent offices. For example, a request for <i style="font-style:italic;">ex parte</i> re-examination was filed with the USPTO on February&#160;16, 2016 against one U.S. patent that we have in-licensed from Broad, acting on behalf of itself and MIT (U.S. Patent No.&#160;8,771,945), which is part of the second interference and referenced in the Suggestions of Interference filed by ToolGen. <i style="font-style:italic;">Ex parte</i> re-examination is a procedure through which a third party can anonymously request the USPTO to re-examine a granted patent because the third party believes the granted patent may not be patentable over prior art in the form of a printed publication or another patent. Before the USPTO will re-examine a granted patent, the third party requestor must establish that the submitted prior art establishes a substantial and new question of patentability. If the USPTO determines there is a substantial and new question of patentability, it grants the re-examination request and re-examines the patent after giving the patent owner the option of filing an initial statement. The request for <i style="font-style:italic;">ex parte</i> re-examination of U.S. Patent No.&#160;8,771,945 was granted on May&#160;9, 2016 thereby initiating a re-examination procedure between the USPTO and Broad, acting on behalf of itself and MIT. The third party requestor does not participate in the re-examination procedure after filing the request except that it has the option of responding if the patent owner chooses to file an initial statement. On May&#160;12, 2016, the PTAB suspended the re-examination noting that it has jurisdiction over any file that involves a patent involved in an interference. On January 3, 2019, the PTAB lifted the suspension in light of the CAFC&#8217;s affirmance of the PTAB&#8217;s no interference-in-fact holding in the first interference. On June 24, 2019, when the PTAB declared the second interference it re-suspended the re-examination. It is uncertain when the PTAB will lift the suspension. If Broad is unsuccessful during the re-examination, U.S. Patent No.&#160;8,771,945 may be revoked or narrowed, which could have a material adverse effect on the scope of our rights under such patent.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The 13 in-licensed U.S. patents and one in-licensed U.S. patent application that are the subject of the second interference (which includes the five in-licensed U.S. patents that are the subject of the Suggestions of Interference filed by ToolGen and the one in-licensed U.S. patent that is the subject of the re-examination) relate generally to the CRISPR/Cas9 system and its use in eukaryotic cells. The claims of the 13 in-licensed U.S. patents and one in-licensed U.S. patent application vary in scope and coverage and include claims that are directed to CRISPR/Cas9 systems that employ viral vectors for delivery, single guide RNAs, modified guide RNAs, <i style="font-style:italic;">S. aureus</i> Cas9, or a Cas9 nickase and are relevant to our genome editing platform technology. The loss or narrowing in scope of one or more of these in-licensed patents could have a material adverse effect on the conduct of our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We or our licensors may also be subject to claims that former employees, collaborators, or other third parties have an interest in our owned or in-licensed patents or patent applications, or other intellectual property rights as an inventor or co-inventor. If we are unable to obtain an exclusive license to any such third party co-owners&#8217; interest in such patents, patent applications or other intellectual property rights, such co-owners may be able to license their rights to other third parties, including our competitors. In addition, we may need the cooperation of any such co-owners to enforce any patents, including any patents that issue from patent applications, against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on the conduct of our business, financial condition, results of operations, and prospects. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">We or our licensors are subject to and may in the future become a party to similar proceedings or priority </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">disputes in Europe or other foreign jurisdictions. For example, four European patents that we have in-licensed from Broad, acting on behalf of itself and MIT, or itself, MIT and Harvard (European Patent Nos. EP 2,764,103 B1, EP 2,771,468 B1, EP 2,784,162 B1, and EP 2,931,898 B1) have been revoked in their entirety by the European Patent Office Opposition Division (the &#8220;Opposition Division&#8221;). Broad, acting on behalf of itself and MIT, or itself, MIT and Harvard has filed notices of appeal to the Boards of Appeal of the EPO for review of the Opposition Division&#8217;s decisions to revoke these four patents. It is uncertain when or in what manner the Boards of Appeal will act on these appeals. Two other European patents that we have in-licensed from Broad, acting on behalf of itself, MIT and Harvard (European Patent Nos. EP 2,896,697 B1 and EP 2,898,075 B1) were maintained with amended patent claims. Broad, acting on behalf of itself, MIT and Harvard has filed notices of appeal to the Boards of Appeal of the EPO for review of the Opposition Division&#8217;s decisions to maintain these two patents with amended patent claims. Two of the opponents also filed a notice of appeal for European Patent No. EP 2,896,697 B1. It is uncertain when or in what manner the Boards of Appeal will act on these appeals. The Opposition Division has also initiated opposition proceedings against seven other European patents that we have in-licensed from Broad, acting on behalf of itself, MIT and Harvard, or itself, MIT, Harvard and The Rockefeller University (&#8220;Rockefeller&#8221;) (European Patent Nos.&#160; EP 2,825,654 B1, EP 2,840,140 B1, EP 2,921,557 B1, EP 2,931,892 B1, EP 2,931,897 B1, EP 2,940,140 B1, and EP 3,009,511 B1), and one European patent that we co-own and in-license from Broad, acting on behalf of itself, MIT and The University of Iowa Research Foundation (European Patent No. EP 3,066,201 B1). The EPO opposition proceedings may involve issues including, but not limited to, procedural formalities related to filing the European patent application, priority, and the patentability of the involved claims. The loss of priority for, or the loss of, these European patents could have a material adverse effect on the conduct of our business. One or more of the third parties that have filed oppositions against these European patents or other third parties may file future oppositions against other European patents that we in-license or own. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we or our licensors are unsuccessful in any patent related disputes, including interference proceedings, patent oppositions, re-examinations, or other priority, inventorship, or validity disputes to which we or they are subject (including any of the proceedings discussed above), we may lose valuable intellectual property rights through the loss of one or more patents owned or licensed or our owned or licensed patent claims may be narrowed, invalidated, or held unenforceable. In addition, if we or our licensors are unsuccessful in any inventorship disputes to which we or they are subject, we may lose valuable intellectual property rights, such as exclusive ownership of, or the exclusive right to use, our owned or in-licensed patents and patent applications. If we or our licensors are unsuccessful in any interference proceeding or other priority or inventorship dispute, we may be required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings or other priority or inventorship disputes. Such licenses may not be available on commercially reasonable terms or at all, or may be non-exclusive. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture, and commercialization of one or more of the product candidates we develop. The loss of exclusivity or the narrowing of our owned and in-licensed patent claims could limit our ability to stop others from using or commercializing similar or identical technology and products. Any of the foregoing could result in a material adverse effect on our business, financial condition, results of operations, or prospects. Even if we are successful in any interference proceeding or other priority, inventorship, or validity disputes, it could result in substantial costs and be a distraction to our management and other employees. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to protect our intellectual property and proprietary rights throughout the world.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. In addition, our intellectual property license agreements may not always include worldwide rights. For example, certain U.S. patent applications licensed to us by Broad include The University of Tokyo (&#8220;Tokyo&#8221;) and NIH as joint applicants. Broad has only granted a license to us with respect to its interests and to Tokyo&#8217;s interests in these U.S. patent applications but not to any foreign equivalents thereof. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection or licenses but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents and our intellectual property rights or marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations, and prospects may be adversely affected.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Periodic maintenance fees, renewal fees, annuity fees, and various other government fees on patents and applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our owned or licensed patents and applications. In certain circumstances, we rely on our licensing partners to pay these fees due to U.S. and non-U.S. patent agencies. The USPTO and various non-U.S. government agencies require compliance with several procedural, documentary, fee payment, and other similar provisions during the patent application process. We are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. In some cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in a partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical products or technology, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have entered into license agreements with third parties and may need to obtain additional licenses from our existing licensors and others to advance our research or allow commercialization of product candidates we develop. It is possible that we may be unable to obtain any additional licenses at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business, financial condition, results of operations, and prospects significantly. We cannot provide any assurances that third party patents do not exist which might be enforced against our current technology, including CRISPR genome editing technology, manufacturing methods, product candidates, or future methods or products resulting in either an injunction prohibiting our manufacture or sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In each of our license agreements, and we expect in our future agreements, we are responsible for bringing any actions against any third party for infringing on the patents we have licensed. Certain of our license agreements also require us to meet development thresholds to maintain the license, including establishing a set timeline for developing and commercializing products. Disputes may arise regarding intellectual property subject to a licensing agreement, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the sublicensing of patent and other rights under our collaborative development relationships;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the priority of invention of patented technology.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, including the amount, if any, that may become due and payable to our licensors in connection with sublicense income. If these events were to occur, they could have a material adverse effect on our business, financial condition, results of operations, and prospects.&#160;Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be successful in obtaining necessary rights to any product candidates we develop through acquisitions and in-licenses.</span></p><a id="_Hlk506296772"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">We currently have rights to intellectual property, through licenses from third parties, to identify and develop product candidates. Many pharmaceutical companies, biotechnology companies, and academic institutions are competing with us in the field of genome editing technology and filing patent applications potentially relevant to our business. For example, we are aware of third party patents and patent applications that may be construed to cover our CRISPR technology and product candidates. In order to avoid infringing these third party patents, or patents that issue from these third party patent applications, we may find it necessary or prudent to obtain licenses from such third party intellectual property holders. We may also require licenses from third parties for certain non-CRISPR technologies including certain delivery methods that we are evaluating for use with product candidates we develop. In addition, with respect to any patents we co-own with third parties, we may require licenses to such co-owners&#8217; interest in such patents. However, we may be unable to secure such licenses or otherwise acquire or in-license any compositions, methods of use, processes, or other intellectual property rights from third parties that we identify as necessary for our CRISPR technology and product candidates we develop. The licensing or acquisition of third party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. For example, certain guide RNA modifications and delivery modes, including certain adeno-associated virus vectors and lipid nanoparticle technologies, we are </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">evaluating for use are covered by patents held by third parties. If we are unable to successfully obtain rights to required third party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file&#160;a patent application was entitled to the patent. After March 2013, under the Leahy-Smith America Invents Act (the &#8220;America Invents Act&#8221;) enacted in September 2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file&#160;a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. The America Invents Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by the USPTO administered post-grant proceedings, including post-grant review, <i style="font-style:italic;">inter partes</i> review, and derivation proceedings. The America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Issued patents covering our technology and product candidates could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad.</span></p><a id="_Hlk506542469"></a><a id="_Hlk8210022"></a><a id="_Hlk506485562"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">If we or one of our licensors or our collaborators were to initiate legal proceedings against a third party to enforce a patent covering a product candidate we develop or our technology, including CRISPR genome editing technology, the defendant could counterclaim that such patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties have raised challenges to the validity of certain of our in-licensed patent claims and may in the future raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, <i style="font-style:italic;">inter partes</i> review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g.,&#160;opposition proceedings). For example, as discussed above, 13 of our in-licensed U.S. patents and one of our in-licensed U.S. patent applications are involved in an interference, and Suggestions of Interference have been filed against certain of our in-licensed U.S. patents, one of these U.S. patents is subject to a re-examination proceeding, opposition proceedings have been initiated against several of our in-licensed European patents and additional interference, re-examination, post-grant review, <i style="font-style:italic;">inter partes</i> review, opposition, and other intellectual property proceedings may be initiated in the future. The opposition proceedings have so far resulted in the revocation of four of our in-licensed European patents while maintaining two of our in-licensed European patents with amended claims. In view of certain arguments made by the third parties against the revoked patents and similar arguments made by the third parties against additional other in-</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">licensed European patents under opposition, the opposition proceedings could potentially lead to the revocation of additional in-licensed European patents. These and other proceedings could result in the revocation or cancellation of, or amendment to our patents in such a way that they no longer cover our technology or platform, or any product candidates that we develop. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we or our licensing partners and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our technology or platform, or any product candidates that we develop. Such a loss of patent protection would have a material adverse impact on our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The intellectual property landscape around genome editing technology, including CRISPR, is highly dynamic, and third parties may initiate legal proceedings alleging that we are infringing, misappropriating, or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The field of genome editing, especially in the area of CRISPR technology, is still in its infancy, and no such products have reached the market. Due to the intense research and development that is taking place by several companies, including us and our competitors, in this field, the intellectual property landscape is in flux, and it may remain uncertain for the coming years. There may be significant intellectual property related litigation and proceedings relating to our owned and in-licensed, and other third party, intellectual property and proprietary rights in the future.</p><a id="_Hlk512591412"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market, and sell any product candidates that we develop and use our proprietary technologies without infringing, misappropriating, or otherwise violating the intellectual property and proprietary rights of third parties. The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual property rights. We are subject to and may in the future become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our technology and any product candidates we develop, including interference, re-examination, post-grant review, <i style="font-style:italic;">inter partes</i> review, and derivation proceedings before the USPTO and similar proceedings in foreign jurisdictions such as oppositions before the EPO. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit. We are aware of certain third party patents and patent applications in this landscape that may be asserted to encompass our CRISPR/Cas9 technology. In particular, we are aware of several separate families of U.S. patents and/or U.S. patent applications and foreign counterparts which relate to CRISPR/Cas9 technology, where the earliest priority dates of each family pre-date the priority dates of our in-licensed patents and patent applications, including PCT Publication No.&#160;WO 2013/141680 (and its related U.S. Patent No. 9,637,739 and other related U.S. patent applications and foreign counterparts including European Patent No. EP 2,828,386 B1) filed by Vilnius University (which is reported to have exclusively licensed its rights to DuPont Pioneer, which is reported to have licensed certain rights to Caribou Biosciences, which is reported to have non-exclusively licensed certain rights to Intellia Therapeutics and CRISPR Therapeutics), WO 2013/176772 (and its related U.S. Patents including U.S. Patent Nos. 10,000,772, 10,113,167, 10,227,611, and 10,266,850, 10,301,651, 10,308,961, 10,337,029, 10,351,878, 10,358,658, and 10,358,659 among others, and other related U.S. patent applications and foreign counterparts including European Patent Nos. EP 2,800,811 B1, EP 3,241,902 B1, and EP 3,401,400 B1 which are being opposed by several parties) filed by the University of California, the University of Vienna (both of which are reported to have exclusively licensed their rights to Caribou Biosciences, which is reported to have exclusively licensed certain rights to Intellia Therapeutics), and Emmanuelle Charpentier (who is reported to have exclusively licensed her rights to CRISPR Therapeutics, ERS Genomics and TRACR Hematology), WO 2014/065596 (and its related U.S. patent applications and foreign counterparts including European Patent No. EP 2,912,175 B1 which is being opposed by several parties) filed by ToolGen, and WO 2014/089290 (and its related U.S. patent applications and foreign counterparts including European Patent Nos.<span style="background-color:#ffffff;color:#0e2034;"> EP 2,928,496&#160;B1 and EP 3,360,964&#160;B1 which have not yet been opposed and European Patent Nos.</span> EP 3,138,910 B1, EP 3,138,911 B1, and EP 3,138,912 B1 which are being opposed by several parties) filed by Sigma-Aldrich Co. LLC. Each of these patent families are owned by a different third party and contain claims that may be construed to cover components and uses of CRISPR/Cas9 technology. If we are not able to obtain or maintain a license on commercially reasonable terms to any third-party patents that cover our product candidates or activities, such third parties could potentially assert infringement claims against us, which could have a material adverse effect on the conduct </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">of our business. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if we believe third-party intellectual property claims are without merit, there is no assurance that a court would find in our favor on questions of infringement, validity, enforceability, or priority. A court of competent jurisdiction could hold that these third party patents are valid, enforceable, and infringed, which could materially and adversely affect our ability to commercialize any product candidates we develop and any other product candidates or technologies covered by the asserted third party patents. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. If we are found to infringe a third party&#8217;s intellectual property rights, and we are unsuccessful in demonstrating that such patents are invalid or unenforceable, we could be required to obtain a license from such third party to continue developing, manufacturing, and marketing any product candidates we develop and our technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We also could be forced, including by court order, to cease developing, manufacturing, and commercializing the infringing technology or product candidates. In addition, we could be found liable for significant monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent or other intellectual property right. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar material adverse effect on our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to claims that our employees, consultants, or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Many of our employees, consultants, and advisors are currently or were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants, and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time consuming, and unsuccessful.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Competitors may infringe our patents or the patents of our licensing partners, or we may be required to defend against claims of infringement. In addition, our patents or the patents of our licensing partners also are, and may in the future become, involved in inventorship, priority, or validity disputes. To counter or defend against such claims can be expensive and time consuming. In an infringement proceeding, a court may decide that a patent owned or in-licensed by us is invalid or unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our owned and in-licensed patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our owned or in-licensed patents at risk of being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>In addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology, and other proprietary information and to maintain our competitive position. With respect to our technology platform, we consider trade secrets and know-how to be one of our primary sources of intellectual property. Trade secrets and know-how can be difficult to protect. In particular, we anticipate that with respect to our technology platform, these trade secrets and know-how will over time be disseminated within the industry through independent development, the publication of journal articles describing the methodology, and the movement of personnel from academic to industry scientific positions.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We seek to protect these trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, collaborators, CROs, contract manufacturers, consultants, advisors, and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be materially and adversely harmed.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we do not obtain patent term extension and data exclusivity for any product candidates we develop, our business may be materially harmed.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984 (the &#8220;Hatch-Waxman Amendments&#8221;). The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or term of any such </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations, and prospects could be materially harmed.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intellectual property rights do not necessarily address all potential threats.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">others may be able to make products that are similar to any product candidates we develop or utilize similar technology but that are not covered by the claims of the patents that we license or may own in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">we, or our license partners or current or future collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent application that we license or may own in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">we, or our license partners or current or future collaborators, might not have been the first to file patent applications covering certain of our or their inventions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">it is possible that our pending licensed patent applications or those that we may own in the future will not lead to issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">we may not develop additional proprietary technologies that are patentable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the patents of others may harm our business; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">we may choose not to file&#160;a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file&#160;a patent covering such intellectual property.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Regulatory Approval and Other Legal Compliance Matters </b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming, and uncertain and may prevent us from obtaining approvals for the commercialization of any product candidates we develop. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize, or will be delayed in commercializing, product candidates we develop, and our ability to generate revenue will be materially impaired.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Any product candidates we develop and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, and distribution, are subject to comprehensive regulation by the FDA and other regulatory authorities in </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">the United States and by comparable authorities in other countries. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate in a given jurisdiction. We have not received approval to market any product candidates from regulatory authorities in any jurisdiction. We have only limited experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party CROs to assist us in this process. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the biologic product candidate&#8217;s safety, purity, and potency. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Any product candidates we develop may not be effective, may be only moderately effective, or may prove to have undesirable or unintended side effects, toxicities, or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The process of obtaining marketing approvals, both in the United States and abroad, is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity, and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that our data is insufficient for approval and require additional preclinical, clinical, or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit, or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved medicine not commercially viable.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we experience delays in obtaining approval or if we fail to obtain approval of any product candidates we develop, the commercial prospects for those product candidates may be harmed, and our ability to generate revenues will be materially impaired.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Failure to obtain marketing approval in foreign jurisdictions would prevent any product candidates we develop from being marketed in such jurisdictions, which, in turn, would materially impair our ability to generate revenue.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In order to market and sell any product candidates we develop in the European Union and many other foreign jurisdictions, we or our collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We or these third parties may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our medicines in any jurisdiction, which would materially impair our ability to generate revenue.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Additionally, on June 23, 2016, the electorate in the United Kingdom voted in favor of leaving the European Union, commonly referred to as Brexit. Brexit has involved a process of lengthy negotiations between the United Kingdom and European Union member states to determine the future terms of the United Kingdom&#8217;s relationship with the European Union. The potential effects of Brexit remain uncertain. Since a significant proportion of the regulatory framework in the United Kingdom is derived from European Union directives and regulations, Brexit could materially impact the regulatory regime with respect to the approval of any future product candidate in the United Kingdom or the European Union. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would prevent us from commercializing our product candidates in the United Kingdom and/or the European Union and restrict our ability to generate revenue and achieve and sustain profitability. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the United Kingdom and/or European Union </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">for our product candidates, which could significantly and materially harm our business.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Even if we, or any collaborators we may have, obtain marketing approvals for any product candidates we develop, the terms of approvals and ongoing regulation of our products could require the substantial expenditure of resources and may limit how we, or they, manufacture and market our products, which could materially impair our ability to generate revenue.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising, and promotional activities for such medicine, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to quality control, quality assurance and corresponding maintenance of records and documents, and requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the medicine may be marketed or to the conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the medicine.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accordingly, assuming we, or any collaborators we may have, receive marketing approval for one or more product candidates we develop, we, and such collaborators, and our and their contract manufacturers will continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance, and quality control. If we and such collaborators are not able to comply with post-approval regulatory requirements, we and such collaborators could have the marketing approvals for our products withdrawn by regulatory authorities and our, or such collaborators&#8217;, ability to market any future products could be limited, which could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our business, operating results, financial condition, and prospects.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any product candidate for which we obtain marketing approval could be subject to restrictions or withdrawal from the market, and we may be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our medicines, when and if any of them are approved.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA and other regulatory agencies closely regulate the post-approval marketing and promotion of medicines to ensure that they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA and other regulatory agencies impose stringent restrictions on manufacturers&#8217; communications regarding off-label use, and if we do not market our medicines for their approved indications, we may be subject to enforcement action for off-label marketing by the FDA and other federal and state enforcement agencies, including the Department of Justice. Violation of the Federal Food, Product, and Cosmetic Act and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription products may also lead to investigations or allegations of violations of federal and state health care fraud and abuse laws and state consumer protection laws.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, later discovery of previously unknown problems with our medicines, manufacturers, or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">restrictions on such medicines, manufacturers, or manufacturing processes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">restrictions on the labeling or marketing of a medicine;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">restrictions on the distribution or use of a medicine;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">requirements to conduct post-marketing clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">receipt of warning or untitled letters;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><div style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:24pt;text-align:center;text-indent:0pt;">75</div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><div style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:30pt;margin-left:0pt;text-indent:0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></div></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">withdrawal of the medicines from the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">refusal to approve pending applications or supplements to approved applications that we submit;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">recall of medicines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">fines, restitution, or disgorgement of profits or revenue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">suspension or withdrawal of marketing approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">suspension of any ongoing clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">refusal to permit the import or export of our medicines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">product seizure; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize any product candidates we develop and adversely affect our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our relationships with healthcare providers, physicians, and third-party payors will be subject to applicable anti-kickback, fraud and abuse, and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, and diminished profits and future earnings.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Healthcare providers, physicians, and third-party payors play a primary role in the recommendation and prescription of any product candidates that we develop for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell, and distribute our medicines for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the federal healthcare anti-kickback statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving, or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order, or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the federal False Claims Act imposes criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval from Medicare, Medicaid, or other government payors that are false or fraudulent or making a false statement to avoid, decrease, or conceal an obligation to pay money to the federal government, with potential liability including mandatory treble damages and significant per-claim penalties, currently set at $5,500 to $11,000 per false claim;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the federal Health Insurance Portability and Accountability Act of 1996, as further amended by the Health Information Technology for Economic and Clinical Health Act, which imposes certain requirements, including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information without appropriate authorization by entities subject to the rule, such as health plans, health care clearinghouses, and health care providers;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><div style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:24pt;text-align:center;text-indent:0pt;">76</div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><div style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:30pt;margin-left:0pt;text-indent:0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></div></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the federal false statements statute, which prohibits knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items, or services;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the federal transparency requirements under the federal Physician Payment Sunshine Act, which requires manufacturers of drugs, devices, biologics, and medical supplies to report to the Department of Health and Human Services information related to payments and other transfers of value to physicians and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">analogous state laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, and certain state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of the laws described above or any other government regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare and Medicaid, imprisonment, and the curtailment or restructuring of our operations, any of which could adversely affect our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order, or use of medicinal products is prohibited in the European Union. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of European Union Member States, such as the UK Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Payments made to physicians in certain European Union Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization, and/or the regulatory authorities of the individual European Union Member States. These requirements are provided in the national laws, industry codes, or professional codes of conduct applicable in the European Union Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines, or imprisonment.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal, and administrative penalties, damages, fines, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil, or administrative sanctions, including exclusions from government funded healthcare programs. Liabilities they incur pursuant to these laws could result in significant costs or an interruption in operations, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The efforts of the current presidential administration to pursue regulatory reform may limit the FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, and that could negatively impact our business.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The current presidential administration has taken several executive actions, including the issuance of a number of executive orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. On January 30, 2017, the president issued an executive order, applicable to all executive agencies, including the FDA, that requires that for each notice of proposed rulemaking or final regulation to be issued in fiscal year 2017, the agency shall identify at least two existing regulations to be repealed, unless prohibited by law. These requirements are referred to as the &#8220;two-for-one&#8221; provisions. This executive order includes a budget neutrality provision that requires the total incremental cost of all new regulations in the 2017 fiscal year, including repealed regulations, to be no greater than zero, except in limited circumstances. For fiscal years 2018 and beyond, the executive order requires agencies to identify regulations to offset any incremental cost of a new regulation. In interim guidance issued by the Office of Information and Regulatory Affairs within the Office of Management and on February 2, 2017, the administration indicates that the &#8220;two-for-one&#8221; provisions may apply not only to agency regulations, but also to significant agency guidance documents. It is difficult to predict how these requirements will be implemented, and the extent to which they will impact the FDA&#8217;s ability to exercise its regulatory authority. If these executive actions impose constraints on FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently enacted and future legislation may increase the difficulty and cost for us and any future collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we, or they, may obtain.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability, or the ability of any future collaborators, to profitably sell any products for which we, or they, obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any future collaborators, may receive for any approved products.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (the &#8220;Medicare Modernization Act&#8221;), changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and introduced a new reimbursement methodology based on average sales prices for physician administered drugs. In addition, this legislation provided authority for limiting the number of drugs that will be covered in any therapeutic class. Cost reduction initiatives and other provisions of this legislation could decrease the coverage and price that we receive for any approved products. While the Medicare Modernization Act applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the Medicare Modernization Act may result in a similar reduction in payments from private payors. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act (the &#8220;PPACA&#8221;), which became law in 2010, contains provisions of importance to our business, including, without limitation, our ability to commercialize and the prices we may obtain for any of our product candidates and that are approved for sale, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">an annual, non-deductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">expansion of federal healthcare fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute, new government investigative powers and enhanced penalties for noncompliance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">extension of manufacturers&#8217; Medicaid rebate liability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">expansion of eligibility criteria for Medicaid programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program new requirements to report financial arrangements with physicians and teaching hospitals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">a new requirement to annually report drug samples that manufacturers and distributors provide to physicians; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, other legislative changes have been proposed and adopted since the PPACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2024 unless additional Congressional action is taken. The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Since enactment of the ACA, there have been numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the Tax Cuts and Jobs Act of 2017, which was signed by the president on December 22, 2017, Congress repealed the &#8220;individual mandate.&#8221; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. According to the Congressional Budget Office, the repeal of the individual mandate will cause 13 million fewer Americans to be insured in 2027 and premiums in insurance markets may rise. Further, on December 14, 2018, a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate portion of the ACA is an essential and inseverable feature of the ACA, and therefore because the mandate was repealed as part of the Tax Cuts and Jobs Act, the remaining provisions of the ACA are invalid as well. The Trump administration and CMS have both stated that the ruling will have no immediate effect, and on December 30, 2018 the same judge issued an order staying the judgment pending appeal.  The Trump administration has represented to the US Court of Appeals for the Fifth Circuit considering this judgment that it does not oppose the lower court&#8217;s ruling. To that end, on May 1, 2019, the Justice Department filed a brief asking the Court to strike down the entirety of the ACA. Thereafter, on July 10, 2019, the Court of Appeals for the Fifth Circuit heard oral argument in this case. In those arguments, the Trump administration argued in support of upholding the lower court decision. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Further, each chamber of the Congress has put forth multiple bills designed to repeal or repeal and replace portions of the ACA. Although none of these measures has been enacted by Congress to date, Congress may consider other legislation to repeal and replace elements of the ACA. The Congress will likely consider other legislation to replace elements of the ACA, during the next Congressional session. It is possible that repeal and replacement initiatives, if enacted into law, could ultimately result in fewer individuals having health insurance coverage or in </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">individuals having insurance coverage with less generous benefits. While the timing and scope of any potential future legislation to repeal and replace ACA provisions is highly uncertain in many respects, it is also possible that some of the ACA provisions that generally are not favorable for the research-based pharmaceutical industry could also be repealed along with ACA coverage expansion provision.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect that these healthcare reforms, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product and/or the level of reimbursement physicians receive for administering any approved product we might bring to market. Reductions in reimbursement levels may negatively impact the prices we receive or the frequency with which our potential products are prescribed or administered. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The current presidential administration has also taken executive actions to undermine or delay implementation of the ACA. Since January 2017, the president has signed two executive orders designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. One executive order directs federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the ACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. The second executive order terminates the cost-sharing subsidies that reimburse insurers under the ACA. Several state Attorneys General filed suit to stop the administration from terminating the subsidies, but their request for a restraining order was denied by a federal judge in California on October 25, 2017. In addition, CMS has recently proposed regulations that would give states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces. Further, on June 14, 2018, U.S. Court of Appeals for the Federal Circuit ruled that the federal government was not required to pay more than $12 billion in ACA risk corridor payments to third-party payors who argued were owed to them. The effects of this gap in reimbursement on third-party payors, the viability of the ACA marketplace, providers, and potentially our business, are not yet known. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The costs of prescription pharmaceuticals has also been the subject of considerable discussion in the United States, and members of Congress and the executive branch have stated that they will address such costs through new legislative and administrative measures. To date, there have been several recent U.S. congressional inquiries and proposed and enacted state and federal legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. At the federal level, the  current presidential administration has pressed for drug price control measures that could be enacted during the 2019 budget process or in other future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for low-income patients. While any proposed measures will require authorization through additional legislation to become effective, Congress and the current presidential administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. </span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fast track designation by the FDA may not actually lead to a faster development or regulatory review or approval process, and does not assure FDA approval of our product candidates.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If a product candidate is intended for the treatment of a serious or life threatening condition and the product candidate demonstrates the potential to address unmet medical need for this condition, the sponsor may apply for FDA fast track designation. However, a fast track designation does not ensure that the product candidate will receive marketing approval or that approval will be granted within any particular timeframe. As a result, while we may seek and receive fast track designation for our product candidates, we may not experience a faster development process, review or approval compared to conventional FDA procedures. In addition, the FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program. Fast track designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Priority review designation by the FDA may not lead to a faster regulatory review or approval process and, in any event, does not assure FDA approval of our product candidates.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If the FDA determines that a product candidate offers major advances in treatment or provides a treatment where no adequate therapy exists, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review an application is six months, rather than the standard review period of ten months. We may request priority review for certain of our product candidates. The FDA has broad discretion with respect to whether or not to grant priority review status to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, the FDA may decide not to grant it. Moreover, a priority review designation does not necessarily mean a faster regulatory review process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. Receiving priority review from the FDA does not guarantee approval within the six-month review cycle or thereafter.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to obtain orphan drug exclusivity for one or more of our product candidates, and even if we do, that exclusivity may not prevent the FDA or the EMA from approving other competing products.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug or biologic intended to treat a rare disease or condition. A similar regulatory scheme governs approval of orphan products by the EMA in the European Union. Generally, if a product candidate with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for the same product for the same therapeutic indication for that time period. The applicable period is seven years in the United States and ten years in the European Union. The exclusivity period in the European Union can be reduced to six years if a product no longer meets the criteria for orphan drug designation, in particular if the product is sufficiently profitable so that market exclusivity is no longer justified.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In order for the FDA to grant orphan drug exclusivity to one of our products, the agency must find that the product is indicated for the treatment of a condition or disease with a patient population of fewer than 200,000 individuals annually in the United States. The FDA may conclude that the condition or disease for which we seek orphan drug exclusivity does not meet this standard. Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different products can be approved for the same condition. In addition, even after an orphan drug is approved, the FDA can subsequently approve the same product for the same condition if the FDA concludes that the later product is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusivity may also be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of the patients with the rare disease or condition.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">On August 3, 2017, the Congress passed the FDA Reauthorization Act of 2017 (&#8220;FDARA&#8221;). FDARA, among other things, codified the FDA&#8217;s pre-existing regulatory interpretation, to require that a drug sponsor demonstrate the clinical superiority of an orphan drug that is otherwise the same as a previously approved drug for the same rare disease in order to receive orphan drug exclusivity. The new legislation reverses prior precedent holding that the Orphan Drug Act unambiguously requires that the FDA recognize the orphan exclusivity period regardless of a showing of clinical </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">superiority. The FDA may further reevaluate the Orphan Drug Act and its regulations and policies. We do not know if, when, or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our employees, principal investigators, consultants, and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are exposed to the risk of fraud or other misconduct by our employees, consultants, and partners, and, if we commence clinical trials, our principal investigators. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in the European Union and other jurisdictions, provide accurate information to the FDA, the European Commission, and other regulatory authorities, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately, or disclose unauthorized activities to us. In particular, sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, results of operations, and prospects, including the imposition of significant fines or other sanctions.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain product candidates outside of the United States and require us to develop and implement costly compliance programs.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are subject to numerous laws and regulations in each jurisdiction outside the United States in which we operate. The creation, implementation and maintenance of international business practices compliance programs is costly and such programs are difficult to enforce, particularly where reliance on third parties is required.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Foreign Corrupt Practices Act (&#8220;FCPA&#8221;) prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. The anti-bribery provisions of the FCPA are enforced primarily by the Department of Justice. The SEC is involved with enforcement of the books and records provisions of the FCPA.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. Our expansion outside of the United States has required, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">and will continue to require, us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain drugs and drug candidates outside of the United States, which could limit our growth potential and increase our development costs. The failure to comply with laws governing international business practices may result in substantial penalties, including suspension or debarment from government contracting. Violation of the FCPA can result in significant civil and criminal penalties. Indictment alone under the FCPA can lead to suspension of the right to do business with the U.S. government until the pending claims are resolved. Conviction of a violation of the FCPA can result in long-term disqualification as a government contractor. The termination of a government contract or relationship as a result of our failure to satisfy any of our obligations under laws governing international business practices would have a negative impact on our operations and harm our reputation and ability to procure government contracts. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Employee Matters, Managing Growth and Information Technology</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our future success depends on our ability to attract and retain key executives and to attract, retain, and motivate qualified personnel.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are highly dependent on the principal members of our management and scientific teams. Each of these individuals is employed &#8220;at will,&#8221; meaning we or the individual may terminate the employment relationship at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees. The loss of the services of any of these persons could impede the achievement of our research, development, and commercialization objectives. Additionally, although we have an interim Chief Financial Officer, we are actively trying to recruit a candidate to fill this position permanently and any inability to fill this position in an expedient manner may have a material adverse effect on our business. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Recruiting and retaining qualified scientific, clinical, manufacturing, and sales and marketing personnel will also be critical to our success. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. The inability to recruit, including a permanent Chief Financial Officer, or loss of services of certain executives, other key employees, consultants, or advisors, may impede the progress of our research, development, and commercialization objectives and have a material adverse effect on our business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have expanded and expect to further expand our development, regulatory, clinical, manufacturing and future sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></p><a id="_Hlk506300025"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, regulatory affairs, clinical development, manufacturing, and sales and marketing. For example, our total number of employees grew from 55 as of December&#160;31, 2015 to 179 as of September 30, 2019. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational, and financial systems, expand our facilities, and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expected expansion of our operations or recruit and train additional qualified personnel. Moreover, the expected physical expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Security breaches and other disruptions to our information technology structure could compromise our information, disrupt our business and expose us to liability, which would cause our business and reputation to suffer.</span> </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of our business, we collect, process and store sensitive data, including intellectual property, as well as our proprietary business information and that of our suppliers and business partners, employee data, and we may collect personally identifiable information of clinical trial participants when we begin clinical trials. We also rely to a large extent on information technology systems to operate our business, including our financial systems.&#160;We have outsourced elements of our confidential information processing and information technology structure, and as a result, we are managing independent vendor relationships with third parties who may or could have access to our confidential information. Similarly, our business partners and other third-party providers possess certain of our sensitive data. The secure maintenance of this information is important to our operations and business strategy. Despite our security measures, our information technology infrastructure (and those of our partners, vendors and third-party providers) may be vulnerable to attacks by hackers or breached due to employee error, malfeasance or other disruptions. We, our partners, vendors, and other third-party providers could be susceptible to third party attacks on our, and their, information security systems, which attacks are of ever-increasing levels of sophistication and are made by groups and individuals with a wide range of motives and expertise, including organized criminal groups, hacktivists, nation states and others.&#160;While we have invested in information technology security measures and the protection of confidential information, there can be no assurance that our efforts will prevent service interruptions or security breaches. Any such interruptions or breach may substantially impair our ability to operate our business and would compromise our, and their, networks and the information stored could be accessed, publicly disclosed, lost, or stolen. Any such access, disclosure, or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, disrupt our operations, and damage our reputation, any of which could adversely affect our business. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Our Common Stock</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">An active trading market for our common stock may not be sustained.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our shares of common stock began trading on The Nasdaq Global Select Market in February 2016. Given the limited trading history of our common stock, there is a risk that an active trading market for our shares will not be sustained, which could put downward pressure on the market price of our common stock and thereby affect the ability of our stockholders to sell their shares.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The market price of our common stock may be volatile, which could result in substantial losses for our stockholders.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our stock price has been, and is likely to remain, volatile. Some of the factors that may cause the market price of our common stock to fluctuate include:</p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the success of existing or new competitive products or technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the timing and results of clinical trials for EDIT-101 and any preclinical studies and clinical trials of any other product candidates that we develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">commencement or termination of collaborations for our product development and research programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">failure or discontinuation of any of our product development and research programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">results of preclinical studies, clinical trials, or regulatory approvals of product candidates of our competitors, or announcements about new research programs or product candidates of our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">developments or changing views regarding the use of genomic medicines, including those that involve genome editing;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><div style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:24pt;text-align:center;text-indent:0pt;">84</div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><div style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:30pt;margin-left:0pt;text-indent:0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></div></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">regulatory or legal developments in the United States and other countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">developments or disputes concerning patent applications, issued patents, or other proprietary rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the recruitment, including of a Chief Financial Officer, or departure of key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the level of expenses related to any of our research programs, clinical development programs, or product candidates that we develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the results of our efforts to develop additional product candidates or products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">actual or anticipated changes in estimates as to financial results, development timelines, or recommendations by securities analysts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">announcement or expectation of additional financing efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">sales of our common stock by us, our insiders, or other stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">variations in our financial results or those of companies that are perceived to be similar to us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">changes in estimates or recommendations by securities analysts, if any, that cover our stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">changes in the structure of healthcare payment systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">market conditions in the pharmaceutical and biotechnology sectors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">general economic, industry, and market conditions; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the other factors described in this &#8220;Risk Factors&#8221; section.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In recent years, the stock market in general, and the market for pharmaceutical and biotechnology companies in particular, has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. Broad market and industry factors may seriously affect the market price of our common stock, regardless of our actual operating performance. Following periods of such volatility in the market price of a company&#8217;s securities, securities class action litigation has often been brought against that company. Because of the potential volatility of our stock price, we may become the target of securities litigation in the future. Securities litigation could result in substantial costs and divert management&#8217;s attention and resources from our business.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock and trading volume could decline.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The trading market for our common stock depends, in part, on the research and reports that industry or financial analysts publish about us or our business. If one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock or fail to regularly publish reports on us, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">A portion of our total outstanding shares may be sold into the market in the near future, which could cause the market price of our common stock to decline significantly, even if our business is doing well.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Sales of a significant number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares of common stock intend to sell </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">shares, could reduce the market price of our common stock.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have registered substantially all shares of common stock that we may issue under our equity compensation plans. These shares can be freely sold in the public market upon issuance and once vested, subject to volume limitations applicable to affiliates. In addition, under the terms of certain of our license agreements and certain promissory notes that we may issue in the future in connection with these license agreements, we may elect to issue shares of our common stock in satisfaction of specified payment obligations of ours, which shares may be subject to rights requiring us to register such shares under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Such an election by us could result in the issuance of a substantial number of shares and upon registration under the Securities Act these shares would be able to be freely sold in the public market, subject to volume limitations applicable to affiliates. If any of the additional shares described above are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, certain of our employees, executive officers, directors, and affiliated stockholders have entered or may enter into Rule&#160;10b5-1 plans providing for sales of shares of our common stock from time to time. Under a Rule&#160;10b5-1 plan, a broker executes trades pursuant to parameters established by the participant establishing the plan when entering into the plan, without further direction from such participant. A Rule&#160;10b5-1 plan may be amended or terminated in some circumstances. Our employees, executive officers, directors, and affiliated stockholders also may buy or sell additional shares outside of a Rule&#160;10b5-1 plan when they are not in possession of material, nonpublic information.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We incur increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives and corporate governance practices.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a public company we have incurred, and will continue to incur, significant legal, accounting, and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Global Select Market, and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. We have had to hire additional accounting, finance, and other personnel in connection with our becoming, and our efforts to comply with the requirements of being, a public company, and our management and other personnel devote a substantial amount of time towards maintaining compliance with these requirements. These requirements increase our legal and financial compliance costs and make some activities more time-consuming and costly. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</p><a id="_Hlk521876"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to SOX Section&#160;404, we are required to furnish a report by our management on our internal control over financial reporting and are required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To maintain compliance with SOX Section&#160;404, we will continue to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to dedicate internal resources, engage outside consultants, adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented, and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that neither we nor our independent registered public accounting firm will be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by SOX Section&#160;404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our consolidated financial statements.</p><a id="_cp_text_1_277"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have broad discretion in the use of our cash reserves and may not use them effectively.</span></p><a id="_cp_text_1_278"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Our management has broad discretion to use our cash reserves and could use our cash reserves in ways that do </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">not improve our results of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline, and delay the development of our product candidates. Pending their use, we may invest our cash reserves in a manner that does not produce income or that loses value.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We do not expect to pay any dividends for the foreseeable future. Accordingly, stockholders must rely on capital appreciation, if any, for any return on their investments.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have never declared or paid cash dividends on our common stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be stockholders&#8217; sole source of gain for the foreseeable future.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Provisions in our restated certificate of incorporation and amended and restated bylaws or Delaware law might discourage, delay, or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our common stock.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Provisions in our restated certificate of incorporation and amended and restated bylaws or Delaware law may discourage, delay, or prevent a merger, acquisition, or other change in control that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares of our common stock. These provisions may also prevent or frustrate attempts by our stockholders to replace or remove our management. These provisions include:</p><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">limitations on the removal of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">a classified board of directors so that not all members of our board of directors are elected at one time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">advance notice requirements for stockholder proposals and nominations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the inability of stockholders to act by written consent or to call special meetings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the requirement that at least 75% of the votes cast by all our stockholders approve the amendment or repeal of certain provisions of our amended and restated bylaws or restated certificate of incorporation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the ability of our board of directors to make, alter, or repeal our amended and restated bylaws; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the ability of our board of directors to designate the terms of and issue new series of preferred stock without stockholder approval, which could be used to institute a rights plan, or a poison pill, that would work to dilute the stock ownership of a potential hostile acquirer, likely preventing acquisitions that have not been approved by our board of directors.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, Section&#160;203 of the General Corporation Law of the State of Delaware prohibits a publicly held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The existence of the foregoing provisions could deter potential acquirers of our company, thereby reducing the likelihood that our stockholders could receive a premium for their shares of common stock in an acquisition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our restated certificate of incorporation designates the state courts in the State of Delaware or, if no state court located within the State of Delaware has jurisdiction, the federal court for the District of Delaware, as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could discourage lawsuits against the company and our directors and officers.</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Our restated certificate of incorporation provides that, unless our board of directors otherwise determines, the state courts in the State of Delaware or, if no state court located within the State of Delaware has jurisdiction, the federal court for the District of Delaware, will be the sole and exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of a fiduciary duty owed by any of our directors or officers to our company or our stockholders, any action asserting a claim against us or any of our directors or officers arising pursuant to any provision of the General Corporation Law of the State of Delaware or our restated certificate of incorporation or amended and restated bylaws, or any action asserting a claim against us or any of our directors or officers governed by the internal affairs doctrine. This exclusive forum provision may limit the ability of our stockholders to bring a claim in a judicial forum that such stockholders find favorable for disputes with us or our directors or officers, which may discourage such lawsuits against us and our directors and officers.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_e1aed1dd_5d0f_4820_82bb_edf47d6b82ef"></a><a id="Item5_Other_Info"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Item 5.&#160;&#160;&#160;&#160;Other Information</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">On November 11, 2019, we entered into a Second Amended and Restated Collaboration and License Agreement (the &#8220;Collaboration Agreement&#8221;) with Juno Therapeutics, Inc., a Celgene company that is a wholly-owned subsidiary of Celgene Corporation (&#8220;Juno Therapeutics&#8221;), which amended and restated in its entirety the Amended and Restated Collaboration and License Agreement by and between Juno Therapeutics and us, dated May 3, 2018 (the &#8220;Existing Agreement&#8221;). Concurrently with the execution of the Collaboration Agreement, we also entered into a License Agreement with Juno Therapeutics (the &#8220;License Agreement&#8221; and together with the Collaboration Agreement, the &#8220;Agreements&#8221;) related to certain intellectual property controlled by us. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Agreements relate to technology used to edit or modify the genome of a cell in connection with the research, development, manufacture, commercialization or other exploitation of T-cells that express or have ever expressed T cell receptor dimers consisting of an alpha (&#945;) chain and a beta (&#946;) chain (such cells, &#8220;Alpha-beta T-Cells&#8221;), and T-cells derived from pluripotent stem cells or any other precursor cell (such cells, &#8220;Other Derived T-Cells&#8221;), subject to certain exclusions for certain of our existing obligations. The exploitation of Alpha-beta T-Cells and Other Derived T-Cells specifically excludes the exploitation of T-Cells that express a T-cell receptor dimer consisting of a gamma (&#947;) chain and a delta (&#948;) chain, which we refer to as gamma-delta T-Cells, and therefore, as a result of the entry into the Collaboration Agreement, we may develop such gamma delta T-Cells, which were previously subject to Juno Therapeutics&#8217; exclusive rights under the Existing Agreement. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">During the research term under the Collaboration Agreement, we may research ribonucleoprotein complexes comprising an RNA-guided engineered nuclease paired with an oligonucleotide (&#8220;RNP Complexes&#8221;) that recognize or modulate the expression of up to twenty gene targets selected by Juno Therapeutics (each, a &#8220;Research Program&#8221;) for the purpose of identifying the RNP Complexes that may be used in the creation of potential drug development candidates. The initial research term is five years from the effective date of the Collaboration Agreement. Juno Therapeutics may extend the research term for up to two one-year periods upon written notice to us and payment to us of a mid to high single digit million dollar payment upon each extension. Juno Therapeutics&#8217; right to extend the research term for the second one-year period is subject to our consent. Juno Therapeutics is obligated to pay us a one-time fee of $70.0 million as a result of the execution of the Collaboration Agreement. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Under the Collaboration Agreement, if Juno Therapeutics elects to opt-in with respect to a Research Program, it shall make a mid six digit dollar payment to us and we shall amend the License Agreement to include such Research Program by executing a licensed program addendum for such Research Program. Following Juno&#8217;s opt-in for each program we shall grant to Juno Therapeutics an exclusive (even as to us), royalty-bearing worldwide right and license under specified intellectual property rights to research, develop, manufacture commercialize or otherwise exploit the RNP Complexes in such program to create products containing, incorporating, comprising or containing Alpha-beta T-Cells and/or Other Derived T-Cells, in each case modified using the RNP Complexes in such program (each, a &#8220;Licensed Product&#8221;). </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">We are entitled to receive high single-digit to low double-digit percentage royalties on net sales made by Juno Therapeutics, its affiliates and sublicensees of any Licensed Products, subject to reductions in certain circumstances. We are also entitled to receive development milestones totaling up to $135.0 million in the aggregate upon achievement of certain clinical milestones and specified regulatory approvals. We are entitled to receive commercial milestone payments totaling up to $60.0 million in the aggregate for each of the first two Licensed Products to achieve specified net sales milestones.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">We have agreed during the term of the Collaboration Agreement not to use (directly or indirectly), or license others to use, genome editing technology in connection with any research, development, manufacture, commercialization or other exploitation of any Alpha-beta T-Cells or Other Derived T-Cells. Our exclusivity obligation will not apply to activities related to (i) any identified RNP Complexes in a program for which Juno Therapeutics elects not to exercise its opt-in right, (ii) certain of our existing obligations to third parties, and (iii) certain existing programs of an acquiror of our company in a change of control. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">We have agreed during the term of any licensed program addendum under the License Agreement not to use (directly or indirectly), or license others to use, any genome editing technology that modulates or recognizes a gene target covered by such licensed program addendum for the conduct of any research, development, manufacture, commercialization or other exploitation with respect to any product that constitutes, incorporates, comprises or contains any Alpha-beta T-Cell or Other Derived T-Cells. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Collaboration Agreement continues in effect until the later of expiration of the research term or expiration of the last to expire of Juno Therapeutics&#8217; right to opt-in with respect to any Research Program. Juno Therapeutics may terminate the Collaboration Agreement in its discretion upon six months&#8217; prior written notice to us. Either party may terminate the Collaboration Agreement for uncured material breach of the other party, provided that the breaching party has had sixty days to cure such breach, or in the event of insolvency or bankruptcy of the other party. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The License Agreement continues in effect on a Licensed Product-by-Licensed Product and country-by-country basis until the expiration of the royalty term with respect to such licensed product in such country and in its entirety upon the expiration of all royalty terms with respect to all Licensed Products in all countries. Juno Therapeutics may terminate the License Agreement in its entirety or on a Licensed Product-by-Licensed Product basis in its discretion upon ninety days&#8217; prior written notice to us. Either party may terminate the License Agreement on a Licensed Product-by-Licensed Product basis in the event of an uncured material breach of the other party, provided that the breaching party has had sixty days to cure such breach, or in the event of insolvency or bankruptcy of the other party. We have the right to terminate the License Agreement on a program-by-program basis in the event that Juno Therapeutics fails to make any undisputed payment to us and has not cured such payment breach within the cure period. Other than Juno Therapeutics&#8217; right to wind-down its operations with respect to Licensed Products during the twelve months following the date of effectiveness of termination, all licenses and other exclusive rights granted under the License Agreement shall terminate.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;">The foregoing is only a summary of the material terms of the Collaboration Agreement and License Agreement, and is qualified in its entirety by reference to the Collaboration Agreement and License Agreement, each of which will be filed as an exhibit to the Company&#8217;s Annual Report on Form&#160;10-K&#160;for year ended December 31, 2019.&#160;</span></p><a id="_19981630_52a8_42d7_a1eb_a710050607ba"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Item6Exhibits_459407"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Item 6.&#160;&#160;&#160;&#160;Exhibits</b><b style="font-weight:bold;"> </b> </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Exhibit Index</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:12.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:85.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Exhibit<br />Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.25;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:85.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.25;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description&#160;of&#160;Exhibit</b></p></td></tr><tr><td style="vertical-align:top;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:11pt;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:11pt;margin:0pt;"><a href="ex-10d1.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:11pt;text-align:left;">Offer Letter, dated August 6, 2019, by and between the Registrant and Cynthia Collins</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:11pt;margin:0pt;">10.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:11pt;margin:0pt;"><a href="ex-10d2.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:11pt;text-align:left;">Letter Agreement, dated September 26, 2019, by and between the Registrant and Vic Myer, Ph.D.</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:11pt;margin:0pt;">31.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:11pt;margin:0pt;"><a href="ex-31d1.htm"><span style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:11pt;text-align:left;">Rule 13a-14(a) Certification of Principal Executive Officer</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:11pt;padding-left:10pt;text-indent:-10pt;margin:0pt;">31.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.25;margin:0pt;"><a href="ex-31d2.htm"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.25;text-align:left;">Rule 13a-14(a) Certification of Principal Financial Officer</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:11pt;padding-left:10pt;text-indent:-10pt;margin:0pt;">32.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:11pt;margin:0pt;"><a href="ex-32d1.htm"><span style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:11pt;text-align:left;">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. &#167;1350</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:11pt;padding-left:10pt;text-indent:-10pt;margin:0pt;">101</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:11pt;margin:0pt;">The following financial statements from the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, formatted in Inline XBRL (eXtensible Business Reporting Language): (i) Consolidated Balance Sheets (unaudited), (ii) Consolidated Statements of Operations (unaudited), (iii) Consolidated Statements of Comprehensive Income (Loss) (unaudited), (iv) Consolidated Statement of Stockholders&#8217; Equity (unaudited), (v) Consolidated Statements of Cash Flows (unaudited)and (vi) Notes to Condensed Consolidated Financial Statements (unaudited), tagged as blocks of text and including detailed tags.</p></td></tr><tr><td style="vertical-align:top;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:11pt;padding-left:10pt;text-indent:-10pt;margin:0pt;">104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:11pt;margin:0pt;"><span style="font-size:11pt;line-height:1.19;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:11pt;margin:0pt;">The cover page from the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, formatted in Inline XBRL.</p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:72pt;text-indent:-72pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_6442b181_39f5_4091_b959_a2aeeace503b"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="SIGNATURES_262108"></a><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="background-color:#ffffff;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:47.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:10pt;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">EDITAS MEDICINE,&#160;INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:10pt;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:10pt;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:10pt;text-indent:-10pt;margin:0pt;">Dated: November 12, 2019</p></td><td style="vertical-align:bottom;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:47.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">/s/ Cynthia Collins</p></td></tr><tr><td style="vertical-align:bottom;width:49.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:10pt;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.42%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Cynthia Collins</p></td></tr><tr><td style="vertical-align:bottom;width:49.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:10pt;text-indent:-10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Chief Executive Officer</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">(Principal Executive Officer) </p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;line-height:1.19;margin-bottom:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex-10d1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.4.0.81-->
<!--Created on: 11/12/2019 2:01:27 PM-->
<html>
	<head>
		<title>
			edit_Ex10_1
		</title>
	</head>
	<body><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p style="margin:0pt;text-align:right;border-bottom:1pt none #D9D9D9 ;color:#23252D;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-weight:bold;color:#23252D;">EXHIBIT 10.1</font>
		</p>
		<p style="margin:0pt;text-align:right;border-top:1pt none #D9D9D9 ;color:#23252D;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 8pt;">
			<font style="display:inline;font-size:8pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td rowspan="4" valign="bottom" style="width:50.00%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<a name="_Hlk23891551"></a><font style="display:inline;"><img src="ex-10d1g001.jpg" style="width: 1.208333in; height: 0.6666667in" alt="Picture 57"></font></p>
				</td>
				<td valign="bottom" style="width:50.00%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">11 Hurley Street</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:50.00%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Cambridge, MA 02141</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:50.00%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#DB812E;font-size:8pt;">P</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> 617-401-9000</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:50.00%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#DB812E;font-size:8pt;">F</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> 617-494-0985</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">August 6, 2019</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;">By Hand</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Cynthia Collins</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Dear Cindy:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">On behalf of Editas Medicine, Inc., a Delaware corporation (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Company</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), I am pleased to offer you employment with the Company.&nbsp;&nbsp;The purpose of this letter is to summarize the terms of your employment with the Company, should you accept our offer:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">You will be employed to serve on a full-time basis as President and Chief Executive Officer (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">CEO</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), effective August 19, 2019 (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Effective Date</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;).&nbsp;&nbsp;As CEO, you will be responsible for such duties as are consistent with such position.&nbsp;&nbsp;You shall report to the Company&#x2019;s Board of Directors (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Board</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;). During your employment as CEO, you will remain a member of the Board.&nbsp;&nbsp;Upon the ending of your employment as CEO, you shall immediately resign from the Board as well as from your position as CEO and any other position(s) with the Company to which you were elected or appointed in connection with your employment or Board membership.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">Your base salary will be at the rate of $26,041.67 per semi-monthly pay period (equivalent to an annualized base salary of $625,000), subject to tax and other withholdings as required by law.&nbsp;&nbsp;Such base salary may be increased from time to time (commencing effective as of January 2021) in accordance with normal business practice and in the sole discretion of the Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">Following the end of each fiscal year and subject to the approval of the Board (or a duly authorized committee thereof), you will be eligible for a retention and performance bonus, targeted at 60% of your annualized base salary, based on the Company&#x2019;s performance during the applicable fiscal year, as determined by the Board (or such committee) in its sole discretion in accordance with certain corporate goals determined by the Board (or such committee) in its sole discretion each year; provided, however, that, for 2019, you shall be entitled to a minimum bonus equal to your target bonus, pro-rated based on the number of days employed divided by 365.&nbsp;&nbsp;You must be an active employee of the Company on the date any bonus is distributed in order to be eligible for and to earn a bonus award, as it also serves as an incentive to remain employed by the Company, provided that the Company will award and pay any bonus for the prior calendar year before March 15</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:6pt;top:-4pt;position:relative;line-height:100%">th</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> of the next succeeding calendar year.&nbsp;&nbsp;Notwithstanding the foregoing, if you die or become disabled &nbsp;(as defined under the Company&#x2019;s long-term disability plan) prior to the date of payment of the bonus, you will be entitled to receive a pro-rata portion of the bonus to which you would otherwise have been entitled (based on the number of days in the year to which the bonus relates prior to your death or disability divided by 365).&nbsp;&nbsp;You will also be eligible to participate in the Company&#x2019;s long-term incentive plan which provides for annual equity awards, as determined in the sole discretion of the Board (or a duly authorized committee thereof) after consideration of</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">1</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">individual employee performance and Company performance benchmarked against the Company&#x2019;s peer group, and such other factors as the Board (or a duly authorized committee thereof) determines to be relevant in its discretion.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">You may participate in any and all benefit programs that the Company establishes and makes available to its employees from time to time, provided you are eligible under (and subject to all provisions of) the plan documents governing those programs.&nbsp;&nbsp;The benefit programs made available by the Company, and the rules, terms and conditions for participation in such benefit plans, may be changed by the Company at any time without advance notice.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">You will be eligible for paid vacation and holidays in accordance with Company policy.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">The Company shall reimburse you for all reasonable and necessary documented out of pocket expenses incurred or paid by you in connection with, or related to, the performance of your services to the Company, including without limitation all travel (first or business class) and hotel and ancillary expenses (it being understood that general travel directly to and from your current residence to the greater Boston area shall not be a reimbursable business expense, except to the extent such travel constitutes Relocation Expenses (as defined below)). You shall abide by the Company&#x2019;s expense reimbursement policy, except as otherwise set forth herein or with the prior written approval of the Chairman of the Board.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">Subject to approval of the Company&#x2019;s Board of Directors, the Company shall grant you, as soon as reasonably practicable following the Effective Date&nbsp;&nbsp;(i) an option to purchase an aggregate of 500,000 shares of the Company&#x2019;s common stock (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Time-Vesting Option</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) at an exercise or purchase price equal to the fair market value of the Company&#x2019;s common stock on the date of grant, (ii) an option to purchase an aggregate of 250,000 shares of the Company&#x2019;s common stock (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Performance-Vesting Option</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) at an exercise or purchase price equal to the fair market value of the Company&#x2019;s common stock on the date of grant, and (iii) a restricted stock unit award for 20,000 shares of the Company&#x2019;s common stock (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">RSU Award</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D; and collectively with the Time-Vesting Option and the Performance-Vesting Option, the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Equity Awards</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;).&nbsp;&nbsp;The Time-Vesting Option will vest over four (4) years at the rate of 25% on the first anniversary of the commencement date of your employment, and an additional 2.0833% of the original number of shares at the end of each successive month following the first anniversary of the vesting commencement date until the fourth anniversary of the commencement date of your employment. The Performance-Vesting Option will vest as to 1/3 of the shares underlying the option as of the date on which the closing price of the Company&#x2019;s common stock, as reported on the Nasdaq Global Select Market, has for 15 consecutive trading days (in the five-year period following grant) equaled or exceeded $50.00, $75.00 and $100.00, respectively.&nbsp;&nbsp;The RSU Award shall vest as to 1/3 of the shares on each of the first, second and third anniversaries of the date of grant.&nbsp;&nbsp;The Equity Awards will be granted under and subject to the terms of the Company&#x2019;s 2015 Stock Incentive Plan and evidenced in writing by, and subject to the terms of a stock option agreement and a restricted stock unit agreement, as applicable, thereunder.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">You may be eligible to receive such future stock option grants as the Board of Directors of the Company shall deem appropriate. &nbsp;During the month of August 2019 or as soon as reasonably practicable thereafter, the Company shall issue to you, in settlement of the restricted</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">2</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">stock unit award for 8,283 shares granted on January 31, 2019 and the special bonus award (being satisfied by grant of a restricted stock unit for 8,283 shares on August 6, 2019) described in Section 3.1(b) and Section 3.1(c) respectively of your Consulting Agreement with the Company dated January 20, 2019, 8,283 and 8,283 fully vested shares of common stock of the Company, &nbsp;respectively, subject to all applicable taxes and other withholdings.&nbsp;&nbsp;You and the Company acknowledge that income and employment taxes with respect to such awards will be met through the sell-to-cover instructions set forth in your Durable Automatic Sale Instruction dated May 11, 2019.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">You will be eligible to participate in the Company&#x2019;s Severance Benefits Plan, a copy of which is attached hereto as </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Exhibit A</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, at the Chief Executive Officer level.&nbsp;&nbsp;Your eligibility under the Severance Benefits Plan is subject to the terms and conditions thereof.&nbsp;&nbsp;Notwithstanding anything to the contrary in the Severance Benefits Plan, the Company agrees:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A &#x201C;Non-Change in Control Termination&#x201D; shall mean a termination of your employment by the Company without Cause or by you with Good Reason, as defined in the Severance Benefits Plan, prior to or more than twelve (12) months following a Change in Control.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding Section 9 of the Severance Benefits Plan, if you terminate your employment for Good Reason or if the Company terminates your employment without Cause at any time in a Covered Termination, the Time-Vesting Option and the RSU Award (but not the Performance-Vesting Option) shall become fully vested and exercisable, or free from forfeiture or repurchase.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">You will work out of the Company&#x2019;s office in Cambridge, Massachusetts, with the understanding that you may be required to travel to other locations in connection with the performance of your duties, at the expense of the Company.&nbsp;&nbsp;The Company further acknowledges and agrees that you may work remotely as you deem reasonable, subject to your fulfillment of the functions of your position.&nbsp;&nbsp;In connection with your employment with the Company, you will establish a residence in the greater Boston area.&nbsp;&nbsp;To assist with your relocation and so long as you are employed by the Company, the Company will reimburse you for (i) the expenses incurred by you prior to December 31, 2019, associated with moving your household goods and personal effects to the greater Boston area; and (ii)&nbsp;beginning on the Effective Date and continuing until the date on which you secure housing in the greater Boston area (though in no event later than December 31, 2019) your travel and hotel expenses for you and your family (collectively, the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Relocation Expenses</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;).&nbsp; The payments and/or reimbursements relating to Relocation Expenses provided for herein shall be subject to all applicable tax and other withholdings as required by law and shall be made upon receipt of documentation of such expenses in a form satisfactory to the Company; provided, however, that no payments or reimbursements hereunder will be made later than March 15, 2020.&nbsp; The Company will also &#x201C;gross up&#x201D; the Relocation Expenses (which will be taxable to you as income) by paying you an additional 0.67x the amount reimbursed to you, if any, each month.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">In addition to the Relocation Expenses, the Company will, for a period of two years following the date you secure housing in the greater Boston area and so long as you are employed by the Company, pay you up to $5,000 per month (equivalent to $60,000 annualized) for housing expenses in the greater Boston area (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Housing Payments</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), subject to all applicable taxes and other withholdings required by law.&nbsp;&nbsp;The Company will also &#x201C;gross up&#x201D; the Housing Payments</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">3</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(which will be taxed to you as income) by paying you an additional 0.67x the amount paid to you each month.&nbsp;&nbsp;All reimbursements and in-kind benefits provided hereunder shall be made or provided in accordance with the requirements of Section 409A to the extent that such reimbursements or in-kind benefits are subject to Section 409A, including, where applicable, the requirements that (i) any reimbursement is for expenses incurred during your lifetime (or during a shorter period of time specified herein), (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year, (iii) the reimbursement of an eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred and (iv) the right to reimbursement is not subject to set off or liquidation or exchange for any other benefit.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The Company shall also reimburse you up to $15,000 for your attorneys&#x2019; fees incurred in connection with the negotiation of this offer letter.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">You will be required to execute an Invention and Non-Disclosure Agreement and a Non-Competition and Non-Solicitation Agreement in the forms attached as </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Exhibit B</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> and </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Exhibit C</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, as a condition of employment.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">You represent that you are not bound by any employment contract, restrictive covenant or other restriction preventing (or that purports to prevent) you from entering into employment with or carrying out your responsibilities for the Company, or which is in any way inconsistent with the terms of this letter.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">You agree to provide to the Company, within three days of your hire date, documentation of your eligibility to work in the United States, as required by the Immigration Reform and Control Act of 1986.&nbsp;&nbsp;You may need to obtain a work visa in order to be eligible to work in the United States.&nbsp;&nbsp;If that is the case, your employment with the Company will be conditioned upon your obtaining a work visa in a timely manner as determined by the Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">This letter shall not be construed as an agreement, either express or implied, to employ you for any stated term, and shall in no way alter the Company&#x2019;s policy of employment at will, under which both you and the Company remain free to terminate the employment relationship, with or without cause, at any time, with or without notice. Although your job duties, title, compensation and benefits, as well as the Company's personnel policies and procedures, may change from time to time, the &#x201C;at-will&#x201D; nature of your employment may only be changed by a written agreement signed by you and the Chairman of the Board</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">,</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> which expressly states the intention to modify the at-will nature of your employment.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">You agree to devote your full business time, best efforts, skill, knowledge, attention, and energies to the advancement of the Company&#x2019;s business and interests and to the performance of your duties and responsibilities as an employee of the Company</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">.&nbsp;&nbsp;The Company is aware that you have existing commitments, including as a member of the board of several companies and industry organizations and as a consultant through your consulting firm Cynthia Collins &amp; Associates LLC, all of which have been disclosed to the Board of Directors of the Company, and nothing in this letter agreement or any other agreement with the Company or Company policy is intended to prohibit or prevent your continued service with those roles and, subject to your compliance with applicable</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">4</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Company policies for approval by the Board (or a committee thereof), similar board assignments in the future.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">As an employee of the Company, you will be required to comply with all Company policies and procedures.&nbsp;&nbsp;Violations of the Company&#x2019;s policies may lead to immediate termination of your employment.&nbsp;&nbsp;Further, the Company's premises, including all workspaces, furniture, documents, and other tangible materials, and all information technology resources of the Company (including computers, data and other electronic files, and all internet and email) are subject to oversight and inspection by the Company at any time.&nbsp;&nbsp;Company employees should have no expectation of privacy with regard to any Company premises, materials, resources, or information.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">For the duration of your employment, the Company agrees to maintain directors and officers liability insurance at its expense, and agrees to indemnify you to the fullest extent permitted by law, the Company&#x2019;s Bylaws, or any other applicable statute, rule of law, contract, or insurance policy.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">This offer letter is your formal offer of employment and supersedes any and all prior or contemporaneous agreements, discussions and understandings, whether written or oral, relating to the subject matter of this letter or your employment with the Company.&nbsp;&nbsp;The resolution of any disputes under this letter will be governed by the laws of the Commonwealth of Massachusetts.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">If you agree with the provisions of this letter, please sign the enclosed duplicate of this letter in the space provided below and return it to the undersigned, by August 6, 2019.&nbsp;&nbsp;If you do not accept this offer by August 6, 2019, this offer will be revoked.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:50.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:45.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:50.84%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:49.16%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Very Truly Yours,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:50.84%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:49.16%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:50.84%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:49.16%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">EDITAS MEDICINE, INC.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:50.84%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:49.16%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:50.84%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:49.16%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:50.84%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:03.34%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">By:&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:45.84%;border-bottom:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">/s/ James C. Mullen</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:50.84%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:03.34%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:45.84%;border-top:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Name: James C. Mullen</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:50.84%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:03.34%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:45.84%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Title: Chairman of the Board</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The foregoing correctly sets forth the terms of my employment by Editas Medicine, Inc. I am not relying on any other representation, except as set forth in this letter.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:270.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Date: August 6, 2019</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:22.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:247.50pt;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">/s/ Cynthia Collins</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:270.00pt;height:17.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:22.50pt;height:17.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:247.50pt;border-top:1pt solid #000000 ;height:17.60pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Cynthia Collins</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 12pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">5</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">EXHIBIT A</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">SEVERANCE BENEFITS PLAN</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Severance Benefits Plan</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Establishment of Plan.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">Editas Medicine, Inc., a Delaware corporation (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Company</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), hereby establishes an unfunded severance benefits plan (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Plan</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) that is intended to be a welfare benefit plan within the meaning of Section 3(1) of ERISA.&nbsp;&nbsp;The Plan is in effect for Covered Employees who experience a Covered Termination occurring after the Effective Date and before the termination of this Plan.&nbsp;&nbsp;This Plan supersedes any and all (i) severance plans and separation policies applying to Covered Employees that may have been in effect before the Effective Date with respect to any termination that would, under the terms of this Plan, constitute a Covered Termination and (ii) the provisions of any agreements between any Covered Employee and the Company that provide for severance benefits solely as such agreements relate to severance benefits.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purpose.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">The purpose of the Plan is to establish the conditions under which Covered Employees will receive the severance benefits described herein if employment with the Company (or its successor in a Change in Control (as defined below)) terminates under the circumstances specified herein.&nbsp;&nbsp;The severance benefits paid under the Plan are intended to assist employees in making a transition to new employment and are not intended to be a reward for prior service with the Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Definitions.</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> &nbsp;For purposes of this Plan,</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Base Salary</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D; shall mean, for any Covered Employee, such Covered Employee&#x2019;s base rate of pay as in effect immediately before a Covered Termination (or prior to the Change of Control, if greater) and exclusive of any bonuses, overtime pay, shift differentials, &#x201C;adders,&#x201D; any other form of premium pay, or other forms of compensation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Benefits Continuation</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D; shall have the meaning set forth in Section 8(a) hereof.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Board</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D; shall mean the Board of Directors of the Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Cause</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D; shall mean any of: (a)&nbsp;&nbsp;your conviction of, or plea of guilty or nolo contendere to, any crime involving dishonesty or moral turpitude or any felony; or (b) a good faith finding by the Company&#x2019;s Board of Directors that you have (i) engaged in dishonesty, willful misconduct or gross negligence that has a material adverse effect on the Company, (ii) committed an act that materially injures or would reasonably be expected to materially injure the reputation, business or business relationships of the Company, (iii) materially breached the terms of any restrictive covenants or confidentiality agreement with the Company (and not cured same within any cure period applicable to such covenants or confidentiality agreement); or (iv) failed or refused to comply in any material respect with the Company&#x2019;s material policies or procedures and</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:right;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">in a manner that materially injures or would reasonably be expected to materially injure the reputation, business or business relationships of the Company, provided that in the case of (iv) that you were given written notice of such violation or failure by the Board and a period of 30 days to cure (provided that the Board reasonably determines that such violation or failure is curable).</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Change in Control</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D; shall mean the occurrence of any of the following events, provided that such event or occurrence constitutes a change in the ownership or effective control of the Company, or a change in the ownership of a substantial portion of the assets of the Company, as defined in Treasury Regulation &#xA7;&#xA7;1.409A-3(i)(5)(v), (vi) and (vii):&nbsp;&nbsp;(i) the acquisition by an individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934 (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Exchange Act</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;)) (a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Person</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) of beneficial ownership of any capital stock of the Company if, after such acquisition, such Person beneficially owns (within the meaning of Rule 13d-3 under the Exchange Act) 50% or more of either (x) the then-outstanding shares of common stock of the Company (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Outstanding Company Common Stock</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) or (y) the combined voting power of the then-outstanding securities of the Company entitled to vote generally in the election of directors (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Outstanding Company Voting Securities</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;); provided, however, that for purposes of this subsection (i), the following acquisitions shall not constitute a Change in Control: (1) any acquisition directly from the Company or (2) any acquisition by any entity pursuant to a Business Combination (as defined below) which complies with clauses (x) and (y) of subsection (iii) of this definition; or (ii) a change in the composition of the Board that results in the Continuing Directors (as defined below) no longer constituting a majority of the Board (or, if applicable, the Board of Directors of a successor corporation to the Company), where the term &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Continuing Director</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D; means at any date a member of the Board (x) who was a member of the Board on the date of the initial adoption of the Plan by the Board or (y) who was nominated or elected subsequent to such date by at least a majority of the directors who were Continuing Directors at the time of such nomination or election or whose election to the Board was recommended or endorsed by at least a majority of the directors who were Continuing Directors at the time of such nomination or election; provided, however, that there shall be excluded from this clause (y) any individual whose initial assumption of office occurred as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents, by or on behalf of a person other than the Board; or (iii) the consummation of a merger, consolidation, reorganization, recapitalization or share exchange involving the Company or a sale or other disposition of all or substantially all of the assets of the Company (a &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Business Combination</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), unless, immediately following such Business Combination, each of the following two conditions is satisfied: (x) all or substantially all of the individuals and entities who were the beneficial owners of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 50% of the then-outstanding shares of common stock and the combined voting power of the then-outstanding securities entitled to vote generally in the election of directors, respectively, of the resulting or acquiring corporation in such Business Combination (which shall include, without limitation, a corporation which as a result of such transaction owns the Company or substantially all of the Company&#x2019;s assets either directly or through one or</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">-7-</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">more subsidiaries) (such resulting or acquiring corporation is referred to herein as the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Acquiring Corporation</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) in substantially the same proportions as their ownership of the Outstanding Company Common Stock and Outstanding Company Voting Securities, respectively, immediately prior to such Business Combination and (y) no Person (excluding any employee benefit plan (or related trust) maintained or sponsored by the Company or by the Acquiring Corporation) beneficially owns, directly or indirectly, 50% or more of the then-outstanding shares of common stock of the Acquiring Corporation, or of the combined voting power of the then-outstanding securities of such corporation entitled to vote generally in the election of directors (except to the extent that such ownership existed prior to the Business Combination); or (iv) the liquidation or dissolution of the Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Change in Control Termination</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D; shall mean a termination of the Covered Employee&#x2019;s employment by the Company without Cause or by the Covered Employee for Good Reason, in either case within the twelve (12) months following a Change in Control.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">COBRA</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;&nbsp;&nbsp;shall mean the Consolidated Omnibus Budget Reconciliation Act.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Code</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D; shall mean the Internal Revenue Code of 1986, as amended.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Company</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D; shall mean Editas Medicine, Inc. or, following a Change in Control, any successor thereto.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Covered Employees</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D; shall mean all Regular Full&#8209;Time Employees (both exempt and non&#8209;exempt) who are (i) Executives or (ii) otherwise designated by the Board or by an authorized committee to be a Covered Employee under this Plan, who experience a Covered Termination and who are not designated as ineligible to receive severance benefits under the Plan as provided in Section 5 hereof. For the avoidance of doubt, neither Temporary Employees nor Part-Time Employees are eligible for severance benefits under the Plan.&nbsp;&nbsp;An employee&#x2019;s full&#8209;time, part-time or temporary status for the purpose of this Plan is determined by the Plan Administrator upon review of the employee&#x2019;s status immediately before termination.&nbsp;&nbsp;Any person who is classified by the Company as an independent contractor or third party employee is not eligible for severance benefits even if such classification is modified retroactively.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Covered Termination</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D; shall mean (i) Non-Change in Control Termination or (ii) a Change in Control Termination.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Effective Date</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D; shall mean December 10, 2015.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">ERISA</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D; shall mean the Employee Retirement Income Security Act of 1974, as amended.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Executive</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D; shall mean any employee of the Company holding the title of Vice President or above.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">-8-</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Good Reason</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D; is defined as: (i) a material diminution in the employee&#x2019;s base compensation; (ii) a material diminution in the employee&#x2019;s authority, duties, or responsibilities; (iii) a material change in the geographic location at which the employee must perform the services; or (iv) any other action or inaction that constitutes a material breach by the Company of any agreement under which the employee provides services; provided, however, that in any case the employee has not consented to the condition which would otherwise give rise to a Good Reason.&nbsp;&nbsp;In order to establish a &#x201C;Good Reason&#x201D; for terminating employment, an employee must provide written notice to the Company of the existence of the condition giving rise to the Good Reason, which notice must be provided within 90 days of the initial existence of such condition, the Company must fail to cure the condition within 30 days thereafter, and an employee&#x2019;s termination of employment must occur no later than one year following the initial existence of the condition giving rise to Good Reason.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Non-Change in Control Termination</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D; shall mean a termination of the Covered Employee&#x2019;s employment by the Company without Cause prior to or more than twelve (12) months following a Change in Control.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Other C-Level Officer</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D; shall mean the Chief Financial Officer, the Chief Operating Officer, the Chief Technology Officer and any other officer of the Company reporting directly to the Chief Executive Officer or otherwise designated by the Board as an Other C-Level Officer for purposes of the Plan.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Part-Time Employees</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D; shall mean employees who are not Regular Full-Time Employees and are treated as such by the Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Participants</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D; shall mean Covered Employees.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Plan Administrator</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D; shall have the meaning set forth in Section 14 hereof.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(u)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Release</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D; shall have the meaning set forth in Section 6 hereof.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Release Effective Date</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D; shall have the meaning set forth in Section 13(c)(i) hereof.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(w)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Regular Full-Time Employees</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D; shall mean employees, other than Temporary Employees, normally scheduled to work at least 30 hours a week unless the Company&#x2019;s local practices, as from time to time in force, whether or not in writing, establish a different hours threshold for regular full-time employees.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Severance Pay</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D; shall have the meaning set forth in Section 7 hereof.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(y)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Severance Period</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D; shall mean the applicable severance period determined under the chart in Section 7 hereof based on the type of Covered Termination and the Title/ Role of the Covered Employee.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(z)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Temporary Employees</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D; are employees treated as such by the Company,</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">-9-</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">whether or not in writing.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Coverage.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">A Covered Employee may be entitled to receive severance benefits under the Plan if such employee experiences a Covered Termination.&nbsp;&nbsp;In order to receive severance benefits under the Plan, Covered Employees must meet the eligibility and other requirements provided below in Sections 5 and 6 of the Plan.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Eligibility for Severance Benefits.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">The following employees will </font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">not</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> be eligible for severance benefits, except to the extent specifically determined otherwise by the Plan Administrator:&nbsp;&nbsp;(a) an employee who is terminated for Cause; (b) an employee who retires, terminates employment as a result of an inability to performs his duties due to physical or mental disability or dies; (c) an employee who voluntarily terminates his employment, except, in the case of a Covered Termination for Good Reason; (d) an employee who is employed for a specific period of time in accordance with the terms of a written employment agreement; and (e) an employee who promptly becomes employed by another member of the controlled group of entities of which the Company (or its successor in the Change in Control) is a member as defined in Sections 414(b) and (c) of Code.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Release; Timing of Severance Benefits.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">Receipt of any severance benefits under the Plan requires that the Covered Employee:&nbsp;&nbsp;(a) comply with the provisions of any applicable noncompetition, nonsolicitation, and other obligations to the Company; and (b) execute and deliver a suitable waiver and release under which the Covered Employee releases and discharges the Company and its affiliates from and on account of any and all claims that relate to or arise out of the employment relationship between the Company and the Covered Employee (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Release</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) which Release becomes binding within 60 days following the Covered Employee&#x2019;s termination of employment</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">The Severance Pay will be paid in accordance with the terms of the Plan and the Company&#x2019;s regular pay practices in effect from time to time and the Benefits Continuation will be paid in the amount and at the time premium payments are made by other participants in the Company&#x2019;s health benefit plans with the same coverage. The payments shall be made or commence on the first payroll date after the Release Effective Date.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash Severance.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">A Covered Employee entitled to severance benefits under this Plan shall be entitled to the continuation of such employee&#x2019;s monthly Base Salary for the Severance Period indicated below (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Severance Pay</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), based upon his or her title/role.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="top" style="width:120.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:122.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:126.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:120.50pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:26.30pt;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 8pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Title/ Role of<br></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Covered Employee</font></p>
				</td>
				<td valign="top" style="width:122.35pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:26.30pt;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 8pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Non-Change in<br></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Control Termination<br>Severance Period</font></p>
				</td>
				<td valign="top" style="width:126.85pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:26.30pt;padding:0pt 6.5pt">
					<p style="margin:0pt 0pt 8pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Change in Control<br></font><font style="display:inline;font-family:Times New Roman,Times,serif;"></font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Termination<br>Severance Period</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:120.50pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:26.30pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Chief Executive Officer</font></p>
				</td>
				<td valign="top" style="width:122.35pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:26.30pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Twelve (12) months</font></p>
				</td>
				<td valign="top" style="width:126.85pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:26.30pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Twelve (12) months</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:120.50pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:26.30pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Other C-Level Officer<br>or Senior Vice&nbsp;President</font></p>
				</td>
				<td valign="top" style="width:122.35pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:26.30pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Twelve (12) months</font></p>
				</td>
				<td valign="top" style="width:126.85pt;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:26.30pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Twelve (12) months</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.16%;"></table></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">-10-</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.16%;">
			<tr>
				<td valign="top" style="width:32.58%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:26.30pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;overflow: hidden;">
						<font style="display:inline;"></font></p>
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Vice President</font></p>
				</td>
				<td valign="top" style="width:33.10%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:26.30pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Six (6) months</font></p>
				</td>
				<td valign="top" style="width:34.32%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;height:26.30pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Nine (9) months</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">For purposes of this Section 7 and Section 8 below, a Covered Employee&#x2019;s title/role shall be such employee&#x2019;s title/role immediately prior to the Covered Termination or, if such employee&#x2019;s title/role was changed in connection with the Change in Control, immediately prior to the Change in Control.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other Severance Benefits.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">In addition to the foregoing Severance Pay, the severance benefits under the Plan shall include the following benefits:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 38.85pt;text-indent: -25.9pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(a)&nbsp;&nbsp;&nbsp;&nbsp;Company contributions to the cost of COBRA coverage on behalf of the Covered Employee and any applicable dependents for no longer than the Covered Employee&#x2019;s applicable Severance Period if the Covered Employee elects COBRA coverage, and only so long as such coverage continues in force.&nbsp;&nbsp;Such costs shall be determined on the same basis as the Company&#x2019;s contribution to Company-provided health and dental insurance coverage in effect for an active employee with the same coverage elections; provided that if the Covered Employee commences new employment and is eligible for a new group health plan, the Company&#x2019;s continued contributions toward health and dental coverage shall end when the new employment begins (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Benefits Continuation</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;).</font>
		</p>
		<p style="margin:0pt 0pt 12pt 38.85pt;text-indent: -25.9pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(b)&nbsp;&nbsp;&nbsp;&nbsp;Any unpaid annual bonus in respect to any completed bonus period which has ended prior to the date of the Participant&#x2019;s Covered Termination and which the Board deems granted to the Participant in its discretion pursuant to the Company&#x2019;s contingent compensation program, payable at the same time as annual bonuses are paid to other employees of the Company or, if later, upon the Release Effective Date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 38.85pt;text-indent: -25.9pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(c)&nbsp;&nbsp;&nbsp;&nbsp;In the case of a Change in Control Termination, a bonus amount equal to the multiple of (i) a fraction the numerator of which is the Severance Period and the denominator of which is twelve (12) and (ii) the Covered Employee&#x2019;s target annual bonus for the year of the Change in Control Termination, payable in a lump sum on the Release Effective Date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equity Awards</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;In the case of a Change in Control Termination, any unvested equity awards shall become fully vested and exercisable, or free from forfeiture or repurchase, effective upon the Release Effective Date.&nbsp;&nbsp;Except as set forth in the foregoing sentence, the treatment of a Covered Employee&#x2019;s equity awards with the Company upon a Covered Termination shall be dictated by the terms of the applicable award agreements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recoupment.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">If a Covered Employee fails to comply with the terms of the Plan, including the provisions of Section 6 above, the Company may require payment to the Company of any benefits described in Sections 7 and 8 above that the Covered Employee has already received to the extent permitted by applicable law and with the &#x201C;value&#x201D; determined in the sole discretion of the Plan Administrator.&nbsp; Payment is due in cash or by check within 10 days after the Company provides notice to a Covered Employee that it is enforcing this provision.&nbsp; Any benefits described in Sections 7 and 8 above not yet received by such Covered Employee will be</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">-11-</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">immediately forfeited.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Death.&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">If a Participant dies after the date of his or her Covered Termination but before all payments or benefits to which such Participant is entitled pursuant to the Plan have been paid or provided, payments will be made to any beneficiary designated by the Participant prior to or in connection with such Participant&#x2019;s Covered Termination or, if no such beneficiary has been designated, to the Participant&#x2019;s estate.&nbsp;&nbsp;For the avoidance of doubt, if a Participant dies during such Participant&#x2019;s applicable Severance Period, Benefits Continuation will continue for the Participant&#x2019;s applicable dependents for the remainder of the Participant&#x2019;s Severance Period.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Withholding.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">The Company may withhold from any payment or benefit under the Plan: (a) any federal, state, or local income or payroll taxes required by law to be withheld with respect to such payment; (b) such sum as the Company may reasonably estimate is necessary to cover any taxes for which the Company may be liable and which may be assessed with regard to such payment; and (c) such other amounts as appropriately may be withheld under the Company&#x2019;s payroll policies and procedures from time to time in effect.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 409A.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">It is expected that the payments and benefits provided under this Plan will be exempt from the application of Section 409A of the Code, and the guidance issued thereunder (&#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Section 409A</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;).&nbsp;&nbsp;The Plan shall be interpreted consistent with this intent to the maximum extent permitted and generally, with the provisions of Section 409A.&nbsp;&nbsp;A termination of employment shall not be deemed to have occurred for purposes of any provision of this Plan providing for the payment of any amounts or benefits upon or following a termination of employment (which amounts or benefits constitute nonqualified deferred compensation within the meaning of Section 409A) unless such termination is also a &#x201C;separation from service&#x201D; within the meaning of Section 409A and, for purposes of any such provision of this Plan, references to a &#x201C;termination,&#x201D; &#x201C;termination of employment&#x201D; or like terms shall mean &#x201C;separation from service&#x201D;.&nbsp;&nbsp;Neither the Participant nor the Company shall have the right to accelerate or defer the delivery of any payment or benefit except to the extent specifically permitted or required by Section 409A.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Notwithstanding the foregoing, to the extent the severance payments or benefits under this Plan are subject to Section 409A, the following rules shall apply with respect to distribution of the payments and benefits, if any, to be provided to Participants under this Plan:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each installment of the payments and benefits provided under this Plan will be treated as a separate &#x201C;payment&#x201D; for purposes of Section 409A.&nbsp;&nbsp;Whenever a payment under this Plan specifies a payment period with reference to a number of days (</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">e.g.</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, &#x201C;payment shall be made within 10 days following the date of termination&#x201D;), the actual date of payment within the specified period shall be in the Company&#x2019;s sole discretion.&nbsp;&nbsp;Notwithstanding any other provision of this Plan to the contrary, in no event shall any payment under this Plan that constitutes &#x201C;non-qualified deferred compensation&#x201D; for purposes of Section 409A be subject to transfer, offset, counterclaim or recoupment by any other amount unless otherwise permitted by Section 409A.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding any other payment provision herein to the contrary, if the Company or appropriately-related affiliates become publicly-traded and a Covered Employee is deemed on the date of termination to be a &#x201C;specified employee&#x201D; within the</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">-12-</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">meaning of that term under Code Section 409A(a)(2)(B) with respect to such entity, then each of the following shall apply:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With regard to any payment that is considered &#x201C;non-qualified deferred compensation&#x201D; under Section 409A payable on account of a &#x201C;separation from service,&#x201D; such payment shall be made on the date which is the earlier of (A) the day following the expiration of the six month period measured from the date of such &#x201C;separation from service&#x201D; of the Covered Employee, and (B) the date of the Covered Employee&#x2019;s death (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Delay Period</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) to the extent required under Section 409A.&nbsp;&nbsp;Upon the expiration of the Delay Period, all payments delayed pursuant to this provision (whether otherwise payable in a single sum or in installments in the absence of such delay) shall be paid to or for the Covered Employee in a lump sum, and all remaining payments due under this Plan shall be paid or provided for in accordance with the normal payment dates specified herein; and</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To the extent that any benefits to be provided during the Delay Period are considered &#x201C;non-qualified deferred compensation&#x201D; under Section 409A payable on account of a &#x201C;separation from service,&#x201D; and such benefits are not otherwise exempt from Section 409A, the Covered Employee shall pay the cost of such benefits during the Delay Period, and the Company shall reimburse the Covered Employee, to the extent that such costs would otherwise have been paid by the Company or to the extent that such benefits would otherwise have been provided by the Company at no cost to the Covered Employee, the Company&#x2019;s share of the cost of such benefits upon expiration of the Delay Period.&nbsp;&nbsp;Any remaining benefits shall be reimbursed or provided by the Company in accordance with the procedures specified in this Plan.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To the extent that severance benefits pursuant to this Plan are conditioned upon a Release, the Covered Employee shall forfeit all rights to such payments and benefits unless such release is signed and delivered (and no longer subject to revocation, if applicable) within 60 days following the date of the termination of the Covered Employee&#x2019;s employment with the Company.&nbsp;&nbsp;If the Release is no longer subject to revocation as provided in the preceding sentence, then the following shall apply:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To the extent any severance benefits to be provided are not &#x201C;non-qualified deferred compensation&#x201D; for purposes of Section 409A, then such benefits shall commence upon the first scheduled payment date immediately after the date the Release is executed and no longer subject to revocation (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Release Effective Date</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;).&nbsp;&nbsp;The first such cash payment shall include all amounts that otherwise would have been due prior thereto under the terms of this Agreement applied as though such payments commenced immediately upon the termination of Covered Employee&#x2019;s employment with the Company, and any payments made after the Release Effective Date shall continue as provided herein.&nbsp;&nbsp;The delayed benefits shall in any event expire at the time such benefits would have expired had such benefits commenced immediately following the termination of Covered Employee&#x2019;s employment with the Company.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">-13-</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To the extent any such severance benefits to be provided are &#x201C;non-qualified deferred compensation&#x201D; for purposes of Section 409A, then the Release must become irrevocable within 60 days of the date of termination and </font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">benefits shall be made or commence upon the date provided in Section 6, provided that if the 60th day following the </font><font style="display:inline;font-family:Times New Roman,Times,serif;">termination of the Covered Employee&#x2019;s employment with the Company falls in the calendar year following the calendar year containing the date of termination, the benefits will be made no earlier than the first business day of that following calendar year</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">The first such cash payment shall include all amounts that otherwise would have been due prior thereto under the terms of this Agreement had such payments commenced immediately upon the termination of Covered Employee&#x2019;s employment with the Company, and any payments made after the first such payment shall continue as provided herein.&nbsp;&nbsp;The delayed benefits shall in any event expire at the time such benefits would have expired had such benefits commenced immediately following the termination of Covered Employee&#x2019;s employment with the Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company makes no representations or warranties and shall have no liability to any Participant or any other person, other than with respect to payments made by the Company in violation of the provisions of this Plan, if any provisions of or payments under this Plan are determined to constitute deferred compensation subject to Section 409A of the Code but not to satisfy the conditions of that section.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section 280G.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">Notwithstanding any other provision of this Plan, except as set forth in Section 14(b), in the event that the Company undergoes a &#x201C;Change in Ownership or Control&#x201D; (as defined below), the following provisions shall apply</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(a) The Company shall not be obligated to provide to the Covered Employee any portion of any &#x201C;Contingent Compensation Payments&#x201D; (as defined below) that the Covered Employee would otherwise be entitled to receive to the extent necessary to eliminate any &#x201C;excess parachute payments&#x201D; (as defined in Section 280G(b)(1) of the Code) for the Covered Employee.&nbsp;&nbsp;For purposes of this Section 14, the Contingent Compensation Payments so eliminated shall be referred to as the &#x201C;Eliminated Payments&#x201D; and the aggregate amount (determined in accordance with Treasury Regulation Section 1.280G-1, Q/A-30 or any successor provision) of the Contingent Compensation Payments so eliminated shall be referred to as the &#x201C;Eliminated Amount.&#x201D;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(b) Notwithstanding the provisions of Section 14(a), no such reduction in Contingent Compensation Payments shall be made if (1) the Eliminated Amount (computed without regard to this sentence) exceeds (2) 100% of the aggregate present value (determined in accordance with Treasury Regulation Section 1.280G-1, Q/A-31 and Q/A-32 or any successor provisions) of the amount of any additional taxes that would be incurred by the Covered Employee if the Eliminated Payments (determined without regard to this sentence) were paid to the Covered Employee (including state and federal income taxes on the Eliminated Payments, the excise tax imposed by Section 4999 of the Code payable with respect to all of the Contingent Compensation Payments in excess of the Covered Employee&#x2019;s &#x201C;base amount&#x201D; (as defined in Section 280G(b)(3) of the Code), and any withholding taxes).&nbsp;&nbsp;The override of such reduction in Contingent Compensation Payments pursuant to this Section 14(b) shall be referred to as a</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">-14-</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201C;Section 14(b) Override.&#x201D;&nbsp;&nbsp;For purpose of this paragraph, if any federal or state income taxes would be attributable to the receipt of any Eliminated Payment, the amount of such taxes shall be computed by multiplying the amount of the Eliminated Payment by the maximum combined federal and state income tax rate provided by law.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(c) For purposes of this Section 14 the following terms shall have the following respective meanings:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(i) &#x201C;Change in Ownership or Control&#x201D; shall mean a change in the ownership or effective control of the Company or in the ownership of a substantial portion of the assets of the Company determined in accordance with Section 280G(b)(2) of the Code.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(ii) &#x201C;Contingent Compensation Payment&#x201D; shall mean any payment (or benefit) in the nature of compensation that is made or made available (under this Agreement or otherwise) to a &#x201C;disqualified individual&#x201D; (as defined in Section 280G(c) of the Code) and that is contingent (within the meaning of Section 280G(b)(2)(A)(i) of the Code) on a Change in Ownership or Control of the Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(d) Any payments or other benefits otherwise due to the Covered Employee following a Change in Ownership or Control that could reasonably be characterized (as determined by the Company) as Contingent Compensation Payments (the &#x201C;Potential Payments&#x201D;) shall not be made until the dates provided for in this Section 14(d).&nbsp;&nbsp;Within thirty (30) days after each date on which the Covered Employee first become entitled to receive (whether or not then due) a Contingent Compensation Payment relating to such Change in Ownership or Control, the Company shall determine and notify the Covered Employee (with reasonable detail regarding the basis for its determinations) (1) which Potential Payments constitute Contingent Compensation Payments, (2) the Eliminated Amount and (3) whether the Section 14(b) Override is applicable.&nbsp;&nbsp;Within thirty (30) days after delivery of such notice to the Covered Employee, the Covered Employee shall deliver a response to the Company (the &#x201C;Covered Employee Response&#x201D;) stating either (A) that the Covered Employee agrees with the Company&#x2019;s determination pursuant to the preceding sentence or (B) that the Covered Employee disagrees with such determination, in which case the Covered Employee shall set forth (x) which Potential Payments should be characterized as Contingent Compensation Payments, (y) the Eliminated Amount, and (z) whether the Section 14(b) Override is applicable.&nbsp;&nbsp;In the event that the Covered Employee fails to deliver an Covered Employee Response on or before the required date, the Company&#x2019;s initial determination shall be final.&nbsp;&nbsp;If the Covered Employee states in the Covered Employee Response that the Covered Employee agrees with the Company&#x2019;s determination, the Company shall make the Potential Payments to the Covered Employee within three (3) business days following delivery to the Company of the Covered Employee Response (except for any Potential Payments which are not due to be made until after such date, which Potential Payments shall be made on the date on which they are due).&nbsp;&nbsp;If the Covered Employee states in the Covered Employee Response that the Covered Employee disagree with the Company&#x2019;s determination, then, for a period of sixty (60) days following delivery of the Covered Employee Response, the Covered Employee and the Company shall use good faith efforts to resolve such dispute.&nbsp;&nbsp;If such dispute is not resolved within such 60-day period, such dispute shall be settled exclusively by arbitration in Boston, Massachusetts, in accordance with the rules of the American Arbitration Association then in effect.&nbsp;&nbsp;Judgment may be entered on the arbitrator&#x2019;s award in any court having</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">-15-</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">jurisdiction.&nbsp;&nbsp;The Company shall, within three (3) business days following delivery to the Company of the Covered Employee Response, make to the Covered Employee those Potential Payments as to which there is no dispute between the Company and the Covered Employee regarding whether they should be made (except for any such Potential Payments which are not due to be made until after such date, which Potential Payments shall be made on the date on which they are due).&nbsp;&nbsp;The balance of the Potential Payments shall be made within three (3) business days following the resolution of such dispute.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(e) The Contingent Compensation Payments to be treated as Eliminated Payments shall be determined by the Company by determining the &#x201C;Contingent Compensation Payment Ratio&#x201D; (as defined below) for each Contingent Compensation Payment and then reducing the Contingent Compensation Payments in order beginning with the Contingent Compensation Payment with the highest Contingent Compensation Payment Ratio.&nbsp;&nbsp;For Contingent Compensation Payments with the same Contingent Compensation Payment Ratio, such Contingent Compensation Payment shall be reduced based on the time of payment of such Contingent Compensation Payments with amounts having later payment dates being reduced first.&nbsp;&nbsp;For Contingent Compensation Payments with the same Contingent Compensation Payment Ratio and the same time of payment, such Contingent Compensation Payments shall be reduced on a pro rata basis (but not below zero) prior to reducing Contingent Compensation Payment with a lower Contingent Compensation Payment Ratio.&nbsp;&nbsp;The term &#x201C;Contingent Compensation Payment Ratio&#x201D; shall mean a fraction the numerator of which is the value of the applicable Contingent Compensation Payment that must be taken into account by the Covered Employee for purposes of Section 4999(a) of the Code, and the denominator of which is the actual amount to be received by the Covered Employee in respect of the applicable Contingent Compensation Payment.&nbsp;&nbsp;For example, in the case of an equity grant that is treated as contingent on the Change in Ownership or Control because the time at which the payment is made or the payment vests is accelerated, the denominator shall be determined by reference to the fair market value of the equity at the acceleration date, and not in accordance with the methodology for determining the value of accelerated payments set forth in Treasury Regulation Section 1.280G-1 Q/A-24(b) or (c)).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(f) The provisions of this Section 14 are intended to apply to any and all payments or benefits available to the Covered Employee under this Plan or any other agreement or plan of the Company under which the Covered Employee receives Contingent Compensation Payments.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Plan Administration.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Plan Administrator</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;The Plan Administrator shall be the Board or a committee thereof designated by the Board (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Committee</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;); provided, however, that the Board or such Committee may in its sole discretion appoint a new Plan Administrator to administer the Plan following a Change in Control.&nbsp;&nbsp;The Plan Administrator shall also serve as the Named Fiduciary of the Plan under ERISA.&nbsp;&nbsp;The Plan Administrator shall be the &#x201C;administrator&#x201D; within the meaning of Section 3(16) of ERISA and shall have all the responsibilities and duties contained therein.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The Plan Administrator can be contacted at the following address:</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Editas Medicine, Inc.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">-16-</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">300 Third Street</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">First Floor<br>Cambridge, MA&nbsp;&nbsp;02142</font>
		</p>
		<p style="margin:0pt 0pt 0pt 108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Decisions, Powers and Duties</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;The general administration of the Plan and the responsibility for carrying out its provisions shall be vested in the Plan Administrator.&nbsp;&nbsp;The Plan Administrator shall have such powers and authority as are necessary to discharge such duties and responsibilities which also include, but are not limited to, interpretation and construction of the Plan, the determination of all questions of fact, including, without limit, eligibility, participation and benefits, the resolution of any ambiguities and all other related or incidental matters, and such duties and powers of the plan administration which are not assumed from time to time by any other appropriate entity, individual or institution.&nbsp;&nbsp;The Plan Administrator may adopt rules and regulations of uniform applicability in its interpretation and implementation of the Plan.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The Plan Administrator shall discharge its duties and responsibilities and exercise its&nbsp;powers and authority in its sole discretion and in accordance with the terms of the&nbsp;controlling legal documents and applicable law, and its actions and decisions that are not&nbsp;arbitrary and capricious shall be binding on any employee, and employee&#x2019;s spouse or&nbsp;other dependent or beneficiary and any other interested parties whether or not in being or&nbsp;under a disability.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indemnification.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">To the extent permitted by law, all employees, officers, directors, agents and representatives of the Company shall be indemnified by the Company and held harmless against any claims and the expenses of defending against such claims, resulting from any action or conduct relating to the administration of the Plan, whether as a member of the Committee or otherwise, except to the extent that such claims arise from gross negligence, willful neglect, or willful misconduct.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Plan Not an Employment Contract.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">The Plan is not a contract between the Company and any employee,&nbsp;nor is it a condition of employment of any employee.&nbsp;&nbsp;Nothing contained in the Plan gives, or is intended to give, any employee the right to be retained in the service of the Company, or to interfere with the right of the Company to discharge or terminate the employment of any employee at any time and for any reason.&nbsp;&nbsp;No employee shall have the right or claim to benefits beyond those expressly provided in this Plan, if any.&nbsp;&nbsp;All rights and claims are limited as set forth in the Plan.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Severability.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">In case any one or more of the provisions of this Plan (or part thereof) shall be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect the other provisions hereof, and this Plan shall be construed as if such invalid, illegal or unenforceable provisions (or part thereof) never had been contained herein.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non&#8209;Assignability.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">No right or interest of any Covered Employee in the Plan shall be assignable or transferable in whole or in part either directly or by operation of law or otherwise, including, but not limited to, execution, levy, garnishment, attachment, pledge or bankruptcy.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">-17-</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">20.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Integration With Other Pay or Benefits Requirements.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">The severance payments and benefits provided for in the Plan are the maximum benefits that the Company will pay to Covered Employees on a Covered Termination, except to the extent otherwise specifically provided in a separate agreement.&nbsp;&nbsp;To the extent that the Company owes any amounts in the nature of severance benefits under any other program, policy or plan of the Company that is not otherwise superseded by this Plan, or to the extent that any federal, state or local law, including, without limitation, so&#8209;called &#x201C;plant closing&#x201D; laws, requires the Company to give advance notice or make a payment of any kind to an employee because of that employee&#x2019;s involuntary termination due to a layoff, reduction in force, plant or facility closing, sale of business, or similar event, the benefits provided under this Plan or the other arrangement shall either be reduced or eliminated to avoid any duplication of payment.&nbsp;&nbsp;The Company intends for the benefits provided under this Plan to partially or fully satisfy any and all statutory obligations that may arise out of an employee&#x2019;s involuntary termination for the foregoing reasons and the Company shall so construe and implement the terms of the Plan.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">21.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amendment or Termination.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">The Board may amend, modify, or terminate the Plan at any time in its sole discretion; provided, however, that (a) any such amendment, modification or termination made prior to a Change in Control that adversely affects the rights of any Covered Employee shall be unanimously approved by the Company&#x2019;s Board of Directors,&nbsp;&nbsp;(b) no such amendment, modification or termination may affect the rights of a Covered Employee then receiving payments or benefits under the Plan without the consent of such person, and (c) no such amendment, modification or termination made after a Change in Control shall be effective for one year. The Board intends to review the Plan at least annually.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">22.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Governing Law.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;">The Plan and the rights of all persons under the Plan shall be construed in accordance with and under applicable provisions of ERISA, and the regulations thereunder, and the laws of the Commonwealth of Massachusetts (without regard to conflict of laws provisions) to the extent not preempted by federal law.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">-18-</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">EXHIBIT B</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">INVENTION AND NON-DISCLOSURE AGREEMENT</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">This Invention and Non-Disclosure Agreement (this &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) made this ____ day of _____________, 2019, is by and between Editas Medicine, Inc., a Delaware corporation (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Company</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;), and Cynthia Collins (the &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Employee</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;).</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">In consideration of the employment or continued employment of the Employee by the Company, the Employee and the Company agree as follows:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Condition of Employment.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The Employee acknowledges that Employee&#x2019;s employment and/or the continuance of that employment with the Company is contingent upon Employee&#x2019;s agreement to sign and adhere to the provisions of this Agreement.&nbsp;&nbsp;The Employee further acknowledges that the nature of the Company&#x2019;s business is such that protection of its proprietary and confidential information is critical to the survival and success of the Company&#x2019;s business.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Proprietary and Confidential Information.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">The Employee agrees that all information and know-how, whether or not in writing, of a private, secret or confidential nature concerning the Company&#x2019;s business or financial affairs (collectively, &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Proprietary Information</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;) is and shall be the exclusive property of the Company.&nbsp;&nbsp;By way of illustration, but not limitation, Proprietary Information may include discoveries, ideas, inventions, products, product improvements, product enhancements, processes, methods, techniques, formulas, compositions, compounds, negotiation strategies and positions, projects, developments, plans (including business and marketing plans), research data, clinical data, financial data (including sales costs, profits, pricing methods), personnel data obtained pursuant to the Employee&#x2019;s duties and responsibilities, computer programs (including software used pursuant to a license agreement), customer, prospect and supplier lists, and contacts at or knowledge of customers or prospective customers of the Company.&nbsp;&nbsp;Except as otherwise permitted by Section 5 below, the Employee will not disclose any Proprietary Information to any person or entity other than employees of the Company or use the same for any purposes (other than in the performance of Employee&#x2019;s duties as an employee of the Company) without written approval by an officer of the Company, either during or after Employee&#x2019;s employment with the Company, unless and until such Proprietary Information has become public knowledge without fault by the Employee.&nbsp;&nbsp;While employed by the Company, the Employee will use the Employee's best efforts to prevent unauthorized publication or disclosure of any of the Company&#x2019;s Proprietary Information.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">The Employee agrees that all files, documents, letters, memoranda, reports, records, data, sketches, drawings, models, laboratory notebooks, program listings, computer equipment or devices, computer programs or other written, photographic, or other tangible or intangible material containing Proprietary Information, whether created by the Employee or others, which come into Employee&#x2019;s custody or possession, shall be and are the exclusive property of the Company to be used by the Employee only in the performance of</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">-19-</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Employee&#x2019;s duties for the Company and shall not be copied or removed from the Company premises except in the pursuit of the business of the Company.&nbsp;&nbsp;All such materials or copies thereof and all tangible property of the Company in the custody or possession of the Employee shall be delivered to the Company, upon the earlier of (i)&nbsp;a request by the Company or (ii)&nbsp;termination of Employee&#x2019;s employment for any reason.&nbsp;&nbsp;After such delivery, the Employee shall not retain any such materials or copies thereof or any such tangible property.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">The Employee agrees that Employee&#x2019;s obligation not to disclose or to use information and materials of the types set forth in Sections 2(a) and 2(b) above, and Employee&#x2019;s obligation to return materials and tangible property, set forth in Section&nbsp;2(b) above, also extends to such types of information, materials and tangible property of customers of the Company or suppliers to the Company or other third parties who may have disclosed or entrusted the same to the Company or to the Employee in the course of the Company&#x2019;s business.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Developments.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">The Employee has attached hereto, as </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Exhibit A</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, a list describing all discoveries, ideas, inventions, improvements, enhancements, processes, methods, techniques, developments, software, and works of authorship, whether patentable or not, which were created, made, conceived or reduced to practice by the Employee prior to the Employee&#x2019;s employment by the Company and which are owned by Employee, which relate directly or indirectly to the current or anticipated future business of the Company, and which are not assigned to the Company hereunder (collectively, &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Prior Developments</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;); or, if no such list is attached, Employee represents that there are no Prior Developments.&nbsp;&nbsp;Employee agrees not to incorporate any Prior Developments into any Company product, material, process or service without prior written consent of an officer of the Company.&nbsp;&nbsp;If Employee does incorporate any Prior Development into any Company product, material, process or service, Employee hereby grants to the Company a non-exclusive, worldwide, perpetual, transferable, irrevocable, royalty-free, fully-paid right and license to make, have made, use, offer for sale, sell, import, reproduce, modify, prepare derivative works, display, perform, transmit, distribute and otherwise exploit such Prior Development and to practice any method related thereto.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">The Employee will make full and prompt disclosure to the Company of all discoveries, ideas, inventions, improvements, enhancements, processes, methods, techniques, developments, software, and works of authorship, whether patentable or not, which are created, made, conceived or reduced to practice by Employee or under Employee&#x2019;s direction or jointly with others during Employee&#x2019;s employment by the Company, whether or not during normal working hours or on the premises of the Company (all of which are collectively referred to in this Agreement as &#x201C;</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">Developments</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&#x201D;).&nbsp;&nbsp;The Employee acknowledges that each original work of authorship which is made by the Employee (solely or jointly with others) within the scope of and during the period of Employee&#x2019;s employment with the Company and which is protectable by copyright is a &#x201C;work made for hire,&#x201D; as that term is defined in the United States Copyright Act. The Employee agrees to assign and does hereby assign to the Company (or any person or entity designated by the Company) all Employee&#x2019;s right, title and interest in and to all Developments (other than Prior Developments listed on </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Exhibit A</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, if any) and all related patents, patent applications, copyrights and copyright applications.&nbsp;&nbsp;However, this Section&nbsp;3(b) shall not apply to Developments which do not relate to the business or research and development conducted or</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">-20-</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">planned to be conducted by the Company at the time such Development is created, made, conceived or reduced to practice and which are made and conceived by the Employee not during normal working hours, not on the Company&#x2019;s premises and not using the Company&#x2019;s tools, devices, equipment or Proprietary Information.&nbsp;&nbsp;The Employee understands that, to the extent this Agreement shall be construed in accordance with the laws of any state which precludes a requirement in an employee agreement to assign certain classes of inventions made by an employee, this Section&nbsp;3(b) shall be interpreted not to apply to any invention which a court rules and/or the Company agrees falls within such classes.&nbsp;&nbsp;The Employee also hereby waives all claims to moral rights in any Developments.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">The Employee agrees to cooperate fully with the Company, both during and after Employee&#x2019;s employment with the Company, with respect to the procurement, maintenance and enforcement of copyrights, patents and other intellectual property rights (both in the United States and foreign countries) relating to Developments.&nbsp;&nbsp;The Employee shall sign all papers, including, without limitation, copyright applications, patent applications, declarations, oaths, formal assignments, assignments of priority rights, and powers of attorney, which the Company may deem necessary or desirable in order to protect its rights and interests in any Development.&nbsp;&nbsp;The Employee further agrees that if the Company is unable, after reasonable effort, to secure the signature of the Employee on any such papers, any executive officer of the Company shall be entitled to execute any such papers as the agent and the attorney-in-fact of the Employee, and the Employee hereby irrevocably designates and appoints each executive officer of the Company as Employee&#x2019;s agent and attorney-in-fact to execute any such papers on Employee&#x2019;s behalf, and to take any and all actions as the Company may deem necessary or desirable in order to protect its rights and interests in any Development, under the conditions described in this sentence.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Obligations to Third Parties.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The Employee represents that, except as the Employee has disclosed in writing to the Company on </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Exhibit A</font><font style="display:inline;font-family:Times New Roman,Times,serif;"> attached hereto, the Employee is not bound by the terms of any agreement with any previous employer or other party to refrain from using or disclosing any trade secret or confidential or proprietary information in the course of Employee&#x2019;s employment with the Company, to refrain from competing, directly or indirectly, with the business of such previous employer or any other party or to refrain from soliciting employees, customers or suppliers of such previous employer or other party.&nbsp;&nbsp;The Employee further represents that Employee&#x2019;s performance of all the terms of this Agreement and the performance of Employee&#x2019;s duties as an employee of the Company do not and will not conflict with or breach any agreement with any prior employer or other party (including, without limitation, any nondisclosure or non-competition agreement), and that the Employee will not disclose to the Company or induce the Company to use any confidential or proprietary information or material belonging to any previous employer or others.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Scope of Disclosure Restrictions.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Nothing in this Agreement prohibits the Employee from communicating with government agencies about possible violations of federal, state, or local laws or otherwise providing information to government agencies, filing a complaint with government agencies, or participating in government agency investigations or proceedings.&nbsp;&nbsp;The Employee is not required</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">-21-</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">to notify the Company of any such communications; provided, however, that nothing herein authorizes the disclosure of information the Employee obtained through a communication that was subject to the attorney-client privilege.&nbsp;&nbsp;Further, notwithstanding the Employee&#x2019;s confidentiality and nondisclosure obligations, the Employee is hereby advised as follows pursuant to the Defend Trade Secrets Act: &#x201C;An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.&nbsp;&nbsp;An individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual (A) files any document containing the trade secret under seal; and (B) does not disclose the trade secret, except pursuant to court order.&#x201D;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">United States Government Obligations.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">The Employee acknowledges that the Company from time to time may have agreements with other persons or with the United States Government, or agencies thereof, which impose obligations or restrictions on the Company regarding inventions made during the course of work under such agreements or regarding the confidential nature of such work.&nbsp;&nbsp;The Employee agrees to be bound by all such obligations and restrictions which are made known to the Employee and to take all action necessary to discharge the obligations of the Company under such agreements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Miscellaneous.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Equitable Remedies</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;The Employee acknowledges that the restrictions contained in this Agreement are necessary for the protection of the business and goodwill of the Company and are considered by the Employee to be reasonable for such purpose.&nbsp;&nbsp;The Employee agrees that any breach or threatened breach of this Agreement is likely to cause the Company substantial and irrevocable damage which is difficult to measure.&nbsp;&nbsp;Therefore, in the event of any such breach or threatened breach, the Employee agrees that the Company, in addition to such other remedies which may be available, shall have the right to obtain an injunction from a court restraining such a breach or threatened breach without posting a bond and the right to specific performance of the provisions of this Agreement and the Employee hereby waives the adequacy of a remedy at law as a defense to such relief.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Disclosure of this Agreement</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;The Employee hereby authorizes the Company to notify others, including but not limited to customers of the Company and any of the Employee&#x2019;s future employers or prospective business associates, of the terms and existence of this Agreement and the Employee&#x2019;s continuing obligations to the Company hereunder.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Not Employment Contract</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;The Employee acknowledges that this Agreement does not constitute a contract of employment, does not imply that the Company will continue Employee&#x2019;s employment for any period of time and does not change the at-will nature of Employee&#x2019;s employment.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">-22-</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Successors and Assigns</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;This Agreement shall be binding upon and inure to the benefit of both parties and their respective successors and assigns, including any corporation with which, or into which, the Company may be merged or which may succeed to the Company&#x2019;s assets or business, provided, however, that the obligations of the Employee are personal and shall not be assigned by Employee.&nbsp;&nbsp;The Employee expressly consents to be bound by the provisions of this Agreement for the benefit of the Company or any subsidiary or affiliate thereof to whose employ the Employee may be transferred without the necessity that this Agreement be re-signed at the time of such transfer.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Severability</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;In case any provision of this Agreement shall be invalid, illegal or otherwise unenforceable, the validity, legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Waivers</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;No delay or omission by the Company in exercising any right under this Agreement will operate as a waiver of that or any other right.&nbsp;&nbsp;A waiver or consent given by the Company on any one occasion is effective only in that instance and will not be construed as a bar to or waiver of any right on any other occasion.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Governing Law</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts (without reference to the conflicts of laws provisions thereof).&nbsp;&nbsp;Any action, suit, or other legal proceeding which is commenced to resolve any matter arising under or relating to any provision of this Agreement shall be commenced only in a court of the Commonwealth of Massachusetts (or, if appropriate, a federal court located within Massachusetts), and the Company and the Employee each consents to the jurisdiction of such a court.&nbsp;&nbsp;The Company and the Employee each hereby irrevocably waive any right to a trial by jury in any action, suit or other legal proceeding arising under or relating to any provision of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Entire Agreement; Amendment</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;This Agreement supersedes all prior agreements, written or oral, between the Employee and the Company relating to the subject matter of this Agreement.&nbsp;&nbsp;This Agreement may not be modified, changed or discharged in whole or in part, except by an agreement in writing signed by the Employee and the Company.&nbsp;&nbsp;The Employee agrees that any change or changes in Employee&#x2019;s duties, salary or compensation after the signing of this Agreement shall not affect the validity or scope of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Captions</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance of any section of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">[Remainder of Page Intentionally Left Blank]</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">-23-</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:10.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">THE EMPLOYEE ACKNOWLEDGES THAT HE/SHE HAS CAREFULLY READ THIS AGREEMENT AND UNDERSTANDS AND AGREES TO ALL OF THE PROVISIONS IN THIS AGREEMENT.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:05.00%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:43.02%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.98%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:48.00%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">EDITAS MEDICINE, INC.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:05.00%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:43.02%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.98%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:48.00%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:05.00%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:43.02%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.98%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:48.00%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:05.00%;background-color: #auto;height:4.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Date:</font></p>
				</td>
				<td valign="top" style="width:43.02%;border-bottom:1pt solid #000000 ;height:4.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.98%;height:4.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.84%;background-color: #auto;height:4.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">By:</font></p>
				</td>
				<td valign="top" style="width:44.16%;border-bottom:1pt solid #000000 ;background-color: #auto;height:4.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:05.00%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:43.02%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.98%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.84%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:44.16%;border-top:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:05.00%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:43.02%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.98%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.84%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:44.16%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:05.00%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:43.02%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.98%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.84%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:44.16%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:05.00%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Date:</font></p>
				</td>
				<td valign="top" style="width:43.02%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.98%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.84%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:44.16%;border-bottom:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:05.00%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:43.02%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.98%;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.84%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:44.16%;border-top:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Cynthia Collins</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;font-weight:bold;">SIGNATURE PAGE TO INVENTION AND NON-DISCLOSURE AGREEMENT</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">EXHIBIT A</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">LIST OF PRIOR INVENTIONS AND ORIGINAL WORKS OF AUTHORSHIP EXCLUDED</font>
		</p>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">UNDER SECTION 3(A) OR CONFLICTING AGREEMENTS DISCLOSED UNDER SECTION 4</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:20.00%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">TITLE</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.00%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:16.66%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">DATE</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:04.40%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:53.94%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">IDENTIFYING&nbsp;NUMBER&nbsp;OR&nbsp;BRIEF&nbsp;DESCRIPTION</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:20.00%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:05.00%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:16.66%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:04.40%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:53.94%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">Except as indicated above on this </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Exhibit A</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, I have no Prior Developments to disclose pursuant to Section 3(a) of this Agreement and no agreements to disclose pursuant to Section 4 of this Agreement.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:270.00pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="3" valign="top" style="width:270.00pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">EMPLOYEE:</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:270.00pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:18.00pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:252.00pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:270.00pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:18.00pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:252.00pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:270.00pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:18.00pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">By:</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:252.00pt;border-bottom:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:270.00pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:18.00pt;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:36.00pt;border-top:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Name:</font></p>
				</td>
				<td valign="bottom" style="width:216.00pt;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">EXHIBIT C</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;">NON-COMPETITION AND NON-SOLICITATION AGREEMENT</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">This Non-Competition and Non-Solicitation Agreement (the &#x201C;Agreement&#x201D;) is made between Editas Medicine, Inc., a Delaware corporation (hereinafter referred to collectively with its subsidiaries as the &#x201C;Company&#x201D;), and the undersigned employee (the &#x201C;Employee&#x201D;).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">For<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                "> good<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                "> consideration, including, without limitation, the employment of the Employee by the Company and,<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                "> with respect to the non-competition restrictions, the additional consideration set forth in Section 1(c), the Employee and the Company agree as follows:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Non-Competition</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">(a)</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the Restricted Period (as defined below), the Employee will not, in the Applicable Territory (as defined below), directly or indirectly, engage or assist others in engaging in any&nbsp;business or enterprise that is competitive with the Company&#x2019;s business, including but not limited to any<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                "> business or enterprise that develops, manufactures, markets, licenses, sells or provides any product or service that competes with any product or service developed, manufactured, marketed, licensed, sold or provided, or planned to be developed, manufactured, marketed, licensed, sold or provided by the Company (a &#x201C;Competitive Company&#x201D;), if the Employee would be performing a job or job duties or services for the Competitive Company that is or are similar to the job or job duties or services that the Employee performed for the Company at any time during the last two (2) years of the Employee&#x2019;s employment.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">(b)</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Certain</font><font style="display:inline;font-family:Times New Roman,Times,serif;"><img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                "></font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;"> Definitions</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;Solely for purposes of this Section 1:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                "> &#x201C;Restricted Period&#x201D; shall include the duration of the Employee&#x2019;s employment with the Company and the twelve (12) month period<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                "> thereafter; provided, however, that the<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                "> Restricted Period shall automatically<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> be<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> extended to two (2) years following the cessation of the Employee&#x2019;s employment if the Employee breaches a<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> fiduciary duty to the Company or the Employee unlawfully<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> takes,<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> physically or electronically, any property<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> belonging to the Company.&nbsp;&nbsp;Notwithstanding the foregoing, the Restricted Period shall end immediately upon the Employee&#x2019;s last day of employment with the Company if: (x)<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> the Company terminates the Employee&#x2019;s employment other than for Cause (as defined below); or (y) the Company notifies the Employee in<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> writing that it is waiving the post-employment restrictions set forth in this Section 1 (such notice to be provided no<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> later than the Employee&#x2019;s last day of employment or by the seventh (7</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-size:6pt;top:-4pt;position:relative;line-height:100%">th</font><font style="display:inline;font-family:Times New Roman,Times,serif;">) business day following an Employee&#x2019;s notice of resignation, if later).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#x201C;Applicable<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> Territory&#x201D; shall mean the geographic areas in which the<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> Employee provided services or had a material presence or influence at any time during<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> his/her last two<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> (2) years of employment.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">-2-</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:108pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#x201C;Cause&#x201D; shall have the same meaning as defined in the Company&#x2019;s Severance Benefits Plan.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">(c)</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Additional</font><font style="display:inline;font-family:Times New Roman,Times,serif;"><img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "></font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;"> Consideration for Non-Competition Restrictions</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> &nbsp;In exchange for the Employee&#x2019;s compliance with the restrictions set forth in this Section 1, and<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> as more fully set forth in the Employee&#x2019;s Offer<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> Letter to which this Agreement is attached, the Company, subject to approval of its Board of Directors where applicable, will grant the Employee the<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> Equity Awards under the Company&#x2019;s 2015 Stock Incentive<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> Plan.<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> The Employee understands and agrees that the above-stated consideration has been mutually agreed upon by the Company and the Employee, is fair and reasonable, and is sufficient consideration in exchange for the restrictions set forth in this Section&nbsp;1.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">9.</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Non-Solicitation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;">While the Employee is employed by the Company and for a period of twelve (12) months after the termination or cessation of such employment for any reason, the Employee will not directly or indirectly:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Either<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> alone or in association with others, solicit, divert or take away, or</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">attempt to divert or take away, the business or patronage of any of the actual or prospective clients, customers, accounts or business partners of the Company which were contacted, solicited, or served by the Company during the Employee&#x2019;s employment with the Company; or</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Either alone or in association with others (I) solicit, induce or attempt to</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">induce, any employee or independent contractor of the Company to terminate his or her employment or other engagement with the Company, or (II) hire or recruit, or attempt to hire or recruit, or engage or attempt to engage as an independent contractor, any person who was employed or otherwise engaged by the Company at any time during the term of the Employee&#x2019;s employment with the Company; </font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">provided</font><font style="display:inline;font-family:Times New Roman,Times,serif;">, that this clause (II) shall not apply to the recruitment or hiring or other engagement of any individual whose employment or other engagement with the Company ended at least six (6) months before the recruitment, hiring, or other engagement.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">(b)</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the Employee violates the provisions of any of the preceding paragraphs of this Section 2, the Employee shall continue to be bound by the restrictions set forth in such paragraph until a period of twelve (12) months has expired without any violation of such provisions.&nbsp;&nbsp;Further, the twelve (12) month post-employment restrictions set forth in this Section 2 shall be extended to two (2) years if the Employee breaches a<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> fiduciary duty to the Company or the Employee unlawfully takes, physically or electronically, any property belonging to the Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;text-decoration:underline;">Notice of New Employment</font><font style="display:inline;font-family:Times New Roman,Times,serif;">. The<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> Employee agrees that during any<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> period of time when the Employee is subject to restrictions pursuant to either Section 1 or Section 2, the Employee will notify<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> any prospective employer or entity for whom employee will act as a consultant (if the consulting engagement will exceed fifteen (15) hours) of the terms and existence of this Agreement and the Employee&#x2019;s continuing obligations to the Company</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">-3-</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">hereunder.<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> &nbsp;The Employee further agrees, during such period, to give notice to the Company of each new employment or consulting engagement (if the consulting engagement will exceed fifteen (15) hours) the Employee plans to undertake, at least ten (10) business days prior to beginning any such employment or engagement.&nbsp;&nbsp;The notice shall state the name and address of the individual, corporation, association or other entity or organization (&#x201C;Entity&#x201D;) for whom such activity is undertaken and the name of the Employee&#x2019;s position with the Entity.&nbsp;&nbsp;The Employee also agrees to provide the Company with other pertinent information concerning such employment or consultancy as the Company may reasonably request in order to determine the Employee&#x2019;s continued compliance with his/her obligations under this Agreement.&nbsp; </font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">The Company is aware that Employee has existing commitments, including as a member of the board of several companies and industry organizations and as a consultant through her consulting firm Cynthia Collins &amp; Associates LLC, all of which have been disclosed to the Board of Directors of the Company, and nothing in this agreement or any other agreement with the Company or Company policy is intended to prohibit or prevent her continued service with those engagements and, during the period Employee is employed by the Company, subject to Employee&#x2019;s compliance with applicable Company policies for approval by the Board (or a committee thereof), of similar board appointments in the future.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Miscellaneous</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">(a)</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Equitable Remedies</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> &nbsp;The Employee acknowledges that the restrictions contained in this Agreement are necessary for the protection of the business and goodwill of the Company and are considered by the Employee to be reasonable for such purpose.&nbsp;&nbsp;The Employee agrees that any breach or threatened breach of this Agreement is likely to cause the Company substantial and irrevocable damage which is difficult to measure.&nbsp;&nbsp;Therefore, in the event of any such breach or threatened breach, the Employee agrees that the Company, in addition to such other remedies which may be available, shall have the right to obtain an injunction from a court restraining such a breach or threatened breach without posting a bond and the right to specific performance of the provisions of this Agreement and the Employee hereby waives the adequacy of a remedy at law as a defense to such relief.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">(b)</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Obligations</font><font style="display:inline;font-family:Times New Roman,Times,serif;"><img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "></font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;"> to Third Parties</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;The Employee represents that, except as the Employee has disclosed in writing to the Company, the Employee is not bound by the terms of any agreement with any previous employer or other party to refrain from using or disclosing any trade secret or confidential or proprietary information in the course of his/her employment with the Company, to refrain from competing, directly or indirectly, with the business of such previous employer or any other party, or to refrain from soliciting employees, customers or suppliers of such previous employer or other party.&nbsp;&nbsp;The Employee further represents that his/her performance of all the terms of this Agreement and the performance of his/her duties as an employee of the Company does not and will not conflict with or breach any agreement with any prior employer or other party (including, without limitation, any nondisclosure or non-competition agreement), and that the Employee will not disclose to the Company or induce the Company to use any confidential or proprietary information or material belonging to any previous employer or others.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">-4-</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Not Employment Contract</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;The Employee acknowledges that this Agreement does not constitute a contract of employment, does not imply that the Company will continue his/her employment for any period of time, and does not change the at-will nature of his/her employment.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">(d)</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Acknowledgments</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;The<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> Employee acknowledges that she was provided this Agreement by the earlier of the date of (x) a formal offer of employment, and (y) ten (10) business days prior to the Employee&#x2019;s commencement of employment with the Company.&nbsp;&nbsp;The Employee further acknowledges that she has the right to consult with counsel prior to signing this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">(e)</font><font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Successors</font><font style="display:inline;font-family:Times New Roman,Times,serif;"><img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "></font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;"> and Assigns</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> &nbsp;This Agreement shall be binding upon and inure to the benefit of both parties and their respective successors and assigns, including any corporation with which, or into which, the Company may be merged or which may succeed to the Company&#x2019;s assets or business, provided, however, that the obligations of the Employee are personal and shall not be assigned by her.&nbsp;&nbsp;The Employee expressly consents to be bound by the provisions of this Agreement for the benefit of the Company or any subsidiary or affiliate thereof to whose employ the Employee may be transferred without the necessity that this Agreement be re-signed at the time of such transfer.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Interpretation</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;If any restriction or definition set forth in Section 1 or Section 2 is found by any court of competent jurisdiction to be unenforceable because it extends for too long a period of time or over too great a range of conduct, activities, or geographic area, it shall be interpreted to extend only over the maximum period of time, range of conduct, activities or geographic area as to which it may be enforceable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Severability</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;In case any provision of this Agreement shall be invalid, illegal or otherwise unenforceable, the validity, legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Waivers</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;No delay or omission by the Company in exercising any right under this Agreement will operate as a waiver of that or any other right.&nbsp;&nbsp;A waiver or consent given by the Company on any one occasion is effective only in that instance and will not be construed as a bar to or waiver of any right on any other occasion.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Tax Withholding; Section 409A</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;Any compensatory payments under or referred to in this Agreement will be subject to all required tax and other withholdings.&nbsp;&nbsp;This<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> Agreement is intended to comply with or be exempt from the provisions of Section 409A of the Internal Revenue Code of 1986, as amended (&#x201C;Section 409A&#x201D;) and the Agreement will, to the extent practicable, be construed in accordance therewith.&nbsp;&nbsp;Terms defined in this Agreement will have the meanings given such terms under Section 409A if and to the extent required to comply with Section 409A and a termination of employment will mean a &#x201C;separation from service&#x201D; as defined in Section 409A. For<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> purposes of this Agreement, each amount to be paid or benefit to be provided, including a series of installment payments, will be construed as a separate identified payment for purposes of Section 409A.&nbsp;&nbsp;If and to the extent any portion of any payment,</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;"></font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">-5-</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">compensation or other benefit provided to the<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> Employee in<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> connection with his/her separation from service (as defined in Section 409A) is determined to constitute &#x201C;nonqualified deferred compensation&#x201D; within the meaning of Section 409A and the Employee is a<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> specified employee as defined in Section 409A(a)(2)(B)(i) of the Code, as determined by the Company in accordance with its procedures, by which determination the<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> Employee hereby agrees that she<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> is bound, such portion of the payment, compensation or other benefit will not be paid before the earlier of (i) the day that is six months plus one day after the date of separation from service (as determined under Section 409A) or (ii) the tenth day after the date of his/her death (as applicable, the &#x201C;New Payment Date&#x201D;).&nbsp;&nbsp;The aggregate of any payments that otherwise would have been paid to the<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> Employee during the period between the date of separation from service and the New Payment Date will be paid to the Employee in a lump sum in the first payroll period beginning after such New Payment Date (or, with respect to payment after death, as soon as reasonably practicable and within the time limits permitted by Section 409A), and any remaining payments will be paid on their original schedule.&nbsp;&nbsp;In any event, the Company makes no representations or warranty and will have no liability to the Employee or any other person if any provisions of or payments under this Agreement are determined to constitute deferred compensation subject to Section 409A but not to satisfy the conditions of that section</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Governing Law and Consent To Jurisdiction</font><font style="display:inline;font-family:Times New Roman,Times,serif;">.&nbsp;&nbsp;This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts (without reference to the conflicts of laws provisions thereof).&nbsp;&nbsp;Any action, suit, or other legal proceeding which is commenced to resolve any matter arising under or relating to any provision of this Agreement shall be commenced only in a court in<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> Suffolk County, Massachusetts (or, if appropriate, a federal court located within Massachusetts), and the Company and the Employee each consents to the jurisdiction of such courts.<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> &nbsp;The Company and the Employee each hereby irrevocably waives any<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> right to a trial by jury in any action, suit or other legal proceeding arising under or relating to any provision of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Entire Agreement; Amendment</font><font style="display:inline;font-family:Times New Roman,Times,serif;">. This Agreement supersedes all prior agreements, written or oral, between the Employee and the Company relating to the subject matter of this Agreement.&nbsp;&nbsp;This Agreement may not be modified, changed or discharged in whole or in part, except by an agreement in writing signed by the Employee and the Company.&nbsp;&nbsp;The Employee agrees that any change or changes in his/her duties, authority, title, reporting relationship, territory, salary or compensation after the signing of this Agreement shall not affect the validity or scope of this Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:72pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Captions</font><font style="display:inline;font-family:Times New Roman,Times,serif;">. The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance of any section of this Agreement.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">[</font><font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;">Remainder of Page Intentionally Left Blank</font><font style="display:inline;font-family:Times New Roman,Times,serif;">]</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">-6-</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">THE<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> EMPLOYEE ACKNOWLEDGES THAT SHE HAS CAREFULLY READ THIS AGREEMENT AND UNDERSTANDS AND AGREES TO ALL OF THE PROVISIONS IN THIS AGREEMENT.</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td colspan="2" valign="top" style="width:252.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:18.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:269.45pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">EMPLOYEE</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:252.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:18.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:269.45pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:27.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Date:</font></p>
				</td>
				<td valign="top" style="width:225.00pt;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:18.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:269.45pt;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:252.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:18.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:35.45pt;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Name:<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "></font></p>
				</td>
				<td valign="top" style="width:234.00pt;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Cynthia<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> Collins</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:252.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:18.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:35.45pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:234.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:252.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:18.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:35.45pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:234.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:252.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:18.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:269.45pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">EDITAS<img src="ex-10d1g002.jpg" style="width: 0.01041667in; height: 0.01041667in" alt="                 "> MEDICINE, INC. </font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:252.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:18.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:269.45pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:27.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Date:</font></p>
				</td>
				<td valign="top" style="width:225.00pt;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:18.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:35.45pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">By:</font></p>
				</td>
				<td valign="top" style="width:234.00pt;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:252.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:18.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:35.45pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Name:</font></p>
				</td>
				<td valign="top" style="width:234.00pt;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:252.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:18.55pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:35.45pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Title:</font></p>
				</td>
				<td valign="top" style="width:234.00pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:avoid;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ex-10d2.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.4.0.81-->
<!--Created on: 11/12/2019 2:01:29 PM-->
<html>
	<head>
		<title>
			edit_Ex10_2
		</title>
	</head>
	<body><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#23252D;font-size:11pt;">EXHIBIT 10.2</font>
		</p>
		<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td rowspan="4" valign="bottom" style="width:275.20pt;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;"><img src="ex-10d2g002.jpg" style="width: 1.208333in; height: 0.5927942in" alt="Picture 1"></font></p>
				</td>
				<td valign="bottom" style="width:269.30pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">11 Hurley Street</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:269.30pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Cambridge, MA 02141</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:269.30pt;padding:0pt;">
					<p style="margin:4pt 0pt 0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#DB812E;font-size:8pt;">P</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> 617-401-9000</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:269.30pt;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#DB812E;font-size:8pt;">F</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> 617-494-0985</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:11pt;text-decoration:underline;">VIA HAND DELIVERY</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">September 26, 2019</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">Vic Myer, Ph.D.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">Dear Vic,</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">As we discussed, your employment with </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Editas Medicine </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">(the &#x201C;Company&#x201D;) will end effective October 7, 2019 (the &#x201C;Separation Date&#x201D;).&nbsp;&nbsp;As we also discussed, as part of your separation with the Company, the Company will pay the Benefits (as defined in paragraph 1 below) if you sign and return this letter agreement to me by September 30, 2019 and provided further that you sign and return the Additional Release of Claims attached hereto as Exhibit A (the &#x201C;Additional Release&#x201D;) no later than October 18, 2019 (but no earlier than the Separation Date), and do not revoke your agreement thereto (as described below).&nbsp;&nbsp;By timely signing and returning this letter agreement and, by timely signing, returning, and not revoking your acceptance of the Additional Release, you will be entering into binding agreements with the Company and will be agreeing to the terms and conditions set forth in the numbered paragraphs below, including the releases of claims set forth in paragraph 2 and in the Additional Release.&nbsp;&nbsp;Therefore, you are advised to consult with an attorney before signing this letter agreement and the Additional Release and you have been given at least twenty-one (21) days to do so.&nbsp;&nbsp;If you sign the Additional Release, you may change your mind and revoke your agreement during the seven (7) day period after you have signed it (the &#x201C;Revocation Period&#x201D;) by notifying me in writing.&nbsp;&nbsp;If you do not so revoke, the Additional Release will become a binding agreement between you and the Company upon the expiration of the Revocation Period.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">Although your receipt of the Benefits is expressly conditioned on your entering into this letter agreement and the Additional Release, the following will apply regardless of whether or not you do so:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent: -18pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Symbol;color:#000000;">&#xF0B7;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of the Separation Date, all salary payments from the Company will cease and any benefits you had as of the Separation Date under Company-provided benefit plans, programs, or practices will terminate, except as required by federal or state law.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent: -18pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Symbol;color:#000000;">&#xF0B7;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You will receive payment for your final wages through the Separation Date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent: -18pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Symbol;color:#000000;">&#xF0B7;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You may, if eligible and at your own cost, elect to continue receiving group medical and dental insurance pursuant to the &#x201C;COBRA&#x201D; law.&nbsp; You will be sent a COBRA qualifying notice under separate cover and subsequent notices as&nbsp;required by applicable law or regulation.&nbsp;&nbsp;Your costs to continue the coverage will be set forth in these notices.&nbsp;&nbsp;The &#x201C;qualifying event&#x201D; under COBRA shall be deemed to have occurred on the Separation Date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent: -18pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Symbol;color:#000000;">&#xF0B7;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You are obligated to keep confidential and not to use or disclose any and all non-public information concerning the Company that you acquired during the course of your employment with the Company, including any non-public information concerning the Company&#x2019;s business affairs, business prospects, and financial </font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt 0pt 6pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;"><img src="ex-10d2g001.jpg" style="width: 1.208333in; height: 0.5927942in" alt="Picture 2"></font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">condition, except as otherwise permitted by paragraph 10 below.&nbsp;&nbsp;Further, you remain subject to your continuing confidentiality, non-competition, and non-solicitation obligations to the Company as set forth in the Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment Agreement you previously executed on November 5, 2015 for the benefit of the Company, which remain in full force and effect.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent: -18pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Symbol;color:#000000;">&#xF0B7;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You must return to the Company no later than the Separation Date all Company property.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent: -18pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Symbol;color:#000000;">&#xF0B7;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You will have three (3) months following the Separation Date to exercise any stock options under the Company&#x2019;s 2013 Stock Incentive Plan and 2015 Stock Incentive Plan that were vested as of the Separation Date.&nbsp;&nbsp;After that three (3) month period, your stock options will expire and you will no longer have any rights with respect thereto.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">If you elect to timely sign and return this letter agreement and the Additional Release and do not revoke it within the Revocation Period, the following terms and conditions will also apply:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:11pt;text-decoration:underline;">Separation Benefits</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;"> &nbsp;&#x2013;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> The Company will provide you with the following separation benefits (the &#x201C;Benefits&#x201D;):</font>
		</p>
		<p style="margin:0pt 0pt 12pt 108pt;text-indent: -18pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">a.&nbsp;&nbsp;&nbsp;Separation Pay</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;The Company will pay to you an amount equivalent to twelve (12) months of your current base salary, less all applicable taxes and withholdings. &nbsp;This separation pay will be paid in installments in accordance with the Company&#x2019;s regular payroll practices, but in no event shall payments begin earlier than the Company&#x2019;s first payroll date following expiration of the Revocation Period.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 108pt;text-indent: -18pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;">b.&nbsp;&nbsp;&nbsp;COBRA Benefits</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">.&nbsp;&nbsp;Should you timely elect and be eligible to continue receiving group health insurance pursuant to the &#x201C;COBRA&#x201D; law, the Company will, until the earlier of (x) the date that is twelve (12) months following the Separation Date, and (y) the date on which you obtain alternative coverage (as applicable, the &#x201C;COBRA Contribution Period&#x201D;), continue to pay the share of the premiums for such coverage to the same extent it was paying such premiums on your behalf immediately prior to the Separation Date.&nbsp;&nbsp;The remaining balance of any premium costs during the COBRA Contribution Period, and all premium costs thereafter, shall be paid by you on a monthly basis for as long as, and to the extent&nbsp;that, you remain eligible for COBRA continuation.&nbsp; You agree that, should you obtain alternative medical and/or dental insurance coverage prior to the date that is twelve (12) months following the Separation Date, you will so inform the Company in writing within five (5) business days of obtaining such coverage.</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">Page 2 of 10</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt 0pt 6pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;"><img src="ex-10d2g001.jpg" style="width: 1.208333in; height: 0.5927942in" alt="Picture 2"></font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">You will not be eligible for, nor shall you have a right to receive, any payments or benefits from the Company following the Separation Date other than as set forth in this paragraph.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:11pt;text-decoration:underline;">Release of Claims</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;"> &#x2013; In consideration of the Benefits, which you acknowledge you would not otherwise be entitled to receive, you hereby fully, forever, irrevocably and unconditionally release, remise and discharge the Company, its affiliates, subsidiaries, parent companies, predecessors, and successors, and all of their respective past and present officers, directors, stockholders, partners, members, employees, agents, representatives, plan administrators, attorneys, insurers and fiduciaries (each in their individual and corporate capacities) (collectively, the &#x201C;Released Parties&#x201D;) from any and all claims, charges, complaints, demands, actions, causes of action, suits, rights, debts, sums of money, costs, accounts, reckonings, covenants, contracts, agreements, promises, doings, omissions, damages, executions, obligations, liabilities, and expenses (including attorneys&#x2019; fees and costs), of every kind and nature that you ever had or now have against any or all of the Released Parties, whether known or unknown, including, but not limited to:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent: -18pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:11pt;">(i) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;"> any and all claims arising out of or relating to your employment with and/or separation from the Company, including, but not limited to, all claims under Title VII of the Civil Rights Act, the Americans With Disabilities Act, the Genetic Information Nondiscrimination Act, the Family and Medical Leave Act, the Worker Adjustment and Retraining Notification Act, the Rehabilitation Act, Executive Order 11246, Executive Order 11141, the Fair Credit Reporting Act, and the Employee Retirement Income Security Act, all as amended; all claims arising out of the Massachusetts Fair Employment Practices Act, Mass. Gen. Laws ch. 151B, &#xA7; 1 </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;text-decoration:underline;">et seq.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">, the Massachusetts Wage Act, Mass. Gen. Laws ch. 149, &#xA7; 148 </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;text-decoration:underline;">et seq.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;"> (Massachusetts law regarding payment of wages and overtime), the Massachusetts Civil Rights Act, Mass. Gen. Laws ch. 12, &#xA7;&#xA7; 11H and 11I, the Massachusetts Equal Rights Act, Mass. Gen. Laws. ch. 93, &#xA7; 102, Mass. Gen. Laws ch. 214, &#xA7; 1C (Massachusetts right to be free from sexual harassment law), the Massachusetts Labor and Industries Act, Mass. Gen. Laws ch. 149, &#xA7; 1 </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;text-decoration:underline;">et seq.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">, Mass. Gen. Laws ch. 214, &#xA7; 1B (Massachusetts right of privacy law), the Massachusetts Maternity Leave Act, Mass. Gen. Laws ch. 149, &#xA7; 105D, and the Massachusetts Small Necessities Leave Act, Mass. Gen. Laws ch. 149, &#xA7; 52D, all as amended;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent: -18pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:11pt;">(ii)&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">all common law claims including, but not limited to, actions in defamation, intentional infliction of emotional distress, misrepresentation, fraud, wrongful discharge, and breach of contract;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent: -18pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:11pt;">(iii) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">all claims to any non-vested ownership interest in the Company, contractual or otherwise;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent: -18pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:11pt;">(iv) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">all state and federal whistleblower claims to the maximum extent permitted by law; and</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">Page 3 of 10</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt 0pt 6pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;"><img src="ex-10d2g001.jpg" style="width: 1.208333in; height: 0.5927942in" alt="Picture 2"></font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent: -18pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:11pt;">(v)&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">any claim or damage arising out of your employment with and/or separation from the Company (including a claim for retaliation) under any common law theory or any federal, state or local statute or ordinance not expressly referenced above;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 54pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;color:#000000;font-size:11pt;">provided, however, that this release of claims does not prevent you from filing a charge with, cooperating with, or participating in any investigation or proceeding before, the Equal Employment Opportunity Commission or a state fair employment practices agency (except that you acknowledge that you may not recover any monetary benefits in connection with any such charge, investigation, or proceeding, and you further waive any rights or claims to any payment, benefit, attorneys&#x2019; fees or other remedial relief in connection with any such charge, investigation or proceeding).</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:11pt;text-decoration:underline;">Restricted Stock Acknowledgment</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;"> &#x2013; You acknowledge and agree that, effective as of the Separation Date, the Restricted Stock Unit granted to you effective as of January 31, 2019 under the 2015 Stock Incentive Plan will be forfeited, no shares will vest thereunder and you will have no rights with respect to any shares of Company common stock issuable thereunder.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Continuing Obligations</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;"> &#x2013; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">You acknowledge and reaffirm your confidentiality and non-disclosure obligations discussed on the first page of this letter agreement, as well as the obligations set forth in the </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment Agreement executed on November 5, 2015</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">, which survive your separation from employment with the Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:11pt;text-decoration:underline;">Non-Disparagement</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;"> &#x2013; You understand and agree that, to the extent permitted by law and except as otherwise permitted by paragraph 10 below, you will not, in public or private, make any false, disparaging, derogatory or defamatory statements, online </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">(including, without limitation, on any social media, networking, or employer review site) or otherwise, to any person or entity, including, but not limited to, any media outlet, industry group, financial institution</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;"> or current or former employee, board member, consultant, client or customer of the Company, regarding the Company or any of the other Released Parties, or regarding the Company&#x2019;s business affairs, business prospects, or financial condition.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:11pt;text-decoration:underline;">Company Affiliation</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;"> &#x2013; You agree that, following the Separation Date, you will not hold yourself out as an officer, employee, or otherwise as a representative of the Company, and you agree to update any directory information that indicates you are currently affiliated with the Company.&nbsp; Without limiting the foregoing, you confirm that, within ten (10) days following the Separation Date, you will update any and all social media accounts (including, without limitation, LinkedIn, Facebook, Twitter and Four Square) to reflect that you are no longer employed by or associated with the Company.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:11pt;text-decoration:underline;">Return of Company Property</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;"> &#x2013; You confirm that you have returned to the Company all keys, files, records (and copies thereof), equipment (including, but not limited to, computer hardware, software, printers, flash drives and other storage devices, wireless handheld devices, cellular phones, tablets, etc.), Company identification, and any other Company owned property in your possession or control, and that you have left </font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">Page 4 of 10</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt 0pt 6pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;"><img src="ex-10d2g001.jpg" style="width: 1.208333in; height: 0.5927942in" alt="Picture 2"></font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">intact all, and have otherwise not destroyed, deleted, or made inaccessible to the Company any, electronic Company documents, including, but not limited to, those that you developed or helped to develop during your employment, and that you have not (a) retained any copies in any form or media; (b) maintained access to any copies in any form, media, or location; (c) stored any copies in any physical or electronic locations that are not readily accessible or not known to the Company or that remain accessible to you; or (d) sent, given, or made accessible any copies to any persons or entities that the Company has not authorized to receive such electronic or hard copies. You further confirm that you have cancelled all accounts for your benefit, if any, in the Company&#x2019;s name, including but not limited to, credit cards, telephone charge cards, cellular phone accounts, and computer accounts.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:11pt;text-decoration:underline;">Business Expenses and Final Compensation</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;"> &nbsp;&#x2013; You acknowledge that you have been reimbursed by the Company for all business expenses incurred in conjunction with the performance of your employment and that no other reimbursements are owed to you.&nbsp;&nbsp;You further acknowledge that you have received payment in full for all services rendered in conjunction with your employment by the Company, including payment for all wages, bonuses, and commissions, that no other compensation is owed to you except as provided herein.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:11pt;text-decoration:underline;">Confidentiality</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;"> &#x2013; You understand and agree that, to the extent permitted by law and except as otherwise permitted by paragraph 10 below, the terms and contents of this letter agreement, and the contents of the negotiations and discussions resulting in this letter agreement, shall be maintained as confidential by you and your agents and representatives and shall not be disclosed except as otherwise agreed to in writing by the Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:11pt;text-decoration:underline;">Scope of Disclosure Restrictions</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;"> &#x2013; Nothing in this letter agreement prohibits you from communicating with government agencies about possible violations of federal, state, or local laws or otherwise providing information to government agencies, filing a complaint with government agencies, or participating in government agency investigations or proceedings.&nbsp;&nbsp;You are not required to notify the Company of any such communications; provided, however, that nothing herein authorizes the disclosure of information you obtained through a communication that was subject to the attorney-client privilege.&nbsp;&nbsp;Further, notwithstanding your confidentiality and nondisclosure obligations, you are hereby advised as follows pursuant to the Defend Trade Secrets Act: &#x201C;An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.&nbsp;&nbsp;An individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the&nbsp;attorney of the individual and use the trade secret information in the court proceeding, if the individual (A) files any document containing the trade secret under seal; and (B) does not disclose the trade secret, except pursuant to court order.&#x201D;</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">Page 5 of 10</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt 0pt 6pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;"><img src="ex-10d2g001.jpg" style="width: 1.208333in; height: 0.5927942in" alt="Picture 2"></font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:11pt;text-decoration:underline;">Cooperation</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;"> &#x2013; You agree that, to the extent permitted by law, you shall cooperate fully with the Company in the investigation, defense or prosecution of any claims or actions which already have been brought, are currently pending, or which may be brought in the future against the Company by a third party or by or on behalf of the Company against any third party, whether before a state or federal court, any state or federal government agency, or a mediator or arbitrator.&nbsp;&nbsp;Your full cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with the Company&#x2019;s counsel, at reasonable times and locations designated by the Company, to investigate or prepare the Company&#x2019;s claims or defenses, to prepare for trial or discovery or an administrative hearing, mediation, arbitration or other proceeding and to act as a witness when requested by the Company.&nbsp; You further agree that, to the extent permitted by law, you will notify the Company promptly in the event that you are served with a subpoena (other than a subpoena issued by a government agency), or in the event that you are asked to provide a third party (other than a government agency) with information concerning any actual or potential complaint or claim against the Company.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-size:11pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:11pt;text-decoration:underline;">Amendment and Waiver</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;"> &#x2013; This letter agreement shall be binding upon the parties and may not be modified in any manner, except by an instrument in writing of concurrent or subsequent date signed by duly authorized representatives of the parties hereto.&nbsp;&nbsp;This letter agreement is binding upon and shall inure to the benefit of the parties and their respective agents, assigns, heirs, executors, successors and administrators.&nbsp;&nbsp;No delay or omission by the Company in exercising any right under this letter agreement shall operate as a waiver of that or any other right.&nbsp;&nbsp;A waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a bar to or waiver of any right on any other occasion.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:11pt;text-decoration:underline;">Validity</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;"> &#x2013; Should any provision of this letter agreement be declared or be determined by any court of competent jurisdiction to be illegal or invalid, the validity of the remaining parts, terms or provisions shall not be affected thereby and said illegal or invalid part, term or provision shall be deemed not to be a part of this letter agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:11pt;text-decoration:underline;">Nature of Agreement</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:11pt;"> &nbsp;&#x2013;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;"> You understand and agree that this letter agreement is a separation agreement and does not constitute an admission of liability or wrongdoing on the part of the Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Acknowledgments</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"> &#x2013; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">You acknowledge that you have been given a reasonable amount of time to consider this letter agreement, and at least twenty-one (21) days to consider the Additional Release, and that the Company is hereby advising you to consult with an attorney of your own choosing prior to signing the Additional Release.&nbsp;&nbsp;You understand that you may revoke this letter agreement for a period of seven (7) days after you sign the Additional Release by notifying me in writing, and the Additional Release shall not be effective or enforceable until the expiration of this seven (7) day revocation period.&nbsp;&nbsp;You understand and agree that by entering into the Additional Release, you are&nbsp;waiving any and all rights or claims you might have under the Age Discrimination in Employment Act, as amended by the Older Workers Benefit Protection Act, and that you will be receiving consideration beyond that to which you were previously entitled.</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">Page 6 of 10</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt 0pt 6pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;"><img src="ex-10d2g001.jpg" style="width: 1.208333in; height: 0.5927942in" alt="Picture 2"></font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Voluntary Assent</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;"> &#x2013; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">You affirm that no other promises or agreements of any kind have been made to or with you by any person or entity whatsoever to cause you to sign this letter agreement, and that you fully understand the meaning and intent of this letter agreement.&nbsp;&nbsp;You further state and represent that you have carefully read this letter agreement, understand the contents herein, freely and voluntarily assent to all of the terms and conditions hereof, and sign your name of your own free act.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:11pt;text-decoration:underline;">Applicable Law</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;"> &#x2013; This letter agreement shall be interpreted and construed by the laws of the Commonwealth of Massachusetts, without regard to conflict of laws provisions.&nbsp;&nbsp;You hereby irrevocably submit to and acknowledge and recognize the jurisdiction of the courts of the Commonwealth of Massachusetts, or if appropriate, a federal court located in the Commonwealth of Massachusetts (which courts, for purposes of this letter agreement, are the only courts of competent jurisdiction), over any suit, action or other proceeding arising out of, under or in connection with this letter agreement or the subject matter hereof.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:11pt;text-decoration:underline;">Entire Agreement</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;"> &#x2013; This letter agreement, including Exhibit A, the Additional Release, contains and constitutes the entire understanding and agreement between the parties hereto with respect to your Benefits and the settlement of claims against the Company and cancels all previous oral and written negotiations, agreements, and commitments in connection therewith, including without limitation the letter agreement by and between you and the Company dated as of March 18, 2015, as amended, and the Company&#x2019;s Severance Benefits Plan.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:11pt;text-decoration:underline;">Tax Acknowledgement</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;"> &#x2013; In connection with the Benefits provided to you pursuant to this letter agreement, the Company shall withhold and remit to the tax authorities the amounts required under applicable law, and you shall be responsible for all applicable taxes with respect to such Benefits under applicable law.&nbsp;&nbsp;You acknowledge that you are not relying upon the advice or representation of the Company with respect to the tax treatment of any of the Benefits set forth in paragraph 1 of this letter agreement.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">If you have any questions about the matters covered in this letter agreement, please call me at 617-401-0118.</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:49.16%;background-color: #auto;height:13.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:50.84%;background-color: #auto;height:13.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">Very truly yours,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:49.16%;background-color: #auto;height:13.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:50.84%;background-color: #auto;height:13.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 12pt;color:#000000;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:49.16%;background-color: #auto;height:13.50pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:50.84%;background-color: #auto;height:13.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 12pt;color:#000000;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:49.16%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.34%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">By:</font></p>
				</td>
				<td valign="bottom" style="width:47.50%;border-bottom:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">/s/ Cynthia Collins</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:49.16%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.34%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:47.50%;border-top:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Cynthia Collins</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:49.16%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.34%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:47.50%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">President &amp; Chief Executive Officer</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">Page 7 of 10</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt 0pt 6pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;"><img src="ex-10d2g001.jpg" style="width: 1.208333in; height: 0.5927942in" alt="Picture 2"></font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">I hereby agree to the terms and conditions set forth above.&nbsp;&nbsp;I further understand that the consideration set forth in paragraph 1 is contingent upon my timely execution, return and non-revocation of the Additional Release, and that I am being given at least twenty-one (21) days to consider such Additional Release, and will have seven (7) days in which to revoke my acceptance after I sign such additional Release.</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:50.00%;border-bottom:1pt solid #000000 ;background-color: #auto;padding:0pt 0pt 0pt 0pt;height:12.60pt">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">/s/ Vic Myer</font></p>
				</td>
				<td valign="top" style="width:01.66%;height:12.60pt;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="width:48.34%;border-bottom:1pt solid #000000 ;background-color: #auto;padding:0pt 0pt 0pt 0pt;height:12.60pt">
					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">September 30, 2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;border-top:1pt solid #000000 ;background-color: #auto;padding:0pt 0pt 0pt 0pt;height:17.00pt">
					<p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">Vic Myer</font></p>
				</td>
				<td valign="top" style="width:01.66%;height:17.00pt;padding:0pt;">
					<p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:48.34%;border-top:1pt solid #000000 ;background-color: #auto;padding:0pt 0pt 0pt 0pt;height:17.00pt">
					<p style="margin:0pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">Date</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">To be returned in a timely manner as set forth on the first page of this letter agreement.</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">Page 8 of 10</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt 0pt 6pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;"><img src="ex-10d2g001.jpg" style="width: 1.208333in; height: 0.5927942in" alt="Picture 2"></font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Exhibit A</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">ADDITIONAL RELEASE OF CLAIMS</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Release</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &#x2013; In exchange for the consideration, including the Benefits (as defined in the Separation Agreement (as defined below)), set forth in the letter agreement dated September 26, 2019 between you (Vic Myer) and the Company (Editas Medicine, Inc.) to which this Additional Release of Claims (the &#x201C;Additional Release&#x201D;) is attached (the &#x201C;Separation Agreement&#x201D;), which you acknowledge you would not otherwise be entitled to receive, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">you hereby fully, forever, irrevocably and unconditionally release, remise and discharge the Company, its affiliates, subsidiaries, parent companies, predecessors, and successors, and all of their respective past and present officers, directors, stockholders, partners, members, employees, agents, representatives, plan administrators, attorneys, insurers and fiduciaries (each in their individual and corporate capacities) (collectively, the &#x201C;Released Parties&#x201D;) from any and all claims, charges, complaints, demands, actions, causes of action, suits, rights, debts, sums of money, costs, accounts, reckonings, covenants, contracts, agreements, promises, doings, omissions, damages, executions, obligations, liabilities, and expenses (including attorneys&#x2019; fees and costs), of every kind and nature that you ever had or now have against any or all of the Released Parties, whether known or unknown, including, but not limited to:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent: -18pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:11pt;">(i) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;"> any and all claims arising out of or relating to your employment with and/or separation from the Company, including, but not limited to, all claims under Title VII of the Civil Rights Act, the Americans With Disabilities Act, the Age Discrimination in Employment Act, the Genetic Information Nondiscrimination Act, the Family and Medical Leave Act, the Worker Adjustment and Retraining Notification Act, the Rehabilitation Act, Executive Order 11246, Executive Order 11141, the Fair Credit Reporting Act, and the Employee Retirement Income Security Act, all as amended; all claims arising out of the Massachusetts Fair Employment Practices Act, Mass. Gen. Laws ch. 151B, &#xA7; 1 </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;text-decoration:underline;">et seq.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">, the Massachusetts Wage Act, Mass. Gen. Laws ch. 149, &#xA7; 148 </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;text-decoration:underline;">et seq.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;"> (Massachusetts law regarding payment of wages and overtime), the Massachusetts Civil Rights Act, Mass. Gen. Laws ch. 12, &#xA7;&#xA7; 11H and 11I, the Massachusetts Equal Rights Act, Mass. Gen. Laws. ch. 93, &#xA7; 102, Mass. Gen. Laws ch. 214, &#xA7; 1C (Massachusetts right to be free from sexual harassment law), the Massachusetts Labor and Industries Act, Mass. Gen. Laws ch. 149, &#xA7; 1 </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;text-decoration:underline;">et seq.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">, Mass. Gen. Laws ch. 214, &#xA7; 1B (Massachusetts right of privacy law), the Massachusetts Maternity Leave Act, Mass. Gen. Laws ch. 149, &#xA7; 105D, and the Massachusetts Small Necessities Leave Act, Mass. Gen. Laws ch. 149, &#xA7; 52D, all as amended;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent: -18pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:11pt;">(ii)&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">all common law claims including, but not limited to, actions in defamation, intentional infliction of emotional distress, misrepresentation, fraud, wrongful discharge, and breach of contract;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent: -18pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:11pt;">(iii) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">all claims to any non-vested ownership interest in the Company, contractual or otherwise;</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:11pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">Page 9 of 10</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt 0pt 6pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;"><img src="ex-10d2g001.jpg" style="width: 1.208333in; height: 0.5927942in" alt="Picture 2"></font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent: -18pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:11pt;">(iv) </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">all state and federal whistleblower claims to the maximum extent permitted by law; and</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent: -18pt;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:11pt;">(v)&nbsp; </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:11pt;">any claim or damage arising out of your employment with and/or separation from the Company (including a claim for retaliation) under any common law theory or any federal, state or local statute or ordinance not expressly referenced above;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 54pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;color:#000000;font-size:11pt;">provided, however, that this release of claims does not prevent you from filing a charge with, cooperating with, or participating in any investigation or proceeding before, the Equal Employment Opportunity Commission or a state fair employment practices agency (except that you acknowledge that you may not recover any monetary benefits in connection with any such charge, investigation, or proceeding, and you further waive any rights or claims to any payment, benefit, attorneys&#x2019; fees or other remedial relief in connection with any such charge, investigation or proceeding).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Acknowledgments</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &#x2013; You acknowledge that you have been given at least twenty-one (21) days to consider this Additional Release, and that the Company advised you in writing to consult with an attorney of your own choosing prior to signing this Additional Release.&nbsp;&nbsp;You understand that you may revoke this Additional Release for a period of seven (7) days after you sign it by notifying me in writing, and the Additional Release shall not be effective or enforceable until the expiration of this seven (7) day revocation period.&nbsp;&nbsp;You understand and agree that by entering into this Additional Release, you are waiving any and all rights or claims you might have under the Age Discrimination in Employment Act, as amended by the Older Workers Benefit Protection Act, and that you have received consideration beyond that to which you were previously entitled.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:11pt;text-decoration:underline;">Voluntary Assent</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;"> &#x2013; You affirm that no other promises or agreements of any kind have been made to or with you by any person or entity whatsoever to cause you to sign this Additional Release, and that you fully understand the meaning and intent of this Additional Release.&nbsp;&nbsp;You state and represent that you have had an opportunity to fully discuss and review the terms of this Additional Release with an attorney.&nbsp;&nbsp;You further state and represent that you have carefully read this Additional Release, understand the contents herein, freely and voluntarily assent to all of the terms and conditions hereof, and sign your name of your own free act.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:11pt;">I hereby provide this Additional Release as of the current date and acknowledge that the execution of this Additional Release is in further consideration of the benefits described in the letter agreement to which this Additional Release is attached, to which I acknowledge I would not be entitled if I did not sign this Additional Release.&nbsp;&nbsp;I intend that this Additional Release will become a binding agreement between me and the Company if I do not revoke my acceptance in seven (7) calendar days.</font>
		</p>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:265.50pt;border-bottom:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt 0pt 1pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 1pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:261.00pt;border-bottom:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt 0pt 1pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:265.50pt;border-top:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt 0pt 1pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Vic Myer</font></p>
				</td>
				<td valign="bottom" style="width:13.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 1pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:261.00pt;border-top:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;">
					<p style="margin:0pt 0pt 1pt;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:11pt;">Date</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Arial,Helvetica,sans-serif;font-size: 11pt;">

			<font style="display:inline;font-size:11pt;">Page 10 of 10</font>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:avoid;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ex-31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.4.0.81-->
<!--Created on: 11/12/2019 2:01:33 PM-->
<html>
	<head>
		<title>
			edit_Ex31_1
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt 0pt 5pt;line-height:100%;text-align:right;font-family:Calibri;font-size: 11pt;">
			<font style="display:inline;font-weight:bold;">Exhibit 31.1</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;color:#000000;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
			<font style="display:inline;font-weight:bold;color:#000000;">CERTIFICATIONS</font>
		</p>
		<p style="margin:0pt 0pt 5pt;color:#000000;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
			<font style="display:inline;color:#000000;">I, Cynthia Collins, certify that:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;font-family:Calibri;line-height:107.92%;font-size: 11pt;margin:0pt 0pt 5pt;">
				<font style="margin:0pt 0pt 5pt;border-bottom:1pt none #D9D9D9;font-family:Calibri;line-height:107.92%;font-size:11pt;;"> 1.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;font-family:Calibri;line-height:107.92%;font-size: 11pt;margin:0pt 0pt 5pt;">
			<font style="display:inline;color:#000000;">I &nbsp;have reviewed this Quarterly Report on Form&nbsp;10-Q of Editas Medicine, Inc.;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 5pt;">
				<font style="margin:0pt 0pt 5pt;line-height:100%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Calibri;font-size:11pt;;"> 2.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 5pt;">
			<font style="display:inline;color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 5pt;">
				<font style="margin:0pt 0pt 5pt;line-height:100%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Calibri;font-size:11pt;;"> 3.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 5pt;">
			<font style="display:inline;color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 5pt;">
				<font style="margin:0pt 0pt 5pt;line-height:100%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Calibri;font-size:11pt;;"> 4.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 5pt;">
			<font style="display:inline;color:#000000;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e) and 15d-15(e))&nbsp;and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 5pt;">
				<font style="margin:0pt 0pt 5pt;line-height:100%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Calibri;font-size:11pt;;"> a.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 5pt;">
			<font style="display:inline;color:#000000;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 5pt;">
				<font style="margin:0pt 0pt 5pt;line-height:100%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Calibri;font-size:11pt;;"> b.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 5pt;">
			<font style="display:inline;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;line-height:100%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Calibri;font-size:11pt;;"> c.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 6pt;">
			<font style="display:inline;color:#000000;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 5pt;">
				<font style="margin:0pt 0pt 5pt;line-height:100%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Calibri;font-size:11pt;;"> d.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 5pt;">
			<font style="display:inline;color:#000000;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 5pt;">
				<font style="margin:0pt 0pt 5pt;line-height:100%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Calibri;font-size:11pt;;"> 5.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 5pt;">
			<font style="display:inline;color:#000000;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 5pt;">
				<font style="margin:0pt 0pt 5pt;line-height:100%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Calibri;font-size:11pt;;"> a.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 5pt;">
			<font style="display:inline;color:#000000;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:5pt 0pt 12pt;">
				<font style="margin:5pt 0pt 12pt;line-height:100%;border-top:1pt none #D9D9D9;font-family:Calibri;font-size:11pt;;"> b.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:5pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p></td></tr></table></div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;line-height:100%;margin-bottom:0pt;">
			<tr>
				<td valign="top" style="width:121.05pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:121.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:243.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:242.15pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">Date: November 12, 2019</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:18.85pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">By:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:225.00pt;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">/s/ Cynthia Collins</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:242.15pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:18.85pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:225.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">Cynthia Collins</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:242.15pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:18.85pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:225.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;font-style:italic;">Principal Executive Officer</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:242.15pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:18.85pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:225.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:avoid;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ex-31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.4.0.81-->
<!--Created on: 11/12/2019 2:01:34 PM-->
<html>
	<head>
		<title>
			edit_Ex31_2
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt 0pt 5pt;line-height:100%;text-align:right;font-family:Calibri;font-size: 11pt;">
			<font style="display:inline;font-weight:bold;">Exhibit 31.2</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;color:#000000;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
			<font style="display:inline;font-weight:bold;color:#000000;">CERTIFICATIONS</font>
		</p>
		<p style="margin:0pt 0pt 5pt;line-height:100%;color:#000000;font-family:Calibri;font-size: 11pt;">
			<font style="display:inline;color:#000000;">I, Eric Ek, certify that:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 5pt;">
				<font style="margin:0pt 0pt 5pt;line-height:100%;border-bottom:1pt none #D9D9D9;font-family:Calibri;font-size:11pt;;"> 1.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 5pt;">
			<font style="display:inline;color:#000000;">I &nbsp;have reviewed this Quarterly Report on Form&nbsp;10-Q of Editas Medicine, Inc.;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 5pt;">
				<font style="margin:0pt 0pt 5pt;line-height:100%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Calibri;font-size:11pt;;"> 2.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 5pt;">
			<font style="display:inline;color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 5pt;">
				<font style="margin:0pt 0pt 5pt;line-height:100%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Calibri;font-size:11pt;;"> 3.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 5pt;">
			<font style="display:inline;color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 5pt;">
				<font style="margin:0pt 0pt 5pt;line-height:100%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Calibri;font-size:11pt;;"> 4.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 5pt;">
			<font style="display:inline;color:#000000;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 5pt;">
				<font style="margin:0pt 0pt 5pt;line-height:100%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Calibri;font-size:11pt;;"> a.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 5pt;">
			<font style="display:inline;color:#000000;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 5pt;">
				<font style="margin:0pt 0pt 5pt;line-height:100%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Calibri;font-size:11pt;;"> b.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 5pt;">
			<font style="display:inline;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 5pt;">
				<font style="margin:0pt 0pt 5pt;line-height:100%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Calibri;font-size:11pt;;"> c.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 5pt;">
			<font style="display:inline;color:#000000;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 5pt;">
				<font style="margin:0pt 0pt 5pt;line-height:100%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Calibri;font-size:11pt;;"> d.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 5pt;">
			<font style="display:inline;color:#000000;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 5pt;">
				<font style="margin:0pt 0pt 5pt;line-height:100%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Calibri;font-size:11pt;;"> 5.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 5pt;">
			<font style="display:inline;color:#000000;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 5pt;">
				<font style="margin:0pt 0pt 5pt;line-height:100%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Calibri;font-size:11pt;;"> a.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 5pt;">
			<font style="display:inline;color:#000000;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;"><p style="width:54pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;line-height:100%;border-top:1pt none #D9D9D9;font-family:Calibri;font-size:11pt;;"> b.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;border-top:1pt none #D9D9D9 ;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p></td></tr></table></div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;line-height:100%;margin-bottom:0pt;">
			<tr>
				<td valign="top" style="width:242.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:243.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:242.35pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">Date: November 12, 2019</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">By:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:229.50pt;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">/s/ Eric Ek</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:242.35pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:229.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">Eric Ek</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:242.35pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:229.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;font-style:italic;">Principal Financial Officer</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:242.35pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:14.15pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:229.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:avoid;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ex-32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.4.0.81-->
<!--Created on: 11/12/2019 2:01:35 PM-->
<html>
	<head>
		<title>
			edit_Ex32_1
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt 0pt 8pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
			<font style="display:inline;font-weight:bold;">Exhibit 32.1</font>
		</p>
		<p style="margin:12pt 0pt 0pt;background-color: #FFFFFF;text-align:center;border-bottom:1pt none #D9D9D9 ;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;color:#000000;font-size:11pt;">CERTIFICATIONS OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350,</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;color:#000000;font-size:11pt;">AS ADOPTED PURSUANT TO</font>
		</p>
		<p style="margin:0pt 0pt 12pt;background-color: #FFFFFF;text-align:center;border-top:1pt none #D9D9D9 ;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;color:#000000;font-size:11pt;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font>
		</p>
		<p style="margin:0pt 0pt 8pt;color:#000000;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
			<font style="display:inline;color:#000000;background-color: #FFFFFF;">In connection with this Quarterly Report on Form 10-Q of Editas Medicine, Inc. (the &#x201C;Company&#x201D;) for the period ended September 30, 2019, as filed with the Securities and Exchange Commission on the date hereof (the &#x201C;Report&#x201D;), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. (section) 1350, as adopted pursuant to (section) 906 of the Sarbanes-Oxley Act of 2002, that to the best of her or his knowledge:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Calibri;line-height:107.92%;font-size: 11pt;margin:0pt 0pt 8pt;">
				<font style="margin:0pt 0pt 8pt;border-bottom:1pt none #D9D9D9;color:#000000;font-family:Calibri;line-height:107.92%;font-size:11pt;;"> (1)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Calibri;line-height:107.92%;font-size: 11pt;margin:0pt 0pt 8pt;">
			<font style="display:inline;color:#000000;background-color: #FFFFFF;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;color:#000000;font-family:Calibri;line-height:107.92%;font-size: 11pt;margin:0pt 0pt 8pt;">
				<font style="margin:0pt 0pt 8pt;border-top:1pt none #D9D9D9;color:#000000;font-family:Calibri;line-height:107.92%;font-size:11pt;;"> (2)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;color:#000000;font-family:Calibri;line-height:107.92%;font-size: 11pt;margin:0pt 0pt 8pt;">
			<font style="display:inline;color:#000000;background-color: #FFFFFF;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 8pt;color:#000000;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;line-height:100%;margin-bottom:0pt;">
			<tr>
				<td valign="top" style="width:241.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:244.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:241.90pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">Date: November 12, 2019</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.10pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">By:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:225.00pt;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">/s/ Cynthia Collins</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:241.90pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.10pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:225.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">Cynthia Collins</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:241.90pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.10pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:225.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">Principal Executive Officer</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:241.90pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:244.10pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:241.90pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:244.10pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:241.90pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">Date: November 12, 2019</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.10pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">By:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:225.00pt;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">/s/ Eric Ek</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:241.90pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.10pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:225.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">Eric Ek</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:241.90pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:19.10pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:225.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 11pt;">
						<font style="display:inline;">Principal Financial Officer</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;color:#000000;font-family:Calibri;line-height:107.92%;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:avoid;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex-10d1g001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex-10d1g001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
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M#8_*FW6HV5D0+N\@@)Z"60+G\Z\?MSH&D_%+1D\(W8\BXS'=11.6CR0<#)_
MU5\/#PS>ZWJB^/&;^V#<,%%VS*@7T&.G^&*+A8]OAGAN8Q)!+'+&>C1L&'YB
MI*X3PMX4CT;Q++?^']4@DT">+#VJRF3:_8@]/Z\FN[IB"BBB@ HHHH ****
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AHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex-10d1g002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex-10d1g002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /G^BBB@
##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ex-10d2g001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex-10d2g001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
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LL%%%%:&84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ex-10d2g002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex-10d2g002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
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LL%%%%:&84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>edit-20190930.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.4.7193.41938 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/12/2019 9:02:03 PM-->
<!--Modified on: 11/12/2019 9:02:03 PM-->
<xsd:schema targetNamespace="http://www.editasmedicine.com/20190930" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:attributeFormDefault="unqualified" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:edit="http://www.editasmedicine.com/20190930" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations" id="StatementCondensedConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" id="StatementCondensedConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>00300 - Statement - Condensed Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>00500 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails" id="DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails">
        <link:definition>40301 - Disclosure - Cash Equivalents, Marketable Securities and Corporate Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" id="DisclosureFairValueMeasurementsRecurringBasisDetails">
        <link:definition>40401 - Disclosure - Fair Value Measurements - Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureAccruedExpensesDetails" id="DisclosureAccruedExpensesDetails">
        <link:definition>40501 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails" id="DisclosurePropertyAndEquipmentNetDetails">
        <link:definition>40601 - Disclosure - Property and Equipment, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseCostsDetails" id="DisclosureCommitmentsAndContingenciesOperatingLeaseCostsDetails">
        <link:definition>40704 - Disclosure - Commitments and Contingencies - Operating Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails" id="DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails">
        <link:definition>40705 - Disclosure - Commitments and Contingencies - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetailsCalc2" id="DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetailsCalc2">
        <link:definition>40705 - Disclosure - Commitments and Contingencies - Maturities of Lease Liabilities (Details) (Calc 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" id="StatementCondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>00400 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" id="StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
        <link:definition>00405 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureNatureOfBusiness" id="DisclosureNatureOfBusiness">
        <link:definition>10101 - Disclosure - Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndEquitySecurities" id="DisclosureCashEquivalentsMarketableSecuritiesAndEquitySecurities">
        <link:definition>10301 - Disclosure - Cash Equivalents, Marketable Securities and Equity Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>10401 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureAccruedExpenses" id="DisclosureAccruedExpenses">
        <link:definition>10501 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNet" id="DisclosurePropertyAndEquipmentNet">
        <link:definition>10601 - Disclosure - Property and Equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>10701 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreements" id="DisclosureCollaborationAndLicenseAgreements">
        <link:definition>10801 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>10901 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>11001 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>11101 - Disclosure - Related-Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11201 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesTables" id="DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesTables">
        <link:definition>30303 - Disclosure - Cash Equivalents, Marketable Securities and Corporate Equity Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>30403 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
        <link:definition>30503 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetTables" id="DisclosurePropertyAndEquipmentNetTables">
        <link:definition>30603 - Disclosure - Property and Equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>30703 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>30903 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>31003 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureNatureOfBusinessDetails" id="DisclosureNatureOfBusinessDetails">
        <link:definition>40101 - Disclosure - Nature of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails">
        <link:definition>40201 - Disclosure - Summary Of Significant Accounting Policies - Recent Accounting Pronouncements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails" id="DisclosureCommitmentsAndContingenciesOperatingLeasesDetails">
        <link:definition>40701 - Disclosure - Commitments and Contingencies - Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesDerecognitionOfBalancesDetails" id="DisclosureCommitmentsAndContingenciesDerecognitionOfBalancesDetails">
        <link:definition>40702 - Disclosure - Commitments and Contingencies - Derecognition of Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesLicensorExpenseReimbursementDetails" id="DisclosureCommitmentsAndContingenciesLicensorExpenseReimbursementDetails">
        <link:definition>40706 - Disclosure - Commitments and Contingencies - Licensor Expense Reimbursement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesResearchFundingPaymentsDetails" id="DisclosureCommitmentsAndContingenciesResearchFundingPaymentsDetails">
        <link:definition>40707 - Disclosure - Commitments and Contingencies - Research Funding Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesNotesPayableDetails" id="DisclosureCommitmentsAndContingenciesNotesPayableDetails">
        <link:definition>40708 - Disclosure - Commitments and Contingencies - Notes Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognitionDetails" id="DisclosureCollaborationAndLicenseAgreementsRevenueRecognitionDetails">
        <link:definition>40801 - Disclosure - Collaboration and License Agreements - Revenue Recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsSummaryOfAgreementDetails" id="DisclosureCollaborationAndLicenseAgreementsSummaryOfAgreementDetails">
        <link:definition>40803 - Disclosure - Collaboration and License Agreements - Summary of Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureStockBasedCompensationExpenseDetails" id="DisclosureStockBasedCompensationExpenseDetails">
        <link:definition>40901 - Disclosure - Stock-based Compensation - Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" id="DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails">
        <link:definition>40902 - Disclosure - Stock-based Compensation - Restricted Stock and Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureNetLossPerShareDetails" id="DisclosureNetLossPerShareDetails">
        <link:definition>41001 - Disclosure - Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureRelatedPartyTransactionsDetails" id="DisclosureRelatedPartyTransactionsDetails">
        <link:definition>41101 - Disclosure - Related-Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>41201 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsTables" id="DisclosureCollaborationAndLicenseAgreementsTables">
        <link:definition>30803 - Disclosure - Collaboration and License Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesRightOfUseAssetAndLeaseLiabilityDetails" id="DisclosureCommitmentsAndContingenciesRightOfUseAssetAndLeaseLiabilityDetails">
        <link:definition>40703 - Disclosure - Commitments and Contingencies - Right of Use Asset and Lease Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilityDetails" id="DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilityDetails">
        <link:definition>40802 - Disclosure - Collaboration and License Agreements - Contract Assets and Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="edit-20190930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="edit-20190930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="edit-20190930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="edit-20190930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="edit_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element id="edit_ReclassificationOfLiabilityForFounderStockRepurchase" name="ReclassificationOfLiabilityForFounderStockRepurchase" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_StockIssuanceCostsIncurredButNotYetPaid" name="StockIssuanceCostsIncurredButNotYetPaid" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_AccruedIntellectualPropertyFees" name="AccruedIntellectualPropertyFees" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_FairValueAssetsAndLiabilitiesTransfers" name="FairValueAssetsAndLiabilitiesTransfers" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_FacilitySubleaseArrangementMember" name="FacilitySubleaseArrangementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_CommitmentToReimburseLicensorMember" name="CommitmentToReimburseLicensorMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_CollaborationAndLicenseAgreementMember" name="CollaborationAndLicenseAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_JunoTherapeuticsMember" name="JunoTherapeuticsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_ResearchProgramTerm" name="ResearchProgramTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_EmployeeAndDirectorMember" name="EmployeeAndDirectorMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_AreaOfLeasedSpace" name="AreaOfLeasedSpace" nillable="true" type="num:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_RentAndFacilityRelatedFeesMember" name="RentAndFacilityRelatedFeesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_BroadAndWageningenUniversityMember" name="BroadAndWageningenUniversityMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_StrategicAllianceMember" name="StrategicAllianceMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_AllerganMember" name="AllerganMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_NumberOfCollaborationDevelopmentPrograms" name="NumberOfCollaborationDevelopmentPrograms" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_HurleyStreetLeaseMember" name="HurleyStreetLeaseMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_CollaborativeArrangementsAbstract" name="CollaborativeArrangementsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_NumberOfAdditionalDevelopmentAndCommercializationLicenseToBePurchased" name="NumberOfAdditionalDevelopmentAndCommercializationLicenseToBePurchased" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_BroadInstituteIncMember" name="BroadInstituteIncMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_InitialNotesMember" name="InitialNotesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_ProcessAndPlatformDevelopmentCostsCurrent" name="ProcessAndPlatformDevelopmentCostsCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_CowenAndCompanyLlcMember" name="CowenAndCompanyLlcMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_DeferredRevenueAdjustmentFromEffectOfNewAccountingPrinciple" name="DeferredRevenueAdjustmentFromEffectOfNewAccountingPrinciple" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock" name="ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_ContractWithCustomerLiabilityAdditions" name="ContractWithCustomerLiabilityAdditions" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_ContractWithCustomerLiabilityDeductions" name="ContractWithCustomerLiabilityDeductions" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_StockIssuedForAssetAcquisition" name="StockIssuedForAssetAcquisition" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_ResearchFundingPaymentsMember" name="ResearchFundingPaymentsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_SponsoredResearchAgreementMember" name="SponsoredResearchAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_FundingPaymentsDueAndPayableOne" name="FundingPaymentsDueAndPayableOne" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_FundingPaymentsDueAndPayableTwo" name="FundingPaymentsDueAndPayableTwo" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_SublicensingAndSuccessPaymentExpenses" name="SublicensingAndSuccessPaymentExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_AccountsReceivableAdditions" name="AccountsReceivableAdditions" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_AccountsReceivableDeductions" name="AccountsReceivableDeductions" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock" name="ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_NoncashInvestmentInEquitySecurities" name="NoncashInvestmentInEquitySecurities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_MarketableSecuritiesUnrealizedGain" name="MarketableSecuritiesUnrealizedGain" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_MarketableSecuritiesUnrealizedLoss" name="MarketableSecuritiesUnrealizedLoss" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_MarketableSecuritiesAmortizedCost" name="MarketableSecuritiesAmortizedCost" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_IncreaseDecreaseInRightOfUseAssets" name="IncreaseDecreaseInRightOfUseAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_IncreaseDecreaseInRightOfUseLiability" name="IncreaseDecreaseInRightOfUseLiability" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_PublicAndAtMarketOfferingMember" name="PublicAndAtMarketOfferingMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_LesseeOperatingLeaseLaboratorySpaceNumber" name="LesseeOperatingLeaseLaboratorySpaceNumber" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_AtMarketOfferingMember" name="AtMarketOfferingMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_AssetsAndLiabilitiesLesseeOperatingLeaseTableTextBlock" name="AssetsAndLiabilitiesLesseeOperatingLeaseTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_StockIssuedDuringPeriodValueRepaymentOfNotes" name="StockIssuedDuringPeriodValueRepaymentOfNotes" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_StockIssuedDuringPeriodSharesRepaymentOfDebt" name="StockIssuedDuringPeriodSharesRepaymentOfDebt" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_ReceivableOfProceedsFromExerciseOfStockOptions" name="ReceivableOfProceedsFromExerciseOfStockOptions" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_ThresholdPeriodInterestFreeDebtInstrumentFaceAmount" name="ThresholdPeriodInterestFreeDebtInstrumentFaceAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_ProgramExpense" name="ProgramExpense" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_ShareOfExpenseRecognizedPercentage" name="ShareOfExpenseRecognizedPercentage" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_StockSalesAgreementThresholdSaleProceedsThatCanBeRaised" name="StockSalesAgreementThresholdSaleProceedsThatCanBeRaised" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_SharesIssuedWeightedAveragePricePerShare" name="SharesIssuedWeightedAveragePricePerShare" nillable="true" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_ProceedsFromIssuanceOfCommonStockGross" name="ProceedsFromIssuanceOfCommonStockGross" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_PercentageOfCashCommissionsPaid" name="PercentageOfCashCommissionsPaid" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_ProceedsFromIssuanceOfCommonStockReceivable" name="ProceedsFromIssuanceOfCommonStockReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_StockSalesAgreementAdditionalSaleProceedsThatCanBeRaised" name="StockSalesAgreementAdditionalSaleProceedsThatCanBeRaised" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_NumberOfOperatingLeasesForManufacturingSpace" name="NumberOfOperatingLeasesForManufacturingSpace" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_CollaborationAndLicenseAgreementAmendmentFeeReceived" name="CollaborationAndLicenseAgreementAmendmentFeeReceived" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_AtMarket2018MarchOfferingMember" name="AtMarket2018MarchOfferingMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="edit_ChiefMedicalOfficerMember" name="ChiefMedicalOfficerMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>edit-20190930_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.4.7193.41938 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/12/2019 9:02:03 PM-->
<!--Modified on: 11/12/2019 9:02:03 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#StatementCondensedConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails" roleURI="http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureFairValueMeasurementsRecurringBasisDetails" roleURI="http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureAccruedExpensesDetails" roleURI="http://www.editasmedicine.com/role/DisclosureAccruedExpensesDetails" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureCommitmentsAndContingenciesOperatingLeaseCostsDetails" roleURI="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseCostsDetails" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails" roleURI="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetailsCalc2" roleURI="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetailsCalc2" />
  <calculationLink xlink:role="http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Condensed Consolidated Balance Sheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637091893198407928" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_637091893198407928" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637091893198407928" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637091893198407928" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637091893198407928" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent_637091893198407928" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637091893198407928" xlink:to="us-gaap_MarketableSecuritiesCurrent_637091893198407928" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent_637091893198407928" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637091893198407928" xlink:to="us-gaap_ReceivablesNetCurrent_637091893198407928" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637091893198407928" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637091893198407928" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637091893198407928" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637091893198407928" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637091893198407928" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637091893198407928" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637091893198407928" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_637091893198407928" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_637091893198407928" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637091893198417918" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_637091893198417918" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637091893198417918" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637091893198417918" xlink:to="us-gaap_LiabilitiesCurrent_637091893198417918" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637091893198417918" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637091893198417918" xlink:to="us-gaap_AccountsPayableCurrent_637091893198417918" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637091893198417918" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637091893198417918" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637091893198417918" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637091893198417918" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637091893198417918" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637091893198417918" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637091893198417918" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637091893198417918" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637091893198417918" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_637091893198417918" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637091893198417918" xlink:to="us-gaap_OtherLiabilitiesCurrent_637091893198417918" order="5" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_637091893198427912" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637091893198417918" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_637091893198427912" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_637091893198427912" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637091893198417918" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_637091893198427912" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637091893198427912" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637091893198417918" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637091893198427912" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637091893198427912" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637091893198417918" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637091893198427912" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637091893198427912" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_637091893198427912" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637091893198427912" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637091893198427912" xlink:to="us-gaap_PreferredStockValue_637091893198427912" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637091893198427912" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637091893198427912" xlink:to="us-gaap_CommonStockValue_637091893198427912" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_637091893198427912" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637091893198427912" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_637091893198427912" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637091893198437916" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637091893198427912" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637091893198437916" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637091893198437916" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637091893198427912" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637091893198437916" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Condensed Consolidated Statements of Operations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637091893198437916" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_637091893198437916" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637091893198437916" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637091893198437916" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637091893198437916" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637091893198437916" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637091893198437916" xlink:to="us-gaap_OperatingExpenses_637091893198437916" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637091893198437916" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637091893198437916" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637091893198437916" order="1" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637091893198447906" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637091893198437916" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637091893198447906" order="2" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_637091893198447906" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense_637091893198447906" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637091893198447906" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_637091893198447906" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637091893198447906" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet_637091893198447906" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_637091893198447906" xlink:to="us-gaap_InvestmentIncomeNet_637091893198447906" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended" xlink:title="00300 - Statement - Condensed Consolidated Statements of Comprehensive Loss">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637091893198447906" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_637091893198447906" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_637091893198447906" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_637091893198447906" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - Condensed Consolidated Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637091893198447906" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637091893198447906" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637091893198447906" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637091893198447906" xlink:to="us-gaap_ProfitLoss_637091893198447906" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637091893198457918" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637091893198447906" xlink:to="us-gaap_ShareBasedCompensation_637091893198457918" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637091893198457918" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637091893198447906" xlink:to="us-gaap_Depreciation_637091893198457918" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_637091893198457918" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637091893198447906" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_637091893198457918" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_NoncashInvestmentInEquitySecurities" xlink:label="edit_NoncashInvestmentInEquitySecurities_637091893198457918" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637091893198447906" xlink:to="edit_NoncashInvestmentInEquitySecurities_637091893198457918" order="5" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense_637091893198457918" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637091893198447906" xlink:to="us-gaap_OtherNoncashIncomeExpense_637091893198457918" order="6" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637091893198457918" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637091893198447906" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637091893198457918" order="7" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637091893198457918" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637091893198447906" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637091893198457918" order="8" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_637091893198457918" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637091893198447906" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_637091893198457918" order="9" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_IncreaseDecreaseInRightOfUseAssets" xlink:label="edit_IncreaseDecreaseInRightOfUseAssets_637091893198457918" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637091893198447906" xlink:to="edit_IncreaseDecreaseInRightOfUseAssets_637091893198457918" order="10" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637091893198467902" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637091893198447906" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637091893198467902" order="11" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_637091893198467902" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637091893198447906" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_637091893198467902" order="12" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637091893198467902" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637091893198447906" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637091893198467902" order="13" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_IncreaseDecreaseInRightOfUseLiability" xlink:label="edit_IncreaseDecreaseInRightOfUseLiability_637091893198467902" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637091893198447906" xlink:to="edit_IncreaseDecreaseInRightOfUseLiability_637091893198467902" order="14" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_637091893198467902" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637091893198447906" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_637091893198467902" order="15" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637091893198467902" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637091893198467902" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637091893198467902" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637091893198467902" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637091893198467902" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_637091893198477902" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637091893198467902" xlink:to="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_637091893198477902" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_637091893198477902" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637091893198467902" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_637091893198477902" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_637091893198477902" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637091893198467902" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_637091893198477902" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637091893198477902" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637091893198477902" order="3" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637091893198477902" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637091893198477902" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637091893198477902" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637091893198477902" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637091893198477902" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637091893198477902" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans_637091893198477902" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637091893198477902" xlink:to="us-gaap_ProceedsFromStockPlans_637091893198477902" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_637091893198487922" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637091893198477902" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_637091893198487922" order="4" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Cash Equivalents, Marketable Securities and Corporate Equity Securities (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_637091893198487922" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_637091893198487922" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_637091893198487922" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_637091893198487922" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637091893198487922" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637091893198487922" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Fair Value Measurements - Recurring Basis (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637091893198487922" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637091893198487922" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_637091893198487922" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_637091893198487922" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.editasmedicine.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Accrued Expenses (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_637091893198497902" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_637091893198497902" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_AccruedIntellectualPropertyFees" xlink:label="edit_AccruedIntellectualPropertyFees_637091893198497902" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="edit_AccruedIntellectualPropertyFees_637091893198497902" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ProcessAndPlatformDevelopmentCostsCurrent" xlink:label="edit_ProcessAndPlatformDevelopmentCostsCurrent_637091893198497902" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="edit_ProcessAndPlatformDevelopmentCostsCurrent_637091893198497902" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_637091893198497902" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_637091893198497902" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_637091893198497902" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_637091893198497902" order="5" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_SublicensingAndSuccessPaymentExpenses" xlink:label="edit_SublicensingAndSuccessPaymentExpenses_637091893198497902" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="edit_SublicensingAndSuccessPaymentExpenses_637091893198497902" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Property and Equipment, net (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637091893198497902" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637091893198497902" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637091893198507917" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637091893198507917" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseCostsDetails" xlink:type="extended" xlink:title="40704 - Disclosure - Commitments and Contingencies - Operating Lease Costs (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_637091893198507917" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost_637091893198507917" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost_637091893198507917" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost_637091893198507917" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails" xlink:type="extended" xlink:title="40705 - Disclosure - Commitments and Contingencies - Maturities of Lease Liabilities (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_637091893198507917" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_637091893198507917" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637091893198507917" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637091893198507917" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637091893198507917" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637091893198507917" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637091893198507917" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637091893198507917" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637091893198517910" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637091893198517910" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_637091893198517910" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_637091893198517910" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetailsCalc2" xlink:type="extended" xlink:title="40705 - Disclosure - Commitments and Contingencies - Maturities of Lease Liabilities (Details) (Calc 2)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637091893198517910" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637091893198517910" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637091893198517910" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability_637091893198517910" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>edit-20190930_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.4.7193.41938 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/12/2019 9:02:03 PM-->
<!--Modified on: 11/12/2019 9:02:03 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#StatementConsolidatedStatementsOfStockholdersEquityParenthetical" roleURI="http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureNatureOfBusinessDetails" roleURI="http://www.editasmedicine.com/role/DisclosureNatureOfBusinessDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" roleURI="http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails" roleURI="http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureFairValueMeasurementsRecurringBasisDetails" roleURI="http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureCommitmentsAndContingenciesOperatingLeasesDetails" roleURI="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureCommitmentsAndContingenciesDerecognitionOfBalancesDetails" roleURI="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesDerecognitionOfBalancesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureCommitmentsAndContingenciesLicensorExpenseReimbursementDetails" roleURI="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesLicensorExpenseReimbursementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureCommitmentsAndContingenciesResearchFundingPaymentsDetails" roleURI="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesResearchFundingPaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureCommitmentsAndContingenciesNotesPayableDetails" roleURI="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesNotesPayableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureCollaborationAndLicenseAgreementsSummaryOfAgreementDetails" roleURI="http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsSummaryOfAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureStockBasedCompensationExpenseDetails" roleURI="http://www.editasmedicine.com/role/DisclosureStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" roleURI="http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureNetLossPerShareDetails" roleURI="http://www.editasmedicine.com/role/DisclosureNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://www.editasmedicine.com/role/DisclosureRelatedPartyTransactionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.editasmedicine.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" xmlns="http://www.xbrl.org/2003/linkbase" />
  <definitionLink xlink:role="http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Stockholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637091893198527916" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_637091893198527916" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_StockIssuedDuringPeriodValueRepaymentOfNotes" xlink:label="edit_StockIssuedDuringPeriodValueRepaymentOfNotes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="edit_StockIssuedDuringPeriodValueRepaymentOfNotes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_StockIssuedDuringPeriodSharesRepaymentOfDebt" xlink:label="edit_StockIssuedDuringPeriodSharesRepaymentOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="edit_StockIssuedDuringPeriodValueRepaymentOfNotes" xlink:to="edit_StockIssuedDuringPeriodSharesRepaymentOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="extended" xlink:title="00405 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637091893198557904" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637091893198557904" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.editasmedicine.com/role/DisclosureNatureOfBusinessDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Nature of Business (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_AtMarket2018MarchOfferingMember" xlink:label="edit_AtMarket2018MarchOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="edit_AtMarket2018MarchOfferingMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_PublicAndAtMarketOfferingMember" xlink:label="edit_PublicAndAtMarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="edit_PublicAndAtMarketOfferingMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637091893198587923" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637091893198587923" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_CowenAndCompanyLlcMember" xlink:label="edit_CowenAndCompanyLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="edit_CowenAndCompanyLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637091893198587923" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_637091893198587923" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_StockSalesAgreementThresholdSaleProceedsThatCanBeRaised" xlink:label="edit_StockSalesAgreementThresholdSaleProceedsThatCanBeRaised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="edit_StockSalesAgreementThresholdSaleProceedsThatCanBeRaised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_SharesIssuedWeightedAveragePricePerShare" xlink:label="edit_SharesIssuedWeightedAveragePricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="edit_SharesIssuedWeightedAveragePricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ProceedsFromIssuanceOfCommonStockGross" xlink:label="edit_ProceedsFromIssuanceOfCommonStockGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="edit_ProceedsFromIssuanceOfCommonStockGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_PercentageOfCashCommissionsPaid" xlink:label="edit_PercentageOfCashCommissionsPaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="edit_PercentageOfCashCommissionsPaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ProceedsFromIssuanceOfCommonStockReceivable" xlink:label="edit_ProceedsFromIssuanceOfCommonStockReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="edit_ProceedsFromIssuanceOfCommonStockReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_StockSalesAgreementAdditionalSaleProceedsThatCanBeRaised" xlink:label="edit_StockSalesAgreementAdditionalSaleProceedsThatCanBeRaised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="edit_StockSalesAgreementAdditionalSaleProceedsThatCanBeRaised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary Of Significant Accounting Policies - Recent Accounting Pronouncements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_637091893198827930" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_637091893198827930" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="srt_RestatementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_637091893198837914" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_637091893198837914" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementAdjustmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_Assets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_Liabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasePracticalExpedientsPackage" xlink:label="us-gaap_LeasePracticalExpedientsPackage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_LeasePracticalExpedientsPackage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasePracticalExpedientUseOfHindsight" xlink:label="us-gaap_LeasePracticalExpedientUseOfHindsight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_LeasePracticalExpedientUseOfHindsight" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Cash Equivalents, Marketable Securities and Corporate Equity Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637091893198857940" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637091893198857940" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="us-gaap_USStatesAndPoliticalSubdivisionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_USStatesAndPoliticalSubdivisionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637091893198867941" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637091893198867941" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="us-gaap_EquitySecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_EquitySecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost" xlink:label="us-gaap_EquitySecuritiesFvNiCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_EquitySecuritiesFvNiCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_EquitySecuritiesFvNi" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_MarketableSecuritiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_MarketableSecuritiesAmortizedCost" xlink:label="edit_MarketableSecuritiesAmortizedCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="edit_MarketableSecuritiesAmortizedCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_MarketableSecuritiesUnrealizedGain" xlink:label="edit_MarketableSecuritiesUnrealizedGain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="edit_MarketableSecuritiesUnrealizedGain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_MarketableSecuritiesUnrealizedLoss" xlink:label="edit_MarketableSecuritiesUnrealizedLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="edit_MarketableSecuritiesUnrealizedLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Fair Value Measurements - Recurring Basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_637091893198897947" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_637091893198897947" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637091893198897947" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637091893198897947" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="us-gaap_USStatesAndPoliticalSubdivisionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_USStatesAndPoliticalSubdivisionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="us-gaap_EquitySecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_EquitySecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost" xlink:label="us-gaap_EquitySecuritiesFvNiCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_EquitySecuritiesFvNiCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_FairValueAssetsAndLiabilitiesTransfers" xlink:label="edit_FairValueAssetsAndLiabilitiesTransfers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="edit_FairValueAssetsAndLiabilitiesTransfers" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Property and Equipment, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637091893198937945" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637091893198937945" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_LaboratoryEquipmentMember" xlink:label="edit_LaboratoryEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="edit_LaboratoryEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Commitments and Contingencies - Operating Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_HurleyStreetLeaseMember" xlink:label="edit_HurleyStreetLeaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="edit_HurleyStreetLeaseMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_FacilitySubleaseArrangementMember" xlink:label="edit_FacilitySubleaseArrangementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="edit_FacilitySubleaseArrangementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_AreaOfLeasedSpace" xlink:label="edit_AreaOfLeasedSpace" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="edit_AreaOfLeasedSpace" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesDerecognitionOfBalancesDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Commitments and Contingencies - Derecognition of Balances (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RestatementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementAdjustmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_LesseeOperatingLeaseLaboratorySpaceNumber" xlink:label="edit_LesseeOperatingLeaseLaboratorySpaceNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="edit_LesseeOperatingLeaseLaboratorySpaceNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_NumberOfOperatingLeasesForManufacturingSpace" xlink:label="edit_NumberOfOperatingLeasesForManufacturingSpace" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="edit_NumberOfOperatingLeasesForManufacturingSpace" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesLicensorExpenseReimbursementDetails" xlink:type="extended" xlink:title="40706 - Disclosure - Commitments and Contingencies - Licensor Expense Reimbursement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain_637091893198977936" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain_637091893198977936" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_CommitmentToReimburseLicensorMember" xlink:label="edit_CommitmentToReimburseLicensorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="edit_CommitmentToReimburseLicensorMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="us-gaap_ProfessionalAndContractServicesExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ProfessionalAndContractServicesExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesResearchFundingPaymentsDetails" xlink:type="extended" xlink:title="40707 - Disclosure - Commitments and Contingencies - Research Funding Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ResearchFundingPaymentsMember" xlink:label="edit_ResearchFundingPaymentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="edit_ResearchFundingPaymentsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637091893198987935" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637091893198987935" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_SponsoredResearchAgreementMember" xlink:label="edit_SponsoredResearchAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="edit_SponsoredResearchAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_BroadInstituteIncMember" xlink:label="edit_BroadInstituteIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="edit_BroadInstituteIncMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_FundingPaymentsDueAndPayableOne" xlink:label="edit_FundingPaymentsDueAndPayableOne" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="edit_FundingPaymentsDueAndPayableOne" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_FundingPaymentsDueAndPayableTwo" xlink:label="edit_FundingPaymentsDueAndPayableTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="edit_FundingPaymentsDueAndPayableTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_NotesPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesNotesPayableDetails" xlink:type="extended" xlink:title="40708 - Disclosure - Commitments and Contingencies - Notes Payable (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_SponsoredResearchAgreementMember" xlink:label="edit_SponsoredResearchAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="edit_SponsoredResearchAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_BroadAndWageningenUniversityMember" xlink:label="edit_BroadAndWageningenUniversityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="edit_BroadAndWageningenUniversityMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_BroadInstituteIncMember" xlink:label="edit_BroadInstituteIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="edit_BroadAndWageningenUniversityMember" xlink:to="edit_BroadInstituteIncMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_637091893199017947" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_637091893199017947" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_InitialNotesMember" xlink:label="edit_InitialNotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="edit_InitialNotesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesAndLoansPayableAbstract" xlink:label="us-gaap_NotesAndLoansPayableAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_NotesAndLoansPayableAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NotesAndLoansPayableAbstract" xlink:to="us-gaap_NotesPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NotesAndLoansPayableAbstract" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ThresholdPeriodInterestFreeDebtInstrumentFaceAmount" xlink:label="edit_ThresholdPeriodInterestFreeDebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NotesAndLoansPayableAbstract" xlink:to="edit_ThresholdPeriodInterestFreeDebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_NotesAndLoansPayableAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsSummaryOfAgreementDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Collaboration and License Agreements - Summary of Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_CollaborationAndLicenseAgreementMember" xlink:label="edit_CollaborationAndLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="edit_CollaborationAndLicenseAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_StrategicAllianceMember" xlink:label="edit_StrategicAllianceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="edit_StrategicAllianceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_JunoTherapeuticsMember" xlink:label="edit_JunoTherapeuticsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="edit_JunoTherapeuticsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_AllerganMember" xlink:label="edit_AllerganMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="edit_AllerganMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ResearchProgramTerm" xlink:label="edit_ResearchProgramTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="edit_ResearchProgramTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_NumberOfCollaborationDevelopmentPrograms" xlink:label="edit_NumberOfCollaborationDevelopmentPrograms" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="edit_NumberOfCollaborationDevelopmentPrograms" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_NumberOfAdditionalDevelopmentAndCommercializationLicenseToBePurchased" xlink:label="edit_NumberOfAdditionalDevelopmentAndCommercializationLicenseToBePurchased" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="edit_NumberOfAdditionalDevelopmentAndCommercializationLicenseToBePurchased" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReceivablesNetCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ProgramExpense" xlink:label="edit_ProgramExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="edit_ProgramExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ShareOfExpenseRecognizedPercentage" xlink:label="edit_ShareOfExpenseRecognizedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="edit_ShareOfExpenseRecognizedPercentage" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.editasmedicine.com/role/DisclosureStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Stock-based Compensation - Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637091893199057941" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_637091893199057941" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Stock-based Compensation - Restricted Stock and Stock Options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637091893199067946" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637091893199067946" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637091893199067946" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637091893199067946" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_EmployeeAndDirectorMember" xlink:label="edit_EmployeeAndDirectorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="edit_EmployeeAndDirectorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.editasmedicine.com/role/DisclosureNetLossPerShareDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Net Loss per Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_AtMarketOfferingMember" xlink:label="edit_AtMarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="edit_AtMarketOfferingMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637091893199127958" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637091893199127958" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.editasmedicine.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Related-Party Transactions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_637091893199137948" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_637091893199137948" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_RentAndFacilityRelatedFeesMember" xlink:label="edit_RentAndFacilityRelatedFeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="edit_RentAndFacilityRelatedFeesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.editasmedicine.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ChiefMedicalOfficerMember" xlink:label="edit_ChiefMedicalOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="edit_ChiefMedicalOfficerMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_JunoTherapeuticsMember" xlink:label="edit_JunoTherapeuticsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="edit_JunoTherapeuticsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_CollaborationAndLicenseAgreementAmendmentFeeReceived" xlink:label="edit_CollaborationAndLicenseAgreementAmendmentFeeReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="edit_CollaborationAndLicenseAgreementAmendmentFeeReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>edit-20190930_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.4.7193.41938 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/12/2019 9:02:03 PM-->
<!--Modified on: 11/12/2019 9:02:03 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_DocumentAndEntityInformationAbstract" xlink:label="edit_DocumentAndEntityInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_DocumentAndEntityInformationAbstract" xlink:to="edit_DocumentAndEntityInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Quarterly Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Consolidated Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASSETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable, Balance at End of Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable, Balance at Beginning of Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use asset</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash and other non-current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LIABILITIES AND STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenue, current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liability, current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liability, noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liability, net of current portion</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenue, net of current portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenue, long-term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Construction financing lease obligation, net of current portion</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (see note 7)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, $0.0001 par value per share: 5,000,000 shares authorized; no shares issued or outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.0001 par value per share: 195,000,000 shares authorized; 51,528,020 and 49,028,907 shares issued, and 51,076,198 and 48,758,951 shares outstanding at September 30, 2019 and December 31, 2018, respectively</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive income (loss)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance, beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockNoParValue" xlink:label="us-gaap_PreferredStockNoParValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockNoParValue" xlink:to="us-gaap_PreferredStockNoParValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockNoParValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, No Par Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockNoParValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Consolidated Statements of Operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Excluding Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration and other research and development revenues</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Product and Service [Extensible List]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue type</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income, net:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other (expense) income, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Income, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other income, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share attributable to common stockholders, basic and diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common shares outstanding, basic and diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Consolidated Statements of Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive (loss) income:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized (loss) gain on marketable debt securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Consolidated Statements of Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Stockholders' Equity (Deficit)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance, end of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance, beginning of period (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:to="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative Effect of New Accounting Principle in Period of Adoption</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative effect adjustment for adoption of new accounting guidance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock from public offering, net of issuance costs of $0.1 million</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common stock issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock from public offering, net of issuance costs of $0.1 million (in shares)</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_StockIssuedDuringPeriodValueRepaymentOfNotes" xlink:label="edit_StockIssuedDuringPeriodValueRepaymentOfNotes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_StockIssuedDuringPeriodValueRepaymentOfNotes" xlink:to="edit_StockIssuedDuringPeriodValueRepaymentOfNotes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_StockIssuedDuringPeriodValueRepaymentOfNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of shares issued during the period as a result of repayment of notes payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_StockIssuedDuringPeriodValueRepaymentOfNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Repayment of Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_StockIssuedDuringPeriodValueRepaymentOfNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock for repayment of notes payable</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_StockIssuedDuringPeriodSharesRepaymentOfDebt" xlink:label="edit_StockIssuedDuringPeriodSharesRepaymentOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_StockIssuedDuringPeriodSharesRepaymentOfDebt" xlink:to="edit_StockIssuedDuringPeriodSharesRepaymentOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_StockIssuedDuringPeriodSharesRepaymentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued during the period as a result of repayment of notes payables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_StockIssuedDuringPeriodSharesRepaymentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Repayment of debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_StockIssuedDuringPeriodSharesRepaymentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock for repayment of notes payable (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Purchase of Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock for asset purchase agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Purchase of Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock for asset purchase agreement (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of restricted common stock units and awards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of restricted common stock units and awards (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of common stock under benefit plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Share-based Compensation, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of common stock under benefit plan (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized gain (loss) on marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock issuance costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Consolidated Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flow from operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development in Process</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash research and development expense</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_NoncashInvestmentInEquitySecurities" xlink:label="edit_NoncashInvestmentInEquitySecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_NoncashInvestmentInEquitySecurities" xlink:to="edit_NoncashInvestmentInEquitySecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_NoncashInvestmentInEquitySecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of purchased equity securities that are acquired in a non-cash transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_NoncashInvestmentInEquitySecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash Investment in Equity Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="edit_NoncashInvestmentInEquitySecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash investment in equity securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Noncash Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-cash items, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_IncreaseDecreaseInRightOfUseAssets" xlink:label="edit_IncreaseDecreaseInRightOfUseAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_IncreaseDecreaseInRightOfUseAssets" xlink:to="edit_IncreaseDecreaseInRightOfUseAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_IncreaseDecreaseInRightOfUseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount represents the increase (decrease) in right of use assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_IncreaseDecreaseInRightOfUseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Right Of Use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="edit_IncreaseDecreaseInRightOfUseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use asset</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Noncurrent Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenue</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_IncreaseDecreaseInRightOfUseLiability" xlink:label="edit_IncreaseDecreaseInRightOfUseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_IncreaseDecreaseInRightOfUseLiability" xlink:to="edit_IncreaseDecreaseInRightOfUseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_IncreaseDecreaseInRightOfUseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of increase (decrease) in right of use liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_IncreaseDecreaseInRightOfUseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Right Of Use Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_IncreaseDecreaseInRightOfUseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Operating Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current and non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flow from investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sale of Machinery and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the sale of equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sale and Maturity of Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from maturities of marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by (used in) investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flow from financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from offering of common stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuances of common stock under benefit plans</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Debt and Capital Lease Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments on construction financing lease obligation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net decrease in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash, beginning of period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosure of cash and non-cash activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Expenditures Incurred but Not yet Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed asset additions included in accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ReceivableOfProceedsFromExerciseOfStockOptions" xlink:label="edit_ReceivableOfProceedsFromExerciseOfStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_ReceivableOfProceedsFromExerciseOfStockOptions" xlink:to="edit_ReceivableOfProceedsFromExerciseOfStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_ReceivableOfProceedsFromExerciseOfStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of receivables from exercise of stock options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_ReceivableOfProceedsFromExerciseOfStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivable of Proceeds from Exercise of Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_ReceivableOfProceedsFromExerciseOfStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivable of proceeds from offering of common stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid in connection with operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets obtained in exchange of operating lease obligations</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ReclassificationOfLiabilityForFounderStockRepurchase" xlink:label="edit_ReclassificationOfLiabilityForFounderStockRepurchase" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_ReclassificationOfLiabilityForFounderStockRepurchase" xlink:to="edit_ReclassificationOfLiabilityForFounderStockRepurchase_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_ReclassificationOfLiabilityForFounderStockRepurchase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of reclassification of liability for founder stock repurchase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_ReclassificationOfLiabilityForFounderStockRepurchase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification of liability for common stock subject to repurchase</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock for settlement of success payments (see note 7)</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_StockIssuedForAssetAcquisition" xlink:label="edit_StockIssuedForAssetAcquisition" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_StockIssuedForAssetAcquisition" xlink:to="edit_StockIssuedForAssetAcquisition_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_StockIssuedForAssetAcquisition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The fair value of stock issued for asset acquisition in non-cash activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_StockIssuedForAssetAcquisition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued for Asset Acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_StockIssuedForAssetAcquisition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock for asset acquisition</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesIssued1" xlink:label="us-gaap_NotesIssued1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesIssued1" xlink:to="us-gaap_NotesIssued1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock for settlement of notes payable (see note 7)</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_DeferredRevenueAdjustmentFromEffectOfNewAccountingPrinciple" xlink:label="edit_DeferredRevenueAdjustmentFromEffectOfNewAccountingPrinciple" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_DeferredRevenueAdjustmentFromEffectOfNewAccountingPrinciple" xlink:to="edit_DeferredRevenueAdjustmentFromEffectOfNewAccountingPrinciple_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_DeferredRevenueAdjustmentFromEffectOfNewAccountingPrinciple_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of adjustment to deferred revenue for adoption of accounting principle.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_DeferredRevenueAdjustmentFromEffectOfNewAccountingPrinciple_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Revenue Adjustment from Effect of New Accounting Principle</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_DeferredRevenueAdjustmentFromEffectOfNewAccountingPrinciple_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustment to deferred revenue for revenue adoption</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_StockIssuanceCostsIncurredButNotYetPaid" xlink:label="edit_StockIssuanceCostsIncurredButNotYetPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_StockIssuanceCostsIncurredButNotYetPaid" xlink:to="edit_StockIssuanceCostsIncurredButNotYetPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_StockIssuanceCostsIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future cash outflow to pay for stock issuance costs incurred.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_StockIssuanceCostsIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial public offering costs incurred but unpaid at period end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_StockIssuanceCostsIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering costs included in accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Business</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Business</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Equivalents, Marketable Securities and Equity Securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, and Marketable Securities [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Equivalents, Marketable Securities and Equity Securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_CollaborativeArrangementsAbstract" xlink:label="edit_CollaborativeArrangementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_CollaborativeArrangementsAbstract" xlink:to="edit_CollaborativeArrangementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_CollaborativeArrangementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_CollaborativeArrangementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration and License Agreements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration and License Agreements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related-Party Transactions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related-Party Transactions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unaudited Interim Financial Information</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent Accounting Pronouncements Adopted And Issued But Not Yet Adopted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents and Investments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of cash equivalents, marketable securities and corporate equity securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of assets measured at fair value on a recurring basis</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of derecognition of balances relating to the building, accumulated depreciation and the corresponding construction financing lease on adoption of ASC 842</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_AssetsAndLiabilitiesLesseeOperatingLeaseTableTextBlock" xlink:label="edit_AssetsAndLiabilitiesLesseeOperatingLeaseTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_AssetsAndLiabilitiesLesseeOperatingLeaseTableTextBlock" xlink:to="edit_AssetsAndLiabilitiesLesseeOperatingLeaseTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_AssetsAndLiabilitiesLesseeOperatingLeaseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of leases included on its condensed consolidated balance sheet.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_AssetsAndLiabilitiesLesseeOperatingLeaseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets and Liabilities, Lessee, Operating Lease [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_AssetsAndLiabilitiesLesseeOperatingLeaseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of leases included on its condensed consolidated balance sheet</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of the operating lease costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of maturities of lease liabilities</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock" xlink:label="edit_ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock" xlink:to="edit_ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of account receivable and contract liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accounts Receivable and Contract Liabilities Table Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accounts receivable and contract liabilities</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="edit_ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="edit_ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of change in contract with customer asset and liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Change in Contract with Customer Asset and Liability [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of change in contract assets and contract liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonvested Restricted Stock Shares Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of changes in unvested restricted stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock option activity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of anti-dilutive common stock equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary, Sale of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate net proceeds</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_StockSalesAgreementThresholdSaleProceedsThatCanBeRaised" xlink:label="edit_StockSalesAgreementThresholdSaleProceedsThatCanBeRaised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_StockSalesAgreementThresholdSaleProceedsThatCanBeRaised" xlink:to="edit_StockSalesAgreementThresholdSaleProceedsThatCanBeRaised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_StockSalesAgreementThresholdSaleProceedsThatCanBeRaised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of threshold aggregate sale proceeds that can be raised under the stock sale agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_StockSalesAgreementThresholdSaleProceedsThatCanBeRaised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Sales Agreement, Threshold Sale Proceeds That Can Be Raised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_StockSalesAgreementThresholdSaleProceedsThatCanBeRaised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold sale proceeds</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_SharesIssuedWeightedAveragePricePerShare" xlink:label="edit_SharesIssuedWeightedAveragePricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_SharesIssuedWeightedAveragePricePerShare" xlink:to="edit_SharesIssuedWeightedAveragePricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_SharesIssuedWeightedAveragePricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average price per share of equity securities issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_SharesIssuedWeightedAveragePricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Weighted Average Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_SharesIssuedWeightedAveragePricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average price per share</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ProceedsFromIssuanceOfCommonStockGross" xlink:label="edit_ProceedsFromIssuanceOfCommonStockGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_ProceedsFromIssuanceOfCommonStockGross" xlink:to="edit_ProceedsFromIssuanceOfCommonStockGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_ProceedsFromIssuanceOfCommonStockGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of gross cash inflow from issuance of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_ProceedsFromIssuanceOfCommonStockGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Issuance Of Common Stock Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_ProceedsFromIssuanceOfCommonStockGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_PercentageOfCashCommissionsPaid" xlink:label="edit_PercentageOfCashCommissionsPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_PercentageOfCashCommissionsPaid" xlink:to="edit_PercentageOfCashCommissionsPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_PercentageOfCashCommissionsPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of cash commission paid on the gross sales price per share of its common stock sold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_PercentageOfCashCommissionsPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Cash Commissions Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_PercentageOfCashCommissionsPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash commission paid</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ProceedsFromIssuanceOfCommonStockReceivable" xlink:label="edit_ProceedsFromIssuanceOfCommonStockReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_ProceedsFromIssuanceOfCommonStockReceivable" xlink:to="edit_ProceedsFromIssuanceOfCommonStockReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_ProceedsFromIssuanceOfCommonStockReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of receivable amount of proceeds from issuance of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_ProceedsFromIssuanceOfCommonStockReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Issuance Of Common Stock Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_ProceedsFromIssuanceOfCommonStockReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock receivable</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_StockSalesAgreementAdditionalSaleProceedsThatCanBeRaised" xlink:label="edit_StockSalesAgreementAdditionalSaleProceedsThatCanBeRaised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_StockSalesAgreementAdditionalSaleProceedsThatCanBeRaised" xlink:to="edit_StockSalesAgreementAdditionalSaleProceedsThatCanBeRaised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_StockSalesAgreementAdditionalSaleProceedsThatCanBeRaised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of additional sale proceeds that can be raised under the stock sale agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_StockSalesAgreementAdditionalSaleProceedsThatCanBeRaised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Sales Agreement, Additional Sale Proceeds That Can Be Raised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_StockSalesAgreementAdditionalSaleProceedsThatCanBeRaised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional sale proceeds</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements or Change in Accounting Principle [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating lease liabilities at September 30, 2019</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasePracticalExpedientsPackage" xlink:label="us-gaap_LeasePracticalExpedientsPackage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasePracticalExpedientsPackage" xlink:to="us-gaap_LeasePracticalExpedientsPackage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasePracticalExpedientsPackage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Practical Expedients, Package [true false]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeasePracticalExpedientsPackage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Practical Expedients, Package</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasePracticalExpedientUseOfHindsight" xlink:label="us-gaap_LeasePracticalExpedientUseOfHindsight" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasePracticalExpedientUseOfHindsight" xlink:to="us-gaap_LeasePracticalExpedientUseOfHindsight_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasePracticalExpedientUseOfHindsight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Practical Expedient, Use of Hindsight [true false]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeasePracticalExpedientUseOfHindsight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Practical Expedient, Use of Hindsight</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restrictions on Cash and Cash Equivalents [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash and Cash Equivalents Items [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Equivalents, Marketable Securities and Corporate Equity Securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available-for-sale Debt Securities, Amortized Cost Basis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortized Cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Unrealized Gains</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Unrealized Losses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available-for-sale Securities, Debt Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments, Debt and Equity Securities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity securities included in other non-current assets:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost" xlink:label="us-gaap_EquitySecuritiesFvNiCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiCost" xlink:to="us-gaap_EquitySecuritiesFvNiCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNiCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Securities, FV-NI, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquitySecuritiesFvNiCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortized Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquitySecuritiesFvNiCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNi" xlink:to="us-gaap_EquitySecuritiesFvNi_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Securities, FV-NI</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Equivalents, Marketable Securities and Equity Securities</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_MarketableSecuritiesAmortizedCost" xlink:label="edit_MarketableSecuritiesAmortizedCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_MarketableSecuritiesAmortizedCost" xlink:to="edit_MarketableSecuritiesAmortizedCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_MarketableSecuritiesAmortizedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortized cost of investments in marketable securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_MarketableSecuritiesAmortizedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities, Amortized Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_MarketableSecuritiesAmortizedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortized Cost</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_MarketableSecuritiesUnrealizedGain" xlink:label="edit_MarketableSecuritiesUnrealizedGain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_MarketableSecuritiesUnrealizedGain" xlink:to="edit_MarketableSecuritiesUnrealizedGain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_MarketableSecuritiesUnrealizedGain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of unrealized gain on investment in marketable security.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_MarketableSecuritiesUnrealizedGain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities, Unrealized Gain</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_MarketableSecuritiesUnrealizedGain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Unrealized Gains</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_MarketableSecuritiesUnrealizedLoss" xlink:label="edit_MarketableSecuritiesUnrealizedLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_MarketableSecuritiesUnrealizedLoss" xlink:to="edit_MarketableSecuritiesUnrealizedLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_MarketableSecuritiesUnrealizedLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of unrealized loss on investment in marketable security.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_MarketableSecuritiesUnrealizedLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities, Unrealized Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="edit_MarketableSecuritiesUnrealizedLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Unrealized Losses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of securities in an unrealized loss position</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Securities held by the Company in an unrealized loss position for less than 12 months</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Available for Sale Securities Held in Continuous Unrealized Loss Position Twelve Months or Longer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of securities in an unrealized loss position for more than 12 months</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Realized Gain (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Realized gains (losses) on available-for-sale securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total financial assets</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_FairValueAssetsAndLiabilitiesTransfers" xlink:label="edit_FairValueAssetsAndLiabilitiesTransfers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_FairValueAssetsAndLiabilitiesTransfers" xlink:to="edit_FairValueAssetsAndLiabilitiesTransfers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_FairValueAssetsAndLiabilitiesTransfers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of transfers between levels of the fair value hierarchy during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_FairValueAssetsAndLiabilitiesTransfers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers between levels</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee related expenses</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_AccruedIntellectualPropertyFees" xlink:label="edit_AccruedIntellectualPropertyFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_AccruedIntellectualPropertyFees" xlink:to="edit_AccruedIntellectualPropertyFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_AccruedIntellectualPropertyFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for fees associated with intellectual property rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_AccruedIntellectualPropertyFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intellectual property and patent related fees</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ProcessAndPlatformDevelopmentCostsCurrent" xlink:label="edit_ProcessAndPlatformDevelopmentCostsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_ProcessAndPlatformDevelopmentCostsCurrent" xlink:to="edit_ProcessAndPlatformDevelopmentCostsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_ProcessAndPlatformDevelopmentCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for fees associated with process and platform development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_ProcessAndPlatformDevelopmentCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Process And Platform Development Costs Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_ProcessAndPlatformDevelopmentCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Process and platform development expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional service expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other expenses</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_SublicensingAndSuccessPaymentExpenses" xlink:label="edit_SublicensingAndSuccessPaymentExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_SublicensingAndSuccessPaymentExpenses" xlink:to="edit_SublicensingAndSuccessPaymentExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_SublicensingAndSuccessPaymentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for fees associated with sublicense and success payment expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_SublicensingAndSuccessPaymentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sublicensing and Success Payment Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_SublicensingAndSuccessPaymentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sublicensing and success payment expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment disclosures</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_AreaOfLeasedSpace" xlink:label="edit_AreaOfLeasedSpace" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_AreaOfLeasedSpace" xlink:to="edit_AreaOfLeasedSpace_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_AreaOfLeasedSpace_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area of leased space.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_AreaOfLeasedSpace_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area of Leased Space</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_AreaOfLeasedSpace_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leased space ( in square feet)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Existence of Option to Extend [true false]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Leasing Arrangements, Operating Leases, Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Extended lease option (in years)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated useful life</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_LesseeOperatingLeaseLaboratorySpaceNumber" xlink:label="edit_LesseeOperatingLeaseLaboratorySpaceNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_LesseeOperatingLeaseLaboratorySpaceNumber" xlink:to="edit_LesseeOperatingLeaseLaboratorySpaceNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_LesseeOperatingLeaseLaboratorySpaceNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of other operating leases for laboratory space.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_LesseeOperatingLeaseLaboratorySpaceNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Laboratory Space, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_LesseeOperatingLeaseLaboratorySpaceNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of other operating leases for laboratory space</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_NumberOfOperatingLeasesForManufacturingSpace" xlink:label="edit_NumberOfOperatingLeasesForManufacturingSpace" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_NumberOfOperatingLeasesForManufacturingSpace" xlink:to="edit_NumberOfOperatingLeasesForManufacturingSpace_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_NumberOfOperatingLeasesForManufacturingSpace_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of operating leases for manufacturing space.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_NumberOfOperatingLeasesForManufacturingSpace_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Operating Leases For Manufacturing Space</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_NumberOfOperatingLeasesForManufacturingSpace_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of other operating leases for manufacturing space</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets and Liabilities, Lessee [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases are included on its condensed consolidated balance sheet</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable lease costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Liabilities, Payments Due [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturity of lease liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2019</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2020</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due after Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereafter</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total minimum lease payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: imputed interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining lease term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average discount rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="us-gaap_ProfessionalAndContractServicesExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalAndContractServicesExpense" xlink:to="us-gaap_ProfessionalAndContractServicesExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional and Contract Services Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense for prosecution and maintenance of patent rights</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_FundingPaymentsDueAndPayableOne" xlink:label="edit_FundingPaymentsDueAndPayableOne" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_FundingPaymentsDueAndPayableOne" xlink:to="edit_FundingPaymentsDueAndPayableOne_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_FundingPaymentsDueAndPayableOne_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The first research funding amount which is due and payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_FundingPaymentsDueAndPayableOne_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Funding Payments Due and Payable, One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_FundingPaymentsDueAndPayableOne_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First research funding amount due and payable</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_FundingPaymentsDueAndPayableTwo" xlink:label="edit_FundingPaymentsDueAndPayableTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_FundingPaymentsDueAndPayableTwo" xlink:to="edit_FundingPaymentsDueAndPayableTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_FundingPaymentsDueAndPayableTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The first research funding amount due and payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_FundingPaymentsDueAndPayableTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Funding Payments Due and Payable, Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_FundingPaymentsDueAndPayableTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second research funding amount due and payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Promissory notes issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate (as a percentage)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesAndLoansPayableAbstract" xlink:label="us-gaap_NotesAndLoansPayableAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansPayableAbstract" xlink:to="us-gaap_NotesAndLoansPayableAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesAndLoansPayableAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes and Loans Payable [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesAndLoansPayableAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes Payable</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ThresholdPeriodInterestFreeDebtInstrumentFaceAmount" xlink:label="edit_ThresholdPeriodInterestFreeDebtInstrumentFaceAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_ThresholdPeriodInterestFreeDebtInstrumentFaceAmount" xlink:to="edit_ThresholdPeriodInterestFreeDebtInstrumentFaceAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_ThresholdPeriodInterestFreeDebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The face value of interest free debt instrument for specified period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_ThresholdPeriodInterestFreeDebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Period Interest Free Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_ThresholdPeriodInterestFreeDebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest free debt instrument</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Issued for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:to="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue, Initial Application Period Cumulative Effect Transition [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:to="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesNetCurrentAbstract" xlink:label="us-gaap_ReceivablesNetCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrentAbstract" xlink:to="us-gaap_ReceivablesNetCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesNetCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables, Net, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesNetCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_AccountsReceivableAdditions" xlink:label="edit_AccountsReceivableAdditions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_AccountsReceivableAdditions" xlink:to="edit_AccountsReceivableAdditions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_AccountsReceivableAdditions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of additions to accounts receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_AccountsReceivableAdditions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Additions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_AccountsReceivableAdditions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Additions</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_AccountsReceivableDeductions" xlink:label="edit_AccountsReceivableDeductions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_AccountsReceivableDeductions" xlink:to="edit_AccountsReceivableDeductions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_AccountsReceivableDeductions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of deductions to accounts receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_AccountsReceivableDeductions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Deductions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="edit_AccountsReceivableDeductions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Deductions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityAbstract" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract liabilities, deferred revenue:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract liabilities, deferred Revenue:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Revenue, Balance at End of Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Revenue, Balance at Beginning of Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenue</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ContractWithCustomerLiabilityAdditions" xlink:label="edit_ContractWithCustomerLiabilityAdditions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_ContractWithCustomerLiabilityAdditions" xlink:to="edit_ContractWithCustomerLiabilityAdditions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_ContractWithCustomerLiabilityAdditions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of additions in obligation to transfer good or service to customer for which consideration from customer has been received or is due.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_ContractWithCustomerLiabilityAdditions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer Liability Additions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_ContractWithCustomerLiabilityAdditions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenue, Additions</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ContractWithCustomerLiabilityDeductions" xlink:label="edit_ContractWithCustomerLiabilityDeductions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_ContractWithCustomerLiabilityDeductions" xlink:to="edit_ContractWithCustomerLiabilityDeductions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_ContractWithCustomerLiabilityDeductions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deductions in obligation to transfer good or service to customer for which consideration from customer has been received or is due.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_ContractWithCustomerLiabilityDeductions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer Liability Deductions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="edit_ContractWithCustomerLiabilityDeductions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenue, Deductions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract" xlink:label="us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract" xlink:to="us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in contract asset and contract liability balances</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Liability, Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amounts included in deferred revenue at the beginning of the period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:label="us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Performance Obligation Satisfied in Previous Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance obligations satisfied in previous periods</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Agreements.</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ResearchProgramTerm" xlink:label="edit_ResearchProgramTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_ResearchProgramTerm" xlink:to="edit_ResearchProgramTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_ResearchProgramTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The term of the research program under the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_ResearchProgramTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research Program Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_ResearchProgramTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreement term</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_NumberOfCollaborationDevelopmentPrograms" xlink:label="edit_NumberOfCollaborationDevelopmentPrograms" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_NumberOfCollaborationDevelopmentPrograms" xlink:to="edit_NumberOfCollaborationDevelopmentPrograms_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_NumberOfCollaborationDevelopmentPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of collaboration development programs for the treatment of ocular disorders under the exclusive license from the company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_NumberOfCollaborationDevelopmentPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Collaboration Development Programs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_NumberOfCollaborationDevelopmentPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Collaboration Development Programs</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_NumberOfAdditionalDevelopmentAndCommercializationLicenseToBePurchased" xlink:label="edit_NumberOfAdditionalDevelopmentAndCommercializationLicenseToBePurchased" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_NumberOfAdditionalDevelopmentAndCommercializationLicenseToBePurchased" xlink:to="edit_NumberOfAdditionalDevelopmentAndCommercializationLicenseToBePurchased_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_NumberOfAdditionalDevelopmentAndCommercializationLicenseToBePurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of additional development and Commercialization License that can be purchased.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_NumberOfAdditionalDevelopmentAndCommercializationLicenseToBePurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Additional Development And Commercialization License To Be Purchased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_NumberOfAdditionalDevelopmentAndCommercializationLicenseToBePurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of additional licenses</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ProgramExpense" xlink:label="edit_ProgramExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_ProgramExpense" xlink:to="edit_ProgramExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_ProgramExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of program expenses incurred during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_ProgramExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Program Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_ProgramExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses incurred</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ShareOfExpenseRecognizedPercentage" xlink:label="edit_ShareOfExpenseRecognizedPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_ShareOfExpenseRecognizedPercentage" xlink:to="edit_ShareOfExpenseRecognizedPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_ShareOfExpenseRecognizedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of share of operating expenses recognized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_ShareOfExpenseRecognizedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share of Expense Recognized, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_ShareOfExpenseRecognizedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of share of expenses recognized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation disclosures</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in unvested restricted stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested restricted shares, end of period(in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested restricted shares, beginning of period (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Grant Date Fair Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance, ending of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance, beginning of period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in unvested stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for recognition</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, end of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, beginning of period (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options granted (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancelled (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, end of period (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, beginning of period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancelled (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable (in dollar per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining contractual life</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable, remaining contractual life</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate intrinsic value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable, aggregated intrinsic value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potentially dilutive securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Anti-dilutive common stock equivalent shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related-Party Transactions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Other Revenues from Transactions with Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fees received from related party</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_CollaborationAndLicenseAgreementAmendmentFeeReceived" xlink:label="edit_CollaborationAndLicenseAgreementAmendmentFeeReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_CollaborationAndLicenseAgreementAmendmentFeeReceived" xlink:to="edit_CollaborationAndLicenseAgreementAmendmentFeeReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_CollaborationAndLicenseAgreementAmendmentFeeReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of amendment fee received during the period under the restated Collaboration and License Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_CollaborationAndLicenseAgreementAmendmentFeeReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration and License Agreement, Amendment Fee Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_CollaborationAndLicenseAgreementAmendmentFeeReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment fee received</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-In Capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive (Loss) Income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale Of Stock Name Of Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">I P O [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial Public Offering</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_AtMarket2018MarchOfferingMember" xlink:label="edit_AtMarket2018MarchOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_AtMarket2018MarchOfferingMember" xlink:to="edit_AtMarket2018MarchOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_AtMarket2018MarchOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2018 at-the-market offering sale of stock after the initial public offering to the public.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_AtMarket2018MarchOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At Market2018 March Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_AtMarket2018MarchOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2018 ATM Program</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_PublicAndAtMarketOfferingMember" xlink:label="edit_PublicAndAtMarketOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_PublicAndAtMarketOfferingMember" xlink:to="edit_PublicAndAtMarketOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_PublicAndAtMarketOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to public and at market offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_PublicAndAtMarketOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public And At Market Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_PublicAndAtMarketOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public and Market Offering</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repurchase Agreement Counterparty Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_CowenAndCompanyLlcMember" xlink:label="edit_CowenAndCompanyLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_CowenAndCompanyLlcMember" xlink:to="edit_CowenAndCompanyLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_CowenAndCompanyLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">It represent Cowen and Company LLC ("Cowen).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_CowenAndCompanyLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cowen And Company Llc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_CowenAndCompanyLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cowen and Company LLC ("Cowen)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for New Accounting Pronouncements [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type Of Adoption [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type of Adoption [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update201602 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASU 2016-02</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restatement [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restatement [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RestatementDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restatement [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAdjustmentMember" xlink:to="srt_RestatementAdjustmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAdjustmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restatement Adjustment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RestatementAdjustmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restatement Adjustment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash and Cash Equivalents [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Equivalents [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money Market Funds [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money market funds</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U S Treasury Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S. Treasuries</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="us-gaap_USStatesAndPoliticalSubdivisionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:to="us-gaap_USStatesAndPoliticalSubdivisionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USStatesAndPoliticalSubdivisionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U S States And Political Subdivisions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_USStatesAndPoliticalSubdivisionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government agency securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="us-gaap_EquitySecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesMember" xlink:to="us-gaap_EquitySecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquitySecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate equity securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Frequency [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements Recurring [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recurring</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Inputs Level1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Inputs Level2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 2</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U S Government Agencies Debt Securities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government agency securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property Plant And Equipment Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_LaboratoryEquipmentMember" xlink:label="edit_LaboratoryEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_LaboratoryEquipmentMember" xlink:to="edit_LaboratoryEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_LaboratoryEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratory equipment used for research and development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_LaboratoryEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratory Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_LaboratoryEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratory equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Construction In Progress [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Construction-in-progress</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture And Fixtures [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and office equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Software And Software Development Costs [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Software</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Building [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BuildingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Building</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_HurleyStreetLeaseMember" xlink:label="edit_HurleyStreetLeaseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_HurleyStreetLeaseMember" xlink:to="edit_HurleyStreetLeaseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_HurleyStreetLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease agreement of office and laboratory space located in Cambridge, Massachusetts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_HurleyStreetLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Hurley Street Lease [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_HurleyStreetLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Hurley Street Lease</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_FacilitySubleaseArrangementMember" xlink:label="edit_FacilitySubleaseArrangementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_FacilitySubleaseArrangementMember" xlink:to="edit_FacilitySubleaseArrangementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_FacilitySubleaseArrangementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Facility sublease arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_FacilitySubleaseArrangementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Facility Sublease Arrangement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_FacilitySubleaseArrangementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Facility Sublease Arrangement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="us-gaap_OtherCommitmentsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCommitmentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Domain]</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_CommitmentToReimburseLicensorMember" xlink:label="edit_CommitmentToReimburseLicensorMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_CommitmentToReimburseLicensorMember" xlink:to="edit_CommitmentToReimburseLicensorMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_CommitmentToReimburseLicensorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitment to reimburse the licensor for prosecution and maintenance of patent rights pursuant to the license agreement by and among the reporting entity, The Broad Institute Inc. and the Fellows of Harvard College.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_CommitmentToReimburseLicensorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitment To Reimburse Licensor [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_CommitmentToReimburseLicensorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensor Expense Reimbursement</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ResearchFundingPaymentsMember" xlink:label="edit_ResearchFundingPaymentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_ResearchFundingPaymentsMember" xlink:to="edit_ResearchFundingPaymentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_ResearchFundingPaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for commitments of research funding payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_ResearchFundingPaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research Funding Payments [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_ResearchFundingPaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research Funding Payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements And Nonarrangement Transactions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_SponsoredResearchAgreementMember" xlink:label="edit_SponsoredResearchAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_SponsoredResearchAgreementMember" xlink:to="edit_SponsoredResearchAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_SponsoredResearchAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for sponsored research agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_SponsoredResearchAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sponsored Research Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_SponsoredResearchAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sponsored Research Agreement</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_BroadInstituteIncMember" xlink:label="edit_BroadInstituteIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_BroadInstituteIncMember" xlink:to="edit_BroadInstituteIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_BroadInstituteIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to The Broad Institute Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_BroadInstituteIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Broad Institute Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_BroadInstituteIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Broad</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_BroadAndWageningenUniversityMember" xlink:label="edit_BroadAndWageningenUniversityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_BroadAndWageningenUniversityMember" xlink:to="edit_BroadAndWageningenUniversityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_BroadAndWageningenUniversityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information related to Broad and Wageningen University.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_BroadAndWageningenUniversityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Broad And Wageningen University [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_BroadAndWageningenUniversityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Broad and Wageningen University</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Debt, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short Term Debt Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Debt, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_InitialNotesMember" xlink:label="edit_InitialNotesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_InitialNotesMember" xlink:to="edit_InitialNotesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_InitialNotesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Initial notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_InitialNotesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_InitialNotesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial Notes</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_CollaborationAndLicenseAgreementMember" xlink:label="edit_CollaborationAndLicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_CollaborationAndLicenseAgreementMember" xlink:to="edit_CollaborationAndLicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_CollaborationAndLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration and license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_CollaborationAndLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration And License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_CollaborationAndLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration and License Agreement</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_StrategicAllianceMember" xlink:label="edit_StrategicAllianceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_StrategicAllianceMember" xlink:to="edit_StrategicAllianceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_StrategicAllianceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to strategic alliance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_StrategicAllianceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Strategic Alliance [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_StrategicAllianceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Strategic Alliance</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_JunoTherapeuticsMember" xlink:label="edit_JunoTherapeuticsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_JunoTherapeuticsMember" xlink:to="edit_JunoTherapeuticsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_JunoTherapeuticsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Juno Therapeutics.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_JunoTherapeuticsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Juno Therapeutics [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_JunoTherapeuticsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Juno Therapeutics</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_AllerganMember" xlink:label="edit_AllerganMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_AllerganMember" xlink:to="edit_AllerganMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_AllerganMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Allergan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_AllerganMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allergan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_AllerganMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allergan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General And Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title Of Individual With Relationship To Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Domain]</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_EmployeeAndDirectorMember" xlink:label="edit_EmployeeAndDirectorMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_EmployeeAndDirectorMember" xlink:to="edit_EmployeeAndDirectorMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_EmployeeAndDirectorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employees and directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_EmployeeAndDirectorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee And Director [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_EmployeeAndDirectorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employees and directors</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Executive Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Executive Officer</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_AtMarketOfferingMember" xlink:label="edit_AtMarketOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_AtMarketOfferingMember" xlink:to="edit_AtMarketOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_AtMarketOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to at market offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_AtMarketOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At Market Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_AtMarketOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At Market Offering</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Domain]</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_RentAndFacilityRelatedFeesMember" xlink:label="edit_RentAndFacilityRelatedFeesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_RentAndFacilityRelatedFeesMember" xlink:to="edit_RentAndFacilityRelatedFeesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_RentAndFacilityRelatedFeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the rent and facility related fees paid to the related parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_RentAndFacilityRelatedFeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rent And Facility Related Fees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_RentAndFacilityRelatedFeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rent and facility related fees</label>
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ChiefMedicalOfficerMember" xlink:label="edit_ChiefMedicalOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edit_ChiefMedicalOfficerMember" xlink:to="edit_ChiefMedicalOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="edit_ChiefMedicalOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Person with designation of chief medical officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="edit_ChiefMedicalOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Medical Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="edit_ChiefMedicalOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Medical Officer</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units R S U [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units (RSUs)</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>edit-20190930_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.4.7193.41938 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/12/2019 9:02:03 PM-->
<!--Modified on: 11/12/2019 9:02:03 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#StatementCondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#StatementCondensedConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#StatementConsolidatedStatementsOfStockholdersEquityParenthetical" roleURI="http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureNatureOfBusiness" roleURI="http://www.editasmedicine.com/role/DisclosureNatureOfBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureCashEquivalentsMarketableSecuritiesAndEquitySecurities" roleURI="http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndEquitySecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureFairValueMeasurements" roleURI="http://www.editasmedicine.com/role/DisclosureFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureAccruedExpenses" roleURI="http://www.editasmedicine.com/role/DisclosureAccruedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosurePropertyAndEquipmentNet" roleURI="http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureCollaborationAndLicenseAgreements" roleURI="http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureStockBasedCompensation" roleURI="http://www.editasmedicine.com/role/DisclosureStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureNetLossPerShare" roleURI="http://www.editasmedicine.com/role/DisclosureNetLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureRelatedPartyTransactions" roleURI="http://www.editasmedicine.com/role/DisclosureRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureSubsequentEvents" roleURI="http://www.editasmedicine.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesTables" roleURI="http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureAccruedExpensesTables" roleURI="http://www.editasmedicine.com/role/DisclosureAccruedExpensesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosurePropertyAndEquipmentNetTables" roleURI="http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureCommitmentsAndContingenciesTables" roleURI="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureCollaborationAndLicenseAgreementsTables" roleURI="http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.editasmedicine.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureNetLossPerShareTables" roleURI="http://www.editasmedicine.com/role/DisclosureNetLossPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureNatureOfBusinessDetails" roleURI="http://www.editasmedicine.com/role/DisclosureNatureOfBusinessDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" roleURI="http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails" roleURI="http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureFairValueMeasurementsRecurringBasisDetails" roleURI="http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureAccruedExpensesDetails" roleURI="http://www.editasmedicine.com/role/DisclosureAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureCommitmentsAndContingenciesOperatingLeasesDetails" roleURI="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureCommitmentsAndContingenciesDerecognitionOfBalancesDetails" roleURI="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesDerecognitionOfBalancesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureCommitmentsAndContingenciesRightOfUseAssetAndLeaseLiabilityDetails" roleURI="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesRightOfUseAssetAndLeaseLiabilityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureCommitmentsAndContingenciesOperatingLeaseCostsDetails" roleURI="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseCostsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails" roleURI="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureCommitmentsAndContingenciesLicensorExpenseReimbursementDetails" roleURI="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesLicensorExpenseReimbursementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureCommitmentsAndContingenciesResearchFundingPaymentsDetails" roleURI="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesResearchFundingPaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureCommitmentsAndContingenciesNotesPayableDetails" roleURI="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesNotesPayableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureCollaborationAndLicenseAgreementsRevenueRecognitionDetails" roleURI="http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognitionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilityDetails" roleURI="http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureCollaborationAndLicenseAgreementsSummaryOfAgreementDetails" roleURI="http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsSummaryOfAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureStockBasedCompensationExpenseDetails" roleURI="http://www.editasmedicine.com/role/DisclosureStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" roleURI="http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureNetLossPerShareDetails" roleURI="http://www.editasmedicine.com/role/DisclosureNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://www.editasmedicine.com/role/DisclosureRelatedPartyTransactionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="edit-20190930.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.editasmedicine.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_DocumentAndEntityInformationAbstract" xlink:label="edit_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637091893199317953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edit_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_637091893199317953" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_637091893199317953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edit_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentQuarterlyReport_637091893199317953" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637091893199317953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edit_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentTransitionReport_637091893199317953" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637091893199317953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edit_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_637091893199317953" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637091893199317953" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edit_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFileNumber_637091893199317953" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637091893199327965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edit_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_637091893199327965" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637091893199327965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edit_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637091893199327965" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637091893199327965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edit_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637091893199327965" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637091893199327965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edit_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine1_637091893199327965" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637091893199327965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edit_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCityOrTown_637091893199327965" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637091893199327965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edit_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressStateOrProvince_637091893199327965" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637091893199327965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edit_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressPostalZipCode_637091893199327965" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637091893199327965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edit_DocumentAndEntityInformationAbstract" xlink:to="dei_CityAreaCode_637091893199327965" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637091893199327965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edit_DocumentAndEntityInformationAbstract" xlink:to="dei_LocalPhoneNumber_637091893199327965" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637091893199327965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edit_DocumentAndEntityInformationAbstract" xlink:to="dei_Security12bTitle_637091893199327965" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637091893199327965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edit_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol_637091893199327965" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637091893199337963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edit_DocumentAndEntityInformationAbstract" xlink:to="dei_SecurityExchangeName_637091893199337963" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637091893199337963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edit_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCurrentReportingStatus_637091893199337963" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637091893199337963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edit_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityInteractiveDataCurrent_637091893199337963" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637091893199337963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edit_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory_637091893199337963" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637091893199337963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edit_DocumentAndEntityInformationAbstract" xlink:to="dei_EntitySmallBusiness_637091893199337963" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637091893199337963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edit_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637091893199337963" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637091893199337963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edit_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityShellCompany_637091893199337963" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637091893199337963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edit_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_637091893199337963" order="24" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637091893199337963" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edit_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate_637091893199337963" order="25" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637091893199347962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edit_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus_637091893199347962" order="26" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637091893199347962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edit_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_637091893199347962" order="27" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637091893199347962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edit_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_637091893199347962" order="28" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637091893199347962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edit_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_637091893199347962" order="29" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Condensed Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637091893199347962" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_637091893199347962" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637091893199357968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637091893199347962" xlink:to="us-gaap_AssetsCurrentAbstract_637091893199357968" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637091893199357968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637091893199357968" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637091893199357968" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent_637091893199357968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637091893199357968" xlink:to="us-gaap_MarketableSecuritiesCurrent_637091893199357968" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent_637091893199357968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637091893199357968" xlink:to="us-gaap_ReceivablesNetCurrent_637091893199357968" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637091893199357968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637091893199357968" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637091893199357968" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637091893199357968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637091893199357968" xlink:to="us-gaap_AssetsCurrent_637091893199357968" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637091893199357968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637091893199347962" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637091893199357968" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637091893199357968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637091893199347962" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637091893199357968" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_637091893199357968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637091893199347962" xlink:to="us-gaap_OtherAssetsNoncurrent_637091893199357968" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637091893199357968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637091893199347962" xlink:to="us-gaap_Assets_637091893199357968" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637091893199357968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637091893199357968" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637091893199357968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637091893199357968" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637091893199357968" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637091893199357968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637091893199357968" xlink:to="us-gaap_AccountsPayableCurrent_637091893199357968" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637091893199367955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637091893199357968" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637091893199367955" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637091893199367955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637091893199357968" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637091893199367955" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637091893199367955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637091893199357968" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637091893199367955" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_637091893199367955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637091893199357968" xlink:to="us-gaap_OtherLiabilitiesCurrent_637091893199367955" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637091893199367955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637091893199357968" xlink:to="us-gaap_LiabilitiesCurrent_637091893199367955" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637091893199367955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637091893199357968" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637091893199367955" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_637091893199367955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637091893199357968" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_637091893199367955" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_637091893199367955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637091893199357968" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_637091893199367955" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637091893199367955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637091893199357968" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637091893199367955" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637091893199367955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637091893199357968" xlink:to="us-gaap_Liabilities_637091893199367955" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637091893199377950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637091893199357968" xlink:to="us-gaap_CommitmentsAndContingencies_637091893199377950" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_637091893199377950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637091893199357968" xlink:to="us-gaap_StockholdersEquityAbstract_637091893199377950" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637091893199377950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637091893199377950" xlink:to="us-gaap_PreferredStockValue_637091893199377950" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637091893199377950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637091893199377950" xlink:to="us-gaap_CommonStockValue_637091893199377950" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_637091893199377950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637091893199377950" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_637091893199377950" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637091893199377950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637091893199377950" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637091893199377950" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637091893199377950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637091893199377950" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637091893199377950" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637091893199377950" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637091893199377950" xlink:to="us-gaap_StockholdersEquity_637091893199377950" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637091893199387964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637091893199357968" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637091893199387964" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_635955513222531726" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockNoParValue" xlink:label="us-gaap_PreferredStockNoParValue_637091893199387964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_635955513222531726" xlink:to="us-gaap_PreferredStockNoParValue_637091893199387964" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_637091893199387964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_635955513222531726" xlink:to="us-gaap_PreferredStockSharesAuthorized_637091893199387964" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_637091893199387964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_635955513222531726" xlink:to="us-gaap_PreferredStockSharesIssued_637091893199387964" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637091893199387964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_635955513222531726" xlink:to="us-gaap_PreferredStockSharesOutstanding_637091893199387964" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637091893199387964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_635955513222531726" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637091893199387964" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637091893199387964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_635955513222531726" xlink:to="us-gaap_CommonStockSharesAuthorized_637091893199387964" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637091893199387964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_635955513222531726" xlink:to="us-gaap_CommonStockSharesIssued_637091893199387964" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637091893199387964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_635955513222531726" xlink:to="us-gaap_CommonStockSharesOutstanding_637091893199387964" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Condensed Consolidated Statements of Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637091893199397967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637091893199397967" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_637091893199397967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637091893199397967" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_637091893199397967" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_637091893199397967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_637091893199397967" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637091893199397967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637091893199397967" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637091893199397967" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637091893199397967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637091893199397967" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637091893199397967" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637091893199397967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637091893199397967" xlink:to="us-gaap_OperatingExpenses_637091893199397967" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637091893199397967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_637091893199397967" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_637091893199397967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_637091893199397967" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637091893199397967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637091893199397967" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637091893199397967" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet_637091893199397967" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637091893199397967" xlink:to="us-gaap_InvestmentIncomeNet_637091893199397967" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_637091893199407966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637091893199397967" xlink:to="us-gaap_NonoperatingIncomeExpense_637091893199407966" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637091893199407966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_637091893199407966" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_637091893199407966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_637091893199407966" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637091893199407966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637091893199407966" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended" xlink:title="00300 - Statement - Condensed Consolidated Statements of Comprehensive Loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637091893199407966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_NetIncomeLoss_637091893199407966" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_637091893199407966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_637091893199407966" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_637091893199407966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_637091893199407966" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_637091893199407966" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_637091893199407966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_637091893199407966" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Stockholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_636914384021574269" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637091893199417958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract_636914384021574269" xlink:to="us-gaap_StatementTable_637091893199417958" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637091893199417958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637091893199417958" xlink:to="us-gaap_StatementEquityComponentsAxis_637091893199417958" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637091893199417958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637091893199417958" xlink:to="us-gaap_CommonStockMember_637091893199417958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637091893199417958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637091893199417958" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637091893199417958" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_637091893199417958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637091893199417958" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_637091893199417958" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637091893199417958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637091893199417958" xlink:to="us-gaap_RetainedEarningsMember_637091893199417958" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637091893199417958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637091893199417958" xlink:to="us-gaap_EquityComponentDomain_637091893199417958" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637091893199417958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637091893199417958" xlink:to="us-gaap_StatementLineItems_637091893199417958" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637091893199417958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637091893199417958" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637091893199417958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637091893199417958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637091893199417958" xlink:to="us-gaap_StockholdersEquity_637091893199417958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637091893199417958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637091893199417958" xlink:to="us-gaap_SharesOutstanding_637091893199417958" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_637091893199417958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637091893199417958" xlink:to="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_637091893199417958" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637091893199417958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637091893199417958" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637091893199417958" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637091893199427965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_637091893199417958" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637091893199427965" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_StockIssuedDuringPeriodValueRepaymentOfNotes" xlink:label="edit_StockIssuedDuringPeriodValueRepaymentOfNotes_637091893199427965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637091893199417958" xlink:to="edit_StockIssuedDuringPeriodValueRepaymentOfNotes_637091893199427965" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_StockIssuedDuringPeriodSharesRepaymentOfDebt" xlink:label="edit_StockIssuedDuringPeriodSharesRepaymentOfDebt_637091893199427965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edit_StockIssuedDuringPeriodValueRepaymentOfNotes_637091893199427965" xlink:to="edit_StockIssuedDuringPeriodSharesRepaymentOfDebt_637091893199427965" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_637091893199427965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637091893199417958" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_637091893199427965" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_637091893199427965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_637091893199427965" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_637091893199427965" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637091893199427965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637091893199417958" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637091893199427965" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637091893199427965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637091893199427965" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637091893199427965" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_637091893199427965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637091893199417958" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_637091893199427965" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_637091893199427965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_637091893199427965" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_637091893199427965" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_637091893199427965" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637091893199417958" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_637091893199427965" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_637091893199437964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_637091893199427965" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_637091893199437964" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637091893199437964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637091893199417958" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637091893199437964" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_637091893199437964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637091893199417958" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_637091893199437964" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637091893199437964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637091893199417958" xlink:to="us-gaap_NetIncomeLoss_637091893199437964" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637091893199437964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637091893199417958" xlink:to="us-gaap_StockholdersEquity_637091893199437964" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637091893199437964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637091893199417958" xlink:to="us-gaap_SharesOutstanding_637091893199437964" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="8" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="extended" xlink:title="00405 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_636915341388727384" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637091893199447961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract_636915341388727384" xlink:to="us-gaap_StatementTable_637091893199447961" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637091893199447961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637091893199447961" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637091893199447961" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637091893199447961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637091893199447961" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637091893199447961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_637091893199447961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637091893199447961" xlink:to="us-gaap_IPOMember_637091893199447961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637091893199447961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637091893199447961" xlink:to="us-gaap_StatementLineItems_637091893199447961" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637091893199447961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637091893199447961" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637091893199447961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - Condensed Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637091893199447961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637091893199447961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637091893199447961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637091893199447961" xlink:to="us-gaap_ProfitLoss_637091893199447961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637091893199447961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637091893199447961" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637091893199447961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637091893199447961" xlink:to="us-gaap_ShareBasedCompensation_637091893199447961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637091893199447961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637091893199447961" xlink:to="us-gaap_Depreciation_637091893199447961" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_637091893199458004" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637091893199447961" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_637091893199458004" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_NoncashInvestmentInEquitySecurities" xlink:label="edit_NoncashInvestmentInEquitySecurities_637091893199458004" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637091893199447961" xlink:to="edit_NoncashInvestmentInEquitySecurities_637091893199458004" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense_637091893199474452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637091893199447961" xlink:to="us-gaap_OtherNoncashIncomeExpense_637091893199474452" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637091893199474452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637091893199447961" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637091893199474452" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637091893199474452" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637091893199474452" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637091893199474452" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637091893199477975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637091893199474452" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637091893199477975" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_IncreaseDecreaseInRightOfUseAssets" xlink:label="edit_IncreaseDecreaseInRightOfUseAssets_637091893199477975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637091893199474452" xlink:to="edit_IncreaseDecreaseInRightOfUseAssets_637091893199477975" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_637091893199477975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637091893199474452" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_637091893199477975" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637091893199477975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637091893199474452" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637091893199477975" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_637091893199477975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637091893199474452" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_637091893199477975" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637091893199477975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637091893199474452" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637091893199477975" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_IncreaseDecreaseInRightOfUseLiability" xlink:label="edit_IncreaseDecreaseInRightOfUseLiability_637091893199477975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637091893199474452" xlink:to="edit_IncreaseDecreaseInRightOfUseLiability_637091893199477975" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_637091893199477975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637091893199474452" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_637091893199477975" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637091893199477975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637091893199447961" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637091893199477975" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637091893199477975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637091893199477975" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637091893199477975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637091893199477975" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637091893199477975" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_637091893199487969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637091893199477975" xlink:to="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_637091893199487969" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_637091893199487969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637091893199477975" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_637091893199487969" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_637091893199487969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637091893199477975" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_637091893199487969" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637091893199487969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637091893199477975" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637091893199487969" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637091893199487969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637091893199487969" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637091893199487969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637091893199487969" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637091893199487969" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637091893199487969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637091893199487969" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637091893199487969" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans_637091893199487969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637091893199487969" xlink:to="us-gaap_ProceedsFromStockPlans_637091893199487969" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_637091893199497964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637091893199487969" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_637091893199497964" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637091893199497964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637091893199487969" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637091893199497964" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637091893199497964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637091893199497964" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637091893199497964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637091893199497964" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6370918931994979641" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6370918931994979641" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_637091893199497964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_637091893199497964" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_637091893199497964" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637091893199497964" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_637091893199497964" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ReceivableOfProceedsFromExerciseOfStockOptions" xlink:label="edit_ReceivableOfProceedsFromExerciseOfStockOptions_637091893199507975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637091893199497964" xlink:to="edit_ReceivableOfProceedsFromExerciseOfStockOptions_637091893199507975" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_637091893199507975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637091893199497964" xlink:to="us-gaap_OperatingLeasePayments_637091893199507975" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637091893199507975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637091893199497964" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637091893199507975" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ReclassificationOfLiabilityForFounderStockRepurchase" xlink:label="edit_ReclassificationOfLiabilityForFounderStockRepurchase_637091893199507975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637091893199497964" xlink:to="edit_ReclassificationOfLiabilityForFounderStockRepurchase_637091893199507975" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1_637091893199507975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637091893199497964" xlink:to="us-gaap_StockIssued1_637091893199507975" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_StockIssuedForAssetAcquisition" xlink:label="edit_StockIssuedForAssetAcquisition_637091893199507975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637091893199497964" xlink:to="edit_StockIssuedForAssetAcquisition_637091893199507975" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesIssued1" xlink:label="us-gaap_NotesIssued1_637091893199507975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637091893199497964" xlink:to="us-gaap_NotesIssued1_637091893199507975" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_DeferredRevenueAdjustmentFromEffectOfNewAccountingPrinciple" xlink:label="edit_DeferredRevenueAdjustmentFromEffectOfNewAccountingPrinciple_637091893199517968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637091893199497964" xlink:to="edit_DeferredRevenueAdjustmentFromEffectOfNewAccountingPrinciple_637091893199517968" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_StockIssuanceCostsIncurredButNotYetPaid" xlink:label="edit_StockIssuanceCostsIncurredButNotYetPaid_637091893199517968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637091893199497964" xlink:to="edit_StockIssuanceCostsIncurredButNotYetPaid_637091893199517968" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureNatureOfBusiness" xlink:type="extended" xlink:title="10101 - Disclosure - Nature of Business" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_637091893199517968" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations_637091893199517968" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_637091893199527978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_637091893199527978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndEquitySecurities" xlink:type="extended" xlink:title="10301 - Disclosure - Cash Equivalents, Marketable Securities and Equity Securities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_637091893199527978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_637091893199527978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="10401 - Disclosure - Fair Value Measurements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_637091893199527978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_637091893199527978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureAccruedExpenses" xlink:type="extended" xlink:title="10501 - Disclosure - Accrued Expenses" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_637091893199527978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_637091893199527978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNet" xlink:type="extended" xlink:title="10601 - Disclosure - Property and Equipment, net" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637091893199527978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637091893199527978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="10701 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637091893199527978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637091893199527978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreements" xlink:type="extended" xlink:title="10801 - Disclosure - Collaboration and License Agreements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_CollaborativeArrangementsAbstract" xlink:label="edit_CollaborativeArrangementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_637091893199537976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edit_CollaborativeArrangementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_637091893199537976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="10901 - Disclosure - Stock-based Compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637091893199537976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637091893199537976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="11001 - Disclosure - Net Loss per Share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_637091893199537976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_637091893199537976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureRelatedPartyTransactions" xlink:type="extended" xlink:title="11101 - Disclosure - Related-Party Transactions" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_637091893199537976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_637091893199537976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11201 - Disclosure - Subsequent Events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_637091893199537976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_637091893199537976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637091893199547959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637091893199547959" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637091893199547959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637091893199547959" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesTables" xlink:type="extended" xlink:title="30303 - Disclosure - Cash Equivalents, Marketable Securities and Corporate Equity Securities (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_637091893199547959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_637091893199547959" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="30403 - Disclosure - Fair Value Measurements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_637091893199547959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_637091893199547959" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureAccruedExpensesTables" xlink:type="extended" xlink:title="30503 - Disclosure - Accrued Expenses (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_637091893199547959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_637091893199547959" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetTables" xlink:type="extended" xlink:title="30603 - Disclosure - Property and Equipment, net (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_637091893199547959" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_637091893199547959" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended" xlink:title="30703 - Disclosure - Commitments and Contingencies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_637091893199557973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_637091893199557973" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_AssetsAndLiabilitiesLesseeOperatingLeaseTableTextBlock" xlink:label="edit_AssetsAndLiabilitiesLesseeOperatingLeaseTableTextBlock_637091893199557973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="edit_AssetsAndLiabilitiesLesseeOperatingLeaseTableTextBlock_637091893199557973" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_637091893199557973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock_637091893199557973" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637091893199557973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637091893199557973" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsTables" xlink:type="extended" xlink:title="30803 - Disclosure - Collaboration and License Agreements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_CollaborativeArrangementsAbstract" xlink:label="edit_CollaborativeArrangementsAbstract" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock" xlink:label="edit_ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock_637091893199557973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edit_CollaborativeArrangementsAbstract" xlink:to="edit_ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock_637091893199557973" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="edit_ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock_637091893199557973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edit_CollaborativeArrangementsAbstract" xlink:to="edit_ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock_637091893199557973" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="30903 - Disclosure - Stock-based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637091893199567979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637091893199567979" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_637091893199567979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_637091893199567979" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637091893199567979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637091893199567979" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="31003 - Disclosure - Net Loss per Share (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637091893199567979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637091893199567979" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureNatureOfBusinessDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Nature of Business (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637091893199567979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637091893199567979" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637091893199567979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637091893199567979" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637091893199567979" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637091893199567979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637091893199567979" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637091893199567979" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_AtMarket2018MarchOfferingMember" xlink:label="edit_AtMarket2018MarchOfferingMember_637091893199577977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637091893199567979" xlink:to="edit_AtMarket2018MarchOfferingMember_637091893199577977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_PublicAndAtMarketOfferingMember" xlink:label="edit_PublicAndAtMarketOfferingMember_637091893199577977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637091893199567979" xlink:to="edit_PublicAndAtMarketOfferingMember_637091893199577977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637091893199577977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637091893199567979" xlink:to="srt_CounterpartyNameAxis_637091893199577977" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637091893199577977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637091893199577977" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637091893199577977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_CowenAndCompanyLlcMember" xlink:label="edit_CowenAndCompanyLlcMember_637091893199577977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637091893199577977" xlink:to="edit_CowenAndCompanyLlcMember_637091893199577977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637091893199577977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637091893199567979" xlink:to="us-gaap_SubsequentEventTypeAxis_637091893199577977" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637091893199577977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637091893199577977" xlink:to="us-gaap_SubsequentEventTypeDomain_637091893199577977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637091893199577977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637091893199577977" xlink:to="us-gaap_SubsequentEventMember_637091893199577977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_637091893199577977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637091893199567979" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_637091893199577977" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637091893199577977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637091893199577977" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637091893199577977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_StockSalesAgreementThresholdSaleProceedsThatCanBeRaised" xlink:label="edit_StockSalesAgreementThresholdSaleProceedsThatCanBeRaised_637091893199577977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637091893199577977" xlink:to="edit_StockSalesAgreementThresholdSaleProceedsThatCanBeRaised_637091893199577977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637091893199577977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637091893199577977" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637091893199577977" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_SharesIssuedWeightedAveragePricePerShare" xlink:label="edit_SharesIssuedWeightedAveragePricePerShare_637091893199577977" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637091893199577977" xlink:to="edit_SharesIssuedWeightedAveragePricePerShare_637091893199577977" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ProceedsFromIssuanceOfCommonStockGross" xlink:label="edit_ProceedsFromIssuanceOfCommonStockGross_637091893199587975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637091893199577977" xlink:to="edit_ProceedsFromIssuanceOfCommonStockGross_637091893199587975" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_PercentageOfCashCommissionsPaid" xlink:label="edit_PercentageOfCashCommissionsPaid_637091893199587975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637091893199577977" xlink:to="edit_PercentageOfCashCommissionsPaid_637091893199587975" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ProceedsFromIssuanceOfCommonStockReceivable" xlink:label="edit_ProceedsFromIssuanceOfCommonStockReceivable_637091893199587975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637091893199577977" xlink:to="edit_ProceedsFromIssuanceOfCommonStockReceivable_637091893199587975" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_StockSalesAgreementAdditionalSaleProceedsThatCanBeRaised" xlink:label="edit_StockSalesAgreementAdditionalSaleProceedsThatCanBeRaised_637091893199587975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637091893199577977" xlink:to="edit_StockSalesAgreementAdditionalSaleProceedsThatCanBeRaised_637091893199587975" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637091893199587975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637091893199577977" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637091893199587975" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary Of Significant Accounting Policies - Recent Accounting Pronouncements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_636783060381355479" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_637091893199587975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_636783060381355479" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_637091893199587975" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637091893199587975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_637091893199587975" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637091893199587975" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_637091893199587975" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637091893199587975" xlink:to="us-gaap_TypeOfAdoptionMember_637091893199587975" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_637091893199597980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember_637091893199587975" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_637091893199597980" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_637091893199597980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_637091893199587975" xlink:to="srt_RestatementAxis_637091893199597980" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_637091893199597980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis_637091893199597980" xlink:to="srt_RestatementDomain_637091893199597980" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember_637091893199597980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain_637091893199597980" xlink:to="srt_RestatementAdjustmentMember_637091893199597980" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637091893199597980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_637091893199587975" xlink:to="us-gaap_StatementEquityComponentsAxis_637091893199597980" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637091893199597980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637091893199597980" xlink:to="us-gaap_EquityComponentDomain_637091893199597980" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637091893199597980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637091893199597980" xlink:to="us-gaap_RetainedEarningsMember_637091893199597980" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_637091893199597980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_637091893199587975" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_637091893199597980" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_637091893199597980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_637091893199597980" xlink:to="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_637091893199597980" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637091893199597980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_637091893199597980" xlink:to="us-gaap_Assets_637091893199597980" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637091893199597980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_637091893199597980" xlink:to="us-gaap_Liabilities_637091893199597980" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637091893199597980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_637091893199597980" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637091893199597980" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637091893199597980" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_637091893199597980" xlink:to="us-gaap_OperatingLeaseLiability_637091893199597980" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasePracticalExpedientsPackage" xlink:label="us-gaap_LeasePracticalExpedientsPackage_637091893199607974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_637091893199597980" xlink:to="us-gaap_LeasePracticalExpedientsPackage_637091893199607974" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasePracticalExpedientUseOfHindsight" xlink:label="us-gaap_LeasePracticalExpedientUseOfHindsight_637091893199607974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_637091893199597980" xlink:to="us-gaap_LeasePracticalExpedientUseOfHindsight_637091893199607974" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Cash Equivalents, Marketable Securities and Corporate Equity Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_637091893199607974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_637091893199607974" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_637091893199607974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_637091893199607974" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_637091893199607974" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637091893199607974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_637091893199607974" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637091893199607974" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember_637091893199607974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637091893199607974" xlink:to="us-gaap_CashEquivalentsMember_637091893199607974" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_637091893199607974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashEquivalentsMember_637091893199607974" xlink:to="us-gaap_MoneyMarketFundsMember_637091893199607974" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember_637091893199607974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashEquivalentsMember_637091893199607974" xlink:to="us-gaap_USTreasurySecuritiesMember_637091893199607974" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="us-gaap_USStatesAndPoliticalSubdivisionsMember_637091893199617978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashEquivalentsMember_637091893199607974" xlink:to="us-gaap_USStatesAndPoliticalSubdivisionsMember_637091893199617978" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_637091893199617978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_637091893199607974" xlink:to="us-gaap_FinancialInstrumentAxis_637091893199617978" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637091893199617978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_637091893199617978" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637091893199617978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="us-gaap_EquitySecuritiesMember_637091893199617978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637091893199617978" xlink:to="us-gaap_EquitySecuritiesMember_637091893199617978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_637091893199617978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_637091893199607974" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_637091893199617978" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_637091893199617978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_637091893199617978" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_637091893199617978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_637091893199617978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_637091893199617978" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_637091893199617978" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_637091893199617978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_637091893199617978" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_637091893199617978" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637091893199617978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_637091893199617978" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637091893199617978" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_637091893199617978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_637091893199617978" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_637091893199617978" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost" xlink:label="us-gaap_EquitySecuritiesFvNiCost_637091893199617978" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_637091893199617978" xlink:to="us-gaap_EquitySecuritiesFvNiCost_637091893199617978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi_637091893199627976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_637091893199617978" xlink:to="us-gaap_EquitySecuritiesFvNi_637091893199627976" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract_637091893199627976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_637091893199617978" xlink:to="us-gaap_MarketableSecuritiesAbstract_637091893199627976" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_MarketableSecuritiesAmortizedCost" xlink:label="edit_MarketableSecuritiesAmortizedCost_637091893199627976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract_637091893199627976" xlink:to="edit_MarketableSecuritiesAmortizedCost_637091893199627976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_MarketableSecuritiesUnrealizedGain" xlink:label="edit_MarketableSecuritiesUnrealizedGain_637091893199627976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract_637091893199627976" xlink:to="edit_MarketableSecuritiesUnrealizedGain_637091893199627976" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_MarketableSecuritiesUnrealizedLoss" xlink:label="edit_MarketableSecuritiesUnrealizedLoss_637091893199627976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract_637091893199627976" xlink:to="edit_MarketableSecuritiesUnrealizedLoss_637091893199627976" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities_637091893199627976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract_637091893199627976" xlink:to="us-gaap_MarketableSecurities_637091893199627976" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_637091893199627976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_637091893199617978" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_637091893199627976" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_637091893199627976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_637091893199617978" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_637091893199627976" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_637091893199627976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_637091893199617978" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_637091893199627976" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_637091893199637970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_637091893199617978" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_637091893199637970" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Fair Value Measurements - Recurring Basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_636235507863557054" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637091893199637970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_636235507863557054" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637091893199637970" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_637091893199637970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637091893199637970" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_637091893199637970" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_637091893199637970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_637091893199637970" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_637091893199637970" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_637091893199637970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_637091893199637970" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_637091893199637970" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637091893199637970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637091893199637970" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637091893199637970" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637091893199637970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637091893199637970" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637091893199637970" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_637091893199637970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637091893199637970" xlink:to="us-gaap_FairValueInputsLevel1Member_637091893199637970" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_637091893199637970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637091893199637970" xlink:to="us-gaap_FairValueInputsLevel2Member_637091893199637970" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_637091893199637970" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637091893199637970" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_637091893199637970" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637091893199647958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_637091893199637970" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637091893199647958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="us-gaap_CashEquivalentsMember_637091893199647958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637091893199647958" xlink:to="us-gaap_CashEquivalentsMember_637091893199647958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_637091893199647958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashEquivalentsMember_637091893199647958" xlink:to="us-gaap_MoneyMarketFundsMember_637091893199647958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember_637091893199647958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashEquivalentsMember_637091893199647958" xlink:to="us-gaap_USTreasurySecuritiesMember_637091893199647958" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="us-gaap_USStatesAndPoliticalSubdivisionsMember_637091893199647958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashEquivalentsMember_637091893199647958" xlink:to="us-gaap_USStatesAndPoliticalSubdivisionsMember_637091893199647958" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_637091893199647958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637091893199637970" xlink:to="us-gaap_FinancialInstrumentAxis_637091893199647958" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637091893199647958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_637091893199647958" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637091893199647958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember_6370918931996479581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637091893199647958" xlink:to="us-gaap_USTreasurySecuritiesMember_6370918931996479581" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_637091893199647958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637091893199647958" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_637091893199647958" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="us-gaap_EquitySecuritiesMember_637091893199647958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637091893199647958" xlink:to="us-gaap_EquitySecuritiesMember_637091893199647958" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637091893199647958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637091893199637970" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637091893199647958" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_637091893199657976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637091893199647958" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_637091893199657976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637091893199657976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_637091893199657976" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637091893199657976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost" xlink:label="us-gaap_EquitySecuritiesFvNiCost_637091893199657976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_637091893199657976" xlink:to="us-gaap_EquitySecuritiesFvNiCost_637091893199657976" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637091893199657976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_637091893199657976" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_637091893199657976" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_637091893199657976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_637091893199657976" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_637091893199657976" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_637091893199657976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_637091893199657976" xlink:to="us-gaap_AssetsFairValueDisclosure_637091893199657976" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_FairValueAssetsAndLiabilitiesTransfers" xlink:label="edit_FairValueAssetsAndLiabilitiesTransfers_637091893199657976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_637091893199657976" xlink:to="edit_FairValueAssetsAndLiabilitiesTransfers_637091893199657976" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Accrued Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_635968566178505279" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_637091893199667973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_635968566178505279" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_637091893199667973" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_AccruedIntellectualPropertyFees" xlink:label="edit_AccruedIntellectualPropertyFees_637091893199667973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_635968566178505279" xlink:to="edit_AccruedIntellectualPropertyFees_637091893199667973" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ProcessAndPlatformDevelopmentCostsCurrent" xlink:label="edit_ProcessAndPlatformDevelopmentCostsCurrent_637091893199667973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_635968566178505279" xlink:to="edit_ProcessAndPlatformDevelopmentCostsCurrent_637091893199667973" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_637091893199667973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_635968566178505279" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_637091893199667973" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_637091893199667973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_635968566178505279" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_637091893199667973" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_SublicensingAndSuccessPaymentExpenses" xlink:label="edit_SublicensingAndSuccessPaymentExpenses_637091893199667973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_635968566178505279" xlink:to="edit_SublicensingAndSuccessPaymentExpenses_637091893199667973" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637091893199667973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_635968566178505279" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637091893199667973" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Property and Equipment, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637091893199667973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637091893199667973" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637091893199667973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637091893199667973" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637091893199667973" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637091893199667973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637091893199667973" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637091893199667973" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_LaboratoryEquipmentMember" xlink:label="edit_LaboratoryEquipmentMember_637091893199667973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637091893199667973" xlink:to="edit_LaboratoryEquipmentMember_637091893199667973" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_637091893199677989" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637091893199667973" xlink:to="us-gaap_LeaseholdImprovementsMember_637091893199677989" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_637091893199677989" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637091893199667973" xlink:to="us-gaap_ComputerEquipmentMember_637091893199677989" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember_637091893199677989" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637091893199667973" xlink:to="us-gaap_ConstructionInProgressMember_637091893199677989" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_637091893199677989" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637091893199667973" xlink:to="us-gaap_FurnitureAndFixturesMember_637091893199677989" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_637091893199677989" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637091893199667973" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_637091893199677989" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember_637091893199677989" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637091893199667973" xlink:to="us-gaap_BuildingMember_637091893199677989" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_637091893199677989" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637091893199667973" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_637091893199677989" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637091893199677989" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637091893199677989" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637091893199677989" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637091893199677989" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637091893199677989" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637091893199677989" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637091893199677989" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637091893199677989" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637091893199677989" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Commitments and Contingencies - Operating Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_637091893199687997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_637091893199687997" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637091893199687997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637091893199687997" xlink:to="srt_CounterpartyNameAxis_637091893199687997" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637091893199687997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637091893199687997" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637091893199687997" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_HurleyStreetLeaseMember" xlink:label="edit_HurleyStreetLeaseMember_637091893199687997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637091893199687997" xlink:to="edit_HurleyStreetLeaseMember_637091893199687997" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_FacilitySubleaseArrangementMember" xlink:label="edit_FacilitySubleaseArrangementMember_637091893199687997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637091893199687997" xlink:to="edit_FacilitySubleaseArrangementMember_637091893199687997" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_637091893199687997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637091893199687997" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_637091893199687997" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_AreaOfLeasedSpace" xlink:label="edit_AreaOfLeasedSpace_637091893199687997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637091893199687997" xlink:to="edit_AreaOfLeasedSpace_637091893199687997" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_637091893199687997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637091893199687997" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_637091893199687997" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_637091893199687997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637091893199687997" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_637091893199687997" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_637091893199687997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637091893199687997" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_637091893199687997" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesDerecognitionOfBalancesDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Commitments and Contingencies - Derecognition of Balances (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_637091893199687997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_637091893199687997" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637091893199687997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637091893199687997" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637091893199687997" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_637091893199698005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637091893199687997" xlink:to="us-gaap_TypeOfAdoptionMember_637091893199698005" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_637091893199698005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember_637091893199698005" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_637091893199698005" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_637091893199698005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637091893199687997" xlink:to="srt_RestatementAxis_637091893199698005" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_637091893199698005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis_637091893199698005" xlink:to="srt_RestatementDomain_637091893199698005" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember_637091893199698005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain_637091893199698005" xlink:to="srt_RestatementAdjustmentMember_637091893199698005" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_637091893199698005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637091893199687997" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_637091893199698005" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637091893199698005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637091893199698005" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637091893199698005" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_637091893199698005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637091893199698005" xlink:to="us-gaap_OtherLiabilitiesCurrent_637091893199698005" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_637091893199698005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637091893199698005" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_637091893199698005" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637091893199698005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637091893199698005" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637091893199698005" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_LesseeOperatingLeaseLaboratorySpaceNumber" xlink:label="edit_LesseeOperatingLeaseLaboratorySpaceNumber_637091893199698005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637091893199698005" xlink:to="edit_LesseeOperatingLeaseLaboratorySpaceNumber_637091893199698005" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_NumberOfOperatingLeasesForManufacturingSpace" xlink:label="edit_NumberOfOperatingLeasesForManufacturingSpace_637091893199698005" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637091893199698005" xlink:to="edit_NumberOfOperatingLeasesForManufacturingSpace_637091893199698005" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesRightOfUseAssetAndLeaseLiabilityDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Commitments and Contingencies - Right of Use Asset and Lease Liability (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract_637091893199708095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_AssetsAndLiabilitiesLesseeAbstract_637091893199708095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637091893199708095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_637091893199708095" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637091893199708095" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637091893199708095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_637091893199708095" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637091893199708095" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637091893199757973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAndLiabilitiesLesseeAbstract_637091893199708095" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637091893199757973" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseCostsDetails" xlink:type="extended" xlink:title="40704 - Disclosure - Commitments and Contingencies - Operating Lease Costs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_636928166899656136" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract_637091893199757973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_636928166899656136" xlink:to="us-gaap_LeaseCostAbstract_637091893199757973" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_637091893199757973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_637091893199757973" xlink:to="us-gaap_OperatingLeaseCost_637091893199757973" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost_637091893199757973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_637091893199757973" xlink:to="us-gaap_VariableLeaseCost_637091893199757973" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost_637091893199757973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_637091893199757973" xlink:to="us-gaap_LeaseCost_637091893199757973" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails" xlink:type="extended" xlink:title="40705 - Disclosure - Commitments and Contingencies - Maturities of Lease Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637091893199757973" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637091893199757973" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_637091893199767984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637091893199757973" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_637091893199767984" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637091893199767984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637091893199757973" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637091893199767984" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637091893199767984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637091893199757973" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637091893199767984" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637091893199767984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637091893199757973" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637091893199767984" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637091893199767984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637091893199757973" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637091893199767984" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_637091893199767984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637091893199757973" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_637091893199767984" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637091893199767984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637091893199757973" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637091893199767984" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637091893199767984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637091893199757973" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637091893199767984" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637091893199767984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637091893199757973" xlink:to="us-gaap_OperatingLeaseLiability_637091893199767984" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_637091893199767984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637091893199757973" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_637091893199767984" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_637091893199767984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_637091893199757973" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_637091893199767984" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesLicensorExpenseReimbursementDetails" xlink:type="extended" xlink:title="40706 - Disclosure - Commitments and Contingencies - Licensor Expense Reimbursement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable_637091893199777999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherCommitmentsTable_637091893199777999" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis_637091893199777999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_637091893199777999" xlink:to="us-gaap_OtherCommitmentsAxis_637091893199777999" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain_637091893199777999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis_637091893199777999" xlink:to="us-gaap_OtherCommitmentsDomain_637091893199777999" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_CommitmentToReimburseLicensorMember" xlink:label="edit_CommitmentToReimburseLicensorMember_637091893199777999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain_637091893199777999" xlink:to="edit_CommitmentToReimburseLicensorMember_637091893199777999" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems_637091893199777999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_637091893199777999" xlink:to="us-gaap_OtherCommitmentsLineItems_637091893199777999" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_637091893199777999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637091893199777999" xlink:to="us-gaap_ProfessionalAndContractServicesExpense_637091893199777999" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesResearchFundingPaymentsDetails" xlink:type="extended" xlink:title="40707 - Disclosure - Commitments and Contingencies - Research Funding Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637091893199777999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_StatementTable_637091893199777999" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis_637091893199777999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637091893199777999" xlink:to="us-gaap_OtherCommitmentsAxis_637091893199777999" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain_637091893199777999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis_637091893199777999" xlink:to="us-gaap_OtherCommitmentsDomain_637091893199777999" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ResearchFundingPaymentsMember" xlink:label="edit_ResearchFundingPaymentsMember_637091893199777999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain_637091893199777999" xlink:to="edit_ResearchFundingPaymentsMember_637091893199777999" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637091893199777999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637091893199777999" xlink:to="us-gaap_TypeOfArrangementAxis_637091893199777999" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637091893199777999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637091893199777999" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637091893199777999" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_SponsoredResearchAgreementMember" xlink:label="edit_SponsoredResearchAgreementMember_637091893199787981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637091893199777999" xlink:to="edit_SponsoredResearchAgreementMember_637091893199787981" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637091893199787981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637091893199777999" xlink:to="srt_CounterpartyNameAxis_637091893199787981" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637091893199787981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637091893199787981" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637091893199787981" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_BroadInstituteIncMember" xlink:label="edit_BroadInstituteIncMember_637091893199787981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637091893199787981" xlink:to="edit_BroadInstituteIncMember_637091893199787981" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems_637091893199787981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637091893199777999" xlink:to="us-gaap_OtherCommitmentsLineItems_637091893199787981" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_FundingPaymentsDueAndPayableOne" xlink:label="edit_FundingPaymentsDueAndPayableOne_637091893199787981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637091893199787981" xlink:to="edit_FundingPaymentsDueAndPayableOne_637091893199787981" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_FundingPaymentsDueAndPayableTwo" xlink:label="edit_FundingPaymentsDueAndPayableTwo_637091893199787981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637091893199787981" xlink:to="edit_FundingPaymentsDueAndPayableTwo_637091893199787981" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_637091893199787981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637091893199787981" xlink:to="us-gaap_NotesPayableCurrent_637091893199787981" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637091893199787981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637091893199787981" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637091893199787981" order="4" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesNotesPayableDetails" xlink:type="extended" xlink:title="40708 - Disclosure - Commitments and Contingencies - Notes Payable (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_636238755337687730" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable_637091893199787981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_636238755337687730" xlink:to="us-gaap_OtherCommitmentsTable_637091893199787981" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637091893199798093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_637091893199787981" xlink:to="srt_CounterpartyNameAxis_637091893199798093" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637091893199798093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637091893199798093" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637091893199798093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_BroadAndWageningenUniversityMember" xlink:label="edit_BroadAndWageningenUniversityMember_637091893199798093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637091893199798093" xlink:to="edit_BroadAndWageningenUniversityMember_637091893199798093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_BroadInstituteIncMember" xlink:label="edit_BroadInstituteIncMember_637091893199798093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edit_BroadAndWageningenUniversityMember_637091893199798093" xlink:to="edit_BroadInstituteIncMember_637091893199798093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637091893199798093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_637091893199787981" xlink:to="us-gaap_TypeOfArrangementAxis_637091893199798093" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637091893199798093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637091893199798093" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637091893199798093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_SponsoredResearchAgreementMember" xlink:label="edit_SponsoredResearchAgreementMember_637091893199798093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637091893199798093" xlink:to="edit_SponsoredResearchAgreementMember_637091893199798093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis_637091893199798093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_637091893199787981" xlink:to="us-gaap_ShortTermDebtTypeAxis_637091893199798093" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_637091893199798093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis_637091893199798093" xlink:to="us-gaap_ShortTermDebtTypeDomain_637091893199798093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_InitialNotesMember" xlink:label="edit_InitialNotesMember_637091893199798093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain_637091893199798093" xlink:to="edit_InitialNotesMember_637091893199798093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems_637091893199798093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_637091893199787981" xlink:to="us-gaap_OtherCommitmentsLineItems_637091893199798093" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesAndLoansPayableAbstract" xlink:label="us-gaap_NotesAndLoansPayableAbstract_637091893199798093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_637091893199798093" xlink:to="us-gaap_NotesAndLoansPayableAbstract_637091893199798093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_637091893199798093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesAndLoansPayableAbstract_637091893199798093" xlink:to="us-gaap_NotesPayableCurrent_637091893199798093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637091893199798093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesAndLoansPayableAbstract_637091893199798093" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637091893199798093" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ThresholdPeriodInterestFreeDebtInstrumentFaceAmount" xlink:label="edit_ThresholdPeriodInterestFreeDebtInstrumentFaceAmount_637091893199807972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesAndLoansPayableAbstract_637091893199798093" xlink:to="edit_ThresholdPeriodInterestFreeDebtInstrumentFaceAmount_637091893199807972" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_637091893199807972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesAndLoansPayableAbstract_637091893199798093" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_637091893199807972" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognitionDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Collaboration and License Agreements - Revenue Recognition (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_CollaborativeArrangementsAbstract" xlink:label="edit_CollaborativeArrangementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesNetCurrentAbstract" xlink:label="us-gaap_ReceivablesNetCurrentAbstract_637091893199807972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edit_CollaborativeArrangementsAbstract" xlink:to="us-gaap_ReceivablesNetCurrentAbstract_637091893199807972" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent_637091893199807972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesNetCurrentAbstract_637091893199807972" xlink:to="us-gaap_ReceivablesNetCurrent_637091893199807972" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_AccountsReceivableAdditions" xlink:label="edit_AccountsReceivableAdditions_637091893199807972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesNetCurrentAbstract_637091893199807972" xlink:to="edit_AccountsReceivableAdditions_637091893199807972" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_AccountsReceivableDeductions" xlink:label="edit_AccountsReceivableDeductions_637091893199807972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesNetCurrentAbstract_637091893199807972" xlink:to="edit_AccountsReceivableDeductions_637091893199807972" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent_6370918931998079721" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesNetCurrentAbstract_637091893199807972" xlink:to="us-gaap_ReceivablesNetCurrent_6370918931998079721" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityAbstract" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract_637091893199817979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edit_CollaborativeArrangementsAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityAbstract_637091893199817979" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_637091893199817979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract_637091893199817979" xlink:to="us-gaap_ContractWithCustomerLiability_637091893199817979" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ContractWithCustomerLiabilityAdditions" xlink:label="edit_ContractWithCustomerLiabilityAdditions_637091893199817979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract_637091893199817979" xlink:to="edit_ContractWithCustomerLiabilityAdditions_637091893199817979" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ContractWithCustomerLiabilityDeductions" xlink:label="edit_ContractWithCustomerLiabilityDeductions_637091893199817979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract_637091893199817979" xlink:to="edit_ContractWithCustomerLiabilityDeductions_637091893199817979" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_6370918931998179791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract_637091893199817979" xlink:to="us-gaap_ContractWithCustomerLiability_6370918931998179791" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="7" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilityDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Collaboration and License Agreements - Contract Assets and Liability (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_CollaborativeArrangementsAbstract" xlink:label="edit_CollaborativeArrangementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract" xlink:label="us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract_637091893199817979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edit_CollaborativeArrangementsAbstract" xlink:to="us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract_637091893199817979" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_637091893199817979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract_637091893199817979" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_637091893199817979" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:label="us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_637091893199817979" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract_637091893199817979" xlink:to="us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_637091893199817979" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsSummaryOfAgreementDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Collaboration and License Agreements - Summary of Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_CollaborativeArrangementsAbstract" xlink:label="edit_CollaborativeArrangementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637091893199827988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edit_CollaborativeArrangementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637091893199827988" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637091893199827988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637091893199827988" xlink:to="us-gaap_TypeOfArrangementAxis_637091893199827988" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637091893199827988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637091893199827988" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637091893199827988" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_CollaborationAndLicenseAgreementMember" xlink:label="edit_CollaborationAndLicenseAgreementMember_637091893199827988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637091893199827988" xlink:to="edit_CollaborationAndLicenseAgreementMember_637091893199827988" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_StrategicAllianceMember" xlink:label="edit_StrategicAllianceMember_637091893199827988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637091893199827988" xlink:to="edit_StrategicAllianceMember_637091893199827988" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_637091893199827988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637091893199827988" xlink:to="srt_CounterpartyNameAxis_637091893199827988" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_637091893199827988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_637091893199827988" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_637091893199827988" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_JunoTherapeuticsMember" xlink:label="edit_JunoTherapeuticsMember_637091893199827988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637091893199827988" xlink:to="edit_JunoTherapeuticsMember_637091893199827988" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_AllerganMember" xlink:label="edit_AllerganMember_637091893199827988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_637091893199827988" xlink:to="edit_AllerganMember_637091893199827988" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637091893199827988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637091893199827988" xlink:to="us-gaap_StatementLineItems_637091893199827988" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ResearchProgramTerm" xlink:label="edit_ResearchProgramTerm_637091893199827988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637091893199827988" xlink:to="edit_ResearchProgramTerm_637091893199827988" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_NumberOfCollaborationDevelopmentPrograms" xlink:label="edit_NumberOfCollaborationDevelopmentPrograms_637091893199827988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637091893199827988" xlink:to="edit_NumberOfCollaborationDevelopmentPrograms_637091893199827988" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_NumberOfAdditionalDevelopmentAndCommercializationLicenseToBePurchased" xlink:label="edit_NumberOfAdditionalDevelopmentAndCommercializationLicenseToBePurchased_637091893199827988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637091893199827988" xlink:to="edit_NumberOfAdditionalDevelopmentAndCommercializationLicenseToBePurchased_637091893199827988" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_637091893199827988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637091893199827988" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_637091893199827988" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_637091893199827988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637091893199827988" xlink:to="us-gaap_ContractWithCustomerLiability_637091893199827988" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637091893199844482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637091893199827988" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637091893199844482" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_637091893199844482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637091893199827988" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_637091893199844482" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent_637091893199844482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637091893199827988" xlink:to="us-gaap_ReceivablesNetCurrent_637091893199844482" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ProgramExpense" xlink:label="edit_ProgramExpense_637091893199847990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637091893199827988" xlink:to="edit_ProgramExpense_637091893199847990" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ShareOfExpenseRecognizedPercentage" xlink:label="edit_ShareOfExpenseRecognizedPercentage_637091893199847990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637091893199827988" xlink:to="edit_ShareOfExpenseRecognizedPercentage_637091893199847990" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Stock-based Compensation - Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637091893199847990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637091893199847990" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637091893199847990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637091893199847990" xlink:to="us-gaap_IncomeStatementLocationAxis_637091893199847990" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637091893199847990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637091893199847990" xlink:to="us-gaap_IncomeStatementLocationDomain_637091893199847990" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637091893199847990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637091893199847990" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637091893199847990" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_637091893199857987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637091893199847990" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_637091893199857987" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637091893199857987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637091893199847990" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637091893199857987" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637091893199857987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637091893199857987" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637091893199857987" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Stock-based Compensation - Restricted Stock and Stock Options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637091893199857987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637091893199857987" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637091893199857987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637091893199857987" xlink:to="us-gaap_AwardTypeAxis_637091893199857987" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637091893199857987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637091893199857987" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637091893199857987" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637091893199857987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637091893199857987" xlink:to="us-gaap_EmployeeStockOptionMember_637091893199857987" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637091893199857987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637091893199857987" xlink:to="srt_TitleOfIndividualAxis_637091893199857987" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637091893199857987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637091893199857987" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637091893199857987" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_EmployeeAndDirectorMember" xlink:label="edit_EmployeeAndDirectorMember_637091893199857987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637091893199857987" xlink:to="edit_EmployeeAndDirectorMember_637091893199857987" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember_637091893199867993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637091893199857987" xlink:to="srt_ChiefExecutiveOfficerMember_637091893199867993" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637091893199867993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637091893199857987" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637091893199867993" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637091893199867993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637091893199867993" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637091893199867993" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637091893199867993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637091893199867993" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637091893199867993" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637091893199867993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637091893199867993" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637091893199867993" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_637091893199867993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637091893199867993" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_637091893199867993" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_637091893199867993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637091893199867993" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_637091893199867993" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6370918931998679931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637091893199867993" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6370918931998679931" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637091893199877993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637091893199867993" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637091893199877993" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637091893199877993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637091893199877993" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637091893199877993" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637091893199877993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637091893199877993" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637091893199877993" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_637091893199877993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637091893199877993" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_637091893199877993" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_637091893199877993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637091893199877993" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_637091893199877993" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6370918931998779931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637091893199877993" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6370918931998779931" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637091893199877993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637091893199867993" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637091893199877993" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637091893199877993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637091893199877993" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637091893199877993" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_637091893199877993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637091893199877993" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_637091893199877993" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637091893199887987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637091893199877993" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637091893199887987" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637091893199887987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637091893199877993" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637091893199887987" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637091893199887987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637091893199877993" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637091893199887987" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_637091893199887987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637091893199877993" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_637091893199887987" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6370918931998879871" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637091893199877993" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6370918931998879871" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637091893199887987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637091893199877993" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637091893199887987" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637091893199887987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637091893199877993" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637091893199887987" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637091893199897997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637091893199877993" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637091893199897997" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637091893199897997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637091893199877993" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637091893199897997" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_637091893199897997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637091893199877993" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_637091893199897997" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637091893199897997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637091893199877993" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637091893199897997" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637091893199897997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637091893199877993" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637091893199897997" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637091893199907996" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637091893199877993" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637091893199907996" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637091893199907996" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637091893199877993" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637091893199907996" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637091893199907996" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637091893199877993" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637091893199907996" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637091893199907996" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637091893199877993" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637091893199907996" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureNetLossPerShareDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Net Loss per Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637091893199917994" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637091893199917994" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637091893199917994" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637091893199917994" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637091893199917994" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637091893199917994" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637091893199917994" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637091893199917994" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_AtMarketOfferingMember" xlink:label="edit_AtMarketOfferingMember_637091893199917994" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637091893199917994" xlink:to="edit_AtMarketOfferingMember_637091893199917994" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637091893199917994" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637091893199917994" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637091893199917994" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637091893199917994" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637091893199917994" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637091893199917994" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_637091893199917994" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637091893199917994" xlink:to="us-gaap_RestrictedStockMember_637091893199917994" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637091893199917994" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637091893199917994" xlink:to="us-gaap_EmployeeStockOptionMember_637091893199917994" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637091893199927997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637091893199917994" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637091893199927997" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637091893199927997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637091893199927997" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637091893199927997" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637091893199927997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637091893199927997" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637091893199927997" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Related-Party Transactions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637091893199927997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637091893199927997" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_637091893199927997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637091893199927997" xlink:to="us-gaap_RelatedPartyTransactionAxis_637091893199927997" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_637091893199927997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_637091893199927997" xlink:to="us-gaap_RelatedPartyTransactionDomain_637091893199927997" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_RentAndFacilityRelatedFeesMember" xlink:label="edit_RentAndFacilityRelatedFeesMember_637091893199927997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_637091893199927997" xlink:to="edit_RentAndFacilityRelatedFeesMember_637091893199927997" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_637091893199927997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637091893199927997" xlink:to="us-gaap_RelatedPartyTransactionLineItems_637091893199927997" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_637091893199927997" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637091893199927997" xlink:to="us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_637091893199927997" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.editasmedicine.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_637091893199937998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable_637091893199937998" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637091893199937998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637091893199937998" xlink:to="us-gaap_SubsequentEventTypeAxis_637091893199937998" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637091893199937998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637091893199937998" xlink:to="us-gaap_SubsequentEventTypeDomain_637091893199937998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637091893199937998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637091893199937998" xlink:to="us-gaap_SubsequentEventMember_637091893199937998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637091893199937998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637091893199937998" xlink:to="srt_TitleOfIndividualAxis_637091893199937998" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637091893199937998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637091893199937998" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637091893199937998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_ChiefMedicalOfficerMember" xlink:label="edit_ChiefMedicalOfficerMember_637091893199937998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637091893199937998" xlink:to="edit_ChiefMedicalOfficerMember_637091893199937998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637091893199937998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637091893199937998" xlink:to="us-gaap_AwardTypeAxis_637091893199937998" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637091893199937998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637091893199937998" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637091893199937998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637091893199937998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637091893199937998" xlink:to="us-gaap_EmployeeStockOptionMember_637091893199937998" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_637091893199937998" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637091893199937998" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_637091893199937998" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637091893199948007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637091893199937998" xlink:to="us-gaap_TypeOfArrangementAxis_637091893199948007" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637091893199948007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637091893199948007" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637091893199948007" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_JunoTherapeuticsMember" xlink:label="edit_JunoTherapeuticsMember_637091893199948007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637091893199948007" xlink:to="edit_JunoTherapeuticsMember_637091893199948007" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_637091893199948007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637091893199937998" xlink:to="us-gaap_SubsequentEventLineItems_637091893199948007" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="edit-20190930.xsd#edit_CollaborationAndLicenseAgreementAmendmentFeeReceived" xlink:label="edit_CollaborationAndLicenseAgreementAmendmentFeeReceived_637091893199948007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637091893199948007" xlink:to="edit_CollaborationAndLicenseAgreementAmendmentFeeReceived_637091893199948007" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637091893199948007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637091893199948007" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637091893199948007" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637091893199948007" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637091893199948007" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637091893199948007" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001558370-19-010798-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-19-010798-xbrl.zip
M4$L#!!0    ( (> ;$]4JQ./J0\  ,JQ   1    961I="TR,#$Y,#DS,"YX
M<V3M7>MSV[@1_]Z9_@^HOS2=.5F2[3SL2:[C1WQUQZ^QG=[UTPU,KB0T%*"
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MR "VSM5F'0<X$TS1(M)&M7EHY#,-_T#2IDG*GU"N#2AJG83-9\M?13WXVV!
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MYHAFOC_>Q-"(*A$?P3\N\?&!2T<-4:QA5'%CNS 6O_+[P?T8,\G)1O&H6OA
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M?&*D BMVT@J@6@?AR6DVK;< $Y ;/'[]W! ]>88F?_T_4$L#!!0    ( (>
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MSX!"DN"(3BZ; $B3CIBTO$SH'-34,2E2WE:PT__.<_$RT@6O0ZHN2Q$3%88
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MQ+/M0?3:[%>:_[EA\RUQ]\.(>-O2W',[&H[@PI/1&IG:3,R1N)]>FYO:,MD
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M-C4GA[G:OJ8E;)O1"E6.3,"-$:@TMK[%64HZ9!G41@$I*HXPA\9V9U/W1<5
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MK>/%Q;"H9+J$O<31VR/XH:._,8;M&2*&C@%*S+A'B.H<8BJ;G)U#X-K_ U/
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MVV44,%H19-6^T'4<0RVTMML5VIV0^GP_I<OK:YT]L%]<TU=@>+4 N(WIAZ)
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MET7 HG%EC1P224*12BI2B$5@@!!),+[D;:JYC0T\49K;84)=E/9FZ]4]LZA
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M.VITZV\(_4BMZHL>]0:H8B9FDR]-EQ\>:J<%2XG?#-I(,XBK.&*,Y*:P1^N
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M1=,EC5=#.4:<+GDL1BR&NGB3JGKNG.:W F]"/_6=X&.4*N[7JULA=;$.M<H
M][P)]H"V1>))5](Y7Q("XYDCU@ET+M3A-&W&HU/K9C3SLCR2B$(60HMD)*IQ
M;J#=$S.<]%-?2L'4Z88==GIJ8>"H+,^P/$N:G#VKT8+BL'+.&>$X3+#V\Y]9
MP>0): KOES_[[CH(?$CA;3GX5#;%C%@="E;'G,WML&-2E]B3QD-)P9PX.?>Y
M#S8GTKZD2PK"5D\Q9]/2(+#\/UD8/>YH[!QHEOINRYI*V1(SK+2K5Z)*<S/L
MH-(A]=#Q!F2)3'=FM)A++9M8,9>.!I&"@0^-GYU0C1!G+3 C0[,Z)2+4O\:.
M! II)XTJ"IXSHX-A50MR-L%@(I7L'8K<A&ZTIP]LO/)UT"UP@L68^@BOO0=2
M'.FAKGQ TM(<\2&)CM3#=P&!-BF)DX*Z]>,]A=:MAWQ=?98YFM4'?JT=EC>B
M#9V(M8QIJR> V+2>SY?+Y.+0DVJ9YK>36Z\?Z?5$[M<]U)>]6Z,;8A_O(_WH
MJZ2P%2X7\BTNOMN]0C2K"4[>%+/G['^F(5L%!TSIM;=G:Q:^!^J_4!UWU^V+
MW.%[F4!V>:V.B)V^G_Q#QWS.A7M]G0\2QY_7#+PX3(V/Q4O'GYW8ZT@:/6V#
MW)D;5:I=!Y8;(';.9CD'[W4 -2R9H$Y,WS&I/'A2BGF86!]+%WC?':LV>;D)
M+G]EDM"#IV0_.ONN--))6"%W@2D-7$]@-<\'L4-.JN[P?%)X%8-S)+)8I'9W
M_]V1R USV8@ !0D:8(H& 0E(:#T#%Z&Y91BUODZ_VA^"Z$CI0QJYOV\.8)[6
M<+VM/7)(ZU15QB5E8\3@TBWST"%;4":<-!&T+4?<TVDKE(PX27,EJI(XE=R2
M_>O4)=E'?W_TTX!NMC>AY[_X7L86%.=!=5L[I"[8J1JXGK(10I?KEG5PY0R@
M"M7P*KJFH^UA(_%7/]W=P]U5\(J=?WB,KG@ITL;@>1B%)8U>/7,HQW5[]Z6,
M>$TMQOG"IN8+P)+(/*'@J^!J*=BT9YD3E#!_ :R88V$[VX^IF[95TFYKC-2S
M]90L\Y24+;&G+'4+/C8R3,1I1$Y\[BS&Z?43YTTY;9OY2[/_E/.&'9<[GVZO
MOO!:ZB\,4>&ILV;,Z6Z-%'0TU2Q"AY:F2,,$'8D'WP0"VJ0D3G+JECS2DK8F
M$XW3#T[\.TT991JKWF5M;XG4S334JQ*0&YMAG]4[I)XT(=E)R9XSA^<H.?>Y
M4Y.G47Z=$D&7%(2M)BO/I:3%XV.V+/+\@./; \.YV$]]FEQ]<8/,H]XU<V78
MNL^$%VRV5TX,0S"YH['8N#\V$V@[C)Z4(U(TG-'<M8/RZ=@A#'[FU'JP[TND
M247;^HE^L\J=I_,:W1;ID>VGYEU]%N<;)H]7%0,<P7&T+=U7[<K/FA6>QKZ;
M4H^?L77E@3>V1>[.K2J>Y'J?-T3LN.WRCDAFSJGF9\O6\[=G4-*F _+BLW=.
MG!ZE%RU:HN7V'NB=L5/=NDLJFZ-VS&ZIAX]<4:R8$Y??:K$>+RJT;@T6N_HL
M<S2KP\36#LL;T8:"I)8Q;34ZQ*;UJ%="PW0=>M>.ZP=^>LQY7].V,J(:?9#Z
M9R^5I>="VSM@WWW6EM_ /K1X CE_&&N;<RPKZ6_AS/+@^%[QH'+QQ8&-=7_V
MJJ0S& ;RKIDE"A:D<&Y@8O<9T3E45PX"DS5-X>3M _O3=8*V4^C.QI@QJU/)
MJEBIJB5VE.H6?.A0O&.>P&;/SY"/YM'$?P[%.5FT)2X_MMT+KG! !FSGKD\Z
MF>+B4#HG;?D WH:J:+;//H5^FMP_?.JSC7;6!RD^]5*Y95NMW@'UFD=';F/;
M;)P^N2</Y!.N+;=Y%/^6<4B^DQ7^MQ\JX6[97^S#XJ.<V'___P%02P,$%
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MG]QH\04U^\(W(J:0BW=?NI+XG$*THIE<1:$'0HAJ^)<D"GP/H?C2"1#/G^<
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MNP]1Z$*VXLWW)4)WM*'K!Z!VC?(2R=$_JC]K'&9%M946!EF2]U LPHXC[L<
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M&8=224'-HB1;4JVV? OR$EVX?V1^#"!?X,)*/QX#)TPO0@_=W>-($,:3&?8
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MB5$M@E G!BC.IJ_IB1OK)KQE8(FU$&I%N(TI9(@,%36QK86*&,6RTN#**9I
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M/CPHOWPX)1IU2GPN\Z?2CH?U1L9ID,[G0@[Z^G."Z/N!D$,8AY/@X21HTJ&
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M8C9D+FAT;>R]:7/BRK(N_/U$W/^@M\\Y=Z\58=R:D$2OX0:#F&<AP'Q1:"A
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M;%?(6AYL;T_A:/PZ1-$G(<C8EJB43 ?2Y[F@9,H;*=C*4 <"76.8MFW1'(&
M)T^/<E/+="SHH+6! ZV%/$Z/;!"VV;P#$$J:)M5EDYWE*+(/\J65F(J<)$'^
M_#K$GXT O<*@5R7H9,D]R-E-IV^Q]I+R2YTLO[#I.>#L96ST"%\N?%] !COS
M K_:,B!7PNQ9((+;5FW@BJH)%%:T3:C?SD;V;(LIP.!QV$<3Q5JG-]*2T\HD
MND;M&*E/0>MA6L\I#.L4NGO 7&U_^>SY32M0(2"SH)LGJE 1L^)4=45],\T,
MYW0R1(>9L" /JJ-<)=F?D;<^S4=)_N*S+4/'WM.#"*CACF$0!9O98!PP<AZ
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M1NR*BIP3%!N86U30RZ^Y1DV;)ATLU>\RA2KKH>VR5),Z&3VZU\[% ORY GS
M0_H],9O2+)5A4<[GQ5JKM^3PUF@TB2YH1VI./\%K^+U)%5I6MCY 'TP6*'6U
M74R7:I52=$.]2$WJ^3=\O+<>1IAIVM8J29M*3K6![#ZNQ'5;W9(V-+(2:LQ[
MALMA7;M-1VYRWZI&\"I]7SK=]-N3GBM@59O1FP*:D#J$T&);2\6-G#<0B4F_
M?,7-CUYXSHTMV^T V\@!R7V^H:]D0H03];KE/H+Y]JF/7).^:.HB*V6M%#OC
M#<7V^WIRDHJ<E;_6->D'YV/3Z?Z$?+R_J%S+?KD2>L1CN9]'F?_03>L5 ^NH
MF:&#<HF4V.LX*LTJD4._1W&*8!WYU/.EPVO-[WZ%Q'&JV>B@\JC,^E+*G=-M
M0BI2D4VD1JQ"8D1F]?CE ";+SN8$U<[P/;UEL@^UH2#XMZZ\5[IK.1*S??+=
M '@S2<]H.UOBU6&]UBM3K2D=W5(P-W(WP,6D0 =S/&FX4H8O##5?GQ14:]2Y
M^&Q=E?C'R#SPYX-J=1L)>"Q+N?N=,O$<=\>G?D*_[0].WK+K8 $E)'!BH4UO
MVI8)_Y2!<4B+-HV@W)F*:"L./U5@7T'E)_3E4L_';N')@?Q,G,QH5&7<Y70^
M?<@R0N34,'#^7TS!NG+FD3GXN"O^KLE[!@)OS]X9 I-H>I+GV8CU''_.=(=B
M2AU4N4J6-'BU@K6XA*)ZK6'DDF-1GE_F,O;EXR7R56:&Y;264.$;O0>\W] -
MRZI$#L8B&BE$9%:/1PH5,./(8MW%-*_2:G>X=*J(KVX]%KS2S9B1F.W3;[ 7
M!KC/UPMEM))8FET@3-.)Z.4G;RQ2N)@4--M^#\\TZ#HKSDN+83&)IKM2]&[&
M/ _Q;YR]/+X24/9,JP.G7IP"SU7E=Z3TLY:NKX^Z!X6+365]0@V\3.PWA%JI
MT\$77:UB+BDIX8Q&?2-RBO-&8O\PERZ;9S^-OQ=;C+SJ.='?D>2TK@-[)+Z\
MP.38HI0+NP,C58:/JB*,HS:/ML>*U9^ 18H%W=Z\TZMV4_-LY%ST-T3V.3LN
MO"1TF)%?4S8/GV&^,LKF[)P[E@&:UOR1/\!J"3O#:I%S3&.4/2#)5S]O?264
MK1*V@5FDZ_%JR^YD]<4#AD6O&O/W1ME/E\U#VY&N"*LUN[,L*EZ"047=>)@/
M<EE7:<?.:Q1A]3/.>GT6--ID,N<T07? 9B4CF41YST.CEVSX7M#X*;NJKPQW
M<B6G^\-,36 3<Q'W1-+"EX5;"WR^'=Q=[N319^'=;)"D6B;&PX ;=422U]F1
M6;DUN?NZ>'>QF\;Y,9&I58NI)0N&+I^HX8,BPT<O37L1L*<%!YBEQ0ROSEDO
MG2LF18K!:\6(%34YVPW'%RQK@;T H(N=DWRZ+3(K.F,(\\$_P0K+7-2#YPY_
M^ZR_FF4"?UVQ*^^9RM:$8PV'$TJ,F$?5Q$/6HL?*HBI'+A8^Y\%D[%PP&<%S
MG;\O)T\C/2PHM^'0?F)QC,NI9)'KY%=U3.;9@CMO*6C#LZNUR/DDL19$5@LN
M4V+CEHP=SW7LL*?]\[]JEVLD1<O,LI[5MRJ.J:5,/G(9CMC@?9ZJORXLMQ'5
MQ.K^BB%5^PG+SZS&+&KX-F?-Y+K)2;&J?V-5_U2K?L-U>2YK@KV\*LDJX"J\
M:&5<9X"EI,'#+<2<7TD5OK;5BYPZO&*BQN,&92^2#0\U++8P$KU>;UR.52&V
M"M\CK_E6#:<C1J1?(<OCD<$G>6,PS*R*3'*52T7VR$OLW'VPSM6GFZO/S$Q^
M 3TM6'-@F^$/(]@7G)V@8,R>UI+96HYMDMP([7GE1=8BM D:O77^6&O/IK6G
MR<47T.'(&$9;U#RB.\A[&D!%/?/@IQ;UZ-XS<IM2_85M440-1[92;%#37&&B
M<9F2DUF0%7*$WH+AN"&I_DI8?>-)\0_@_U@BQ:3I<CS;,QHBF01)X'[M4O/?
MW,7ZRGF\+Z"HIT9&N%YBIAT%9[.%A:S[ALNU1K':?EVUO:JUO>%D_ =,8X9-
M^0UUNLIKO7Z_Q:<F#V.V=@LZ=D-B_96M441-AU=I&NJ"Z2]XO*)TS(&W7 S<
M6*QCM#XY_K_L>O\JRY@MU$/G*.>/6K9EVCG3CNPBYTTNKE\\0W06"0F+0SFP
M6=/2(4]D4><\*;@+(9B!Q[LXDW,9XYQ^@\7;0X[D<Z,VU8YLIN<\TG(*8[ZQ
MY+RR>8+&DM.4WDG6^42-(@E6KLG BJS=N[F="I?/R%W6[#BKGE@IM#LFJ^))
M?-8?Z'PW-CM1=DPN)2(GV9V*W7]HI%A>97U7$)=I:S0>:I%=-[MYNW,3HO.*
MX>D4,J2^K*P&FE=BVM2BA/LCZTN+2KQ%[K,O'-87YE@6&DT7Q?T>6C)&6,*9
M1-8-_J8W!D?*P;K-+68CQFLZ%#:L\@FU*7#XP/+=662Q])NN>]R.G)]'*.N5
MQ'!LU'24]W/N,)MO3O2%%=G0X9O*P656CB]NV+.XEC,H<ES1*'6UP$K)G,"F
M(YNUB W[]1W8&]TB 6A,* Q[7D,SO#QMUC,C/5..+7LLZ%==?:TYUG@E9BF3
M+>13I4I+4A>=ZBW [[<2A*A?/O>@L< F!Q+'SH;E0M[&]42*C%QT_HWNC?NP
M9WJ>B]M>5CA/[58X?PI8TG!8BJI[KCH'3ZEZ=BGKG@*4O&T9P84XGAN^JS'<
M7F[6!#8W%FT(!H=?\$R0G])^NS>%-<R5GLSF^Q;JX>T4I4SR-4&,;&1S03[M
M7B%W@%'G%+1GM<U3I]<V3UVJ[OX5I9(UIKKE Q"RNC$-WK0US#4ES?N-Y)"E
MN$&J**4F[:(0.4C]5,E\E5E?6CI?W IQ?<SL9;0ARYK3!9L8:E))DX9-QXAL
M(/,%,3."=Y5$ S.Q[&)>JT[*!NN1F=("1;W*:AS98.:+8N95I9,^:M'7-RD^
MWLE8M>1UG?@7F >")$<:#B9(8EC3H"F[G 9UY#=RMAA,%GEEK)-H8N9)_G3*
M&95&9&WS$:J?(=A;9%_2RIYZB]CYK>S'):8 3&"+.N1<6C%44W6"FO!0)9_+
MC"V0@#.]+(,:GC*L>&.,[+J1M9HGR<Q)A']-J3D>.9P+9\2Z.!F Q,.2![9<
MLB8U6K&9R-JS6\"9JWOS%\>9FC>=.6P&$[1*QU\DR62V(*4CF]&X#9RYGM0<
MOG_UW#BCK3*CK#DM4&B%']7G<CZ5\;38G[G)6U$_+C&GX4Q;I/&TK$P+O#^I
M]6:MX;A46]ZV;;HNSD3P+MUSXXPZ\#PFZQ,\JMIZM38HT2VT<]L^\)5Q)JIY
MH//A3&<^%?/>HMS2"M1(<3AI.9Q,8IRY4:DY'FT_\BW8>._Z0?K+,O>6I-O
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MHUM7L4]=X;YMEVY?(@1ZD<11C5WR*ME>S/F*8^?E6")N B..'R$^MN(5E.\
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MZE@DCM&_X",?Z-"9#5UAY=OX0)2GK*9.9L5N5<5FF)'>Z]%S[5]!^P]TI[K
M$&P=T^1%K3_0LJ5!PE[-^P]=;K^[T/ $#WR@O]#Q$'K51:FH=R<26U"*#VV^
MB[:9A\7A#L,G/M#C%+876&8)U*;6G/ -,6NT'C+UN2+N3^%&.N&?[^\PI\ZA
M<H4"LY'469G%@=0;\+RJ8=@*N /YP7]BJQ(^L/NRNF= K]RU[-\4K;WG@R]S
MP+0,U3STVE-UY-DK?CX?_3.^_%27O^"[+,^6@;/^. :B$H(-?.#?O^%_$,?U
M=8A9AKA,+%3%'?_"4/1__YJ*2I#;2.A@Z,)O[HGDTW>V.AH_?6DYX0DLV)$>
M7C_XUX\7[[5'JIEPK>DO'+NGINY?<.B),0C?06+W=!)^M=,Q?'JZ?78(@2@Q
M% U5]W_]IP.=,0>I@P72M@S1_,]?X:^.N@+P0?@.737!]KW8/9;Z:]WS+_@;
M$OR?V/P1]" B8QL,__GQWYU&%GYTIJ+Y6WVN/P8/_C(MVQ#U]3>+]2@V7^T-
M+ #7A*BK(_-7P%XXH(X(0P#$&B+9 'I-%TY_,"8X32+\__3 =,E0#^U?DN6.
M_WHY<WL3LL-P#+M/KEFP\Z[MO 9SA-VCT^5?DF5#*0F_(.X#OCF6KBK(?Z/A
M_\XX1\^ZA@UV.L8.=/PTI7\=FK:P(QK^.%<=50J#JU]C58$V%C;_O__-X"CQ
MUR-GIX$8!' A$#B%)8?#E*!0*5(@)5(44C3-"!2>5 B,3 X9*?EC,Q?A/)R)
M^!TYD$$06;R@3]HG#B.W4K>1,<G2%=B6KY<Z; [A.ND.R_W]4UK3%[UQ<FR6
M;Y<Z)99#TO4<PO:SQ72]P"+91JU6XKA2H_[[@V<^/O;G@^VEN6*I7N@TZG=(
M[CY[C^!HDDP]#G!'@T[G;R#4FR$DH/:ZEA&.9%=%X;"!<4"-GX/D3N^2*&LC
M&P:G2D*V=,O^M567[1MA!_NO"W0,O:=@5^L7X\E[^.:U D+H,L$CIQ#1<ZV@
MS[7T1U4'\HUV[?_^-T:A?X53!(T=I"*TP:J,;'S:=H#ZO^?](Z88^/8*4'_E
M+-DS-NG#'R&&U$7;%E2^]."QR5*+]9+)Q+RIIA1LT7H?$3"P;ZTE[-GX8XG[
M#8E+'?<*WE+_/X)]6TC#!'\^JKP;VNDM$]:V"C) %Z<.^+7]8TM1:"==Z&NY
MRO:1.;!=51;UC<2'P@^Y\M=B#/WX!#1,<N!(+&QQNN5] &H;([D=\UG=HV<B
M\>2J;;IZKD/#P)]Q__FAPE'#N!;RR=(E4=<M5[*6/RZC8BT/1K7 UOTVF%JV
MNZ-M*W*E=WL%>ZY5Q*'.EGM:HI\>[<WIEC\<&%D X4L(YQMP@O]S2/G^[W^G
M:)+ZZU7]^^DJN[-YO7DY)K8M/MWNL.WJ ])FFXUV!VGR;8Y/USM(IX% ^]N!
M1G8-DQB!--H(EOQ#^7/]12./=(HLLF.D'PUT.MM!&OG-<RF"?%2)D"<_ S'_
M&6I'% QWWK(1=PR0V59XD'6& P&F A3D@'G8$>U?2G"<%;YTK(B^#[UL8%Y(
MMIOAH-AU,F9'LB6,'HP[K92 JF"I3GN)4<$8[DOV"\\*3-UUUII [Y!@)*^*
M\2>9[L/N.77([IWHKU]?LAKMSW:N7^?BB4R+;=9GVZR.+9IKWV?/:+EL,N-K
M751#J7JB0!=4RO>4],>-%GGC1JO33M>Y4F":8JOE/HK/UFP-;<M A)W_(:[U
M^/G<@'0*_"1/AY^KPN0EQWGV^0\WFSG!<C.25R%D0RT.S/FE@UDV7&\*>EQW
MN(-68W'8;6>'$PLM*"X-Q@NVY\J+-\A 42Q!T!1#7SR,?9%,_JIA[.\IQ,4E
MI@U&JA-@E1OLA=B1&J)>'&?P1M7G14H>KBI:W^ZZ^^[KFK:#[N"/?]E<J9/F
MD!K\-UNJLW=K""_5L_?7]FJ/9@S8I2B[(:>"9+[]R"%$=!!G"N1@I5=!5!-1
M70>1QV%T\F><4/Q,O?@D?_J%B&\F*%Q-"XG??+%>2@N_>;;BACZYT)LVZ-XR
MF6MO1[$S+3^.N.YK\=B\A2#N"?)_=YGSPC/<D8>=]UOPG4/=6FQ9M/V<" *
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MET-BI+.BM"R-QYRX&,^#T($X)F1[5=-VBJ1MA.SH&LO5\"7V Z)E*&_4#[@
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M<73(T_"0/SQ3]!35!<J?[V-[#&D1,JDW#%)GG[1HX$'6,L-P*=CJGQ%UJ'B
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MM@H&VAL(-"9EQS6ETQ+(_99>QA)ZGDRE4%_OK)P*E:869$M([K<<JL-D'N1
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M(U./^SM;"XZ^H@DB0[=S7[1 [!<#XPLD$& ?P#Z ?0#[ /8![ /8![ /8!_
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M*LI*( \(#E:B""M!/;QZ&14L! "GS[82P'4JRDI0#]2KCW*#E0#H]-E6 GF
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ME=A!APJZ \(5>"6>"98 CUJ^?G$<**&_ @//8N>'F7S# ?0;#I1-JH008IN
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M$:J\GMY:$5UV "W-9?\0E]EHMI\=L^^T7?KUT;N>H);N$]72@;P$J.P"E5U
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MWZ$/^<I"!_"21GR3Z'0F2'7;@>IP),%8%DG&[C&*N.("DW??4S]I6/B6H[]
MDS_32?'J0[9 DZ_C4>"BL7U-X3Z@R "2;R-&!S3Y,T7<KCZP]AXMTR\70QJ$
MGK*4#V6)+R)'JN;=S35;6QC!W<:2;5"H" H50;3IE4+%]-_RRR9H=>_P#,K+
M(),\;RSDYJS3A$3=QEIBI=L06[H$XVF0"2;N$>2T(!/(<(%J15"M"(P"U$*
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M7GNLCDBE5U'TE#3'&*-2L;DFXBTD1F--[>SP&>ER*6F.L>%H7<:JG-4SD:[
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MV?Y+@XTLH!W94UC*H["68%E\T:+-F9DT.*W>:2I4;5+J6I7U'_]0/^@S\HK
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M6X\46YR+U+S<1>(@^<<_-!$$I+[@[93;N&8A\/*EALB)Y45B*,RINK-IZU5
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MC//SY:H_B6GNJLK0:F]1<-D<SZ1Q4;_,&]ND$#E#]"H!C1%R_P[!Q_L!C5U
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MU>?7?!P7$&5";CM)B(6$6(@$N$$CZ#D),+1:75U93P9<;*;GF\UT8[5K80F
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M;$*A*O7X!U3F=07WQ A'W'X/Z^@&KG.>%UJW%HK]"E_N<PT4)&W0?^R!=WK
M=BQ5<H",_@"=N],/CD9V@*6:\GF76$EWT3FP&VDF& KH"0Y@IU,@.2_EM"F/
M@+<ZXYG( 6<Z85*32;62Z/)QKP@LJAOP8M,G$ARZQTL;(A"^V@*Y(H%0L^:]
M=+XF:<*4,5.U6*S36ZZ10$ W/HEHEGEOR?H;"1;Y":[1,ZL&FSK6?O/QWZ,1
M$<#O&7XVT@*? (D:D:@1\0(_4 ;G;+X]Y6D&(>VPU#6MQ38M3RI%3G"WQ7&O
MM"J7B^O+2-VP;A_JKE^9Q828%IOW'AJSK"'$%U!VXN*T=#P5C6=)[.B;QXZN
M:'N(>#D1+VG>!D9UO60:*];-%2M)(95AFI4+&74AXL4>Z[F%EIRY7*%=FG?
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MX1]O$SB2)7QZ@Z"07^;3^"[.CN?-A,@*O8*63,2:U'#317R*\GWNMUY)#TA
M76%# 5T-O*E\+'&FB3-]I_[#79@M ,J^GP?&;D^/JQ<$99O:T^-B3F&=7F;3
M3DEA:BG.[=6:[,,DUQ]W<GP"5XQ]:Q6VNPDK?(1)<S=!AFO:C*L3&6?U &XA
MKH [E2R@:83354S# )Z\6ZO.+&(N !);^]H>NBK@\R;=<^]>L=\Z,]ZD_@[<
MF7; =[A>05!Z)T15;QS5-C(J)W&I1J&:G7?6XFH,537M-65+A:2DD###=809
M;F#-5\?4;]&P-^2!H\]CYC3F0M6*(_MVQ!0= 7X):V/@9Z,@+_RI)CY4V2(5
M.(A3_ETL[)M6ZIC=VU/.!CG$ZVV?TZM&D'56,JU3Q=_PS>UMB.8?;VI<F^X7
M)A2HY'9CF>/%3K7+)W#!43H;3:3>!@DD?CKQT[^9%+E)/[T')!W:".H4S@K+
M/F@4!.[X%@FATYKCMBL^0D\^XI@1"RQ<"TH8&Q"?_;[U_MTQ)O%0OYO2N742
MOLE;].#:Z$3!M*=[\Q,:IB43=[' -T>]O4()L4NMI$2U$\QV1JG--)=K;.R*
M^0CM4EP^\Z5HU$V[\D'SC[/>'T@Q0V/?\>#KN >9"Q=A8Y2>5U#[3QN B&$Z
M()(.+1=#?'GBRW\'*YSXI,0G_;;<<)-V0Q#9PE8!4H% ID-, MI]9./L(E?B
M1L-^G^T7\L6EH_ )7/8Q&TW&WYG5=EO:WX?L2TL74CP^6^*&W[?*OG591-QP
MXH;?. G?I#K%;OB1+H5N-[XIRAUT1XAV?73'==OIFQ9;9FK;1'O8&!;&T.'&
M50CI:#;QSLY3=^ET(_?ZD!A'/&[B<7]#'X-XW,3C)MQPTR;"O@T#TF?/>]Q)
MQAPNP 0\4/7IF*H,%S.>%J%-X)6_8Z))ZM9=[IS\Z-H.5N^."7=Q"E"N7\0"
M*V"X %L P<^";"Y(.\K[U]L7%DBA:</$ZR9>]\U0\/=4J=CK+OH*I.?IC(-V
MP8F3N!- >PHW+>?56(&[W+%40U(7>M@=^+#4FFYZSJ[/M9.M7&$W$#;=/E2_
MN)!;(GVWM^#M(&U<,FWG@XK3W(TO?O1-^N+6^,55_%7MQK69 C<)<S^-7J*X
M7 %)@;>6X>@UJ66](;(SK;YDNE([W=W6^CD^D<%X]F_6"^":'/>[L*RN55)\
M8Y/KUT6%'E=4N=BHYJA8B:56&[73[YI=)"J@><6\>MWQ'P<9()]Q6!(T&('U
M BG+JKW0A>U/U<"/$76X!2$4[=&:]_TGM"U:D?_\,Y@!;%#-X4=;9&]YUQN"
MA<PJ:&TY0+$$'9I:%K[\<.!P>,@RLK%D]!-N6R&@]@!^1V\XV';@!QB0^,,#
M* AXNWDA)3*R+*5Y*2VF^$0\+?(9291Y*4[+@D1GIXDT#5?Y'P'^)ZNK?_X+
M_PF6*^E L!!/S?P]V9>A1FOSQ0M%_<_GL,[I:3")HR;GWM9F/,+ L\;__M__
M<SS[<YGA5\P^6I;_:@:+ @6>J 4$+29,X8M_"OI:V-J!/9[]$0^*<?_<%]U&
M^Q"AJ1_QY/]$CGY&^W&VF7-A$SO:,E_RQ'0PA4OWOA9\9GG[X7]H>E>'/RV@
M0]Y> ?3TD^?BDW',Q4^&_I&"*YG#7_V%)>@?Z>1GG=615,.2[7 RD/AF%I)'
M_QJT"V'JX*WO]'Y%7X02 4HEW?O$+R_M?_02$:'MA1,:!'6R"DA8XOZMOJX1
M_CFBHN=H__3DP@[$XS86"D;!;D+Y*,$Y07G()ZAX-NWSUQ<)K)<J<7L3C 0S
MC'J-O>!$?^QK;5_!+'%T',6%"WNI5SB6>J6]U.OOI=XUS?]/UQ!<N-- _NNK
MIW7&:<<S>Z/MY:G?ECL'EBI]A"?RY.Y#0/7]VE,_5Q;7L,*6@<CW5ZJFZ^,8
MP\4,2YI0S=EX;L ' &A#+. C',L%GV6ROG2@](^(-VLD0O*N#9]D?P[%J8C@
MG9]Q+,=_-\#^)1-[7J1$_D26"YH70_U=\*P=_!O]]U\1%=H[J!8"4GC1B 1?
MBLQX9,8H(*( PYR#"+(SO7 4_BXT4V64W (E +XS6@'=7*"_+TPDTZ$\T+<1
MQQ(,V[-@H6CVG@2I>.Y/#XL5!VIY![Y>M$Q!CEA!C08;M5=R;=2A &5O0T,*
M&6K^Q"-K 4?$3&MA6G@.JH$M,VQXH:\7H3I8(QL._J$/%E NB<"*0,:(_XA4
M4>3,BSC"19K3J2KY!A\<7!#FHJ7*"HA&FH)M"]+,1>@7^P>AKG_Z*@((J5XT
M$N![P"C>]N!89O!8("F8Z$1L5X2G$5 "_ <="_HN]!1-R\%G+_K<&X&&/&YJ
M&D7MMJ"NE[P^%#Y9(9V"_B)9KD>#<"V0,O&%)1KF &FVI]CI-.KU[1+@SB%Z
M]:J9GM(/FB@D ;@ZN$^^X8ZH"!4-V4M"N#1HL2JSR$KP:!&U!G."X?#9=O20
M>&3A0H'P&3BU"]+S?B'0WM4%T?0>ZI4"J[F&B>8#?6'@0I<9/@CQ*)QXI !T
MR"9@SV;.#'('YL_U##YH&S/7AK^[JJP*UA8;4OZ7"CY#H!?]Z?/ZV;L"KO>V
MZ?D%V YB+07R*SP\%6/#T!>\^]^(H%C .P&\HIRN TN!9-N9"9#=)?PJZ,3"
M=4&]:. IP?-IJ'.DB?>3"[X6S,EWE[XWFQT3*CSYX^QSU=;L )X'?_>(1 5V
M(/]$U<3, %TL!7[9D%UXBMNH?WN V$%T'>3A1G3_)!PSZC\6TM%44'5?L2X@
M/1ST /PN\-KA[3]T+,C9ML?_!O#4@%=P![*GI0',J,)B89DK.!J#]Y'6L%P%
MU<>57;@B"3X06Y$^E3OPFW#6:%O4Z?98 IR^QL_ZF[I(LJ#=0+4XH1VV\RA4
M.<P!>?904 7 1A5+_B<OAVN0 2IU#/ H(Z*!+>KN9Z/Z?7H4?<'QZ_AYM7VA
MX  .XKS#5D?Q4?A<@AE",5>0[C&#6$!Q=4^D1(]%6D3$LU_ K7),"Q_ _HEX
MBU7#@)OGR2)\Q>,7*,!:$VI6+P,"%QE>J+H)20Y%=Y!T=*>"!$TD= 1PL ZI
M"_A_])=_6 WZ[9MHMU,W/P.''$\UAC]YXD=C7SKU7!P5^\)(NZC2WR&6:D.%
M"@.:3=LO%R%7*]MRF,P/%EF<BB*K+'MN1R#]C9IT(%4#=8WB&W;__MK['-]/
MXOM[?=L7]*#J;VZCVCRRB_F.*T(:R!ERSFEBP1/<WC;Q,GDUN6D^U(1QB^WG
MS:S*+X%4K)PVD$Z^ [%V7(DXB/I6X?*A$/1F$KQ^'_!->6Y=2[#@9$#U02G8
MVHR==XKI8JVL,@]\]X]_XFGJQ_EU>@32@8XV&@I5 TK4?7'SP#K"=K?@171L
MJ/V!'8C:$QPY_/H"SVU?$!W:]%4#6MG(2$(1\5,:P XUMNRA!!/P&^RG5D?!
M7 ,#BT;_6]%(HU'86Q?XSP=SQS-LUC-5FIV\"0M0!](Y%JSH?R44^46 0/QL
M&T#C]865!1OAS0;=SSLQ^/R8KX+VR_64X)Z8%<N$EJ^WKOVF?@*%>XW[XOMF
MYF\DZ8"2T7?P&3TAZ:(]G[!9:U3GU.)$I,<[E6\;RKM)^G!]@69AYX(#'LS@
M=D.+5T8?!_0^@&9"03#RH(>%0RAU2^.X'B^K:9X=V:/M9)3+UQI"%UU[4C_.
M@9I[ZCYVCP\D&<D-FA'X=L42Y@<;-0^M8NRNH,/.N0HTLK 0\YR1([:0?:$U
MA=(7J>(9-.>ZKF!!RH:62P] 8]U!%D<)[E*$IF+=4Q:PX?+/!. ;J<.C5YZ;
MU6OL8W^1I>K;2EZ49_V,K76?$8&9(Q%(TZA#]9D,A"X0/!QVA4YHNP"87)[Y
MNT\G'T1N(\%*NDNA6=&6>L&EN,Y,3B]/;LNJK=*OI=D6L:'4P?V<^WC;H+K#
M?SI4B:6.*&PGU>(96ISU*: LY-:Z;DUFZS7*#THSZ6@R>7Z__I+T6+@6$N#8
MOD>''TY\4?1=3W1](@&D?T<'OG:"FB/F.XU-3*)&75-)<UMKU.I<Y@2;NZS-
MFMO-CA*:^=&NJ.]<>^F?(/PO_OP)KJ%.\OA2]LWK&?)>H-"*P"-U9C9J#PZU
M5IB%@\-<GH4(Y)@ _0,47H/>A/06RZ:HKJ!GA*6^?[3+&LL <33A.%6CZ1UP
M)M)XF[M+WF;>K$GPUGA4,?*W.N?M= =M-*01/"24+&J&"$KU4L%F4X8]:6;R
MRW6Y"54'D_P1 II!/J)'%EBQ>^K\,Q7YG9SEV\V",#.W/2U@Z8FG549['FH%
M5&OR<@ZFI0>VG-7F@_1D93,9>)2)^(_SEAM[(\"S$)^7PJ=!1%SHWS=!WRJ5
MH;0'/)O9 +6C=1ZYME"8=\?YUDH6WGG8MN7P!80"!1:")FQ;<-L.IX1G!=T1
M?ZH-70HYY8O1R$-LW.SFG7F?:J]B;%%1U5JYV_TE?H?\C*[>('M#PD MI"%Q
M0,L=A4Q. "\QYH@XTKOE T7ULKJF%K<RD^VLNO., AV@,\KX'Z\GLK1_*K+6
M$'V<&N](@A^D09B6QRKC=?+RW.-WZ)1C<W$?P3UQTSY3$%W87O@22>).QUJ.
M&<I=KEZI+GE[L)#3 V@K))@?YT6! TER9*Y]CCOWX;NM<\F.T\V.LE2A1T]2
MU<'*5OJ?M=N'KDJA6[ZP,_UR61@U6+6[:,UGI>5,=G-__$/]R#PON]&5(.0
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M1S'\Q'2A08<.(GIVB6NYNN]W'8'_@O?T]RXB'A%T+(L<8M<G:(0^6SA #PK
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MP,HI9PZ1AHH(-T;0L=[JJT1GOD0XH<BTYF29GR4_GGLB"HK]5'NNW?^'!/
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MH;<SX_6KW3H]-21@3!,M[V7T&(K%9F!3)E:,"^*#F,M9L?]W$4SYR,['$Q^
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M"2P94N;_?F&_SDL0(%DG_0OGH<A;W'.*1BW'L$7!ITO35'A8<>^B4!.QR '
M(.?%WK-S2 ?\E2*!)>EVQ!J7/XI/FS<_^RC^OB?Q5Y7_JVKZ]\@]-T]2"S-I
M(O4_4O\C$=,CHV"K^BBZK^I0//2\W9?6]SV9)OQF0@-VD8I8Y?:LDGY,7L&.
MNHA%&6G!T1$=:<&A(TWHM>!(HL)^*-V!TNM7-;-\S5<R(ETF!&QS!VKOV!+-
M);Q%%/'+[?DE_+HOHQM_X)A(^8V.ZC#($(J<FX7.+D1'-U&O$IF+N.=[*'HE
M>'\8+FGKY-R6PHMXY]:\$WYMSR\P$O'*[7DE_)I>$*^<4\>[8F75+V;2/#>
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MM__F]MQ_";D^5E-^HES?P/D3+-C]V5!D$ADLQ\SR;5>UR=X$:WJ=7Z'K!WG
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M >V3>VB?W%8-2;/Q17&XZ#8S,A(OYY@$ND:+??/3<.]C.;R;M _X4.^I =&
MR>=>IOJ?[S:PS#([R#*)"=V8;#9ZWIT*2LK]..+/]A^WO9EVD)[G75+0/-A-
M^Q"]_?MG>/31-R?RN\1"S(>:9V@G'O:@4EOOS;)[V!_.! +"Z!Z"OMS,>0^6
M/F>LG7C4Z[>&G,7%)&7EI3L?'"&G+_>$+#/Q[@N%)*)"(5&AD) 4"MD6OTB)
M*0$1TREVC$HIED@*$IL6D22;$$@)3:($*HR/RCC,<^--7$VK1:132MMCFI@V
MYC055!:C2S%T;A OUABEIV^*4T-8=H3 LACC]MI2Y^5U3\W&M4%/RJNMU*H%
M1A*'(S>*W5-,!5VJF(W$5Z-47N>&@64QRDY\6"XFD(JZF*4IAW!YB^+@R*,Y
M:_2\R>.%.J^N,SEL824E,S<)+*"Q*+O*I$"GAJJ"D"T>5\M:"I&#"F@P')IB
MF)+"TIBH%PHC+<&2"O36'SV=;>?S3B75YVEL.,B-;#Y36C7EH%(;><7I4FP[
M2:N*(!;:<Q(KXV(KJ-1&83/3VMG28H@X*ZD_HS*]$CV%(X^>[N8S755S:E6Z
MP9;*SG S[??C@44Y*FS-5CL)"E4YAL"EJ=MJRWUWKRC'\\AZ:C@CI4%E0,_&
M2SG98A>5#"F#D:^?SJ)C$L5146+'. ZV.BWR; K#Q^R8X#"2QWA22(F'<R?4
ML5)!%DL766QHLY:<56?%?&!1%A?KUGL5T4HQ7,\JLK0PZM(XY-,C&A0SI0XG
M2/2(%JG.H&N-$NVU*0?QJ=%/NJ6ZD1[1:]&:M76$LRVE%52^14RZ=6>3:C&(
MPI-(BV/2I2D7R*<MCDTF$:+0I>,S8NF.4&-2:K2"^+2M)LI,P<3Z2)P>:XFZ
M)9'UGAO$IXG<T+(65"^'B,2233?JO9R]".33;C4_G+;U19*)M\=2>5(W9P6K
M%<2G=K]"(SQ&5VALG*.'G=IFTNX$\JF;'<=K(H*/$&4JE*U,WY5'5B"?#MJK
MF92?365$F:^+UH*I)_(5]XA/61PCQ22.)]AT D580B0 8G% AT5$!$VD<0(1
M4D?OFY2ISM"MY,J,F&NO<UJ64Z1!"ZK"AR.7^$IT-F.=0];U5+XX)?*5LK?_
MQS*0S68I?E&SF4:MU:7KI4*ZTZ'@E>(C&5@/6NJ,P)*(N*!*=5*KHL@ZD%,P
M@T^7\SJ28RI#GF<F$L\TS%80IYA.*LVGV@U5S=+EN5E?VQL%;07M_QAUL^U&
M-:,A"\4LN C0K[.)5N#^<^E"JV^Y5824&3,QKR%<*A.XJT7!Q=A)HS=0L32_
MFLZXI=A5 PO]Y'2Y5D[4ZS3"U>.V(E4;TP3>"L*4D2G4B^UI0:?CZU0U1:U2
M3'K2"L*4RGCJ)!M)FJ8+ UKOS =)1@-42A[/F9S%NWC#,$ITHT_*0ZLBHW2?
M@D;0D8R6]#2A;S@:Z0P;TURIZ[(IL$>IXSF'W&95EBI4D<XF*6TLSG)5@X<C
MC^;4$KS2SO!,BND(.)\V'7+=3L)6O4=S.GK&DL><5%*YKMBJ]XU4PJ[*8.31
MG.2ZU:UFJBJ'+(H#<<)+B4T/G#I $HXFI3>FZ&Z8MH4T@!0N>DBK/00;#R_4
M'>U\>]#;S#4AR538858VEKERKN<UU#EF^U+17%G9DJXN^F)B6$SW1WG+&[I7
MD&EKA_B^A9,5D7:5CCY0%PG*UX4NF_CW[SUG!J4+>S'Y( ^FIY@=WR@9H/%>
MO277JT@_K0V2](CKY/OGNE'R>;_"\VW/G3_-%%\NSVZO$$/?)'20><Y!+Z/2
MBW4=W ^%MC7T.ED']YN>0F4BAO0JS%L)KB3QB*5OF/5_G.H/K;,$6*U_61J8
M+4_>3S >]!?R$ =?_7V?UP&^4B@]NB,3BIU B3=*>D=;<:VMP".A",E.1/ 4
MEIT \'2Z44JT%5>^PO<^'>N*Q$CM/,6?J+%Y=-DJ\;'+5F]">N(Q>=]WK2C+
M;Y9E2.>]S/>]V>B#=_;>1$'R$0OW?<^..+>].*G/+3CRL.NQ-O[]KFSJ3TG7
M&\=TQ#T[[L'/V[7G@C<Z(Y2Y,<K<\V%U?!LX[(@32(+W+]@'V>-_CXAP86SY
M7DSSA>M=7W9.7@*+VD>)AA?N&QV.RQAGZ^7ZEHOLF]S2N%AOPX.BWW!M#8FQ
M1"],%' 38D)NM%FC8 _4105GRS5UU"^F=W<SDP]D"GU7;\-S[?_-U<Q;-W#^
M?O)\E>:[MY;GY_!MH=AK+5(RDZ4;HX8=GQ%)=+B\GCBW''J-;2;5G+K.416A
M/9S6"06FSR2 .*<?"/*4.+]]T3&41V[U=0W(A]V5Z?,T&0Z'/-[?,7JYB\]7
M.CN?[QB_5#@XE#9T-388:;7NTI55/C5)Y7BMC+K^O6+B@2!2IZX57RQV%=(S
M\N>(WJU/O"O4'+CH,?<.R7,Y@NXKY6R/YO+X0,8K^GHT@LE_X)S#'U*G)>^"
M)47"<0#JSU41 F_\1]IJ=&Q>_MA\59KC4'ZE$D^C)0UO(^*X9IKR@%I-I99_
M 1_%'S#DN/-VX-$9V9V1)$>G\&5/X9."3/02R)J>K715,8M67. '"8N#-V:@
MP9EX2"/I-T_BFU73.&8V"?P/0=X;)+IP#P%O%[*&9?\A=3MIUEMQEBL82&-%
M+A1>=EI%W;U=ZK:?9^UUB_"RF2%!.$6WO+9LL/'$>G=)][#7@]_:::\:POX%
M?[][AG]O6M%]9MZVM[*WY1"V?3,.<\>/;EGO]1RS)Z;H7TK68<&%&7C7B17S
M"V4\!]AC..)710C,';_X]@>4(=G)9(V#U\3M]1]80S&E2M6($RC#H16LD,R)
MJWI?ODZ'YN^3_?XZLHT\DB<+@4?9<>=.5-RJ)DB4E!B._-#D(W(R-2K:BNLE
M34?--B(L^@%D_R,6)1[3T5:$*5?]CQ[1M_2F']DQQ.>0]"-RWI*D9T_8ZGIF
M4LVWCFC/.OI2TM^K];]UBOV07-'7/)%\3(><)^K08#[!$N=)) X';-S@GLLK
M=L#3CSAZWSF??[JN<)%V0K?CG4:03^L<+NYW:9[WYZ!_RYB\^\2PP"*6+TY
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M/J_3^$M=C/,I29[D6\N74GM:ZP\+I<4GV*^SS,/]HI-LF2W>6/)WCREA95K
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M(Q^O/+_MELR;9&4P_#G"T@O";%[:"GN<H%97QV;I7IJRXV)*"LYCRUQ3!$[
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ML2 V&8QT(V0Y+:FAI33D%DP,'6@!+SC$-'U-PA63<9M9D_ZXT"U75 QF!MS
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MD)0)'C+@G+O[2P^I"IKM? TM>\9['J>%*+>_5: ^JKS][5A<;G^%H:SM?&>
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MUWB6.%6<ES*Z,=&WA,W.7'X% Y #&2[S11#N .3H*TB5:;AQC%\/ZII$%/2
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M7L1B%.+^")A(")>@)&58)IC#86@*PV*"$64X"IDK!^= Q(^Q2!-?1!C.@7T
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MC21/$^&Y,"+F;D)C[B<TX!Y!7HR(] =KL"B,) T3@N,@P0)).!IQ$P_%@LG
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M?Q_(FI:AT+@,%4^C\Y;6*F?ZO"3S"R"9P]8&VP?-$$LSAZ09]5+FO&GF%_W
MPGFKGTOLE7A>F']C;R3E3X,SMS3^6-4#6$=7(Q;'/KQ"^$>1,U6[0+U 6LQH
M)?/B;L,3UI'K[9V2576$4HQ/R!\\6+V@L0[T6)+P:9:6C">^OZV(OZ5V2^W/
M23H]36KW)\0GEMKW?_S#1U/W2NV'CX&.0>W!!,?;.O&,!9VC&P5'IO;#!S:/
MT _T\+')T^D'>G@+Y=W=8I9_$:*MH;3-(KF,R^D,-*[#G_(\C8YPX@?;NAU8
M@KY@@CY'NR*8>/'7=K"]0((^<L[E04YYGJ:#-_'"$27TF5H(9V\([(1KA,8#
MP6F8!OMIXGEX*^#/*F<?KU)=&I+E=\H",,5*V_)MUHGUHERV)W3\\[0L_$FH
M4FZL@]?RA@U^/."-P#V$._CB>>,LS9K+#I5XGF\#)9<7*-E-;AX -.=@-YV<
M>?0K99J6;7#D''S)FQM#7X1E@B8XW)9Z8NGT1.C4QCQV=1$'6W.I+$&?B'$P
MFN ]3]4^]D>,S)VI!G\9BGHX(J+/02$_GT#&>]TJQKZJ>)&.V<WWRV7'(F)D
M'U:\2((_H>.?J^G@(<_RQDN,1.S_,CB^%;(KF7_GQ='W-JQP 6&%W2F"'((@
MSL%X.3D;Y<]E.LO@'*7J<6LC"L_2PPY8\. DH6 ,E:-#861U38')0Z,2BV6)
MRV$)9:$<'0JC1_-08!]\/,L>.3HIG,2#D*-#80QM5G/!-H7V,@R9\[-7=GLO
M?I96QYC/PL\DP-)@TO&07N%#7M&94XA2T(+=ZBI7MKC5$;S2?1GO@XSG^5(U
MXS[.57> ZE?'/_'H;^,FD;OM?9QE&,LP7Q&Y.?Z)QP[M1!.,#Y$Q??$,\]"6
M>MD,L\YN>@$,$X -=8@7BV=J6[V@(-&SWIYL<S*]['#1#Q4%OCX=PMS[/GA6
M+F;TRW4VUX/26<X^&J!E<]A5I<<8C/FA&6ZV]^%6.-F<%8*6ZH?'+3]'YH53
MP:A*=R"\RW4'0J$[$+8=9H#V)H[J8*!+#] "_E;E.X\BSCTMG461P7D!4 ZM
MJB)+EQJG,,_U84"Z(VK-KAJN,C<,4S75%Z6X;GYX,\8FFXM+?:7^I,H7^E>]
MB2L@@'Q97<OLL^#=!K!F5\T9^VZ* 4WTA<23=CT0')KX8'];Q"IY("[^\DT<
M1O&;X3X&,J6+I5IXU1?XDS9L?E73P+Z*.SKKE82O/]HFB69"JOW0Q:+(/P.Q
M5@*(]74P#1S8P$S5VLCF+7-Q(.@=*X<[O,@^B;F3?NF,AA,L)675LE Q9C4'
M@[TI@+=U_EA>5N5$C9DM%;P<D.[ 5?FR4&O+#$Y[2\WPHE!EV?6J]UEUZ_P\
MFXGBANH=*S;]QSQ3,_Y9P<2&Y=_]\MN'*\_UWC@M]>]+W-;HOE+P-532E617
M^I,U'JR&B+OD4?.)GDD3J65JR]3/8&HPF=8SM=A4;+-S?ZW8F<Y[EZWB-+5U
M)Y>:2^_SXB/P&A.6R2R371Z3N=-X/9/)YK'VD,G>J(O0LHIEE<MC%6\]JY0;
MRKY-]\XE:S@@P*-QP$E;T.7*ABZ=>U$(!VS>*J,S0%4N92DJ??GW48BF?A>%
M7+0H7)=,ZO"ELGTW_#&_-Q8V _:@,%FM3YAOYD6I%F#Y?"Z8+@&H5?Y",)%]
M4M,H->1_WO[LN<[[A?[[N\^B8!F<Z@_Z1=L(W%@=QH#/"N[\<PD'5+:%U ;[
M1!LD#V@4K3]@WGO1-STI<WXO^\AZDQIID%7 WPS^^I]B+@JPXC0$^1W8=&55
M ,]^$IUH>S;J[KIDK8GY5,"V?6,[0*HC"5/-8[@AP8GBC]=>,(W,,Y.&,I_F
MSI)%?@>S^!W>?<H$9.HHAYN$&SN_UQQE+O;EG3(5_J4X&=CV9H=S/FW;:B;#
MIU5^(S3[:1F@9F"Z0UMI[)%<B3(8K7_ENC5@Z7QG_K0L89KR>SV9&EB(<J$$
M"FQKT39\*Y5(,%.>EI^..AG_Z57B4T)1Z*9)Z-,PP4SZ"1$N322A+*!>F$H6
M*M%.VQ$I1]+E493X,>$)]@.<4!"=29J*D(HHY +)_H@8!R$F,4I<3&0"O_A)
MS(A(XB 2H<^8P 'OCW!1B%@D<8)\A!(L(S])HX D*2#-3QESI1SL2G(_)9S2
M1+@\5+OB"<743SQ/^DB2"-&8]4<$A&"!!$YBQ& $!1A0ZD8)(T'H<A&Z 8[Z
M(WP4I]A/91)&$9P\PC(AB'M)&(;(I]*'V6A_!$>!\$*? TQ#+\'"QTF*(YIP
MX=,X]L,@E8,1(G(CA*(X"8(T3G!*XX2&<"(>4( "]5G(W?X(Y+H\\%R2>$$(
MT(W=($F9$$G$/)B,<2](@_X(F"_RPP@EG'"28,1%0D*"$LDH)HBF82@&T&4T
MHJ&+ :;ZY-2%7:4B3OS4I0*+5' L^B,\/X:#(R]!04 3F!9.+BA+0E=Z5+I!
M] "#;A#&!(5!(@- (Y9ID!"64B":F*5NG,:>&*Q!8$(NI4B0B . %0"6Q!(E
M$9=(,EB2H@%T(Q)@[@.2>9HRH!*?)90 =$E(>:S #B <G!S@Y!(J$P[, /S!
M7$7.L! /4AQ@(?#PY+&0L701'!4!Q6(UC#+&$R%1A!B#;4H\&)&BV*>,),!]
M<'(@\22-90R[XI$(0I[Z0PQZQ NX&TC%OA'LB@#.74H2Q%'$4C\* 9&#DX<8
M#@A@XCZ!-6*/P485.?+4#4/."<4#?'!!0H\(&('4KJ3P@/U@2=AKB&3H1SP=
MG -%$0IE[":^"X?!#'!.D0"N%1ZP._>13X94$@LX2L@2B5D*_!%$"9&<)9'G
M8L2"*!6D.<<33#XC-L.5H;/2KIL/=#RQH\)JDTW;:<T2C;"M[;==WUH%VX)_
M//NT9OH<II1P_S7BNOE=!RZO4[B^/U[=PX'?+/(R4_KHM3;[X9X9S-DQ5=NO
MTK3,9\M*#,YYP-ZRWNY&S0]PF/;?KWT$8#%Q(IC8_L388N)0F"#3:&O6AL7$
M :73UOPABPDKG2X-$R"=B,7$*6#"2J?3P02R-_9)8"*>NEO3.BTF#H4)=QI;
MZ702F/! /-DK^R10@:;^UM)U%A-/Q,0N#YCILLH?>[V\U0EU0%B0)O6B3K1(
M\QG?&3B/O)38!H?G^N?.##0 "/7A3Z^"5Z.""8&(C4>%$]D89MY2!B#MK=*%
MTZN_?M !U]]-P/6=#KC^^$.Z5\HY[MNK4V:J[>;"!8/F,?W]"/4T3A=8CZG8
M%TQ'C^J\EI">H):>$R%9C=!JA*>C$1ZPY-GH&F.;CV<2#WUWTA2ZMFKCT<D+
M3\F!G_8?\GZS0OS,A/A:X;.[J#&"Y>&_#T1-RT]H7'Z*I^2\A;5*ESXOP?P"
M2.:P17[W03/$TLPA:<9SIX>M@SLZS?RBWU8X;_5+B;T2SPOS;NR-I/QI<.:&
MQA_M*YRU=#5BD=J#ZX._ 2AF,\&J)9VI8B8+V-\74TF%5NJ%8O,R7(J]%Z<]
MKC)\[-*!AV^9MN]2FF=8V@U/$(H.4RCSH@O_O4!J/[ W?QQJ]Z+04OL!RL(>
M/)RZ[ZJO!PZ"CE+4]1#=+8]N%!R]HNNAPYJC%,@^2$'7@\0P]]G_[^ *^A]%
M+D599OD<K)-2%)\R)D9N WB.1L<9:%N;6\Y>A!WA3V(R;BNR<[Q5+HQ.S_'B
MF\1H6R<52Z<GHL^/1J?GJ;NCB1N0,7O:G:66?O;*^%@][4Y!DSZ%GG8'5U[?
M;:K*;$,#+\I9>D+'/U<#P/<.X54X4XW+\L8%AQW\B7N0%DH7SQM'?L5UW..?
MJ:%#;)3"1BG6T\8A.A*>AFUU7E&*/S>T!E@5E;:ABA/6YRX\5($F,;:AB@NC
MTS.\_?R)%V_K86WI]$1L@!<4JMB5-K]#@?^]#4^<G1:^,W[)B-@]!Q7[; (2
M[WLMCVP48L^>U@.^XOFJFV;<X,/13SUZU@>R>=^69?89DSCZJ4=G&=?;9GU8
MEADQ9G%TXCDPRQA#Y^BG'MNQ%!Z"8<[45KKP4 8ZA/IQ#H;62=E3;7]A#^D5
M/N05G>W2-=/&-[Y")?1!TO-\J;K2'>>"6_M6< 1#Z1@'&UOM"R:1CZW7V5+Y
M1MOF)5"Y/_$ME3\OMG)\8AB=RM>9(R^ RM$$NR,&NL_4\+@,^\(;\;'0:9H1
M/^@^QB=$9KKG2:>7"YL)6BC@WM:3MZ)$+;*79BX;08APQ[@Q9U1E?OH-6_[]
MWWJM:!X8H;78ZYRK7AMIFK@15Z;3#96P\C6=W=,O97W.*%Z5U;MN):>O32UW
MZ@??.IV?%4 >0/..?K[JP*S7C[H>UF])W7SX2,>=&C55OE 5H56K:S#P&J!B
M;QH%^T+6P.ST.QQ.G=M"R)]>??/A_=L!-3YI3?.K&@@<7=S16:](7OW1-BI2
MX%5VL&X9GDOG+0P'PBI;PJ>[$'\?<^L0LG<FYEFYF-$OU]E<#TIG.?MH#IK-
M@:6['<S]T PW1_QP*YQLSH"P2_7#+LX 1^:%4\&X2G=TN<MU1Q>A.[JT);L!
MWQ-'U835&9.T@+]5^<ZCB'-/2V=19'!B )5#JZK(TJ5I[5[EUQHI8PJ5&DH:
M-E\M*I_0@?XK2:$1N6Z[;<WIZE>]B2N@B7Q97<OLL^!=-F]$E3ECWV4U()/^
MW?JD70\N8@UIV-\6;80\N'[_\DT<1O&;X3X&=W072WUQ?A2!0A>+(O\,U%L)
MH-[7:.HYL(&9RAG.YBV_<560<7/]$X<O%;$#*_8X-%\6SK+4XFKM</CP4P;(
M+=\X+5'N2ZOH7U,*>5UNNM*?K'$_-K35Q5I-OGHF33N6URRO/8/70"U:SVMB
MT]/F#7RF[BJU6\5HBN?N\^(CW'Q,6+ZR?&7YJN6KO)>A]T9ICI8_+']<'G]L
MT/&RIU3@GNZ===:P18!'8XN]&[J;'(+F?V#-EBM[MG3N10$*,04*I3- 4BYE
M*2HG?2C.N&C053[VV&]ZT/-VJ#6K@/[843&1;=Y6DZH-P,_OQ,29B^K''[)1
M]S*^I7Z0C?WZ%'?)I+Y/.V#4OI#7WC1L"';B !>PV^T^$BUW"E%6]53&H\.
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MX;\LOYD#<#G\.*,5_!<&YLO"T?6KQ4W&' K#Z9S!:EEUZ_P\FXGBA@(0<NF
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M8>H.>9!Z,7<9<!2!DR,,5!+ 6(:ISZ1 *'8')X\\%GLA $?$'NR*(,"Y!$
M+EV/>D"Y#_@<:)?CT(,OIS""T3") TR2-$Q1G%(>P^?]$8!3(&J?*L8&Z2/@
MT'&DQ ,.(Q0#\].TH?;ZDJC59.-1U=;6HA37S0]=L1FN'$U&8>UXGFIM]:%)
M4!7-$HVP-0)VYR@QV>KKZ^AJG?ESF%/"7=C(Z^9W[8R[-NK]/9SX4;6Z-G7T
MPLU7:5KFLV4E]JU.KS?I]$CXXY/,N?K?I_L<M?.R=2Y;1)P&(ES+$B>!"3*-
MMKKA+28.*)RVUG^PF+#2Z=(P8:73J6#"2J?3P02R6NQ)8"*V]\2)8 ),;,L3
M)X$)#Y2GR*+B%%"!I@&RF!@1$[N\T:?+*G_L@?YV=^ !@4&:P'0=AD[S&=\9
M.H^\(-H&B&?ZY\X,,@ ']>%/KX)7HT()P2G&K11)GI3!4J^2]E;IPNG57_^F
MHJ^_F^CK.QU]_?&'=*]T<]PN&Z?,4MNMA0L&S6/J^Q$>*YXNL![3L"^8CAY5
M>2TA/4$K'>?RVOVJ:DH(=*\GJ^A91>]T%+T#%I\871%LL^L,F_GN9!V_6770
MJH-'!XU5!ZTZ:-5!JPY:=="J@^.H@VA<=3">1F>N#:I'%^>E^8TB31[^^P (
MEF:VT RQ-'-(FE'/-<^;9G[1;[(,V-[J9U9[I: 7I@SOC:[\:1"?-V']T3[A
M<];1U8A%W ^O*_Y1Y$R4IOS 8D8KF1=W&Y[CCEQ \H0TP2/4"WU"XO'!*EJ-
M=:#'\G=/L\P1PA,_\ Z"[R,[*BVY6W)WD#N)P]"2^_Z/?WC?^U[)_? >\W&Z
M1OED;^T"3LDJ.#*U']X-/DJ)PT,(PM&=WJ/4/GQ2X?/#VR?O[A:S_(L0;>&S
M;?;(19@=9Z!N'?Z4YZF#>='$#;;U?;H,5<M2],NA:#R)XVV7J:7H$[$1#G_*
M\S0<$(CHKVT??O[VP868 2/>Q>>@[9]/F.+/*F<?KU)=P9+E=\H$,'65VQ*0
M-C[QDARV)W3\,U7$W G9:EI8]ZYECHME#F^"/629XR7&/D[H^,<W>'9EB.^"
M@&QKYV2C(R\E.K([11R"'L[!2#HY6^A7RC0%VU#(&>AJFWN57X2F%4Y\?T3O
MV9GJ4Y9.3YU.,1@$ED[/0+T?C4Z/KYP_RW*=Q,BUT8BS4[N?)9.^MN_JF2G:
MYQ.->*_;1-F7$2_1N;KY@KELGZD_\;S(NDPMR5\.R:-)A.V#H!<9)=@_R9^G
M?>%'A\B$/U.SXP6% 4;/CK(1@6-F1RU3T]]=M=!5+[G+)=.ONIN^\#92\!PM
M[( U"TX2"D9K.SH4QK[BXFWO "]#=;/L8-FA??HXB=$VP]YRQ$:;Y>BT<!(O
M.HX.A3'278 - A]MRWFY#!OG_$R9G5$<;TUQ>X%VRID$5)H;R_&07N%#7M&9
M4XA2T(+=:GO&%J0ZO ^Z+]9]$.L\!SM3'.EV.T )G^.?>.SL*S3QW-AZL"W#
M6(;9B6$B;X+#;?DUEF%&#/D<GWP.QS#K3*438YC=%6E5*-$^%[F$.-'N]K-_
MN>]%?J@H\/#ID./>]\&S<C&C7ZZSN1Z4SG+VT0 MF\.N*CW&8,P/S7"SO0^W
M FPY5@A:"B>;/V[D.3(OG I&S55OT;M<]Q85NK=HVV3*\=V)HYH,Z,H M("_
M5?FN@XAS3TMG461P6@"30ZNJR-*EQBA,<^T<!J([8M9LJV$J<YDP5?9\48KK
MYH<W8VRRN:/45^I/JGRA?]6;N +\Y\OJ6F:?!>\V=C:[:L[8=T@,2*(O(YZT
MZX'<T+0'^]LB2\D#:?&7;^(PBM\,]S$0*5TLU;*KOJN?M&'SJYH&]E7<T5FO
M8'O]T39!-!-2[8<N%D7^&:BU$D"MK[UP&CBP@YFJA0$,U3"7"@'O&!.> (>4
M%4S65-@#YGGMH?Z\\[P2>JCABUM:.?>B !XNRZ49\A]%3KE92%35##[DRT*M
MK1BQ%"R'O_QS20N0IDXN#>O!Q/#Y7#!=RN,^JVZ=I>)4^(X:F<UA7NJ4BWQ>
MYHJM5^+BIA!"GT(/TFM/G-=XBKN;[H% "CA ?F\VRX!\*'P#-I(O"\=\*R_*
M=3LJ!!/9I^8D__/V9\]UWB_TW]]]%@7+0)3]4<.T<^3J-BL>G'C2KDSA^UR/
M42"#38NRRD%:U=@IZV5AN[+([YS_7LYS!Z0G$+18 N67.T 7;EOU&YQ/2P9@
M3%,R12T(-+U<P,RP?D,/_05I#10AUL$$A@/S7]5?<6A1J++XAJP4]F 6C;Q'
M-_E&[::5</NZ46N6OE(\9"1!][*ZTI^L\4<V@JHK FI9J&?2@L@*;BNXGR&X
MW6FX06X_4NFHD=9\J?03X-.N/C7/YU>BJ9BJ9W+R17?T=.^\MLZO3T;CHS$5
M_)K]-57W-#.0L^5*3RW-30>*9971&4 ^EQ*N."<%9;&/4[]__63S!J>+79ML
M=.]@.,A24E89$:J&,CB'XIWV6PQ( >YO6&BV5*3?$?FPI,P !K?4#.](:"W!
M?Y[-1'%#]4:5>/['/%,S_EG1JM:ZW_WRVX<KS_4FPV.BJ;?^F&)3K=Z66%??
M;M952&JNX?N\^ @K,_%@26\:KU]2-F_AATM.S#4W9+H-",I[#WJF)Z7S[V4?
M66]2(]ZR"@06@[_^IYB#HC$S$.1W0'1EI72'3Z(3?,L.9&N>DF#8 3 =H@(!
M\3J8DH;B)EJQQE%'\#_)N-5JV6OLK6;<VK3(44V*GK  F2K]$K8TF^7W6FDS
M*LOR3EG&_U+*,[#HS0X0>-*IU$1&,Z[R&Z'94,LG-0'3S99*(RIR)3-@M/Z5
MZU9?I?.=^=.RA&G*[_5D:B#8"0NEKL*N%FWOIE*)&3/EB5GUU,GX3Z\2'TL:
M".DG7DC]!&.7)H2[<8*C&*>I8&X4N$K[HNT('K/(CUPWB61*881P$TH\E!#J
M>MR/48HY'HP(/>0&$7R9DRC!:< 2F#E-XI"D7NCZ;N#+_HC0BQB*9)@$'+:&
MN703$H<\\6@D8A:Z$:6B/\(E(O1)A)/(3=,$>P(E-(H8#,.@MV'*(L;[(WQ,
M*"<2-A1%*,$"SA&+($A@4YBZ),1!& QVA3T_Q1Z%\\8LP0B'< Z$$I<'5,2(
M^X%'^B,\B5(?NR0)/.;"R;&?$-A^PFB:!ERX(?.BP:ZDD)QS+Y%$C?!QG-!0
MX@1QCAGHD3Y%; !=CE-.$08PA41A$/#!D9<0&7IQ0!F1<3@X1R!XA%.1N#X"
M6*6N2*BO$)]*F$.0V!4##%(&BS/&$Y1Z'HR@\.4(P:\QB=P03A[QP1I$("F(
M% D.):RA,$-#6$VBT(U9X(4<H?Z(2*_-$1!8 .?P6900XGJ)3WPBL2>EF[(A
M!H,P=6,_24%M@H4P3H!D@X2EDJ5Q*D,F^7!7KD\04**',2!>8C=)PQ0G0<I\
M'B+? ZSW1\2 :BX0!;H"BL4*3)2Q,*$TC16!N7"^_@B9IMP3(4J8C#F<G/A)
M3&&8YW&/NR3R0T8':\1^%"(XAPPBP'G(99(BP1."$(\Q<7V?>0,,LBB*4Q_6
MB"B<(TR!T -@%QH"57H1D",?G#R50*JI (J-&7"4!]B/"5!B##S@!<BG.!I@
MT'5CCOT8\(;]$/B#Q0G!P@.V<I4;W:6PSH!*0 30@,1)Z(:P1@Q(42P.#.8"
M,D@(U-;@_ FFJ1&"X<H@6^GOS0<Z@-#Q_X)I.771M\:D;%9II&=M:N[ZL"+8
MYOKGV:<UT^<PI80+K9&_S>\Z<'&=PDW]\0K43OYFD9>9,I2NM2()-\=@SHY5
MW7Z5IF4^6U:B:T4?(BK5&;F[Y?0#'*;]]VLS?"TF3@03V]\86DP<"A-D&A&+
MB5/ !$BGK3D#%A-6.ET:)JQT.A5,6.ET.IA 6W.K+"8.A8E8&X@6$\?'A#N-
MK70Z"4QX5CR="BK0U-]:N\IBXHF8V.6E(EU6^6//%+<ZH0X("])DB70#<"-E
MCF^#PW/]<V<&&@"$^O"G5\&K4<&$O.FX[US)QH#RYE3RK2'<OZD ZN\F@/I.
M!U!53'>?='/<UQ:GS%+;;^,+!LUCVOMAGF2<"; >4[ OF(X>U7@M(3U!*1WG
M\MK]JFKJ:7:O)ZOG63WO9/2\ Q8I&ET/;-/F#)?Y[F0=NUEMT&J#1P>-U0:M
M-FBU0:L-6FW0:H/C:(-H7&TPGI+#%G$=71M4SR;.2_,;19H\_/<!$"S-;*$9
M8FGFD#3CN>=N=?ZBWU@9L+W5SZ;V2D$O3!G>&UWYTR ^;\+ZHWV2YZRCJQ$+
MV1Y<(?H-0#&;"58MZ4P]P5[ _KZ89]^T,D4VS#-E58UDS_4%CZL-'KN^X.&[
MJ.V[WN;6#-[3+*?I^9,@.E YS8LN%&C)_23(/9RXARJW?-GD?GC_^[Z+PQ[8
M:_[L.I]H@OWX,+5?CVP/'+WVZZ$=X,^O_1H<IO;KR$[NPW<&/+A*_D>12U&6
M63X'>Z04Q:>,B9&; 9ZCF7$&ZM7F!K67H4JY$[)5E;H,C<D2ZJD3:C#QMK9,
MMG1Z(@K\:'1Z?&7]>70:^OZ8W>T.KYV/AL$3T*T'*)S_<#=*3[I3T)"?+4[.
MV?'_YR-5>TO'>OM?E/MSLS"Z<!^H.W&#;1>-]8%:FG]A-$\FQ+=N_Q?I]M\_
MR9^G.>%-D(=?:!1@_S@_/0-D-Z0? N.G8<2<EYO_W:;&"];%?\+JU.%/>9[J
M53P)(L^Z6"U!OQ2")I,0V]C6&6C_AS_E>5H#,4+G'5HX CF?J0DPXD5\#IK^
MV00@WO<ZF-E@PYX=KP=\?W,2'@NC:!W]U"-+,W\2^H%UW%J6L2RS.\MX@8UU
M'"C6<73B.4HLY.BG'IEE\-8$01LI>8EFTB&TBG.PGT[*3%HU)$=ZA0]Y16>[
MM+2U892OT/1\$. \7ZHFD\>YM]8^W1M!F3O&P4:_FL "(M85;:G\15.Y-R'^
MB![J2Z'RAR;(BZ#R=5;&"Z#R8$+<$5\BG98]<2%FP[8$JQ=A'?R@NXW_M6X'
MU&ESQ&:"%NI0M_4$+6>JB?;2YVCCUA'NV KF'"@>]C+Z]W_K=6EZ8-/54J1S
MKGIMI'%Q(ZY,$R@J8>5K.KNG7\KZG%&\JAUWW0HB7ULN[M0/OG4Z/RN /(#F
M'?U\U8%9KUM[/:S?L+WY\)%F5#5JJGRARJJK1O!@+S5 Q=XT"O:%K($5YW<X
MBSJWA9 _O?KFP_NW T9[TIKF5S40.*FXH[->$;CZHVU4I,"KS$I%XDXNG;<P
M' BK;)F:_K5#19N(OX^Y=0@Y%?UB[_O@6;F8T2_7V5P/2F<Y^V@ GLUA5]7U
M2C;XH1ENMO?A5CC9G &#E>J'76Q\1^:%4\&XN>JZ=)?KKDM"=UUJZ^\#V4T<
M57]5O_&B!?RMRG<=1)Q[6CJ+(H/S J <6E5%EBZU0(1IKG],"^>'9^'!3-%(
M(J/7,%6]<5&*Z^:'-V,@J1'*ZBL=6:!^U9NX FSER^I:9I\%[PJ"1I@9)/5]
M1 ,$]F^])^UZ<$5J2H'];=$3R(.+\2_?Q&$4OQGN8W![=K'4%_A'$3ETL2CR
MST!9E0#*>AU,0P<V,%,/$+-YRPE<E23<7 ^D0YM-'C%0-YWW."E?%LZRU.*-
MY?-R.:L *LU4Y1NGIN*:.I\MBW>G/WVG=7XW]YFFAAVXYX%B8GG)\E*/E\"2
M6,]+Y:-/?OE2K.$@T23KZPF<?-$=],;RC^6?%\4_[C1>SS]BTZ.5#7RCU"RU
M6W7UJ%OH/B\^@L[&Q!NEUFVFR)&TU+X-I7#5542O]"=K0DT-*761-.0\J^99
MUGH>:P7K62OO)8.J/\R6ZEB.I$S3V0.>F^Z=?T[%VNQRK2;&WL; <"Q7IF/I
MW(M".&#I51F= <AS*4M1.2E8;WU4H"GNHH*+!A794RJ"3YW#V-7'M.^SWJ2&
M*;(*R)RU6<P _OQ.3)RYJ'[\(3N0K^&4J/#7)[@B)C6W=X"F'0U@!+;28>*
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M0O>WI/R3X1'%(,NB, [&VN4-%^5-0>]6S7ZZ_K1._Z/.8F_,(.5+TZRR[MO
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M=YTP:^;SGOMETNBH>N+F.NJXTU:1#74;\:<5TU<3Z<K;+Y%BGB!W-U;D>)9
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M5($=L#8&E^.H;@FMUU ^GB38ZN8:MI&3LJZI^['%*C4WHFSSM6/.'!$EH[/
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M$<84SB@-Y36OY;#0N5+QPC\0JO/IC.J<49TSJO,/N'E_6;OV>'>([-6[IH
MLPF\?)PGVCC-((Q\]T3S*LRW./L,L\]PA,^0(2>C=Q.$RQ#WO,9=(+\,!DJ-
MNRK@B3AM/D=(L]5]%D]5Z:E&*[-I8ACKFIA-W:"@YJWRN]FAA'94)<7R/*9,
MC>7/2/?9K(],:#$*(=0F;V:\\B0S-[%-W2OKFY%3]\OXE*-R:%[N%ZS#<-F
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M$&P,!6I9$6LQO0@)"?G#F<::6QOPG@'MN[0W1JCS55Z4S %.L@)1(Q+[D#<
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M)*\.#[/%J_P(NR1AKQ%W3:V+:8, UG@(.3^R4G2^*)>?,^Q#)X:P^>3CX+Y
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M%ZTS^!5A>"9?R#2>^<4C .5_5-2']KZC,2(W1;82WS'56,%JOHCO7ZMZXE>
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M1P19X)*&3((D^NC >6%M7*FN</S"?H0>6Q5]S[2XHZ?TBX>8EOFU^.P8N'
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M&,T6-%O0M 6A'WKBMZ&9LG VEX/F4DF;9-0>6M6*8I/N#$(E?%FT@V\\5N%
MF,K81\^(P$#!02V2F)00CGB2"GZ@6@5^G:G( TQ6TRJ]\(P++(C+4!SL2.D
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M?CY#Z.F5T 9WNMUUIERNA" UL/?C,>/=KF_SHNP;E[X^^TNW?!"OJ!5TK>R
M;Y@QT;O469#;:L' !')N.@T@2&OZG4SCG\F SZM]TIIVJ[0*I3%I,F(] I[4
MT"'T:4FOT\7W46[5Z>(BK>R\,K<:C1!2Z;-A@$9A*S4J-3+_M$S-+'WYUO Y
MDZ%_3PB0E#D*5G^(] ^#-R4"9,7"7R3+9 #^QO X*2+9 NR,I48'L[? /^&X
M5.1EF&A#EHVQD)75MG&"PF]#ETL0,")K]^ID49\"F?0ULK<>%L5) _6O[E"
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M?Y8BE92>K[T4'IX)_4K%ATG,J\RK2@!$\E=ADW6>X6>\:7;0JQ[+EG_6(/U
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MJAQI*WC9H+H@.H%@D7F5QE^C!R3?2XA3(:.K8;E-ZK+K4J] HU):VQ="^(Z
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M*1I_3U_X^O)4A(<V?0W5>[Z(5.?/0'50L$+=W%M-WH7E=E ,5==<%T69>[&
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MC69BO J\*&S(-?WE'T/W3D*=W*A_T?$+='#4C_0UVR ?DB@5Z54@<FY[H=
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MI[C33A&NL ^!J)26[HPPLVS-A;L*'T81!\#JX>@]06T>SG[04DK<)P*C8RQ
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M_I3QG^GR (G(FAH&$\.X55A2&'TM/[9YZH\O7\0Q:"SX(-*2@.!FQ& ",*(
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MJ3IACJ $],2'P.)R8_;I&#]<'#U0^VV(Q<$=* 3Q ,,!3UG=,32KOZGQ.^Y
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MG! ,KVB/F9QS:7YX0XL[BR-)>K-,.2>IL*X7"#RN*I]>:E08"L">*PO09)>
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M%0_]C)&UKO=![D9TVA*?TL7]PR519BGM&G8-(MN$*'L!#P."SV-)?'2H%8U
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MP+RZP_>ZF!]28^Z+;$D! Z_=&9F00A87[J0OMP?P]]%_FZ>X/,C@E2]9Q?M
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ML:D\\-8K=7"(W6?G NEMMK3W;J/*_&",2_8F (-U;Y&;58CW0_^];"J-07M
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M3PNXI)80C<,<PA/40_X-=-PJ%UR=4^<!4UL7 ?><NBO:'90E(ITT\,I_%2]
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M\%40AGD&+.^(?&\+Q23<O' \@JJ<9#F= .2V&+1VTM)SE8T&[O6M8!_-W1T
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M[C)?.6J%G&N\'%!FX;3HF!5-:;Y<>UGOBO."$?JIR.X$S@GD20_0>;WZ(7V
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M8<(ONPKOJ&[F+/501'/["MY1;-@ZSK">P$ET]:4CQG6%-<S@<1HF5:3D@;I
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MF)R@^TK%F=S8[J7&8HA/#FWG$LY?A*YAWUMS3LR!6^>.ME?+@+4V./6E[[5
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MJB84"E=C+![(PJKN &3%"9/@BH\!Q39"9AUN_2-BFSUYPNW\?$D4SCE4$@;
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M0;K^M4Q0QHIH O\^;2VRZ]"_7@O@&3MVB)ZRB1-^EG*Z%^E4*2-99'4+TP5
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MIB! PG#R6ZJK9TJ/OE=@%(EL2[I-=9'*<L*;TR6$Q.1Q?8)]NP>>H'C6R2]
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MQV2^",?8.9<FRXT[/=3JBJ"SD]1_@#'D/D#>!\A7"9#O[_8!\CY W@?('TF
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MLYS5:=4I[ZU3*Y<.9@UTO<;13/)HDZY11DMYY1,'2=Z-U<GU?2O5M]K)3DX
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M]KBF!4>2.L5(W*G+;"'1-$"92>3TZ7<TZ*]E%N6AOH/LNC)1R T'B@'ZD1)
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M/R['XS3^1LM1)H!D&\L ZP"5-I,".[(8 U!F5:@[*F&H<1KP46Q:]3M7L"6
MBX]=D[QEG1^%3QWVAJ$2\?WRSKMF+!^Y]DJKU@^VBT!G#8 M^]?W"BEUO,0$
MBD UI'^)\-]$IGM\D,W(MX=J1M#L+JLA06^\(3"D.^F][>JZ$IX1*8R<(3VA
MHML280 +&1Q#B98RM!&L.]$5(;.A1>JBB?\;=TBKY[9\+C%HH$+IJ&R:AAQQ
M#W1U36BJ[R<^$U(C/G0E-J?S@"-K&PNP%:S57-=:"51TT64/M7H3&UWZ _8
MO^*^9&XQ.2G>DDQHQD0;\B01F9'?B[B5!B331SIW$LT& ,KH>VF&UFM^K$FD
MCK=9Q8"FA&"15>,"=:8G.&0?KL\/TMF<#MF]ZF#5$3]L:L&./[N#4YWYY-=
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M !WD.CD82)W##>Z_@4N]& ,K*5@)QLL@BQ$L-XT.^&;\"ZS^?&[73GF?KH7
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ME3BGN))"8]QFJ!P['3 *=!.X?#(S255R8:U/))4B5=1^3$Z/P'H@20/_B3A
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M?)0_DF^&3U<9?0P"S]@(A[2<ZI'F,+J[2P+8L%"-U5CXDY]W].[Z4BU;"$D
M/1>(3J:BN 8*EL506<XB:XTOM-: P)([*VE<<_I1N #VUGY!OBY^/S_WP17
M4%+QB=V;IW%ITXU&L,\8-BS^P)6<Z<)32OW0?\$% Y"!"ZB.</R ?!\S RG+
M +_QC_]"8"6XO+?VCG<*Z< _\8?)O\(:3Y._JJ+T?L1/"DB?K0L?,(U*QS,#
M?U)#7EWP_5NF>4QC104*T*]W^*SMZ^YAURT/&.R;'"MCP8C 5^EL:##GS?0!
M,K DN"%HA><9)6!]AG%S#(3A%]!<#V<.3R0J.5F"!SCL>UD4P.:!@99P!K2.
MMS4J?/0)'#0T/KR/H-\7[^2D /Z\+[I'W=<1,OG3YR>BNRX\7R87@5!;J+_W
MUT9Q40L@_T KP&*8';ZL07;XXD<$FMAI @R#^#FW#!'4Y9]@BAGEG" 5H&$/
M#?R[;0"?9R6M@.\YN#OH=W^EL;O=\[91WV)X_[)1]VG8EP?U<79Z[5/WNH?U
M0V]FM^\U/A" !VBY)6Y;J"N<'Z0@>)@  F!JW?X[V3></W&>)<# <KV49D/\
M^Q&Q[P9']+K]B  CQ[F^E/%TX5F\QV"T#/EQ<,5<>PR=H[.:V3<'_#Q"'OZ!
M- V^!E<8^*AW-G<G; 4S)YCI7>LS61OJT75L1J"#$,^S-_-UHA2K.JB,)0J6
M8 -A02%";9E"G'0V2'7L=' U,O;[!+4^0!S0&G41*H<XP""750("?FZR"]"K
M:[V841$-RJ "8BD JP-M4:=&G75*]8$0A\4Z;):/C5,$50ST]Z$>$T+  9<N
MJMJ+ZN[\*LZN]0:7[7GZ\[Q<\W%RAC,976S:\V0(M)JJ?FHFH![4QXTG.9)7
M>E2-G/.\$>\/?.0$!UI;-M9:3;9;;^CW[@T]V'I#M][0K3?T_E/:'N&U?+E^
M 1V$*[I[*<N;[/BSAK-;6DP;EGT[QX",L:5$EQ.\LVM-I;2(6DN 04S.AOK,
METF)K @!WZ8&+9KX9\5?&+2C4/@6JA)UK:!<#4! A.\3(?OF\A;RW]'A)KAY
M>60<X5@C\.+K3M75JXG$$*0K<AS:E!U=.!=A4/,L,:!E(^@P?="E$M)YHG>0
MSX\=B'CV*%]C5IGT$6M<_@8=*+$>\]<8=D>A;2BU6S\0%\DQL5*$%'U;(XWL
MO61Z"FRQOXW1+ER180$0ROJ:""<L(F#:?HB6=?D== [&@'\V=30H/%"[9/V7
M6,*,,V1<58XIN<Q*K"[D P\T>7XS%=?%$RE+BV+PK [9V&O4W&SDTYY<,<.)
MU,V$)Y//Z#S6+!BY542+'&1.Q4&?+T:.8F6;5*O!ZJMN+GKWEF$1F\B%0^HX
M>%1A$6C^C%$WXC2_4X_DB#P/$"3QYPRED7<NB,^MRYXNS#ATSJ:9K?T_X ;B
M(I>9+5Q"[MZ9T?ZOS"JDW(.NK<I9ITXNSH5T*1O CP8*S5 8J<31WC;?#6F$
M@Y_=C14D,9*+&5YHS5QD6K9C8?"*O1WM?<=YDL#=*DXW\5-\KR%)<YAQN'G4
MM@)]86R\+0WP6QW0\ !D=8_Y)6T4BU'^ YV/?(&$N1H$:)*S98&JNJ00&6Y]
M"6)7ZLDE&UW8[(F61%:J5CQ1;+K'=\(!YPHHK.T [J52P[+2#/=XSBX\#<[K
M$GG?;$UHDOB6E%YZ'.+ -0=^M'GLZM;" :+H&:P!PUS5 XH#M":0VFW(5B@-
M-!*!Y@R]-E1LY0HP45AAH(RHE#/7"",!5U^2D#&27UD"'\@40R83"RJ2UV'%
MY@+C!TD1M7XH_(NT#QL59PAF]\F;=P)?&=(CZN3D*W-:!NM9A:$*923^@_"B
MRHG)O])+QBE)I!]<:C41!8@XNPW'2.1U#C@G5@,H,/4&84^H+N&L:"T GHXO
MD$M^RKF&45 _#4/P=$GQ@>M#1%,G^\)'#)]2'B*P[[Z1>6)#3"-7FUOB=12#
M"L4OP5U6FA'G-3;\3'4(1VCWL'8+^S!K9O-AAES#<?[U54O4F3R L(\%_EZE
MQVM.\]DC8LX.74YM"/9:J:*IK07\^*:9C,@',%:;A(A"I0.R%F+41>:BNZ.
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M"FJZ1"ZVK%BW.:Q1H70NA*%)Q]1:,5=ZU$?+%QE)FB5).,'<&VM]JCM0+#?
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M#&(\W;EG=423BS]\H("O#P8]2XMQ'V\U:F%>U.':>%-6&9F,;6BVN,"H9@Y
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MNNOJ-%*#1Z\HP"#&=06?.B2+A&_:CD6E&0TK_L*@*872:5";4%<H^1?D.1N
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M4Z\44S?-X_\HCJ^2>+P<P9=9]XSL=C:9W2_CF>>C-@LP1QF2F*^8%RG"=$+
MDLPBXSUA.B\*)8TTQ8NZF' .V SS&L)1 *(0.1\5XU8]%I# T]>Q0TR:=-<Z
MA<%:(YXHA,"$*![S=LIAKLK\C<@Z"T?O@VX45E=./ZH3;7I AVY%&<Z(DS"B
M;G90S83#LDS=[\*N([UYD2X^L]J">*;LOBU0<^8Z>[99L>XG^62GF=Q!>?0^
M-"U/[[ L%&?S2;0Q16MV+G?LHU?U^'S_XHK*'A?7[H#Y/@T69"(=\>$-62)?
M<9NY\,A"(]6NJ1/0J>AZ]()3N-<A>Z:=.V3-#HGU9D6B/(#6BF _Q8^W*/K\
MGKA##!_4PV-<$EPX0]?%&US;23:X#S'@Z>C^6J OQS[5ZTI"M\T!]]/8_04@
M[T?JWBB\RP=I&#K["6$708\$9SZD*S%L$)2EJ 2-<: &C&#JP?%JE(O"NL!>
M;17,->"W8+D.L!XG$YL#9JX KR5J<P7(%6 =8)Y+%G@L)!R:-]0;*79%H95\
M&Y*KP<M&\$.[XA>/YFP__HJ S0,W#]P\</^\P,UOR^2W95[+;9FF9!XT+W,Q
MV-@-1,[]?#.V#C!?@OGK^!8M9_[CH7X S#^.^4]B]HJ!N7G,G]Z&.9D\//*(
MVS"__?F0V><I5OOVV5K\^CE[7&1-[Z4<I9;A\(<%NW $<X_6/.N0(>E3HRLI
MN31(3U'IDBO!]!LHLR,L/(F4.<#CE$@7@W:0/0#@3+)6U\J>@BIG'LP.IF_T
M9%ZOE>)7AMZ^J97BUX_^ U!+ 0(4 Q0    ( (> ;$]4JQ./J0\  ,JQ   1
M              "  0    !E9&ET+3(P,3DP.3,P+GAS9%!+ 0(4 Q0    (
M (> ;$]RO:.<RPT  -+)   5              "  =@/  !E9&ET+3(P,3DP
M.3,P7V-A;"YX;6Q02P$"% ,4    " "'@&Q/)I?R(1LD  #A<P( %0
M        @ '6'0  961I="TR,#$Y,#DS,%]D968N>&UL4$L! A0#%     @
MAX!L3UF@4GL69P  K=,& !4              ( !)$(  &5D:70M,C Q.3 Y
M,S!?;&%B+GAM;%!+ 0(4 Q0    ( (> ;$_[E@%RJ4,  $<'!0 5
M      "  6VI  !E9&ET+3(P,3DP.3,P7W!R92YX;6Q02P$"% ,4    " "'
M@&Q/.R&]98,T P #M"  &P              @ %)[0  961I="TR,#$Y,#DS
M,'@Q,'%C-F9B-F0N:'1M4$L! A0#%     @ AX!L3R@*,V<YA@  VUL$  L
M             ( !!2($ &5X+3$P9#$N:'1M4$L! A0#%     @ AX!L3Q;!
ME_)D+0  @#8!  L              ( !9Z@$ &5X+3$P9#(N:'1M4$L! A0#
M%     @ AX!L3WJYMA=&"0  'TT   L              ( !]-4$ &5X+3,Q
M9#$N:'1M4$L! A0#%     @ AX!L3S3AX#4;"0  0$L   L
M ( !8]\$ &5X+3,Q9#(N:'1M4$L! A0#%     @ AX!L3VJ)E)]J!@  \C0
M  L              ( !I^@$ &5X+3,R9#$N:'1M4$L%!@     +  L L0(
' #KO!     $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6799259296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Restricted Stock and Stock Options (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Changes in unvested restricted stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted shares, beginning of period (in shares)</a></td>
<td class="nump">270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Issued (in shares)</a></td>
<td class="nump">445,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(77,052)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(51,182)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted shares, end of period(in shares)</a></td>
<td class="nump">586,892<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance, beginning of period | $ / shares</a></td>
<td class="nump">$ 28.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Issued (in dollars per share) | $ / shares</a></td>
<td class="nump">21.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">26.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">21.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance, ending of period | $ / shares</a></td>
<td class="nump">$ 24.20<span></span>
</td>
<td class="nump">$ 28.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Changes in unvested stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation expense | $</a></td>
<td class="nump">$ 9,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="nump">4,689,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,500,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(502,234)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Cancelled (in shares)</a></td>
<td class="num">(546,799)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, end of period (in shares)</a></td>
<td class="nump">5,141,255<span></span>
</td>
<td class="nump">4,689,786<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">2,386,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 23.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">24.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">11.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled (in dollars per share) | $ / shares</a></td>
<td class="nump">28.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">24.69<span></span>
</td>
<td class="nump">$ 23.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollar per share) | $ / shares</a></td>
<td class="nump">$ 21.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining contractual life</a></td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, remaining contractual life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value | $</a></td>
<td class="nump">$ 14,899<span></span>
</td>
<td class="nump">$ 20,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, aggregated intrinsic value | $</a></td>
<td class="nump">$ 13,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=edit_EmployeeAndDirectorMember', window );">Employees and directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Changes in unvested stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition</a></td>
<td class="text">2 years 7 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation expense | $</a></td>
<td class="nump">$ 38,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Changes in unvested stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=edit_EmployeeAndDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=edit_EmployeeAndDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6789212160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Maturities of Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Maturity of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2019</a></td>
<td class="nump">$ 1,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2020</a></td>
<td class="nump">6,398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2021</a></td>
<td class="nump">4,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2022</a></td>
<td class="nump">4,588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2023</a></td>
<td class="nump">3,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">20,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(3,256)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities at September 30, 2019</a></td>
<td class="nump">$ 17,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">9.27%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6786799504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Revenue Recognition (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrentAbstract', window );"><strong>Accounts receivable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts receivable, Balance at Beginning of Period</a></td>
<td class="nump">$ 30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_AccountsReceivableAdditions', window );">Accounts Receivable, Additions</a></td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_AccountsReceivableDeductions', window );">Accounts Receivable, Deductions</a></td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts receivable, Balance at End of Period</a></td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Contract liabilities, deferred Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred Revenue, Balance at Beginning of Period</a></td>
<td class="nump">131,326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_ContractWithCustomerLiabilityAdditions', window );">Deferred revenue, Additions</a></td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_ContractWithCustomerLiabilityDeductions', window );">Deferred revenue, Deductions</a></td>
<td class="num">(7,928)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred Revenue, Balance at End of Period</a></td>
<td class="nump">$ 128,398<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_AccountsReceivableAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of additions to accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_AccountsReceivableAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_AccountsReceivableDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of deductions to accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_AccountsReceivableDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_ContractWithCustomerLiabilityAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of additions in obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_ContractWithCustomerLiabilityAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_ContractWithCustomerLiabilityDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deductions in obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_ContractWithCustomerLiabilityDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e604059-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6787812672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Property and equipment, net consisted of the following (in thousands):<b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:27.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Laboratory equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,892</p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 974</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 289</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Computer equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 826</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 733</p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Construction-in-progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 451</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Furniture and office equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 166</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 166</p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 118</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 118</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Building</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,167</p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Total property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,535</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,365</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Less: accumulated depreciation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (6,460)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (7,133)</p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,075</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,232</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6784505488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Unaudited Interim Financial Information</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-style:italic;font-weight:bold;">Unaudited Interim Financial Information</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;) have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2018 (the &#8220;Annual Report&#8221;).</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The unaudited condensed consolidated financial statements include the accounts of Editas Medicine, Inc. and its wholly owned subsidiary, Editas Securities Corporation. All intercompany transactions and balances of the subsidiary have been eliminated in consolidation. In the opinion of management, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the results for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The three months ended September 30, 2019 and 2018 are referred to as the third quarter of 2019 and 2018, respectively. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements Adopted And Issued But Not Yet Adopted</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements &#8211;Adopted</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Leases </i></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Effective January 1, 2019, the Company adopted Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, <i style="font-style:italic;">Leases</i> (Topic 842) (&#8220;ASC 842&#8221;), which amends a number of aspects of lease accounting and requires entities to recognize right-of-use assets and operating lease liabilities on the balance sheet. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">At the inception of an arrangement the Company determines whether the arrangement contains a lease. If a lease is identified in an arrangement, the Company recognizes a right-of-use asset and liability on its balance sheet and determines whether the lease should be classified as a finance or operating lease. The Company does not recognize assets or liabilities for leases with lease terms of less than 12 months. Lease payments for short-term leases are recorded to operating expense on a straight-line basis over the lease term and variable lease payments are recorded in the period in which the obligation for those payments is incurred. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, and (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Finance and operating lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the rate is not readily determinable, the Company utilizes its incremental borrowing rate at the lease commencement date. Operating lease assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 9pt 0pt;">straight-line method as an operating expense over the lease term. Finance lease assets are amortized to depreciation expense using the straight-line method over the shorter of the useful life of the related asset or the lease term. Finance lease payments are bifurcated into (i) a portion that is recorded as imputed interest expense and (ii) a portion that reduces the finance liability associated with the lease.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">The Company does not separate lease and non-lease components when determining which lease payments to include in the calculation of its lease assets and liabilities. Variable lease payments are expensed as incurred. If a lease includes an option to extend or terminate the lease, the Company reflects the option in the lease term if it is reasonably certain it will exercise the option.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">The Company elected the modified-retrospective transition method, pursuant to which the Company recognized a cumulative-effect adjustment of $0.8 million to the opening balance of accumulated deficit on January 1, 2019 associated with de-recognizing the net asset balance recorded in property and equipment, net and the offsetting construction financing lease liability related to the Company&#8217;s headquarters which was previously accounted for under the built-to-suit guidance in Accounting Standards Codification (&#8220;ASC&#8221;) 840, <i style="font-style:italic;">Leases </i>(&#8220;ASC 840&#8221;). This resulted in a reversal of $32.6 million from total assets and $33.4 million from total liabilities. All prior period balances are presented in accordance with ASC 840. As of January 1, 2019, the Company recorded a right-of-use asset of $19.5 million and lease liability of $19.7 million associated with the adoption of ASC 842. In addition, the Company elected to adopt the package of three practical expedients for leases that commenced prior to January 1, 2019, allowing it not to reassess (i) whether any expired or existing contracts contain leases, (ii) the lease classification for any expired or existing leases and (iii) the initial indirect costs for any existing leases. The Company did not elect the hindsight practical expedient <span style="white-space:pre-wrap;">which allows the Company to reassess the lease term as it was not relevant to the Company&#8217;s leases.  </span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"><i style="font-style:italic;">Stock-Based Compensation Expense </i></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Effective January 1, 2019, the Company adopted ASU No. 2018-07, <i style="font-style:italic;">Compensation &#8211; Stock Compensation: Improvements to Nonemployee Share-Based Payment Accounting </i>(&#8220;ASU 2018-07&#8221;), which simplified the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expands the scope of ASC 718, <i style="font-style:italic;">Compensation &#8211; Stock Compensation </i>(&#8220;ASC 718&#8221;), which supersedes the guidance in ASC 505-50, <i style="font-style:italic;">Equity-Based Payments to Non-Employees </i>(&#8220;ASC 505-50&#8221;). In accordance with the new guidance, the Company accounts for share-based payments to non-employees by recognizing stock-based compensation expense equal to the grant date fair value of the share-based payment ratably over the requisite service period. The Company estimates the grant date fair value for each stock option using the Black-Scholes option-pricing model. For restricted stock awards and restricted stock unit awards, the Company estimates the value of each award using intrinsic value, which is based on the value of the underlying common stock less any purchase price. On the date of adoption, the Company estimated the fair value for all unvested non-employee stock options and restricted shares. The unvested stock-based compensation will be recorded over the remaining requisite service period.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:24pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:24pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements &#8211; Issued But Not Yet Adopted</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/>In August 2018, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2018-13, <i style="font-style:italic;">Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement </i>(&#8220;ASU 2018-13&#8221;), which modifies certain disclosure requirements on fair value measurements. The amendments regarding changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements and the narrative description of measurement uncertainty are required to be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments are required to be applied retrospectively to all periods presented upon their effective date. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019 and interim periods within those years. The Company does not anticipate a material impact to disclosures as a result of the adoption of ASU 2018-13.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In June 2016, the FASB issued ASU No. 2016-13, <i style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </i>(&#8220;ASU 2016-13&#8221;). The standard requires that a financial asset or a group of financial assets measured at amortized cost basis to be presented at the net amount expected to be collected. Under current GAAP, a company only considered past events and current conditions in measuring an incurred loss. Under ASU 2016-13, the information that a company must consider is broadened in developing an expected credit </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">loss estimate for assets measured either collectively or individually. The use of forecasted information incorporates more timely information in the estimate of expected credit loss. The new guidance will be effective for annual and interim periods beginning after December 15, 2019. Early adoption is permitted for annual and interim periods beginning after December 15, 2018. The guidance is applied using a modified retrospective, or prospective approach, depending on a specific amendment. The Company does not anticipate a material impact on its consolidated financial statements as a result of the adoption of ASU 2016-13.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6784522576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of anti-dilutive common stock equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The following common stock equivalents were excluded from the calculation of diluted net loss per share allocable to common stockholders because their inclusion would have been anti-dilutive:</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:73.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:21.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of September&#160;30,&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:73.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Unvested restricted stock and restricted stock unit awards</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 586,892</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 288,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Outstanding stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,141,255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,822,486</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,728,147</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,110,486</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>23
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "edit-20190930x10qc6fb6d.htm": {
   "axisCustom": 0,
   "axisStandard": 19,
   "contextCount": 178,
   "dts": {
    "calculationLink": {
     "local": [
      "edit-20190930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "edit-20190930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "edit-20190930x10qc6fb6d.htm"
     ]
    },
    "labelLink": {
     "local": [
      "edit-20190930_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "edit-20190930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "edit-20190930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd"
     ]
    }
   },
   "elementCount": 421,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 10,
    "http://xbrl.sec.gov/dei/2019-01-31": 6,
    "total": 16
   },
   "keyCustom": 42,
   "keyStandard": 288,
   "memberCustom": 19,
   "memberStandard": 28,
   "nsprefix": "edit",
   "nsuri": "http://www.editasmedicine.com/20190930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Cash Equivalents, Marketable Securities and Equity Securities",
     "role": "http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndEquitySecurities",
     "shortName": "Cash Equivalents, Marketable Securities and Equity Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Fair Value Measurements",
     "role": "http://www.editasmedicine.com/role/DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Accrued Expenses",
     "role": "http://www.editasmedicine.com/role/DisclosureAccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Property and Equipment, net",
     "role": "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNet",
     "shortName": "Property and Equipment, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Commitments and Contingencies",
     "role": "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Collaboration and License Agreements",
     "role": "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreements",
     "shortName": "Collaboration and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Stock-based Compensation",
     "role": "http://www.editasmedicine.com/role/DisclosureStockBasedCompensation",
     "shortName": "Stock-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Net Loss per Share",
     "role": "http://www.editasmedicine.com/role/DisclosureNetLossPerShare",
     "shortName": "Net Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Related-Party Transactions",
     "role": "http://www.editasmedicine.com/role/DisclosureRelatedPartyTransactions",
     "shortName": "Related-Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - Subsequent Events",
     "role": "http://www.editasmedicine.com/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - Cash Equivalents, Marketable Securities and Corporate Equity Securities (Tables)",
     "role": "http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesTables",
     "shortName": "Cash Equivalents, Marketable Securities and Corporate Equity Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://www.editasmedicine.com/role/DisclosureAccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - Property and Equipment, net (Tables)",
     "role": "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetTables",
     "shortName": "Property and Equipment, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "edit:ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - Collaboration and License Agreements (Tables)",
     "role": "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsTables",
     "shortName": "Collaboration and License Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "edit:ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30903 - Disclosure - Stock-based Compensation (Tables)",
     "role": "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationTables",
     "shortName": "Stock-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31003 - Disclosure - Net Loss per Share (Tables)",
     "role": "http://www.editasmedicine.com/role/DisclosureNetLossPerShareTables",
     "shortName": "Net Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - Nature of Business (Details)",
     "role": "http://www.editasmedicine.com/role/DisclosureNatureOfBusinessDetails",
     "shortName": "Nature of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "As_Of_3_31_2018_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarket2018MarchOfferingMember_DsmZE9rWKUiDZb1Yzi_Ong",
      "decimals": "-5",
      "lang": null,
      "name": "edit:StockSalesAgreementThresholdSaleProceedsThatCanBeRaised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "As_Of_3_31_2019_lev25mtbBUGfkyljGiogTQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - Summary Of Significant Accounting Policies - Recent Accounting Pronouncements (Details)",
     "role": "http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails",
     "shortName": "Summary Of Significant Accounting Policies - Recent Accounting Pronouncements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:LeasePracticalExpedientsPackage",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "edit:MarketableSecuritiesAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Cash Equivalents, Marketable Securities and Corporate Equity Securities (Details)",
     "role": "http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails",
     "shortName": "Cash Equivalents, Marketable Securities and Corporate Equity Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "edit:MarketableSecuritiesAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "edit:FairValueAssetsAndLiabilitiesTransfers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_rl1kcwMXZkCIZ-rzvXYVSA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Fair Value Measurements - Recurring Basis (Details)",
     "role": "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "edit:FairValueAssetsAndLiabilitiesTransfers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_rl1kcwMXZkCIZ-rzvXYVSA",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Accrued Expenses (Details)",
     "role": "http://www.editasmedicine.com/role/DisclosureAccruedExpensesDetails",
     "shortName": "Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Property and Equipment, net (Details)",
     "role": "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails",
     "shortName": "Property and Equipment, net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "As_Of_10_1_2016_srt_CounterpartyNameAxis_edit_HurleyStreetLeaseMember_2ldT7Pk_sEy-LRFeHacLUw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "edit:AreaOfLeasedSpace",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_sqft_zyr2ZacpEkijqHVLi1q1mA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Commitments and Contingencies - Operating Leases (Details)",
     "role": "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails",
     "shortName": "Commitments and Contingencies - Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "As_Of_10_1_2016_srt_CounterpartyNameAxis_edit_HurleyStreetLeaseMember_2ldT7Pk_sEy-LRFeHacLUw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "edit:AreaOfLeasedSpace",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_sqft_zyr2ZacpEkijqHVLi1q1mA",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40702 - Disclosure - Commitments and Contingencies - Derecognition of Balances (Details)",
     "role": "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesDerecognitionOfBalancesDetails",
     "shortName": "Commitments and Contingencies - Derecognition of Balances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_1_1_2019_uaR1Uv2lmUWJZyFgpnp2JQ",
      "decimals": "INF",
      "lang": null,
      "name": "edit:LesseeOperatingLeaseLaboratorySpaceNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_rl1kcwMXZkCIZ-rzvXYVSA",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40703 - Disclosure - Commitments and Contingencies - Right of Use Asset and Lease Liability (Details)",
     "role": "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesRightOfUseAssetAndLeaseLiabilityDetails",
     "shortName": "Commitments and Contingencies - Right of Use Asset and Lease Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "edit:AssetsAndLiabilitiesLesseeOperatingLeaseTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "As_Of_1_1_2019_GHVQq8gUCEOZOt-m471YvA",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40704 - Disclosure - Commitments and Contingencies - Operating Lease Costs (Details)",
     "role": "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseCostsDetails",
     "shortName": "Commitments and Contingencies - Operating Lease Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40705 - Disclosure - Commitments and Contingencies - Maturities of Lease Liabilities (Details)",
     "role": "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails",
     "shortName": "Commitments and Contingencies - Maturities of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_7_1_2019_To_9_30_2019_us-gaap_OtherCommitmentsAxis_edit_CommitmentToReimburseLicensorMember_DOloV0XhME-N4IXu1IWfqQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfessionalAndContractServicesExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40706 - Disclosure - Commitments and Contingencies - Licensor Expense Reimbursement (Details)",
     "role": "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesLicensorExpenseReimbursementDetails",
     "shortName": "Commitments and Contingencies - Licensor Expense Reimbursement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_7_1_2019_To_9_30_2019_us-gaap_OtherCommitmentsAxis_edit_CommitmentToReimburseLicensorMember_DOloV0XhME-N4IXu1IWfqQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfessionalAndContractServicesExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "As_Of_6_30_2018_srt_CounterpartyNameAxis_edit_BroadInstituteIncMember_us-gaap_OtherCommitmentsAxis_edit_ResearchFundingPaymentsMember_us-gaap_TypeOfArrangementAxis_edit_SponsoredResearchAgreementMember_7EHzXBh5f0uI6WsTuZTqoQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "edit:FundingPaymentsDueAndPayableOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40707 - Disclosure - Commitments and Contingencies - Research Funding Payments (Details)",
     "role": "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesResearchFundingPaymentsDetails",
     "shortName": "Commitments and Contingencies - Research Funding Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "As_Of_6_30_2018_srt_CounterpartyNameAxis_edit_BroadInstituteIncMember_us-gaap_OtherCommitmentsAxis_edit_ResearchFundingPaymentsMember_us-gaap_TypeOfArrangementAxis_edit_SponsoredResearchAgreementMember_7EHzXBh5f0uI6WsTuZTqoQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "edit:FundingPaymentsDueAndPayableOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_6_1_2018_To_6_30_2018_srt_CounterpartyNameAxis_edit_BroadInstituteIncMember_us-gaap_TypeOfArrangementAxis_edit_SponsoredResearchAgreementMember_e3dA74ixPEqD64XeFIza9A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40708 - Disclosure - Commitments and Contingencies - Notes Payable (Details)",
     "role": "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesNotesPayableDetails",
     "shortName": "Commitments and Contingencies - Notes Payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_6_1_2018_To_6_30_2018_srt_CounterpartyNameAxis_edit_BroadInstituteIncMember_us-gaap_TypeOfArrangementAxis_edit_SponsoredResearchAgreementMember_e3dA74ixPEqD64XeFIza9A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Collaboration and License Agreements - Revenue Recognition (Details)",
     "role": "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognitionDetails",
     "shortName": "Collaboration and License Agreements - Revenue Recognition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": "-3",
      "lang": null,
      "name": "edit:AccountsReceivableAdditions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "edit:ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40802 - Disclosure - Collaboration and License Agreements - Contract Assets and Liability (Details)",
     "role": "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilityDetails",
     "shortName": "Collaboration and License Agreements - Contract Assets and Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "edit:ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "edit:ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40803 - Disclosure - Collaboration and License Agreements - Summary of Agreement (Details)",
     "role": "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsSummaryOfAgreementDetails",
     "shortName": "Collaboration and License Agreements - Summary of Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_7_1_2018_To_9_30_2018_srt_CounterpartyNameAxis_edit_JunoTherapeuticsMember_us-gaap_TypeOfArrangementAxis_edit_CollaborationAndLicenseAgreementMember_O_MITT2wVkKnx6b-sggXmw",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Stock-based Compensation - Expense (Details)",
     "role": "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationExpenseDetails",
     "shortName": "Stock-based Compensation - Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40902 - Disclosure - Stock-based Compensation - Restricted Stock and Stock Options (Details)",
     "role": "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails",
     "shortName": "Stock-based Compensation - Restricted Stock and Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Net Loss per Share (Details)",
     "role": "http://www.editasmedicine.com/role/DisclosureNetLossPerShareDetails",
     "shortName": "Net Loss per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - Condensed Consolidated Statements of Comprehensive Loss",
     "role": "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2018_To_9_30_2018_us-gaap_RelatedPartyTransactionAxis_edit_RentAndFacilityRelatedFeesMember_Exbi6JGLz0aiPwGT7WbBAw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - Related-Party Transactions (Details)",
     "role": "http://www.editasmedicine.com/role/DisclosureRelatedPartyTransactionsDetails",
     "shortName": "Related-Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2018_To_9_30_2018_us-gaap_RelatedPartyTransactionAxis_edit_RentAndFacilityRelatedFeesMember_Exbi6JGLz0aiPwGT7WbBAw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.editasmedicine.com/role/DisclosureSubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_11_1_2019_To_11_30_2019_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_edit_JunoTherapeuticsMember_9ZN4nSHh5EeubrbKBSQ-Jw",
      "decimals": "-5",
      "lang": null,
      "name": "edit:CollaborationAndLicenseAgreementAmendmentFeeReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GwYJtLes4kK1jip8o4AlWw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2018_To_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KQblBVk_v0SKWAMPvbYtyQ",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_7_1_2019_To_9_30_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_7zcER-83lEe2S7gZNEWllQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00405 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "role": "http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_7_1_2019_To_9_30_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_7zcER-83lEe2S7gZNEWllQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00500 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Nature of Business",
     "role": "http://www.editasmedicine.com/role/DisclosureNatureOfBusiness",
     "shortName": "Nature of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edit-20190930x10qc6fb6d.htm",
      "contextRef": "Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 50,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "edit_AccountsReceivableAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the amount of additions to accounts receivable.",
        "label": "Accounts Receivable, Additions",
        "terseLabel": "Accounts Receivable, Additions"
       }
      }
     },
     "localname": "AccountsReceivableAdditions",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "edit_AccountsReceivableDeductions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the amount of deductions to accounts receivable.",
        "label": "Accounts Receivable, Deductions",
        "negatedLabel": "Accounts Receivable, Deductions"
       }
      }
     },
     "localname": "AccountsReceivableDeductions",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "edit_AccruedIntellectualPropertyFees": {
     "auth_ref": [],
     "calculation": {
      "http://www.editasmedicine.com/role/DisclosureAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for fees associated with intellectual property rights.",
        "label": "Intellectual property and patent related fees"
       }
      }
     },
     "localname": "AccruedIntellectualPropertyFees",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "edit_AllerganMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to Allergan.",
        "label": "Allergan [Member]",
        "terseLabel": "Allergan"
       }
      }
     },
     "localname": "AllerganMember",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsSummaryOfAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "edit_AreaOfLeasedSpace": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area of leased space.",
        "label": "Area of Leased Space",
        "terseLabel": "Leased space ( in square feet)"
       }
      }
     },
     "localname": "AreaOfLeasedSpace",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "edit_AssetsAndLiabilitiesLesseeOperatingLeaseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The tabular disclosure of leases included on its condensed consolidated balance sheet.",
        "label": "Assets and Liabilities, Lessee, Operating Lease [Table Text Block]",
        "terseLabel": "Summary of leases included on its condensed consolidated balance sheet"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeOperatingLeaseTableTextBlock",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "edit_AtMarket2018MarchOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "March 2018 at-the-market offering sale of stock after the initial public offering to the public.",
        "label": "At Market2018 March Offering [Member]",
        "terseLabel": "March 2018 ATM Program"
       }
      }
     },
     "localname": "AtMarket2018MarchOfferingMember",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "edit_AtMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to at market offering.",
        "label": "At Market Offering [Member]",
        "terseLabel": "At Market Offering"
       }
      }
     },
     "localname": "AtMarketOfferingMember",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "edit_BroadAndWageningenUniversityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information related to Broad and Wageningen University.",
        "label": "Broad And Wageningen University [Member]",
        "terseLabel": "Broad and Wageningen University"
       }
      }
     },
     "localname": "BroadAndWageningenUniversityMember",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesNotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "edit_BroadInstituteIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to The Broad Institute Inc.",
        "label": "Broad Institute Inc [Member]",
        "terseLabel": "Broad"
       }
      }
     },
     "localname": "BroadInstituteIncMember",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesNotesPayableDetails",
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesResearchFundingPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "edit_ChiefMedicalOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Person with designation of chief medical officer.",
        "label": "Chief Medical Officer [Member]",
        "terseLabel": "Chief Medical Officer"
       }
      }
     },
     "localname": "ChiefMedicalOfficerMember",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "edit_CollaborationAndLicenseAgreementAmendmentFeeReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of amendment fee received during the period under the restated Collaboration and License Agreement.",
        "label": "Collaboration and License Agreement, Amendment Fee Received",
        "terseLabel": "Amendment fee received"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementAmendmentFeeReceived",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "edit_CollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration and license agreement.",
        "label": "Collaboration And License Agreement [Member]",
        "terseLabel": "Collaboration and License Agreement"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementMember",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsSummaryOfAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "edit_CollaborativeArrangementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "No definition available.",
        "label": "Collaboration and License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementsAbstract",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "xbrltype": "stringItemType"
    },
    "edit_CommitmentToReimburseLicensorMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commitment to reimburse the licensor for prosecution and maintenance of patent rights pursuant to the license agreement by and among the reporting entity, The Broad Institute Inc. and the Fellows of Harvard College.",
        "label": "Commitment To Reimburse Licensor [Member]",
        "terseLabel": "Licensor Expense Reimbursement"
       }
      }
     },
     "localname": "CommitmentToReimburseLicensorMember",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesLicensorExpenseReimbursementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "edit_ContractWithCustomerLiabilityAdditions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of additions in obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer Liability Additions",
        "terseLabel": "Deferred revenue, Additions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAdditions",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "edit_ContractWithCustomerLiabilityDeductions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deductions in obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer Liability Deductions",
        "negatedLabel": "Deferred revenue, Deductions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityDeductions",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "edit_CowenAndCompanyLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "It represent Cowen and Company LLC (\"Cowen).",
        "label": "Cowen And Company Llc [Member]",
        "terseLabel": "Cowen and Company LLC (\"Cowen)"
       }
      }
     },
     "localname": "CowenAndCompanyLlcMember",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "edit_DeferredRevenueAdjustmentFromEffectOfNewAccountingPrinciple": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of adjustment to deferred revenue for adoption of accounting principle.",
        "label": "Deferred Revenue Adjustment from Effect of New Accounting Principle",
        "terseLabel": "Adjustment to deferred revenue for revenue adoption"
       }
      }
     },
     "localname": "DeferredRevenueAdjustmentFromEffectOfNewAccountingPrinciple",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "edit_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "xbrltype": "stringItemType"
    },
    "edit_EmployeeAndDirectorMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employees and directors.",
        "label": "Employee And Director [Member]",
        "terseLabel": "Employees and directors"
       }
      }
     },
     "localname": "EmployeeAndDirectorMember",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "edit_FacilitySubleaseArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Facility sublease arrangement.",
        "label": "Facility Sublease Arrangement [Member]",
        "terseLabel": "Facility Sublease Arrangement"
       }
      }
     },
     "localname": "FacilitySubleaseArrangementMember",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "edit_FairValueAssetsAndLiabilitiesTransfers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of transfers between levels of the fair value hierarchy during the period.",
        "label": "Transfers between levels"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesTransfers",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "edit_FundingPaymentsDueAndPayableOne": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The first research funding amount which is due and payable.",
        "label": "Funding Payments Due and Payable, One",
        "terseLabel": "First research funding amount due and payable"
       }
      }
     },
     "localname": "FundingPaymentsDueAndPayableOne",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesResearchFundingPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "edit_FundingPaymentsDueAndPayableTwo": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The first research funding amount due and payable",
        "label": "Funding Payments Due and Payable, Two",
        "terseLabel": "Second research funding amount due and payable"
       }
      }
     },
     "localname": "FundingPaymentsDueAndPayableTwo",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesResearchFundingPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "edit_HurleyStreetLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease agreement of office and laboratory space located in Cambridge, Massachusetts.",
        "label": "Hurley Street Lease [Member]",
        "terseLabel": "Hurley Street Lease"
       }
      }
     },
     "localname": "HurleyStreetLeaseMember",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "edit_IncreaseDecreaseInRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount represents the increase (decrease) in right of use assets.",
        "label": "Increase (Decrease) in Right Of Use Assets",
        "negatedLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "IncreaseDecreaseInRightOfUseAssets",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "edit_IncreaseDecreaseInRightOfUseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of increase (decrease) in right of use liability.",
        "label": "Increase (Decrease) in Right Of Use Liability",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInRightOfUseLiability",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "edit_InitialNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to Initial notes.",
        "label": "Initial Notes [Member]",
        "terseLabel": "Initial Notes"
       }
      }
     },
     "localname": "InitialNotesMember",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesNotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "edit_JunoTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Juno Therapeutics.",
        "label": "Juno Therapeutics [Member]",
        "terseLabel": "Juno Therapeutics"
       }
      }
     },
     "localname": "JunoTherapeuticsMember",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsSummaryOfAgreementDetails",
      "http://www.editasmedicine.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "edit_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Laboratory equipment used for research and development.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "edit_LesseeOperatingLeaseLaboratorySpaceNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of other operating leases for laboratory space.",
        "label": "Lessee, Operating Lease, Laboratory Space, Number",
        "terseLabel": "Number of other operating leases for laboratory space"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLaboratorySpaceNumber",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesDerecognitionOfBalancesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "edit_MarketableSecuritiesAmortizedCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investments in marketable securities.",
        "label": "Marketable Securities, Amortized Cost",
        "terseLabel": "Amortized Cost"
       }
      }
     },
     "localname": "MarketableSecuritiesAmortizedCost",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "edit_MarketableSecuritiesUnrealizedGain": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized gain on investment in marketable security.",
        "label": "Marketable Securities, Unrealized Gain",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGain",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "edit_MarketableSecuritiesUnrealizedLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized loss on investment in marketable security.",
        "label": "Marketable Securities, Unrealized Loss",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedLoss",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "edit_NoncashInvestmentInEquitySecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of purchased equity securities that are acquired in a non-cash transaction.",
        "label": "Noncash Investment in Equity Securities",
        "negatedLabel": "Non-cash investment in equity securities"
       }
      }
     },
     "localname": "NoncashInvestmentInEquitySecurities",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "edit_NumberOfAdditionalDevelopmentAndCommercializationLicenseToBePurchased": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of additional development and Commercialization License that can be purchased.",
        "label": "Number Of Additional Development And Commercialization License To Be Purchased",
        "terseLabel": "Number of additional licenses"
       }
      }
     },
     "localname": "NumberOfAdditionalDevelopmentAndCommercializationLicenseToBePurchased",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsSummaryOfAgreementDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "edit_NumberOfCollaborationDevelopmentPrograms": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of collaboration development programs for the treatment of ocular disorders under the exclusive license from the company.",
        "label": "Number of Collaboration Development Programs",
        "terseLabel": "Number of Collaboration Development Programs"
       }
      }
     },
     "localname": "NumberOfCollaborationDevelopmentPrograms",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsSummaryOfAgreementDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "edit_NumberOfOperatingLeasesForManufacturingSpace": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of operating leases for manufacturing space.",
        "label": "Number Of Operating Leases For Manufacturing Space",
        "terseLabel": "Number of other operating leases for manufacturing space"
       }
      }
     },
     "localname": "NumberOfOperatingLeasesForManufacturingSpace",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesDerecognitionOfBalancesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "edit_PercentageOfCashCommissionsPaid": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of cash commission paid on the gross sales price per share of its common stock sold.",
        "label": "Percentage Of Cash Commissions Paid",
        "terseLabel": "Cash commission paid"
       }
      }
     },
     "localname": "PercentageOfCashCommissionsPaid",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "edit_ProceedsFromIssuanceOfCommonStockGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of gross cash inflow from issuance of common stock.",
        "label": "Proceeds From Issuance Of Common Stock Gross",
        "terseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockGross",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "edit_ProceedsFromIssuanceOfCommonStockReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of receivable amount of proceeds from issuance of common stock.",
        "label": "Proceeds From Issuance Of Common Stock Receivable",
        "terseLabel": "Proceeds from issuance of common stock receivable"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockReceivable",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "edit_ProcessAndPlatformDevelopmentCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.editasmedicine.com/role/DisclosureAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for fees associated with process and platform development.",
        "label": "Process And Platform Development Costs Current",
        "terseLabel": "Process and platform development expenses"
       }
      }
     },
     "localname": "ProcessAndPlatformDevelopmentCostsCurrent",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "edit_ProgramExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of program expenses incurred during the period.",
        "label": "Program Expense",
        "terseLabel": "Expenses incurred"
       }
      }
     },
     "localname": "ProgramExpense",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsSummaryOfAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "edit_PublicAndAtMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to public and at market offering.",
        "label": "Public And At Market Offering [Member]",
        "terseLabel": "Public and Market Offering"
       }
      }
     },
     "localname": "PublicAndAtMarketOfferingMember",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "edit_ReceivableOfProceedsFromExerciseOfStockOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of receivables from exercise of stock options.",
        "label": "Receivable of Proceeds from Exercise of Stock Options",
        "terseLabel": "Receivable of proceeds from offering of common stock"
       }
      }
     },
     "localname": "ReceivableOfProceedsFromExerciseOfStockOptions",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "edit_ReclassificationOfLiabilityForFounderStockRepurchase": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of reclassification of liability for founder stock repurchase",
        "label": "Reclassification of liability for common stock subject to repurchase"
       }
      }
     },
     "localname": "ReclassificationOfLiabilityForFounderStockRepurchase",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "edit_RentAndFacilityRelatedFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the rent and facility related fees paid to the related parties.",
        "label": "Rent And Facility Related Fees [Member]",
        "terseLabel": "Rent and facility related fees"
       }
      }
     },
     "localname": "RentAndFacilityRelatedFeesMember",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "edit_ResearchFundingPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This member stands for commitments of research funding payments.",
        "label": "Research Funding Payments [Member]",
        "terseLabel": "Research Funding Payments"
       }
      }
     },
     "localname": "ResearchFundingPaymentsMember",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesResearchFundingPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "edit_ResearchProgramTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The term of the research program under the agreement.",
        "label": "Research Program Term",
        "terseLabel": "Agreement term"
       }
      }
     },
     "localname": "ResearchProgramTerm",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsSummaryOfAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "edit_ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of account receivable and contract liabilities.",
        "label": "Schedule of Accounts Receivable and Contract Liabilities Table Text Block",
        "terseLabel": "Schedule of accounts receivable and contract liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "edit_ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of change in contract with customer asset and liability.",
        "label": "Schedule of Change in Contract with Customer Asset and Liability [Table Text Block]",
        "terseLabel": "Schedule of change in contract assets and contract liabilities"
       }
      }
     },
     "localname": "ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "edit_ShareOfExpenseRecognizedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of share of operating expenses recognized.",
        "label": "Share of Expense Recognized, Percentage",
        "terseLabel": "Percentage of share of expenses recognized"
       }
      }
     },
     "localname": "ShareOfExpenseRecognizedPercentage",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsSummaryOfAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "edit_SharesIssuedWeightedAveragePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price per share of equity securities issued.",
        "label": "Shares Issued, Weighted Average Price Per Share",
        "terseLabel": "Weighted average price per share"
       }
      }
     },
     "localname": "SharesIssuedWeightedAveragePricePerShare",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "edit_SponsoredResearchAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This member stands for sponsored research agreement.",
        "label": "Sponsored Research Agreement [Member]",
        "terseLabel": "Sponsored Research Agreement"
       }
      }
     },
     "localname": "SponsoredResearchAgreementMember",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesNotesPayableDetails",
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesResearchFundingPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "edit_StockIssuanceCostsIncurredButNotYetPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for stock issuance costs incurred.",
        "label": "Initial public offering costs incurred but unpaid at period end",
        "terseLabel": "Offering costs included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "StockIssuanceCostsIncurredButNotYetPaid",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "edit_StockIssuedDuringPeriodSharesRepaymentOfDebt": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of repayment of notes payables.",
        "label": "Stock Issued During Period, Shares, Repayment of debt",
        "terseLabel": "Issuance of common stock for repayment of notes payable (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRepaymentOfDebt",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "edit_StockIssuedDuringPeriodValueRepaymentOfNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of shares issued during the period as a result of repayment of notes payable.",
        "label": "Stock Issued During Period, Value, Repayment of Notes",
        "terseLabel": "Issuance of common stock for repayment of notes payable"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRepaymentOfNotes",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "edit_StockIssuedForAssetAcquisition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fair value of stock issued for asset acquisition in non-cash activities.",
        "label": "Stock Issued for Asset Acquisition",
        "terseLabel": "Issuance of common stock for asset acquisition"
       }
      }
     },
     "localname": "StockIssuedForAssetAcquisition",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "edit_StockSalesAgreementAdditionalSaleProceedsThatCanBeRaised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of additional sale proceeds that can be raised under the stock sale agreement.",
        "label": "Stock Sales Agreement, Additional Sale Proceeds That Can Be Raised",
        "terseLabel": "Additional sale proceeds"
       }
      }
     },
     "localname": "StockSalesAgreementAdditionalSaleProceedsThatCanBeRaised",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "edit_StockSalesAgreementThresholdSaleProceedsThatCanBeRaised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of threshold aggregate sale proceeds that can be raised under the stock sale agreement.",
        "label": "Stock Sales Agreement, Threshold Sale Proceeds That Can Be Raised",
        "terseLabel": "Threshold sale proceeds"
       }
      }
     },
     "localname": "StockSalesAgreementThresholdSaleProceedsThatCanBeRaised",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "edit_StrategicAllianceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to strategic alliance.",
        "label": "Strategic Alliance [Member]",
        "terseLabel": "Strategic Alliance"
       }
      }
     },
     "localname": "StrategicAllianceMember",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsSummaryOfAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "edit_SublicensingAndSuccessPaymentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.editasmedicine.com/role/DisclosureAccruedExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for fees associated with sublicense and success payment expenses.",
        "label": "Sublicensing and Success Payment Expenses",
        "terseLabel": "Sublicensing and success payment expenses"
       }
      }
     },
     "localname": "SublicensingAndSuccessPaymentExpenses",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "edit_ThresholdPeriodInterestFreeDebtInstrumentFaceAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The face value of interest free debt instrument for specified period.",
        "label": "Threshold Period Interest Free Debt Instrument, Face Amount",
        "terseLabel": "Interest free debt instrument"
       }
      }
     },
     "localname": "ThresholdPeriodInterestFreeDebtInstrumentFaceAmount",
     "nsuri": "http://www.editasmedicine.com/20190930",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Chief Executive Officer"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r41",
      "r79"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsSummaryOfAgreementDetails",
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesNotesPayableDetails",
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails",
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesResearchFundingPaymentsDetails",
      "http://www.editasmedicine.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsSummaryOfAgreementDetails",
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesNotesPayableDetails",
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails",
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesResearchFundingPaymentsDetails",
      "http://www.editasmedicine.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAdjustmentMember": {
     "auth_ref": [
      "r82",
      "r84",
      "r85",
      "r86"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restatement Adjustment [Member]",
        "terseLabel": "Restatement Adjustment"
       }
      }
     },
     "localname": "RestatementAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesDerecognitionOfBalancesDetails",
      "http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restatement [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesDerecognitionOfBalancesDetails",
      "http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restatement [Domain]",
        "terseLabel": "Restatement [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesDerecognitionOfBalancesDetails",
      "http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r98",
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails",
      "http://www.editasmedicine.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title Of Individual With Relationship To Entity [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails",
      "http://www.editasmedicine.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update201602 [Member]",
        "terseLabel": "ASU 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesDerecognitionOfBalancesDetails",
      "http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/DisclosureAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureAccruedExpensesDetails",
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accrued Expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r34"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/DisclosureAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional service expenses"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r26",
      "r124"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r45",
      "r46",
      "r47"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r44",
      "r47",
      "r48",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive (Loss) Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by new accounting pronouncement.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesDerecognitionOfBalancesDetails",
      "http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r145",
      "r147",
      "r174",
      "r175"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r147",
      "r169",
      "r173"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive common stock equivalent shares"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Potentially dilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsSummaryOfAgreementDetails",
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesNotesPayableDetails",
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesResearchFundingPaymentsDetails",
      "http://www.editasmedicine.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r96",
      "r230",
      "r238"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Total assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails",
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsAndLiabilitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets and Liabilities, Lessee [Abstract]",
        "terseLabel": "Leases are included on its condensed consolidated balance sheet"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesRightOfUseAssetAndLeaseLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r2",
      "r3",
      "r40"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r188"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Financial Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r102",
      "r115"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available-for-sale Debt Securities, Amortized Cost Basis",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r100",
      "r103",
      "r115"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available-for-sale Securities, Debt Securities",
        "terseLabel": "Fair Value",
        "verboseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails",
      "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r149",
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails",
      "http://www.editasmedicine.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Unaudited Interim Financial Information"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Building"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r74",
      "r75",
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Fixed asset additions included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Equivalents, Marketable Securities and Equity Securities"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r0",
      "r24",
      "r73"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r8",
      "r109"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "terseLabel": "Cash Equivalents, Marketable Securities and Equity Securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndEquitySecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r68",
      "r73",
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r68",
      "r197"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails",
      "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Change in contract asset and contract liability balances"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerAssetAndLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r178",
      "r179",
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration and License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r38",
      "r129",
      "r234",
      "r244"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies.",
        "terseLabel": "Commitments and contingencies (see note 7)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r128",
      "r130"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r14",
      "r131"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.0001 par value per share: 195,000,000 shares authorized; 51,528,020 and 49,028,907 shares issued, and 51,076,198 and 48,758,951 shares outstanding at September 30, 2019 and December 31, 2018, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r51",
      "r53",
      "r54"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Condensed Consolidated Statements of Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction In Progress [Member]",
        "terseLabel": "Construction-in-progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r133",
      "r134",
      "r138"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Deferred Revenue, Balance at End of Period",
        "periodStartLabel": "Deferred Revenue, Balance at Beginning of Period",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognitionDetails",
      "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsSummaryOfAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Contract liabilities, deferred revenue:",
        "terseLabel": "Contract liabilities, deferred Revenue:"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r133",
      "r134",
      "r138"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue, current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsSummaryOfAgreementDetails",
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r133",
      "r134",
      "r138"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion",
        "verboseLabel": "Deferred revenue, long-term"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsSummaryOfAgreementDetails",
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r139"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized",
        "verboseLabel": "Amounts included in deferred revenue at the beginning of the period"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilityDetails",
      "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsSummaryOfAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Performance obligations satisfied in previous periods"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.",
        "label": "Cumulative Effect of New Accounting Principle in Period of Adoption",
        "terseLabel": "Cumulative effect adjustment for adoption of new accounting guidance"
       }
      }
     },
     "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails",
      "http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate (as a percentage)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesNotesPayableDetails",
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesResearchFundingPaymentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Number of Available for Sale Securities Held in Continuous Unrealized Loss Position Twelve Months or Longer",
        "terseLabel": "Number of securities in an unrealized loss position for more than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r107",
      "r118"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "terseLabel": "Securities held by the Company in an unrealized loss position for less than 12 months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "auth_ref": [
      "r108"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain (Loss)",
        "terseLabel": "Realized gains (losses) on available-for-sale securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r106",
      "r116"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of securities in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r71",
      "r122"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stock-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders, basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/DisclosureAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee related expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r170"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized",
        "verboseLabel": "Unrecognized stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureNetLossPerShareDetails",
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails",
      "http://www.editasmedicine.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails",
      "http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r196"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.",
        "label": "Equity Securities, FV-NI, Cost",
        "terseLabel": "Amortized Cost",
        "verboseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails",
      "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r9",
      "r12",
      "r109",
      "r233",
      "r237",
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Corporate equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails",
      "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r141",
      "r142",
      "r144",
      "r189",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r188",
      "r189",
      "r191",
      "r192",
      "r195"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r141",
      "r142",
      "r144",
      "r189",
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r141",
      "r142",
      "r144",
      "r189",
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r193",
      "r195"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value Measurements Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r203"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Construction financing lease obligation, net of current portion"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesDerecognitionOfBalancesDetails",
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r117",
      "r119",
      "r120",
      "r121"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails",
      "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture And Fixtures [Member]",
        "terseLabel": "Furniture and office equipment"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "I P O [Member]",
        "terseLabel": "Initial Public Offering"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Condensed Consolidated Statements of Operations"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other current and non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Statement of Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r59",
      "r61",
      "r62"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Net",
        "terseLabel": "Interest income, net"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Equity securities included in other non-current assets:"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r213",
      "r215"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Operating Lease Costs"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of the operating lease costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasePracticalExpedientUseOfHindsight": {
     "auth_ref": [
      "r199",
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates (true false) whether practical expedient is elected to use hindsight in determining lease term and in assessing impairment of right-of-use asset.",
        "label": "Lease, Practical Expedient, Use of Hindsight [true false]",
        "terseLabel": "Lease, Practical Expedient, Use of Hindsight"
       }
      }
     },
     "localname": "LeasePracticalExpedientUseOfHindsight",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LeasePracticalExpedientsPackage": {
     "auth_ref": [
      "r198",
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates (true false) whether practical expedients are elected for not reassessing whether any expired or existing contract is or contains lease, lease classification for expired or existing lease, and initial direct cost for any existing lease.",
        "label": "Lease, Practical Expedients, Package [true false]",
        "terseLabel": "Lease, Practical Expedients, Package"
       }
      }
     },
     "localname": "LeasePracticalExpedientsPackage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Leases",
        "verboseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesDerecognitionOfBalancesDetails",
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesDerecognitionOfBalancesDetails",
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of maturities of lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r214"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r214"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r214"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r214"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r214"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r214"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r214"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year",
        "terseLabel": "2019"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r214"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Leasing Arrangements, Operating Leases, Renewal Term",
        "terseLabel": "Extended lease option (in years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "Total liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails",
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r20",
      "r231",
      "r241"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecurities": {
     "auth_ref": [
      "r235"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in marketable security.",
        "label": "Marketable Securities",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Marketable Securities [Abstract]",
        "terseLabel": "Cash Equivalents, Marketable Securities and Equity Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r1",
      "r33"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails",
      "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r94",
      "r95"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureNatureOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flow from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flow from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r68",
      "r69",
      "r72"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flow from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r49",
      "r52",
      "r56",
      "r72",
      "r89",
      "r236",
      "r245"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss",
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r81",
      "r83"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements Adopted And Issued But Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income, net:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Schedule of changes in unvested restricted stock"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NotesAndLoansPayableAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Notes and Loans Payable [Abstract]",
        "terseLabel": "Notes Payable"
       }
      }
     },
     "localname": "NotesAndLoansPayableAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesNotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesIssued1": {
     "auth_ref": [
      "r74",
      "r75",
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fair value of notes issued in noncash investing and financing activities.",
        "label": "Notes Issued",
        "terseLabel": "Issuance of common stock for settlement of notes payable (see note 7)"
       }
      }
     },
     "localname": "NotesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Promissory notes issued"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesNotesPayableDetails",
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesResearchFundingPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r207",
      "r215"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Lease Liabilities, Payments Due [Abstract]",
        "terseLabel": "Maturity of lease liabilities:"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r203"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetailsCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Lease liability",
        "verboseLabel": "Total operating lease liabilities at September 30, 2019"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails",
      "http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r203"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Lease liability, current",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesRightOfUseAssetAndLeaseLiabilityDetails",
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r203"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "negatedLabel": "Lease liability, noncurrent",
        "terseLabel": "Operating lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesRightOfUseAssetAndLeaseLiabilityDetails",
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r204",
      "r209"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "verboseLabel": "Cash paid in connection with operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r202"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesRightOfUseAssetAndLeaseLiabilityDetails",
      "http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails",
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r212",
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r211",
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Nature of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r7",
      "r34"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/DisclosureAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Restricted cash and other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesLicensorExpenseReimbursementDetails",
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesResearchFundingPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other future obligation.",
        "label": "Other Commitments [Domain]",
        "terseLabel": "Other Commitments [Domain]"
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesLicensorExpenseReimbursementDetails",
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesResearchFundingPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesLicensorExpenseReimbursementDetails",
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesNotesPayableDetails",
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesResearchFundingPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesLicensorExpenseReimbursementDetails",
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesNotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r42",
      "r43",
      "r45"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax",
        "terseLabel": "Unrealized (loss) gain on marketable debt securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r50",
      "r53",
      "r55",
      "r131"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Unrealized gain (loss) on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive (loss) income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r34"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesDerecognitionOfBalancesDetails",
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other non-cash items, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other (expense) income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockNoParValue": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, No Par Value",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value per share: 5,000,000 shares authorized; no shares issued or outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r2",
      "r22",
      "r23"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Aggregate net proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from offering of common stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfMachineryAndEquipment": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from sale of machinery and equipment.",
        "label": "Proceeds from Sale of Machinery and Equipment",
        "terseLabel": "Proceeds from the sale of equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfMachineryAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r65",
      "r172"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Issuances of common stock under benefit plans"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfessionalAndContractServicesExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.",
        "label": "Professional and Contract Services Expense",
        "terseLabel": "Expense for prosecution and maintenance of patent rights"
       }
      }
     },
     "localname": "ProfessionalAndContractServicesExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesLicensorExpenseReimbursementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r49",
      "r52",
      "r67",
      "r96",
      "r97",
      "r182",
      "r183",
      "r184",
      "r186",
      "r187"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r26",
      "r125"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r25",
      "r123"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property and equipment disclosures"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r125",
      "r243"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesDerecognitionOfBalancesDetails",
      "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r10",
      "r125"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r10",
      "r123"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r15",
      "r21",
      "r242",
      "r247"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "periodEndLabel": "Accounts receivable, Balance at End of Period",
        "periodStartLabel": "Accounts receivable, Balance at Beginning of Period",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognitionDetails",
      "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsSummaryOfAgreementDetails",
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Receivables, Net, Current [Abstract]",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "ReceivablesNetCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r143",
      "r216",
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related-Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.",
        "label": "Related Party Transaction, Other Revenues from Transactions with Related Party",
        "terseLabel": "Fees received from related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Related-Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related-Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations": {
     "auth_ref": [],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for short-term and long-term debt and lease obligation.",
        "label": "Repayments of Debt and Capital Lease Obligations",
        "negatedLabel": "Payments on construction financing lease obligation"
       }
      }
     },
     "localname": "RepaymentsOfDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r177",
      "r249"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Non-cash research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r8",
      "r73",
      "r77",
      "r229",
      "r239"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.",
        "label": "Restricted Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails",
      "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails",
      "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restricted Cash and Cash Equivalents Items [Line Items]",
        "verboseLabel": "Cash Equivalents, Marketable Securities and Corporate Equity Securities"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsItemsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units R S U [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r17",
      "r132",
      "r240"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesDerecognitionOfBalancesDetails",
      "http://www.editasmedicine.com/role/DisclosureNatureOfBusinessDetails",
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Other Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails",
      "http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r136",
      "r137"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Collaboration and other research and development revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.",
        "label": "Revenue from Contract with Customer, Product and Service [Extensible List]",
        "terseLabel": "Revenue type"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r210",
      "r215"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "verboseLabel": "Right-of-use assets obtained in exchange of operating lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureNatureOfBusinessDetails",
      "http://www.editasmedicine.com/role/DisclosureNetLossPerShareDetails",
      "http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of anti-dilutive common stock equivalents"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of cash equivalents, marketable securities and corporate equity securities"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]",
        "terseLabel": "Significant Agreements."
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsSummaryOfAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r147",
      "r168",
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r188",
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of assets measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r81",
      "r83",
      "r91",
      "r92",
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.",
        "label": "Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]",
        "verboseLabel": "Summary of derecognition of balances relating to the building, accumulated depreciation and the corresponding construction financing lease on adoption of ASC 842"
       }
      }
     },
     "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r26",
      "r125"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r78",
      "r216",
      "r218",
      "r219",
      "r220",
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable": {
     "auth_ref": [
      "r8",
      "r77",
      "r229",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r149",
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationExpenseDetails",
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r152",
      "r163",
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Shares granted",
        "verboseLabel": "Issued (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails",
      "http://www.editasmedicine.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Issued (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested restricted shares, end of period(in shares)",
        "periodStartLabel": "Unvested restricted shares, beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Changes in unvested restricted stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Balance, ending of period",
        "periodStartLabel": "Balance, beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Stock-based compensation disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationExpenseDetails",
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollar per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails",
      "http://www.editasmedicine.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r171"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r154",
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, end of period (in shares)",
        "periodStartLabel": "Outstanding, beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Changes in unvested stock options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, end of period (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r146",
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails",
      "http://www.editasmedicine.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r171"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable, aggregated intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable, remaining contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Remaining contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance, end of period (in shares)",
        "periodStartLabel": "Balance, beginning of period (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesNotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short Term Debt Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesNotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software And Software Development Costs [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r39",
      "r131"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails",
      "http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsSummaryOfAgreementDetails",
      "http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Condensed Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Condensed Consolidated Balance Sheets"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Condensed Consolidated Statements of Stockholders' Equity"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesResearchFundingPaymentsDetails",
      "http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r74",
      "r75",
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Issuance of common stock for settlement of success payments (see note 7)"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Common stock issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesNotesPayableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r131",
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Number of common stock issued",
        "verboseLabel": "Issuance of common stock from public offering, net of issuance costs of $0.1 million (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureNatureOfBusinessDetails",
      "http://www.editasmedicine.com/role/DisclosureNetLossPerShareDetails",
      "http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.",
        "label": "Stock Issued During Period, Shares, Purchase of Assets",
        "verboseLabel": "Issuance of common stock for asset purchase agreement (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r13",
      "r14",
      "r131",
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Vesting of restricted common stock units and awards (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Shares, Share-based Compensation, Gross",
        "terseLabel": "Purchase of common stock under benefit plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r13",
      "r14",
      "r131",
      "r132",
      "r156"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails",
      "http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r131",
      "r132"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock from public offering, net of issuance costs of $0.1 million"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.",
        "label": "Stock Issued During Period, Value, Purchase of Assets",
        "verboseLabel": "Issuance of common stock for asset purchase agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r131",
      "r132"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Vesting of restricted common stock units and awards"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r13",
      "r14",
      "r132",
      "r148",
      "r164"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures",
        "verboseLabel": "Purchase of common stock under benefit plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r39",
      "r131",
      "r132"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r18",
      "r19",
      "r99"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance, end of period",
        "periodStartLabel": "Balance, beginning of period",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureNatureOfBusinessDetails",
      "http://www.editasmedicine.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureNatureOfBusinessDetails",
      "http://www.editasmedicine.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureNatureOfBusinessDetails",
      "http://www.editasmedicine.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureNatureOfBusinessDetails",
      "http://www.editasmedicine.com/role/DisclosureNetLossPerShareDetails",
      "http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Liquidity"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash and non-cash activities:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails",
      "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.",
        "label": "Type Of Adoption [Member]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesDerecognitionOfBalancesDetails",
      "http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsSummaryOfAgreementDetails",
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesNotesPayableDetails",
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesResearchFundingPaymentsDetails",
      "http://www.editasmedicine.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r141",
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "U S Government Agencies Debt Securities [Member]",
        "terseLabel": "Government agency securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USStatesAndPoliticalSubdivisionsMember": {
     "auth_ref": [
      "r141",
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bonds or similar securities issued by state, city, or local US governments or the agencies operated by state, city, or local governments. Debt securities issued by state governments may include bond issuances of US state authorities including, for example, but not limited to, housing authorities, dormitory authorities, and general obligations while debt securities issued by political subdivisions of US states would include, for example, debt issuances by county, borough, city, or municipal governments.",
        "label": "U S States And Political Subdivisions [Member]",
        "terseLabel": "Government agency securities"
       }
      }
     },
     "localname": "USStatesAndPoliticalSubdivisionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails",
      "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r141",
      "r144",
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "U S Treasury Securities [Member]",
        "terseLabel": "U.S. Treasuries"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails",
      "http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r208",
      "r215"
     ],
     "calculation": {
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease costs"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average common shares outstanding, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27337-111563"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922890-210455"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL108322424-203045"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=6488278&loc=d3e604059-122996"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r251": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r252": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r253": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r254": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r255": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e725-108305"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e765-108305"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.10-01.(b)(6))",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4647-111522"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6789239200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Right of Use Asset and Lease Liability (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract', window );"><strong>Leases are included on its condensed consolidated balance sheet</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">$ 17,681<span></span>
</td>
<td class="nump">$ 19,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability, current</a></td>
<td class="num">(4,448)<span></span>
</td>
<td class="num">(3,848)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, noncurrent</a></td>
<td class="num">$ (13,202)<span></span>
</td>
<td class="num">$ (15,909)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAndLiabilitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6789363168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 12, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 511,451<span></span>
</td>
<td class="nump">$ 511,451<span></span>
</td>
<td class="nump">$ 416,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=edit_AtMarket2018MarchOfferingMember', window );">March 2018 ATM Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_StockSalesAgreementThresholdSaleProceedsThatCanBeRaised', window );">Threshold sale proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,721,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_ProceedsFromIssuanceOfCommonStockGross', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_ProceedsFromIssuanceOfCommonStockReceivable', window );">Proceeds from issuance of common stock receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=edit_AtMarket2018MarchOfferingMember', window );">March 2018 ATM Program | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock issued</a></td>
<td class="nump">1,727,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_SharesIssuedWeightedAveragePricePerShare', window );">Weighted average price per share</a></td>
<td class="nump">$ 25.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_ProceedsFromIssuanceOfCommonStockGross', window );">Gross proceeds</a></td>
<td class="nump">$ 43,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_StockSalesAgreementAdditionalSaleProceedsThatCanBeRaised', window );">Additional sale proceeds</a></td>
<td class="nump">$ 106,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=edit_AtMarket2018MarchOfferingMember', window );">March 2018 ATM Program | Cowen and Company LLC ("Cowen) | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_PercentageOfCashCommissionsPaid', window );">Cash commission paid</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=edit_PublicAndAtMarketOfferingMember', window );">Public and Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Aggregate net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 370,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_PercentageOfCashCommissionsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of cash commission paid on the gross sales price per share of its common stock sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_PercentageOfCashCommissionsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_ProceedsFromIssuanceOfCommonStockGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of gross cash inflow from issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_ProceedsFromIssuanceOfCommonStockGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_ProceedsFromIssuanceOfCommonStockReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of receivable amount of proceeds from issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_ProceedsFromIssuanceOfCommonStockReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_SharesIssuedWeightedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price per share of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_SharesIssuedWeightedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_StockSalesAgreementAdditionalSaleProceedsThatCanBeRaised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additional sale proceeds that can be raised under the stock sale agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_StockSalesAgreementAdditionalSaleProceedsThatCanBeRaised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_StockSalesAgreementThresholdSaleProceedsThatCanBeRaised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of threshold aggregate sale proceeds that can be raised under the stock sale agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_StockSalesAgreementThresholdSaleProceedsThatCanBeRaised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=edit_AtMarket2018MarchOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=edit_AtMarket2018MarchOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=edit_CowenAndCompanyLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=edit_CowenAndCompanyLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=edit_PublicAndAtMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=edit_PublicAndAtMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6778241184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee related expenses</a></td>
<td class="nump">$ 4,134<span></span>
</td>
<td class="nump">$ 5,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_AccruedIntellectualPropertyFees', window );">Intellectual property and patent related fees</a></td>
<td class="nump">1,645<span></span>
</td>
<td class="nump">1,939<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_ProcessAndPlatformDevelopmentCostsCurrent', window );">Process and platform development expenses</a></td>
<td class="nump">1,171<span></span>
</td>
<td class="nump">1,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional service expenses</a></td>
<td class="nump">853<span></span>
</td>
<td class="nump">475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other expenses</a></td>
<td class="nump">335<span></span>
</td>
<td class="nump">404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_SublicensingAndSuccessPaymentExpenses', window );">Sublicensing and success payment expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,750<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 8,138<span></span>
</td>
<td class="nump">$ 12,813<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_AccruedIntellectualPropertyFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for fees associated with intellectual property rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_AccruedIntellectualPropertyFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_ProcessAndPlatformDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for fees associated with process and platform development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_ProcessAndPlatformDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_SublicensingAndSuccessPaymentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for fees associated with sublicense and success payment expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_SublicensingAndSuccessPaymentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6781167152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">9</b>. <b style="font-weight:bold;">Stock-based Compensation</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Stock-based compensation expense by classification included in the condensed consolidated statements of operations was as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.04%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:22.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:middle;white-space:nowrap;width:20.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:middle;white-space:nowrap;width:22.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,619</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,506</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,854</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,412</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,940</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,193</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,053</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,839</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Total stock-based compensation expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,559</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,699</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,907</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,251</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-style:italic;font-weight:bold;">Restricted Stock and Restricted Stock Unit Awards</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The following table summarizes restricted stock and restricted stock unit awards activity for the nine months ended September 30, 2019:</p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant&#160;Date</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Per&#160;Share</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Unvested restricted stock and restricted stock unit awards as of December&#160;31,&#160;2018</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 270,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28.05</p></td></tr><tr><td style="vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 445,126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.94</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Vested</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (77,052)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26.47</p></td></tr><tr><td style="vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (51,182)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.40</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Unvested restricted stock and restricted stock unit awards as of September 30, 2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 586,892</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24.20</p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">As of September 30, 2019, the Company had $9.8 million in unrecognized stock-based compensation expense related to unvested restricted stock and unvested restricted stock unit awards.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/><span style="font-style:italic;font-weight:bold;">Stock Options</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The following table summarizes stock option activity for the nine months ended September 30, 2019:</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate&#160;Intrinsic</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:17.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual&#160;Life (years)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value&#160;(in&#160;thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Outstanding at December&#160;31,&#160;2018</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,689,786</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23.80</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.9</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,686</p></td></tr><tr><td style="vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,500,502</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (502,234)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.46</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (546,799)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28.15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Outstanding at September 30, 2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,141,255</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24.69</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.5</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,899</p></td></tr><tr><td style="vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Exercisable at September 30, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,386,635</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,238</p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The stock options granted in the nine months ended September 30, 2019 include an option granted to the Company&#8217;s Chief Executive Officer to purchase 250,000 shares of the Company&#8217;s common stock that contains market-based vesting provisions. The Company is recognizing the fair value of these options over the earlier of the derived service period, valued using the Monte-Carlo simulation model, or when the market-based vesting conditions are met. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">As of September 30, 2019, the Company had unrecognized stock-based compensation expense related to its employee and director stock options that contain service-based vesting of $38.1 million, which the Company expects to recognize over the remaining weighted average vesting period of 2.64 years.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6592008208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">5. Accrued Expenses</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Accrued expenses consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:normal;width:27.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:normal;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:normal;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:normal;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:normal;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Employee related expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,134</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,201</p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Intellectual property and patent related fees</p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,645</p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,939</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Process and platform development expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,171</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,044</p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Professional service expenses</p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 853</p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 475</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Other expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 335</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 404</p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Sublicensing expenses</p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,750</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Total accrued expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,138</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,813</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6800874288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Income</div></th>
<th class="th"><div>Other Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period at Dec. 31, 2017</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 514,002<span></span>
</td>
<td class="num">$ (76)<span></span>
</td>
<td class="num">$ (305,850)<span></span>
</td>
<td class="nump">$ 208,080<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, beginning of period (in shares) at Dec. 31, 2017</a></td>
<td class="nump">44,507,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Statement of Stockholders' Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock from public offering, net of issuance costs of $0.1 million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from public offering, net of issuance costs of $0.1 million (in shares)</a></td>
<td class="nump">1,429,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_StockIssuedDuringPeriodValueRepaymentOfNotes', window );">Issuance of common stock for repayment of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_StockIssuedDuringPeriodSharesRepaymentOfDebt', window );">Issuance of common stock for repayment of notes payable (in shares)</a></td>
<td class="nump">305,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Issuance of common stock for asset purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Issuance of common stock for asset purchase agreement (in shares)</a></td>
<td class="nump">56,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">305,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted common stock units and awards (in shares)</a></td>
<td class="nump">107,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,939)<span></span>
</td>
<td class="num">(30,939)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Mar. 31, 2018</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">584,825<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="num">(337,263)<span></span>
</td>
<td class="nump">247,514<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, end of period (in shares) at Mar. 31, 2018</a></td>
<td class="nump">46,711,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period at Dec. 31, 2017</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">514,002<span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="num">(305,850)<span></span>
</td>
<td class="nump">208,080<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, beginning of period (in shares) at Dec. 31, 2017</a></td>
<td class="nump">44,507,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Statement of Stockholders' Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84,899)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Sep. 30, 2018</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">615,748<span></span>
</td>
<td class="num">(82)<span></span>
</td>
<td class="num">(391,224)<span></span>
</td>
<td class="nump">224,447<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, end of period (in shares) at Sep. 30, 2018</a></td>
<td class="nump">47,503,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period at Dec. 31, 2017</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">514,002<span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="num">(305,850)<span></span>
</td>
<td class="nump">208,080<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, beginning of period (in shares) at Dec. 31, 2017</a></td>
<td class="nump">44,507,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Dec. 31, 2018</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">652,464<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="num">(416,278)<span></span>
</td>
<td class="nump">236,162<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, end of period (in shares) at Dec. 31, 2018</a></td>
<td class="nump">48,758,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Statement of Stockholders' Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect adjustment for adoption of new accounting guidance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(474)<span></span>
</td>
<td class="num">(474)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period at Mar. 31, 2018</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">584,825<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="num">(337,263)<span></span>
</td>
<td class="nump">247,514<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, beginning of period (in shares) at Mar. 31, 2018</a></td>
<td class="nump">46,711,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Statement of Stockholders' Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_StockIssuedDuringPeriodValueRepaymentOfNotes', window );">Issuance of common stock for repayment of notes payable</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,501<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_StockIssuedDuringPeriodSharesRepaymentOfDebt', window );">Issuance of common stock for repayment of notes payable (in shares)</a></td>
<td class="nump">330,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">192,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted common stock units and awards (in shares)</a></td>
<td class="nump">103,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Purchase of common stock under benefit plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Purchase of common stock under benefit plan (in shares)</a></td>
<td class="nump">14,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38,723)<span></span>
</td>
<td class="num">(38,723)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Jun. 30, 2018</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">607,310<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(375,986)<span></span>
</td>
<td class="nump">231,330<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, end of period (in shares) at Jun. 30, 2018</a></td>
<td class="nump">47,352,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Statement of Stockholders' Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">132,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted common stock units and awards (in shares)</a></td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(83)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(83)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,238)<span></span>
</td>
<td class="num">(15,238)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Sep. 30, 2018</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">615,748<span></span>
</td>
<td class="num">(82)<span></span>
</td>
<td class="num">(391,224)<span></span>
</td>
<td class="nump">224,447<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, end of period (in shares) at Sep. 30, 2018</a></td>
<td class="nump">47,503,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period at Dec. 31, 2018</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">652,464<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="num">(416,278)<span></span>
</td>
<td class="nump">236,162<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, beginning of period (in shares) at Dec. 31, 2018</a></td>
<td class="nump">48,758,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Statement of Stockholders' Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">146,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted common stock units and awards (in shares)</a></td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,249)<span></span>
</td>
<td class="num">(29,249)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Mar. 31, 2019</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">661,852<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="num">(444,724)<span></span>
</td>
<td class="nump">217,162<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, end of period (in shares) at Mar. 31, 2019</a></td>
<td class="nump">48,923,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period at Dec. 31, 2018</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">652,464<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="num">(416,278)<span></span>
</td>
<td class="nump">$ 236,162<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, beginning of period (in shares) at Dec. 31, 2018</a></td>
<td class="nump">48,758,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Statement of Stockholders' Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">502,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (95,976)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Sep. 30, 2019</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">721,397<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="num">(511,451)<span></span>
</td>
<td class="nump">209,990<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, end of period (in shares) at Sep. 30, 2019</a></td>
<td class="nump">51,076,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Statement of Stockholders' Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect adjustment for adoption of new accounting guidance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">803<span></span>
</td>
<td class="nump">803<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning of period at Mar. 31, 2019</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">661,852<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="num">(444,724)<span></span>
</td>
<td class="nump">217,162<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, beginning of period (in shares) at Mar. 31, 2019</a></td>
<td class="nump">48,923,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Statement of Stockholders' Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,894<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">277,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted common stock units and awards (in shares)</a></td>
<td class="nump">24,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Purchase of common stock under benefit plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Purchase of common stock under benefit plan (in shares)</a></td>
<td class="nump">16,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,786)<span></span>
</td>
<td class="num">(33,786)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Jun. 30, 2019</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">671,522<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="num">(478,510)<span></span>
</td>
<td class="nump">193,062<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, end of period (in shares) at Jun. 30, 2019</a></td>
<td class="nump">49,241,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Statement of Stockholders' Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock from public offering, net of issuance costs of $0.1 million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from public offering, net of issuance costs of $0.1 million (in shares)</a></td>
<td class="nump">1,721,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">78,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted common stock units and awards (in shares)</a></td>
<td class="nump">34,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,941)<span></span>
</td>
<td class="num">(32,941)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, end of period at Sep. 30, 2019</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 721,397<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="num">$ (511,451)<span></span>
</td>
<td class="nump">$ 209,990<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, end of period (in shares) at Sep. 30, 2019</a></td>
<td class="nump">51,076,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_StockIssuedDuringPeriodSharesRepaymentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of repayment of notes payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_StockIssuedDuringPeriodSharesRepaymentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_StockIssuedDuringPeriodValueRepaymentOfNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during the period as a result of repayment of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_StockIssuedDuringPeriodValueRepaymentOfNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6798535168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 104,772<span></span>
</td>
<td class="nump">$ 134,776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">227,844<span></span>
</td>
<td class="nump">234,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">311<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">6,284<span></span>
</td>
<td class="nump">5,791<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">339,211<span></span>
</td>
<td class="nump">374,776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">10,075<span></span>
</td>
<td class="nump">40,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">17,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Restricted cash and other non-current assets</a></td>
<td class="nump">5,392<span></span>
</td>
<td class="nump">5,378<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">372,359<span></span>
</td>
<td class="nump">420,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,624<span></span>
</td>
<td class="nump">5,327<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">8,138<span></span>
</td>
<td class="nump">12,813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">46,019<span></span>
</td>
<td class="nump">15,712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">4,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">1,558<span></span>
</td>
<td class="nump">2,048<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">66,787<span></span>
</td>
<td class="nump">35,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">13,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">82,379<span></span>
</td>
<td class="nump">115,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Construction financing lease obligation, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">162,369<span></span>
</td>
<td class="nump">184,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (see note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value per share: 5,000,000 shares authorized; no shares issued or outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value per share: 195,000,000 shares authorized; 51,528,020 and 49,028,907 shares issued, and 51,076,198 and 48,758,951 shares outstanding at September 30, 2019 and December 31, 2018, respectively</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">721,397<span></span>
</td>
<td class="nump">652,464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">39<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(511,451)<span></span>
</td>
<td class="num">(416,278)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">209,990<span></span>
</td>
<td class="nump">236,162<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 372,359<span></span>
</td>
<td class="nump">$ 420,386<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e604059-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6798808432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">445,126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Juno Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_CollaborationAndLicenseAgreementAmendmentFeeReceived', window );">Amendment fee received</a></td>
<td class="nump">$ 70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Chief Medical Officer | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Chief Medical Officer | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_CollaborationAndLicenseAgreementAmendmentFeeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of amendment fee received during the period under the restated Collaboration and License Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_CollaborationAndLicenseAgreementAmendmentFeeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=edit_JunoTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=edit_JunoTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=edit_ChiefMedicalOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=edit_ChiefMedicalOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6797719312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary Of Significant Accounting Policies - Recent Accounting Pronouncements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Recent Accounting Pronouncements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect adjustment for adoption of new accounting guidance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (474)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 372,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 420,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">162,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 184,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">17,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">$ 17,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasePracticalExpedientsPackage', window );">Lease, Practical Expedients, Package</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasePracticalExpedientUseOfHindsight', window );">Lease, Practical Expedient, Use of Hindsight</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Other Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Recent Accounting Pronouncements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect adjustment for adoption of new accounting guidance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (474)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASU 2016-02 | Restatement Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Recent Accounting Pronouncements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASU 2016-02 | Restatement Adjustment | Other Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Recent Accounting Pronouncements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect adjustment for adoption of new accounting guidance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasePracticalExpedientUseOfHindsight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether practical expedient is elected to use hindsight in determining lease term and in assessing impairment of right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=119364159&amp;loc=SL77916155-209984<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=119364159&amp;loc=SL77916155-209984<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasePracticalExpedientUseOfHindsight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasePracticalExpedientsPackage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether practical expedients are elected for not reassessing whether any expired or existing contract is or contains lease, lease classification for expired or existing lease, and initial direct cost for any existing lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=119364159&amp;loc=SL77916155-209984<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=119364159&amp;loc=SL77916155-209984<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasePracticalExpedientsPackage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>178</ContextCount>
  <ElementCount>330</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>50</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Condensed Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00405 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00500 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureNatureOfBusiness</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Cash Equivalents, Marketable Securities and Equity Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndEquitySecurities</Role>
      <ShortName>Cash Equivalents, Marketable Securities and Equity Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Property and Equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Related-Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related-Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Cash Equivalents, Marketable Securities and Corporate Equity Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesTables</Role>
      <ShortName>Cash Equivalents, Marketable Securities and Corporate Equity Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.editasmedicine.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.editasmedicine.com/role/DisclosureAccruedExpenses</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Property and Equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Collaboration and License Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsTables</Role>
      <ShortName>Collaboration and License Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.editasmedicine.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.editasmedicine.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Nature of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureNatureOfBusinessDetails</Role>
      <ShortName>Nature of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.editasmedicine.com/role/DisclosureNatureOfBusiness</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Summary Of Significant Accounting Policies - Recent Accounting Pronouncements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRecentAccountingPronouncementsDetails</Role>
      <ShortName>Summary Of Significant Accounting Policies - Recent Accounting Pronouncements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Cash Equivalents, Marketable Securities and Corporate Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesDetails</Role>
      <ShortName>Cash Equivalents, Marketable Securities and Corporate Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.editasmedicine.com/role/DisclosureCashEquivalentsMarketableSecuritiesAndCorporateEquitySecuritiesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Fair Value Measurements - Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureFairValueMeasurementsRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.editasmedicine.com/role/DisclosureAccruedExpensesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Property and Equipment, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.editasmedicine.com/role/DisclosurePropertyAndEquipmentNetTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Commitments and Contingencies - Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesOperatingLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40702 - Disclosure - Commitments and Contingencies - Derecognition of Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesDerecognitionOfBalancesDetails</Role>
      <ShortName>Commitments and Contingencies - Derecognition of Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40703 - Disclosure - Commitments and Contingencies - Right of Use Asset and Lease Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesRightOfUseAssetAndLeaseLiabilityDetails</Role>
      <ShortName>Commitments and Contingencies - Right of Use Asset and Lease Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40704 - Disclosure - Commitments and Contingencies - Operating Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesOperatingLeaseCostsDetails</Role>
      <ShortName>Commitments and Contingencies - Operating Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40705 - Disclosure - Commitments and Contingencies - Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40706 - Disclosure - Commitments and Contingencies - Licensor Expense Reimbursement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesLicensorExpenseReimbursementDetails</Role>
      <ShortName>Commitments and Contingencies - Licensor Expense Reimbursement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40707 - Disclosure - Commitments and Contingencies - Research Funding Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesResearchFundingPaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Research Funding Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40708 - Disclosure - Commitments and Contingencies - Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureCommitmentsAndContingenciesNotesPayableDetails</Role>
      <ShortName>Commitments and Contingencies - Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Collaboration and License Agreements - Revenue Recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognitionDetails</Role>
      <ShortName>Collaboration and License Agreements - Revenue Recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40802 - Disclosure - Collaboration and License Agreements - Contract Assets and Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilityDetails</Role>
      <ShortName>Collaboration and License Agreements - Contract Assets and Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40803 - Disclosure - Collaboration and License Agreements - Summary of Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureCollaborationAndLicenseAgreementsSummaryOfAgreementDetails</Role>
      <ShortName>Collaboration and License Agreements - Summary of Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Stock-based Compensation - Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based Compensation - Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Stock-based Compensation - Restricted Stock and Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureStockBasedCompensationRestrictedStockAndStockOptionsDetails</Role>
      <ShortName>Stock-based Compensation - Restricted Stock and Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureNetLossPerShareDetails</Role>
      <ShortName>Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.editasmedicine.com/role/DisclosureNetLossPerShareTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Related-Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureRelatedPartyTransactionsDetails</Role>
      <ShortName>Related-Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.editasmedicine.com/role/DisclosureRelatedPartyTransactions</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="edit-20190930x10qc6fb6d.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.editasmedicine.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>51</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="edit-20190930x10qc6fb6d.htm">edit-20190930x10qc6fb6d.htm</File>
    <File>edit-20190930.xsd</File>
    <File>edit-20190930_cal.xml</File>
    <File>edit-20190930_def.xml</File>
    <File>edit-20190930_lab.xml</File>
    <File>edit-20190930_pre.xml</File>
    <File>ex-10d1.htm</File>
    <File>ex-10d2.htm</File>
    <File>ex-31d1.htm</File>
    <File>ex-31d2.htm</File>
    <File>ex-32d1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6797595696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 16,535<span></span>
</td>
<td class="nump">$ 47,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(6,460)<span></span>
</td>
<td class="num">(7,133)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">10,075<span></span>
</td>
<td class="nump">40,232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=edit_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">14,000<span></span>
</td>
<td class="nump">10,892<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">974<span></span>
</td>
<td class="nump">289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">826<span></span>
</td>
<td class="nump">733<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction-in-progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">166<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 118<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,167<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=edit_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=edit_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6784499104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Operating Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Operating Lease Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 1,451<span></span>
</td>
<td class="nump">$ 4,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">276<span></span>
</td>
<td class="nump">804<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 1,727<span></span>
</td>
<td class="nump">$ 5,097<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6787759088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_CollaborativeArrangementsAbstract', window );"><strong>Collaboration and License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">8</b>. <b style="font-weight:bold;">Collaboration and License Agreements</b><span style="white-space:pre-wrap;">  </span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company has entered into multiple collaboration, license and strategic agreements with third parties that </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">typically involve the Company granting licenses to the Company&#8217;s intellectual property, receiving licenses to intellectual property rights and/or performing research and development services in exchange for upfront fees, milestone payments and royalty payments to or from the Company. The terms and conditions as well as the accounting analysis for the Company&#8217;s significant collaboration, license and strategic agreements are described in Note 9, &#8220;Significant Agreements,&#8221; to the consolidated financial statements included in the Annual Report. There have been no material changes to the terms and conditions, or the accounting conclusions previously disclosed in the Annual Report. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Collaboration Revenue</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">As of September 30, 2019, the Company&#8217;s contract liabilities were primarily related to the Company&#8217;s collaboration with Juno Therapeutics and strategic alliance with Allergan. The following table presents changes in the Company&#8217;s accounts receivable and contract liabilities for the nine months ended September 30, 2019 (in thousands):</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">For the nine months ended September 30, 2019</b></p></td><td colspan="2" style="background-color:auto;vertical-align:middle;width:13.51%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2018</b></p></td><td style="background-color:auto;vertical-align:middle;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:middle;width:11.97%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additions</b></p></td><td style="background-color:auto;vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:middle;width:11.35%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deductions</b></p></td><td style="background-color:auto;vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:middle;width:13.78%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at September&#160;30,&#160;2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Accounts receivable</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">30</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 311</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:middle;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (30)</p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 311</p></td></tr><tr><td style="vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Contract liabilities:</p></td><td style="vertical-align:bottom;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:45.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"><span style="white-space:pre-wrap;">  Deferred revenue</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:middle;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 131,326</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:middle;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (7,928)</p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 128,398</p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">During the three and nine months ended September 30, 2019, the Company recognized the following collaboration revenue (in thousands):</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:62.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:15.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:15.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:62.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:middle;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="background-color:auto;vertical-align:middle;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:middle;width:17.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="background-color:auto;vertical-align:middle;width:62.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Revenue recognized in the period from:</b></p></td><td colspan="5" style="background-color:auto;vertical-align:middle;width:37.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:62.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Amounts included in deferred revenue at the beginning of the period</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:middle;width:15.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,354</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:middle;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,733</p></td></tr><tr><td style="vertical-align:middle;width:62.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Performance obligations satisfied in previous periods</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:middle;width:15.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,194</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:middle;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,194</p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Juno Therapeutics Collaboration Agreement </span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In May 2015, the Company entered into a Collaboration and License Agreement with Juno Therapeutics and in May 2018 the Company and Juno Therapeutics entered into an Amended and Restated Collaboration and License Agreement (collectively, the &#8220;Juno Agreement&#8221;). </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">There have been no material changes to the transaction price in the three or nine months ended September 30, 2019. As of September 30, 2019, the only milestones that were included in the transaction price were milestones that had been contractually earned and received. The outstanding milestones were fully constrained, as a result of the uncertainty regarding whether any of the milestones will be achieved. As of September 30, 2019, Juno Therapeutics has not exercised any of its options associated with the material rights identified in the Juno Agreement and no revenue has been recognized related to the material rights. Amounts allocated to each of the material rights will be recognized when the material right has been exercised or when the respective option has lapsed.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">During the three and nine months ended September 30, 2019, the Company did not recognize revenue related to the Juno Agreement. During the three and nine months ended September 30, 2018, the Company recognized $0.7 million and $5.2 million in revenue related to the Juno Agreement. As of September 30, 2019 and December 31, 2018, there was approximately $32.0 million of deferred revenue related to the Juno Agreement, of which $32.0 million and $2.8 million were classified as short-term, respectively, in the accompanying condensed consolidated balance sheets. In addition, there were no amounts classified in accounts receivable on the condensed consolidated balance sheets related to the Juno Agreement as of September 30, 2019 or December 31, 2018.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;min-height:10.0pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Allergan Pharmaceuticals Strategic Alliance and Option Agreement and Profit-Sharing Agreement</span></p><p style="font-family:'Times New Roman';font-size:10pt;min-height:10.0pt;margin:0pt;">&#160;&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In March 2017, the Company entered into a Strategic Alliance and Option Agreement with Allergan to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders (the &#8220;Allergan Agreement&#8221;). Over a seven-year research term, Allergan will have an exclusive option to exclusively license from the </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Company up to five collaboration development programs for the treatment of ocular disorders (each a &#8220;CDP&#8221;), including the Company&#8217;s Leber congenital amaurosis 10 (&#8220;LCA10&#8221;) program and the related experimental therapeutic EDIT-101 to treat LCA10 (the &#8220;LCA10 Program&#8221;).</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">There have been no material changes to the transaction price in the three or nine months ended September 30, 2019. As of September 30, 2019, the only milestone that was included in the transaction price had been contractually earned and received. The outstanding milestones were fully constrained, as a result of the uncertainty regarding whether any of the milestones will be achieved. The Company has concluded that the options to purchase five<span style="white-space:pre-wrap;"> development and commercialization licenses are considered a marketing offer as the options did not provide any discounts or other rights that would be considered a material right in the arrangement. In August 2018, Allergan exercised its right to the LCA10 Program and the option fee was recognized as revenue during the three months ended September 30, 2018 when the control transferred to Allergan.  </span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">During the three and nine months ended September 30, 2019, the Company recognized revenue related to the Allergan Agreement of approximately $3.4 million and $7.7 million, respectively. During the three and nine months ended September 30, 2018, the Company recognized revenue related to the Allergan Agreement of approximately $13.8 million and $16.7 million, respectively. As of September 30, 2019 and December 31, 2018, there was $91.6 million and $99.2 million of deferred revenue related to the Allergan Agreement, respectively, of which $79.0 million and $86.4 million is classified as long-term on the condensed consolidated balance sheet, respectively. There were no amounts classified in accounts receivable on the condensed consolidated balance sheets related to the Allergan Agreement. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:31.7pt;margin:0pt 0pt 0pt 4.3pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company and an affiliate of Allergan (together with Allergan, the &#8220;Allergan Entities&#8221;) agreed to equally split U.S. profits and losses for the LCA10 Program in the United States and to co-develop the LCA10 Program in the United States (the &#8220;Profit-Sharing Agreement&#8221;). The Company accounts for the Profit-Sharing Arrangement with respect to the LCA10 Program within the scope of ASC Topic 808, <i style="font-style:italic;">Collaborative Arrangements</i>, given that the Company and the Allergan Entities are active participants in future research and development activities and all parties are exposed to significant risks and rewards dependent on the commercial success of such activities. During the three and nine months ended September 30, 2019, the Company and the Allergan Entities incurred $4.9 million and $13.9 million in expense associated with the LCA10 Program, respectively, of which the Company recognized 50% in operating expense during such periods.<span style="white-space:pre-wrap;">  </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_CollaborativeArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_CollaborativeArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6781184480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">4. Fair Value Measurements</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Assets measured at fair value on a recurring basis as of September 30, 2019 were as follows (in thousands):</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">  </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">in&#160;Active</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Markets&#160;for</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical&#160;Assets</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Financial Assets</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Cash equivalents:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 104,772</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 104,772</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Marketable securities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">U.S. Treasuries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,587</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,587</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Government agency securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 144,257</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 144,257</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Restricted cash and other non-current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Corporate equity securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,667</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,667</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,619</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,619</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Total financial assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 337,902</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 334,235</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,667</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Assets measured at fair value on a recurring basis as of December&#160;31, 2018 were as follows (in thousands):</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:-0.020606995%;padding-left:0pt;padding-right:0pt;width:100.04%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">in&#160;Active</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Markets&#160;for</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical&#160;Assets</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Financial Assets</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Cash equivalents:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 130,049</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 130,049</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">U.S. Treasuries</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,487</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,487</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">U.S. Treasuries</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 204,243</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 204,243</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,935</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,935</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Restricted cash and other non-current assets:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Corporate equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,667</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,667</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Money market funds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,619</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,619</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Total financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 374,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 370,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,667</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">There were no transfers between fair value measurement levels during the nine months ended September 30, 2019.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6784575824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6797502592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Condensed Consolidated Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNoParValue', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">195,000,000<span></span>
</td>
<td class="nump">195,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">51,528,020<span></span>
</td>
<td class="nump">49,028,907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">51,076,198<span></span>
</td>
<td class="nump">48,758,951<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6778933232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=edit_RentAndFacilityRelatedFeesMember', window );">Rent and facility related fees</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related-Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty', window );">Fees received from related party</a></td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=edit_RentAndFacilityRelatedFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=edit_RentAndFacilityRelatedFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6778026208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Licensor Expense Reimbursement (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=edit_CommitmentToReimburseLicensorMember', window );">Licensor Expense Reimbursement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalAndContractServicesExpense', window );">Expense for prosecution and maintenance of patent rights</a></td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="nump">$ 10.1<span></span>
</td>
<td class="nump">$ 11.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalAndContractServicesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalAndContractServicesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=edit_CommitmentToReimburseLicensorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=edit_CommitmentToReimburseLicensorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6800950560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Contract Assets and Liability (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract', window );"><strong>Change in contract asset and contract liability balances</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Amounts included in deferred revenue at the beginning of the period</a></td>
<td class="nump">$ 2,354<span></span>
</td>
<td class="nump">$ 6,733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Performance obligations satisfied in previous periods</a></td>
<td class="nump">$ 1,194<span></span>
</td>
<td class="nump">$ 1,194<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6801754080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potentially dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive common stock equivalent shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,728,147<span></span>
</td>
<td class="nump">5,110,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potentially dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive common stock equivalent shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">586,892<span></span>
</td>
<td class="nump">288,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potentially dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive common stock equivalent shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,141,255<span></span>
</td>
<td class="nump">4,822,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=edit_AtMarketOfferingMember', window );">At Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potentially dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock issued</a></td>
<td class="nump">1,721,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,536,205<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=edit_AtMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=edit_AtMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6784639552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation expense</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Stock-based compensation expense by classification included in the condensed consolidated statements of operations was as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.04%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:22.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:middle;white-space:nowrap;width:20.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:middle;white-space:nowrap;width:22.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,619</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,506</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,854</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,412</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,940</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,193</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,053</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,839</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Total stock-based compensation expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,559</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,699</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,907</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,251</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Schedule of changes in unvested restricted stock</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The following table summarizes restricted stock and restricted stock unit awards activity for the nine months ended September 30, 2019:</p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant&#160;Date</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Per&#160;Share</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Unvested restricted stock and restricted stock unit awards as of December&#160;31,&#160;2018</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 270,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28.05</p></td></tr><tr><td style="vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 445,126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.94</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Vested</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (77,052)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26.47</p></td></tr><tr><td style="vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (51,182)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.40</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Unvested restricted stock and restricted stock unit awards as of September 30, 2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 586,892</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24.20</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The following table summarizes stock option activity for the nine months ended September 30, 2019:</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate&#160;Intrinsic</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:17.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual&#160;Life (years)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value&#160;(in&#160;thousands)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Outstanding at December&#160;31,&#160;2018</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,689,786</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23.80</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.9</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,686</p></td></tr><tr><td style="vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,500,502</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (502,234)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.46</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (546,799)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28.15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Outstanding at September 30, 2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,141,255</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24.69</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.5</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,899</p></td></tr><tr><td style="vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Exercisable at September 30, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,386,635</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,238</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6784521424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Accrued expenses consisted of the following (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:normal;width:27.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:normal;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:normal;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:normal;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:normal;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Employee related expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,134</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,201</p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Intellectual property and patent related fees</p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,645</p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,939</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Process and platform development expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,171</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,044</p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Professional service expenses</p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 853</p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 475</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Other expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 335</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 404</p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Sublicensing expenses</p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,750</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Total accrued expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,138</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,813</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6784505936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">12. Subsequent Events</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In November 2019, the Company entered into a Second Amended and Restated Collaboration and License Agreement with Juno, pursuant to which the Company is entitled to receive a $70.0 million payment, and a related License Agreement.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In October 2019, the Company&#8217;s board of directors approved an inducement grant to the Company&#8217;s recently hired Chief Medical Officer, including an option to purchase up to 150,000 shares of the Company&#8217;s common stock and an award of 25,000 restricted stock units.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6787684128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">6. Property and Equipment, net</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Property and equipment, net consisted of the following (in thousands):<b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:27.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Laboratory equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,892</p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 974</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 289</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Computer equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 826</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 733</p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Construction-in-progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 451</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Furniture and office equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 166</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 166</p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 118</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 118</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Building</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35,167</p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Total property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,535</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,365</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Less: accumulated depreciation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (6,460)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (7,133)</p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,075</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,232</p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">For additional information related to the removal of the building asset, refer to Note 7.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6781197920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">2. Summary of Significant Accounting Policies</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-style:italic;font-weight:bold;">Unaudited Interim Financial Information</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;) have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2018 (the &#8220;Annual Report&#8221;).</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The unaudited condensed consolidated financial statements include the accounts of Editas Medicine, Inc. and its wholly owned subsidiary, Editas Securities Corporation. All intercompany transactions and balances of the subsidiary have been eliminated in consolidation. In the opinion of management, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the results for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The three months ended September 30, 2019 and 2018 are referred to as the third quarter of 2019 and 2018, respectively. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Summary of Significant Accounting Policies</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-family:'inherit';visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company&#8217;s significant accounting policies are described in Note 2, &#8220;Summary of significant accounting policies,&#8221; to the consolidated financial statements included in the Annual Report. There have been no material changes to the significant accounting policies previously disclosed in the Annual Report other than as noted below. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements &#8211;Adopted</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Leases </i></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Effective January 1, 2019, the Company adopted Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, <i style="font-style:italic;">Leases</i> (Topic 842) (&#8220;ASC 842&#8221;), which amends a number of aspects of lease accounting and requires entities to recognize right-of-use assets and operating lease liabilities on the balance sheet. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">At the inception of an arrangement the Company determines whether the arrangement contains a lease. If a lease is identified in an arrangement, the Company recognizes a right-of-use asset and liability on its balance sheet and determines whether the lease should be classified as a finance or operating lease. The Company does not recognize assets or liabilities for leases with lease terms of less than 12 months. Lease payments for short-term leases are recorded to operating expense on a straight-line basis over the lease term and variable lease payments are recorded in the period in which the obligation for those payments is incurred. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, and (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Finance and operating lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the rate is not readily determinable, the Company utilizes its incremental borrowing rate at the lease commencement date. Operating lease assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 9pt 0pt;">straight-line method as an operating expense over the lease term. Finance lease assets are amortized to depreciation expense using the straight-line method over the shorter of the useful life of the related asset or the lease term. Finance lease payments are bifurcated into (i) a portion that is recorded as imputed interest expense and (ii) a portion that reduces the finance liability associated with the lease.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">The Company does not separate lease and non-lease components when determining which lease payments to include in the calculation of its lease assets and liabilities. Variable lease payments are expensed as incurred. If a lease includes an option to extend or terminate the lease, the Company reflects the option in the lease term if it is reasonably certain it will exercise the option.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 0pt;">The Company elected the modified-retrospective transition method, pursuant to which the Company recognized a cumulative-effect adjustment of $0.8 million to the opening balance of accumulated deficit on January 1, 2019 associated with de-recognizing the net asset balance recorded in property and equipment, net and the offsetting construction financing lease liability related to the Company&#8217;s headquarters which was previously accounted for under the built-to-suit guidance in Accounting Standards Codification (&#8220;ASC&#8221;) 840, <i style="font-style:italic;">Leases </i>(&#8220;ASC 840&#8221;). This resulted in a reversal of $32.6 million from total assets and $33.4 million from total liabilities. All prior period balances are presented in accordance with ASC 840. As of January 1, 2019, the Company recorded a right-of-use asset of $19.5 million and lease liability of $19.7 million associated with the adoption of ASC 842. In addition, the Company elected to adopt the package of three practical expedients for leases that commenced prior to January 1, 2019, allowing it not to reassess (i) whether any expired or existing contracts contain leases, (ii) the lease classification for any expired or existing leases and (iii) the initial indirect costs for any existing leases. The Company did not elect the hindsight practical expedient <span style="white-space:pre-wrap;">which allows the Company to reassess the lease term as it was not relevant to the Company&#8217;s leases.  </span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"><i style="font-style:italic;">Stock-Based Compensation Expense </i></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Effective January 1, 2019, the Company adopted ASU No. 2018-07, <i style="font-style:italic;">Compensation &#8211; Stock Compensation: Improvements to Nonemployee Share-Based Payment Accounting </i>(&#8220;ASU 2018-07&#8221;), which simplified the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expands the scope of ASC 718, <i style="font-style:italic;">Compensation &#8211; Stock Compensation </i>(&#8220;ASC 718&#8221;), which supersedes the guidance in ASC 505-50, <i style="font-style:italic;">Equity-Based Payments to Non-Employees </i>(&#8220;ASC 505-50&#8221;). In accordance with the new guidance, the Company accounts for share-based payments to non-employees by recognizing stock-based compensation expense equal to the grant date fair value of the share-based payment ratably over the requisite service period. The Company estimates the grant date fair value for each stock option using the Black-Scholes option-pricing model. For restricted stock awards and restricted stock unit awards, the Company estimates the value of each award using intrinsic value, which is based on the value of the underlying common stock less any purchase price. On the date of adoption, the Company estimated the fair value for all unvested non-employee stock options and restricted shares. The unvested stock-based compensation will be recorded over the remaining requisite service period.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:24pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:24pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements &#8211; Issued But Not Yet Adopted</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/>In August 2018, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2018-13, <i style="font-style:italic;">Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement </i>(&#8220;ASU 2018-13&#8221;), which modifies certain disclosure requirements on fair value measurements. The amendments regarding changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements and the narrative description of measurement uncertainty are required to be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments are required to be applied retrospectively to all periods presented upon their effective date. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019 and interim periods within those years. The Company does not anticipate a material impact to disclosures as a result of the adoption of ASU 2018-13.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In June 2016, the FASB issued ASU No. 2016-13, <i style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </i>(&#8220;ASU 2016-13&#8221;). The standard requires that a financial asset or a group of financial assets measured at amortized cost basis to be presented at the net amount expected to be collected. Under current GAAP, a company only considered past events and current conditions in measuring an incurred loss. Under ASU 2016-13, the information that a company must consider is broadened in developing an expected credit </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">loss estimate for assets measured either collectively or individually. The use of forecasted information incorporates more timely information in the estimate of expected credit loss. The new guidance will be effective for annual and interim periods beginning after December 15, 2019. Early adoption is permitted for annual and interim periods beginning after December 15, 2018. The guidance is applied using a modified retrospective, or prospective approach, depending on a specific amendment. The Company does not anticipate a material impact on its consolidated financial statements as a result of the adoption of ASU 2016-13.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6787711648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">10. Net Loss per Share</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury stock and if converted methods. Contingently issuable shares are included in the calculation of basic loss per share as of the beginning of the period in which all the necessary conditions have been satisfied. Contingently issuable shares are included in diluted loss per share based on the number of shares, if any, that would be issuable under the terms of the arrangement if the end of the reporting period was the end of the contingency period, if the results are dilutive.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">For purposes of the diluted net loss per share calculation, stock options are considered to be common stock equivalents, but they were excluded from the Company&#8217;s calculation of diluted net loss per share allocable to common stockholders because their inclusion would have been anti-dilutive. Therefore, basic and diluted net loss per share applicable to common stockholders was the same for all periods presented.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In connection with at-the-market offerings consummated by the Company during 2018 and during the third quarter of 2019, the Company sold 2,536,205 and 1,721,735 shares of its common stock, respectively. The issuance of </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">these shares resulted in a significant increase in the Company&#8217;s weighted-average shares outstanding and is expected to continue to impact the year-over-year comparability of the Company&#8217;s net loss per share calculations for the remainder of 2019 and 2020.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The following common stock equivalents were excluded from the calculation of diluted net loss per share allocable to common stockholders because their inclusion would have been anti-dilutive:</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:73.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:21.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of September&#160;30,&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:73.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Unvested restricted stock and restricted stock unit awards</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 586,892</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 288,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Outstanding stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,141,255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,822,486</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,728,147</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,110,486</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6799786736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Recurring Basis (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_FairValueAssetsAndLiabilitiesTransfers', window );">Transfers between levels | item</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Corporate equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Equity securities</a></td>
<td class="nump">$ 3,667<span></span>
</td>
<td class="nump">$ 3,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">104,772<span></span>
</td>
<td class="nump">130,049<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">83,587<span></span>
</td>
<td class="nump">208,730<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">Government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">144,257<span></span>
</td>
<td class="nump">29,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">337,902<span></span>
</td>
<td class="nump">374,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">83,587<span></span>
</td>
<td class="nump">204,243<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">144,257<span></span>
</td>
<td class="nump">29,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Corporate equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Equity securities</a></td>
<td class="nump">3,667<span></span>
</td>
<td class="nump">3,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">104,772<span></span>
</td>
<td class="nump">130,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">1,619<span></span>
</td>
<td class="nump">1,619<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">334,235<span></span>
</td>
<td class="nump">370,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">83,587<span></span>
</td>
<td class="nump">204,243<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | Government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">144,257<span></span>
</td>
<td class="nump">29,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">104,772<span></span>
</td>
<td class="nump">130,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">1,619<span></span>
</td>
<td class="nump">1,619<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">3,667<span></span>
</td>
<td class="nump">3,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | Corporate equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Equity securities</a></td>
<td class="nump">$ 3,667<span></span>
</td>
<td class="nump">$ 3,667<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_FairValueAssetsAndLiabilitiesTransfers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of transfers between levels of the fair value hierarchy during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_FairValueAssetsAndLiabilitiesTransfers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6789588544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Derecognition of Balances (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>lease</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,075<span></span>
</td>
<td class="nump">$ 40,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,558<span></span>
</td>
<td class="nump">2,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Construction financing lease obligation, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (511,451)<span></span>
</td>
<td class="num">$ (416,278)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_LesseeOperatingLeaseLaboratorySpaceNumber', window );">Number of other operating leases for laboratory space | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_NumberOfOperatingLeasesForManufacturingSpace', window );">Number of other operating leases for manufacturing space | lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASU 2016-02 | Restatement Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 32,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="num">(1,014)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Construction financing lease obligation, net of current portion</a></td>
<td class="num">(32,417)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_LesseeOperatingLeaseLaboratorySpaceNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of other operating leases for laboratory space.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_LesseeOperatingLeaseLaboratorySpaceNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_NumberOfOperatingLeasesForManufacturingSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of operating leases for manufacturing space.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_NumberOfOperatingLeasesForManufacturingSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>52
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( (> ;$\?(\\#P    !,"   +    7W)E;',O+G)E;'.MDD^+
MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V
M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F'
M.>RGGD7E2B.5^S3%":4A+<TXP)6E/S/WJVR;A5ND9T*YKCM+1[873T$7LF<;
M!I99-G\LCNVW<+ZT+/0:S>,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C
M-R."?S]PN -02P,$%     @ AX!L3R?HAPZ"    L0   !    !D;V-0<F]P
M<R]A<' N>&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(?
MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M0F31@4Q&X&BT%(W L9=E66RBR]P##CY+P0<<:9#G;!BX"E74C<P]X."C2-L
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M&+TWD2]]3X+&U_"\ 6)\VS6=?0_SG_NA8_TMJT]YU01OMG6=4-^O'*UMC1/
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M):4!FV*TLE/=V)V?# :5<=>=O:LP^<$PLAN7FDS_+/E_4$L#!!0    ( (>
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MG)KNIYNN/D[_4%B<_ZNQ_ ]02P,$%     @ AX!L3UQ4_BBT 0  T@,  !@
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M._^RL?^-U@Z\E,V-'Z'.?[#9$-"X<-S[LYG&;#*<[M,/(O,W+G\#4$L#!!0
M   ( (> ;$]5(S/<M0$  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#$T
M+GAM;'U388_4(!#]*X0?<+3LJNNF;7)[QFBBR>:,YV>VG;;DH%2@V_/?.]!>
MK5[/+\ ,\]Z\&89L-/;1M0">/&G5N9RVWO='QES9@A;NQO30X4UMK!8>3=LP
MUUL0501IQ7B2O&5:R(X66?2=;9&9P2O9P=D2-V@M[*\3*#/F-*7/CGO9M#XX
M6)'UHH%OX+_W9XL66U@JJ:%STG3$0IW3V_1XVH?X&/ @872K,PF57(QY#,;G
M*J=)$ 0*2A\8!&Y7N .E A'*^#ESTB5E *[/S^P?8^U8RT4XN#/JAZQ\F],#
M)1748E#^WHR?8*[G#25S\5_@"@K#@Q+,41KEXDK*P7FC9Q:4HL73M,LN[N-T
MPP\S;!O 9P!? (>8ATV)HO(/PHLBLV8D=NI]+\(3IT>.O2F#,[8BWJ%XA]YK
MP=/W&;L&HCGF-,7P54RZ1#!D7U+PK10G_@+.M^&[386["-^]HO O@OTFP3X2
M[/];XD8,3_Y)PE8]U6";.$V.E&;HXB2OO,O WO+X)G_"IVG_*FPC.T<NQN/+
MQO[7QGA *<D-CE"+'VPQ%-0^'-_AV4YC-AG>]/,/8LLW+GX#4$L#!!0    (
M (> ;$\A%^)OL@$  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM
M;'U3VV[;, S]%4$?4"5*MA6!;:!I,6S !@0=MCXK-FT+U<63Y+C[^U&RXWJ;
MUQ=)I'@.#RDJ&ZQ[]BU ("]:&9_3-H3NP)@O6]#"W]@.#-[4UFD1T'0-\YT#
M42605HQO-N^9%M+0(DN^DRLRVP<E#9P<\;W6POTZ@K)#3K?TZGB431NB@Q59
M)QKX!N%[=W)HL9FEDAJ,E]80!W5.[[:'XS[&IX ?$@:_.)-8R=G:YVA\KG*Z
MB8) 01DB@\#M O>@5"1"&3\G3CJGC,#E^<K^,=6.M9R%AWNKGF05VIS>4E)!
M+7H5'NWP":9ZWE$R%?\%+J P/"K!'*55/JVD['VP>F)!*5J\C+LT:1_&F]T5
MM@[@$X#/@-L$8&.BI/Q!!%%DS@[$C;WO1'SB[8%C;\KH3*U(=RC>H_=2<+[-
MV"4233'',88O8EXC&++/*?A:BB/_!\[7X;M5A;L$W_U'X1\$^U6"?2+8OUGB
M6LS?*MFBIQI<DZ;)D]+V)DWRPCL/[!U/;_(:/D[[5^$::3PYVX OF_I?6QL
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M-AL*ZA"/[_#LQC$;C6"[Z0>Q^1L7OP!02P,$%     @ AX!L3V?X' RT 0
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M?3C>XME.8S89WO3I!['Y&Q>_ 5!+ P04    " "'@&Q/*J.M[K4!  #2 P
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MBV<WC=ED!-O//X@MW[C\"5!+ P04    " "'@&Q/M/;.$[(!  #2 P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q]4]MNVS ,_15!'U E2K8%@6V@
M:3%LP 8$';8^*S9M"]7%D^2X^_M1LNMZF]<72:1X#@\I*ANL>_(M0"#/6AF?
MTS:$[LB8+UO0PM_8#@S>U-9I$=!T#?.= U$ED%:,;S;OF1;2T")+OK,K,ML'
M)0V<'?&]UL+].H&R0TZW],7Q()LV1 <KLDXT\ W"]^[LT&(S2R4U&"^M(0[J
MG-YNCZ=]C$\!/R0,?G$FL9*+M4_1^%SE=!,%@8(R1 :!VQ7N0*E(A#)^3IQT
M3AF!R_,+^\=4.]9R$1[NK'J456AS>J"D@EKT*CS8X1-,];RC9"K^"UQ!87A4
M@CE*JWQ:2=G[8/7$@E*T>!YW:=(^3#>'";8.X!. SX!#RL/&1$GYO0BBR)P=
MB!M[WXGXQ-LCQ]Z4T9E:D>Y0O$?OM>"[;<:ND6B*.8TQ?!'S&L&0?4[!UU*<
M^#]PO@[?K2K<)?CN/PK_(-BO$NP3P?[-$M=B_E;)%CW5X)HT39Z4MC=IDA?>
M>6!O>7J3U_!QVK\*UTCCR<4&?-G4_]K: "AE<X,CU.('FPT%=8C'#WAVXYB-
M1K#=](/8_(V+WU!+ P04    " "'@&Q/8++XK<0!   W!   &0   'AL+W=O
M<FMS:&5E=',O<VAE970R,2YX;6QU5.^.G" 0?Q7" QPKKK>7C9K<7M.T29ML
MKFG[F=51R8%8P/7Z]@7T/+NE7P2&WY\98,PGI5],!V#1JQ2]*7!G[7 DQ%0=
M2&;NU "]VVF4ELRZI6Z)&32P.I"D('2WNR>2\1Z7>8B==9FKT0K>PUDC,TK)
M].\3"#45.,%O@6?>=M8'2)D/K(5O8+\/9^U69%6IN83><-4C#4V!'Y/C*?/X
M /C!83*;.?*57)1Z\8O/=8%W/B$04%FOP-QPA2<0P@NY-'XMFGBU],3M_$W]
M8ZC=U7)A!IZ4^,EKVQ7X :,:&C8*^ZRF3[#4DV&T%/\%KB <W&?B/"HE3/BB
M:C16R47%I2+9ZSSR/HS3O'.@"RU.H N!KH2'X$-FHY#Y!V99F6LU(3V?_<#\
M%2='ZLZF\L%P%&'/)6]<]%K2-,W)U0LMF-.,H1M,LB*(4U\M:,SB1/^ATS@]
MC6:8!GJZI2?_\=]'!?9!8/]7B?N;$F.8+&Z214VRB,#]C4D,<[@Q(9N+DZ#;
M\&0-JM38AW;91->N> POA;S#YY;ZRG3+>X,NRKKG$RZY4<J"2V5WYW+I7!>O
M"P&-]=.#F^OY+<\+JX:E3<GZKRC_ %!+ P04    " "'@&Q/8?(:';,!  #2
M P  &0   'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6QM4]MNG# 0_17+'Q"#
MH6VZ J1LHJB56FF5JNVS%P:PX@NUS9+^?6W#4KKE!<\,YYRY>%Q,VKS:'L"A
M-RF4+7'OW' @Q-8]2&;O] #*_VFUD<QYUW3$#@98$TE2$)HD[XED7.&JB+&3
MJ0H].L$5G RRHY3,_#Z"T%.)4WP-O/"N=R% JF)@'7P#]WTX&>^15:7A$I3E
M6B$#;8D?TL,Q#_@(^,%ALAL;A4[.6K\&YW-3XB04! )J%Q28/R[P"$($(5_&
MKT43KRD#<6M?U9]C[[Z7,[/PJ,5/WKB^Q/<8-="R4;@7/7V"I9]W&"W-?X$+
M" \/E?@<M18V?E$]6J?EHN)+D>QM/KF*Y[3H7VG[!+H0Z V!S(EBY4_,L:HP
M>D)FGOW PA6G!^IG4X=@'$7\YXNW/GJI:'9?D$L06C#'&4,WF'1%$*^^IJ![
M*8[T/SK=IV>[%6:1GFWI:;8OD.\*Y%$@_Z?%CS<M[F#RY"8)V<Q4@NGB-EE4
MZU'%3=Y$UX5]H/%._L+G;?_*3,>516?M_,W&^;=:._"E)'=^A7K_P%9'0.N"
M^<';9EZSV7%Z6%X069]Q]0=02P,$%     @ AX!L3UC%X<RV 0  T@,  !D
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MV<YC-AO>#,L/8NLW+O\"4$L#!!0    ( (> ;$^CXB24MP$  -(#   9
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MC3VC_B354AJPI40/MN'6/A5KP*$V;GJP<S5?F#DP<EC> K(^2,4?4$L#!!0
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MOFSL?V6,!TQE<X4CU. 'FPT%E0_'/9[M.&:CX4TW_2 V?^/\'5!+ P04
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MY0LS!XI]SYS^&SNS4L%;)8ICP\M&__4VIT;RRF114JK\M7L6M7Y>3/ZW,#@
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M>!IGAF,D,$8"8B1&+HD5XX8<05(8) 5!4B.1%-8UXP:7U,XW)9XQ3">#=#)
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M#*/L\*#D81S3@_/_"I9_ 5!+ P04    " "'@&Q/14I&D3T$  !N%P  &0
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MGM5@]*+,M-!S,5_ LZ'XN+PM8'W@ZK]02P,$%     @ AX!L3V"8G^O= @
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MF'8([K7H@[Y\]).*[909YGHLNA.XFRC>NMM%TE]QYO\ 4$L#!!0    ( (>
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M^AC;PU9SKD!;!H_:L]'7S[R@4"LSW>BY&/^$XT+Q?KI?T'S)%7\ 4$L#!!0
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M2!(G:9T$A?D&) 8A\0H297A!&31D1DFB?&,O"$@A "5:4,B*$F<I@2D)2$D
M2KR@)&L*R39J24%*"E#(@I*N*%&.8YB2@90,H"0+2K:FA# C!QDYP$@7C'S%
MP&$>)C &A?!Q"P%0MCQOX8KT(<)DB[1QL!% RI<DM#XU:4(VM@[!IQOA-2E?
M]1!(M'$\$=P$T+H+F+_2D@.)H@4GF'5'>_M\I_):M\H["FT:K6N'%R$T,X;A
MD_D,E;GPI@EG%VV'J1G+H>L/$RVZ\48+IFNU_ =02P,$%     @ AX!L3W$H
MD+83 @  T 4  !D   !X;"]W;W)K<VAE971S+W-H965T-#$N>&ULC53;CMHP
M$/V5*!^ <V4+2B(MEZJ56@EMM>VS"0.)UHY3VY#MW]<WLB%$M"_8,SGG^,S8
M3-8Q_B8J .F]4]*(W*^D;)<(B;("BL6,M="H+T?&*98JY"<D6@[X8$B4H"@(
MYHCBNO&+S.1VO,C869*Z@1WWQ)E2S/^L@+ N]T/_FGBI3Y74"51D+3[!#Y"O
M[8ZK"/4JAYI"(VK6>!R.N?\<+K>IQAO SQHZ,=A[NI(]8V\Z^'K(_4 ; @*E
MU I8+1=8 R%:2-GX[33]_DA-'.ZOZI]-[:J6/1:P9N17?9!5[G_RO0,<\9G(
M%]9] 5=/ZGNN^&]P :+@VHDZHV1$F%^O/ O)J%-15BA^MVO=F+5S^E?:-"%R
MA*@GA.E#0NP(\0<A>4A('"'YWQ-21TA')R!;NVGF!DM<9)QU'K?/H<7ZU87+
M5%U7J9/F=LPWU4^ALI<B7B09NF@AAUE93#3 A$%TB]E,8'H$4@YZ&]&4C55T
M1Q\=L+Y'A$$\,O%/E>UCE1NC\62_8B.0W/0KG19()@42(Q#?",RG!=))@73"
MP=/HQBQF83"-Q<S"44/O,=%L,6KH/28,QD);"YH/0>.[1X/G2(&?S&P07LG.
MC=3-&&3[\?,<Z><\RJ_"Y3J<R&_4N++3Y4/>SKKOF)_J1GA[)M6?R#SU(V,2
ME/-@IJQ7:KSV 8&CU-LGM>=VR-A LM;-3]0/\>(O4$L#!!0    ( (> ;$\S
MR9"8K0$  +T#   9    >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;&U3VV[;
M, S]%4$?$#F.FS:!;6#I4&S !@0=MCTK-AT+U<65E+C[^U&R8[B!7R22.CR'
MI*2\-_;-M0">?"BI74%;[[L]8ZYJ07&W,AUH/&F,5=RC:\_,=19X'9.49&F2
M;)GB0M,RC[&C+7-S\5)H.%KB+DIQ^^\ TO0%7=-;X%6<6Q\"K,P[?H9?X']W
M1XL>FUAJH4 [832QT!3TRWI_R (^ OX(Z-W,)J&3DS%OP?E>%S0)!8&$R@<&
MCML5GD'*0(1EO(^<=)(,B7/[QOX2>\=>3MS!LY%_1>W;@CY14D/#+]*_FOX;
MC/T\4#(V_P.N(!$>*D&-RD@75U)=G#=J9,%2%/\8=J'CWH_\M[3EA'1,2*>$
M=.AE$(J5?^6>E[DU/;'#[#L>KGB]3W$V50C&4<0S+-YA]%IN=D\YNP:B$7,8
M,.DGS&[",.2?1-)%D302;#X1;)<)-HL$FTB0S0BR)+FK<L!L(T9'S,.R1+8H
MD2U(K.\D!LQN)O&XNA=AL\F'A_V3V[/0CIR,QTN,HVZ,\8!\R0I?2XM_:7(D
M-#Z8CVC;X44-CC?=^%G8]&/+_U!+ P04    " "'@&Q/@7D4% T"  #>!0
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M>B_<=72!XL/TTJ#YN2O^ %!+ P04    " "'@&Q/?B=L7:T#  !5$0  &0
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MFSU0*HA,'CS)6U'(V3YL*G(0:CF3:]8-N&XC:-L/;V_X!Y'] U!+ P04
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M<R]S:&5E=#0Y+GAM;)56VXZ;,!3\%<0'++Y@(%&"E,M6K=1*T59MGQWB!+2
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MYIDQ295*]*3T96KP=H>"GJ7>QFK/[?2Q!\GJ=K)ZW7A/_@)02P,$%     @
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MY3DB+NQ[SSHVR$>F1NI9G#H_1I;%X/S\X$#JU%L/_41LRN-YE\"O2$A \=[
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M?"-"?%7LKHHU\G/D$8S!?#C1&UE;OCBBG:!%%;B>,MFG#2@_%4,J+#PZ3[<
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M')35$<>J\4$BLRVS*#WP#NBS4(PK<9X/B:48";U)4$WMA;INLBV(GL6@:N!
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M@S&KX)B5I2+1[3U0D+K4 YW#TU/"&/(H[SC1XK%%IB!SI8H\&>"!#N"*D+;
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M4A$N@2O7\L!$:@7E2W(0(%9+5+;<4&\ILT_>N=DGSWT9ANE\7VW#R4"[S(T
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M3%1I%'H=<S+24EG?I3K( 6[[ H:".WHC E-%T4Z2B*D$>8&01(4;J$ACMLF
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MA7=8.<@)W?XC1P+^UQXF7WN8*'#_VL/D)^AA<KA]0S\S@EF:N;66=#>V?ZU
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M+A2 30PE9_=0X(_8$'O4\N.AQ7CX9#L4@S_', 8*<!C?BR%NFXPS.]\GZQ\
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M(I#E()#S@ .W1I 5 ED-")E$<H) 3L@AG\;/.V:6<&3J"'**0$X'A$PB>8!
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ME]4PS+BE5YB%JB$7UM*6CEFH&FAA#49'82 28V(6JH::_X1!G(N7?"O,0M4
M\Y\=H[@*4U!%K*#G%P1[UGBK$U/0A'P.]&A5<&<D)YA^)KU^1MLO&AJQA/E>
M<P[9.TBON:HO+ L_FUV6:A*609>=4A\@[:L^,[S_!B'DL?VXX^TO4$L#!!0
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MUHS@3OEC'T^?<9SZY_Z1TGG8$L/Q\^2WY3CU*R+\>#U^]PE02P,$%     @
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MTR]02P$"% ,4    " "'@&Q/'R// \     3 @  "P              @ $
M    7W)E;',O+G)E;'-02P$"% ,4    " "'@&Q/)^B'#H(   "Q    $
M            @ 'I    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( (>
M;$^KA:Y=[0   "L"   1              "  9D!  !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( (> ;$^97)PC$ 8  )PG   3              "
M ;4"  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ AX!L3TM7.? T
M P  .@\  !@              ( !]@@  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( (> ;$]8+K 6_ ,  +H2   8              "
M 6 ,  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " "'@&Q/
MQYZ&0DD"  "W!P  &               @ &2$   >&PO=V]R:W-H965T<R]S
M:&5E=#,N>&UL4$L! A0#%     @ AX!L3Y)6 BFR P  E@\  !@
M     ( !$1,  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    (
M (> ;$_H426T8P(  (<'   8              "  ?D6  !X;"]W;W)K<VAE
M971S+W-H965T-2YX;6Q02P$"% ,4    " "'@&Q/(;JB0@<)  !1.0  &
M            @ &2&0  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#
M%     @ AX!L3XP[ZY39 0  900  !@              ( !SR(  'AL+W=O
M<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( (> ;$_&V\8E  4  .$8
M   8              "  =XD  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q0
M2P$"% ,4    " "'@&Q/7%3^*+0!  #2 P  &               @ $4*@
M>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ AX!L3R))6H*R
M 0  T@,  !D              ( !_BL  'AL+W=O<FMS:&5E=',O<VAE970Q
M,"YX;6Q02P$"% ,4    " "'@&Q/P.LAE+0!  #2 P  &0
M@ 'G+0  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( (>
M;$\]1*38M $  -(#   9              "  =(O  !X;"]W;W)K<VAE971S
M+W-H965T,3(N>&UL4$L! A0#%     @ AX!L3V6& ^VT 0  T@,  !D
M         ( !O3$  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
M    " "'@&Q/52,SW+4!  #2 P  &0              @ &H,P  >&PO=V]R
M:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( (> ;$\A%^)OL@$  -(#
M   9              "  90U  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL
M4$L! A0#%     @ AX!L3P12\NRT 0  T@,  !D              ( !?3<
M 'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " "'@&Q/UURQ
M"K4!  #2 P  &0              @ %H.0  >&PO=V]R:W-H965T<R]S:&5E
M=#$W+GAM;%!+ 0(4 Q0    ( (> ;$]G^!P,M $  -(#   9
M  "  50[  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @
MAX!L3RJCK>ZU 0  T@,  !D              ( !/ST  'AL+W=O<FMS:&5E
M=',O<VAE970Q.2YX;6Q02P$"% ,4    " "'@&Q/M/;.$[(!  #2 P  &0
M            @ $K/P  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4
M Q0    ( (> ;$]@LOBMQ $  #<$   9              "  11!  !X;"]W
M;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ AX!L3V'R&AVS 0
MT@,  !D              ( !#T,  'AL+W=O<FMS:&5E=',O<VAE970R,BYX
M;6Q02P$"% ,4    " "'@&Q/6,7AS+8!  #2 P  &0              @ 'Y
M1   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( (> ;$^C
MXB24MP$  -(#   9              "  >9&  !X;"]W;W)K<VAE971S+W-H
M965T,C0N>&UL4$L! A0#%     @ AX!L3\3"=A"U 0  T@,  !D
M     ( !U$@  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (> ;$]&?&O6!0,   <,   9              "
M <-2  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ AX!L
M3Z0?"2\- P  40P  !D              ( !_U4  'AL+W=O<FMS:&5E=',O
M<VAE970S,2YX;6Q02P$"% ,4    " "'@&Q/"+TF<),#   W$   &0
M        @ %#60  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0
M   ( (> ;$]%2D:1/00  &X7   9              "  0U=  !X;"]W;W)K
M<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ AX!L3V!5+T0W @  [ 8
M !D              ( !@6$  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q0
M2P$"% ,4    " "'@&Q/8)B?Z]T"   E#   &0              @ 'O8P
M>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( (> ;$\E6TO@
M#@(  %\&   9              "  0-G  !X;"]W;W)K<VAE971S+W-H965T
M,S8N>&UL4$L! A0#%     @ AX!L3[?=4I.0 @  [@@  !D
M ( !2&D  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " "'
M@&Q/*""S!^L!  #P!   &0              @ $/;   >&PO=V]R:W-H965T
M<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( (> ;$^E(ZH0" (  (,%   9
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M970T,RYX;6Q02P$"% ,4    " "'@&Q/2 MQ9CT"  #I!@  &0
M    @ %8>0  >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    (
M (> ;$\<Z PVZ0$  /H$   9              "  <Q[  !X;"]W;W)K<VAE
M971S+W-H965T-#4N>&UL4$L! A0#%     @ AX!L3WXG;%VM P  51$  !D
M             ( !['T  'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"
M% ,4    " "'@&Q/2'"'WGL"  !-"   &0              @ '0@0  >&PO
M=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( (> ;$_?ZEHV# 0
M ,P2   9              "  8*$  !X;"]W;W)K<VAE971S+W-H965T-#@N
M>&UL4$L! A0#%     @ AX!L3WMDY\N% @  G@@  !D              ( !
MQ8@  'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " "'@&Q/
M]L+C_,H!   5!   &0              @ &!BP  >&PO=V]R:W-H965T<R]S
M:&5E=#4P+GAM;%!+ 0(4 Q0    ( (> ;$\:4*FP80(  .H'   9
M      "  8*-  !X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%
M  @ AX!L3SG[5,EH2@  >F$! !0              ( !&I   'AL+W-H87)E
M9%-T<FEN9W,N>&UL4$L! A0#%     @ AX!L3YH&Q!9* @  @ L   T
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52P4&     #P / !6$   E.4

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6787730512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Business</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">1. Nature of Business</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Editas Medicine,&#160;Inc. (the &#8220;Company&#8221;) is a leading, clinical stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The Company was incorporated in the state of Delaware in September 2013. Its principal offices are in Cambridge, Massachusetts.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, and raising capital. The Company has primarily financed its operations through various equity financings, payments received under a research collaboration with Juno Therapeutics, Inc., a Celgene company that is a wholly-owned subsidiary of Celgene Corporation (&#8220;Juno Therapeutics&#8221;), and payments received under a strategic alliance and option agreement with Allergan Pharmaceuticals International Limited (&#8220;Allergan&#8221;). </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company is subject to risks common to companies in the biotechnology industry, including but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations and ability to transition from pilot-scale manufacturing to large-scale production of products.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-style:italic;font-weight:bold;">Liquidity</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">As of September 30, 2019, the Company has raised an aggregate of $370.4 million in net proceeds through the sale of shares of its common stock in public offerings. In March 2018, the Company entered into a sales agreement with Cowen and Company, LLC (&#8220;Cowen&#8221;), under which the Company from time to time can issue and sell shares of its common stock through Cowen in at-the-market offerings for aggregate gross sales proceeds of $150.0 million (the &#8220;March 2018 ATM Program&#8221;). Beginning in August 2019 and through the date of filing this Quarterly Report on Form 10-Q, the Company sold an aggregate of 1,727,555 shares of its common stock pursuant to the March 2018 ATM Program, of which 1,721,735 shares were sold during the three months ended September 30, 2019, at a weighted-average price of $25.15 per share for gross proceeds of $43.6 million under the March 2018 ATM Program. The Company paid Cowen a 3% cash commission on the gross sales price per share of its common stock sold under the March 2018 ATM Program. As of the three months ended September 30, 2019, the Company received net proceeds of $42.1 million, of which $0.8 million was recorded as a receivable in other current assets in the condensed consolidated balance sheet. As of the date of this Quarterly Report on Form 10-Q, the Company has an ability to raise an additional $106.4 million in aggregate gross sales proceeds under the March 2018 ATM Program.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;">The Company has incurred annual net operating losses in every year since its inception. The Company expects that its existing cash, cash equivalents and marketable securities</span> <span style="font-size:10pt;">at September 30, 2019 and anticipated interest income will enable it to fund its operating expenses and capital expenditure requirements for at least 24 months following the date of this Quarterly Report on Form 10-Q. The Company had an accumulated deficit of </span><span style="font-size:10pt;">$511.5</span><span style="font-size:10pt;"> million at September 30, 2019 and will require substantial additional capital to fund its operations. The Company has never generated any product revenue. There can be no assurance that the Company will be able to obtain additional debt or equity financing or generate product revenue or revenues from collaborative partners, on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company&#8217;s business, results of operations, and financial condition.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6798119856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Condensed Consolidated Statements of Comprehensive Loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (32,941)<span></span>
</td>
<td class="num">$ (15,238)<span></span>
</td>
<td class="num">$ (95,976)<span></span>
</td>
<td class="num">$ (84,899)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive (loss) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized (loss) gain on marketable debt securities</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(83)<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (32,947)<span></span>
</td>
<td class="num">$ (15,321)<span></span>
</td>
<td class="num">$ (95,908)<span></span>
</td>
<td class="num">$ (84,905)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6797436592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Nov. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EDITAS MEDICINE,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-4097528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11 Hurley Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">401-9000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EDIT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,302,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001650664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6797631456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Notes Payable (Details) - Broad - Sponsored Research Agreement - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansPayableAbstract', window );"><strong>Notes Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued</a></td>
<td class="nump">330,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=edit_BroadInstituteIncMember', window );">Initial Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansPayableAbstract', window );"><strong>Notes Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Promissory notes issued</a></td>
<td class="nump">$ 12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percentage)</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_ThresholdPeriodInterestFreeDebtInstrumentFaceAmount', window );">Interest free debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_ThresholdPeriodInterestFreeDebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The face value of interest free debt instrument for specified period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_ThresholdPeriodInterestFreeDebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=edit_BroadInstituteIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=edit_BroadInstituteIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=edit_SponsoredResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=edit_SponsoredResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=edit_InitialNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=edit_InitialNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6786804816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td>
<td class="nump">$ 6,559<span></span>
</td>
<td class="nump">$ 6,699<span></span>
</td>
<td class="nump">$ 20,907<span></span>
</td>
<td class="nump">$ 20,251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td>
<td class="nump">3,619<span></span>
</td>
<td class="nump">3,506<span></span>
</td>
<td class="nump">10,854<span></span>
</td>
<td class="nump">11,412<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td>
<td class="nump">$ 2,940<span></span>
</td>
<td class="nump">$ 3,193<span></span>
</td>
<td class="nump">$ 10,053<span></span>
</td>
<td class="nump">$ 8,839<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6669960736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Summary of derecognition of balances relating to the building, accumulated depreciation and the corresponding construction financing lease on adoption of ASC 842</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:middle;white-space:nowrap;width:23.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of </b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:middle;white-space:nowrap;width:23.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">January 1, 2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Property and equipment, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,627</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (1,014)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Construction financing lease obligation, net of current portion</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (32,417)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Accumulated deficit </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 803</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_AssetsAndLiabilitiesLesseeOperatingLeaseTableTextBlock', window );">Summary of leases included on its condensed consolidated balance sheet</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company&#8217;s leases are included on its condensed consolidated balance sheet as follows (in thousands):</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:64.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:64.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:35.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:64.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">January 1,</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:64.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:64.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Right-of-use asset</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,681</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,461</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:64.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Lease liability, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (4,448)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (3,848)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:64.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Lease liability, noncurrent </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (13,202)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (15,909)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of the operating lease costs</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The following table contains a summary of the operating lease costs recognized under ASC 842 and other information pertaining to the Company&#8217;s operating leases during the three and nine months ended September 30, 2019 (in thousands):</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:60.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:middle;width:19.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="background-color:auto;vertical-align:middle;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:middle;width:17.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:60.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:middle;width:39.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Operating lease costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,451</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,293</p></td></tr><tr><td style="vertical-align:bottom;width:60.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Variable lease costs</p></td><td style="vertical-align:bottom;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 276</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 804</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Total lease costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,727</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,097</p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Maturities of the Company&#8217;s lease liabilities in accordance with ASC 842 as of September 30, 2019 were as follows (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:21.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:middle;width:21.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Maturity of lease liabilities:</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:middle;width:21.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,091</p></td></tr><tr><td style="vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,398</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,875</p></td></tr><tr><td style="vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,588</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">2023</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,924</p></td></tr><tr><td style="vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Total minimum lease payments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,906</p></td></tr><tr><td style="vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (3,256)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Total operating lease liabilities at September 30, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,650</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of maturities of lease liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:60.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:middle;width:19.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="background-color:auto;vertical-align:middle;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:middle;width:17.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:60.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:middle;width:39.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Operating lease costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,451</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,293</p></td></tr><tr><td style="vertical-align:bottom;width:60.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Variable lease costs</p></td><td style="vertical-align:bottom;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 276</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 804</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Total lease costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,727</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,097</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_AssetsAndLiabilitiesLesseeOperatingLeaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of leases included on its condensed consolidated balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_AssetsAndLiabilitiesLesseeOperatingLeaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e765-108305<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.10-01.(b)(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=27015980&amp;loc=d3e46468-122699<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e725-108305<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6784639552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents, Marketable Securities and Corporate Equity Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash Equivalents, Marketable Securities and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of cash equivalents, marketable securities and corporate equity securities</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Cash equivalents, marketable securities and equity securities consisted of the following at September 30, 2019 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Cash equivalents and marketable securities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 104,772</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 104,772</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">U.S. Treasuries</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,564</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,587</p></td></tr><tr><td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 144,241</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 144,257</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Equity securities included in other non-current assets:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Corporate equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,667</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,667</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 24pt;">Total </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 336,244</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 336,283</p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:24pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Cash equivalents, marketable securities and equity securities consisted of the following at December 31, 2018 (in thousands):<b style="font-weight:bold;"><br/></b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Cash equivalents and marketable securities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 130,049</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 130,049</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">U.S. Treasuries</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 208,754</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (24)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 208,730</p></td></tr><tr><td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,940</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,935</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Equity securities included in other non-current assets:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Corporate equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,667</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,667</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 24pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 372,410</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (29)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 372,381</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6797611408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Research Funding Payments (Details) - Research Funding Payments - Sponsored Research Agreement - Broad<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_FundingPaymentsDueAndPayableOne', window );">First research funding amount due and payable</a></td>
<td class="nump">$ 5.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_FundingPaymentsDueAndPayableTwo', window );">Second research funding amount due and payable</a></td>
<td class="nump">$ 7.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_FundingPaymentsDueAndPayableOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The first research funding amount which is due and payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_FundingPaymentsDueAndPayableOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_FundingPaymentsDueAndPayableTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The first research funding amount due and payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_FundingPaymentsDueAndPayableTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=edit_ResearchFundingPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=edit_ResearchFundingPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=edit_SponsoredResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=edit_SponsoredResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=edit_BroadInstituteIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=edit_BroadInstituteIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6785409872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Summary of Agreement (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>item</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 131,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, long-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=edit_CollaborationAndLicenseAgreementMember', window );">Collaboration and License Agreement | Juno Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=edit_StrategicAllianceMember', window );">Strategic Alliance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_ShareOfExpenseRecognizedPercentage', window );">Percentage of share of expenses recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=edit_StrategicAllianceMember', window );">Strategic Alliance | Allergan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_ResearchProgramTerm', window );">Agreement term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_NumberOfCollaborationDevelopmentPrograms', window );">Number of Collaboration Development Programs | item</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_NumberOfAdditionalDevelopmentAndCommercializationLicenseToBePurchased', window );">Number of additional licenses | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="nump">$ 13,800<span></span>
</td>
<td class="nump">$ 7,700<span></span>
</td>
<td class="nump">$ 16,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, long-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_ProgramExpense', window );">Expenses incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_NumberOfAdditionalDevelopmentAndCommercializationLicenseToBePurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of additional development and Commercialization License that can be purchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_NumberOfAdditionalDevelopmentAndCommercializationLicenseToBePurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_NumberOfCollaborationDevelopmentPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of collaboration development programs for the treatment of ocular disorders under the exclusive license from the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_NumberOfCollaborationDevelopmentPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_ProgramExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of program expenses incurred during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_ProgramExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_ResearchProgramTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The term of the research program under the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_ResearchProgramTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_ShareOfExpenseRecognizedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of share of operating expenses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_ShareOfExpenseRecognizedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e604059-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=edit_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=edit_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=edit_JunoTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=edit_JunoTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=edit_StrategicAllianceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=edit_StrategicAllianceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=edit_AllerganMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=edit_AllerganMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6800960080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_CollaborativeArrangementsAbstract', window );"><strong>Collaboration and License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock', window );">Schedule of accounts receivable and contract liabilities</a></td>
<td class="text">The following table presents changes in the Company&#8217;s accounts receivable and contract liabilities for the nine months ended September 30, 2019 (in thousands):<p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">For the nine months ended September 30, 2019</b></p></td><td colspan="2" style="background-color:auto;vertical-align:middle;width:13.51%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2018</b></p></td><td style="background-color:auto;vertical-align:middle;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:middle;width:11.97%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additions</b></p></td><td style="background-color:auto;vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:middle;width:11.35%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deductions</b></p></td><td style="background-color:auto;vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:middle;width:13.78%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Balance at September&#160;30,&#160;2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Accounts receivable</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">30</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 311</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:middle;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (30)</p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 311</p></td></tr><tr><td style="vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Contract liabilities:</p></td><td style="vertical-align:bottom;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:45.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"><span style="white-space:pre-wrap;">  Deferred revenue</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:middle;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 131,326</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:middle;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (7,928)</p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 128,398</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of change in contract assets and contract liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">During the three and nine months ended September 30, 2019, the Company recognized the following collaboration revenue (in thousands):</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:62.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:15.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:15.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:62.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:middle;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="background-color:auto;vertical-align:middle;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:middle;width:17.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="background-color:auto;vertical-align:middle;width:62.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Revenue recognized in the period from:</b></p></td><td colspan="5" style="background-color:auto;vertical-align:middle;width:37.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;width:62.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Amounts included in deferred revenue at the beginning of the period</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:middle;width:15.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,354</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:middle;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,733</p></td></tr><tr><td style="vertical-align:middle;width:62.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Performance obligations satisfied in previous periods</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:middle;width:15.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,194</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:middle;width:15.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,194</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_CollaborativeArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_CollaborativeArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of account receivable and contract liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of change in contract with customer asset and liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6788358960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of assets measured at fair value on a recurring basis</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Assets measured at fair value on a recurring basis as of September 30, 2019 were as follows (in thousands):</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">  </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">in&#160;Active</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Markets&#160;for</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical&#160;Assets</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Financial Assets</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Cash equivalents:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 104,772</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 104,772</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Marketable securities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">U.S. Treasuries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,587</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,587</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Government agency securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 144,257</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 144,257</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Restricted cash and other non-current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Corporate equity securities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,667</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,667</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,619</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,619</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Total financial assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 337,902</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 334,235</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,667</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Assets measured at fair value on a recurring basis as of December&#160;31, 2018 were as follows (in thousands):</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:-0.020606995%;padding-left:0pt;padding-right:0pt;width:100.04%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">in&#160;Active</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Markets&#160;for</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical&#160;Assets</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:54.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Financial Assets</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Cash equivalents:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 130,049</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 130,049</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">U.S. Treasuries</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,487</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,487</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">U.S. Treasuries</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 204,243</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 204,243</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,935</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,935</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Restricted cash and other non-current assets:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Corporate equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,667</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,667</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Money market funds</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,619</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,619</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Total financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 374,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 370,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,667</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6787682240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related-Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Transactions</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">11. Related-Party Transactions </b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company received $0.4 million in rent and facility-related fees from a related party during the nine months ended September 30, 2018 in connection with the Company&#8217;s Hurley Street sublease. No rent or facility-related payments were received from this related party during the nine months ended September 30, 2019. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6787699936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">7. Commitments and Contingencies</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In 2016, the Company entered into a lease agreement for 59,783 square feet of office and laboratory space located on Hurley Street in Cambridge, Massachusetts. The term of the lease began on October 1, 2016 and continues until October 2023. The Company has the <span style="white-space:pre-wrap;">option to extend</span><span style="white-space:pre-wrap;"> the lease for an additional </span><span style="white-space:pre-wrap;">five-year</span><span style="white-space:pre-wrap;"> term at market-based rates. The base rent payments commenced in November 2016 and continue through the term of the lease and are subject to increases over the term of the lease. The Company subleased approximately 10,000 square feet of the Hurley Street premises pursuant to a sublease, which commenced in February 2017 and terminated in June 2018. </span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In accordance with ASC 840 and for accounting purposes, the Company was deemed the owner of the building during the construction period due to the fact that the Company was involved in the construction project, including having responsibilities for cost overruns for planned tenant improvements that did not qualify as &#8220;normal tenant improvements&#8221; under the lease accounting guidance<i style="font-style:italic;">. </i>Throughout the construction period, the Company recorded the project construction costs incurred as an asset, along with a corresponding construction financing lease obligation, on its balance sheet for the total amount of the project costs incurred whether funded by the Company or the landlord. Construction was completed in October 2016 and the Company considered the requirements for sale-leaseback accounting treatment, which included an evaluation of whether all risks of ownership had transferred back to the landlord, as evidenced by a lack of continuing involvement in the leased property. The Company determined that the arrangement did not qualify for sale-leaseback accounting treatment, the building asset would remain on the Company&#8217;s balance sheet at its historical cost, and such asset would be depreciated over its estimated useful life of 30 years. The Company bifurcated its future lease payments pursuant to the lease into (i) a portion that was allocated to the building and (ii) a portion that was allocated to the land on which the building is located, which was recorded as rental expense. Although the Company did not begin making lease payments pursuant to the lease until November 2016, the portion of the lease obligation allocated to the land was treated for accounting purposes as an operating lease that commenced upon execution of the lease in February 2016. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Effective January 1, 2019, the Company adopted ASC 842 and derecognized the balances relating to the building, accumulated depreciation and the corresponding construction financing lease as summarized in the table below (in thousands). In applying the ASC 842 transition guidance, the Company determined that the lease should be classified as an operating lease and recorded a right-of-use asset and lease liability on the effective date, accordingly. </p><p style="font-family:'Times New Roman';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:middle;white-space:nowrap;width:23.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of </b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:middle;white-space:nowrap;width:23.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">January 1, 2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Property and equipment, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,627</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (1,014)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Construction financing lease obligation, net of current portion</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (32,417)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Accumulated deficit </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 803</p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">At adoption, the Company had two other operating leases for laboratory space. One of those leases, which commenced in April 2017, was amended in April 2018 and continues until March 2021. The second lease commenced in January 2018 and continues until June 2021. Base rent payments commenced at the beginning of each lease term and continue through the term of the respective lease. Base rent is also subject to increases over the term of the lease. In prior periods, the Company accounted for these leases as operating leases under ASC 840 and recognized straight-line rent expense over the remaining non-cancellable lease terms. As part of its adoption of ASC 842, effective January 1, 2019, the Company elected to apply the package of practical expedients which, among other things, allowed the Company to carry forward its existing lease classification under ASC 840. Additionally, the Company recorded right-of-use assets and lease liabilities for these operating leases on the effective date.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company has two other operating leases for manufacturing space that commenced in July 2019. The leases continue until December 2020 and March 2024, respectively. The lease that continues until March 2024 is subject to base rent increases over the term of the lease and the lease that continues until December 2020 has a fixed base rent payment through the term of the lease. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company&#8217;s leases are included on its condensed consolidated balance sheet as follows (in thousands):</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:64.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:64.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:35.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:64.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">January 1,</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:64.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:64.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Right-of-use asset</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,681</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,461</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:64.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Lease liability, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (4,448)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (3,848)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:64.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Lease liability, noncurrent </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (13,202)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (15,909)</p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="background-color:#ffff00;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The following table contains a summary of the operating lease costs recognized under ASC 842 and other information pertaining to the Company&#8217;s operating leases during the three and nine months ended September 30, 2019 (in thousands):</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:60.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:middle;width:19.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="background-color:auto;vertical-align:middle;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:middle;width:17.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:60.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="background-color:auto;vertical-align:middle;width:39.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Operating lease costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,451</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,293</p></td></tr><tr><td style="vertical-align:bottom;width:60.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Variable lease costs</p></td><td style="vertical-align:bottom;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 276</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 804</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Total lease costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,727</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,097</p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Maturities of the Company&#8217;s lease liabilities in accordance with ASC 842 as of September 30, 2019 were as follows (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:21.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:middle;width:21.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Maturity of lease liabilities:</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:middle;width:21.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2019</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,091</p></td></tr><tr><td style="vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,398</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,875</p></td></tr><tr><td style="vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,588</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">2023</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,924</p></td></tr><tr><td style="vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Total minimum lease payments</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,906</p></td></tr><tr><td style="vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (3,256)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Total operating lease liabilities at September 30, 2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,650</p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The weighted-average remaining lease terms are 3.7 years and the weighted-average discount rate is 9.27%.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-style:italic;font-weight:bold;">Licensor Expense Reimbursement</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-style:italic;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company is obligated to reimburse The Broad Institute, Inc. (&#8220;Broad&#8221;) and the President and Fellows of Harvard College (&#8220;Harvard&#8221;) for expenses incurred by each of them associated with the prosecution and maintenance of the patent rights that the Company licenses from them pursuant to the license agreement by and among the Company, Broad and Harvard, including the interference and opposition proceedings involving patents licensed to the Company under the license agreement, and other license agreements between the Company and Broad. As such, the Company anticipates that it has a substantial commitment in connection with these proceedings until such time as these proceedings have been resolved, but the amount of such commitment is not determinable. During the three and nine months ended September 30, 2019, the Company recognized $3.1 million and $10.1 million in expense for such reimbursement, respectively. During the three and nine months ended September 30, 2018, the Company recognized $2.9 million and $11.0 million in expense for such reimbursement, respectively. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-style:italic;font-weight:bold;">Success Payments </span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-style:italic;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In 2016, the Company entered into patent license agreements with each of The General Hospital Corporation, d/b/a Massachusetts General Hospital (&#8220;MGH&#8221;), and Broad (collectively, the &#8220;2016 License Agreements&#8221;). Pursuant to the terms of the 2016 License Agreements, the Company is required to make certain success payments to MGH, Broad and Wageningen University (&#8220;Wageningen&#8221; and such payments, collectively, the &#8220;Success Payments&#8221;), payable in cash </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">or, at the Company&#8217;s election, common stock in the case of MGH or, in the case of Broad and Wageningen, promissory notes payable in cash or, at the Company&#8217;s election subject to certain conditions, common stock of the Company. The Success Payments are payable, if and when, the Company&#8217;s market capitalization reaches specified thresholds for a specific period of time or upon a sale of the Company for consideration in excess of those thresholds (collectively, the &#8220;Payment Conditions&#8221;). </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Success Payments were historically accounted for under the provisions of ASC 505-50. Effective January 1, 2019, the Company adopted ASU 2018-07, which expands the scope of ASC 718 and superseded ASC 505-50. In accordance with ASC 718, the Company will recognize a Success Payment when it becomes probable that the Payment Conditions will be met. However, the Company has the right to terminate any of the 2016 License Agreements at will upon written notice. Absent any of the Payment Conditions being achieved prior to termination, the Company would not be obligated to pay any Success Payments. As such, the Company will recognize the expense and liability associated with each Success Payment when it is probable that the amounts will become due. The Company records this expense as a research and development expense in its condensed consolidated statements of operations. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-style:italic;font-weight:bold;">Research Funding Payments</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In June 2018, the Company entered into a sponsored research agreement (the &#8220;Sponsored Research Agreement&#8221;) with Broad. Pursuant to the terms of the Sponsored Research Agreement, the Company is required to make certain research funding payments to Broad, payable by promissory note, cash or common stock. Under the Sponsored Research Agreement, the Company is obligated to make payments of research funding to Broad in the event the Company&#8217;s market capitalization reaches specified thresholds ranging from a mid-nine digit dollar amount to a low-eleven digit dollar amount (&#8220;Market Cap Research Funding&#8221;) or a Company sale for consideration ranging from a mid-nine digit dollar amount to a low-eleven digit dollar amount (&#8220;Company Sale Research Funding&#8221; and, collectively with the Market Cap Research Funding, the &#8220;Research Funding Payments&#8221;). In connection with entering into the Sponsored Research Agreement, the Company confirmed that the first two Research Funding Payments of $5.0 million and $7.5 million were due and payable to Broad (the &#8220;Initial Research Payments&#8221;). </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Other than the Initial Research Payments, the Company is not required to make additional Research Funding Payments if the Company, whether directly or through its affiliates or sublicensees, is not researching, developing, or commercializing products based on or incorporating inventions developed under the Sponsored Research Agreement and exclusively licensed to the Company from Broad or based on or incorporating CRISPR technology owned, co-owned, or controlled by Broad and otherwise licensed to the Company, subject to certain exclusions. The Research Funding Payments were historically accounted for under the provisions of ASC Topic 505-50. Effective January 1, 2019, the Company adopted ASU 2018-07, which expands the scope of ASC 718 and superseded ASC 505-50. Under ASC 718, the Company will recognize the expenses and liability associated with each Research Funding Payment when it is probable that the amounts will become due. The Company records this expense as a research and development expense in its statements of operations. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In June 2018, in connection with the Company&#8217;s entry into the Sponsored Research Agreement and the trigger of the Initial Research Payments, the Company issued promissory notes in an aggregate principal amount of $12.5 million to Broad (the &#8220;Initial Research Notes&#8221;) bearing interest at a rate of 4.8% per annum, except with respect to $7.5 million of the principal, which would not start accruing interest until November 2018. The Company fully settled the outstanding principal and accrued interest on the Initial Research Notes by issuing 330,617 shares of common stock to Broad in June 2018.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-style:italic;font-weight:bold;">Litigation</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company is not a party to any litigation and did not have contingency reserves established for any litigation liabilities as of September 30, 2019 or December 31, 2018.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6787683328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents, Marketable Securities and Equity Securities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash Equivalents, Marketable Securities and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash Equivalents, Marketable Securities and Equity Securities</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">3. Cash Equivalents, Marketable Securities and Equity Securities </b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Cash equivalents, marketable securities and equity securities consisted of the following at September 30, 2019 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2019</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Cash equivalents and marketable securities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 104,772</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 104,772</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">U.S. Treasuries</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,564</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,587</p></td></tr><tr><td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 144,241</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 144,257</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Equity securities included in other non-current assets:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Corporate equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,667</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,667</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 24pt;">Total </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 336,244</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 336,283</p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:24pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Cash equivalents, marketable securities and equity securities consisted of the following at December 31, 2018 (in thousands):<b style="font-weight:bold;"><br/></b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized </b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b></p></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2018</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Cash equivalents and marketable securities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 130,049</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 130,049</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">U.S. Treasuries</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 208,754</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (24)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 208,730</p></td></tr><tr><td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Government agency securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,940</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,935</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Equity securities included in other non-current assets:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Corporate equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,667</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,667</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 24pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-family:'Calibri';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 372,410</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (29)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"> 372,381</p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:24pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">At September 30, 2019, the Company held five securities that were in an unrealized loss position. The aggregate fair value of securities held by the Company in an unrealized loss position for less than 12 months at September 30, 2019 was $51.9 million, and there were no securities held by the Company in an unrealized loss position for more than 12 months. Pursuant to the adoption of ASU No. 2016-01, <i style="font-style:italic;">Recognition and Measurement of Financial Assets and Financial Liabilities</i>, the Company records changes in the fair value of its investments in corporate equity securities to &#8220;Other (expense) income, net&#8221; in the Company&#8217;s condensed consolidated statements of operations. The Company records unrealized gains (losses) on available-for-sale debt securities as a component of accumulated other comprehensive income (loss) until such gains and losses are realized. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">As of September 30, 2019, the Company did not intend to sell, and was not more likely than not required to sell, the debt securities in an unrealized loss position before recovery of their amortized cost bases. Furthermore, the Company has determined that there were no material changes in the credit risk of the debt securities. As a result, the Company determined it did not hold any marketable securities with any other-than-temporary impairment as of September 30, 2019. </p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">There were no realized gains or losses on available-for-sale securities during the nine months ended September 30, 2019 or 2018. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>edit-20190930x10qc6fb6d_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:edit="http://www.editasmedicine.com/20190930"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="edit-20190930.xsd" xlink:type="simple"/>
    <context id="Duration_7_1_2019_To_9_30_2019_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarketOfferingMember_-kac0ehTwkynz560Ie4IPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edit:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarketOfferingMember_Ow36SSy4wUiSEqoR3C4BvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edit:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2018_To_6_30_2018_srt_CounterpartyNameAxis_edit_BroadInstituteIncMember_us-gaap_TypeOfArrangementAxis_edit_SponsoredResearchAgreementMember_e3dA74ixPEqD64XeFIza9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:BroadInstituteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:SponsoredResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ro8GtWifX0-HMTWgk5pKjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8SsTB3T8jEeFeLgDK5Xq4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_QDEnyWCKbE-v_F_kksLS2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CLnS6hMVNk2ckOkEXszSCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OpvknL2x3ESG-o3hybcgdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_UQYMfrodxUe3emORrxVIsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2019_2G5oRVxKzkqQpy_gyikO0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nMeFIR_iT0a90Nmvw6wHEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vgNcL3n5HUes97GAN6fT0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_BoilOwqVH0CvgLnHZM0KIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wisiSvmZ8E-68zg_-iKPEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CFIibCPWyUS3wh08WaAL2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Al0rqf8nLUSh7WEbnbdGzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NnhClH-fjkiCwW8cwRH_Kg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bKV0YxMVaESgorD_NKUdmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_45_zEcvCkkiGkk1UjUVA3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2018_k2-PAGdm9k2xoicTgC3nXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9kN0cK_j1U-lUz16kqWtFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JikrGEaYFEypNiwSuiHOuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_r16dcPMx-kOPqovKKF9rIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-tPNp-KA0UuSArvAtBVJpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TUxeAzXexUCs6hW2FNI9iA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_nqEnFNcXVUSFrUGRoV0Jlg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LwBc87JgzUC7Dp8J7KafdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7H2GbZDTB0WB00Z3wAbzxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GwYJtLes4kK1jip8o4AlWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="Duration_10_1_2019_To_10_31_2019_srt_TitleOfIndividualAxis_edit_ChiefMedicalOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_ER3lg9N5AUW1GcUOCxl1VQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">edit:ChiefMedicalOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_9_30_2019_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_dmEKC8zRkUGaNSfj2wtDJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2019_To_10_31_2019_srt_TitleOfIndividualAxis_edit_ChiefMedicalOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_oocRI-BsJkm3KP9_DGx7bQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">edit:ChiefMedicalOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_9_30_2018_us-gaap_RelatedPartyTransactionAxis_edit_RentAndFacilityRelatedFeesMember_Exbi6JGLz0aiPwGT7WbBAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">edit:RentAndFacilityRelatedFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2016_To_10_1_2016_srt_CounterpartyNameAxis_edit_HurleyStreetLeaseMember_msxFNwKEn0ud3R-lueFJbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:HurleyStreetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-10-01</startDate>
            <endDate>2016-10-01</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_ydne4f47BUCTZCvWtZzh0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_SBBNY-YWV0KhHhYb30myIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_xWgifcmBZESG7eQtghdpug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_H7ziJoGIK0maKshFPMdlhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_guUaGiUbe0iwk4T9ixbwSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_edit_LaboratoryEquipmentMember_AVb7DBqk10uTIad92YeUNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">edit:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_MnMT4XcDHE2E28jOhj7_4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_U6z0qkSp50GiyOi7BDlDRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_DjJ0hyYREUOZJlShodxbbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_VqUZ0FvBIkWcvm4vgvlr_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember_qQjfOtD8P0q3C93XNNQvxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_edit_LaboratoryEquipmentMember_jNlcWv83W0a_5q-w_7GeGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">edit:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_us-gaap_OtherCommitmentsAxis_edit_CommitmentToReimburseLicensorMember_DOloV0XhME-N4IXu1IWfqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">edit:CommitmentToReimburseLicensorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_9_30_2019_us-gaap_OtherCommitmentsAxis_edit_CommitmentToReimburseLicensorMember_qcBes6J9yk26oesBBlSUnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">edit:CommitmentToReimburseLicensorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2018_To_9_30_2018_us-gaap_OtherCommitmentsAxis_edit_CommitmentToReimburseLicensorMember_KLzreovHakCeVBoLv9ifJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">edit:CommitmentToReimburseLicensorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_9_30_2018_us-gaap_OtherCommitmentsAxis_edit_CommitmentToReimburseLicensorMember_niHDm0_cQUaXcYlHB5oJPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">edit:CommitmentToReimburseLicensorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_9_30_2019_us-gaap_SubsidiarySaleOfStockAxis_edit_PublicAndAtMarketOfferingMember_i5xMXJaYNESBo9i_qecDHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edit:PublicAndAtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_7zcER-83lEe2S7gZNEWllQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_3_knFgtCBkGl58HqlEgFpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_1_1_2019_GHVQq8gUCEOZOt-m471YvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_edit_HurleyStreetLeaseMember_zmU6W-bAi0i3mDk8ot7nVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:HurleyStreetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember_Ax4WwMw3P0elxef4gwaY2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember_PL8oKMla10qvL9b1_2n3mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember_6CXnaUT_fUyJlybGjgEz6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember_jT19XV8GLEu0RJbMbTBl4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember_p7E6BE0SyUaMQWxS2Qggjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember__QoCNZ0YnEedNiRHAIMKIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_9_30_2019_srt_TitleOfIndividualAxis_edit_EmployeeAndDirectorMember_VQVIkfmCb0mvWmtS1VrR7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">edit:EmployeeAndDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2019_srt_TitleOfIndividualAxis_edit_EmployeeAndDirectorMember_DG1Lr8lP_0-bT3_QEQxdtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">edit:EmployeeAndDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2018_srt_CounterpartyNameAxis_edit_BroadInstituteIncMember_us-gaap_ShortTermDebtTypeAxis_edit_InitialNotesMember_us-gaap_TypeOfArrangementAxis_edit_SponsoredResearchAgreementMember_wPlaEbCo9EqUmdryXl5j9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:BroadInstituteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">edit:InitialNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:SponsoredResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rKm1TiBfs0S-9aWTsi7EdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_h9POT0cgJEyb9tv7R3bH6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nEEqv36RBUWlQnEYMf__yQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2P57q7rCIUifNMWJ6Qp70Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2019_lev25mtbBUGfkyljGiogTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="As_Of_1_1_2019_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9DeFqajq70i8txpvpYC8_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9iZLSKC4mUiK1QS-diuQfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_i8q1DkQ_KUOWY2XOlmooKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KeqS4HNt1kuKQRTSA9H2zg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_B_Z2yUNGJ0K-xnVe_pA-9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2018_PRyW2BO7NEavIwfH50AVbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2018_To_9_30_2018_srt_CounterpartyNameAxis_edit_JunoTherapeuticsMember_us-gaap_TypeOfArrangementAxis_edit_CollaborationAndLicenseAgreementMember_O_MITT2wVkKnx6b-sggXmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:JunoTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2018_To_9_30_2018_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_RhdoXjew9EeVWvTWLV9vCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:AllerganMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:StrategicAllianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_9_30_2018_srt_CounterpartyNameAxis_edit_JunoTherapeuticsMember_us-gaap_TypeOfArrangementAxis_edit_CollaborationAndLicenseAgreementMember_DrDthce0AkygyZ1M-rBEkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:JunoTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_9_30_2018_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_L3rm1o4tuUiQrTClwY11ug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:AllerganMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:StrategicAllianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2019_srt_CounterpartyNameAxis_edit_JunoTherapeuticsMember_us-gaap_TypeOfArrangementAxis_edit_CollaborationAndLicenseAgreementMember_MrTxHdu-80almYvZDCtdRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:JunoTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_r45DsPeVZECbm550Uuu09w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:AllerganMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:StrategicAllianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_srt_CounterpartyNameAxis_edit_JunoTherapeuticsMember_us-gaap_TypeOfArrangementAxis_edit_CollaborationAndLicenseAgreementMember_cKDlyfBM_E-va2ua4o2xGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:JunoTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_qZ56Qn1U9Ee0sa4UlEgnKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:AllerganMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:StrategicAllianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2018_Uh3BMLH9xEeftU-M2ZH8Ug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2017_senIwq2LvEuADH5a682MHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_1OsS_I8aF0i-YCo7hdwLcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_HSTFzN1cUEGtvQd0OurLMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USTreasurySecuritiesMember_iVSO5aonCEuoXoKsnk9nUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_iX-oyBzhE0myrSoqcNnSbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USTreasurySecuritiesMember_uFibcieSKUaoBtsZ19bZYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_hhO6rw5Ou0moEGgauWWhJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_XK4JhgmU5UmZfBzH85zD9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_4CMDEP4Sg0WuJwCo3kj0GA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_raku3VZFuke0alBYy9wNpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_CKHO6pDGjkSBIsBw4K4g0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_hb4a5ntSUEWmOa45e5et6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_42lI8pTd2ECGwclymtSQgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_BE9yOipzFkWXXQU9jYhEMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uKPmiw8XwU2KdTnZuxwZtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USTreasurySecuritiesMember_zC8nQ0u0v0SygQronrDnrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember_A5vc1SsXOE2RfS4UDgR6RA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_715p9lT5NU-M643EcMceow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USTreasurySecuritiesMember_szWaKGRTnEi252qXZlUVrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember_KrXYO9EUiEyt_axAoghfkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_TGB4lxKzZkuI8R6wI2ygoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_lwnhc_OPt02yW0Img1-sjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_g8uPs61fLU-iP_S2ZoytqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_NK-fhmMl0UyDtfCFPjlwog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_C2kDm64hKk6izw1I5D_EAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_e71_GfWuOkmuF7nNBglBJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_MsohzaC6nEGF9IKQbiwTLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_1_2019_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_YkEer4ZbSEqfJGFr2l-94A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_9_30_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_Onzl5CFXo0u2R96djFM_ag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_9_30_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_MMdAUyO5fE6SZ9Hb9jRH_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_9_30_2018_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_WBkfEEnpwE-fkbIkbfPsmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_9_30_2018_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_1CwvMLjJmEu4BIw00uKzhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_wZjwFdhl40-qubyppSmKOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_r_4eSnuC80mudfKuh14VtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_aNajZe-YxUercIojM7dr8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_MupqsEB1_kKTyw545CGbAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2018_To_9_30_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_kzBgCnpG60KUgNvcF9BukA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2018_To_9_30_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_Ra72AcdpGUyjMWqQfhIMxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_9_30_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_iZuu8Cy3U0irlLMZI7Q0TQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_9_30_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_TvpaFuwJQkG6gdsSbxfjjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_glvMcDSGgEK7XZEP1zULNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_f703YUdgg0ypJsTTIsOBXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EmQrsfCBQUC6f66ZGe1HZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ezqBpnSOV0CfZMYTrjUW-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_H2z2rvDZXkOkv51mcbXxgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UKNKz4e0eEu5S7yXBgg4mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_hscTLrz67Emlv2qjXnQvGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_66x9bELQuEiMrFfDAUufxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2019_To_6_30_2019_-E0JkxGkvUqIxq8-rSrd2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_GigIkbq07E-4a5thn7D8wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BKKnagJhZUiQ6JZnEBvRvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VR9IQo6tqkWK5mvhHDkVjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_w2MduKaWh0K0KsF7xNNuCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_3_31_2019_g469-FKLDES3WXIXPTgVBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_SlLFJ70IdkulefAZvOR4-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YQeK5YPDZE6CK0bMIfhrGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_U69fKqLuvUeTW_gO2s8dmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_kZBghsf38ECtgyS7q_eESQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2019_srt_CounterpartyNameAxis_edit_BroadInstituteIncMember_us-gaap_ShortTermDebtTypeAxis_edit_InitialNotesMember_us-gaap_TypeOfArrangementAxis_edit_SponsoredResearchAgreementMember_wmULTOG4pU6RGgo-NX-daA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:BroadInstituteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">edit:InitialNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:SponsoredResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2018_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarket2018MarchOfferingMember_DsmZE9rWKUiDZb1Yzi_Ong">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edit:AtMarket2018MarchOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="As_Of_11_12_2019_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarket2018MarchOfferingMember_3TF1cgWHa06EgyHnRTyzJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edit:AtMarket2018MarchOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-12</instant>
        </period>
    </context>
    <context id="Duration_4_1_2018_To_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_67JgMcg-AU-r8nQZpiGRBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2018_To_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bUbGp4Vam0KtxOlIe1z2Ow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2018_To_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_xxLzL0DPwky5SLbxx4KehQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2018_To_6_30_2018_k2bzYrObrkCCSC2SDouEQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PcyLV57phkSeAKHvNp6DsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KQblBVk_v0SKWAMPvbYtyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Wtxux8gUD0CRzeyMEreftQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_3_31_2018_BPXZh5LFWk-0JSgUuxyu1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2018_To_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rB_fSol7XE2Vj1rue5g-gQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__7w520kExUi4RwvUKsrFcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_i04SOq9XXU-b-tSVEl5LSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:StrategicAllianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_9_30_2019_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_FOjXNGrOA0OHMOM6s36fPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:StrategicAllianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_xU8d1nrnWkeSzheIpGvdWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:AllerganMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:StrategicAllianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarket2018MarchOfferingMember_lU5PtQ9W90CR1Z6ITvsgSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edit:AtMarket2018MarchOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="Duration_8_1_2019_To_11_12_2019_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarket2018MarchOfferingMember_War5uqaMHkqlCu0UPhd7qA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edit:AtMarket2018MarchOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-11-12</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_9_30_2019_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarket2018MarchOfferingMember_ktbBPLx-c0WQog7UyrWNPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edit:AtMarket2018MarchOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2019_To_11_12_2019_srt_CounterpartyNameAxis_edit_CowenAndCompanyLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarket2018MarchOfferingMember_X-YMQBtmS0Ov-EDgiiJGQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:CowenAndCompanyLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edit:AtMarket2018MarchOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-11-12</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2019_To_7_31_2019_-qHYqTPBg0-JDU51y1HWrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2017_To_3_31_2017_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_2xE0WJjMoEOm6FHj79hUVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:AllerganMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:StrategicAllianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_Nw7YnWbU5EWBxR7zlJEm8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:AllerganMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:StrategicAllianceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_zrodnEw_VUizLBhcAZpOsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_1_1_2019_uaR1Uv2lmUWJZyFgpnp2JQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-01</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2018_srt_CounterpartyNameAxis_edit_BroadInstituteIncMember_us-gaap_OtherCommitmentsAxis_edit_ResearchFundingPaymentsMember_us-gaap_TypeOfArrangementAxis_edit_SponsoredResearchAgreementMember_7EHzXBh5f0uI6WsTuZTqoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:BroadInstituteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">edit:ResearchFundingPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:SponsoredResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2019_To_11_30_2019_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_edit_JunoTherapeuticsMember_9ZN4nSHh5EeubrbKBSQ-Jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edit:JunoTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="As_Of_2_28_2017_srt_CounterpartyNameAxis_edit_FacilitySubleaseArrangementMember_7tYFtpo8HkifSJ3u_1lnhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:FacilitySubleaseArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-02-28</instant>
        </period>
    </context>
    <context id="As_Of_10_1_2016_srt_CounterpartyNameAxis_edit_HurleyStreetLeaseMember_2ldT7Pk_sEy-LRFeHacLUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edit:HurleyStreetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-10-01</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_11_1_2019_lR7Cn3S_YUa3NkSSGGHXEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <instant>2019-11-01</instant>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_sqft_zyr2ZacpEkijqHVLi1q1mA">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Unit_Standard_item_rl1kcwMXZkCIZ-rzvXYVSA">
        <measure>edit:item</measure>
    </unit>
    <unit id="Unit_Standard_lease_WLwIHlVjbEGdHYRUV0R8Yw">
        <measure>edit:lease</measure>
    </unit>
    <unit id="Unit_Standard_pure_E8xeiPkPjUOaCmQYBNvdag">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      id="Hidden_h6VG0qiHoEyay1EhTfDk_w"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      id="Hidden_BJ15kV5Xp0GyL7mvevxAxQ"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      id="Hidden_L7eslJNbgkKEO1HBmZSNGg"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      id="Hidden_YAlOUFWUaUCCEGBek868bQ"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      id="Hidden_qxfAEboOfUyoL_gpNTXraA">us-gaap:ServiceMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA"
      id="Hidden_IdhogenAO0uj_i0Sg0yxzw">us-gaap:ServiceMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Hidden_yB5PE3LhYUyZ_fd2Gl8HLQ">us-gaap:ServiceMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw"
      id="Hidden_Ro2J8_6UIEy8qFcxHonyng">us-gaap:ServiceMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="INF"
      id="Hidden_lLBeRbK1dkqISfajDjUCGA"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="INF"
      id="Hidden_FjdVttUkiUqSdOE6f0lKew"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">0</us-gaap:PreferredStockSharesOutstanding>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Hidden_SA-Sn93bZUeV8TJ2a_Ppgg">0001650664</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Hidden_3HcjKOGPekKrPOJ7K9I2Xg">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Hidden_UYw-oM8r8kmjn6Ek3L6uZw">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Hidden_jlBHd2duokWV3uAGcnCc8Q">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Hidden_R84zHJlrqkqIc_XObvSLUg">2019</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Hidden_AetiG5IjEkq8fqsRxDks2w">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Narr_iUIYuE5IQEu55-vPi9d1wQ">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Narr_z4zlVWGrvkKaflEJWk-XAg">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Narr_b17ZhTQ9_0iexipW-gGmfg">2019-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Narr_tE5BykV0k06N-G7Gi6yudA">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Narr_hafVRCfjo0Gdt7ehwEWtcw">001-37687</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Narr_3NHhB2OLyUa6cfzKkXrVtg">EDITAS MEDICINE,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Narr_flP1_4e3CEyhkFA4P42Ecw">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Narr_R2cQVG6F50GtE8GsKvHtLQ">46-4097528</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Narr_jt9r4X27r0CXqCeFQo-Sow">11 Hurley Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Narr_6gz42S-QmE2cprtkiq-V3w">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Narr_OUduXkxbcEimcW6KyS6PIg">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Narr_K_V65LUXg0ygnH4KSPQH2A">02141</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Narr_1PE7KRDTskGQ6MrerJzwsA">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Narr_9asZvvYQoUS_MKT8lskmGw">401-9000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Narr_TbpWdLgQUUOzFkyx5b9fzw">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Tc_ShQ6sfMMSkKsNu01f8m6sw_3_1">EDIT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Tc_nCcwy8Qg7UWCTCoauMHyog_3_2">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Narr_confx3Ae_E6U-Arn78nZvw">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Narr_2ztxblvoFUSq2bSG_I2Q3A">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Tc_htDlxf3glEabxIhhSawhvw_2_3">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Tc_hLWTB8Y4Gk2H8-i7xSlLvw_3_3">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Narr_AVDtmBhXykyzOk-adOeEEw">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_11_1_2019_lR7Cn3S_YUa3NkSSGGHXEQ"
      decimals="INF"
      id="Narr_dKCBHA_sMUaj86C9hZK-VA"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">51302885</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_Fq_ljOnEW0er2Dh3qcVVUw_5_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">104772000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_8xm_hcOhwkimAsMaAK4ulw_5_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">134776000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_PG6vCWlFGUSzySuCakXtEA_6_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">227844000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_ebGFQxlUM0mHfOnVGqj96g_6_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">234179000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_g-B1mQlOLUSPtVrkbj8QqA_7_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">311000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_9VW7a_xrr0OR2URMq6exgw_7_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">30000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_IPKHYjdDDUWEVdzUvdt8Dg_8_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">6284000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_6QfPhpoYnk2oUGptabYNyw_8_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">5791000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_ZX7cuZ9GrUO_rF4vAKMzyQ_9_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">339211000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_tqPBf-U6FEiNFL7co_j0cg_9_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">374776000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_zFUDLZGi-Um8uqfZ2lg_iA_10_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">10075000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_QqqlLeY4p0-a0YbU0NLkRQ_10_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">40232000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_JND5z6MTX0KYiIqQ_DFFqQ_11_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">17681000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_ykVV3sY7qU2471CeplPcYg_12_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">5392000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_nNvIqGnQnkmm2Ux4-cuWzg_12_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">5378000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_IqaeXeyKAka131VkSww0vg_13_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">372359000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_fQDX7kf3JEWDUTSA66RArg_13_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">420386000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_BFxVZFN8EUSS83HufRczgw_16_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">6624000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_RTINkI38fU-pBrxzHjBVLA_16_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">5327000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_Z_xaBWHBaEK_c7qeXmK1nA_17_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">8138000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_Rp-kj-F85UyXC7RrI-yLpQ_17_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">12813000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_bo1Hdi7C2EWLx8gB2ZiMsA_18_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">46019000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_EHmBSJwpx0m8ICTc-fAlyg_18_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">15712000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_KvF8QMJWCkO06Bj2t0sh8A_19_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">4448000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_Yn91HT7sXEyOaONKwZ5MOw_20_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">1558000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_eaWtwA5SjEi7tGXdXfyddg_20_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">2048000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_U7dHZ5_gYEmtUNm9pMemqA_21_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">66787000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_ArPZH1NCjkKg0wL7VdFdKQ_21_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">35900000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_wnQW-mj_BEapEwx6Dt8dIg_22_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">13202000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_HYDEUThSQEyFfqTTvmn8Aw_23_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">82379000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_5xXTbdRKEUK2KzSYEooPGw_23_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">115614000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_kb8ROt6oC0O4z8w4xBoSNQ_24_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">32417000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_9c31PWyNhECaxVkCwuGcGQ_25_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">1000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_sxg9MQB3QkK9jjqSWgHR3A_25_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">293000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_tEs0MJ7ijkKpYOK3HEyUww_26_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">162369000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_a43EvaYbaU-AJ18O4xcTlQ_26_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">184224000</us-gaap:Liabilities>
    <us-gaap:PreferredStockNoParValue
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="INF"
      id="Narr_P98_NjDFDUypgtvuVAcsJw"
      unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA">0.0001</us-gaap:PreferredStockNoParValue>
    <us-gaap:PreferredStockNoParValue
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="INF"
      id="Narr_vwRfZR4RH0q7p1rJNtZm9Q"
      unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA">0.0001</us-gaap:PreferredStockNoParValue>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="INF"
      id="Narr_DScrtPzG9k66V-r44co_3g"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="INF"
      id="Narr_f-ZwMJQ9rka74aJnQsFWVA"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="INF"
      id="Narr_99L1a6H5i0q0uIeiD4uX3w"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="INF"
      id="Narr_wGFoPftf7ki3m3gFPbw36Q"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="INF"
      id="Narr_m2tzGemfBES7hPnBc0zSKA"
      unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="INF"
      id="Narr_W_XfBrw4EEO0MhtCWMKSeA"
      unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="INF"
      id="Narr_OBT8sbHumUWvyyrlTetd9g"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">195000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="INF"
      id="Narr_aSFpLdVd8ke_gB25XwR_Ww"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">195000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="INF"
      id="Narr_YFTKbC2H0UikRbemQx7CoA"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">51528020</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="INF"
      id="Narr_wCR_sZUb1kuyLlnVhj8VCA"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">49028907</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="INF"
      id="Narr_LOLewTjbYUCLZIZwH6vL1Q"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">51076198</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="INF"
      id="Narr_j620onv7kkCep50eo7CEmg"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">48758951</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_0bn1NZZ8Lk6CZCUgX2ALmQ_30_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">5000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_feMtGn7GNEaGQN_z1QdLYA_30_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">5000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_q1NPw485DE6QPH_rURudew_31_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">721397000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_oRo-JhgI6E6C2P9o0mO_PQ_31_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">652464000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_3oUxaaKHDkCeosG54lXZvQ_32_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">39000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_qrHNSOKpHE-XcJI869C_aw_32_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-29000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_tNQtTBl0iEmmy2VoTA3Jww_33_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-511451000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc__OB_jyLBi0qBqioCHI1y4A_33_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-416278000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_rAxoE_rZVEC7bE8R7XHXQw_34_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">209990000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_SoU_Y71zu0ykr5FHkGPNbA_34_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">236162000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_Jiq82nGdKEmgc604J4s2bA_35_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">372359000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_IMMxP46U8Euf52V06HMjnw_35_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">420386000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw"
      decimals="-3"
      id="Tc_yVtYbl0azUCp0YxrcGA-XA_4_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">3848000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA"
      decimals="-3"
      id="Tc_9RwnzFO7ek2LCcKPc_5e_g_4_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">14519000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_BB68KFijJ0GaGmEXwWILJw_4_9"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">8247000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_vVGJU5UVxUu9FH5CgAtQIg_4_12"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">25818000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw"
      decimals="-3"
      id="Tc_bSK1UsmwWUGOa6fCgk9kgw_6_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">22702000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA"
      decimals="-3"
      id="Tc_C5qkhRX0a0KRsLo4C4eZjQ_6_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">17443000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_CLJtyJJntk6ARwFJeWL29A_6_9"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">62109000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_cIR1_oYk-USr5aknPMiQsw_6_12"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">71460000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw"
      decimals="-3"
      id="Tc_XbiNaXByDkypKz0CfDXxcA_7_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">15734000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA"
      decimals="-3"
      id="Tc_ij7q54s-SUeuxk0pujJtrw_7_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">13334000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_l_Qj8phSbkm9sxWxrQQ8Rw_7_9"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">47638000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_BDwufR2AhkKrqMJdb62Byg_7_12"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">41832000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw"
      decimals="-3"
      id="Tc_iBmJrWSPAUOKjs-H5j4sow_8_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">38436000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA"
      decimals="-3"
      id="Tc_fMcg_pikeUeK9yAmrkV9bg_8_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">30777000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_RTZMG8PlLkSR-4MHLvWpiQ_8_9"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">109747000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_Fzd6ys45TEmE_w7Bgj5JXA_8_12"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">113292000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw"
      decimals="-3"
      id="Tc_hMjCXmoo00KLr-RasyDPQg_9_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-34588000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA"
      decimals="-3"
      id="Tc_ioI_nEyjLEmjvc45pnlPkQ_9_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-16258000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_lEKjf_Tb90q7JhwmWWEqEg_9_9"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-101500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc__jGeyqNrd0O1iwTygsPwjg_9_12"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-87474000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw"
      decimals="-3"
      id="Tc_ZxADWvSL7kq1c2UP6EmqSw_11_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-33000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA"
      decimals="-3"
      id="Tc_xCKgDCBL10-KJw3-sn8veA_11_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-4000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_9lbBxIywWUuKMdYlWHLFcA_11_9"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-144000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_AhyIFjgEmEOlJL8x3cslVw_11_12"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">332000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InvestmentIncomeNet
      contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw"
      decimals="-3"
      id="Tc_tCXJwmEtk0a9K6T9-mpUGw_12_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">1680000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA"
      decimals="-3"
      id="Tc_Wg_tc4LACEC5RqVxEMoSzQ_12_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">1024000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_IFUjvS1E7EOtQtQ5OdQUcw_12_9"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">5668000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_rj2l2gJfHECjmG3VjvzfkQ_12_12"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">2243000</us-gaap:InvestmentIncomeNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw"
      decimals="-3"
      id="Tc_RUqyfiy5Gk2prszPIMZvWQ_13_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">1647000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA"
      decimals="-3"
      id="Tc_wgfaMk3yukWV_PZ2aO-j4Q_13_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">1020000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_h9iBmuMwN0-Bq8h5iLI55g_13_9"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">5524000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_DFl4IFV-QUaBNTxOw6z8-Q_13_12"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">2575000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw"
      decimals="-3"
      id="Tc_GzNT-fgvD0m-Ggi1s7CqZQ_14_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-32941000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA"
      decimals="-3"
      id="Tc_ajERkqIm0Uu86Jf4flGsWg_14_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-15238000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_HlN5NYugGkuXbJTdk678kw_14_9"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-95976000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_RWxn5QhpXUeVBIbSznxBsg_14_12"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-84899000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw"
      decimals="2"
      id="Tc_hDr7WIC_PUyXk4vsNQwyKQ_15_3"
      unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA">-0.66</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA"
      decimals="2"
      id="Tc_dWOjUGDJO0WoB0jsotiGDQ_15_6"
      unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA">-0.32</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="2"
      id="Tc_JxhAlpu3WEGb6b95FBwUaA_15_9"
      unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA">-1.95</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="2"
      id="Tc_KklgzjkNo06YpW3s2LX1iw_15_12"
      unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA">-1.81</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw"
      decimals="0"
      id="Tc_v-cDETGPf0-tIarcu-Q2eA_16_3"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">49820455</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA"
      decimals="0"
      id="Tc_F7Fl-eyz00iMIQnF0mHdbg_16_6"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">47414271</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="0"
      id="Tc_8lLJcmp08U-rhwgCqoHQ5w_16_9"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">49246684</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="0"
      id="Tc_UF4DeD0JSkqw0_xQstn1FQ_16_12"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">46791322</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw"
      decimals="-3"
      id="Tc_HYSqRbxQm06Wgg8mRD2BBQ_4_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-32941000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA"
      decimals="-3"
      id="Tc_UqaTpa7jX0uQJ7MMY-C7hQ_4_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-15238000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_3XkSukynFkOAjKnggb6Ftw_4_9"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-95976000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_uqpS6XgKOEKsVbGFnekUUQ_4_12"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-84899000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw"
      decimals="-3"
      id="Tc_v7NFnEPcSU25J-Atj2d8NA_6_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-6000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA"
      decimals="-3"
      id="Tc_QEnqazN3-UO-SKSiPXQqhQ_6_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-83000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc__aFBA6Pb_UGl8HZiM1LrjQ_6_9"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">68000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_pzswhRtbW0eOMELOeHTmdg_6_12"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-6000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw"
      decimals="-3"
      id="Tc_JIoQEcTxuU2NQTAR2oprCg_7_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-32947000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA"
      decimals="-3"
      id="Tc_2oD6sT2S8kKdFXH0hvdOaA_7_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-15321000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_aqd9EUl6a0--Ybo3KuKBSg_7_9"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-95908000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_MgFKVswoAEaH0d7LULkxHA_7_12"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-84905000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_nqEnFNcXVUSFrUGRoV0Jlg"
      decimals="INF"
      id="Tc_PW853cBCGUyOiD19k_lmtA_5_2"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">48758951</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_nqEnFNcXVUSFrUGRoV0Jlg"
      decimals="-3"
      id="Tc_Bk8-26WK60Oni4v8n2WXow_5_5"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vgNcL3n5HUes97GAN6fT0Q"
      decimals="-3"
      id="Tc_l4MvERyWZUil1lWXk-I_Cw_5_8"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">652464000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_BoilOwqVH0CvgLnHZM0KIg"
      decimals="-3"
      id="Tc_d5q3yhay7U-aTQmCDu2O0w_5_11"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-29000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nMeFIR_iT0a90Nmvw6wHEg"
      decimals="-3"
      id="Tc_w76B66l9dE6o9FOYRsqyOA_5_14"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-416278000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_5oKjW0rqukafCqmo8AsJDA_5_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">236162000</us-gaap:StockholdersEquity>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rKm1TiBfs0S-9aWTsi7EdQ"
      decimals="-3"
      id="Tc__Dw0-o6txE633pTwWQPHkQ_6_14"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">803000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="As_Of_3_31_2019_lev25mtbBUGfkyljGiogTQ"
      decimals="-3"
      id="Tc_CFsWrdt5F0CFkQbg-EtWvw_6_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">803000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BKKnagJhZUiQ6JZnEBvRvg"
      decimals="INF"
      id="Tc_fMq7buNrxkipd9dfTsH0rA_7_2"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">146171</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VR9IQo6tqkWK5mvhHDkVjQ"
      decimals="-3"
      id="Tc_KiUMja_xPUetPknd1E4aPQ_7_8"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">1533000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2019_To_3_31_2019_g469-FKLDES3WXIXPTgVBA"
      decimals="-3"
      id="Tc_QBwWtwethUu3ddNOaXwkkw_7_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">1533000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BKKnagJhZUiQ6JZnEBvRvg"
      decimals="INF"
      id="Tc_2olRNQ23rUaY2-rGPsZFGA_8_2"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">18000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VR9IQo6tqkWK5mvhHDkVjQ"
      decimals="-3"
      id="Tc_YaDsZT-MOU2zUYZ_6k1KSw_9_8"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">7855000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2019_To_3_31_2019_g469-FKLDES3WXIXPTgVBA"
      decimals="-3"
      id="Tc_54xexqDLWkyZGQ-g5zdx4w_9_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">7855000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_w2MduKaWh0K0KsF7xNNuCQ"
      decimals="-3"
      id="Tc_-VMKqsKjHkKD1ELA7B8nAQ_10_11"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">58000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="Duration_1_1_2019_To_3_31_2019_g469-FKLDES3WXIXPTgVBA"
      decimals="-3"
      id="Tc_HotVK6Ihpk-Xf1vyoVWc_Q_10_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">58000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_GigIkbq07E-4a5thn7D8wg"
      decimals="-3"
      id="Tc_7CxxqS1kzUWJOHl2H6Nfew_11_14"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-29249000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_3_31_2019_g469-FKLDES3WXIXPTgVBA"
      decimals="-3"
      id="Tc_cFNL_krYPUyYvsVdmX7kZg_11_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-29249000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_h9POT0cgJEyb9tv7R3bH6g"
      decimals="INF"
      id="Tc_9YvVeiVDc0yz7x0bh5-gUw_12_2"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">48923122</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_h9POT0cgJEyb9tv7R3bH6g"
      decimals="-3"
      id="Tc_ZMyVJICMTE-U7GALp0maEA_12_5"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_nEEqv36RBUWlQnEYMf__yQ"
      decimals="-3"
      id="Tc_q8xNow-uU06Wg42fy65rIA_12_8"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">661852000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2P57q7rCIUifNMWJ6Qp70Q"
      decimals="-3"
      id="Tc_u2tcx_sDX0iNiTHEwK6QGg_12_11"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">29000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rKm1TiBfs0S-9aWTsi7EdQ"
      decimals="-3"
      id="Tc_fB2oL9aLDEijviLEOtA6mQ_12_14"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-444724000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2019_lev25mtbBUGfkyljGiogTQ"
      decimals="-3"
      id="Tc_e0XAEpe_6EaL4tNLNjKtBA_12_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">217162000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UKNKz4e0eEu5S7yXBgg4mg"
      decimals="INF"
      id="Tc_EQtvdUOqGkSyGnp2pxkWig_13_2"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">277259</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_hscTLrz67Emlv2qjXnQvGg"
      decimals="-3"
      id="Tc_OWvcsG6g6kiify7BWj2j7Q_13_8"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">2894000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2019_To_6_30_2019_-E0JkxGkvUqIxq8-rSrd2w"
      decimals="-3"
      id="Tc_Imh8qSubOkGHT2sAA9kDtQ_13_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">2894000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UKNKz4e0eEu5S7yXBgg4mg"
      decimals="INF"
      id="Tc_jl3P1h92sk6LLX2DvL0G1w_14_2"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">24486</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UKNKz4e0eEu5S7yXBgg4mg"
      decimals="INF"
      id="Tc_abHfaIZLI0Wgn4JWCMHWJg_15_2"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">16226</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_hscTLrz67Emlv2qjXnQvGg"
      decimals="-3"
      id="Tc_I9vvBh4_40WGCuMRfz4JLg_15_8"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">283000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_4_1_2019_To_6_30_2019_-E0JkxGkvUqIxq8-rSrd2w"
      decimals="-3"
      id="Tc_B-NPKSRoE02viPPlwxz_aw_15_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">283000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_hscTLrz67Emlv2qjXnQvGg"
      decimals="-3"
      id="Tc_VcS_2Rok4kWYiggtOXlLGA_16_8"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">6493000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2019_To_6_30_2019_-E0JkxGkvUqIxq8-rSrd2w"
      decimals="-3"
      id="Tc_wQ8-tnJhgUu1Yu44rVB1VA_16_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">6493000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_66x9bELQuEiMrFfDAUufxA"
      decimals="-3"
      id="Tc_ZFrswRcWQ0yJ_4PWY9df4g_17_11"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">16000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="Duration_4_1_2019_To_6_30_2019_-E0JkxGkvUqIxq8-rSrd2w"
      decimals="-3"
      id="Tc_MDN9133OQES9zbxMT1ldKQ_17_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">16000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2019_To_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_H2z2rvDZXkOkv51mcbXxgw"
      decimals="-3"
      id="Tc_uDq6ZRjp9E2htOrm0yEw3w_18_14"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-33786000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2019_To_6_30_2019_-E0JkxGkvUqIxq8-rSrd2w"
      decimals="-3"
      id="Tc_df6nChkbME6o2fymSMrrwQ_18_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-33786000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TUxeAzXexUCs6hW2FNI9iA"
      decimals="INF"
      id="Tc_O6CxX8uD-0icJ5AkZlpvqQ_19_2"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">49241093</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TUxeAzXexUCs6hW2FNI9iA"
      decimals="-3"
      id="Tc_Id4VTkiGL0iDXdOrl9dX1w_19_5"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OpvknL2x3ESG-o3hybcgdw"
      decimals="-3"
      id="Tc_X_WTwvrgBkqmxiGy1RTmkg_19_8"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">671522000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_UQYMfrodxUe3emORrxVIsg"
      decimals="-3"
      id="Tc_rPQh7CmUr0i2C8eDXmIhyA_19_11"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">45000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CLnS6hMVNk2ckOkEXszSCw"
      decimals="-3"
      id="Tc_SZbmrnOJcUeYJaj6xbYOTg_19_14"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-478510000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2019_2G5oRVxKzkqQpy_gyikO0w"
      decimals="-3"
      id="Tc_dA7zYFNEeUK05Nj5v2sDXA_19_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">193062000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_f703YUdgg0ypJsTTIsOBXA"
      decimals="INF"
      id="Tc_vvgKIBx29kymh8lYNIkoxw_20_2"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">78804</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EmQrsfCBQUC6f66ZGe1HZA"
      decimals="-3"
      id="Tc_ZQYQdmkBqEWB-Ok4msKD_A_20_8"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">1329000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw"
      decimals="-3"
      id="Tc_4OOA9JZr_UK_Eup8p2Mwgg_20_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">1329000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_f703YUdgg0ypJsTTIsOBXA"
      decimals="INF"
      id="Tc_JDy-b_R4y0myhk34YdFQyA_21_2"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">34566</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EmQrsfCBQUC6f66ZGe1HZA"
      decimals="-3"
      id="Tc_krd3FV_VcE29-aWt6cNtZA_22_8"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">6559000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw"
      decimals="-3"
      id="Tc_sNjEt6EoEka9Xkqycga1qA_22_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">6559000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_7zcER-83lEe2S7gZNEWllQ"
      decimals="-5"
      id="Narr_qsWevZuRR0uN5N6t2U57jg"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_f703YUdgg0ypJsTTIsOBXA"
      decimals="INF"
      id="Tc_N0vZ9lDOdESb_0UOsFzZxQ_23_2"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">1721735</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EmQrsfCBQUC6f66ZGe1HZA"
      decimals="-3"
      id="Tc_mComzcCR8UaVi_iZGzLJ-A_23_8"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">41987000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw"
      decimals="-3"
      id="Tc_sVPXNxOWPUiMoOeV1oyvSQ_23_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">41987000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ezqBpnSOV0CfZMYTrjUW-w"
      decimals="-3"
      id="Tc_-MhAiKiIhEKNfJCKiekkmw_24_11"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-6000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw"
      decimals="-3"
      id="Tc_uXQ_bhIKIEmhlnMOcv5lbg_24_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-6000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_glvMcDSGgEK7XZEP1zULNA"
      decimals="-3"
      id="Tc_eBG5vWZ6-keCUwICrI8dQg_25_14"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-32941000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw"
      decimals="-3"
      id="Tc_3Sn29t9NpUGDxwIW2HKRvg_25_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-32941000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-tPNp-KA0UuSArvAtBVJpA"
      decimals="INF"
      id="Tc_qmk7dZc2EEiFIpavDmTGDg_26_2"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">51076198</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-tPNp-KA0UuSArvAtBVJpA"
      decimals="-3"
      id="Tc_a56N3zuQnUGlB-yVxywsSQ_26_5"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8SsTB3T8jEeFeLgDK5Xq4Q"
      decimals="-3"
      id="Tc_uOBx0WskiEO9B8tbkymQpw_26_8"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">721397000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_QDEnyWCKbE-v_F_kksLS2A"
      decimals="-3"
      id="Tc_nc82If56CkGnUUyo7WG_gg_26_11"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">39000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ro8GtWifX0-HMTWgk5pKjQ"
      decimals="-3"
      id="Tc_peTSap7NDU-V-ne794_JJg_26_14"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-511451000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_2qjJxm1aTUajDdnmNNVvUw_26_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">209990000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GwYJtLes4kK1jip8o4AlWw"
      decimals="INF"
      id="Tc_4NaYqr8sNkaqPftnLpEmHA_5_2"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">44507960</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GwYJtLes4kK1jip8o4AlWw"
      decimals="-3"
      id="Tc_rbBlXspEPUqDpiKx9Vtpzw_5_5"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JikrGEaYFEypNiwSuiHOuQ"
      decimals="-3"
      id="Tc_-ASGUtGJjUm9ZqsHIGNMww_5_8"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">514002000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_r16dcPMx-kOPqovKKF9rIg"
      decimals="-3"
      id="Tc_Gtr1HJHBi0S0UxgClrbYbg_5_11"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-76000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9kN0cK_j1U-lUz16kqWtFQ"
      decimals="-3"
      id="Tc_l0rl0B5FMEu9DKXS9Mw9CQ_5_14"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-305850000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2017_senIwq2LvEuADH5a682MHA"
      decimals="-3"
      id="Tc_ss9H0sqQeEGGlFaRm3QHuA_5_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">208080000</us-gaap:StockholdersEquity>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="As_Of_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9iZLSKC4mUiK1QS-diuQfA"
      decimals="-3"
      id="Tc_MRao8O2lbkiffO0r5NRbUQ_6_14"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-474000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="As_Of_3_31_2018_PRyW2BO7NEavIwfH50AVbg"
      decimals="-3"
      id="Tc_owaFKjSud0iV0MxPQb6ulw_6_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-474000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_3_knFgtCBkGl58HqlEgFpQ"
      decimals="-5"
      id="Narr_Dr1oho5nUkKPMg0JZFQrHw"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__7w520kExUi4RwvUKsrFcQ"
      decimals="INF"
      id="Tc_B_pDlMwGCkePbx-JzFssww_7_2"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">1429205</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KQblBVk_v0SKWAMPvbYtyQ"
      decimals="-3"
      id="Tc_PK_exSNsj0-KJQXt4MwUAA_7_8"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">48493000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2018_To_3_31_2018_BPXZh5LFWk-0JSgUuxyu1Q"
      decimals="-3"
      id="Tc_EgmnmXV2wUu5MqcKfr6NNA_7_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">48493000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <edit:StockIssuedDuringPeriodSharesRepaymentOfDebt
      contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__7w520kExUi4RwvUKsrFcQ"
      decimals="INF"
      id="Tc_xsgoB8k7eUWVDhdexWP2cA_8_2"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">305909</edit:StockIssuedDuringPeriodSharesRepaymentOfDebt>
    <edit:StockIssuedDuringPeriodValueRepaymentOfNotes
      contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KQblBVk_v0SKWAMPvbYtyQ"
      decimals="-3"
      id="Tc_zDmlzvpgtEy8wLewGcN8sg_8_8"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">9530000</edit:StockIssuedDuringPeriodValueRepaymentOfNotes>
    <edit:StockIssuedDuringPeriodValueRepaymentOfNotes
      contextRef="Duration_1_1_2018_To_3_31_2018_BPXZh5LFWk-0JSgUuxyu1Q"
      decimals="-3"
      id="Tc_pT6Uh_AJIkKTeVw2NMtPWw_8_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">9530000</edit:StockIssuedDuringPeriodValueRepaymentOfNotes>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__7w520kExUi4RwvUKsrFcQ"
      decimals="INF"
      id="Tc_NksQ430hxE6J7ksMQYHA6w_9_2"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">56099</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KQblBVk_v0SKWAMPvbYtyQ"
      decimals="-3"
      id="Tc_p40kAUP2vk-FWIfISBKKCw_9_8"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">1942000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="Duration_1_1_2018_To_3_31_2018_BPXZh5LFWk-0JSgUuxyu1Q"
      decimals="-3"
      id="Tc_GxEvNJBm9UmNBUYhUnyhQg_9_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">1942000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__7w520kExUi4RwvUKsrFcQ"
      decimals="INF"
      id="Tc_Gdof2Yf3a0C1DKpo5o_2cw_10_2"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">305408</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KQblBVk_v0SKWAMPvbYtyQ"
      decimals="-3"
      id="Tc_jrxxf5rRiEWvZXgvQYQhIA_10_8"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">4328000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2018_To_3_31_2018_BPXZh5LFWk-0JSgUuxyu1Q"
      decimals="-3"
      id="Tc_Xyb7pIlKj0yFgGAB6GroZw_10_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">4328000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__7w520kExUi4RwvUKsrFcQ"
      decimals="INF"
      id="Tc_KyWDefMaLUeD1wuTiR7LzQ_11_2"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">107114</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KQblBVk_v0SKWAMPvbYtyQ"
      decimals="-3"
      id="Tc_NOhYf47JjUOSHDYluyTDog_12_8"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">6530000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2018_To_3_31_2018_BPXZh5LFWk-0JSgUuxyu1Q"
      decimals="-3"
      id="Tc_ROl7himTLE27688v7kessQ_12_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">6530000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Wtxux8gUD0CRzeyMEreftQ"
      decimals="-3"
      id="Tc_8QlIOQbc-kmGisjOgnvQMQ_13_11"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">24000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="Duration_1_1_2018_To_3_31_2018_BPXZh5LFWk-0JSgUuxyu1Q"
      decimals="-3"
      id="Tc_q3KA8eCSp0y5LrMNetnhhA_13_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">24000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PcyLV57phkSeAKHvNp6DsQ"
      decimals="-3"
      id="Tc_QLJmaBTvjkWGChzRKb0DUA_14_14"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-30939000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2018_To_3_31_2018_BPXZh5LFWk-0JSgUuxyu1Q"
      decimals="-3"
      id="Tc_Xo1qdgcRgU-gFda3NjSioA_14_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-30939000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_i8q1DkQ_KUOWY2XOlmooKQ"
      decimals="INF"
      id="Tc_7Iy_o9Ot_kKGhT5aiBh-ow_15_2"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">46711695</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_i8q1DkQ_KUOWY2XOlmooKQ"
      decimals="-3"
      id="Tc_ImskcNZqu0WnlaUuf8pGVw_15_5"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KeqS4HNt1kuKQRTSA9H2zg"
      decimals="-3"
      id="Tc_xkK95YnU7E-D55AQ2bOOBw_15_8"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">584825000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_B_Z2yUNGJ0K-xnVe_pA-9w"
      decimals="-3"
      id="Tc_KNNiST4s1UaFoaZSonNxTA_15_11"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-52000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9iZLSKC4mUiK1QS-diuQfA"
      decimals="-3"
      id="Tc_Be1y2oE0TU6U_MqoB3yYzA_15_14"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-337263000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2018_PRyW2BO7NEavIwfH50AVbg"
      decimals="-3"
      id="Tc_yTW-z9ygbEKr0ZiDKtI8eg_15_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">247514000</us-gaap:StockholdersEquity>
    <edit:StockIssuedDuringPeriodSharesRepaymentOfDebt
      contextRef="Duration_4_1_2018_To_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rB_fSol7XE2Vj1rue5g-gQ"
      decimals="INF"
      id="Tc_eOy3jAso6UerkKBePQMPVA_16_2"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">330617</edit:StockIssuedDuringPeriodSharesRepaymentOfDebt>
    <edit:StockIssuedDuringPeriodValueRepaymentOfNotes
      contextRef="Duration_4_1_2018_To_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rB_fSol7XE2Vj1rue5g-gQ"
      decimals="-3"
      id="Tc_qDxtaAY5zUSrj0EDmb0mGQ_16_5"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">1000</edit:StockIssuedDuringPeriodValueRepaymentOfNotes>
    <edit:StockIssuedDuringPeriodValueRepaymentOfNotes
      contextRef="Duration_4_1_2018_To_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bUbGp4Vam0KtxOlIe1z2Ow"
      decimals="-3"
      id="Tc_wiBTTFVhLUGPKt7nCzqJGg_16_8"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">12500000</edit:StockIssuedDuringPeriodValueRepaymentOfNotes>
    <edit:StockIssuedDuringPeriodValueRepaymentOfNotes
      contextRef="Duration_4_1_2018_To_6_30_2018_k2bzYrObrkCCSC2SDouEQw"
      decimals="-3"
      id="Tc_5JSGQ5BLu0yebuzY6_V1tg_16_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">12501000</edit:StockIssuedDuringPeriodValueRepaymentOfNotes>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_4_1_2018_To_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rB_fSol7XE2Vj1rue5g-gQ"
      decimals="INF"
      id="Tc_J25Zwiwxgki39j4NS_VTsA_17_2"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">192687</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2018_To_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bUbGp4Vam0KtxOlIe1z2Ow"
      decimals="-3"
      id="Tc_dN19MudOr0SAQE1or6zjjw_17_8"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">2597000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2018_To_6_30_2018_k2bzYrObrkCCSC2SDouEQw"
      decimals="-3"
      id="Tc_P2cUfHkSQUKzYssIvdcHAA_17_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">2597000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_4_1_2018_To_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rB_fSol7XE2Vj1rue5g-gQ"
      decimals="INF"
      id="Tc_xo2J7JE0206bBLKveFX7cg_18_2"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">103481</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="Duration_4_1_2018_To_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rB_fSol7XE2Vj1rue5g-gQ"
      decimals="INF"
      id="Tc_Bm-_uVSG5UKlPZvdOOyj0w_19_2"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">14273</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_4_1_2018_To_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bUbGp4Vam0KtxOlIe1z2Ow"
      decimals="-3"
      id="Tc_xzxrHqA3NEqfm77HaszUWw_19_8"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">362000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_4_1_2018_To_6_30_2018_k2bzYrObrkCCSC2SDouEQw"
      decimals="-3"
      id="Tc_KUi6eSc7eket0cZY-q5Pdg_19_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">362000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2018_To_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bUbGp4Vam0KtxOlIe1z2Ow"
      decimals="-3"
      id="Tc_ciFDar3bDUaBfpHeu2KA_Q_20_8"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">7026000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2018_To_6_30_2018_k2bzYrObrkCCSC2SDouEQw"
      decimals="-3"
      id="Tc_PtYDTikQY0KdpAfm6nx4MQ_20_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">7026000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="Duration_4_1_2018_To_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_xxLzL0DPwky5SLbxx4KehQ"
      decimals="-3"
      id="Tc_Aw5E-1zSFUGL4Nab0UIn2w_21_11"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">53000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="Duration_4_1_2018_To_6_30_2018_k2bzYrObrkCCSC2SDouEQw"
      decimals="-3"
      id="Tc_eKwelPf9SEOyScFtfQj9Rg_21_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">53000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2018_To_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_67JgMcg-AU-r8nQZpiGRBw"
      decimals="-3"
      id="Tc_z-1YxTyZtUS3JXJRSw0JtQ_22_14"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-38723000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2018_To_6_30_2018_k2bzYrObrkCCSC2SDouEQw"
      decimals="-3"
      id="Tc_O6n38RjneU-AVmjKGTQivQ_22_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-38723000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7H2GbZDTB0WB00Z3wAbzxA"
      decimals="INF"
      id="Tc_vAcElrDXDkWdoGvxph-OOg_23_2"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">47352753</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7H2GbZDTB0WB00Z3wAbzxA"
      decimals="-3"
      id="Tc_yYkb7n39kU6pyTaRJLzT5A_23_5"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bKV0YxMVaESgorD_NKUdmA"
      decimals="-3"
      id="Tc_yWYJVx-Ty0izLTmwvZvEUA_23_8"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">607310000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_45_zEcvCkkiGkk1UjUVA3Q"
      decimals="-3"
      id="Tc_mdgg4KdTR0-4tpiO_blNOQ_23_11"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NnhClH-fjkiCwW8cwRH_Kg"
      decimals="-3"
      id="Tc_wu-hjRaiLUehUm7CXPE82g_23_14"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-375986000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2018_k2-PAGdm9k2xoicTgC3nXg"
      decimals="-3"
      id="Tc_RpT36JpciESjV4dqQrZrIQ_23_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">231330000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_7_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YQeK5YPDZE6CK0bMIfhrGA"
      decimals="INF"
      id="Tc_kcz_ffqlsUu3GFu1ImxkOw_24_2"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">132856</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_U69fKqLuvUeTW_gO2s8dmw"
      decimals="-3"
      id="Tc_zek4b--TikytVNMk09PPFQ_24_8"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">1739000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA"
      decimals="-3"
      id="Tc_3gTZUNiBB0y2w37XneD3UQ_24_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">1739000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_7_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YQeK5YPDZE6CK0bMIfhrGA"
      decimals="INF"
      id="Tc_3BQHLnmOg06P-52xLHAkfA_25_2"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">18000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_U69fKqLuvUeTW_gO2s8dmw"
      decimals="-3"
      id="Tc_a_FaS9c1ekOTT1DUMuY5dA_26_8"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">6699000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA"
      decimals="-3"
      id="Tc_eumgKdTNsEu71I6ZvbXiWQ_26_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">6699000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="Duration_7_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_kZBghsf38ECtgyS7q_eESQ"
      decimals="-3"
      id="Tc_gYBmqvSZ-kuvI21iRpCuEA_27_11"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-83000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA"
      decimals="-3"
      id="Tc_dmbfQuTpMEOZmgcCU2AqrA_27_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-83000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2018_To_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_SlLFJ70IdkulefAZvOR4-A"
      decimals="-3"
      id="Tc_C-llumSAH0ezsnkEjWgNZA_28_14"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-15238000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA"
      decimals="-3"
      id="Tc_YX1DGZP3zkKqgCu22ncxjg_28_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-15238000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LwBc87JgzUC7Dp8J7KafdA"
      decimals="INF"
      id="Tc_XUS1m4FrOk-sYxAlEwPUrQ_29_2"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">47503609</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LwBc87JgzUC7Dp8J7KafdA"
      decimals="-3"
      id="Tc__oLR9SgY10SVgvY-JP0duA_29_5"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CFIibCPWyUS3wh08WaAL2Q"
      decimals="-3"
      id="Tc_QvjreW4TukSLMqDbunvYDQ_29_8"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">615748000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Al0rqf8nLUSh7WEbnbdGzA"
      decimals="-3"
      id="Tc_k2eBpoe0qUa8yvo1vFctyw_29_11"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-82000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wisiSvmZ8E-68zg_-iKPEA"
      decimals="-3"
      id="Tc_GROiG7EfTEix7zEcM7ioBQ_29_14"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-391224000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2018_Uh3BMLH9xEeftU-M2ZH8Ug"
      decimals="-3"
      id="Tc_-AFRV6R3zkGBRgrg2IjJ8g_29_17"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">224447000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_tXR1DpScwk6agprEnTbCcw_5_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-95976000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_YuvzZbnpuEOOZhQmvTitPg_5_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-84899000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_biJY8Nz1L0Oa__zmMtx_zg_7_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">20907000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_o4CdEW97REmIGPKH_JCpEQ_7_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">20251000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_ayKxYeQjeEqth6bShT43Hw_8_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">2048000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_0otFrEgLfkmXVyyz8Q0TOA_8_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">2374000</us-gaap:Depreciation>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_e7DLCPrVykS6b9i8mN57vw_9_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">14442000</us-gaap:ResearchAndDevelopmentInProcess>
    <edit:NoncashInvestmentInEquitySecurities
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_th1odD2WUE2-2jM6GM1mpg_10_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">3667000</edit:NoncashInvestmentInEquitySecurities>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_RMte_aop0E2mTNGZ93g0-A_11_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">2427000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_6R8592c-mUqDC2gdN3Tu-A_11_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">2129000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_cpagh28P_UyWdSub1M0Lig_13_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">281000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_9UPdWO_lfEuR2FKLUH-nEQ_13_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-636000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_UJ1O3UqgvEuaBcEkZNZu_w_14_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-263000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_7zgdasMbzkC7tspUkILwWw_14_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">2349000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <edit:IncreaseDecreaseInRightOfUseAssets
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_7YTTPLPB-E68oeayJmsSbA_15_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-1780000</edit:IncreaseDecreaseInRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_i7bSGP2RqEuvBIlMXsRw3g_16_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">14000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_WYs5KKDAPUecO4oIaM4oBg_16_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">92000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_RF2p3feCFka0i6wgcPX0Ag_17_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">1005000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_zET7ZHrjx0qZWaOo4AP8oA_17_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">1667000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_WlhZBfnR-EqeHMP0QLANog_18_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-4491000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_BiOLS07lIE64P-JxFBH60w_18_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">2344000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_LBW1_rz5tkC_rknP_EYGyw_19_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-2928000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_ucbVlkfBI0-CQVWw91CGrw_19_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">4388000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <edit:IncreaseDecreaseInRightOfUseLiability
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_ULE970UaTUq4T712NzPinw_20_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-2107000</edit:IncreaseDecreaseInRightOfUseLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_-7nDmOwiWk68-LysRtl-9g_21_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">528000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_4flNQHEI7Emg5FeaRNM52w_22_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-81693000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_VzJwMcR7VEKeTYyn-OlgQg_22_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-47034000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_FbJ311uwwUmMd7iKVIr3Cg_24_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">4476000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_BA8Bgc4J70uBqFXfaBK5Ww_24_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">3339000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_C_aHnXAA6kOF3TNKAVoKbw_25_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">36000</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_VVIbmDG2Y0miYnVs3N1EXg_25_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">18000</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_9wWvRuZvsU6vjddgOQpVLQ_26_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">305126000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_SOVVIgozg0aPJJii25Mv6g_26_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">351162000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_LExRQo2LrEi5aSDVxQ4idQ_27_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">314000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_ajeKf4200EGvNK5VgiojaA_27_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">310000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_QZyZQ2F-dECMwKXvdvQTTg_28_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">4434000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_tHL4jC8R40SVJ9cJo4ARXw_28_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-44483000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_Alb0vFYGFUymmgl_uAJffQ_30_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">41216000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_4jgGYrdFvUei48Ulq5Y4Vg_30_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">48471000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_ok1Ku6RV80uku2PwJv_1jQ_31_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">5756000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_lV4XRfbUSkGEvlYwgzSgTA_31_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">8376000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_mQSmroFqtkyIZXq0Ai6S_w_32_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">283000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_VrNQlgwZTU-hlBMM7LvzNw_32_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">362000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_4LvrZh4FH0KBdS8NbY1lig_33_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">621000</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_A5VgU__kL0Omndn9Octdlw_34_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">47255000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc__mM3KkyZ806Pdu2CbZhDOw_34_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">56588000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_gje_rPYhbUetfZ26ZZIH4Q_35_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-30004000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_gJrmR7BJckaf2o6J--PRqw_35_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-34929000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_BizSHh-a-k-mRXLh9na3pw_36_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">136395000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2017_senIwq2LvEuADH5a682MHA"
      decimals="-3"
      id="Tc_sYlApk5huUCOFmPeXeicxw_36_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">148249000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_gVKCwkPTREyi7O--aEyw3Q_37_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">106391000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2018_Uh3BMLH9xEeftU-M2ZH8Ug"
      decimals="-3"
      id="Tc_dIKXw8nptUOoCOeGuSu0_A_37_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">113320000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_fiOLQArwBUqvOm9aw6ipiw_39_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">772000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_3z3EYmM4bEaRCk54-M0VxQ_39_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">676000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <edit:ReceivableOfProceedsFromExerciseOfStockOptions
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_QhfPFg2J6UuRJMEXZASYPA_40_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">756000</edit:ReceivableOfProceedsFromExerciseOfStockOptions>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_xtisn8iUcU6LCI9mPwbvYA_41_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">4604000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_YxJUO1SCZ0eHAzYdU_bPIQ_42_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">19461000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <edit:ReclassificationOfLiabilityForFounderStockRepurchase
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_r5c0O42yh0iM7UALxsHojQ_43_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">4000</edit:ReclassificationOfLiabilityForFounderStockRepurchase>
    <us-gaap:StockIssued1
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_1ujE3EpAFUWVSSESCBDqtg_44_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">9530000</us-gaap:StockIssued1>
    <edit:StockIssuedForAssetAcquisition
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_juYKstSorEG2Jy4OVLVCYQ_45_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">1942000</edit:StockIssuedForAssetAcquisition>
    <us-gaap:NotesIssued1
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_52oVpeZeX0KfY0HVph_1bQ_46_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">12500000</us-gaap:NotesIssued1>
    <edit:DeferredRevenueAdjustmentFromEffectOfNewAccountingPrinciple
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_VFNfxRtzSUO5NACzTaxQSQ_47_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">474000</edit:DeferredRevenueAdjustmentFromEffectOfNewAccountingPrinciple>
    <edit:StockIssuanceCostsIncurredButNotYetPaid
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_RM0qKLbEhkKq2QcO7QyJSA_48_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">15000</edit:StockIssuanceCostsIncurredButNotYetPaid>
    <edit:StockIssuanceCostsIncurredButNotYetPaid
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_l3gidDLIA0-FE0vxiPSQoQ_48_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">22000</edit:StockIssuanceCostsIncurredButNotYetPaid>
    <us-gaap:NatureOfOperations
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Tb_SvikllY-2U-nrcZ0MhYmnA">&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1. Nature of Business&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Editas Medicine,&#160;Inc. (the &#x201c;Company&#x201d;) is a leading, clinical stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The Company was incorporated in the state of Delaware in September 2013. Its principal offices are in Cambridge, Massachusetts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, and raising capital. The Company has primarily financed its operations through various equity financings, payments received under a research collaboration with Juno Therapeutics, Inc., a Celgene company that is a wholly-owned subsidiary of Celgene Corporation (&#x201c;Juno Therapeutics&#x201d;), and payments received under a strategic alliance and option agreement with Allergan Pharmaceuticals International Limited (&#x201c;Allergan&#x201d;). &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The Company is subject to risks common to companies in the biotechnology industry, including but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations and ability to transition from pilot-scale manufacturing to large-scale production of products.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Liquidity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;As of September 30, 2019, the Company has raised an aggregate of $370.4 million in net proceeds through the sale of shares of its common stock in public offerings. In March 2018, the Company entered into a sales agreement with Cowen and Company, LLC (&#x201c;Cowen&#x201d;), under which the Company from time to time can issue and sell shares of its common stock through Cowen in at-the-market offerings for aggregate gross sales proceeds of $150.0 million (the &#x201c;March 2018 ATM Program&#x201d;). Beginning in August 2019 and through the date of filing this Quarterly Report on Form 10-Q, the Company sold an aggregate of 1,727,555 shares of its common stock pursuant to the March 2018 ATM Program, of which 1,721,735 shares were sold during the three months ended September 30, 2019, at a weighted-average price of $25.15 per share for gross proceeds of $43.6 million under the March 2018 ATM Program. The Company paid Cowen a 3% cash commission on the gross sales price per share of its common stock sold under the March 2018 ATM Program. As of the three months ended September 30, 2019, the Company received net proceeds of $42.1 million, of which $0.8 million was recorded as a receivable in other current assets in the condensed consolidated balance sheet. As of the date of this Quarterly Report on Form 10-Q, the Company has an ability to raise an additional $106.4 million in aggregate gross sales proceeds under the March 2018 ATM Program.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:9pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;The Company has incurred annual net operating losses in every year since its inception. The Company expects that its existing cash, cash equivalents and marketable securities&lt;/span&gt; &lt;span style="font-size:10pt;"&gt;at September 30, 2019 and anticipated interest income will enable it to fund its operating expenses and capital expenditure requirements for at least 24 months following the date of this Quarterly Report on Form 10-Q. The Company had an accumulated deficit of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$511.5&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million at September 30, 2019 and will require substantial additional capital to fund its operations. The Company has never generated any product revenue. There can be no assurance that the Company will be able to obtain additional debt or equity financing or generate product revenue or revenues from collaborative partners, on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company&#x2019;s business, results of operations, and financial condition.&lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_SubsidiarySaleOfStockAxis_edit_PublicAndAtMarketOfferingMember_i5xMXJaYNESBo9i_qecDHw"
      decimals="-5"
      id="Narr_ieIXgCskhEmPD7DJGi2X_Q"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">370400000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <edit:StockSalesAgreementThresholdSaleProceedsThatCanBeRaised
      contextRef="As_Of_3_31_2018_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarket2018MarchOfferingMember_DsmZE9rWKUiDZb1Yzi_Ong"
      decimals="-5"
      id="Narr_cY3l3Gi7_EWsWyZWABJLaQ"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">150000000.0</edit:StockSalesAgreementThresholdSaleProceedsThatCanBeRaised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_8_1_2019_To_11_12_2019_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarket2018MarchOfferingMember_War5uqaMHkqlCu0UPhd7qA"
      decimals="INF"
      id="Narr_zcJ381bhS0egpdNwKrZhww"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">1727555</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarket2018MarchOfferingMember_ktbBPLx-c0WQog7UyrWNPA"
      decimals="INF"
      id="Narr_Mz9sEoyxz0aMBWzDlzusqw"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">1721735</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <edit:SharesIssuedWeightedAveragePricePerShare
      contextRef="Duration_8_1_2019_To_11_12_2019_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarket2018MarchOfferingMember_War5uqaMHkqlCu0UPhd7qA"
      decimals="2"
      id="Narr_JnbeFKFCsE6nsZM8BqwGMQ"
      unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA">25.15</edit:SharesIssuedWeightedAveragePricePerShare>
    <edit:ProceedsFromIssuanceOfCommonStockGross
      contextRef="Duration_8_1_2019_To_11_12_2019_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarket2018MarchOfferingMember_War5uqaMHkqlCu0UPhd7qA"
      decimals="-5"
      id="Narr_IJdqmefFXEG9kmT7Zvs28Q"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">43600000</edit:ProceedsFromIssuanceOfCommonStockGross>
    <edit:PercentageOfCashCommissionsPaid
      contextRef="Duration_8_1_2019_To_11_12_2019_srt_CounterpartyNameAxis_edit_CowenAndCompanyLlcMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarket2018MarchOfferingMember_X-YMQBtmS0Ov-EDgiiJGQQ"
      decimals="2"
      id="Narr_7zqX00R9lkiDyd29PvQm8g"
      unitRef="Unit_Standard_pure_E8xeiPkPjUOaCmQYBNvdag">0.03</edit:PercentageOfCashCommissionsPaid>
    <edit:ProceedsFromIssuanceOfCommonStockGross
      contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarket2018MarchOfferingMember_ktbBPLx-c0WQog7UyrWNPA"
      decimals="-5"
      id="Narr_ufYkA2VdQUKHIq_sTpd7Tw"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">42100000</edit:ProceedsFromIssuanceOfCommonStockGross>
    <edit:ProceedsFromIssuanceOfCommonStockReceivable
      contextRef="As_Of_9_30_2019_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarket2018MarchOfferingMember_lU5PtQ9W90CR1Z6ITvsgSA"
      decimals="-5"
      id="Narr_ps8SGGaWLEiQpNmhFqhduA"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">800000</edit:ProceedsFromIssuanceOfCommonStockReceivable>
    <edit:StockSalesAgreementAdditionalSaleProceedsThatCanBeRaised
      contextRef="As_Of_11_12_2019_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarket2018MarchOfferingMember_3TF1cgWHa06EgyHnRTyzJA"
      decimals="-5"
      id="Narr_beFwgM0ld0ez_FYYB8J1Dg"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">106400000</edit:StockSalesAgreementAdditionalSaleProceedsThatCanBeRaised>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-5"
      id="Narr_xUU2_O6n-k2SEwk2kv7wfw"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-511500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Tb_TRuhwncKwUSIHJN0kyGeWw">&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2. Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;) have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2018 (the &#x201c;Annual Report&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The unaudited condensed consolidated financial statements include the accounts of Editas Medicine, Inc. and its wholly owned subsidiary, Editas Securities Corporation. All intercompany transactions and balances of the subsidiary have been eliminated in consolidation. In the opinion of management, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the results for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The three months ended September 30, 2019 and 2018 are referred to as the third quarter of 2019 and 2018, respectively. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-family:'inherit';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The Company&#x2019;s significant accounting policies are described in Note 2, &#x201c;Summary of significant accounting policies,&#x201d; to the consolidated financial statements included in the Annual Report. There have been no material changes to the significant accounting policies previously disclosed in the Annual Report other than as noted below. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements &#x2013;Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Leases &lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Effective January 1, 2019, the Company adopted Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02, &lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt; (Topic 842) (&#x201c;ASC 842&#x201d;), which amends a number of aspects of lease accounting and requires entities to recognize right-of-use assets and operating lease liabilities on the balance sheet. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"&gt;At the inception of an arrangement the Company determines whether the arrangement contains a lease. If a lease is identified in an arrangement, the Company recognizes a right-of-use asset and liability on its balance sheet and determines whether the lease should be classified as a finance or operating lease. The Company does not recognize assets or liabilities for leases with lease terms of less than 12 months. Lease payments for short-term leases are recorded to operating expense on a straight-line basis over the lease term and variable lease payments are recorded in the period in which the obligation for those payments is incurred. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"&gt;A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, and (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Finance and operating lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the rate is not readily determinable, the Company utilizes its incremental borrowing rate at the lease commencement date. Operating lease assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 9pt 0pt;"&gt;straight-line method as an operating expense over the lease term. Finance lease assets are amortized to depreciation expense using the straight-line method over the shorter of the useful life of the related asset or the lease term. Finance lease payments are bifurcated into (i) a portion that is recorded as imputed interest expense and (ii) a portion that reduces the finance liability associated with the lease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"&gt;The Company does not separate lease and non-lease components when determining which lease payments to include in the calculation of its lease assets and liabilities. Variable lease payments are expensed as incurred. If a lease includes an option to extend or terminate the lease, the Company reflects the option in the lease term if it is reasonably certain it will exercise the option.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"&gt;The Company elected the modified-retrospective transition method, pursuant to which the Company recognized a cumulative-effect adjustment of $0.8 million to the opening balance of accumulated deficit on January 1, 2019 associated with de-recognizing the net asset balance recorded in property and equipment, net and the offsetting construction financing lease liability related to the Company&#x2019;s headquarters which was previously accounted for under the built-to-suit guidance in Accounting Standards Codification (&#x201c;ASC&#x201d;) 840, &lt;i style="font-style:italic;"&gt;Leases &lt;/i&gt;(&#x201c;ASC 840&#x201d;). This resulted in a reversal of $32.6 million from total assets and $33.4 million from total liabilities. All prior period balances are presented in accordance with ASC 840. As of January 1, 2019, the Company recorded a right-of-use asset of $19.5 million and lease liability of $19.7 million associated with the adoption of ASC 842. In addition, the Company elected to adopt the package of three practical expedients for leases that commenced prior to January 1, 2019, allowing it not to reassess (i) whether any expired or existing contracts contain leases, (ii) the lease classification for any expired or existing leases and (iii) the initial indirect costs for any existing leases. The Company did not elect the hindsight practical expedient &lt;span style="white-space:pre-wrap;"&gt;which allows the Company to reassess the lease term as it was not relevant to the Company&#x2019;s leases.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Stock-Based Compensation Expense &lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Effective January 1, 2019, the Company adopted ASU No. 2018-07, &lt;i style="font-style:italic;"&gt;Compensation &#x2013; Stock Compensation: Improvements to Nonemployee Share-Based Payment Accounting &lt;/i&gt;(&#x201c;ASU 2018-07&#x201d;), which simplified the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expands the scope of ASC 718, &lt;i style="font-style:italic;"&gt;Compensation &#x2013; Stock Compensation &lt;/i&gt;(&#x201c;ASC 718&#x201d;), which supersedes the guidance in ASC 505-50, &lt;i style="font-style:italic;"&gt;Equity-Based Payments to Non-Employees &lt;/i&gt;(&#x201c;ASC 505-50&#x201d;). In accordance with the new guidance, the Company accounts for share-based payments to non-employees by recognizing stock-based compensation expense equal to the grant date fair value of the share-based payment ratably over the requisite service period. The Company estimates the grant date fair value for each stock option using the Black-Scholes option-pricing model. For restricted stock awards and restricted stock unit awards, the Company estimates the value of each award using intrinsic value, which is based on the value of the underlying common stock less any purchase price. On the date of adoption, the Company estimated the fair value for all unvested non-employee stock options and restricted shares. The unvested stock-based compensation will be recorded over the remaining requisite service period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:24pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:24pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements &#x2013; Issued But Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"/&gt;In August 2018, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU No. 2018-13, &lt;i style="font-style:italic;"&gt;Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement &lt;/i&gt;(&#x201c;ASU 2018-13&#x201d;), which modifies certain disclosure requirements on fair value measurements. The amendments regarding changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements and the narrative description of measurement uncertainty are required to be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments are required to be applied retrospectively to all periods presented upon their effective date. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019 and interim periods within those years. The Company does not anticipate a material impact to disclosures as a result of the adoption of ASU 2018-13.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;i style="font-style:italic;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments &lt;/i&gt;(&#x201c;ASU 2016-13&#x201d;). The standard requires that a financial asset or a group of financial assets measured at amortized cost basis to be presented at the net amount expected to be collected. Under current GAAP, a company only considered past events and current conditions in measuring an incurred loss. Under ASU 2016-13, the information that a company must consider is broadened in developing an expected credit &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;loss estimate for assets measured either collectively or individually. The use of forecasted information incorporates more timely information in the estimate of expected credit loss. The new guidance will be effective for annual and interim periods beginning after December 15, 2019. Early adoption is permitted for annual and interim periods beginning after December 15, 2018. The guidance is applied using a modified retrospective, or prospective approach, depending on a specific amendment. The Company does not anticipate a material impact on its consolidated financial statements as a result of the adoption of ASU 2016-13.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Tb_WN2HbNItwE26N5Sh8yOPaQ">&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;) have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2018 (the &#x201c;Annual Report&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The unaudited condensed consolidated financial statements include the accounts of Editas Medicine, Inc. and its wholly owned subsidiary, Editas Securities Corporation. All intercompany transactions and balances of the subsidiary have been eliminated in consolidation. In the opinion of management, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the results for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The three months ended September 30, 2019 and 2018 are referred to as the third quarter of 2019 and 2018, respectively. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Tb_tgMUttXIRkqfbRUIpjkLSg">&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements &#x2013;Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Leases &lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Effective January 1, 2019, the Company adopted Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02, &lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt; (Topic 842) (&#x201c;ASC 842&#x201d;), which amends a number of aspects of lease accounting and requires entities to recognize right-of-use assets and operating lease liabilities on the balance sheet. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"&gt;At the inception of an arrangement the Company determines whether the arrangement contains a lease. If a lease is identified in an arrangement, the Company recognizes a right-of-use asset and liability on its balance sheet and determines whether the lease should be classified as a finance or operating lease. The Company does not recognize assets or liabilities for leases with lease terms of less than 12 months. Lease payments for short-term leases are recorded to operating expense on a straight-line basis over the lease term and variable lease payments are recorded in the period in which the obligation for those payments is incurred. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"&gt;A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to the Company by the end of the lease term, (ii) the Company holds an option to purchase the leased asset that it is reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, and (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no alternative use at the end of the lease term. All other leases are recorded as operating leases.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Finance and operating lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the rate is not readily determinable, the Company utilizes its incremental borrowing rate at the lease commencement date. Operating lease assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 9pt 0pt;"&gt;straight-line method as an operating expense over the lease term. Finance lease assets are amortized to depreciation expense using the straight-line method over the shorter of the useful life of the related asset or the lease term. Finance lease payments are bifurcated into (i) a portion that is recorded as imputed interest expense and (ii) a portion that reduces the finance liability associated with the lease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"&gt;The Company does not separate lease and non-lease components when determining which lease payments to include in the calculation of its lease assets and liabilities. Variable lease payments are expensed as incurred. If a lease includes an option to extend or terminate the lease, the Company reflects the option in the lease term if it is reasonably certain it will exercise the option.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"&gt;The Company elected the modified-retrospective transition method, pursuant to which the Company recognized a cumulative-effect adjustment of $0.8 million to the opening balance of accumulated deficit on January 1, 2019 associated with de-recognizing the net asset balance recorded in property and equipment, net and the offsetting construction financing lease liability related to the Company&#x2019;s headquarters which was previously accounted for under the built-to-suit guidance in Accounting Standards Codification (&#x201c;ASC&#x201d;) 840, &lt;i style="font-style:italic;"&gt;Leases &lt;/i&gt;(&#x201c;ASC 840&#x201d;). This resulted in a reversal of $32.6 million from total assets and $33.4 million from total liabilities. All prior period balances are presented in accordance with ASC 840. As of January 1, 2019, the Company recorded a right-of-use asset of $19.5 million and lease liability of $19.7 million associated with the adoption of ASC 842. In addition, the Company elected to adopt the package of three practical expedients for leases that commenced prior to January 1, 2019, allowing it not to reassess (i) whether any expired or existing contracts contain leases, (ii) the lease classification for any expired or existing leases and (iii) the initial indirect costs for any existing leases. The Company did not elect the hindsight practical expedient &lt;span style="white-space:pre-wrap;"&gt;which allows the Company to reassess the lease term as it was not relevant to the Company&#x2019;s leases.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Stock-Based Compensation Expense &lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Effective January 1, 2019, the Company adopted ASU No. 2018-07, &lt;i style="font-style:italic;"&gt;Compensation &#x2013; Stock Compensation: Improvements to Nonemployee Share-Based Payment Accounting &lt;/i&gt;(&#x201c;ASU 2018-07&#x201d;), which simplified the accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expands the scope of ASC 718, &lt;i style="font-style:italic;"&gt;Compensation &#x2013; Stock Compensation &lt;/i&gt;(&#x201c;ASC 718&#x201d;), which supersedes the guidance in ASC 505-50, &lt;i style="font-style:italic;"&gt;Equity-Based Payments to Non-Employees &lt;/i&gt;(&#x201c;ASC 505-50&#x201d;). In accordance with the new guidance, the Company accounts for share-based payments to non-employees by recognizing stock-based compensation expense equal to the grant date fair value of the share-based payment ratably over the requisite service period. The Company estimates the grant date fair value for each stock option using the Black-Scholes option-pricing model. For restricted stock awards and restricted stock unit awards, the Company estimates the value of each award using intrinsic value, which is based on the value of the underlying common stock less any purchase price. On the date of adoption, the Company estimated the fair value for all unvested non-employee stock options and restricted shares. The unvested stock-based compensation will be recorded over the remaining requisite service period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:24pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:24pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements &#x2013; Issued But Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"/&gt;In August 2018, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU No. 2018-13, &lt;i style="font-style:italic;"&gt;Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement &lt;/i&gt;(&#x201c;ASU 2018-13&#x201d;), which modifies certain disclosure requirements on fair value measurements. The amendments regarding changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements and the narrative description of measurement uncertainty are required to be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments are required to be applied retrospectively to all periods presented upon their effective date. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019 and interim periods within those years. The Company does not anticipate a material impact to disclosures as a result of the adoption of ASU 2018-13.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;i style="font-style:italic;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments &lt;/i&gt;(&#x201c;ASU 2016-13&#x201d;). The standard requires that a financial asset or a group of financial assets measured at amortized cost basis to be presented at the net amount expected to be collected. Under current GAAP, a company only considered past events and current conditions in measuring an incurred loss. Under ASU 2016-13, the information that a company must consider is broadened in developing an expected credit &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;loss estimate for assets measured either collectively or individually. The use of forecasted information incorporates more timely information in the estimate of expected credit loss. The new guidance will be effective for annual and interim periods beginning after December 15, 2019. Early adoption is permitted for annual and interim periods beginning after December 15, 2018. The guidance is applied using a modified retrospective, or prospective approach, depending on a specific amendment. The Company does not anticipate a material impact on its consolidated financial statements as a result of the adoption of ASU 2016-13.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="As_Of_1_1_2019_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9DeFqajq70i8txpvpYC8_Q"
      decimals="-5"
      id="Narr_Mm7lLmZEV0aN6PGpvsTtlQ"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">800000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:Assets
      contextRef="As_Of_1_1_2019_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_YkEer4ZbSEqfJGFr2l-94A"
      decimals="-5"
      id="Narr_6F05i4M4r0ueux1EUKdQCQ"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">32600000</us-gaap:Assets>
    <us-gaap:Liabilities
      contextRef="As_Of_1_1_2019_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_YkEer4ZbSEqfJGFr2l-94A"
      decimals="-5"
      id="Narr_eUQ0vbzgF0aiF_c9y9YMCg"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">33400000</us-gaap:Liabilities>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_1_1_2019_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_YkEer4ZbSEqfJGFr2l-94A"
      decimals="-5"
      id="Narr_7KMNhXMWV0Ka7NndmP8Hrw"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">19500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_1_1_2019_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_YkEer4ZbSEqfJGFr2l-94A"
      decimals="-5"
      id="Narr_xUPK7Fq5ZkmUP6J_Q07XvQ"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">19700000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeasePracticalExpedientsPackage
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Narr_YHzGm5Ci9EGU6gh-mm5uLw">true</us-gaap:LeasePracticalExpedientsPackage>
    <us-gaap:LeasePracticalExpedientUseOfHindsight
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Narr_aRcstP91PkCfwgrNwpvmhA">false</us-gaap:LeasePracticalExpedientUseOfHindsight>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Tb_6GOs_j_K_UKPpKOezxwLuA">&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;3. Cash Equivalents, Marketable Securities and Equity Securities &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Cash equivalents, marketable securities and equity securities consisted of the following at September 30, 2019 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:51.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Cash equivalents and marketable securities:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 104,772&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 104,772&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;U.S. Treasuries&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 83,564&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 83,587&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Government agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 144,241&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 144,257&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Equity securities included in other non-current assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Corporate equity securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,667&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,667&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 24pt;"&gt;Total &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 336,244&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 336,283&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:24pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Cash equivalents, marketable securities and equity securities consisted of the following at December 31, 2018 (in thousands):&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:51.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Cash equivalents and marketable securities:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 130,049&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 130,049&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;U.S. Treasuries&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 208,754&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (24)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 208,730&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Government agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,940&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,935&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Equity securities included in other non-current assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Corporate equity securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,667&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,667&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 24pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 372,410&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (29)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 372,381&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:24pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;At September 30, 2019, the Company held five securities that were in an unrealized loss position. The aggregate fair value of securities held by the Company in an unrealized loss position for less than 12 months at September 30, 2019 was $51.9 million, and there were no securities held by the Company in an unrealized loss position for more than 12 months. Pursuant to the adoption of ASU No. 2016-01, &lt;i style="font-style:italic;"&gt;Recognition and Measurement of Financial Assets and Financial Liabilities&lt;/i&gt;, the Company records changes in the fair value of its investments in corporate equity securities to &#x201c;Other (expense) income, net&#x201d; in the Company&#x2019;s condensed consolidated statements of operations. The Company records unrealized gains (losses) on available-for-sale debt securities as a component of accumulated other comprehensive income (loss) until such gains and losses are realized. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;As of September 30, 2019, the Company did not intend to sell, and was not more likely than not required to sell, the debt securities in an unrealized loss position before recovery of their amortized cost bases. Furthermore, the Company has determined that there were no material changes in the credit risk of the debt securities. As a result, the Company determined it did not hold any marketable securities with any other-than-temporary impairment as of September 30, 2019. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;There were no realized gains or losses on available-for-sale securities during the nine months ended September 30, 2019 or 2018. &lt;/p&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Tb_C64Kwb2pkk-60p_cWZndDA">&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Cash equivalents, marketable securities and equity securities consisted of the following at September 30, 2019 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:51.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Cash equivalents and marketable securities:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 104,772&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 104,772&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;U.S. Treasuries&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 83,564&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 83,587&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Government agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 144,241&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 144,257&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Equity securities included in other non-current assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Corporate equity securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,667&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,667&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 24pt;"&gt;Total &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 336,244&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 336,283&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:24pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Cash equivalents, marketable securities and equity securities consisted of the following at December 31, 2018 (in thousands):&lt;b style="font-weight:bold;"&gt;&lt;br/&gt;&lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:51.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Cash equivalents and marketable securities:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 130,049&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 130,049&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;U.S. Treasuries&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 208,754&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (24)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 208,730&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Government agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,940&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,935&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Equity securities included in other non-current assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Corporate equity securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,667&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,667&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:51.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 24pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 372,410&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (29)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 372,381&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_9_30_2019_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_715p9lT5NU-M643EcMceow"
      decimals="-3"
      id="Tc_yruINJ63KEywesZRr-Xw8Q_5_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">104772000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_9_30_2019_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_715p9lT5NU-M643EcMceow"
      decimals="-3"
      id="Tc_00gP4tyS9kaIZ_PQJLyiDw_5_12"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">104772000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_9_30_2019_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USTreasurySecuritiesMember_zC8nQ0u0v0SygQronrDnrg"
      decimals="-3"
      id="Tc_I0vTsnE7XEqxARtKrEJMJQ_6_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">83564000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_9_30_2019_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USTreasurySecuritiesMember_zC8nQ0u0v0SygQronrDnrg"
      decimals="-3"
      id="Tc_H_dEQpPePk2itE8fubhAeQ_6_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">23000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_9_30_2019_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USTreasurySecuritiesMember_zC8nQ0u0v0SygQronrDnrg"
      decimals="-3"
      id="Tc_hJIEMPo4vEeUvVKrwwbbXg_6_12"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">83587000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_9_30_2019_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember_A5vc1SsXOE2RfS4UDgR6RA"
      decimals="-3"
      id="Tc_E1WMVWVP30KXzWkGaf2kHA_7_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">144241000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_9_30_2019_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember_A5vc1SsXOE2RfS4UDgR6RA"
      decimals="-3"
      id="Tc_fxAXP64sEkS_olrN6SYCJg_7_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">16000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_9_30_2019_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember_A5vc1SsXOE2RfS4UDgR6RA"
      decimals="-3"
      id="Tc_b6rpzoizR0Ojn0ub6cnxSg_7_12"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">144257000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="As_Of_9_30_2019_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember_p7E6BE0SyUaMQWxS2Qggjw"
      decimals="-3"
      id="Tc_9WWJenTkcEy3w-DhrW13kQ_9_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">3667000</us-gaap:EquitySecuritiesFvNiCost>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="As_Of_9_30_2019_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember_p7E6BE0SyUaMQWxS2Qggjw"
      decimals="-3"
      id="Tc_suuAapnigU61pxBeZHlroQ_9_12"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">3667000</us-gaap:EquitySecuritiesFvNi>
    <edit:MarketableSecuritiesAmortizedCost
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_tEsdOvOjyUCVD2LzeUTFUg_10_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">336244000</edit:MarketableSecuritiesAmortizedCost>
    <edit:MarketableSecuritiesUnrealizedGain
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_g0YBkpJEsU-5Na7rOazWxQ_10_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">39000</edit:MarketableSecuritiesUnrealizedGain>
    <us-gaap:MarketableSecurities
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_JeE-TxCVZUq4ZnXXAQwadw_10_12"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">336283000</us-gaap:MarketableSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2018_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_TGB4lxKzZkuI8R6wI2ygoQ"
      decimals="-3"
      id="Tc_2C08MW1w30ilya4qNvTpHQ_5_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">130049000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2018_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_TGB4lxKzZkuI8R6wI2ygoQ"
      decimals="-3"
      id="Tc_ICRHGmneEUKH2SVI993Hqg_5_12"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">130049000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2018_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USTreasurySecuritiesMember_szWaKGRTnEi252qXZlUVrg"
      decimals="-3"
      id="Tc_-mC4tFbimESQg1Ko4Jx0Ng_6_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">208754000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2018_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USTreasurySecuritiesMember_szWaKGRTnEi252qXZlUVrg"
      decimals="-3"
      id="Tc_xcpODkkQsEOTkCY3mwTiLA_6_9"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">24000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2018_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USTreasurySecuritiesMember_szWaKGRTnEi252qXZlUVrg"
      decimals="-3"
      id="Tc_-TRTIh4ce0mwhEt4AYTPFg_6_12"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">208730000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2018_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember_KrXYO9EUiEyt_axAoghfkQ"
      decimals="-3"
      id="Tc__tQeIhfL40eFSt83NhN0wg_7_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">29940000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2018_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember_KrXYO9EUiEyt_axAoghfkQ"
      decimals="-3"
      id="Tc_OFUPCCe8Lkqt2zGjlnEb8g_7_9"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2018_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember_KrXYO9EUiEyt_axAoghfkQ"
      decimals="-3"
      id="Tc_iZJUu0fAYEut46SBpvdIkA_7_12"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">29935000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="As_Of_12_31_2018_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember__QoCNZ0YnEedNiRHAIMKIA"
      decimals="-3"
      id="Tc_bxUVBMLLf0qDR6bhYyMZEA_9_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">3667000</us-gaap:EquitySecuritiesFvNiCost>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="As_Of_12_31_2018_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember__QoCNZ0YnEedNiRHAIMKIA"
      decimals="-3"
      id="Tc_aTKg4VK1nkq_W8sjQ_0P-Q_9_12"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">3667000</us-gaap:EquitySecuritiesFvNi>
    <edit:MarketableSecuritiesAmortizedCost
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_KivQU_GExEu8KxV4IADesQ_10_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">372410000</edit:MarketableSecuritiesAmortizedCost>
    <edit:MarketableSecuritiesUnrealizedLoss
      contextRef="Duration_1_1_2018_To_12_31_2018_zrodnEw_VUizLBhcAZpOsg"
      decimals="-3"
      id="Tc_yBeFi6cK4kqVAk4tYIdE0Q_10_9"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">29000</edit:MarketableSecuritiesUnrealizedLoss>
    <us-gaap:MarketableSecurities
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_UbJlzaFqAUGu1YKl2c89Yg_10_12"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">372381000</us-gaap:MarketableSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="INF"
      id="Narr_4VRHxdSAVUig1dgrcYOiaQ"
      unitRef="Unit_Standard_item_rl1kcwMXZkCIZ-rzvXYVSA">5</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-5"
      id="Narr_GkTFRB68R0OVVzVjYbfPAQ"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">51900000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="0"
      id="Narr_SIF4DtkSfEKIuguyymOXyQ"
      unitRef="Unit_Standard_item_rl1kcwMXZkCIZ-rzvXYVSA">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-5"
      id="Narr_zFXj0XBubUqlWHj3_aBuhg"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-5"
      id="Narr_kTP1N0ttEkCTC450lHJRYg"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Tb__L-S_yzHU0WhFoGSsQ4u0g">&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;4. Fair Value Measurements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Assets measured at fair value on a recurring basis as of September 30, 2019 were as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;  &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in&#160;Active&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Markets&#160;for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical&#160;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:54.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Financial Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 104,772&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 104,772&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;U.S. Treasuries&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 83,587&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 83,587&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Government agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 144,257&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 144,257&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Restricted cash and other non-current assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Corporate equity securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,667&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,667&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,619&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,619&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 337,902&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 334,235&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,667&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Assets measured at fair value on a recurring basis as of December&#160;31, 2018 were as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:-0.020606995%;padding-left:0pt;padding-right:0pt;width:100.04%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:54.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in&#160;Active&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Markets&#160;for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical&#160;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:54.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Financial Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 130,049&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 130,049&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;U.S. Treasuries&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,487&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,487&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;U.S. Treasuries&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 204,243&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 204,243&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Government agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,935&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,935&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Restricted cash and other non-current assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Corporate equity securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,667&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,667&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,619&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,619&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 374,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 370,333&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,667&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;There were no transfers between fair value measurement levels during the nine months ended September 30, 2019.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Tb_4HDVtoj_HkK33c41D95nEA">&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Assets measured at fair value on a recurring basis as of September 30, 2019 were as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;  &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in&#160;Active&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Markets&#160;for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical&#160;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:54.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Financial Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 104,772&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 104,772&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;U.S. Treasuries&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 83,587&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 83,587&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Government agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 144,257&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 144,257&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Restricted cash and other non-current assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Corporate equity securities&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,667&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,667&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,619&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,619&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 337,902&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 334,235&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,667&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Assets measured at fair value on a recurring basis as of December&#160;31, 2018 were as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:-0.020606995%;padding-left:0pt;padding-right:0pt;width:100.04%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:54.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in&#160;Active&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Markets&#160;for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical&#160;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:54.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Financial Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 130,049&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 130,049&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;U.S. Treasuries&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,487&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,487&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;U.S. Treasuries&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 204,243&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 204,243&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Government agency securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,935&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,935&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Restricted cash and other non-current assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Corporate equity securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,667&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,667&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,619&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,619&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 374,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 370,333&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,667&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_9_30_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_HSTFzN1cUEGtvQd0OurLMA"
      decimals="-3"
      id="Tc_Yshd_OYqIkWWQgf4bJk1ew_7_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">104772000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_9_30_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_1OsS_I8aF0i-YCo7hdwLcg"
      decimals="-3"
      id="Tc_IeztJUM0h0-q_gi8idXbaA_7_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">104772000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_9_30_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_raku3VZFuke0alBYy9wNpQ"
      decimals="-3"
      id="Tc_Npxy0oReSUCnaA55ISdvWw_9_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">83587000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_9_30_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_XK4JhgmU5UmZfBzH85zD9Q"
      decimals="-3"
      id="Tc_I9o8bXGl3E-0X1y4g_HSsA_9_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">83587000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_9_30_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_CKHO6pDGjkSBIsBw4K4g0A"
      decimals="-3"
      id="Tc_hUQNQGlNV0uaX84DAlKQtw_10_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">144257000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_9_30_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_4CMDEP4Sg0WuJwCo3kj0GA"
      decimals="-3"
      id="Tc_tK9ohXMHQEW7_peiKJLsXQ_10_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">144257000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="As_Of_9_30_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember_PL8oKMla10qvL9b1_2n3mg"
      decimals="-3"
      id="Tc_zBuqDVwYk0eXNWCKiwMoug_12_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">3667000</us-gaap:EquitySecuritiesFvNiCost>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="As_Of_9_30_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember_Ax4WwMw3P0elxef4gwaY2A"
      decimals="-3"
      id="Tc_YEMGr90f6kCWe6bVAVkfGg_12_9"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">3667000</us-gaap:EquitySecuritiesFvNiCost>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="As_Of_9_30_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_HSTFzN1cUEGtvQd0OurLMA"
      decimals="-3"
      id="Tc_5LJ0UrmNBEGv7z2tR5kZgQ_13_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">1619000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="As_Of_9_30_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_1OsS_I8aF0i-YCo7hdwLcg"
      decimals="-3"
      id="Tc_aVgWQWuXME-etuZmrs65Wg_13_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">1619000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_9_30_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_NK-fhmMl0UyDtfCFPjlwog"
      decimals="-3"
      id="Tc_senYD8yNyku5G_GFnCEYFg_14_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">337902000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_9_30_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_g8uPs61fLU-iP_S2ZoytqQ"
      decimals="-3"
      id="Tc_dHGx2Gx5WEG0DmEcNRNOJw_14_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">334235000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_9_30_2019_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_lwnhc_OPt02yW0Img1-sjA"
      decimals="-3"
      id="Tc_mOlsZc2mgESZabFv3hsWBw_14_9"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">3667000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_hhO6rw5Ou0moEGgauWWhJg"
      decimals="-3"
      id="Tc_JqYw0GHRekuC1iEFd8QaNA_7_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">130049000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_iX-oyBzhE0myrSoqcNnSbw"
      decimals="-3"
      id="Tc_kOcguPVnrE2cA5bXiDnn1A_7_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">130049000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USTreasurySecuritiesMember_uFibcieSKUaoBtsZ19bZYg"
      decimals="-3"
      id="Tc_3-QnBz7jzUiYawvwRJridw_8_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">4487000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_USTreasurySecuritiesMember_iVSO5aonCEuoXoKsnk9nUw"
      decimals="-3"
      id="Tc_5ysDQHb4sky3Hcg7yP0nWA_8_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">4487000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_BE9yOipzFkWXXQU9jYhEMw"
      decimals="-3"
      id="Tc_hxEXmruBMEm3us-Jftd-lA_10_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">204243000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember_hb4a5ntSUEWmOa45e5et6w"
      decimals="-3"
      id="Tc_VM-m4BqCyEWpYtSjKQ25xw_10_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">204243000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_uKPmiw8XwU2KdTnZuxwZtw"
      decimals="-3"
      id="Tc_KdEiLtOIGkCxGvOmBR5Mfw_11_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">29935000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_42lI8pTd2ECGwclymtSQgw"
      decimals="-3"
      id="Tc_0iVAZ9WP10aaqU0dGStYMQ_11_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">29935000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember_jT19XV8GLEu0RJbMbTBl4Q"
      decimals="-3"
      id="Tc_3jWwnr9VK0GIYUgkoEqkmw_13_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">3667000</us-gaap:EquitySecuritiesFvNiCost>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember_6CXnaUT_fUyJlybGjgEz6w"
      decimals="-3"
      id="Tc_7ob_lulOkE6RD87gyC_zpg_13_9"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">3667000</us-gaap:EquitySecuritiesFvNiCost>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_hhO6rw5Ou0moEGgauWWhJg"
      decimals="-3"
      id="Tc_kIGTUrWaLk-hGgYZ5QXUhg_14_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">1619000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_iX-oyBzhE0myrSoqcNnSbw"
      decimals="-3"
      id="Tc_Vea2NgTbgkOCfzpV8enkrg_14_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">1619000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2018_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_MsohzaC6nEGF9IKQbiwTLw"
      decimals="-3"
      id="Tc_a0d8dY7YE0yuDEBvv7lrTg_15_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">374000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_e71_GfWuOkmuF7nNBglBJQ"
      decimals="-3"
      id="Tc_kKLDaaVz9UuszOotb_n1Vw_15_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">370333000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_C2kDm64hKk6izw1I5D_EAw"
      decimals="-3"
      id="Tc_7n2kDHAQYEmi8_RgDsQEVg_15_9"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">3667000</us-gaap:AssetsFairValueDisclosure>
    <edit:FairValueAssetsAndLiabilitiesTransfers
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="INF"
      id="Narr_G6Sr5XII_0KFMzptFRoxkw"
      unitRef="Unit_Standard_item_rl1kcwMXZkCIZ-rzvXYVSA">0</edit:FairValueAssetsAndLiabilitiesTransfers>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Tb_obpeRYGmOUS1cXAAGxKLew">&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;5. Accrued Expenses&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Accrued expenses consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:10.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:normal;width:27.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:normal;width:13.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:normal;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:normal;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:normal;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Employee related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,134&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,201&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Intellectual property and patent related fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,645&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:10.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,939&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Process and platform development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,171&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,044&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Professional service expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 853&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:10.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 475&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Other expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 335&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 404&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Sublicensing expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,750&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Total accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,138&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,813&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:10.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Tb_LZNwjLSPaECxSSJyxpAnbg">&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Accrued expenses consisted of the following (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:10.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:normal;width:27.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:normal;width:13.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:normal;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:normal;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:normal;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Employee related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,134&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,201&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Intellectual property and patent related fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,645&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:10.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,939&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Process and platform development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,171&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,044&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Professional service expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 853&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:10.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 475&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Other expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 335&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 404&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Sublicensing expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,750&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Total accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:11.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,138&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:1.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:normal;width:10.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,813&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:normal;width:10.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc__VCx3vaxrUap2d1HXg9F8Q_4_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">4134000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_SDyde_uFA0ySzCxOj-YQBA_4_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">5201000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <edit:AccruedIntellectualPropertyFees
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_XBfbTdGIr0WL3YQXuSVHTQ_5_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">1645000</edit:AccruedIntellectualPropertyFees>
    <edit:AccruedIntellectualPropertyFees
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_UHB1nDQk80eHN2PzvGpDTw_5_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">1939000</edit:AccruedIntellectualPropertyFees>
    <edit:ProcessAndPlatformDevelopmentCostsCurrent
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_VpY8PmjW3EOL5Gn-SqjUrQ_6_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">1171000</edit:ProcessAndPlatformDevelopmentCostsCurrent>
    <edit:ProcessAndPlatformDevelopmentCostsCurrent
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_VCXH9UjZ_E6n9jxnfDMvhw_6_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">1044000</edit:ProcessAndPlatformDevelopmentCostsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_7K6Spl38v0uz5jeAneniAg_7_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">853000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_f4RySEGuskKYvCRPuwu_RQ_7_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">475000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_thxk9jIux0OhEYELP94rfQ_8_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">335000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_PnQ79waiuk-0Y5EB74gVQQ_8_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">404000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <edit:SublicensingAndSuccessPaymentExpenses
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_BpPqb1LKd0ehHGOjCWdfFQ_9_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">3750000</edit:SublicensingAndSuccessPaymentExpenses>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_DIoYN0JIM0STSTcG4V2Cyg_10_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">8138000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_zRcPiXtqNUmzB4k7iVB39A_10_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">12813000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Tb_kexGQf5vS02dSmRFV1slzg">&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;6. Property and Equipment, net&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Property and equipment, net consisted of the following (in thousands):&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:27.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,892&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 974&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 289&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 826&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 733&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Construction-in-progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 451&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Furniture and office equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 166&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 166&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 118&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 118&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Building&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,167&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total property and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,535&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 47,365&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (6,460)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (7,133)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,075&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40,232&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;For additional information related to the removal of the building asset, refer to Note 7.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Tb_ey5CfoZpEE-2gumqB4uDeQ">&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Property and equipment, net consisted of the following (in thousands):&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:27.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,892&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 974&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 289&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 826&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 733&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Construction-in-progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 451&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Furniture and office equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 166&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 166&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 118&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 118&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Building&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35,167&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total property and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,535&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 47,365&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (6,460)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (7,133)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,075&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40,232&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_9_30_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_edit_LaboratoryEquipmentMember_AVb7DBqk10uTIad92YeUNQ"
      decimals="-3"
      id="Tc_DS92dTw1Xk-2RfeCSHhU-g_4_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">14000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_edit_LaboratoryEquipmentMember_jNlcWv83W0a_5q-w_7GeGw"
      decimals="-3"
      id="Tc_zaSz9C0tiU2qOdHdw7rZgw_4_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">10892000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_9_30_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_SBBNY-YWV0KhHhYb30myIg"
      decimals="-3"
      id="Tc_W7G_RUz1uUSrbWMnYuIPpA_5_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">974000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_U6z0qkSp50GiyOi7BDlDRA"
      decimals="-3"
      id="Tc_ZafL4udyWkuic0C4R-j7Zg_5_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">289000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_9_30_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_guUaGiUbe0iwk4T9ixbwSg"
      decimals="-3"
      id="Tc_DcVVImLUD0ylfiAYpX0S4Q_6_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">826000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_VqUZ0FvBIkWcvm4vgvlr_A"
      decimals="-3"
      id="Tc_svsCCq45V0W1wNB1di_2iw_6_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">733000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_9_30_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_H7ziJoGIK0maKshFPMdlhw"
      decimals="-3"
      id="Tc_uWTU3WxGMUyisnl9d-DaeA_7_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">451000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_9_30_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_xWgifcmBZESG7eQtghdpug"
      decimals="-3"
      id="Tc_AnJaP3jv0UOgZV7vhHCY4A_8_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">166000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_DjJ0hyYREUOZJlShodxbbQ"
      decimals="-3"
      id="Tc_lVpf4VP_QEyuyFAdgVz1yg_8_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">166000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_9_30_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_ydne4f47BUCTZCvWtZzh0Q"
      decimals="-3"
      id="Tc_aWTLTkeYxka_5uGXMwHAGA_9_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">118000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_MnMT4XcDHE2E28jOhj7_4w"
      decimals="-3"
      id="Tc_JR7xpch7Tk-A2jRziEeCqQ_9_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">118000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2018_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember_qQjfOtD8P0q3C93XNNQvxA"
      decimals="-3"
      id="Tc_YtehB3T6QUqtwjYB7v8dnA_10_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">35167000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_RVsC-lZa7UCJOZb0AMa2lw_11_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">16535000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_fFN0YgsF506wmNMSATtG7g_11_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">47365000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_WtJ5liQW-02iEzYTRouDSQ_12_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">6460000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_2gKBlYW8bUClal-TtjRy9A_12_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">7133000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_o7zK4heOCUmSfI2rQvzFTQ_13_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">10075000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_WmYeU5B2DUmFRwkt6Vh2Pw_13_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">40232000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Tb_UD5TkFcegk-Tlcx1TtoDgg">&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;7. Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"/&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;In 2016, the Company entered into a lease agreement for 59,783 square feet of office and laboratory space located on Hurley Street in Cambridge, Massachusetts. The term of the lease began on October 1, 2016 and continues until October 2023. The Company has the &lt;span style="white-space:pre-wrap;"&gt;option to extend&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt; the lease for an additional &lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt;five-year&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt; term at market-based rates. The base rent payments commenced in November 2016 and continue through the term of the lease and are subject to increases over the term of the lease. The Company subleased approximately 10,000 square feet of the Hurley Street premises pursuant to a sublease, which commenced in February 2017 and terminated in June 2018. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;In accordance with ASC 840 and for accounting purposes, the Company was deemed the owner of the building during the construction period due to the fact that the Company was involved in the construction project, including having responsibilities for cost overruns for planned tenant improvements that did not qualify as &#x201c;normal tenant improvements&#x201d; under the lease accounting guidance&lt;i style="font-style:italic;"&gt;. &lt;/i&gt;Throughout the construction period, the Company recorded the project construction costs incurred as an asset, along with a corresponding construction financing lease obligation, on its balance sheet for the total amount of the project costs incurred whether funded by the Company or the landlord. Construction was completed in October 2016 and the Company considered the requirements for sale-leaseback accounting treatment, which included an evaluation of whether all risks of ownership had transferred back to the landlord, as evidenced by a lack of continuing involvement in the leased property. The Company determined that the arrangement did not qualify for sale-leaseback accounting treatment, the building asset would remain on the Company&#x2019;s balance sheet at its historical cost, and such asset would be depreciated over its estimated useful life of 30 years. The Company bifurcated its future lease payments pursuant to the lease into (i) a portion that was allocated to the building and (ii) a portion that was allocated to the land on which the building is located, which was recorded as rental expense. Although the Company did not begin making lease payments pursuant to the lease until November 2016, the portion of the lease obligation allocated to the land was treated for accounting purposes as an operating lease that commenced upon execution of the lease in February 2016. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Effective January 1, 2019, the Company adopted ASC 842 and derecognized the balances relating to the building, accumulated depreciation and the corresponding construction financing lease as summarized in the table below (in thousands). In applying the ASC 842 transition guidance, the Company determined that the lease should be classified as an operating lease and recorded a right-of-use asset and lease liability on the effective date, accordingly. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:middle;white-space:nowrap;width:23.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:middle;white-space:nowrap;width:23.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;January 1, 2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,627&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Other current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (1,014)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Construction financing lease obligation, net of current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (32,417)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Accumulated deficit &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 803&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;At adoption, the Company had two other operating leases for laboratory space. One of those leases, which commenced in April 2017, was amended in April 2018 and continues until March 2021. The second lease commenced in January 2018 and continues until June 2021. Base rent payments commenced at the beginning of each lease term and continue through the term of the respective lease. Base rent is also subject to increases over the term of the lease. In prior periods, the Company accounted for these leases as operating leases under ASC 840 and recognized straight-line rent expense over the remaining non-cancellable lease terms. As part of its adoption of ASC 842, effective January 1, 2019, the Company elected to apply the package of practical expedients which, among other things, allowed the Company to carry forward its existing lease classification under ASC 840. Additionally, the Company recorded right-of-use assets and lease liabilities for these operating leases on the effective date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The Company has two other operating leases for manufacturing space that commenced in July 2019. The leases continue until December 2020 and March 2024, respectively. The lease that continues until March 2024 is subject to base rent increases over the term of the lease and the lease that continues until December 2020 has a fixed base rent payment through the term of the lease. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The Company&#x2019;s leases are included on its condensed consolidated balance sheet as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:64.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:64.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:35.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:64.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;January 1,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:64.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:64.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Right-of-use asset&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,681&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,461&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:64.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Lease liability, current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (4,448)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (3,848)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:64.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Lease liability, noncurrent &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (13,202)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (15,909)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="background-color:#ffff00;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The following table contains a summary of the operating lease costs recognized under ASC 842 and other information pertaining to the Company&#x2019;s operating leases during the three and nine months ended September 30, 2019 (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:60.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:middle;width:19.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:middle;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:middle;width:17.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:60.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:auto;vertical-align:middle;width:39.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:60.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Operating lease costs&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,451&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,293&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Variable lease costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 276&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 804&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:60.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total lease costs&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,727&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,097&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Maturities of the Company&#x2019;s lease liabilities in accordance with ASC 842 as of September 30, 2019 were as follows (in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:21.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:middle;width:21.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Maturity of lease liabilities:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:middle;width:21.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,091&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,398&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,875&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,588&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,924&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,906&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (3,256)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total operating lease liabilities at September 30, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,650&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The weighted-average remaining lease terms are 3.7 years and the weighted-average discount rate is 9.27%.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Licensor Expense Reimbursement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The Company is obligated to reimburse The Broad Institute, Inc. (&#x201c;Broad&#x201d;) and the President and Fellows of Harvard College (&#x201c;Harvard&#x201d;) for expenses incurred by each of them associated with the prosecution and maintenance of the patent rights that the Company licenses from them pursuant to the license agreement by and among the Company, Broad and Harvard, including the interference and opposition proceedings involving patents licensed to the Company under the license agreement, and other license agreements between the Company and Broad. As such, the Company anticipates that it has a substantial commitment in connection with these proceedings until such time as these proceedings have been resolved, but the amount of such commitment is not determinable. During the three and nine months ended September 30, 2019, the Company recognized $3.1 million and $10.1 million in expense for such reimbursement, respectively. During the three and nine months ended September 30, 2018, the Company recognized $2.9 million and $11.0 million in expense for such reimbursement, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Success Payments &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;In 2016, the Company entered into patent license agreements with each of The General Hospital Corporation, d/b/a Massachusetts General Hospital (&#x201c;MGH&#x201d;), and Broad (collectively, the &#x201c;2016 License Agreements&#x201d;). Pursuant to the terms of the 2016 License Agreements, the Company is required to make certain success payments to MGH, Broad and Wageningen University (&#x201c;Wageningen&#x201d; and such payments, collectively, the &#x201c;Success Payments&#x201d;), payable in cash &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;or, at the Company&#x2019;s election, common stock in the case of MGH or, in the case of Broad and Wageningen, promissory notes payable in cash or, at the Company&#x2019;s election subject to certain conditions, common stock of the Company. The Success Payments are payable, if and when, the Company&#x2019;s market capitalization reaches specified thresholds for a specific period of time or upon a sale of the Company for consideration in excess of those thresholds (collectively, the &#x201c;Payment Conditions&#x201d;). &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The Success Payments were historically accounted for under the provisions of ASC 505-50. Effective January 1, 2019, the Company adopted ASU 2018-07, which expands the scope of ASC 718 and superseded ASC 505-50. In accordance with ASC 718, the Company will recognize a Success Payment when it becomes probable that the Payment Conditions will be met. However, the Company has the right to terminate any of the 2016 License Agreements at will upon written notice. Absent any of the Payment Conditions being achieved prior to termination, the Company would not be obligated to pay any Success Payments. As such, the Company will recognize the expense and liability associated with each Success Payment when it is probable that the amounts will become due. The Company records this expense as a research and development expense in its condensed consolidated statements of operations. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Research Funding Payments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-style:italic;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;In June 2018, the Company entered into a sponsored research agreement (the &#x201c;Sponsored Research Agreement&#x201d;) with Broad. Pursuant to the terms of the Sponsored Research Agreement, the Company is required to make certain research funding payments to Broad, payable by promissory note, cash or common stock. Under the Sponsored Research Agreement, the Company is obligated to make payments of research funding to Broad in the event the Company&#x2019;s market capitalization reaches specified thresholds ranging from a mid-nine digit dollar amount to a low-eleven digit dollar amount (&#x201c;Market Cap Research Funding&#x201d;) or a Company sale for consideration ranging from a mid-nine digit dollar amount to a low-eleven digit dollar amount (&#x201c;Company Sale Research Funding&#x201d; and, collectively with the Market Cap Research Funding, the &#x201c;Research Funding Payments&#x201d;). In connection with entering into the Sponsored Research Agreement, the Company confirmed that the first two Research Funding Payments of $5.0 million and $7.5 million were due and payable to Broad (the &#x201c;Initial Research Payments&#x201d;). &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Other than the Initial Research Payments, the Company is not required to make additional Research Funding Payments if the Company, whether directly or through its affiliates or sublicensees, is not researching, developing, or commercializing products based on or incorporating inventions developed under the Sponsored Research Agreement and exclusively licensed to the Company from Broad or based on or incorporating CRISPR technology owned, co-owned, or controlled by Broad and otherwise licensed to the Company, subject to certain exclusions. The Research Funding Payments were historically accounted for under the provisions of ASC Topic 505-50. Effective January 1, 2019, the Company adopted ASU 2018-07, which expands the scope of ASC 718 and superseded ASC 505-50. Under ASC 718, the Company will recognize the expenses and liability associated with each Research Funding Payment when it is probable that the amounts will become due. The Company records this expense as a research and development expense in its statements of operations. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;In June 2018, in connection with the Company&#x2019;s entry into the Sponsored Research Agreement and the trigger of the Initial Research Payments, the Company issued promissory notes in an aggregate principal amount of $12.5 million to Broad (the &#x201c;Initial Research Notes&#x201d;) bearing interest at a rate of 4.8% per annum, except with respect to $7.5 million of the principal, which would not start accruing interest until November 2018. The Company fully settled the outstanding principal and accrued interest on the Initial Research Notes by issuing 330,617 shares of common stock to Broad in June 2018.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Litigation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The Company is not a party to any litigation and did not have contingency reserves established for any litigation liabilities as of September 30, 2019 or December 31, 2018.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <edit:AreaOfLeasedSpace
      contextRef="As_Of_10_1_2016_srt_CounterpartyNameAxis_edit_HurleyStreetLeaseMember_2ldT7Pk_sEy-LRFeHacLUw"
      decimals="0"
      id="Narr_flrizsc2W0OJhSGZKj7E4w"
      unitRef="Unit_Standard_sqft_zyr2ZacpEkijqHVLi1q1mA">59783</edit:AreaOfLeasedSpace>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="Duration_1_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_edit_HurleyStreetLeaseMember_zmU6W-bAi0i3mDk8ot7nVw"
      id="Narr_km40cFzdZ0KBbkLJEbUccA">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_10_1_2016_srt_CounterpartyNameAxis_edit_HurleyStreetLeaseMember_2ldT7Pk_sEy-LRFeHacLUw"
      id="Narr_B3k3c8gj0ECqjRBGPyrgSg">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <edit:AreaOfLeasedSpace
      contextRef="As_Of_2_28_2017_srt_CounterpartyNameAxis_edit_FacilitySubleaseArrangementMember_7tYFtpo8HkifSJ3u_1lnhA"
      decimals="0"
      id="Narr_RqMGsXftzEuXoCVYms82yA"
      unitRef="Unit_Standard_sqft_zyr2ZacpEkijqHVLi1q1mA">10000</edit:AreaOfLeasedSpace>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_10_1_2016_To_10_1_2016_srt_CounterpartyNameAxis_edit_HurleyStreetLeaseMember_msxFNwKEn0ud3R-lueFJbQ"
      id="Narr_ZcufFjMEnE-huyP4NVV5UQ">P30Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Tb_c6yVsK13tUigZocVwPrFRA">&lt;p style="font-family:'Times New Roman';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:middle;white-space:nowrap;width:23.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:middle;white-space:nowrap;width:23.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;January 1, 2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,627&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Other current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (1,014)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Construction financing lease obligation, net of current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (32,417)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Accumulated deficit &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 803&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_1_1_2019_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_YkEer4ZbSEqfJGFr2l-94A"
      decimals="-3"
      id="Tc_9BFEd6zgmUqOFKpOVhM_6g_3_2"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">32627000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_1_1_2019_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_YkEer4ZbSEqfJGFr2l-94A"
      decimals="-3"
      id="Tc_vha--vT3SUS_9JNhqiXt1A_4_2"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-1014000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_1_1_2019_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_YkEer4ZbSEqfJGFr2l-94A"
      decimals="-3"
      id="Tc_-nsuZOhT-UiTx3wKQ2yxEQ_5_2"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">-32417000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_1_1_2019_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_YkEer4ZbSEqfJGFr2l-94A"
      decimals="-3"
      id="Tc_p4s9heUczEus3Ig57jmXXw_6_2"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">803000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <edit:LesseeOperatingLeaseLaboratorySpaceNumber
      contextRef="Duration_1_1_2019_To_1_1_2019_uaR1Uv2lmUWJZyFgpnp2JQ"
      decimals="INF"
      id="Narr_eWV8cR3WUUqiFulO5ktrZQ"
      unitRef="Unit_Standard_item_rl1kcwMXZkCIZ-rzvXYVSA">2</edit:LesseeOperatingLeaseLaboratorySpaceNumber>
    <edit:NumberOfOperatingLeasesForManufacturingSpace
      contextRef="Duration_7_1_2019_To_7_31_2019_-qHYqTPBg0-JDU51y1HWrQ"
      decimals="INF"
      id="Narr__UvCXCU5hEOhzznFwjdi8w"
      unitRef="Unit_Standard_lease_WLwIHlVjbEGdHYRUV0R8Yw">2</edit:NumberOfOperatingLeasesForManufacturingSpace>
    <edit:AssetsAndLiabilitiesLesseeOperatingLeaseTableTextBlock
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Tb_X1-VNQgNL0W9lX7EZaSFWA">&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The Company&#x2019;s leases are included on its condensed consolidated balance sheet as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:64.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:64.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:35.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:64.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;January 1,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:64.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;white-space:nowrap;width:64.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Right-of-use asset&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,681&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,461&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:64.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Lease liability, current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (4,448)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (3,848)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:64.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Lease liability, noncurrent &lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (13,202)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (15,909)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</edit:AssetsAndLiabilitiesLesseeOperatingLeaseTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_h6zlmOGtXkqK3_JMkZWH9A_4_2"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">17681000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_1_1_2019_GHVQq8gUCEOZOt-m471YvA"
      decimals="-3"
      id="Tc_QuEy2zhLDkyDAKdRYjN4ig_4_5"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">19461000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_1xboUfxyTEKxF8h8DclJ1w_5_2"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">4448000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_1_1_2019_GHVQq8gUCEOZOt-m471YvA"
      decimals="-3"
      id="Tc_wa4EWiJCVEaF3Xg3KnyZZg_5_5"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">3848000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_fIcE1Il3R0ebMrrgXAxjfQ_6_2"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">13202000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_1_1_2019_GHVQq8gUCEOZOt-m471YvA"
      decimals="-3"
      id="Tc_4V50yEmxnkirHs-dcX5sag_6_5"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">15909000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Tb_7rNQ-_aGo0Ox6qicguQHnw">&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The following table contains a summary of the operating lease costs recognized under ASC 842 and other information pertaining to the Company&#x2019;s operating leases during the three and nine months ended September 30, 2019 (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:60.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:middle;width:19.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:middle;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:middle;width:17.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:60.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:auto;vertical-align:middle;width:39.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:60.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Operating lease costs&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,451&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,293&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Variable lease costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 276&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 804&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:60.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total lease costs&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,727&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,097&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.19;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Maturities of the Company&#x2019;s lease liabilities in accordance with ASC 842 as of September 30, 2019 were as follows (in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:21.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:76.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:middle;width:21.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Maturity of lease liabilities:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:middle;width:21.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,091&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,398&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,875&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,588&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,924&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,906&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (3,256)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:76.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total operating lease liabilities at September 30, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:21.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,650&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Tb_irfKLo-41Ua1K2G7DexNWg">&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:60.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:middle;width:19.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:middle;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:middle;width:17.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:60.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:auto;vertical-align:middle;width:39.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:60.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Operating lease costs&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,451&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,293&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Variable lease costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 276&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 804&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:60.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Total lease costs&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,727&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,097&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw"
      decimals="-3"
      id="Tc_pvEEBPzQf0yFZ_2hCQ3CoA_3_2"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">1451000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_YO1uM4P9FEie8-eSu8LX8A_3_5"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">4293000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw"
      decimals="-3"
      id="Tc_FJLUczfrL0e4GOPtKK3E4w_4_2"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">276000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_gL7AsYzHyUagaUwuNuhpTg_4_5"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">804000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw"
      decimals="-3"
      id="Tc_N58P9_sfaEu1Ni4oICU9qw_5_2"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">1727000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_NnrcR1msZU2WsieyJp2I_A_5_5"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">5097000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_R2WZoo8T4ECV42Of4H_esA_3_2"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">1091000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_fMQc3QhcLEy6gCw_KfNUmA_4_2"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">6398000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_xMiFVym9z0CZiv4b5cy0wA_5_2"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">4875000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_Zg7dHF81PUG1NHTSJh7x9A_6_2"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">4588000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_lGaPUO8VK0CJR_C7MKjaGQ_7_2"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">3924000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_Tw85xGqji0S1YUecxakzxA_8_2"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">30000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc__hw-K-Pu3U-7KVZWlO6iRA_9_2"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">20906000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_cCXH6svF5EiG_bR_E1aHlQ_10_2"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">3256000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_bhcal9qFLEap_XOdghXHCw_11_2"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">17650000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      id="Narr_mNqxo7UNvk-yQTIi3pxF4w">P3Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="4"
      id="Narr_-xTKlKvJOkqDO-2KF-LcRw"
      unitRef="Unit_Standard_pure_E8xeiPkPjUOaCmQYBNvdag">0.0927</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_OtherCommitmentsAxis_edit_CommitmentToReimburseLicensorMember_DOloV0XhME-N4IXu1IWfqQ"
      decimals="-5"
      id="Narr_vB-NLN1_dk-QGxlwINgpEQ"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">3100000</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_OtherCommitmentsAxis_edit_CommitmentToReimburseLicensorMember_qcBes6J9yk26oesBBlSUnQ"
      decimals="-5"
      id="Narr_nMNEyRDTkkiz2f-8pHoFvQ"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">10100000</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="Duration_7_1_2018_To_9_30_2018_us-gaap_OtherCommitmentsAxis_edit_CommitmentToReimburseLicensorMember_KLzreovHakCeVBoLv9ifJA"
      decimals="-5"
      id="Narr_mcU6seBpNESdH9nJoUVDgA"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">2900000</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_OtherCommitmentsAxis_edit_CommitmentToReimburseLicensorMember_niHDm0_cQUaXcYlHB5oJPA"
      decimals="-5"
      id="Narr_rCf5d1gsjkmLRtRdgtiZcg"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">11000000.0</us-gaap:ProfessionalAndContractServicesExpense>
    <edit:FundingPaymentsDueAndPayableOne
      contextRef="As_Of_6_30_2018_srt_CounterpartyNameAxis_edit_BroadInstituteIncMember_us-gaap_OtherCommitmentsAxis_edit_ResearchFundingPaymentsMember_us-gaap_TypeOfArrangementAxis_edit_SponsoredResearchAgreementMember_7EHzXBh5f0uI6WsTuZTqoQ"
      decimals="-5"
      id="Narr_viQ7nwBuAEeIURZEJxRE6A"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">5000000.0</edit:FundingPaymentsDueAndPayableOne>
    <edit:FundingPaymentsDueAndPayableTwo
      contextRef="As_Of_6_30_2018_srt_CounterpartyNameAxis_edit_BroadInstituteIncMember_us-gaap_OtherCommitmentsAxis_edit_ResearchFundingPaymentsMember_us-gaap_TypeOfArrangementAxis_edit_SponsoredResearchAgreementMember_7EHzXBh5f0uI6WsTuZTqoQ"
      decimals="-5"
      id="Narr_QdtaC6YWqEGi2wLWVMjO1g"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">7500000</edit:FundingPaymentsDueAndPayableTwo>
    <us-gaap:NotesPayableCurrent
      contextRef="As_Of_6_30_2018_srt_CounterpartyNameAxis_edit_BroadInstituteIncMember_us-gaap_ShortTermDebtTypeAxis_edit_InitialNotesMember_us-gaap_TypeOfArrangementAxis_edit_SponsoredResearchAgreementMember_wPlaEbCo9EqUmdryXl5j9w"
      decimals="-5"
      id="Narr_LRZ4fG-ewE2LdaLx2U7yjA"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">12500000</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_6_30_2018_srt_CounterpartyNameAxis_edit_BroadInstituteIncMember_us-gaap_ShortTermDebtTypeAxis_edit_InitialNotesMember_us-gaap_TypeOfArrangementAxis_edit_SponsoredResearchAgreementMember_wPlaEbCo9EqUmdryXl5j9w"
      decimals="3"
      id="Narr_soMdz5K6fEKE2cK0v8lr8Q"
      unitRef="Unit_Standard_pure_E8xeiPkPjUOaCmQYBNvdag">0.048</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <edit:ThresholdPeriodInterestFreeDebtInstrumentFaceAmount
      contextRef="As_Of_9_30_2019_srt_CounterpartyNameAxis_edit_BroadInstituteIncMember_us-gaap_ShortTermDebtTypeAxis_edit_InitialNotesMember_us-gaap_TypeOfArrangementAxis_edit_SponsoredResearchAgreementMember_wmULTOG4pU6RGgo-NX-daA"
      decimals="-5"
      id="Narr_6auklxNgN0ueLpWPiTbiyQ"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">7500000</edit:ThresholdPeriodInterestFreeDebtInstrumentFaceAmount>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="Duration_6_1_2018_To_6_30_2018_srt_CounterpartyNameAxis_edit_BroadInstituteIncMember_us-gaap_TypeOfArrangementAxis_edit_SponsoredResearchAgreementMember_e3dA74ixPEqD64XeFIza9A"
      decimals="INF"
      id="Narr_ouVUIAr4Rkyu-22O1Nk7mw"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">330617</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Tb_ZfiSiebApUqWNMzeIP_ysQ">&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;8&lt;/b&gt;. &lt;b style="font-weight:bold;"&gt;Collaboration and License Agreements&lt;/b&gt;&lt;span style="white-space:pre-wrap;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The Company has entered into multiple collaboration, license and strategic agreements with third parties that &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;typically involve the Company granting licenses to the Company&#x2019;s intellectual property, receiving licenses to intellectual property rights and/or performing research and development services in exchange for upfront fees, milestone payments and royalty payments to or from the Company. The terms and conditions as well as the accounting analysis for the Company&#x2019;s significant collaboration, license and strategic agreements are described in Note 9, &#x201c;Significant Agreements,&#x201d; to the consolidated financial statements included in the Annual Report. There have been no material changes to the terms and conditions, or the accounting conclusions previously disclosed in the Annual Report. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Collaboration Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;As of September 30, 2019, the Company&#x2019;s contract liabilities were primarily related to the Company&#x2019;s collaboration with Juno Therapeutics and strategic alliance with Allergan. The following table presents changes in the Company&#x2019;s accounts receivable and contract liabilities for the nine months ended September 30, 2019 (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the nine months ended September 30, 2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:middle;width:13.51%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance at December&#160;31,&#160;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:middle;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:middle;width:11.97%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Additions&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:middle;width:11.35%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deductions&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:middle;width:13.78%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance at September&#160;30,&#160;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Accounts receivable&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;30&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 311&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (30)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 311&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Contract liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:45.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 131,326&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (7,928)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 128,398&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;During the three and nine months ended September 30, 2019, the Company recognized the following collaboration revenue (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:62.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:62.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:middle;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:middle;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:middle;width:17.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:middle;width:62.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue recognized in the period from:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:auto;vertical-align:middle;width:37.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:62.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Amounts included in deferred revenue at the beginning of the period&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:15.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,354&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,733&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:62.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Performance obligations satisfied in previous periods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,194&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,194&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Juno Therapeutics Collaboration Agreement &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;In May 2015, the Company entered into a Collaboration and License Agreement with Juno Therapeutics and in May 2018 the Company and Juno Therapeutics entered into an Amended and Restated Collaboration and License Agreement (collectively, the &#x201c;Juno Agreement&#x201d;). &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;There have been no material changes to the transaction price in the three or nine months ended September 30, 2019. As of September 30, 2019, the only milestones that were included in the transaction price were milestones that had been contractually earned and received. The outstanding milestones were fully constrained, as a result of the uncertainty regarding whether any of the milestones will be achieved. As of September 30, 2019, Juno Therapeutics has not exercised any of its options associated with the material rights identified in the Juno Agreement and no revenue has been recognized related to the material rights. Amounts allocated to each of the material rights will be recognized when the material right has been exercised or when the respective option has lapsed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;During the three and nine months ended September 30, 2019, the Company did not recognize revenue related to the Juno Agreement. During the three and nine months ended September 30, 2018, the Company recognized $0.7 million and $5.2 million in revenue related to the Juno Agreement. As of September 30, 2019 and December 31, 2018, there was approximately $32.0 million of deferred revenue related to the Juno Agreement, of which $32.0 million and $2.8 million were classified as short-term, respectively, in the accompanying condensed consolidated balance sheets. In addition, there were no amounts classified in accounts receivable on the condensed consolidated balance sheets related to the Juno Agreement as of September 30, 2019 or December 31, 2018.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;min-height:10.0pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Allergan Pharmaceuticals Strategic Alliance and Option Agreement and Profit-Sharing Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;min-height:10.0pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;In March 2017, the Company entered into a Strategic Alliance and Option Agreement with Allergan to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders (the &#x201c;Allergan Agreement&#x201d;). Over a seven-year research term, Allergan will have an exclusive option to exclusively license from the &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Company up to five collaboration development programs for the treatment of ocular disorders (each a &#x201c;CDP&#x201d;), including the Company&#x2019;s Leber congenital amaurosis 10 (&#x201c;LCA10&#x201d;) program and the related experimental therapeutic EDIT-101 to treat LCA10 (the &#x201c;LCA10 Program&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;There have been no material changes to the transaction price in the three or nine months ended September 30, 2019. As of September 30, 2019, the only milestone that was included in the transaction price had been contractually earned and received. The outstanding milestones were fully constrained, as a result of the uncertainty regarding whether any of the milestones will be achieved. The Company has concluded that the options to purchase five&lt;span style="white-space:pre-wrap;"&gt; development and commercialization licenses are considered a marketing offer as the options did not provide any discounts or other rights that would be considered a material right in the arrangement. In August 2018, Allergan exercised its right to the LCA10 Program and the option fee was recognized as revenue during the three months ended September 30, 2018 when the control transferred to Allergan.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;During the three and nine months ended September 30, 2019, the Company recognized revenue related to the Allergan Agreement of approximately $3.4 million and $7.7 million, respectively. During the three and nine months ended September 30, 2018, the Company recognized revenue related to the Allergan Agreement of approximately $13.8 million and $16.7 million, respectively. As of September 30, 2019 and December 31, 2018, there was $91.6 million and $99.2 million of deferred revenue related to the Allergan Agreement, respectively, of which $79.0 million and $86.4 million is classified as long-term on the condensed consolidated balance sheet, respectively. There were no amounts classified in accounts receivable on the condensed consolidated balance sheets related to the Allergan Agreement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:31.7pt;margin:0pt 0pt 0pt 4.3pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The Company and an affiliate of Allergan (together with Allergan, the &#x201c;Allergan Entities&#x201d;) agreed to equally split U.S. profits and losses for the LCA10 Program in the United States and to co-develop the LCA10 Program in the United States (the &#x201c;Profit-Sharing Agreement&#x201d;). The Company accounts for the Profit-Sharing Arrangement with respect to the LCA10 Program within the scope of ASC Topic 808, &lt;i style="font-style:italic;"&gt;Collaborative Arrangements&lt;/i&gt;, given that the Company and the Allergan Entities are active participants in future research and development activities and all parties are exposed to significant risks and rewards dependent on the commercial success of such activities. During the three and nine months ended September 30, 2019, the Company and the Allergan Entities incurred $4.9 million and $13.9 million in expense associated with the LCA10 Program, respectively, of which the Company recognized 50% in operating expense during such periods.&lt;span style="white-space:pre-wrap;"&gt;  &lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <edit:ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Group_hbm0RhZlZ02d0mCKGAReQQ">The following table presents changes in the Company&#x2019;s accounts receivable and contract liabilities for the nine months ended September 30, 2019 (in thousands):&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the nine months ended September 30, 2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:middle;width:13.51%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance at December&#160;31,&#160;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:middle;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:middle;width:11.97%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Additions&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:middle;width:11.35%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deductions&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:middle;width:13.78%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance at September&#160;30,&#160;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Accounts receivable&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;30&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 311&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (30)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 311&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Contract liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:45.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 131,326&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (7,928)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 128,398&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</edit:ScheduleOfAccountsReceivableAndContractLiabilitiesTableTextBlock>
    <us-gaap:ReceivablesNetCurrent
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_wFhTaVWGqE-qRy3rD_lFow_2_2"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">30000</us-gaap:ReceivablesNetCurrent>
    <edit:AccountsReceivableAdditions
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_ns0oxaymU0yKE208DuEJvg_2_5"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">311000</edit:AccountsReceivableAdditions>
    <edit:AccountsReceivableDeductions
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_xPCr_nhiLUC9yjMIYPOmZA_2_8"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">30000</edit:AccountsReceivableDeductions>
    <us-gaap:ReceivablesNetCurrent
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_i2Yu3FkB4EeJNEdi4_ZKdw_2_11"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">311000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_bTv-ObLdbUug-s-5LeJ9hg_4_2"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">131326000</us-gaap:ContractWithCustomerLiability>
    <edit:ContractWithCustomerLiabilityAdditions
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_dCvewnzqRkehb26ZEmgnXw_4_5"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">5000000</edit:ContractWithCustomerLiabilityAdditions>
    <edit:ContractWithCustomerLiabilityDeductions
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_4fBrA1PezUaWGiZ9TNVenw_4_8"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">7928000</edit:ContractWithCustomerLiabilityDeductions>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_WtJJw79uWUy49b5_MTMHdg_4_11"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">128398000</us-gaap:ContractWithCustomerLiability>
    <edit:ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Tb_Y2ZI_-g4Ok6Mb2N5VQBzBg">&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;During the three and nine months ended September 30, 2019, the Company recognized the following collaboration revenue (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:62.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:62.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:middle;width:17.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:middle;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:middle;width:17.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:middle;width:62.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue recognized in the period from:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:auto;vertical-align:middle;width:37.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:62.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Amounts included in deferred revenue at the beginning of the period&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:15.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,354&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:middle;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,733&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:62.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"&gt;Performance obligations satisfied in previous periods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,194&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-family:'Calibri';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,194&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</edit:ScheduleOfChangeInContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw"
      decimals="-3"
      id="Tc_MynIM7cofkujAs9QEZjFtQ_3_2"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">2354000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_8XPFdUFTgEK2gfmSKtXj8w_3_5"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">6733000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw"
      decimals="-3"
      id="Tc_QA6T6_9tBUCxx4vveYSBzQ_4_2"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">1194000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_bWb79DtdU0ykvGFS_r2_5Q_4_5"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">1194000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_7_1_2018_To_9_30_2018_srt_CounterpartyNameAxis_edit_JunoTherapeuticsMember_us-gaap_TypeOfArrangementAxis_edit_CollaborationAndLicenseAgreementMember_O_MITT2wVkKnx6b-sggXmw"
      decimals="-5"
      id="Narr_PEdDQmw27E6UHxr8lRW76w"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">700000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_1_1_2018_To_9_30_2018_srt_CounterpartyNameAxis_edit_JunoTherapeuticsMember_us-gaap_TypeOfArrangementAxis_edit_CollaborationAndLicenseAgreementMember_DrDthce0AkygyZ1M-rBEkg"
      decimals="-5"
      id="Narr_DYQz2qFVLUSHllSoAOCOiQ"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">5200000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_9_30_2019_srt_CounterpartyNameAxis_edit_JunoTherapeuticsMember_us-gaap_TypeOfArrangementAxis_edit_CollaborationAndLicenseAgreementMember_MrTxHdu-80almYvZDCtdRw"
      decimals="-5"
      id="Narr_4Ra3H5PwYEG_N7v546SPdA"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">32000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_edit_JunoTherapeuticsMember_us-gaap_TypeOfArrangementAxis_edit_CollaborationAndLicenseAgreementMember_cKDlyfBM_E-va2ua4o2xGA"
      decimals="-5"
      id="Narr_3_236uygw0iHVLK4gxf3IA"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">32000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_9_30_2019_srt_CounterpartyNameAxis_edit_JunoTherapeuticsMember_us-gaap_TypeOfArrangementAxis_edit_CollaborationAndLicenseAgreementMember_MrTxHdu-80almYvZDCtdRw"
      decimals="-5"
      id="Narr_3vT_oUGr-k-d06k8CVJ2mQ"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">32000000.0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_edit_JunoTherapeuticsMember_us-gaap_TypeOfArrangementAxis_edit_CollaborationAndLicenseAgreementMember_cKDlyfBM_E-va2ua4o2xGA"
      decimals="-5"
      id="Narr_qyj2tXjiqkObgGlwpz_drA"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">2800000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="As_Of_9_30_2019_srt_CounterpartyNameAxis_edit_JunoTherapeuticsMember_us-gaap_TypeOfArrangementAxis_edit_CollaborationAndLicenseAgreementMember_MrTxHdu-80almYvZDCtdRw"
      decimals="-5"
      id="Narr_SXe7DUg3rkiW7QKVqDE67g"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">0</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_edit_JunoTherapeuticsMember_us-gaap_TypeOfArrangementAxis_edit_CollaborationAndLicenseAgreementMember_cKDlyfBM_E-va2ua4o2xGA"
      decimals="-5"
      id="Narr_QLgVSZZoM0a8szCboh7vEQ"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">0</us-gaap:ReceivablesNetCurrent>
    <edit:ResearchProgramTerm
      contextRef="Duration_3_1_2017_To_3_31_2017_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_2xE0WJjMoEOm6FHj79hUVg"
      id="Narr_3klupBCLF0yFG8FIy66aXQ">P7Y</edit:ResearchProgramTerm>
    <edit:NumberOfCollaborationDevelopmentPrograms
      contextRef="Duration_3_1_2017_To_3_31_2017_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_2xE0WJjMoEOm6FHj79hUVg"
      decimals="INF"
      id="Narr_QyBtA99WIEuWA_GzyNL_Qg"
      unitRef="Unit_Standard_item_rl1kcwMXZkCIZ-rzvXYVSA">5</edit:NumberOfCollaborationDevelopmentPrograms>
    <edit:NumberOfAdditionalDevelopmentAndCommercializationLicenseToBePurchased
      contextRef="Duration_1_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_Nw7YnWbU5EWBxR7zlJEm8g"
      decimals="INF"
      id="Narr_Vtoct5J0o0iXKezJwApRJw"
      unitRef="Unit_Standard_item_rl1kcwMXZkCIZ-rzvXYVSA">5</edit:NumberOfAdditionalDevelopmentAndCommercializationLicenseToBePurchased>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_7_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_xU8d1nrnWkeSzheIpGvdWg"
      decimals="-5"
      id="Narr_UXeDdZsvMEWay8ecksKzAw"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">3400000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_1_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_Nw7YnWbU5EWBxR7zlJEm8g"
      decimals="-5"
      id="Narr_gvtyph14pk6l8Z9B6Dsk_A"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">7700000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_7_1_2018_To_9_30_2018_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_RhdoXjew9EeVWvTWLV9vCA"
      decimals="-5"
      id="Narr_RA2S-AEBtUu1BF5XIzs1cg"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">13800000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_1_1_2018_To_9_30_2018_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_L3rm1o4tuUiQrTClwY11ug"
      decimals="-5"
      id="Narr_KKY9iYe2TUifDEzYCKcpeA"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">16700000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_9_30_2019_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_r45DsPeVZECbm550Uuu09w"
      decimals="-5"
      id="Narr_SECKh8DA6EqPyWmwG6Q8ug"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">91600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_qZ56Qn1U9Ee0sa4UlEgnKA"
      decimals="-5"
      id="Narr_9BYCDNKFG0SjRgy53-v_Ew"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">99200000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_9_30_2019_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_r45DsPeVZECbm550Uuu09w"
      decimals="-5"
      id="Narr_sM00V3-ivEO7wBG5lx3gow"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">79000000.0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_qZ56Qn1U9Ee0sa4UlEgnKA"
      decimals="-5"
      id="Narr_MPPX_Iol-UGDNseZO4AgXQ"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">86400000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="As_Of_9_30_2019_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_r45DsPeVZECbm550Uuu09w"
      decimals="-5"
      id="Narr_JKFUDNlE1kOaxTnM1HFvWw"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">0</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="As_Of_12_31_2018_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_qZ56Qn1U9Ee0sa4UlEgnKA"
      decimals="-5"
      id="Narr_GGgdktEcKECroUWYzF5eNA"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">0</us-gaap:ReceivablesNetCurrent>
    <edit:ProgramExpense
      contextRef="Duration_7_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_xU8d1nrnWkeSzheIpGvdWg"
      decimals="-5"
      id="Narr_Xjo_H7TZrEGM9-CDEU6nYw"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">4900000</edit:ProgramExpense>
    <edit:ProgramExpense
      contextRef="Duration_1_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_edit_AllerganMember_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_Nw7YnWbU5EWBxR7zlJEm8g"
      decimals="-5"
      id="Narr_U5NjSa_jJESL5dp1nwRCUA"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">13900000</edit:ProgramExpense>
    <edit:ShareOfExpenseRecognizedPercentage
      contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_FOjXNGrOA0OHMOM6s36fPg"
      decimals="2"
      id="Narr_1_JBo8bUBE2EHMW8oYvn-g"
      unitRef="Unit_Standard_pure_E8xeiPkPjUOaCmQYBNvdag">0.50</edit:ShareOfExpenseRecognizedPercentage>
    <edit:ShareOfExpenseRecognizedPercentage
      contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_TypeOfArrangementAxis_edit_StrategicAllianceMember_i04SOq9XXU-b-tSVEl5LSA"
      decimals="2"
      id="Narr_k-hIcrtfZ0G5aJ7ldZ849g"
      unitRef="Unit_Standard_pure_E8xeiPkPjUOaCmQYBNvdag">0.50</edit:ShareOfExpenseRecognizedPercentage>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Tb__U0toaE7U06YCU8hVP0VJw">&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;9&lt;/b&gt;. &lt;b style="font-weight:bold;"&gt;Stock-based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Stock-based compensation expense by classification included in the condensed consolidated statements of operations was as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.04%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:22.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:auto;vertical-align:middle;white-space:nowrap;width:20.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:auto;vertical-align:middle;white-space:nowrap;width:22.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,619&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,506&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,854&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,412&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,940&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,193&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,053&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,839&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,559&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,699&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,907&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,251&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Restricted Stock and Restricted Stock Unit Awards&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The following table summarizes restricted stock and restricted stock unit awards activity for the nine months ended September 30, 2019:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant&#160;Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Per&#160;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unvested restricted stock and restricted stock unit awards as of December&#160;31,&#160;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 270,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28.05&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Issued&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 445,126&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.94&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (77,052)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26.47&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (51,182)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.40&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unvested restricted stock and restricted stock unit awards as of September 30, 2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 586,892&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24.20&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;As of September 30, 2019, the Company had $9.8 million in unrecognized stock-based compensation expense related to unvested restricted stock and unvested restricted stock unit awards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"/&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The following table summarizes stock option activity for the nine months ended September 30, 2019:&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&#160;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:17.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&#160;Life (years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&#160;(in&#160;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding at December&#160;31,&#160;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,689,786&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23.80&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.9&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,686&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,500,502&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24.30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (502,234)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.46&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (546,799)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28.15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding at September 30, 2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,141,255&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24.69&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.5&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,899&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Exercisable at September 30, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,386,635&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,238&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The stock options granted in the nine months ended September 30, 2019 include an option granted to the Company&#x2019;s Chief Executive Officer to purchase 250,000 shares of the Company&#x2019;s common stock that contains market-based vesting provisions. The Company is recognizing the fair value of these options over the earlier of the derived service period, valued using the Monte-Carlo simulation model, or when the market-based vesting conditions are met. &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;As of September 30, 2019, the Company had unrecognized stock-based compensation expense related to its employee and director stock options that contain service-based vesting of $38.1 million, which the Company expects to recognize over the remaining weighted average vesting period of 2.64 years.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Tb_2QZibGcvtUGVLl3RcSnEpA">&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Stock-based compensation expense by classification included in the condensed consolidated statements of operations was as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.04%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:22.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:auto;vertical-align:middle;white-space:nowrap;width:20.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="background-color:auto;vertical-align:middle;white-space:nowrap;width:22.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,619&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,506&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,854&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,412&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,940&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,193&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,053&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,839&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:51.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,559&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,699&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,907&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,251&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_wZjwFdhl40-qubyppSmKOA"
      decimals="-3"
      id="Tc_wdFJ_a_wo02PkjfVGPeTJg_6_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">3619000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2018_To_9_30_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_kzBgCnpG60KUgNvcF9BukA"
      decimals="-3"
      id="Tc_4H10lNivfkukj9nX3F_pUg_6_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">3506000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_aNajZe-YxUercIojM7dr8w"
      decimals="-3"
      id="Tc_13fjCH205Ee83Qkd41IJCQ_6_9"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">10854000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_iZuu8Cy3U0irlLMZI7Q0TQ"
      decimals="-3"
      id="Tc_yTvXndE91kCKsWcy6NYbzA_6_12"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">11412000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_r_4eSnuC80mudfKuh14VtQ"
      decimals="-3"
      id="Tc_sVcFwUUsFEe556nbxfYm7g_7_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">2940000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2018_To_9_30_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_Ra72AcdpGUyjMWqQfhIMxw"
      decimals="-3"
      id="Tc_vCLJxZ9UsU2ry2HVAEzstg_7_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">3193000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_MupqsEB1_kKTyw545CGbAg"
      decimals="-3"
      id="Tc_E2EgieR3EUupdhTS7J2DYw_7_9"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">10053000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_TvpaFuwJQkG6gdsSbxfjjw"
      decimals="-3"
      id="Tc_glGBGvEUq0-sVj4fHZbNVA_7_12"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">8839000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2019_To_9_30_2019_cn06udDyfUSMXG_gJ9zkIw"
      decimals="-3"
      id="Tc_cKrfQzryfk6tQ5mROSQU4A_8_3"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">6559000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2018_To_9_30_2018_P5c0vDTfSUOjxX5GzNZvYA"
      decimals="-3"
      id="Tc_rZyp4HmROECdEBsl4O59kQ_8_6"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">6699000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="-3"
      id="Tc_wEm76r3da0ms8DP88TCM6A_8_9"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">20907000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="-3"
      id="Tc_XEUJzT9vdEiE5bOWBK-nMg_8_12"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">20251000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Tb_YRLQ0llqPkar_3QClLiz2A">&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The following table summarizes restricted stock and restricted stock unit awards activity for the nine months ended September 30, 2019:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant&#160;Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Per&#160;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unvested restricted stock and restricted stock unit awards as of December&#160;31,&#160;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 270,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28.05&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Issued&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 445,126&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.94&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (77,052)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26.47&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (51,182)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.40&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:75.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unvested restricted stock and restricted stock unit awards as of September 30, 2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 586,892&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24.20&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="INF"
      id="Tc_hR1_hOzi8U-JsdyKF-ouEg_6_2"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">270000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="2"
      id="Tc_Ofn2wj5VDka2uMI7PnuzBQ_6_5"
      unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA">28.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="INF"
      id="Tc_z_etvWkh9EKOAYpXhPrUPg_7_2"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">445126</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="2"
      id="Tc_-VkosgBrbEuztEmLi0sDqA_7_5"
      unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA">21.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="INF"
      id="Tc_zBq-y1XrJUSCPuE-Zqz4ag_8_2"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">77052</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="2"
      id="Tc_1tRilcdMi06E34-jvD5Jyg_8_5"
      unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA">26.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="INF"
      id="Tc_ZfumXWt9OUSeUE1dzJZQBA_9_2"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">51182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="2"
      id="Tc_CSYKem6hQkG88y7U_n5r9g_9_5"
      unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA">21.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="INF"
      id="Tc_Src3gru270yYn6QbtZPNgQ_10_2"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">586892</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="2"
      id="Tc_gMp2Qf3U50Chb3zPYgiJoQ_10_5"
      unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA">24.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-5"
      id="Narr_ah7_ygEBvkeMLN39fq2XmA"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">9800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Tb_owSKrmD0lUa9OgyIChbPPQ">&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The following table summarizes stock option activity for the nine months ended September 30, 2019:&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&#160;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:13.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:17.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&#160;Life (years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:14.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&#160;(in&#160;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding at December&#160;31,&#160;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,689,786&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23.80&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.9&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,686&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,500,502&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24.30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (502,234)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.46&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt; (546,799)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28.15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding at September 30, 2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,141,255&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24.69&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.5&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,899&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:38.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Exercisable at September 30, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,386,635&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,238&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="INF"
      id="Tc_VoIrlRhZgECWwjHv6DWUog_3_2"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">4689786</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="2"
      id="Tc_Md0cXRjNj0K1e_ezSRhCeA_3_5"
      unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA">23.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2018_To_12_31_2018_zrodnEw_VUizLBhcAZpOsg"
      id="Tc_3KtGDTjz30uYsMw-h4P5xA_3_7">P7Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2018_orpy7dZHDUauyDYRFvGGDw"
      decimals="-3"
      id="Tc_QRlmsMJcq0mKAc-w6yFTaA_3_10"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">20686000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="INF"
      id="Tc_y1Z4kjvoeUKYhWCGets99Q_4_2"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">1500502</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="2"
      id="Tc_U2I9CFu4MkWwMIrbIQAMsw_4_5"
      unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA">24.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="INF"
      id="Tc_65XfnVWiGUmTMg-cRWM-wQ_5_2"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">502234</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="2"
      id="Tc_6JeZSfPbgE2RFse7mb3XxA_5_5"
      unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA">11.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="INF"
      id="Tc_IilO5R9m5EWQ5ukopEe93Q_6_2"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">546799</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="2"
      id="Tc_Omlk2rdPfUam4XIM0kycIA_6_5"
      unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA">28.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="INF"
      id="Tc_E-UD6FOgb0OU5q-KT8V_jg_7_2"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">5141255</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="2"
      id="Tc_8uMbigJPPUeD3J5Zob1A6Q_7_5"
      unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA">24.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Tc_w_fMiNXZj0K_CWE8G5S6mw_7_7">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_H_jnsxV0OUCavztryWYF1A_7_10"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">14899000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="INF"
      id="Tc_-32e8Kt1iEmNCFZpoh5ZJQ_8_2"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">2386635</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="2"
      id="Tc_IcsbWfWGjE6rPqR-FTRe2A_8_5"
      unitRef="Unit_Divide_USD_shares_qJE2ebWZUUik11zetZcYyA">21.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Tc_odJhoKDQbUikZHiL8KRvqg_8_7">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_9_30_2019_bnQWk4Spv0adHUQp6Jcm7A"
      decimals="-3"
      id="Tc_Vw2IHVWCJkG6LtIf6HYlDA_8_10"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">13238000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2019_To_9_30_2019_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_dmEKC8zRkUGaNSfj2wtDJQ"
      decimals="INF"
      id="Narr_3pU8SHZF50atL5xDZ2SLyg"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_9_30_2019_srt_TitleOfIndividualAxis_edit_EmployeeAndDirectorMember_DG1Lr8lP_0-bT3_QEQxdtQ"
      decimals="-5"
      id="Narr_BpQcS0XJcEy-Fl4mFIB3Jw"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">38100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2019_To_9_30_2019_srt_TitleOfIndividualAxis_edit_EmployeeAndDirectorMember_VQVIkfmCb0mvWmtS1VrR7A"
      id="Narr_tcxWla1U80CGPqth5KtA1Q">P2Y7M20D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Tb_4aESkqvYokqcE7OZFvq3lQ">&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;10. Net Loss per Share&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury stock and if converted methods. Contingently issuable shares are included in the calculation of basic loss per share as of the beginning of the period in which all the necessary conditions have been satisfied. Contingently issuable shares are included in diluted loss per share based on the number of shares, if any, that would be issuable under the terms of the arrangement if the end of the reporting period was the end of the contingency period, if the results are dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;For purposes of the diluted net loss per share calculation, stock options are considered to be common stock equivalents, but they were excluded from the Company&#x2019;s calculation of diluted net loss per share allocable to common stockholders because their inclusion would have been anti-dilutive. Therefore, basic and diluted net loss per share applicable to common stockholders was the same for all periods presented.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;In connection with at-the-market offerings consummated by the Company during 2018 and during the third quarter of 2019, the Company sold 2,536,205 and 1,721,735 shares of its common stock, respectively. The issuance of &lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;these shares resulted in a significant increase in the Company&#x2019;s weighted-average shares outstanding and is expected to continue to impact the year-over-year comparability of the Company&#x2019;s net loss per share calculations for the remainder of 2019 and 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The following common stock equivalents were excluded from the calculation of diluted net loss per share allocable to common stockholders because their inclusion would have been anti-dilutive:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:73.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:21.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:73.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Unvested restricted stock and restricted stock unit awards&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 586,892&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 288,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Outstanding stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,141,255&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,822,486&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,728,147&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,110,486&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarketOfferingMember_Ow36SSy4wUiSEqoR3C4BvA"
      decimals="INF"
      id="Narr_CBlyT3oUVEW93F9G-MnLUw"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">2536205</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_1_2019_To_9_30_2019_us-gaap_SubsidiarySaleOfStockAxis_edit_AtMarketOfferingMember_-kac0ehTwkynz560Ie4IPQ"
      decimals="INF"
      id="Narr_uyCMlsmsM0WBLfGwc4S4zg"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">1721735</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Tb_nDIFvXt7IU2-xh3WCEvsyA">&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The following common stock equivalents were excluded from the calculation of diluted net loss per share allocable to common stockholders because their inclusion would have been anti-dilutive:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:73.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:21.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:auto;vertical-align:bottom;width:73.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:8pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Unvested restricted stock and restricted stock unit awards&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 586,892&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 288,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;Outstanding stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,141,255&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,822,486&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,728,147&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,110,486&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_Onzl5CFXo0u2R96djFM_ag"
      decimals="INF"
      id="Tc_7qXsvjIKnkmoa3TrVC9ybA_3_3"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">586892</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember_WBkfEEnpwE-fkbIkbfPsmQ"
      decimals="INF"
      id="Tc_6fJP79XifE-x3bT5BUJRCQ_3_5"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">288000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2019_To_9_30_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_MMdAUyO5fE6SZ9Hb9jRH_A"
      decimals="INF"
      id="Tc_Wb-aALSW8Uim5oInDpisYQ_4_3"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">5141255</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_1CwvMLjJmEu4BIw00uKzhw"
      decimals="INF"
      id="Tc_IIwNZ3KbnUyyiWoECGZ9kg_4_5"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">4822486</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      decimals="INF"
      id="Tc_6GTQ_ffYe0GkSEJ1rVrRcg_5_3"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">5728147</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2018_To_9_30_2018_qqdSRsdCtEKBn9oNIVBDYA"
      decimals="INF"
      id="Tc_zrUAbPPrfkq7RJxKPRxgvQ_5_5"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">5110486</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Tb_lADh72CDJE6-0zWiy7qqdQ">&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;11. Related-Party Transactions &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The Company received $0.4 million in rent and facility-related fees from a related party during the nine months ended September 30, 2018 in connection with the Company&#x2019;s Hurley Street sublease. No rent or facility-related payments were received from this related party during the nine months ended September 30, 2019. &lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_RelatedPartyTransactionAxis_edit_RentAndFacilityRelatedFeesMember_Exbi6JGLz0aiPwGT7WbBAw"
      decimals="-5"
      id="Narr_J6tkY7rsdUGVK1TR3Lg6_A"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">400000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2019_To_9_30_2019_ThLzqm705UmHOhUa0V_juA"
      id="Tb_kAHSBUDHkE-pkp41fFvDSA">&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;12. Subsequent Events&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;In November 2019, the Company entered into a Second Amended and Restated Collaboration and License Agreement with Juno, pursuant to which the Company is entitled to receive a $70.0 million payment, and a related License Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;In October 2019, the Company&#x2019;s board of directors approved an inducement grant to the Company&#x2019;s recently hired Chief Medical Officer, including an option to purchase up to 150,000 shares of the Company&#x2019;s common stock and an award of 25,000 restricted stock units.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <edit:CollaborationAndLicenseAgreementAmendmentFeeReceived
      contextRef="Duration_11_1_2019_To_11_30_2019_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_edit_JunoTherapeuticsMember_9ZN4nSHh5EeubrbKBSQ-Jw"
      decimals="-5"
      id="Narr_imk9VWL5BkOMU7icuuoQBA"
      unitRef="Unit_Standard_USD_EPL8tMP6qUScyZUlU1TJsg">70000000.0</edit:CollaborationAndLicenseAgreementAmendmentFeeReceived>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_10_1_2019_To_10_31_2019_srt_TitleOfIndividualAxis_edit_ChiefMedicalOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_ER3lg9N5AUW1GcUOCxl1VQ"
      decimals="INF"
      id="Narr_F6ENTTYMfkWfz7Uq9KC2pg"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_10_1_2019_To_10_31_2019_srt_TitleOfIndividualAxis_edit_ChiefMedicalOfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_oocRI-BsJkm3KP9_DGx7bQ"
      decimals="INF"
      id="Narr_uL4HdvpntUSB7uGn4SEv-A"
      unitRef="Unit_Standard_shares_UhKJEjSp90KyHBbdhS8skQ">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6797696624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents, Marketable Securities and Corporate Equity Securities (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Cash Equivalents, Marketable Securities and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_MarketableSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">$ 336,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 372,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_MarketableSecuritiesUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_MarketableSecuritiesUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Fair Value</a></td>
<td class="nump">$ 336,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">372,381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of securities in an unrealized loss position | item</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Securities held by the Company in an unrealized loss position for less than 12 months</a></td>
<td class="nump">$ 51,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of securities in an unrealized loss position for more than 12 months | item</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Realized gains (losses) on available-for-sale securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Corporate equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Equity securities included in other non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Amortized Cost</a></td>
<td class="nump">3,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Fair Value</a></td>
<td class="nump">3,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Cash Equivalents, Marketable Securities and Corporate Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">104,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">104,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,049<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Cash Equivalents, Marketable Securities and Corporate Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">83,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,754<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">83,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,730<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">Government agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Cash Equivalents, Marketable Securities and Corporate Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">144,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 144,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,935<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_MarketableSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investments in marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_MarketableSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_MarketableSecuritiesUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_MarketableSecuritiesUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_MarketableSecuritiesUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_MarketableSecuritiesUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6789367360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Operating Leases (Details) - ft&#178;<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2016</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=edit_HurleyStreetLeaseMember', window );">Hurley Street Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_AreaOfLeasedSpace', window );">Leased space ( in square feet)</a></td>
<td class="nump">59,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, Operating Lease, Existence of Option to Extend [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Extended lease option (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=edit_FacilitySubleaseArrangementMember', window );">Facility Sublease Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_AreaOfLeasedSpace', window );">Leased space ( in square feet)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_AreaOfLeasedSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of leased space.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_AreaOfLeasedSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=edit_HurleyStreetLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=edit_HurleyStreetLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=edit_FacilitySubleaseArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=edit_FacilitySubleaseArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6780635376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Condensed Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration and other research and development revenues</a></td>
<td class="nump">$ 3,848<span></span>
</td>
<td class="nump">$ 14,519<span></span>
</td>
<td class="nump">$ 8,247<span></span>
</td>
<td class="nump">$ 25,818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList', window );">Revenue type</a></td>
<td class="text">us-gaap:ServiceMember<span></span>
</td>
<td class="text">us-gaap:ServiceMember<span></span>
</td>
<td class="text">us-gaap:ServiceMember<span></span>
</td>
<td class="text">us-gaap:ServiceMember<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 22,702<span></span>
</td>
<td class="nump">$ 17,443<span></span>
</td>
<td class="nump">$ 62,109<span></span>
</td>
<td class="nump">$ 71,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">15,734<span></span>
</td>
<td class="nump">13,334<span></span>
</td>
<td class="nump">47,638<span></span>
</td>
<td class="nump">41,832<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">38,436<span></span>
</td>
<td class="nump">30,777<span></span>
</td>
<td class="nump">109,747<span></span>
</td>
<td class="nump">113,292<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(34,588)<span></span>
</td>
<td class="num">(16,258)<span></span>
</td>
<td class="num">(101,500)<span></span>
</td>
<td class="num">(87,474)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(144)<span></span>
</td>
<td class="nump">332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income, net</a></td>
<td class="nump">1,680<span></span>
</td>
<td class="nump">1,024<span></span>
</td>
<td class="nump">5,668<span></span>
</td>
<td class="nump">2,243<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">1,647<span></span>
</td>
<td class="nump">1,020<span></span>
</td>
<td class="nump">5,524<span></span>
</td>
<td class="nump">2,575<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (32,941)<span></span>
</td>
<td class="num">$ (15,238)<span></span>
</td>
<td class="num">$ (95,976)<span></span>
</td>
<td class="num">$ (84,899)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders, basic and diluted</a></td>
<td class="num">$ (0.66)<span></span>
</td>
<td class="num">$ (0.32)<span></span>
</td>
<td class="num">$ (1.95)<span></span>
</td>
<td class="num">$ (1.81)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares outstanding, basic and diluted</a></td>
<td class="nump">49,820,455<span></span>
</td>
<td class="nump">47,414,271<span></span>
</td>
<td class="nump">49,246,684<span></span>
</td>
<td class="nump">46,791,322<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118944142&amp;loc=SL49130690-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6797439040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flow from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (95,976)<span></span>
</td>
<td class="num">$ (84,899)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">20,907<span></span>
</td>
<td class="nump">20,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">2,048<span></span>
</td>
<td class="nump">2,374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Non-cash research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_NoncashInvestmentInEquitySecurities', window );">Non-cash investment in equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,667)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash items, net</a></td>
<td class="num">(2,427)<span></span>
</td>
<td class="num">(2,129)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(281)<span></span>
</td>
<td class="nump">636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">263<span></span>
</td>
<td class="num">(2,349)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_IncreaseDecreaseInRightOfUseAssets', window );">Right-of-use asset</a></td>
<td class="nump">1,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(92)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,005<span></span>
</td>
<td class="nump">1,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(4,491)<span></span>
</td>
<td class="nump">2,344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(2,928)<span></span>
</td>
<td class="nump">4,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_IncreaseDecreaseInRightOfUseLiability', window );">Operating lease liability</a></td>
<td class="num">(2,107)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other current and non-current liabilities</a></td>
<td class="nump">528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(81,693)<span></span>
</td>
<td class="num">(47,034)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flow from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(4,476)<span></span>
</td>
<td class="num">(3,339)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment', window );">Proceeds from the sale of equipment</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(305,126)<span></span>
</td>
<td class="num">(351,162)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">314,000<span></span>
</td>
<td class="nump">310,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">4,434<span></span>
</td>
<td class="num">(44,483)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flow from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from offering of common stock, net of issuance costs</a></td>
<td class="nump">41,216<span></span>
</td>
<td class="nump">48,471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">5,756<span></span>
</td>
<td class="nump">8,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Issuances of common stock under benefit plans</a></td>
<td class="nump">283<span></span>
</td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations', window );">Payments on construction financing lease obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(621)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">47,255<span></span>
</td>
<td class="nump">56,588<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(30,004)<span></span>
</td>
<td class="num">(34,929)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">136,395<span></span>
</td>
<td class="nump">148,249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">106,391<span></span>
</td>
<td class="nump">113,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash and non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Fixed asset additions included in accounts payable and accrued expenses</a></td>
<td class="nump">772<span></span>
</td>
<td class="nump">676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_ReceivableOfProceedsFromExerciseOfStockOptions', window );">Receivable of proceeds from offering of common stock</a></td>
<td class="nump">756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid in connection with operating lease liabilities</a></td>
<td class="nump">4,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange of operating lease obligations</a></td>
<td class="nump">19,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_ReclassificationOfLiabilityForFounderStockRepurchase', window );">Reclassification of liability for common stock subject to repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock for settlement of success payments (see note 7)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_StockIssuedForAssetAcquisition', window );">Issuance of common stock for asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Issuance of common stock for settlement of notes payable (see note 7)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_DeferredRevenueAdjustmentFromEffectOfNewAccountingPrinciple', window );">Adjustment to deferred revenue for revenue adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_edit_StockIssuanceCostsIncurredButNotYetPaid', window );">Offering costs included in accounts payable and accrued expenses</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_DeferredRevenueAdjustmentFromEffectOfNewAccountingPrinciple">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of adjustment to deferred revenue for adoption of accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_DeferredRevenueAdjustmentFromEffectOfNewAccountingPrinciple</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_IncreaseDecreaseInRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount represents the increase (decrease) in right of use assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_IncreaseDecreaseInRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_IncreaseDecreaseInRightOfUseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) in right of use liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_IncreaseDecreaseInRightOfUseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_NoncashInvestmentInEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased equity securities that are acquired in a non-cash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_NoncashInvestmentInEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_ReceivableOfProceedsFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables from exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_ReceivableOfProceedsFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_ReclassificationOfLiabilityForFounderStockRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reclassification of liability for founder stock repurchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_ReclassificationOfLiabilityForFounderStockRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_StockIssuanceCostsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for stock issuance costs incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_StockIssuanceCostsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edit_StockIssuedForAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued for asset acquisition in non-cash activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edit_StockIssuedForAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edit_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of notes issued in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sale of machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt and lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
